HGVSc	SYMBOL	Consequence	gnomADe_non_cancer_AN_nfe	gnomADe_non_cancer_AC_nfe	gnomADg_AN_nfe	gnomADg_AC_nfe	clinvar_clnsig	clinvar_golden_stars	clinvar_rs	clinvar_trait	ClinVar	ClinVar_ALLELEID	ClinVar_CLNDN	ClinVar_CLNDNINCL	ClinVar_CLNDISDB	ClinVar_CLNDISDBINCL	ClinVar_CLNHGVS	ClinVar_CLNREVSTAT	ClinVar_CLNSIG	ClinVar_CLNSIGCONF	ClinVar_CLNSIGINCL	ClinVar_CLNVC	ClinVar_CLNVCSO	ClinVar_CLNVI	ClinVar_DBVARID	ClinVar_GENEINFO	ClinVar_MC	ClinVar_ORIGIN	ClinVar_RS	ClinVar_SSR	ClinVar_CLNSUBA	ClinVar_CLNSIGA	ClinVar_CLNDATEA	ClinVar_CLNDATESUBA	ClinVar_CLNREVSTATA	ClinVar_CLNORA	ClinVar_CLNSCVA	ClinVar_CLNDNA	ClinVar_CLNCOMA
NM_003000.2:c.685_686insCGCTTCACAGAGG	SDHB	frameshift_variant	102706	1	NA	NA	-	-	-	-	468238	447490	Pheochromocytoma|Gastrointestinal_stroma_tumor|Paragangliomas_4	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C1861848,OMIM:115310	-	NC_000001.10:g.17349193_17349194insCGCCTCTGTGAAG	_single_submitter	Pathogenic	-	-	Insertion	SO:0000667	-	-	SDHB:6390	SO:0001589|frameshift_variant	1	1209914140	-	Invitae	Pathogenic	2018-07-06	2019-03-28	_single_submitter	germline	SCV000644764	Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma	This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_SDHB_gene_(p.Glu229Alafs*31)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_52_amino_acids_of_the_SDHB_protein._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_pheochromocytoma_or_paraganglioma_(PMID:_23072324).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_468238)._A_different_truncation_(deletion_of_exon_8)_that_lies_downstream_of_this_variant_has_been_determined_to_be_pathogenic_(Invitae)._This_suggests_that_deletion_of_this_region_of_the_SDHB_protein_is_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_003000.2:c.683_684del	SDHB	frameshift_variant	102700	1	NA	NA	-	-	-	-	438428	432026	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_4	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1861848,OMIM:115310	-	NC_000001.10:g.17349184_17349185CT[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	SDHB:6390	SO:0001589|frameshift_variant	1	762812025	-	National_Institutes_of_Health|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	0000-00-00|2018-10-08|2019-03-09	2017-07-10|2019-03-28|2020-02-26	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000599527|SCV000937776|SCV001187946	Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma|Hereditary_cancer-predisposing_syndrome	|This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_SDHB_gene_(p.Glu228Glyfs*27)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_53_amino_acids_of_the_SDHB_protein._This_variant_is_present_in_population_databases_(rs762812025,_ExAC_0.002%)._This_variant_has_been_observed_in_several_individuals_affected_with_malignant_paraganglioma_(PMID:_24694336,16912137)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_438428)._Different_truncations_(p.Ser239Tyrfs*8,_deletion_of_exon_8)_that_lie_downstream_of_this_variant_has_been_determined_to_be_pathogenic_(PMID:_15328326,_Invitae)._This_suggests_that_deletion_of_this_region_of_the_SDHB_protein_is_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_003000.2:c.541-30_541-2dup	SDHB	splice_acceptor_variant	102478	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_003000.2:c.343C>T	SDHB	stop_gained	102738	2	NA	NA	5&5	1&1	rs751000085	Pheochromocytoma&Paragangliomas 4	197210	194371	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_4|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1861848,OMIM:115310|MedGen:CN517202	-	NC_000001.10:g.17355175G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	SDHB:6390	SO:0001587|nonsense	1	751000085	-	EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-05-04|0000-00-00|2016-06-22|2018-06-08	2018-09-19|2017-07-10|2019-03-21|2018-08-29	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000230200|SCV000599499|SCV000711787|SCV000644757	not_provided|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma	||The_p.Arg115X_variant_in_SDHB_has_been_reported_in_at_least_two_individuals_with_hereditary_paragangliomas_and_pheochromocytomas_and_segregated_with_disease_in_1_affected_relative_(Bayley_2006,_Benn_2006,_Lefebvre_2006)._It_has_also_been_id_entified_in_2/66740_European_chromosomes_by_the_Exome_Aggregation_Consortium_(Ex_AC,_http://exac.broadinstitute.org:_dbSNP_rs751000085)._This_frequency_is_low_en_ough_to_be_consistent_with_the_frequency_of_hereditary_paragangliomas_and_pheoch_romocytomas_in_the_general_population._This_nonsense_variant_is_predicted_to_res_ult_in_a_premature_termination_codon_at_position_115,_leading_to_a_truncated_or_absent_protein._Heterozygous_loss-of-function_variants_in_the_SDHB_gene_are_asso_ciated_with_hereditary_paragangliomas_and_pheochromocytomas._In_summary,_this_va_riant_meets_our_criteria_to_be_classified_as_pathogenic_for_hereditary_paragangl_iomas_and_pheochromocytomas_in_an_autosomal_dominant_manner_based_on_the_predict_ed_impact_to_the_protein_and_low_frequency_in_controls.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg115*)_in_the_SDHB_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs751000085,_ExAC_0.003%)._This_variant_has_been_reported_in_two_families_and_several_individuals_affected_with_paraganglioma_and/or_pheochromocytoma_(PMID:_16405730,_24523625,_25047027,21348866,_28490599)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_197210)._Loss-of-function_variants_in_SDHB_are_known_to_be_pathogenic_(PMID:_19454582,_19802898)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_003000.2:c.311_312insG	SDHB	frameshift_variant	102730	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_003000.2:c.268C>T	SDHB	stop_gained	102674	1	NA	NA	5&5&5&5&5&5	1&1&1&1&1&1	rs74315366	Paragangliomas 4&Hereditary Paraganglioma-Pheochromocytoma Syndromes&Pheochromocytoma&Hereditary Paraganglioma-Pheochromocytoma Syndromes&not provided&Hereditary cancer-predisposing syndrome	12778	27817	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paraganglioma_and_gastric_stromal_sarcoma|Paragangliomas_4|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1847319,OMIM:606864,Orphanet:ORPHA97286|MedGen:C1861848,OMIM:115310|MedGen:CN517202	-	NC_000001.10:g.17359573G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:185470.0001	-	SDHB:6390	SO:0001587|nonsense	1	74315366	-	OMIM|UCLA_Clinical_Genomics_Center,_UCLA|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|GeneDx|Ambry_Genetics|Invitae|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2001-07-01|2014-01-21|2011-08-18|2019-03-08|0000-00-00|2018-07-23|2017-12-21|2018-11-08|2018-10-31	2016-01-07|2015-05-14|0000-00-00|2019-03-21|2017-07-10|2019-01-29|2020-02-26|2019-03-28|2018-11-14	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline|germline|germline|unknown	SCV000033863|SCV000255462|SCV000053299|SCV000061380|SCV000599490|SCV000235630|SCV000274572|SCV000554022|SCV000893916	Paragangliomas_4|Paragangliomas_4|Pheochromocytoma/Hereditary_Paraganglioma-Pheochromocytoma_Syndromes/Pheochromocytoma/Paraganglioma|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|not_provided|Hereditary_cancer-predisposing_syndrome|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma|Paraganglioma_and_gastric_stromal_sarcoma/Paragangliomas_4/Pheochromocytoma	||Converted_during_submission_to_Pathogenic.|proposed_classification_-_variant_undergoing_re-assessment,_contact_laboratory||This_variant_is_denoted_SDHB_c.268C>T_at_the_cDNA_level_and_p.Arg90Ter_(R90X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_many_individuals_with_a_personal_and/or_family_history_of_paraganglioma,_pheochromocytoma,_gastrointestinal_stromal_tumor,_and/or_renal_cell_carcinoma,_with_several_tumors_showing_absence_of_SDHB_by_immunohistochemistry_(Astuti_2001,_van_Nederveen_2009,_Gill_2011,_Ricketts_2012,_Elston_2017,_Jochmanova_2017)._We_consider_this_variant_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_90_(p.Arg90*)_of_the_SDHB_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs74315366,_ExAC_0.002%)._This_variant_has_been_reported_in_the_literature_in_individuals_and_families_affected_with_pheochromocytoma,_paraganglioma_and_renal_cell_carcinoma_(PMID:_11404820,_23083876,_21348866,_24466223,_12618761,_163114641,_25326637,_16317055,_21934479,_19454582,18419787)._This_variant_is_also_known_as_R91X_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12778)._Loss-of-function_variants_in_SDHB_are_known_to_be_pathogenic_(PMID:_19454582,_19802898)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_003000.2:c.136C>T	SDHB	stop_gained	102656	1	15428	0	5&5&5&5&5	1&1&1&1&1	rs74315370	Hereditary cancer-predisposing syndrome&not provided&Gastrointestinal stromal tumor&Paragangliomas 4&Pheochromocytoma	142763	152477	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_4|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1861848,OMIM:115310|MedGen:CN517202	-	NC_000001.10:g.17371320G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	_Inc:SCN5A-A2	-	SDHB:6390	SO:0001587|nonsense	1	74315370	-	Ambry_Genetics|GeneDx|Gharavi_Laboratory,Columbia_University|Invitae|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|Center_for_Human_Genetics,_Inc	Pathogenic|Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic	2018-10-09|2018-03-26|2018-09-16|2018-12-21|0000-00-00|2016-11-01	2020-02-26|2019-01-29|2019-03-05|2019-03-28|2017-07-10|2017-12-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000187222|SCV000235644|SCV000920697|SCV000287758|SCV000599486|SCV000782271	Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_4	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|This_variant_is_denoted_SDHB_c.136C>T_at_the_cDNA_level_and_p.Arg46Ter_(R46X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_several_individuals_with_a_personal_and/or_family_history_of_paraganglioma_(Benn_2003,_Brouwers_2006,_Srirangalingam_2008,_Hensen_2012,_Mason_2013,_Jochmanova_2017)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_46_(p.Arg46*)_of_the_SDHB_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_SDHB_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_pheochromocytoma,_paraganglioma,_and_renal_cell_carcinoma_(PMID:_12618761,_16405730,_18728283,_21348866,_23797725)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||
NM_003000.2:c.88del	SDHB	frameshift_variant	102516	1	NA	NA	-	-	-	-	186518	181625	Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072	-	NC_000001.10:g.17371370del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	SDHB:6390	SO:0001589|frameshift_variant	1	747198089	-	National_Institutes_of_Health	Pathogenic|Pathogenic	2019-04-04|0000-00-00	2020-02-26|2017-07-10	_single_submitter|no_assertion_criteria_provided	germline|germline	SCV000216897|SCV000599485	Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|
NM_003000.2:c.73-2A>T	SDHB	splice_acceptor_variant	102006	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_003000.2:c.72+1G>T	SDHB	splice_donor_variant	98496	3	NA	NA	-	-	-	-	142764	152478	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paraganglioma_and_gastric_stromal_sarcoma|Paragangliomas_4|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1847319,OMIM:606864,Orphanet:ORPHA97286|MedGen:C1861848,OMIM:115310|MedGen:CN169374|MedGen:CN517202	-	NC_000001.10:g.17380442C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:185470.0012|HGMD:CS062096|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:7263	-	SDHB:6390	SO:0001575|splice_donor_variant	1	587782703	-	OMIM|Ambry_Genetics|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Invitae|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2008-01-01|2018-07-31|2018-01-26|2013-12-10|2018-02-22|2018-08-05|0000-00-00|2019-06-10	2016-08-31|2020-02-26|2018-04-23|2018-09-19|2019-01-29|2019-03-28|2017-07-10|2019-08-05	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000033877|SCV000187223|SCV000992189|SCV000203540|SCV000279239|SCV000287785|SCV000599479|SCV001158674	Paraganglioma_and_gastric_stromal_sarcoma|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|not_specified	|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Well-characterized_mutation_at_same_position|Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.||This_variant_is_denoted_SDHB_c.72+1G>T_or_IVS1+1G>T_and_consists_of_a_G>T_nucleotide_substitution_at_the_+1_position_of_intron_1_of_the_SDHB_gene._This_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._Of_note,_cDNA_studies_revealed_that_SDHB_c.72+1G>T_encoded_for_an_aberrant_transcript_predicted_to_result_in_a_significantly_truncated_protein_(Pasini_2008)._This_variant_has_been_observed_in_many_individuals_with_personal_and/or_family_history_of_paraganglioma_and/or_pheochromocytoma,_and_has_also_been_observed_in_individuals_with_renal_cell_carcinoma_or_gastrointestinal_stromal_tumor_(GIST),_and_may_be_a_Scottish_founder_variant_(Benn_2006,_Brouwers_2006,_Elston_2006,_Pasini_2008,_Srirangalingam_2008,_Timmers_2009,_Housley_2010,_Lodish_2010,_Rattenberry_2013,_Tsang_2014,_Jha_2017,_Andrews_2018)._We_consider_SDHB_c.72+1G>T_to_be_pathogenic.|This_sequence_change_affects_a_donor_splice_site_in_intron_1_of_the_SDHB_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_inÂ¬â€ individuals_affected_with_pheochromocytoma_(PMID:_16317055,_23666964),_paraganglioma_(PMID:_16472267,_16912137,_18419787,_20418362),_gastrointestinal_stromal_tumor_(PMID:_17667967),_and_renal_cell_carcinoma_(PMID:_20459544)._This_variant_is_also_known_as_IVS1+1G>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142764)._Experimental_studies_carried_out_using_the_blood_and_tumor_RNA_of_an_affected_individual_have_shown_that_this_splicing_change_results_in_an_aberrant_transcript_predicted_to_result_in_a_truncated_protein_product_(PMID:_17667967)._Two_different_variants_affecting_this_nucleotide_(c.72+1G>A_and_c.72+1G>C_)_have_been_reported_in_individuals_affected_with_paraganglioma_and_pheochromocytoma_(PMID:_19454582,_19802898),_indicating_that_this_nucleotide_may_be_crucial_for_normal_mRNA_splicing._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_SDHB_are_known_to_be_pathogenic_(PMID:_19454582,_19802898)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_SDHB_c.72+1G>T_variant_(rs587782703)_is_reported_in_the_literature_in_individuals_affected_with_pheochromocytoma_(Benn_2006,_Timmers_2007,_Tsang_2014),_paraganglioma_(Brouwers_2006),_gastrointestinal_tumor_(Pasini_2008,_McWhinney_2008),_and_renal_cell_carcinoma_(Schrader_2016)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_142764),_and_is_absent_from_general_population_databases_(Exome_Variant_Server,_Genome_Aggregation_Database),_indicating_it_is_not_a_common_polymorphism._This_variant_disrupts_the_canonical_splice_donor_site_of_intron_1,_which_is_likely_to_negatively_impact_gene_function,_and_functional_analyses_of_patient_mRNA_shows_aberrant_splicing_(Pasini_2008)._Additionally,_other_variants_at_this_nucleotide_(c.72+1G>A,_c.72+1G>C)_have_been_reported_in_individuals_with_pheochromocytoma_or_paraganglioma_and_are_considered_pathogenic_(Burnichon_2009,_Ricketts_2010)._Based_on_available_information,_the_c.72+1G>T_variant_is_considered_to_be_pathogenic._References:_Benn_DE_et_al._Clinical_presentation_and_penetrance_of_pheochromocytoma/paraganglioma_syndromes._J_Clin_Endocrinol_Metab._2006_Mar:91(3):827-36._Brouwers_FM_et_al._High_frequency_of_SDHB_germline_mutations_in_patients_with_malignant_catecholamine-producing_paragangliomas:_implications_for_genetic_testing._J_Clin_Endocrinol_Metab._2006_Nov:91(11):4505-9._Burnichon_N_et_al._The_succinate_dehydrogenase_genetic_testing_in_a_large_prospective_series_of_patients_with_paragangliomas._J_Clin_Endocrinol_Metab._2009_Aug:94(8):2817-27._McWhinney_SR_et_al._Familial_gastrointestinal_stromal_tumors_and_germ-line_mutations._N_Engl_J_Med._2007_Sep_6:357(10):1054-6._Pasini_B_et_al._Clinical_and_molecular_genetics_of_patients_with_the_Carney-Stratakis_syndrome_and_germline_mutations_of_the_genes_coding_for_the_succinate_dehydrogenase_subunits_SDHB,_SDHC,_and_SDHD._Eur_J_Hum_Genet._2008_Jan:16(1):79-88._Ricketts_CJ_et_al._Tumor_risks_and_genotype-phenotype-proteotype_analysis_in_358_patients_with_germline_mutations_in_SDHB_and_SDHD._Hum_Mutat._2010_Jan:31(1):41-51._Schrader_KA_et_al._Germline_Variants_in_Targeted_Tumor_Sequencing_Using_Matched_Normal_DNA._JAMA_Oncol._2016_Jan:2(1):104-11._Timmers_HJ_et_al._Clinical_presentations,_biochemical_phenotypes,_and_genotype-phenotype_correlations_in_patients_with_succinate_dehydrogenase_subunit_B-associated_pheochromocytomas_and_paragangliomas._J_Clin_Endocrinol_Metab._2007_Mar:92(3):779-86._Tsang_VH_et_al._Overexpression_of_miR-210_is_associated_with_SDH-related_pheochromocytomas,_paragangliomas,_and_gastrointestinal_stromal_tumours._Endocr_Relat_Cancer._2014_May_6:21(3):415-26.
NM_003000.2:c.72+1G>A	SDHB	splice_donor_variant	98496	1	NA	NA	-	-	-	-	428927	420751	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000001.10:g.17380442C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	SDHB:6390	SO:0001575|splice_donor_variant	1	587782703	-	Ambry_Genetics	Pathogenic	2018-06-28	2020-02-26	_single_submitter	germline	SCV000581207	Hereditary_cancer-predisposing_syndrome	_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Well-characterized_mutation_at_same_position
NM_001128425.1:c.1227_1228dup	MUTYH	frameshift_variant	102544	5	15424	1	-	-	-	-	127831	133288	Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45797188_45797189dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	Illumina:897451	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	587780078	-	Ambry_Genetics|Color|Pathway_Genomics|Invitae|GeneReviews|Counsyl|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Illumina_Clinical_Services_Laboratory,Illumina|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-07-27|2016-02-17|2014-07-24|2018-12-28|2019-10-08|2015-10-23|2016-08-15|2017-04-28|2017-01-27|2018-01-30|2017-12-15|2016-10-28	2020-02-26|2017-10-26|2014-08-08|2019-03-28|2019-12-13|2017-06-22|2019-03-21|2019-02-01|2017-07-13|2018-09-19|2018-08-31|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000184139|SCV000685556|SCV000189963|SCV000166444|SCV000246167|SCV000678199|SCV000712103|SCV000915414|SCV000149658|SCV000859446|SCV000888298|SCV000697671	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Carcinoma_of_colon|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided|not_provided|MUTYH-associated_polyposis	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu410Glyfs*43)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780078,_ExAC_0.04%)._This_particular_variant_has_been_observed_in_individuals_affected_with_polyposis,_colorectal_cancer,_breast_cancer,_and_cervical_cancer_(PMID:_15188161,_19531215,_19732775,_15366000)._This_variant_is_also_known_as_c.1186_1187insGG_(p.Glu396GlyfsX43)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127831)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||The_p.Glu410fs_variant_in_MUTYH_has_been_previously_reported_as_heterozygous_in_2_individuals_with_Lynch_syndrome_and_as_homozygous_or_compound_heterozygous_in_11_individuals_with_MUTYH-associated_polyposis_(MAP:_Venesio_2004,_Vogt_2009,_Da_mmak_2012,_Ruggieri_2013,_Yurgelun_2015)._It_segregated_with_disease_in_2_affect_ed_individuals_from_2_families_(Dammak_2012)._In_vitro_functional_studies_provid_e_some_evidence_that_the_p.Glu410fs_variant_may_impact_protein_function_(Ruggier_i_2013)._It_has_been_identified_in_30/34416_Latino_chromosomes_by_the_Genome_Agg_regation_Database_(gnomAD,_http://gnomad.broadinstitute.org/:_dbSNP_rs587780078)_._Although_this_variant_has_been_seen_in_the_general_population,_its_frequency_i_s_low_enough_to_be_consistent_with_a_recessive_carrier_frequency._This_variant_i_s_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequenc_e_beginning_at_position_410_and_leads_to_a_premature_termination_codon_43_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_ab_sent_protein._Homozygous_loss_of_function_of_the_MUTYH_gene_is_an_established_di_sease_mechanism_in_individuals_with_MAP._In_summary,_this_variant_meets_criteri_a_to_be_classified_as_pathogenic_for_FAP_in_an_autosomal_recessive_manner_based_upon_predicted_impact_to_the_protein,_presence_in_multiple_affected_individuals,_and_functional_studies._ACMG/AMP_Criteria_applied:_PVS1,_PS4,_PP3_supporting_(R_ichards_2015).|The_MUTYH_c.1185_1186dupGG_(p.Glu396GlyfsTer43)_variant_results_in_a_frameshift_and_is_predicted_to_result_in_premature_termination_of_the_protein._The_p.Glu396GlyfsTer43_variant_has_been_reported_in_two_studies_in_which_it_is_found_in_a_total_of_three_individuals_with_MYH-associated_polyposis,_including_in_two_in_a_compound_heterozygous_state_and_in_one_in_a_heterozygous_state_(Nielson_et_al._2005:_LeJeune_et_al._2006)._The_p.Glu396GlyfsTer43_variant_was_absent_from_50_controls_and_is_reported_at_a_frequency_of_0.00043_in_the_Latino_population_of_the_Exome_Aggregation_Consortium._Based_on_the_evidence_and_potential_impact_of_frameshift_variants,_the_p.Glu396GlyfsTer43_variant_is_classified_as_likely_pathogenic_for_MYH-associated_polyposis._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|This_pathogenic_variant_is_denoted_MUTYH_c.1227_1228dupGG_at_the_cDNA_level_and_p.Glu410GlyfsX43_(E410GfsX43)_at_the_protein_level._The_normal_sequence_with_the_bases_that_are_duplicated_in_brackets_is_CCTG[dupGG]AGCC._The_duplication_causes_a_frameshift,_changing_a_Glutamic_Acid_to_a_Glycine_at_codon_410,_and_creating_a_premature_stop_codon_at_position_43_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MUTYH_c.1227_1228dupGG,_previously_reported_as_c.1186_1187insGG_and_1187insGG_using_an_alternate_transcript,_has_been_reported_in_both_the_homozygous_and_compound_heterozygous_state_in_patients_with_polyposis_and/or_early-onset_colorectal_cancer_(Venesio_2004,_Vogt_2009,_Abdelmaksoud-Dammak_2012)._We_consider_MUTYH_c.1227_1228dupGG_to_be_pathogenic.|||Variant_summary:_The_MUTYH_c.1227_1228dupGG_(p.Glu410Glyfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MUTYH_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_likely_pathogenic_by_our_laboratory_(e.g.c.1435G>T/p.Glu479X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_7/120274_control_chromosomes_at_a_frequency_of_0.0000582,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MUTYH_variant_(0.0045644)._This_variant_has_been_reported_in_numerous_MAP_patients_and_colorectal_cancer_patients._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.
NM_001128425.1:c.1187-2A>G	MUTYH	splice_acceptor_variant	102048	4	15426	1	-	-	-	-	141282	150996	Neoplasm_of_stomach|Pilomatrixoma|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	Human_Phenotype_Ontology:HP:0006753,MeSH:D013274,MedGen:C0038356,OMIM:613659,SNOMED_CT:126824007|Human_Phenotype_Ontology:HP:0030434,MeSH:D018296,MedGen:C0206711,OMIM:132600,Orphanet:ORPHA91414|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45797230T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:755636	-	MUTYH:4595	SO:0001574|splice_acceptor_variant	1	587781628	-	Ambry_Genetics|Color|Pathway_Genomics|Illumina_Clinical_Services_Laboratory,Illumina|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|GeneDx|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-09|2017-02-06|2014-10-30|2016-06-14|2018-12-14|2016-03-18|2018-07-06|2018-10-31	2020-02-26|2017-10-26|2015-05-28|2016-10-18|2019-03-28|2019-03-21|2019-01-29|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown	SCV000184535|SCV000685552|SCV000223785|SCV000357894|SCV000545702|SCV000711779|SCV000568579|SCV000894023	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Carcinoma_of_colon|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|MYH-associated_polyposis/Pilomatrixoma/Neoplasm_of_stomach	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_splicing_assay_data_in_support_of_pathogenicity:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|||The_c.1187-2A>G_variant,_also_referred_to_as_c.1145-2A>G_and_IVS12-2A>G,_occurs_in_a_canonical_splice_site_(acceptor)_and_is_therefore_predicted_to_disrupt_or_distort_the_normal_gene_product._Across_three_studies,_this_variant_was_reported_in_three_colorectal_cancer_patients,_including_two_patients_who_carried_the_variant_in_a_compound_heterozygous_state_with_a_second_known_pathogenic_variant_and_in_one_patient_who_was_heterozygous_for_the_c.1187-2A>G_variant_(Wang_et_al._2004:_Eliason_et_al._2005:_Farrington_et_al._2005)._The_variant_was_absent_from_1845_control_individuals_but_is_reported_at_a_frequency_of_0.00003_in_the_European_(Non-Finnish)_population_of_the_Exome_Aggregation_Consortium._This_frequency_is_based_on_only_two_alleles_so_it_is_presumed_to_be_rare._RNA_transcript_analysis_of_RNA_from_one_of_the_compound_heterozygous_patients_revealed_only_the_missense_variant_transcript_and_no_wild_type_transcript,_indicating_that_the_splice_acceptor_variant_is_a_null_allele_(Farrington_et_al._2005)._Based_on_the_evidence_and_due_to_the_potential_impact_of_splice_acceptor_variants,_the_c.1187-2A>G_variant_is_classified_as_likely_pathogenic_for_MYH-associated_polyposis.|This_sequence_change_affects_an_acceptor_splice_site_in_intron_12_of_the_MUTYH_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781628,_ExAC_0.003%)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_a_pathogenic_variant_in_individuals_affected_withÂ¬â€ polyposis_and/or_colon/rectum_cancer_(PMID:_15931596,_15236166).Â¬â€ In_the_one_case_with_a_confirmed_adenocarcinoma_of_the_colon_or_rectum,_the_two_variants_were_confirmed_to_be_in_trans_(PMID:_15931596).Â¬â€ This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease.Â¬â€ This_variant_is_also_known_as_9639A>G_and_IVS12-2A>G_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141282)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_c.1187-2A>G_variant_has_been_reported_in_2_individuals_with_colorectal_cance_r_(Wang_2004,_Eliason_2005)_and_has_also_been_identified_in_2/65402_European_chr_omosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.o_rg:_dbSNP_rs587781628)._However,_this_frequency_is_low_enough_to_be_consistent_w_ith_the_frequency_of_MUTYH-related_attenuated_familial_adenomatous_polyposis_in_the_general_population._This_variant_occurs_in_the_invariant_region_(+/-_1,2)_of_the_splice_consensus_sequence_and_is_predicted_to_cause_altered_splicing_leadin_g_to_an_abnormal_or_absent_protein._In_summary,_this_variant_meets_criteria_to_b_e_classified_as_pathogenic_for_MUTYH-related_attenuated_familial_adenomatous_pol_yposis_in_an_autosomal_recessive_manner_based_upon_its_predict_impact_to_the_pro_tein._ACMG/AMP_criteria_applied:_PVS1,_PM3,_PS4_P.|This_variant_is_denoted_MUTYH_c.1187-2A>G_or_IVS12-2A>G_and_consists_of_an_A>G_nucleotide_substitution_at_the_-2_position_of_intron_12_of_the_MUTYH_gene._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant,_also_reported_as_MUTYH_9639A>G_using_an_alternate_transcript,_has_been_reported_in_the_compound_heterozygous_state_with_a_second_pathogenic_variant_in_at_least_two_individuals_with_colorectal_cancer,_one_of_whom_also_had_20-50_polyps_(Wang_2004,_Farrington_2005)._Farrington_et_al._(2005)_confirmed_this_variant_to_be_in_trans_with_a_pathogenic_variant_in_one_patient_with_colorectal_cancer_and_reported_that_this_variant_led_to_nonsense_mediated_mRNA_decay_by_cDNA_analysis_utilizing_patient_RNA._Based_on_the_currently_available_information,_we_consider_MUTYH_c.1187-2A>G_to_be_pathogenic.|
NM_001128425.1:c.1171C>T	MUTYH	stop_gained	102162	3	NA	NA	5	0	rs587783057	Carcinoma of colon	156509	166274	Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45797348G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	587783057	-	Pathway_Genomics|Counsyl|Invitae|Mendelics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2014-07-24|2016-06-08|2018-12-18|2018-07-02|2018-08-06|2017-11-24|2018-05-31|2016-11-28	2014-08-08|2016-11-23|2019-03-28|2018-08-20|2019-01-29|2018-08-31|2020-02-26|2017-10-26	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|unknown|germline|germline|germline|germline	SCV000189962|SCV000487361|SCV000545766|SCV000837752|SCV000490628|SCV000888297|SCV000670131|SCV000685548	Carcinoma_of_colon|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_391_(p.Gln391*)_of_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587783057,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_MUTYH-associated_polyposis_in_the_homozygous_state_or_in_combination_with_another_pathogenic_variant_(PMID:_16140997,_19732775,_24444654)._This_variant_is_also_known_as_c.1129C>T_(p.Q377X)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_156509)._An_experimental_study_has_shown_that_this_missense_change_disrupts_MUTYH_protein_function_and_results_in_reduced_glycosylase_activity_and_DNA_binding_activity._(PMID:_18534194)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_MUTYH_c.1171C>T_at_the_cDNA_level_and_p.Gln391Ter_(Q391X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_reported_as_MUTYH_Gln377Ter_using_an_alternate_reference_sequence_(NM_001048171.1),_has_been_reported_in_the_homozygous_or_compound_heterozygous_state_in_several_individuals_with_multiple_adenomatous_polyps_and/or_colorectal_cancer_(Nielsen_2005,_Aretz_2006,_Croitoru_2007,_Cleary_2009),_and_functional_studies_by_Ali_et._al._(2008)_demonstrated_severely_defective_glycosylase_and_DNA_binding_activities._Based_on_currently_available_evidence,_we_consider_MUTYH_Gln391Ter_to_be_pathogenic.||Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion):Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|
NM_001128425.1:c.1147del	MUTYH	frameshift_variant	102208	10	15422	2	-	-	-	-	134860	138599	Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|Familial_colorectal_cancer|not_specified|not_provided	-	MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN029768|MedGen:CN169374|MedGen:CN517202	-	NC_000001.10:g.45797374del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	Illumina:719162|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2834333	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	5	587778536	-	ITMI|Pathway_Genomics|Ambry_Genetics|Color|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Counsyl|Mendelics|Illumina_Clinical_Services_Laboratory,Illumina|GeneReviews|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Genomic_Research_Center,_Shahid_Beheshti_University_of_Medical_Sciences|Integrated_Genetics/Laboratory_Corporation_of_America	not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2013-09-19|2014-07-24|2018-06-28|2016-06-23|2018-12-25|2014-10-27|2015-11-06|2018-07-02|2018-10-04|2019-10-08|2018-08-15|2017-03-23|2017-12-18|2017-09-12	2014-05-29|2014-08-08|2020-02-26|2017-10-26|2019-03-28|2017-04-19|2017-06-22|2018-08-20|2019-02-01|2019-12-13|2019-01-29|2018-08-31|2017-12-18|2019-04-24	no_assertion_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|inherited|germline	SCV000085789|SCV000189959|SCV000214918|SCV000685545|SCV000253862|SCV000592709|SCV000678198|SCV000837754|SCV000915416|SCV001167334|SCV000292629|SCV000601627|SCV000746949|SCV000917797	not_specified|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided|Familial_colorectal_cancer|MUTYH-associated_polyposis	||Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion):Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ala385Profs*23)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587778536,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_affected_with_multiple_colorectal_adenomas_(PMID:Â¬â€ 12606733,Â¬â€ 23108399,Â¬â€ 19732775,Â¬â€ 23561487)._This_variant_is_also_known_as_c.1103delC_and_c.1145delC_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_134860)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||The_MUTYH_c.1105delC_(p.Ala371ProfsTer23)_variant_causes_a_frameshift,_and_is_predicted_to_result_in_premature_termination_of_the_protein._Truncating_variants_in_the_MUTYH_gene_are_known_to_be_disease-causing._Across_five_studies_as_a_representation_of_the_available_literature,_the_p.Ala371ProfsTer23_variant_was_identified_in_a_total_of_17_individuals_with_polyposis_including_sixteen_in_a_compound_heterozygous_state_and_one_in_a_homozygous_state_(Sieber_et_al._2003:_Nielsen_et_al._2005:_Aretz_et_al._2006:_Middeldorp_et_al._2008:_Laarabi_et_al._2012)._The_variant_was_absent_from_223_control_subjects_and_is_reported_at_a_frequency_of_0.001212_in_the_European_American_population_of_the_Exome_Sequencing_Project._Functional_studies_demonstrate_that_the_p.Ala371ProfsTer23_variant_results_in_a_truncated_protein_expressed_at_<1%_of_wild_type_levels_which_is_completely_devoid_of_glycosylase_and_DNA_binding_activities._These_results_are_supported_by_position_of_the_variant_with_respect_to_the_domain_structure_of_the_protein_where_the_variant_is_predicted_to_cause_the_loss_of_the_catalytic_domain_of_the_enzyme_(Ali_et_al._2008:_Ruggierie_et_al._2013)._Based_on_the_collective_evidence,_the_p.Ala371ProfsTer23_variant_is_classified_as_pathogenic_for_MYH-associated_polyposis._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.||This_deletion_of_one_nucleotide_in_MUTYH_is_denoted_c.1147delC_at_the_cDNA_level_and_p.Ala385ProfsX23_(A385PfsX23)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_GGCC[C]TTGG._The_deletion_causes_a_frameshift,_which_changes_an_Alanine_to_a_Proline_at_codon_385,_and_creates_a_premature_stop_codon_at_position_23_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MUTYH_c.1147delC,_also_published_as_MUTYH_c.1103delC,_c.1105delC,_c.1138delC,_and_c.1145delC,_has_been_reported_in_both_the_homozygous_and_compound_heterozygous_state_in_multiple_individuals_with_MUTYH-associated_polyposis_(Sieber_2003,_Aretz_2006,_Vogt_2009,_Nielsen_2009,_Giraldez_2010,_Morak_2010,_Pin_2013,_Ruggieri_2013,_Segui_2015)._Additionally,_Ali_et_al._(2008)_showed_that_MUTYH_c.1147delC_is_dysfunctional_with_respect_to_both_DNA_binding_and_base_excision_repair_activities_while_Ruggieri_et_al._(2013)_demonstrated_that_this_variant,_in_the_compound_heterozygous_state_with_a_second_truncating_MUTYH_variant,_was_associated_with_a_50%_decrease_in_MUTYH_expression_levels_when_compared_to_wild-type._We_therefore_consider_MUTYH_c.1147delC_to_be_pathogenic.|||Variant_summary:_The_MUTYH_c.1147delC_(p.Ala385ProfsX23)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MUTYH_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.1227_1228dupGG_[p.Glu410fsX43]_and_c.1435G>T_[p.Glu479X])._MutationTaster_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_9/119682_control_chromosomes_at_a_frequency_of_0.0000752,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MUTYH_variant_(0.0045644)._The_variant_has_been_identified_in_numerous_MAP_patients,_including_homozygous_family_members_(Vogt_2009)._In_addition,_functional_studies_show_that_the_variant_is_completely_defective_in_glycosylase_and_DNA_binding_activities_(Ali_2008)._Multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.
NM_001128425.1:c.1101del	MUTYH	frameshift_variant	102194	1	NA	NA	-	-	-	-	491999	483124	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000001.10:g.45797423del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	768130289	-	Color|Ambry_Genetics	Pathogenic|Pathogenic	2016-08-05|2018-07-25	2017-12-21|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000690499|SCV001178377	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense):Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous
NM_001128425.1:c.1012C>T	MUTYH	stop_gained	94524	2	15422	1	5&5	1&1	rs587780082	Hereditary cancer-predisposing syndrome&not provided	127835	133292	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45797507G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	587780082	-	Ambry_Genetics|Color|GeneDx|PreventionGenetics,PreventionGenetics|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|CSER__CC_NCGL,_University_of_Washington	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-07-04|2016-03-25|2018-11-27|2016-12-30|2018-11-28|0000-00-00|2016-10-01	2020-02-26|2017-10-26|2019-01-29|2018-01-29|2019-03-28|2017-04-19|2017-10-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000216400|SCV000685534|SCV000149662|SCV000806334|SCV000545804|SCV000592706|SCV000700131	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|MYH-associated_polyposis|MYH-associated_polyposis|MUTYH-associated_polyposis	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_MUTYH_c.1012C>T_at_the_cDNA_level_and_p.Gln338Ter_(Q338X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_c.970C>T_(p.Gln324Ter)_and_c.928C>T_(p.Gln310Ter)_using_alternate_transcripts,_has_been_reported_in_the_compound_heterozygous_state_in_several_individuals_with_autosomal_recessive_MUTYH-Associated_Polyposis_(Sampson_2003,_Aretz_2006,_Bouguen_2007,_Cattaneo_2008,_Vogt_2009)._In_addition,_a_functional_study_demonstrated_that_this_variant_is_associated_with_severely_defective_DNA_glyosylase_activity_(Goto_2010)._We_therefore_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln338*)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780082,_ExAC_0.1%)._This_variant_has_been_reported_in_individuals_affected_with_MUTYH-associated_polyposis_(MAP)_(PMID:_12853198,_2084865,_19732775,_16557584,_24470512)._This_variant_is_also_known_as_Q310X_and_Q324X_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127835)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_20663686,Â¬â€ 18534194)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Found_in_patient_having_exome_sequencing_due_to_suspicion_for_hereditary_colon_cancer_and/or_polyps._Patient_is_a_53_year_old_male_diagnosed_with_colon_cancer_at_age_47._Patient_is_compound_heterozygous_for_a_second_pathogenic_variant_in_MUTYH._This_interpretation_considers_GERP_score_and_allele_frequency_data,_in_addition_to_published_reports_of_the_variant_in_the_literature,_available_at_the_time_of_review.
NM_001128425.1:c.940C>T	MUTYH	stop_gained	102746	3	NA	NA	5	1	rs587781338	Hereditary cancer-predisposing syndrome	140876	150590	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45797752G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	587781338	-	Ambry_Genetics|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic	2017-10-03|2017-04-17|2018-12-21	2020-02-26|2019-01-29|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000183814|SCV000568581|SCV000639366	Hereditary_cancer-predisposing_syndrome|not_provided|MYH-associated_polyposis	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_variant_is_denoted_MUTYH_c.940C>T_at_the_cDNA_level_and_p.Gln314Ter_(Q314X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_MUTYH_Gln300Ter_(Q300X)_using_alternate_nomenclature,_has_been_reported_in_the_compound_heterozygous_state_in_at_least_one_individual_with_polyposis_and_in_the_heterozygous_state_in_at_least_one_family_with_familial_prostate_cancer_(Eliason_2005,_Leongamornlert_2014)._This_variant_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln314*)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_particular_variant_has_been_reported_to_co-occur_with_a_second_pathogenic_MUTYH_variant_(p.Tyr179Cys,_also_called_Y165C)_in_an_individual_affected_with_MUTYH-associated_polyposis_(PMID:_15635083)._It_has_also_been_observed_in_an_individual_with_a_personal_and_family_history_of_prostate_cancer_(PMID:_24556621)._This_variant_is_also_known_as_Q300X_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140876)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_001128425.1:c.628C>T	MUTYH	stop_gained	102740	1	NA	NA	5	1	rs376561094	Hereditary cancer-predisposing syndrome	233460	232257	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45798308G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	376561094	-	Ambry_Genetics|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic	2018-03-23|2017-09-25|2017-04-25	2020-02-26|2019-01-29|2017-10-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000277834|SCV000517268|SCV000639348	Hereditary_cancer-predisposing_syndrome|not_provided|MYH-associated_polyposis	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_pathogenic_variant_is_denoted_MUTYH_c.628C>T_at_the_cDNA_level_and_p.Gln210Ter_(Q210X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_MUTYH_c.586C>T_(Q196X)_using_an_alternate_transcript,_has_been_reported_in_the_compound_heterozygous_state_in_at_least_one_individual_with_multiple_colorectal_adenomatous_polyps_(Aretz_2006,_Nielsen_2009)_and_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_210_(p.Gln210*)_of_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_compound_heterozygous_state_with_pathogenic_variants_in_individuals_affected_with_MUTYH-associated_polyposis_(PMID:_16557584,_19732775)._This_variant_is_also_known_as_Q196X_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_001128425.1:c.586G>T	MUTYH	stop_gained	102748	1	NA	NA	-	-	-	-	406822	391331	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45798350C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:209628	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	745921592	-	Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|GeneDx|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2016-09-28|2015-11-20|2017-11-21|2018-04-30|2019-04-30|2018-08-13	2017-03-14|2017-04-19|2019-01-29|2018-10-10|2020-02-26|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000545711|SCV000592688|SCV000567562|SCV000885750|SCV000662650|SCV000913516	MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_196_(p.Glu196*)_of_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Truncating_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_20663686,_18534194)._This_variant_has_been_found_in_the_compound_heterozygous_state_with_a_pathogenic_MUTYH_variant_in_an_individual_with_suspected_familial_adenomatous_polyposis_(PMD:_15635083)._This_variant_is_also_known_as_E182X_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_MUTYH_c.586G>T_at_the_cDNA_level_and_p.Glu196Ter_(E196X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_MUTYH_Glu182Ter_(E182X)_using_alternate_nomenclature,_has_been_reported_in_the_compound_heterozygous_state_with_a_known_pathogenic_MUTYH_variant_in_an_individual_with_a_history_suspicious_for_familial_adenomatous_polyposis_and_negative_APC_testing_(Eliason_2005)._We_consider_this_variant_to_be_pathogenic.|The_MUTYH_c.544G>T:_p.Glu182Ter_variant,_also_known_as_c.586G>T:_p.Glu196Ter_for_transcript_NM_001128425.1,_is_reported_in_the_medical_literature_in_at_least_one_individual_with_suspected_polyposis_with_an_additional_pathogenic_variant._The_variant_is_reported_as_pathogenic_by_several_sources_in_the_ClinVar_database_(Variation_ID:_406822)_and_only_reported_in_1_out_of_246262_alleles_in_the_Genome_Aggregation_Database,_indicating_it_is_not_a_common_polymorphism._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Loss_of_function_variants_are_a_known_pathogenic_mechanism_in_MUTYH-associated_polyposis_(Nielsen_2011)._Considering_available_information,_this_variant_is_classified_as_pathogenic._References:_Eliason_K_et_al._The_potential_for_increased_clinical_sensitivity_in_genetic_testing_for_polyposis_colorectal_cancer_through_the_analysis_of_MYH_mutations_in_North_American_patients._J_Med_Genet._2005_Jan:42(1):95-6._Nielsen_M_et_al._MUTYH-associated_polyposis_(MAP)._Crit_Rev_Oncol_Hematol._2011_Jul:79(1):1-16.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_001128425.1:c.577-1G>T	MUTYH	splice_acceptor_variant	102748	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_001128425.1:c.563_576+1del	MUTYH	splice_donor_variant,coding_sequence_variant	102750	1	NA	NA	-	-	-	-	533312	516007	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_specified	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN169374	-	NC_000001.10:g.45798437_45798451del	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(2)	-	Deletion	SO:0000159	-	-	MUTYH:4595	SO:0001575|splice_donor_variant	1	766553845	-	Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics	Uncertain_significance|Uncertain_significance|Likely_pathogenic	2017-10-04|2018-08-01|2019-07-01	2018-04-02|2019-04-24|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000761970|SCV000917810|SCV001186341	MYH-associated_polyposis|not_specified|Hereditary_cancer-predisposing_syndrome	This_sequence_change_deletes_15_nucleotides_from_exon_7_and_intron_7_of_the_MUTYH_mRNA_(c.563_576+1del)._This_leads_to_the_deletion_of_5_amino_acid_residues_in_the_MUTYH_protein_(p.Glu188_Lys192del)_but_otherwise_preserves_the_adjacent_donor_splice_site_and_the_integrity_of_the_reading_frame._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MUTYH-related_disease._Experimental_studies_and_prediction_algorithms_are_not_available_for_this_variant,_and_the_functional_significance_of_the_deleted_amino_acids_is_currently_unknown._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|Variant_summary:_MUTYH_c.563_576+1del_involves_the_deletion_of_15_nucleotides_from_exon_7_and_intron_7,_leading_to_an_in-frame_deletion_of_5_amino_acids_(p.Glu188_Lys192del)._5/5_computational_tools_predict_no_significant_impact_on_normal_splicing._However,_these_predictions_have_yet_to_be_confirmed_by_functional_studies._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_246264_control_chromosomes_(gnomAD)._The_available_data_on_variant_occurrences_in_the_general_population_are_insufficient_to_allow_any_conclusion_about_variant_significance._To_our_knowledge,_no_occurrence_of_c.563_576+1del_in_individuals_affected_with_MUTYH-associated_Polyposis_and_no_experimental_evidence_demonstrating_its_impact_on_protein_function_have_been_reported._A_ClinVar_submission_from_another_clinical_diagnostic_laboratory_(evaluation_after_2014)_cites_the_variant_as_uncertain_significance._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_uncertain_significance.|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_splicing_assay_data_in_support_of_pathogenicity:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous
NM_001128425.1:c.504+2T>C	MUTYH	splice_donor_variant	102076	1	NA	NA	-	-	-	-	142805	152519	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798	-	NC_000001.10:g.45798588A>G	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001575|splice_donor_variant	1	587782730	-	Ambry_Genetics|Invitae	Likely_pathogenic|Likely_pathogenic	2014-04-11|2017-03-07	2020-02-26|2017-10-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000187310|SCV000639329	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis	|This_sequence_change_affects_a_donor_splice_site_in_intron_6_of_the_MUTYH_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_a_MUTYH-related_disease._In_summary,_donor_and_acceptor_splice_site_variants_are_typically_loss-of-function_(PMID:_16199547),_and_loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_20663686,_18534194)._However,_without_additional_functional_and/or_genetic_data,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_001128425.1:c.379del	MUTYH	frameshift_variant	102644	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_001128425.1:c.358del	MUTYH	frameshift_variant	102686	1	NA	NA	-	-	-	-	186778	181725	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798	-	NC_000001.10:g.45798987del	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	Deletion	SO:0000159	Illumina:1647846	-	MUTYH:4595	SO:0001582|initiatior_codon_variant,SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	786203213	-	Illumina|Invitae	Pathogenic|Uncertain_significance|Pathogenic	2019-06-13|2018-03-01|2018-11-08	2020-02-26|2019-02-01|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000217221|SCV000915417|SCV000955048	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MYH-associated_polyposis	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|The_MUTYH_c.316delG_(p.Glu106ArgfsTer26)_variant_results_in_a_frameshift,_and_is_predicted_to_result_in_premature_termination_of_the_protein._It_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population._It_had_not_been_previously_curated_by_ICSL_or_reported_in_the_Human_Gene_Mutation_Database_(HGMD:_prior_to_June_1st,_2018)_and_was_therefore_a_candidate_for_classification_through_an_automated_scoring_system._Utilizing_variant_allele_frequency,_disease_prevalence_and_penetrance_estimates,_and_inheritance_mode,_an_automated_score_was_calculated_to_assess_if_this_variant_is_too_frequent_to_cause_the_disease._Based_on_the_score_for_this_variant,_it_could_not_be_ruled_out_of_causing_disease_and_therefore_its_association_with_disease_required_further_investigation._A_literature_search_was_performed_for_the_gene_and_cDNA_change,_and_amino_acid_change._No_publications_were_found_based_on_this_search._Due_to_the_potential_impact_of_frameshift_variants_and_the_lack_of_clarifying_evidence,_this_variant_is_classified_as_a_variant_of_unknown_significance_but_suspicious_for_pathogenicity_for_MYH-associated_polyposis.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu120Argfs*26)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MUTYH-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186778)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_001128425.1:c.312C>A	MUTYH	stop_gained	102746	10	15424	0	5&5	1&1	rs121908380	MYH-associated polyposis&Hereditary cancer-predisposing syndrome	5296	20335	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|Familial_colorectal_cancer|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN029768|MedGen:CN517202	-	NC_000001.10:g.45799121G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:604933.0004	-	MUTYH:4595	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	5	121908380	-	OMIM|Invitae|GeneReviews|Counsyl|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Genomic_Research_Center,_Shahid_Beheshti_University_of_Medical_Sciences|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Genomic_Research_Center,_Shahid_Beheshti_University_of_Medical_Sciences|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-11-01|2018-12-28|2019-10-08|2015-12-22|2016-11-23|2018-03-05|2018-11-05|2017-03-28|2017-08-17|2019-01-20|2018-03-05|2017-11-24	2015-04-24|2019-03-28|2019-12-13|2016-11-23|2017-04-19|2018-03-05|2020-02-26|2017-10-26|2019-01-29|2020-03-06|2018-03-05|2019-04-24	no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|inherited|germline|germline|germline|germline|inherited|germline	SCV000025799|SCV000218794|SCV000246163|SCV000487327|SCV000592679|SCV000784261|SCV000213540|SCV000685609|SCV000567387|SCV001134474|SCV000784260|SCV000919790	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Familial_colorectal_cancer|MUTYH-associated_polyposis	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr104*)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_has_been_observed_in_an_individual_affected_with_colorectal_cancer_(PMID:_24444654)_and_as_homozygous_in_several_individuals_affected_with_MUTYH-associated_polyposis_syndrome_(PMID:_12393807,_19732775)._This_variant_is_also_known_as_p.Tyr90*_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_5296)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_MUTYH_c.312C>A_at_the_cDNA_level_and_p.Tyr104Ter_(Y104X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_MUTYH_c.270C>A_or_Y90X_using_alternate_nomenclature,_has_been_reported_in_the_homozygous_or_compound_heterozygous_state_with_another_pathogenic_MUTYH_variant_in_several_individuals_with_adenomatous_polyposis_and/or_colorectal_cancer_(Jones_2002,_Croitoru_2004,_Gismondi_2004,_Croitoru_2007,_Cattaneo_2007)._Functional_studies_have_demonstrated_that_this_variant_abrogates_glycosylase_and_DNA_binding_activities_(Ali_2008)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_multiple_symptomatic_patients,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity._Occurs_in_multiple_cases_with_a_recessive_pathogenic_variant_in_the_same_gene._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.||Variant_summary:_The_MUTYH_c.312C>A_(p.Tyr104X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MUTYH_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.1147delC,_p.Ala385fsX23:_c.1227_1228dupGG,_p.Glu410fsX43)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_31/277196_control_chromosomes_at_a_frequency_of_0.0001118,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MUTYH_variant_(0.0045644)._The_variant_has_been_reported_in_numerous_affected_individuals_in_the_literature_in_the_homozygous_and_compound_heterozygous_state,_and_has_been_shown_to_be_completely_devoid_of_both_glycosylase_and_DNA_binding_activities_(Ali_2008)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.
NM_001128425.1:c.309G>A	MUTYH	stop_gained	102750	1	NA	NA	5&5	1&1	rs748170941	Hereditary cancer-predisposing syndrome&MYH-associated polyposis	184976	181727	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45799124C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(1),Pathogenic(7),Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	Illumina:1648219	-	MUTYH:4595	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	748170941	-	Ambry_Genetics|Color|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Counsyl|Illumina_Clinical_Services_Laboratory,Illumina|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic	2018-05-09|2016-03-17|2018-12-20|2014-10-23|2017-03-15|2018-08-15|2018-12-10|2018-02-21|2017-11-24	2020-02-26|2017-12-21|2019-03-28|2017-04-19|2017-06-22|2019-02-01|2019-08-02|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|unknown|germline|germline	SCV000214957|SCV000690556|SCV000253865|SCV000592677|SCV000678197|SCV000915418|SCV000993569|SCV000617565|SCV000888311	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Trp103*)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs748170941,_ExAC_0.001%)._This_variant_has_been_reported_as_co-occurring_with_a_pathogenic_variant_(p.Gly396Asp,_also_known_as_G382D)_in_MUTYH_in_an_individual_with_adenomatous_polyposis_(PMID:_15761860)._This_variant_is_also_known_as_G267A_(W89X)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_184976)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||The_MUYTH_c.267G>A_(p.Trp89Ter)_variant_is_a_stop-gained_variant_that_is_predicted_to_result_in_premature_termination_of_the_protein._The_p.Trp89Ter_variant_has_been_reported_in_at_least_one_study_in_which_it_is_found_in_one_patient_in_a_compound_heterozygous_state_with_a_second_known_pathogenic_missense_variant_(Kairupan_et_al._2005)._The_female_proband_was_reported_to_have_more_than_50_polyps_at_34_years_of_age,_but_no_colorectal_cancer_or_other_types_of_cancer_at_the_time_of_study_(Kairupan_et_al._2005)._Control_data_are_unavailable_for_this_variant_which_is_reported_at_a_frequency_of_0.000015_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium,_however_this_is_based_on_a_single_allele_and_the_variant_is_presumed_to_be_rare._Based_on_the_available_evidence_and_potential_impact_of_stop-gained_variants,_the_p.Trp89Ter_variant_is_classified_as_a_variant_of_unknown_significance_but_suspicious_for_pathogenicity_for_MYH-associated_polyposis.||This_pathogenic_variant_is_denoted_MUTYH_c.309G>A_at_the_cDNA_level,_p.Trp103Ter_(W103X)_at_theprotein_level,_and_results_in_the_change_of_a_Tryptophan_to_Nonsense_(TGG>TGA)._This_variant,_also_published_asMUTYH_c.267G>A_(p.W89X)_using_alternate_nomenclature,_has_been_observed_in_at_least_one_individual_with_a_historyof_polyposis_who_was_also_found_to_harbor_a_known_pathogenic_MUTYH_variant_(Kairupan_2005)._MUTYH_Trp103Terwas_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(NHLBI_Exome_Sequencing_Project,_The1000_Genomes_Consortium_2015,_Lek_2016)._Based_on_currently_available_evidence,_we_consider_this_variant_to_bepathogenic._Of_note,_MUTYH-Associated_Polyposis_(MAP)_is_a_recessive_condition_associated_with_two_pathogenicvariants_on_opposite_chromosomes_in_MUTYH.|
NM_001128425.1:c.289C>T	MUTYH	stop_gained	102750	1	15424	0	5&5	1&1	rs138775799	Hereditary cancer-predisposing syndrome&not provided	140827	150541	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45799144G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:913701	-	MUTYH:4595	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	138775799	-	Illumina|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-02-02|2017-08-21|2018-04-02|2017-03-29|2018-12-20|2017-04-28|2017-11-09	2020-02-26|2018-11-06|2019-01-29|2018-08-31|2019-03-28|2019-02-01|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000172918|SCV000911727|SCV000293115|SCV000601644|SCV000545773|SCV000915419|SCV000919788	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|MYH-associated_polyposis|MYH-associated_polyposis|MUTYH-associated_polyposis	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_MUTYH_c.289C>T_at_the_cDNA_level_and_p.Arg97Ter_(R97X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_c.247C>T_(p.Arg83Ter)_and_c.205C>T_(p.Arg69Ter)_using_alternate_transcripts,_has_been_reported_in_the_compound_heterozygous_state_in_several_individuals_with_autosomal_recessive_MUTYH-Associated_Polyposis_and_in_the_heterozygous_state_in_several_individuals_with_colorectal_cancer_and_polyps_(Sieber_2003,_Aretz_2006,_Olschwang_2007,_Vogt_2009,_Morak_2010)._In_addition,_a_functional_study_demonstrated_that_MUTYH_Arg97Ter_is_associated_with_severely_impaired_glycosylase_activity_(Goto_2010)._We_therefore_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg97*)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs138775799,_ExAC_0.01%)._This_variant_has_been_reported_as_homozygous_or_compound_heterozygous_in_individuals_affected_with_MUTYH-associated_polyposis_(PMID:_19793053,_19732775,_20618354),_and_in_heterozygous_individuals_affected_with_colorectal_cancer_(PMID:_12606733,_17949294)._It_also_has_been_reported_in_an_individual_affected_with_Lynch_syndrome_who_also_carried_a_pathogenic_MSH6_variant_(PMID:_18301448)._This_variant_is_also_known_as_R83X_and_R69X_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140827)._An_experimental_study_has_shown_that_this_nonsense_change_severely_impacts_the_DNA_glycosylase_activity_of_the_MUTYH_protein_(PMID:_20848659)._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_MUTYH_c.247C>T_(p.Arg83Ter)_variant,_also_reported_as_c.289C>T_(p.Arg97Ter),_is_a_stop-gained_variant_that_is_predicted_to_result_in_premature_termination_of_the_protein._The_p.Arg83Ter_variant_has_been_reported_in_at_least_six_studies_in_which_it_is_found_in_at_least_six_individuals_with_MYH-associated_polyposis,_including_in_two_in_a_homozygous_state,_in_two_in_a_compound_heterozygous_state_with_a_missense_variant_on_the_second_allele,_and_in_two_in_a_heterozygous_state_with_a_second_variant_remaining_undetected_(Sieber_et_al._2003:_Aretz_et_al._2006:_Olschwang_et_al._2007:_Steinke_et_al._2008:_Filipe_et_al._2009:_Morak_et_al._2010)._One_of_the_individuals_who_was_heterozygous_for_the_p.Arg83Ter_variant_also_carried_a_known_pathogenic_variant_in_the_MSH6_gene_in_a_heterozygous_state_(Steinke_et_al._2008)._The_p.Arg83Ter_variant_was_absent_from_446_control_chromosomes_but_is_reported_at_a_frequency_of_0.00023_in_the_African_American_population_from_the_Exome_Sequencing_Project._This_is_based_on_two_alleles_in_a_region_of_good_sequence_coverage_so_the_variant_is_presumed_to_be_rare._In_vitro_functional_studies_demonstrated_that_the_adenine_DNA_glycosylase_activity_of_the_p.Arg83Ter_variant_protein_was_similar_to_background_levels_and_severely_impaired_compared_to_wild_type_(Goto_et_al._2010)._Based_on_the_evidence_from_the_literature_and_the_potential_impact_of_stop-gained_variants,_the_p.Arg83Ter_variant_is_classified_as_pathogenic_for_MYH-associated_polyposis._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|Variant_summary:_The_MUTYH_c.289C>T_(p.Arg97X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MUTYH_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_4/277650_control_chromosomes_at_a_frequency_of_0.0000144,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MUTYH_variant_(0.0045644)._This_variant_has_been_reported_in_multiple_affected_individuals._Functional_assay_showed_variant_with_extremely_severely_defective_DNA_glycosylase_activity_(Goto_2010)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.
NM_001128425.1:c.200del	MUTYH	frameshift_variant	102520	3	NA	NA	-	-	-	-	419735	405207	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45799234del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	MUTYH:4595	SO:0001627|intron_variant	1	746449748	-	GeneDx|Ambry_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Invitae	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2015-08-18|2018-06-29|2018-11-06|2018-11-28	2019-01-29|2020-02-26|2019-04-24|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000567734|SCV000581683|SCV000917812|SCV000940904	not_provided|Hereditary_cancer-predisposing_syndrome|MUTYH-associated_polyposis|MYH-associated_polyposis	This_deletion_of_one_nucleotide_in_MUTYH_is_denoted_c.200delG_at_the_cDNA_level_and_p.Gly67AlafsX24_(G67AfsX24)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_GCAG[G]CCTG._The_deletion_causes_a_frameshift,_which_changes_a_Glycine_to_an_Alanine_at_codon_67,_and_creates_a_premature_stop_codon_at_position_24_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._we_consider_this_variant_to_be_pathogenic.Although_this_variant_is_considered_pathogenic,_a_second_mutation,_as_would_be_required_for_expression_of_the_recessive_condition_MAP,_was_not_detected_in_this_individual._The_possibility_that_this_patient_harbors_a_second_disease-causing_MUTYH_mutation_that_is_undetectable_by_this_test_cannot_be_excluded._While_a_single_variant_in_the_MUTYH_gene_has_been_reported_in_association_with_a_slightly_increased_risk_for_colon_cancer,_endometrial_cancer,_and_breast_cancer,_particularly_among_those_with_a_family_history_of_colorectal_cancer_(Jenkins_2006,_Win_2011,_Rennert_2012),_there_are_conflicting_data_regarding_these_associations_(Santonocito_2011,_Out_2012)._MUTYH-associated_polyposis_(MAP)_is_an_autosomal_recessive_condition_caused_by_two_mutations_(one_affecting_each_allele)_in_the_MUTYH_gene_which_results_in_an_increased_risk_for_the_development_of_colon_cancer_and_colon_polyps._If_a_MUTYH_mutation_carrier'spartner_is_also_heterozygous_for_a_MUTYH_mutation,_the_risk_to_have_a_child_with_MAP_is_25%_with_each_pregnancy._One_study_from_the_UK_estimated_the_overall_carrier_frequency_for_any_MUTYH_mutation_to_be_about_2%_(Aretz_2010).|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|Variant_summary:_MUTYH_c.200delG_(p.Gly67AlafsX24)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.289C>T_(p.Arg97X),_c.312C>A_(p.Tyr104X),_and_c.1147delC_(p.Ala385fsX23))._The_variant_allele_was_found_at_a_frequency_of_1.6e-05_in_245776_control_chromosomes_(gnomAD)._To_our_knowledge,_no_occurrence_of_c.200delG_in_individuals_affected_with_MUTYH-associated_Polyposis_and_no_experimental_evidence_demonstrating_its_impact_on_protein_function_have_been_reported._Two_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gly67Alafs*24)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs746449748,_ExAC_0.003%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MUTYH-related_conditions._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_419735)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_create_or_strengthen_a_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_001128425.1:c.37-2A>G	MUTYH	splice_acceptor_variant	102734	1	NA	NA	-	-	-	-	560804	551823	MYH-associated_polyposis|not_provided	-	MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45800185T>C	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001574|splice_acceptor_variant	1	1383826978	-	PreventionGenetics|Invitae	Uncertain_significance|Likely_pathogenic	2017-06-12|2018-05-27	2018-01-29|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000806356|SCV000815301	not_provided|MYH-associated_polyposis	|This_sequence_change_affects_an_acceptor_splice_site_in_intron_1_of_the_MUTYH_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MUTYH-related_disease._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_003001.3:c.20+1G>T	SDHC	splice_donor_variant	102450	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_003001.3:c.43C>T	SDHC	stop_gained	100298	1	NA	NA	5&5&5&5	0&1&1&1	rs201286421	Paragangliomas 3&Hereditary cancer-predisposing syndrome&Gastrointestinal stromal tumor&Paragangliomas 3	41776	50215	Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_3|not_provided	-	Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1854336,OMIM:605373|MedGen:CN517202	-	NC_000001.10:g.161293426C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	_Inc:SDHC-A2	-	SDHC:6391	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	201286421	-	Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Center_for_Human_Genetics,_Inc|Ambry_Genetics|GeneDx|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Invitae	pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-07-13|2016-11-01|2018-09-28|2018-04-23|0000-00-00|2017-03-01|2018-12-12	0000-00-00|2017-12-20|2020-02-26|2019-01-29|2017-07-10|2019-03-21|2019-03-28	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000043489|SCV000782282|SCV000172731|SCV000565546|SCV000599553|SCV000731535|SCV000287805	Paragangliomas_3|Paragangliomas_3|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Gastrointestinal_stroma_tumor/Paragangliomas_3	Converted_during_submission_to_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_variant_is_denoted_SDHC_c.43C>T_at_the_cDNA_level_and_p.Arg15Ter_(R15X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_multiple_times_in_association_with_hereditary_paraganglioma/pheochromocytoma_(PGL/PCC)_syndrome_(Pasini_2008,_Vandy_2011,_Illouz_2012,_Renella_2014,_Bennedbaek_2016)._We_consider_this_variant_to_be_pathogenic.||The_p.Arg15X_variant_in_SDHC_has_been_reported_in_at_least_6_individuals_with_SD_HC-associated_cancers_(Pasini_2008,_Vandy_2011,_Illouz_2012,_Renella_2014,_Else_2014)._This_variant_has_been_identified_in_1/16446_South_Asian_chromosomes_by_th_e_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs20_1286421)._This_nonsense_variant_leads_to_a_premature_termination_codon_at_positi_on_15,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_SDHC_gene_is_an_established_disease_mechanism_in_indivi_duals_with_hereditary_paragangliomas_and_pheochromocytomas._In_summary,_this_var_iant_meets_criteria_to_be_classified_as_pathogenic_for_hereditary_paragangliomas_and_pheochromocytomas_in_an_autosomal_dominant_manner.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg15*)_in_the_SDHC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_paraganglioma,_Hodgkin's_lymphoma,_pheochromocytoma,_and/or_gastrointestinal_stromal_tumors_(PMID:_17667967,_21106325,_22868853,_24781345,_19351833)._Loss-of-function_variants_in_SDHC_are_known_to_be_pathogenic_(PMID:_19454582,_24758179)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_003001.3:c.77+2dup	SDHC	splice_donor_variant	99666	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_003001.3:c.278dup	SDHC	frameshift_variant	100218	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_003001.3:c.397C>T	SDHC	stop_gained	100324	6	15422	1	5&5&5	1&1&1	rs764575966	Hereditary cancer-predisposing syndrome&Gastrointestinal stromal tumor&Paragangliomas 3	183753	181600	Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_3|not_provided	-	Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1854336,OMIM:605373|MedGen:CN517202	-	NC_000001.10:g.161326622C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	_Inc:SDHC-A3	-	SDHC:6391	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	764575966	-	Ambry_Genetics|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Center_for_Human_Genetics,_Inc	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-11|2018-12-18|2018-10-25|2017-04-24|2017-09-13|0000-00-00|2017-08-11|2016-11-01	2020-02-26|2019-03-28|2019-01-29|2017-08-01|2018-10-10|2017-07-10|2019-03-21|2017-12-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000212830|SCV000287802|SCV000329512|SCV000602179|SCV000605081|SCV000599552|SCV000711450|SCV000782283	Hereditary_cancer-predisposing_syndrome|Gastrointestinal_stroma_tumor/Paragangliomas_3|not_provided|not_provided|not_provided|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_3	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_penultimate_exon_of_the_SDHC_mRNA_at_codon_133_(p.Arg133*)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_delete_the_last_37_amino_acids_of_the_SDHC_protein._This_variant_is_present_in_population_databases_(rs764575966,_ExAC_0.01%)._This_variant_has_been_reported_in_several_individuals_with_paragangliomas_(PGLs)_(PMID:_24423348,_24758179,_24523625,_17898811),_an_individual_with_gastrointestinal_stromal_tumor_(PMID:_23282968),_and_as_a_recurrent_mutation_causing_PGLs_in_the_French_Canadian_population_(PMID:_27700540)._It_has_also_been_found_to_segregate_with_clear_cell_renal_carcinoma_in_a_large_family_(PMID:_23083876)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_183753)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_pathogenic_variant_is_denoted_SDHC_c.397C>T_at_the_cDNA_level_and_p.Arg133Ter_(R133X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA)._Even_though_nonsense-mediated_decay_is_not_expected_to_occur,_it_is_significant_since_the_last_37_amino_acids_are_no_longer_translated_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._SDHC_Arg133Ter_has_been_observed_in_individuals_with_paraganglioma/pheochromocytoma,_renal_cell_carcinoma,_and_gastrointestinal_stromal_tumors_(GIST)_(Zbuk_2007,_Burnichon_2009,_Ricketts_2012,_Miettinen_2013,_Bickmann_2014,_Else_2014,_Bordeau_2016)_and_is_considered_pathogenic.||The_SDHC_c.397C>T,_p.Arg133Ter_variant_(rs764575966)_has_been_reported_in_multiple_patients_diagnosed_with_hereditary_paraganglioma_syndrome_(Bickmann_2014,_Zbuk_2007),_renal_cancer_(Ricketts_2012)_or_gastrointestinal_tumors_(Miettinen_2013)._It_is_reported_as_pathogenic_in_ClinVar_(Variation_ID:_183753),_and_observed_in_the_general_population_with_an_allele_frequency_of_0.003_percent_(9/274720_alleles)_in_the_Genome_Aggregation_Database._The_variant_introduces_a_premature_termination_codon,_and_is_predicted_to_result_in_a_truncated_protein_or_an_absent_transcript._Based_on_the_above_information,_the_variant_is_classified_as_pathogenic._REFERENCES_Bickmann_J_et_al._Phenotypic_variability_and_risk_of_malignancy_in_SDHC-linked_paragangliomas:_lessons_from_three_unrelated_cases_with_an_identical_germline_mutation_(p.Arg133*)._J_Clin_Endocrinol_Metab._2014:_99(3):E489-96._Miettinen_M_et_al._Immunohistochemical_loss_of_succinate_dehydrogenase_subunit_A_(SDHA)_in_gastrointestinal_stromal_tumors_(GISTs)_signals_SDHA_germline_mutation._Am_J_Surg_Pathol._2013:_37(2):234-40._Ricketts_C_et_al._Succinate_dehydrogenase_kidney_cancer:_an_aggressive_example_of_the_Warburg_effect_in_cancer._J_Urol._2012:_188(6):2063-71._Zbuk_K_et_al._Germline_mutations_in_PTEN_and_SDHC_in_a_woman_with_epithelial_thyroid_cancer_and_carotid_paraganglioma._Nat_Clin_Pract_Oncol._2007:_4(10):608-12.||The_p.Arg133X_variant_in_SDHC_is_believed_to_be_a_French_Canadian_founder_varian_t_and_been_reported_in_>20_individuals_of_mainly_French_Canadian_and_French_ance_stry_with_paraganglioma/pheochromocytoma_(PGL/PCC:_Zbuk_2007,_Burnichon_2009,_Ri_cketts_2012,_Lefevre_2014,_Bickmann_2014,_Shuch_2016,_Bourdeau_2016)._This_varia_nt_segregated_with_PGL/PCC_in_at_least_4_affected_relatives_from_2_families_(Bou_rdeau_2016)._In_another_family_(Shuch_2016),_the_p.Arg133X_variant_segregated_wi_th_both_renal_cell_carcinoma_(2_affected_relatives)_and_PGL/PCC_(1_affected_rela_tive)._The_p.Arg133X_variant_has_also_been_identified_in_3/30782_South_Asian_chr_omosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitut_e.org:_dbSNP_rs764575966)._Please_note_that_for_diseases_with_clinical_variabil_ity,_reduced_penetrance,_or_recessive_inheritance,_pathogenic_variants_may_be_pr_esent_at_a_low_frequency_in_the_general_population._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_133._This_alteration_occurs_within_the_terminal_50_bases_of_the_second_to_last_exon_and_is_more_likely_to_escape_no_nsense_mediated_decay_(NMD)_and_result_in_a_truncated_protein._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_hereditary_paraganglio_ma-pheochromocytoma_syndromes_in_an_autosomal_dominant_manner_based_on_its_prese_nce_in_multiple_affected_individuals,_segregation_studies,_and_low_frequency_in_controls._ACMG/AMP_criteria_applied:_PVS1,_PS4,_PM2,_PP1_Moderate.|
NM_003001.3:c.405+1G>T	SDHC	splice_donor_variant	100334	2	NA	NA	-	-	-	-	7242	22281	Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Paragangliomas_3|not_provided	-	Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1854336,OMIM:605373|MedGen:CN517202	-	NC_000001.10:g.161326631G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:602413.0002	-	SDHC:6391	SO:0001627|intron_variant	1	587776653	-	Columbia_University	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2000-11-01|2016-08-15|2018-01-03|2018-09-16	2017-02-21|2020-02-26|2018-04-02|2018-09-24	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline	SCV000027865|SCV000675103|SCV000763567|SCV000809424	Paragangliomas_3|Hereditary_cancer-predisposing_syndrome|Gastrointestinal_stroma_tumor/Paragangliomas_3|not_provided	|Other_strong_data_supporting_pathogenic_classification:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|This_sequence_change_affects_a_donor_splice_site_in_the_last_intron_(intron_5)_of_the_SDHC_gene._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_likely_alters_RNA_splicing_and_results_in_a_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587776653,_ExAC_0.001%)._This_variant_has_been_reported_in_an_individual_affected_with_metastatic_paraganglioma_at_the_carotid_bifurcation_(PMID:_12658451),_and_in_an_individual_with_sporadic_paraganglioma_(PMID:_22517554)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_7242)._Different_variants_at_this_nucleotide_(c.405+1G>A,_c.405+1G>C)_have_been_reported_in_individuals_affected_with_paraganglioma_and_gastrointestinal_stromal_tumors_(GIST)_(PMID:_17667967,_24402737,_24758179)._Experimental_studies_have_shown_that_this_intronic_change_alters_RNA_splicing,_and_results_in_skipping_of_exon_5_and_a_truncated_protein_product_lacking_C-terminal_amino_acid_sequence_(PMID:_12658451)._While_experimental_studies_elucidating_the_function_of_the_truncated_protein_have_not_been_published,_a_deletion_of_exon_6_has_been_determined_to_be_pathogenic_(PMID:_15342702)._This_suggests_that_disruption_of_the_C-terminal_region_of_the_SDHC_protein_is_causative_of_disease._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_002354.2:c.13C>T	EPCAM	stop_gained	70002	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002354.2:c.30del	EPCAM	frameshift_variant	77048	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002354.2:c.297_298insTCTCATCCTGC	EPCAM	frameshift_variant	102744	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002354.2:c.412C>T	EPCAM	stop_gained	102474	1	NA	NA	5	0	rs397514661	Diarrhea 5, with tufting enteropathy, congenital	40256	48740	Diarrhea_5,_with_tufting_enteropathy,_congenital	-	OMIM:613217	-	NC_000002.11:g.47601174C>T	no_assertion_criteria_provided	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:185535.0007	-	EPCAM:4072	SO:0001587|nonsense	1	397514661	-	OMIM	Pathogenic	2013-07-01	2014-11-11	no_assertion_criteria_provided	germline	SCV000057113	Diarrhea_5,_with_tufting_enteropathy,_congenital	
NM_002354.2:c.426-1G>A	EPCAM	splice_acceptor_variant	102612	2	NA	NA	-	-	-	-	12772	27811	Diarrhea_5,_with_tufting_enteropathy,_congenital|not_provided	-	OMIM:613217|MedGen:CN517202	-	NC_000002.11:g.47602372G>A	_single_submitter	Uncertain_significance	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:185535.0002	-	EPCAM:4072	SO:0001574|splice_acceptor_variant	1	373597944	-	_University_of_Washington|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Uncertain_significance|Uncertain_significance	2013-07-01|2014-06-01|2017-06-16	2016-08-04|2014-08-28|2018-01-25	_single_submitter	germline|germline|germline	SCV000033857|SCV000190191|SCV000697920	Diarrhea_5,_with_tufting_enteropathy,_congenital|Diarrhea_5,_with_tufting_enteropathy,_congenital|not_provided	||Variant_summary:_The_EPCAM_c.426-1G>A_variant_involves_the_alteration_of_a_conserved_intronic_nucleotide._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._5/5_splice_prediction_tools_predict_a_significant_impact_on_normal_splicing,_which_has_been_shown_to_occur_via_Western_blot_(see_Schnell_HMG_2013_below),_although_this_has_not_been_corroborated_by_RNA_studies._This_variant_was_found_in_the_large_control_database_ExAC_at_a_frequency_of_0.0000167_(2/119674_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_EPCAM_variant_(0.0000284)._The_variant_has_been_identified_in_at_least_1_homozygous_patient_diagnosed_with_congenital_tufting_enteropathy_(CTE)(SIVAGNANAM_Gastro_2008),_but_has_not_been_associated_with_Lynch_syndrome_phenotypes_in_the_literature._A_functional_analysis_showed_that_the_variant,_which_was_predicted_to_cause_a_deletion_of_~20_amino_acids_that_verified_by_Western_blot,_impairs_proper_localization_of_EPCAM_to_the_plasma_membrane_(Schnell_HMG_2013)._However,_the_role_of_this_dysfunction_in_Lynch_syndrome_development_was_not_established._In_addition,_two_submissions_to_ClinVar_have_classified_this_variant_with_conflicting_interpretations_including_uncertain_significance_and_pathogenic,_though_both_were_submitted_under_the_condition_of_CTE._Although_there_is_evidence_that_the_variant_is_deleterious_in_the_context_of_CTE,_there_is_no_data_regarding_whether_the_variant_is_involved_in_Lynch_syndrome_phenotype_manifestations_or_not._As_such,_this_variant_is_classified_as_VUS_specifically_in_the_context_of_an_inherited_predisposition_to_cancers_including_Lynch_syndrome.
NM_002354.2:c.429G>A	EPCAM	stop_gained	102624	2	NA	NA	5	1	rs878854488	Lynch syndrome	239127	238788	Diarrhea_5,_with_tufting_enteropathy,_congenital	-	OMIM:613217	-	NC_000002.11:g.47602376G>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	EPCAM:4072	SO:0001587|nonsense	1	878854488	-	Invitae	Pathogenic	2015-09-03	2018-10-25	_single_submitter	germline	SCV000287352	Diarrhea_5,_with_tufting_enteropathy,_congenital	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_143_(p.Trp143*)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_truncating_variants_in_EPCAM_are_known_to_be_pathogenic_(PMID:_24142340)._Exon_level_deletions_at_the_3'_end_of_EPCAM,_involving_exon_9_minimally,_lead_to_transcriptional_read-through_into_the_neighboring_MSH2_gene,_triggering_epigenetic_silencing_and_inactivation_of_MSH2_(PMID:_19098912,_23938213)._Loss_of_MSH2_subsequently_causes_Lynch_syndrome_(PMID:_23264089,_19455606,_15849733)._Other_pathogenic_sequence_changes,_such_as_this_variant_c.429G>A_p.Trp143*,_which_disrupt_EPCAM_protein_function_alone,_are_known_causes_of_autosomal_recessive_congenital_tufting_enteropathy_(PMID:_18572020,_20034091,_23462293)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002354.2:c.491+1G>T	EPCAM	splice_donor_variant	102606	1	NA	NA	-	-	-	-	220128	221191	Diarrhea_5,_with_tufting_enteropathy,_congenital	-	OMIM:613217	-	NC_000002.11:g.47602439G>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	EPCAM:4072	SO:0001575|splice_donor_variant	1	606231203	-	Invitae	Pathogenic	2015-09-03	2018-10-25	_single_submitter	germline	SCV000260442	Diarrhea_5,_with_tufting_enteropathy,_congenital	This_sequence_change_affects_a_donor_splice_site_in_intron_4._It_is_expected_to_disrupt_mRNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_a_similar_change_(c.491+1G>A)_has_been_observed_as_homozygous_or_compound_heterozygous_with_another_pathogenic_variant_in_individuals_with_congenital_tufting_enteropathy_(PMID:_18572020,_20981223)._Experimental_studies_have_shown_that_the_c.491+1G>A_change_results_in_an_in-frame_deletion_of_exon_4,_which_leads_to_reduced_expression_and_mislocalization_of_EPCAM_protein_(PMID:_18572020,_23462293)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002354.2:c.610C>T	EPCAM	stop_gained	102556	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002354.2:c.655_656del	EPCAM	frameshift_variant,splice_region_variant	102552	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002354.2:c.858+1G>C	EPCAM	splice_donor_variant	97422	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002354.2:c.903+1G>A	EPCAM	splice_donor_variant	102714	7	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000251.2:c.367-1G>T	MSH2	splice_acceptor_variant	102380	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000251.2:c.704_705del	MSH2	frameshift_variant	102680	1	NA	NA	-	-	-	-	91182	96657	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.47639611_47639612del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.704_705del	-	MSH2:4436	SO:0001589|frameshift_variant	1	281864944	-	_Partners_HealthCare_Personalized_Medicine|GeneDx|Ambry_Genetics|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2017-04-20|2018-03-09|2016-08-01|2018-05-30|2018-06-22	2013-12-18|2018-01-25|2019-03-21|2019-01-29|2020-02-26|2018-08-29	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000107721|SCV000696280|SCV000967752|SCV000568623|SCV000580443|SCV000815741	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon|Variant_summary:_The_MSH2_c.704_705delAA_(p.Lys235Argfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.1030C>T/_p.Gln344X:_c.1147C>T/_p.Arg383X:_c.1165C>T/_p.Arg389X:_c.1189C>T/_p.Gln397X)._In_addition,_the_variant_of_interest_has_been_reported_as_pathogenic_in_multiple_affected_individuals_via_publications_(Mangold_IJC_2005:_Syngal_MLH1_JAMA_1999)_and_in_one_reputable_database._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._The_variant_of_interest_is_absent_in_a_large,_broad_control_population,_ExAC_in_121020_control_chromosomes._Taken_together,_this_variant_is_classified_as_pathogenic.|The_p.Lys235fs_variant_in_MSH2_has_been_reported_in_3_individuals_with_Lynch_syn_drome-associated_cancers_(Mangold_2005,_Syngal_1999)_and_been_identified_in_1/11_1640_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gno_mad.broadinstitute.org:_dbSNP_rs281864944)._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_positio_n_235_and_leads_to_a_premature_termination_codon_20_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozy_gous_loss_of_function_of_the_MSH2_gene_is_an_established_disease_mechanism_in_in_dividuals_with_Lynch_syndrome._In_addition,_this_variant_was_classified_as_patho_genic_on_Sep_5,_2013_by_the_ClinGen-approved_InSiGHT_expert_panel_(ClinVar_SCV00_0107721.2)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogen_ic_for_Lynch_syndrome_in_an_autosomal_dominant_manner_based_upon_presence_in_mul_tiple_affected_individuals,_low_frequency_in_the_general_population,_and_the_pre_dicted_impact_on_the_protein._ACMG/AMP_Criteria_applied_(Richards_2015):_PVS1:_P_M2:_PS4_Supporting.|This_deletion_of_two_nucleotides_in_MSH2_is_denoted_c.704_705delAA_at_the_cDNA_level_and_p.Lys235ArgfsX20_(K235RfsX20)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_ACAA[AA]GACA._The_deletion_causes_a_frameshift_which_changes_a_Lysine_to_an_Arginine_at_codon_235,_and_creates_a_premature_stop_codon_at_position_20_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH2_c.704_705delAA_has_been_identified_in_association_with_colon_cancer_(Syngal_1999,_Mangold_2005)._We_consider_this_variant_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys235Argfs*20)_in_the_MSH2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_suspected_of_having_Lynch_syndrome_(PMID:Â¬â€ 10422993,Â¬â€ 15849733)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 91182)._Loss-of-function_variants_in_MSH2_are_known_to_be_pathogenic_(PMID:_15849733,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000251.2:c.970_971del	MSH2	frameshift_variant	102712	1	NA	NA	-	-	-	-	91262	96737	Lynch_syndrome	-	Orphanet:ORPHA144	-	NC_000002.11:g.47643462_47643463del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.970_971del	-	MSH2:4436	SO:0001589|frameshift_variant	1	63751044	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)	Pathogenic	2013-09-05	2013-12-18	reviewed_by_expert_panel	germline	SCV000107805	Lynch_syndrome	Coding_sequence_variation_resulting_in_a_stop_codon
NM_000251.2:c.1119del	MSH2	frameshift_variant	102704	1	NA	NA	-	-	-	-	90547	96022	Lynch_syndrome	-	Orphanet:ORPHA144	-	NC_000002.11:g.47656923del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1119del	-	MSH2:4436	SO:0001589|frameshift_variant	1	63750516	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)	Pathogenic	2013-09-05	2013-12-18	reviewed_by_expert_panel	germline	SCV000107055	Lynch_syndrome	Coding_sequence_variation_introducing_a_premature_termination_codon
NM_000251.2:c.1510+1G>A	MSH2	splice_donor_variant	102578	1	NA	NA	-	-	-	-	428517	419364	Hereditary_cancer-predisposing_syndrome|Lynch_syndrome	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144	-	NC_000002.11:g.47690294G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MSH2:4436	SO:0001575|splice_donor_variant	1	1114167852	-	Ambry_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_pathogenic|Likely_pathogenic	2018-06-27|2018-04-30	2020-02-26|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000580558|SCV000917699	Hereditary_cancer-predisposing_syndrome|Lynch_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|Variant_summary:_MSH2_c.1510+1G>A_is_located_in_a_canonical_splice-site_and_is_predicted_to_affect_mRNA_splicing_resulting_in_a_significantly_altered_protein_due_to_either_exon_skipping,_shortening,_or_inclusion_of_intronic_material._Several_computational_tools_predict_a_significant_impact_on_normal_splicing:_Five_predict_the_variant_abolishes_a_5_splicing_donor_site._However,_these_predictions_have_yet_to_be_confirmed_by_functional_studies._The_variant_was_observed_with_an_allele_frequency_of_4.1e-06_in_246122_control_chromosomes_(gnomAD)._The_variant,_c.1510+1G>A,_has_been_reported_in_the_literature_as_a_pathogenic/likely_pathogenic_variant_reported_by_a_clinical_diagnostic_laboratory_with_limited_information_(LaDuca_2017)._These_report(s)_do_not_provide_unequivocal_conclusions_about_association_of_the_variant_with_Lynch_Syndrome._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._No_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014._In_2014,_one_clinical_diagnostic_laboratory_reporting_the_single_published_occurrence_of_this_variant_submitted_clinical-significance_assessment_for_this_variant_as_Likely_Pathogenic_in_ClinVar._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_Likely_Pathogenic.
NM_000251.2:c.2541del	MSH2	frameshift_variant	102702	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.10C>T	MSH6	stop_gained	100368	6	15400	1	5&5&5	1&2&0	rs786201042	Hereditary cancer-predisposing syndrome&Lynch syndrome&Hereditary nonpolyposis colorectal cancer type 5	183723	181998	Endometrial_carcinoma|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	Human_Phenotype_Ontology:HP:0012114,MedGen:C0476089,OMIM:608089,SNOMED_CT:254878006|MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48010382C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	_Inc:MSH6-A2|OMIM_Allelic_Variant:600678.0018	-	MSH6:2956	SO:0001623|5_prime_UTR_variant	1	786201042	-	Ambry_Genetics|Color|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|OMIM|Center_for_Human_Genetics,_Inc|Counsyl|Fulgent_Genetics,Fulgent_Genetics|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-04-10|2016-12-19|2015-11-20|2014-08-21|2017-03-01|2017-10-06|0000-00-00|2018-08-02|2019-04-04|2015-06-01|2016-11-01|2017-06-13|2017-05-18|2018-12-30	2020-02-26|2017-10-26|2016-03-03|2017-04-19|2019-03-21|2019-04-24|2015-11-19|2019-01-29|2020-03-06|2016-09-13|2017-12-20|2018-06-20|2017-05-23|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|unknown|unknown|germline	SCV000212772|SCV000685163|SCV000266087|SCV000592561|SCV000731537|SCV000919725|SCV000257203|SCV000279088|SCV001134388|SCV000257496|SCV000781779|SCV000785255|SCV000611207|SCV000253772	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Endometrial_carcinoma/Turcot_syndrome/Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colon_cancer	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||The_p.Gln4X_variant_in_MSH6_has_been_reported_in_>10_individuals_with_MSH6-assoc_iated_cancers,_segregated_with_disease_in_at_least_4_affected_relatives_from_3_f_amilies_(Baglietto_2010,_Castellsague_2015,_Yurgelun_2015),_is_present_in_ClinVa_r_(Variation_ID#_183723),_and_was_absent_from_large_population_studies._This_non_sense_variant_leads_to_a_premature_termination_codon_at_position_4,_which_is_pre_dicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_o_f_the_MSH6_gene_is_an_established_disease_mechanism_in_Lynch_Syndrome._In_summar_y,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_Lynch_Syndrome_in_an_autosomal_dominant_manner.|Variant_summary:_The_MSH6_c.10C>T_(p.Gln4X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH6_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._This_variant_was_found_in_5/270892_control_chromosomes_at_a_frequency_of_0.0000185,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MSH6_variant_(0.0001421)._The_variant_has_been_reported_to_cosegregate_in_11_French-Canadian_families_and_was_determined_to_be_a_founder_mutation._One_individual_was_homozygous_for_the_variant_and_consistent_with_CMMR-D_phenotype_(Castellsague_2014)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||This_variant_is_denoted_MSH6_c.10C>T_at_the_cDNA_level_and_p.Gln4Ter_(Q4X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_and_families_with_suspected_Lynch_Syndrome_and_as_a_founder_pathogenic_variant_in_the_French_Canadian_population_(Baglietto_2010,_Castellsagu?_2014,_Yurgelun_2015,_Shirts_2016,_Yurgelun_2017)._We_consider_this_variant_to_be_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln4*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_is_a_known_common_cause_of_Lynch_syndrome_in_the_French_Canadian_population_of_Quebec_(PMID:_25318681,_20028993)._This_variant_was_found_in_approximately_1/400_newborns_in_this_population,_making_it_one_of_the_most_common_Lynch_syndrome_variants_described_(PMID:_25318681)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_183723)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.467C>G	MSH6	stop_gained	102528	1	NA	NA	5&5&5	3&1&1	rs63749873	Lynch syndrome&Lynch syndrome I&not provided	89534	95008	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.48023042C>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.467C>G	-	MSH6:2956	SO:0001587|nonsense,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	63749873	-	Mayo_Clinic|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Invitae|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2019-04-15|2014-10-30|0000-00-00|2018-12-26|2018-04-19|2018-09-24|2018-12-13|2017-02-15	2013-12-18|2019-09-24|2015-05-28|2015-11-19|2019-01-29|2018-08-31|2020-02-26|2019-03-28|2017-06-22	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|unknown	SCV000108220|SCV000917758|SCV000223779|SCV000257301|SCV000279092|SCV000888290|SCV000580104|SCV000551041|SCV000677750	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome_I|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colon_cancer|Hereditary_nonpolyposis_colorectal_cancer_type_5	Coding_sequence_variation_resulting_in_a_stop_codon|Variant_summary:_MSH6_c.467C>G_(p.Ser156X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.718C>T_(p.Arg240X),_c.742C>T(p.Arg248X))._The_variant_allele_was_found_at_a_frequency_of_8e-06_in_251286_control_chromosomes_(gnomAD_and_DeRycke_2017)_and_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_colon_cancer,_pancreatic_cancer_and_constitutional_mismatch_repair_deficiency_syndrome_(Wijnen_1999,_Steinke_2008,_vanLier_2012,_DeRycke_2017,_Hu_2018,_Tesch_2018)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._Five_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|||This_pathogenic_variant_is_denoted_MSH6_c.467C>G_at_the_cDNA_level_and_p.Ser156Ter_(S156X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_several_individuals_meeting_Amsterdam_or_Bethesda_criteria,_whose_tumors_often_exhibited_microsatellite_instability_and_lacked_expression_of_the_MSH6_protein_on_immunohistochemistry_(Winjen_1999,_Plaschke_2004,_Stormorken_2005,_Overbeek_2007,_van_Puijenbroek_2008,_Sjursen_2010,_Leenan_2012,_van_Lier_2012)._MSH6_p.Ser156Ter_was_found_to_segregate_with_disease_in_at_least_one_family_(Pallauf_2012)._We_consider_this_variant_to_be_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_156_(p.Ser156*)_of_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_rectal_and_ovarian_cancer_(PMID:_15483016,_24728189)_and_in_numerous_individuals_and_families_with_Lynch_syndrome_(PMID:_10508506,_18301448,_22081473,_16034045,_17453009,_18625694)._This_variant_has_also_been_described_as_a_founder_mutation_in_the_Netherlands,_causing_Lynch_syndrome_in_individuals_of_Dutch_ancestry_(PMID:_18625694)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000179.2:c.679_680del	MSH6	frameshift_variant	102300	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.1135_1139del	MSH6	frameshift_variant	102314	1	NA	NA	-	-	-	-	89174	94648	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48026252_48026256AGAGA[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1135_1139del	-	MSH6:2956	SO:0001587|nonsense	1	267608077	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Genetic_Services_Laboratory,_University_of_Chicago|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2013-09-05|2015-11-20|2018-12-26|2019-02-23|2015-03-30|2018-01-15|0000-00-00|2016-08-19|2018-12-07	2013-12-18|2016-03-03|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2015-11-19|2017-07-05|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000107835|SCV000266088|SCV000917791|SCV000184650|SCV000685168|SCV000211383|SCV000257205|SCV000595850|SCV000750903	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||Variant_summary:_MSH6_c.1135_1139delAGAGA_(p.Arg379X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_245726_control_chromosomes_(gnomAD)._c.1135_1139delAGAGA_has_been_reported_in_the_literature_in_individuals_affected_with_Breast_cancer,_Ovarian_cancer,_polyups,_and_cervical_cancer_(Frolova_2017,_Kets_2006,_Shirts_2015,_Susswein_2015)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification||This_deletion_of_5_nucleotides_is_denoted_MSH6_c.1135_1139delAGAGA_at_the_cDNA_level_and_p.Arg379Ter_(R379X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_GAGA[AGAGA]TGAG._The_deletion_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_1135_1139delAGAGA_has_been_observed_in_at_least_two_individuals_with_a_personal_history_of_endometrial_cancer_and_a_family_history_of_Lynch_syndrome-related_cancers_(Kets_2006,_Frolova_2015)._This_variant_is_considered_pathogenic.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg379*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs777907133,_ExAC_0.001%)._This_variant_has_beenÂ¬â€ observedÂ¬â€ in_several_individuals_affected_with_colorectal_polyps,_endometrial_cancer,_and_cervical_cancer_(PMID:_26845104,_17117178,_26681312,_25617771),_as_well_as_in_individualsÂ¬â€ undergoing_testing_for_Lynch_syndrome_(PMID:Â¬â€ 28514183)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89174)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.1190_1191del	MSH6	frameshift_variant	102508	1	NA	NA	-	-	-	-	89178	94652	Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48026312_48026313del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1190_1191del	-	MSH6:2956	SO:0001589|frameshift_variant	1	63750439	-	Mayo_Clinic	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2017-11-15|2019-01-29|2018-08-23|0000-00-00	2013-12-18|2019-04-24|2020-02-26|2019-01-29|2017-10-31	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|unknown	SCV000107842|SCV000919727|SCV000580232|SCV000211379|SCV000691923	Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	Coding_sequence_variation_resulting_in_a_stop_codon|Variant_summary:_The_MSH6_c.1190_1191delAT_(p.Tyr397CysfsX3)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH6_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.1444C>T_(p.Arg482X),_c.1572C>A_(p.Tyr524X),_c.1634_1637delAAGA_(p.Lys545fsX25))._The_variant_has_been_observed_in_patients_with_HNPCC-associated_cancers_(i.e._CRC_and_cancer_of_the_endometrium),_in_one_of_them_a_CRC_tumor_sample_showing_loss_of_MSH6_and_microsatellite_instability_(Plaschke_2004,_Susswein_2015)._This_variant_was_found_in_2/245974_control_chromosomes_at_a_frequency_of_0.0000081,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MSH6_variant_(0.0001421)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_deletion_of_2_nucleotides_in_MSH6_is_denoted_c.1190_1191delAT_at_the_cDNA_level_and_p.Tyr397CysfsX3_(Y397CfsX3)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CTCT[delAT]GTGC._The_deletion_causes_a_frameshift,_which_changes_a_Tyrosine_to_a_Cysteine_at_codon_397,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_c.1190_1191delAT_has_been_observed_in_individuals_with_early-onset_colon_cancer_who_had_tumors_showing_microsatellite_instability_(Plaschke_2004,_Steinke_2008,_You_2010)._We_consider_this_variant_to_be_pathogenic._This_deletion_of_two_nucleotides_in_MSH6_is_denoted_c.1190_1191delAT_at_the_cDNA_level_and_p.Tyr397CysfsX3_(Y397CfsX3)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CTCT[delAT]GTGC._The_deletion_causes_a_frameshift_which_changes_a_Tyrosine_to_a_Cysteine_at_codon_397,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._MSH6_Tyr397CysfsX3_has_been_LIT_SUMMARY._We_consider_this_variant_to_be_pathogenic.|
NM_000179.2:c.1248dup	MSH6	frameshift_variant	102654	1	NA	NA	-	-	-	-	649212	630241	Hereditary_nonpolyposis_colon_cancer	-	Orphanet:ORPHA443090	-	NC_000002.11:g.48026370dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	MSH6:2956	SO:0001587|nonsense	1	-	-	Invitae	Pathogenic	2018-12-19	2019-03-28	_single_submitter	germline	SCV000943986	Hereditary_nonpolyposis_colon_cancer	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys417*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MSH6-related_disease._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.1421_1422dup	MSH6	frameshift_variant	102504	1	NA	NA	-	-	-	-	89193	94667	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48026543_48026544dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1421_1422dup|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2846327	-	MSH6:2956	SO:0001589|frameshift_variant	1	63750854	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Ambry_Genetics|Invitae|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2018-06-08|2018-06-19|2018-06-11	2013-12-18|2020-02-26|2018-08-29|2018-08-31	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000107857|SCV000276852|SCV000624646|SCV000888238	Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colon_cancer|not_provided	Coding_sequence_variation_resulting_in_a_stop_codon|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln475Cysfs*7)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_rectal_cancer,_breast_cancer,_adenomatous_polyps,_and_cafe_au_lait_macules_(PMID:_11807791,_21039432,_27616075,_15483016)._In_the_literature,_this_variant_is_also_known_as_1510insTG._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89193)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89193)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000179.2:c.1458_1459del	MSH6	frameshift_variant	102492	1	NA	NA	-	-	-	-	428371	419468	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000002.11:g.48026580_48026581del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	1114167750	-	Ambry_Genetics	Pathogenic	2014-12-16	2020-02-26	_single_submitter	germline	SCV000580259	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000179.2:c.1871del	MSH6	frameshift_variant	102316	1	NA	NA	-	-	-	-	428321	419483	Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1833477,OMIM:614350	-	NC_000002.11:g.48026993del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	777159874	-	_University_of_Chicago	Pathogenic|Pathogenic	2017-03-07|2017-01-27	2020-02-26|2017-07-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000580158|SCV000595851	Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5	_nonsense)|
NM_000179.2:c.1937del	MSH6	frameshift_variant	102474	1	NA	NA	-	-	-	-	428368	419485	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000002.11:g.48027059del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	1114167747	-	Ambry_Genetics	Pathogenic	2018-01-25	2020-02-26	_single_submitter	germline	SCV000580250	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000179.2:c.2194C>T	MSH6	stop_gained	102224	1	NA	NA	5&5&5	3&1&1	rs63751127	Lynch syndrome&Hereditary cancer-predisposing syndrome&not provided	89262	94736	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48027316C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.2194C>T	-	MSH6:2956	SO:0001587|nonsense	1	63751127	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2015-05-26|2016-03-18|2018-09-04|2018-10-24|2018-06-07|2018-03-23|2018-02-01|2018-12-13	2013-12-18|2017-04-19|2019-03-21|2019-04-24|2020-02-26|2018-11-06|2019-01-29|2018-08-31|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000107934|SCV000592600|SCV000711432|SCV000919757|SCV000187309|SCV000905454|SCV000211293|SCV000889471|SCV000253776	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||The_p.Arg732X_variant_in_MSH6_has_been_reported_in_at_least_5_individuals_with_h_ereditary_non-polyposis_colorectal_cancer_(HNPCC)_and_related_tumors_(Plaschke_2_004,_Steinke_2008,_Baglietto_2010,_Giraldez_2010,_Song_2014)_and_was_absent_from_large_population_studies._This_nonsense_variant_leads_to_a_premature_terminatio_n_codon_at_position_732,_which_is_predicted_to_lead_to_a_truncated_or_absent_pro_tein._Heterozygous_loss-of-function_of_the_MSH6_gene_is_an_establish_disease_mec_hanism_for_Lynch_syndrome._In_summary,_this_variant_meets_criteria_to_be_classif_ied_as_pathogenic_for_Lynch_syndrome_in_an_autosomal_dominant_manner.|Variant_summary:_MSH6_c.2194C>T_(p.Arg732X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.2230dupG,_p.Glu744fsX12:_c.2503C>T,_p.Gln835X:_c.2731C>T_,_p.Arg911X)._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_245604_control_chromosomes_(gnomAD)._The_variant,_c.2194C>T,_has_been_reported_in_the_literature_in_individuals_affected_with_Lynch_Syndrome_(Susswein_2015,_Rossi_2017,_Baglietto_2010,_Song_2014)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Five_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_MSH6_c.2194C>T_at_the_cDNA_level_and_p.Arg732Ter_(R732X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_an_Arginine_to_a_premature_stop_codon_(CGA>TGA)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_several_individuals_with_personal_and/or_family_histories_suggestive_of_Lynch_syndrome_(Plaschke_2004,_Steinke_2008,_Giraldez_2010,_Song_2014,_Lagerstedt-Robinson_2016)_and_is_considered_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg732*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_with_Lynch_syndrome_(PMID:_15483016,_18301448,_20028993),_and_an_individual_affected_with_ovarian_cancer_(PMID:_24728189)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89262)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.2199_2200del	MSH6	frameshift_variant	102226	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.2219T>G	MSH6	stop_gained	102240	1	NA	NA	-	-	-	-	820891	807270	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000002.11:g.48027341T>G	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MSH6:2956	SO:0001587|nonsense	1	-	-	Ambry_Genetics	Pathogenic	2018-08-23	2020-02-26	_single_submitter	germline	SCV001175542	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000179.2:c.2230dup	MSH6	frameshift_variant	102234	1	15432	1	-	-	-	-	183739	182101	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48027352dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	Illumina:692386	-	MSH6:2956	SO:0001589|frameshift_variant	1	786201050	-	Illumina	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2018-05-11|2016-12-06|2016-08-08|2018-10-18|2019-06-24|2018-11-08|2018-05-04	2020-02-26|2017-10-26|2018-01-25|2019-01-29|2020-03-06|2019-03-28|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000212804|SCV000685267|SCV000695803|SCV000279101|SCV001134407|SCV000255260|SCV000430969	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_nonpolyposis_colorectal_cancer_type_5	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||Variant_summary:_The_MSH6_c.2230dupG_(p.Glu744Glyfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH6_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Mutation_taster_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_1/121164_control_chromosomes_at_a_frequency_of_0.0000083,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MSH6_variant_(0.0001421)._The_variant_was_reprted_in_a_colorectal_cancer_patient_who_had_family_history_of_the_disease_indicating_pathogenicity._Moreover,_truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Arg911X,_p.Arg1035X)_further_supporting_a_deleterious_outcome._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_duplication_of_one_nucleotide_in_MSH6_is_denoted_c.2230dupG_at_the_cDNA_level_and_p.Glu744GlyfsX12_(E744GfsX12)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_CTTG[dupG]AGAT._The_duplication_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_a_Glycine_at_codon_744_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_c.2230dupG_has_been_reported_in_association_with_Lynch_syndrome_(Ward_2013,_Brand_2018,_Chan_2018)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu744Glyfs*12)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs773290953,_ExAC_0.002%)._This_variant_has_been_reported_in_an_individual_affected_with_colorectal_cancer_(PMID:_23733757)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_183739)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_MSH6_c.2230dupG_(p.Glu744GlyfsTer12)_variant,_also_reported_as_c.2228_2229insG,_results_in_a_frameshift,_and_is_predicted_to_result_in_premature_termination_of_the_protein._The_p.Glu744GlyfsTer12_variant_has_been_reported_in_two_studies_and_is_found_in_a_compound_heterozygous_state_in_two_probands_with_colorectal_cancer_(Ward_et_al._2013:_DeRycke_et_al._2017)._The_variant_is_reported_at_a_frequency_of_0.000016_in_the_European_(non-Finnish)_population_from_the_Genome_Aggregation_Database_but_this_is_based_on_two_alleles_in_a_region_of_good_sequence_coverage_so_the_variant_is_presumed_to_be_rare._Due_to_the_potential_impact_of_frameshift_variants_and_evidence_from_literature,_the_p.Glu744GlyfsTer12_variant_is_classified_as_likely_pathogenic_for_Lynch_syndrome._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_000179.2:c.2779dup	MSH6	frameshift_variant	102444	2	NA	NA	-	-	-	-	142168	151882	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000002.11:g.48027901dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	587782277	-	Ambry_Genetics|Color|GeneDx	Pathogenic|Pathogenic|Pathogenic	2013-01-22|2017-05-10|2017-01-10	2020-02-26|2017-10-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000186066|SCV000685324|SCV000279367	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_one_nucleotide_in_MSH6_is_denoted_c.2779dupA_at_the_cDNA_level_and_p.Ile927AsnfsX8_(I927NfsX8)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_ACTT[A]TTAC._The_duplication_causes_a_frameshift,_which_changes_an_Isoleucine_to_an_Asparagine_at_codon_927,_and_creates_a_premature_stop_codon_at_position_8_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_c.2779dupA_has_been_identified_in_an_individual_undergoing_hereditary_cancer_panel_testing_(LaDuca_2014)._We_consider_this_variant_to_be_pathogenic.
NM_000179.2:c.3103C>T	MSH6	stop_gained	101330	2	NA	NA	5&5	3&1	rs63749999	Lynch syndrome&Hereditary cancer-predisposing syndrome	89338	94812	Endometrial_carcinoma|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	Human_Phenotype_Ontology:HP:0012114,MedGen:C0476089,OMIM:608089,SNOMED_CT:254878006|MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48028225C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3103C>T	-	MSH6:2956	SO:0001587|nonsense	1	63749999	-	Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2018-12-19|2015-02-23|2018-06-14|2017-06-22|2018-12-19|2018-10-31	2013-12-18|2020-02-26|2018-11-06|2019-01-29|2018-08-31|2019-03-28|2018-11-14	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown	SCV000108014|SCV000273005|SCV000904986|SCV000568723|SCV000601559|SCV000260888|SCV000894282	Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Endometrial_carcinoma/Turcot_syndrome/Hereditary_nonpolyposis_colorectal_cancer_type_5	Coding_sequence_variation_resulting_in_a_stop_codon|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_MSH6_c.3103C>T_at_the_cDNA_level_and_p.Arg1035Ter_(R1035X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_multiple_individuals_with_a_personal_and_family_history_of_Lynch_syndrome-associated_tumors,_several_of_which_showed_absence_of_MSH6_protein_on_immunohistochemistry_and/or_microsatellite_instability_(Planck_1999,_Hendriks_2004,_Plaschke_2004,_Walsh_2011,_Everett_2014,_Kidambi_2016)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg1035*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs63749999,_ExAC_0.002%)._This_variant_has_been_observedÂ¬â€ in_a_family_affected_with_endometrial_and/or_ovarian_cancer_(PMID:_15236168)._It_has_also_been_reported_in_an_individual_affected_with_endometrial_cancer_with_a_family_history_consistent_with_Lynch_syndrome_(PMID:_15483016),_and_in_individuals_with_ovarian_cancer_(PMID:_22006311,_23047549)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89338)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000179.2:c.3261dup	MSH6	frameshift_variant	102176	6	15310	0	-	-	-	-	89364	94838	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48030647dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	HGMD:CI972618|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2585908|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3261dup	-	MSH6:2956	SO:0001589|frameshift_variant	1	267608078	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|GeneKor_MSA|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Mendelics|Invitae	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2015-11-20|2013-08-13|2016-08-01|2017-10-19|2014-01-24|2018-06-18|0000-00-00|2015-11-18|2018-07-17|2017-06-01|2018-08-01|2016-10-26|2017-07-31|2019-05-28|2018-12-16	2013-12-18|2016-03-03|2017-04-19|2018-01-25|2019-03-21|2015-06-09|2019-01-29|2017-10-31|2018-08-31|2020-02-26|2017-12-21|2018-08-08|2016-11-23|2018-06-14|2019-10-22|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|unknown|germline	SCV000108042|SCV000266095|SCV000592631|SCV000695854|SCV000711433|SCV000110155|SCV000149321|SCV000257248|SCV000888268|SCV000185790|SCV000690338|SCV000821740|SCV000489547|SCV000840011|SCV001135836|SCV000255263	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon|||Variant_summary:_The_MSH6_c.3261dupC_(p.Phe1088Leufs)_variant_is_located_in_exon_5_and_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH6_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_was_observed_in_a_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_211/120336_(1/570),_which_is_approximately_12_times_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_MSH6_variant_of_1/7031._The_high_prevalence_of_the_variant_in_controls_can_be_explained_by_possibility_of_sequencing_error,_although_the_low_penetrance_is_possibility_too._The_reason_for_low_penetrance_could_be_the_existence_of_alternative_splice_acceptor_site_7bp_downstream_of_duplicated_base,_which_can_result_in_alternative_protein_lacking_32_amino_acids._The_variant_of_interest_has_been_reported_in_multiple_affected_individuals_with_varying_phenotypes,_Lynch_syndrome,_atypical_HNPCC,_HNPCC_(fulfilling_either_Bethesda_or_Amsterdam_criteria),_along_with_a_family_that_had_three_homozygous_children_diagnosed_with_constitutional_mismatch_repair_deficiency_syndrome._In_addition,_one_family_(Palmer_2010)_did_indicate_a_lack_of_co-segregation_with_disease,_along_with_another_study,_Yurgelun_2015_indicating_the_variant_to_have_co-occurred_with_another_pathogenic_STK11_variant,_c.375-1C>T._While_other_publications_did_indicate_the_variant_segregated_with_disease_(Akiyama_1997_and_Ollikinen_2005)._Furthermore,_multiple_reputable_databases/clinical_laboratories_and_publications_cite_the_variant_as_pathogenic._Therefore,_taking_all_available_lines_of_evidence_into_consideration,_the_variant_of_interest_has_been_classified_as_Likely_Pathogenic.|The_p.Phe1088fs_variant_in_MSH6_has_been_reported_in_>_20_individuals_with_Lynch_syndrome-associated_cancers_and_segregated_with_disease_in_>3_affected_relative_s_from_2_families_(Akiyama_1997,_Plaschke_2004,_Ollikainen_2005,_Barnetson_2006,_Kets_2006,_Overbeek_2007_,_Steinke_2008,_Sjursen_2010_,_Bonadona_2011,_Terui_2_013,_Hansen_2014,_Rosty_2014,_Susswein_2015)._Tumors_sampled_from_some_of_these_individuals_lacked_MSH6_expression_(Ollikainen_2005,_Sjursen_2010,_Terui_2013,_R_osty_2014)._Additionally,_this_variant_has_been_reported_in_the_compound_heteroz_ygous_state_in_1_individual_with_constitutional_mismatch_repair_deficiency_(CMMR_D)_and_family_history_of_Lynch_syndrome-associated_cancers_(Bougeard_2014,_Lavoi_ne_2015)._This_variant_has_also_been_identified_in_1/8652_African_chromosomes_by_the_Genome_Aggregation_Database_(GnomAD,_http://gnomad.broadinstitute.org:_dbSN_P_rs748452299)._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_th_e_protein?s_amino_acid_sequence_beginning_at_position_1088_and_leads_to_a_premat_ure_termination_codon_5_amino_acids_downstream._This_alteration_is_then_predicte_d_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_MSH6_gene_is_an_established_disease_mechanism_in_Lynch_syndrome._In_addition,_t_his_variant_was_classified_as_pathogenic_on_September_5,_2013_by_the_ClinGen-app_roved_InSiGHT_expert_panel_(ClinVar_SCV000108042.2)._In_summary,_this_variant_me_ets_criteria_to_be_classified_as_pathogenic_for_Lynch_syndrome_in_an_autosomal_d_ominant_manner_based_upon_the_predicted_impact_to_the_protein,_presence_in_multi_ple_affected_individuals,_segregation_studies_and_very_low_frequency_in_the_gene_ral_population.||This_pathogenic_variant_is_denoted_MSH6_c.3261dupC_at_the_cDNA_level_and_p.Phe1088LeufsX5_(F1088LfsX5)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_ACCCCCCC[dupC]TTCT._The_duplication_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Leucine_at_codon_1088,_and_creates_a_premature_stop_codon_at_position_5_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_c.3261dupC_has_been_observed_in_several_individuals_with_colorectal_cancer,_with_loss_of_MSH6_protein_expression_observed_in_most_studied_tumors_(Hampel_2008,_Sjursen_2010,_Terui_2013,_Kumamoto_2015,_Rubio_2016,_Lee_2017,_Suzuki_2017)._In_addition,_this_variant_has_been_seen_in_the_homozygous_state_in_several_individuals_from_a_consanguineous_family_with_constitutional_mismatch_repair_deficiency_(Ilencikova_2011)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||This_c.3261dupC_variant_has_been_reported_in_multiple_individuals_with_Lynch_Syndrome_(PMID9929971,_15483016,_26318770),_3_additional_patients_with_colon_cancer_(PMID17117178,_16807412,_24100870)_and_5_more_patients_with_endometrial_cancer_including_3_from_the_same_family_showing_co-segregation_from_one_generation_to_the_next_(PMID1711717,_PMID17453009,_PMID15837969)._This_variant_is_predicted_to_cause_a_frameshift_and,_and_create_a_premature_stop_codon._Based_upon_the_above_evidence,_this_c.3261_3262insC_variant_in_the_MSH6_gene_is_classified_as_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Phe1088Leufs*5)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_with_Lynch_syndrome_(PMID:_9307272,_12658575,_15483016,_17117178,_17453009,_18301448,_26318770),_colorectal_cancer_(PMID:_16807412,_9929971,_24100870,_24689082),_prostate_cancer_(PMID:_25117503),_and_endometrial_cancer_(PMID:_15837969)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89364)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_24362816,_18269114)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.3260_3261dup	MSH6	frameshift_variant	102176	1	NA	NA	-	-	-	-	428313	419535	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000002.11:g.48030646_48030647dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	267608078	-	Ambry_Genetics	Pathogenic	2018-11-15	2020-02-26	_single_submitter	germline	SCV000580143	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000179.2:c.3261del	MSH6	frameshift_variant	102176	1	15310	0	-	-	-	-	89363	94837	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48030647del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3261del|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:3204|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2646814	-	MSH6:2956	SO:0001589|frameshift_variant	1	267608078	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|0000-00-00|2016-08-29|2017-01-18|2018-11-08|2016-05-16|2018-11-12|0000-00-00|2015-12-10|2017-12-18|2018-12-16	2013-12-18|2017-04-19|2018-01-25|2019-03-21|2020-02-26|2017-10-26|2019-01-29|2017-10-31|2018-08-31|2018-10-10|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline	SCV000108041|SCV000592632|SCV000695853|SCV000711434|SCV000187451|SCV000685379|SCV000149320|SCV000257247|SCV000601570|SCV000884140|SCV000255262	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||Variant_summary:_The_MSH6_c.3261delC_(p.Phe1088Serfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH6_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Arg1172fs)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_21/120336_control_chromosomes_at_a_frequency_of_0.0001745,_which_is_approximately_equal_to_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MSH6_variant_(0.0001421)._However,_the_variant_has_been_reported_in_many_HNPCC_patients_in_the_literature_in_heterozygous_state._The_variant_has_also_been_cited_in_homozygous_and_compound_heterozygous_states_in_patients_with_early_onset_cancer_phenotypes_(Ilencikova_PedBlodCanc_2011_and_Auclair_HumMut_2007,_respectively)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|The_p.Phe1088fs_variant_in_MSH6_has_been_reported_in_>5_individuals_with_Lynch_S_yndrome-related_cancers_(Baglietto_2010,_Meric-Bernstam_2016),_as_well_as_one_in_dividual_with_constitutional_mismatch_repair_deficiency_syndrome_(CMMRD)_who_was_compound_heterozygous_for_this_variant_and_another_MSH6_variant_(Lavoine_2015)._This_variant_has_been_identified_in_4/10336_African_chromosomes_by_the_Exome_Ag_gregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs267608078)._It_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_seq_uence_beginning_at_position_1088_and_leads_to_a_premature_termination_codon_2_am_ino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_o_r_absent_protein._Heterozygous_loss_of_function_of_function_of_the_MSH6_gene_is_an_established_disease_mechanism_in_Lynch_Syndrome._Furthermore,_this_variant_wa_s_classified_as_Pathogenic_on_Sept._5,_2013_by_the_ClinGen-approved_InSiGHT_Expe_rt_Panel_(ClinVar_SCV000108041.2)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_Lynch_Syndrome_in_an_autosomal_dominant_manner_bas_ed_upon_the_predicted_impact_to_the_protein,_low_frequency_in_the_general_popula_tion_and_presence_in_multiple_affected_individuals.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification||This_deletion_of_one_nucleotide_in_MSH6_is_denoted_c.3261delC_at_the_cDNA_level_and_p.Phe1088SerfsX2_(F1088SfsX2)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ACCCCCCC[delC]TTCT._The_deletion_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Serine_at_codon_1088,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_c.3261delC_has_been_reported_in_at_least_one_individual_with_a_clinical_diagnosis_of_Muir-Torre_syndrome_(Tavakkol_2012)_and_several_others_with_Lynch_syndrome-related_cancers,_most_of_whom_met_Bethesda_and/or_Amsterdam_criteria_(Plaschke_2004,_Hampel_2005,_Baglietto_2010,_Sjursen_2010,_Talseth-Palmer_2010,_Meric-Bernstam_2016)._MSH6_c.3261delC_has_also_been_observed,_in_the_compound_heterozygous_state,_in_one_individual_with_suspected_constitutional_mismatch_repair_deficiency_syndrome_(Auclair_2007)._We_consider_this_variant_to_be_pathogenic.|||The_MSH6_c.3261delC,_p.Phe1088fs_variant_(rs267608078)_is_a_recurrent_alteration_in_individuals_diagnosed_with_hereditary_nonpolyposis_colorectal_cancer_and_other_familial_cancers_(Baglietto_2010,_Lavoine_2015,_Tavakkol_2012,_van_der_Post_2010,_Wijnen_1999)._It_is_classified_as_pathogenic_in_ClinVar_(Variation_ID:_89363),_and_observed_once_in_the_Genome_Aggregation_Database_general_population_database_(1/30714_alleles)._The_variant_introduces_a_frameshift,_and_is_predicted_to_result_in_a_truncated_protein_or_an_absent_transcript._Based_on_the_above_information,_the_variant_is_classified_as_pathogenic._References:_Baglietto_L_et_al._Risks_of_Lynch_syndrome_cancers_for_MSH6_mutation_carriers._J_Natl_Cancer_Inst._2010:_102(3):193-201._Lavoine_N_et_al._Constitutional_mismatch_repair_deficiency_syndrome:_clinical_description_in_a_French_cohort._J_Med_Genet._2015:_52(11):770-8._Tavakkol_Z_et_al._Germline_mutation_in_MSH6_associated_with_multiple_malignant_neoplasms_in_a_patient_With_Muir-Torre_syndrome._J_Clin_Oncol._2012:_30(22):e195-8._van_der_Post_R_et_al._Risk_of_urothelial_bladder_cancer_in_Lynch_syndrome_is_increased,_in_particular_among_MSH2_mutation_carriers._J_Med_Genet._2010:_47(7):464-70._Wijnen_J_et_al._Familial_endometrial_cancer_in_female_carriers_of_MSH6_germline_mutations._Nat_Genet._1999:_23(2):142-4.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Phe1088Serfs*2)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs770288143,_ExAC_0.04%)._This_variant_has_been_reported_in_the_literature_in_individuals_and_families_with_Lynch_syndrome_(PMID:_10508506,_15483016,_18301448,_20007843,_20028993,_20587412,_20591884,_22734033)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89363)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.3332_3335dup	MSH6	frameshift_variant	102634	1	NA	NA	-	-	-	-	218061	214607	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48030718_48030721dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	MSH6:2956	SO:0001587|nonsense	1	587782562	-	Ambry_Genetics|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-11-21|0000-00-00|0000-00-00|2018-07-13|2018-12-28	2020-02-26|2017-10-31|2017-04-19|2019-03-21|2019-03-28	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline	SCV000275618|SCV000257251|SCV000592636|SCV000966977|SCV000283798	Hereditary_cancer-predisposing_syndrome|not_provided|Lynch_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colon_cancer	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||The_p.Asp1112GlufsX2_variant_in_MSH6_has_been_reported_in_at_least_3_families_wi_th_Lynch_Syndrome-related_cancers_and_segregated_with_disease_in_at_least_one_af_fected_relative_(Choi_2009,_Rosty_2014,_Goodfellow_2015)._This_variant_has_also_been_reported_in_ClinVar_(Variation_ID#_218061)._This_variant_has_been_identifie_d_in_1/111584_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_h_ttp://gnomad.broadinstitute.org)._This_variant_is_predicted_to_cause_a_frameshif_t,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1112_and_leads_to_a_premature_termination_codon_2_amino_acids_downstream._This_alteratio_n_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_MSH6_gene_is_an_established_disease_mechanism_in_Lynch_Syndro_me._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_L_ynch_Syndrome_in_an_autosomal_dominant_manner_based_upon_the_presence_in_affecte_d_probands,_low_frequency_in_controls,_and_the_predicted_impact_on_the_protein._ACMG/AMP_Criteria_applied:_PVS1,_PM2,_PS4_Supporting.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asp1112Glufs*2)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_observed_in_an_individual_affected_with_Lynch_syndrome_(PMID:_20028993),_multiple_individuals_with_colorectal_cancer_(PMID:_25117503,_19698169),_and_an_individual_with_endometrial_cancer_(PMID:_26552419)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_218061)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.3438+2dup	MSH6	splice_donor_variant	102554	2	NA	NA	-	-	-	-	428415	419543	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000002.11:g.48030826dup	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	-	-	Duplication	SO:1000035	-	-	MSH6:2956	SO:0001575|splice_donor_variant	1	1114167778	-	Ambry_Genetics|Invitae	Uncertain_significance|Uncertain_significance	2016-04-12|2018-09-28	2020-02-26|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000580337|SCV000624863	Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colon_cancer	Insufficient_or_conflicting_evidence|This_sequence_change_falls_in_intron_5_of_the_MSH6_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_MSH6_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_a_family_affected_with_colorectal_cancer_(PMID:_20028993)._Nucleotide_substitutions_within_the_consensus_splice_site_are_relatively_common_causes_of_aberrant_splicing_(PMID:_17576681,_9536098)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_this_variant_has_uncertain_impact_on_MSH6_function._The_available_evidence_is_currently_insufficient_to_determine_its_role_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.
NM_000179.2:c.3465_3466del	MSH6	frameshift_variant	102692	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.3514dup	MSH6	frameshift_variant	102632	1	15428	1	-	-	-	-	89404	94878	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48032124dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3514dup|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2564205	-	MSH6:2956	SO:0001589|frameshift_variant	1	63751327	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx|Counsyl|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2014-01-15|2018-10-19|2018-05-23|2018-04-11|0000-00-00|2015-10-08|2018-12-19|2015-12-16|2018-11-29	2013-12-18|2017-04-19|2019-04-24|2020-02-26|2018-11-06|2015-11-19|2018-08-31|2019-10-15|2016-11-23|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|unknown|germline	SCV000108084|SCV000592646|SCV000917779|SCV000217134|SCV000905457|SCV000257260|SCV000888277|SCV001168605|SCV000488032|SCV000283809	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||Variant_summary:_MSH6_c.3514dupA_(p.Arg1172LysfsX5)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_1.1e-05_in_277060_control_chromosomes_(gnomAD)._c.3514dupA_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Lynch_Syndrome_or_related_tumor_phenotypes_(Nilbert_2009,_Schofield_2009,_Sjursen_2010,_Steinke2008,_Wijnen_1999,_Plaschke_2004,_Haraldsdottir_2017)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Three_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_duplication_of_one_nucleotide_in_MSH6_is_denoted_c.3514dupA_at_the_cDNA_level_and_p.Arg1172LysfsX5_(R1172KfsX5)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_TGAT[dupA]GAGT._The_duplication_causes_a_frameshift_which_changes_an_Arginine_to_a_Lysine_at_codon_1172,_and_creates_a_premature_stop_codon_at_position_5_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_c.3514dupA,_also_reported_as_MSH6_3514insA,_has_been_reported_in_individuals_meeting_Bethesda_guidelines_and_Amsterdam_criteria_for_Lynch_syndrome._(Plaschke_2004_,_Overbeek_2007,_Nilbert_2009,_Sjursen_2010,_van_der_Post_2010,_Haraldsdottir_2017)._This_variant_was_also_observed_in_the_compound_heterozygous_state_in_an_individual_with_constitutional_mismatch_repair_deficiency_(CMMR-D)_syndrome_(Soplepmann_2016)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_inserts_1_nucleotide_in_exon_6_of_the_MSH6_mRNA_(c.3514dupA),_causing_a_frameshift_at_codon_1172._This_creates_a_premature_translational_stop_signal_(p.Arg1172Lysfs*5)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_families_with_suspected_Lynch_syndrome_(PMID:_10508506,_18566915,_20587412)_and_in_individuals_affected_with_urothelial,_colorectal,_bladder_and_ovarian_cancer_(PMID:_20591884,_20682701,_24728189,_19130300)._This_variant_is_also_known_as_1172insA_or_c.3514_3515insA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89404)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.3577_3580dup	MSH6	frameshift_variant	102706	1	NA	NA	-	-	-	-	455271	451638	Hereditary_nonpolyposis_colon_cancer	-	Orphanet:ORPHA443090	-	NC_000002.11:g.48032777_48032780dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	MSH6:2956	SO:0001587|nonsense	1	773262801	-	Invitae	Pathogenic	2018-09-13	2019-03-28	_single_submitter	germline	SCV000624885	Hereditary_nonpolyposis_colon_cancer	This_sequence_change_inserts_4_nucleotides_in_exon_7_of_the_MSH6_mRNA_(c.3577_3580dupGAAT),_causing_a_frameshift_at_codon_1194._This_creates_a_premature_translational_stop_signal_(p.Leu1194*)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_24362816,_18269114)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.3647-2A>C	MSH6	splice_acceptor_variant	102542	1	NA	NA	-	-	-	-	89435	94909	Lynch_syndrome	-	Orphanet:ORPHA144	-	NC_000002.11:g.48033341A>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3647-2A>C	-	MSH6:2956	SO:0001574|splice_acceptor_variant	1	267608111	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)	Pathogenic	2013-09-05	2013-12-18	reviewed_by_expert_panel	germline	SCV000108115	Lynch_syndrome	Variant_causes_splicing_aberration_(not_quantified),_>2_tumours_with_MSH6_protein_loss,_co-segregation_with_disease_&_absent_in_1000_genomes.
NM_000179.2:c.3699_3702del	MSH6	frameshift_variant	102582	1	NA	NA	-	-	-	-	36593	45255	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48033395_48033398del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3699_3702del	-	MSH6:2956	SO:0001589|frameshift_variant	1	193922343	-	Mayo_Clinic|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-04-03|2013-09-05|2019-01-29|2016-10-12|0000-00-00|2017-12-04|2016-07-14|2018-12-26|2015-06-03	2015-11-20|2013-12-18|2020-02-26|2018-11-06|2015-11-19|2019-01-29|2017-08-01|2019-03-28|2017-06-22	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|unknown	SCV000052938|SCV000108129|SCV000172781|SCV000903767|SCV000257273|SCV000279110|SCV000601584|SCV000551259|SCV000677728	Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_nonpolyposis_colorectal_cancer_type_5	|Coding_sequence_variation_resulting_in_a_stop_codon|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_deletion_of_four_nucleotides_in_MSH6_is_denoted_c.3699_3702delAGAA_at_the_cDNA_level_and_p.Lys1233AsnfsX6_(K1233NfsX6)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TTAA[delAGAA]CTTG._The_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_an_Asparagine_at_codon_1233,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_c.3699_3702delAGAA_has_been_reported_in_association_with_Lynch_syndrome_(Bonadona_2011,_Goldberg_2014,_Raymond_2015,_Yurgelun_2015,_Ring_2016)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys1233Asnfs*6)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_Lynch_syndrome_(PMID:_18389388,_21642682)._This_variant_is_also_known_as_c.3697_3700delAAAG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_36593)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000179.2:c.3939_3957dup	MSH6	frameshift_variant	101838	1	NA	NA	-	-	-	-	89486	94960	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48033728_48033746dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2655028|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3939_3957dup	-	MSH6:2956	SO:0001587|nonsense	1	63750767	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2015-11-20|0000-00-00|2019-07-17|2018-09-10|2015-07-24|2018-07-27|0000-00-00|2016-08-12|2018-12-24	2013-12-18|2016-03-03|2017-04-19|2019-09-24|2020-02-26|2017-12-21|2019-01-29|2017-10-31|2018-08-31|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000108169|SCV000266096|SCV000592661|SCV000695901|SCV000184335|SCV000690421|SCV000211388|SCV000257288|SCV000888282|SCV000283830	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon|||Variant_summary:_MSH6_c.3939_3957dup19_(p.Ala1320SerfsX5)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory._The_variant_was_absent_in_249800_control_chromosomes._c.3939_3957dup19_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Lynch_Syndrome_(Goodfellow_2003,_Barnetson_2006,_Chong_2009,_Baglietto_2009,_Kerr_2016)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_19_nucleotides_is_denoted_MSH6_c.3939_3957dup19_at_the_cDNA_level_and_p.Ala1320SerfsX5_(A1320SfsX5)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_duplicated_in_brackets,_is_TTAT[dup19]GCAA._The_duplication_causes_a_frameshift,_which_changes_an_Alanine_to_a_Serine_at_codon_1320,_and_creates_a_premature_stop_codon_at_position_5_of_the_new_reading_frame_resulting_in_the_last_41_amino_acids_being_replaced_by_four_incorrect_ones._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._MSH6_c.3939_3957dup19_has_been_reported_in_association_with_Lynch_syndrome_(Goodfellow_2003,_Barnetson_2006,_Hampel_2008,_Chong_2009,_Yurgelun_2015,_Kerr_2016,_Nowak_2016)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|||This_sequence_change_inserts_19_nucleotides_in_exon_9_of_the_MSH6_mRNA_(c.3939_3957dup),_causing_a_frameshift_at_codon_1320._This_creates_a_premature_translational_stop_signal_within_the_last_15_codons_in_the_penultimate_exon_of_the_MSH6_mRNA_(p.Ala1320Serfs*5)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_41_amino_acids_of_the_MSH6_protein._This_variant_has_been_reported_in_individuals_with_colorectal_cancer,_and_families_affected_with_Lynch_syndrome_(PMID:_18809606,_19459153,_25980754,_27456091,_26845104)._It_has_also_been_reported_in_an_individual_affected_with_breast_cancer_(PMID:_25186627),_and_individuals_affected_with_endometrial_and_ovarian_cancer_(PMID:_26552419,_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89486)._A_different_MSH6_variant,_c.3959_3962delCAAG_(p.Ala1320Glufs*6),_creating_a_frameshift_at_the_same_Ala1320_amino_acid,_has_been_reported_as_an_Ashkenazi_Jewish_founder_mutation_known_to_cause_Lynch_syndrome_(PMID:_21155762)._While_no_functional_studies_have_been_performed_to_test_the_effects_of_this_particular_variant_on_MSH6_protein_function_or_stability,_it_is_expected_to_delete_the_C-terminal_portion_of_the_conserved_MutS_domain_(PMID:_17531815,_24100870)._This_domain_is_necessary_for_the_heterodimerization_of_MSH6_and_MSH2_(PMID:_15952900,_16464007)._This_suggests_that_deletion_of_this_region_of_the_MSH6_protein_is_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.3957dup	MSH6	frameshift_variant	101534	1	NA	NA	-	-	-	-	433931	427192	Lynch_syndrome	-	Orphanet:ORPHA144	-	NC_000002.11:g.48033746dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	587779297	-	Sinai_Health_System	Pathogenic	2015-03-11	2017-04-19	_single_submitter	germline	SCV000592664	Lynch_syndrome	
NM_000179.2:c.3959_3962del	MSH6	frameshift_variant	101508	1	NA	NA	-	-	-	-	89488	94962	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48033748_48033751del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	_Inc:MSH6-A19|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2830312	-	MSH6:2956	SO:0001589|frameshift_variant	1	267608120	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|Color|Counsyl|Center_for_Human_Genetics,_Inc|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2015-06-08|2016-07-05|2018-03-09|2019-05-05|2016-09-06|2016-09-21|2016-11-01|2018-10-16|2016-07-25|2019-01-05	2013-12-18|2017-04-19|2018-01-25|2019-03-21|2020-02-26|2017-10-26|2016-11-23|2017-12-20|2019-01-29|2018-08-31|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline	SCV000108171|SCV000592665|SCV000695902|SCV000966976|SCV000273693|SCV000685467|SCV000489342|SCV000781796|SCV000566279|SCV000601592|SCV000551155	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||Variant_summary:_The_MSH6_c.3959_3962delCAAG_(p.Ala1320Glufs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH6_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._If_this_variant_escapes_NMD,_it_is_expected_to_truncate_P-loop_containing_nucleoside_triphosphate_hydrolase._Other_similar_truncations_variants_in_this_gene_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Ala1320fs)._This_variant_is_absent_in_122768_control_chromosomes._This_variant_has_been_reported_in_literature_as_a_pathogenic_variant_found_in_several_patients_with_Lynch_syndrome_related_cancers_(Goodfellow_2003,_Raskin_2015)._It_is_regarded_as_a_founder_mutation_in_Ashkenazi_Jews._Multiple_clinical_labs/reputable_databases_have_classified_it_as_pathogenic._Taken_together,_this_variant_is_classified_as_Pathogenic.|The_p.Ala1320fs_variant_in_MSH6_has_been_reported_in_at_least_15_individuals_wit_h_Lynch_Syndrome-associated_cancers_(Goodfellow_2003,_Hampel_2005,_Raskin_2011,_Goldberg_2014,_Yurgelun_2015)_and_is_believed_to_be_an_Ashkenazi_Jewish_founder_variant_(Raskin_2011)._It_has_also_been_reported_in_the_compound_heterozygous_st_ate_in_one_family_with_constitutional_mismatch_repair_deficiency_syndrome,_where_the_variant_was_identified_in_3_siblings_who_also_had_a_second_pathogenic_varia_nt_in_MSH6_(Bakry_2014)._This_variant_has_been_identified_in_3/9796_Ashkenazi_Je_wish_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broad_institute.org:_dbSNP_rs267608120)._This_variant_is_predicted_to_cause_a_frameshi_ft,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1320_an_d_leads_to_a_premature_termination_codon_6_amino_acids_downstream._Although_nons_ense_mediated_decay_is_generally_less_likely_to_occur_at_this_position_(within_t_he_terminal_50_bases_of_the_penultimate_exon),_tumors_from_two_patients_with_thi_s_variant_have_been_found_to_have_loss_of_MSH6_protein_expression_(Raskin_2011,_Bakry_2014)._Heterozygous_loss_of_function_of_the_MSH6_gene_is_an_established_di_sease_mechanism_in_individuals_with_Lynch_syndrome._Additionally,_this_variant_h_as_been_classified_as_pathogenic_on_Sept._5,_2013_by_the_ClinGen-approved_InSiGH_T_expert_panel_(SCV000108171.2)._In_summary,_this_variant_meets_criteria_to_be_c_lassified_as_pathogenic_for_Lynch_Syndrome_in_an_autosomal_dominant_manner_based_upon_presence_in_multiple_affected_individuals,_very_low_frequency_in_the_gener_al_population,_functional_evidence._ACMG/AMP_Criteria_applied_(Richards_2015):_P_S4,_PS3,_PM2,_PM4.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_deletion_of_four_nucleotides_in_MSH6_is_denoted_c.3959_3962delCAAG_at_the_cDNA_level_and_p.Ala1320GlufsX6_(A1320EfsX6)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AAAG[delCAAG]AGAA._The_deletion_causes_a_frameshift,_which_changes_an_Alanine_to_a_Glutamic_Acid_at_codon_1320,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame,_resulting_in_the_last_41_correct_amino_acids_being_replaced_by_5_incorrect_ones._This_frameshift_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._MSH6_c.3959_3962delCAAG_has_been_observed_in_several_individuals_with_Lynch_syndrome,_has_been_reported_in_the_compound_heterozygous_state_in_one_family_with_three_individuals_with_Constitutional_Mismatch_Repair_Deficiency_(CMMR-D),_and_is_published_as_an_Ashkenazi_Jewish_founder_variant_(Goodfellow_2003,_Raskin_2011,_Baris_2016)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_MSH6_gene_(p.Ala1320Glufs*6)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_41_amino_acids_of_the_MSH6_protein._This_variant_is_present_in_population_databases_(rs267608119,_ExAC_0.002%)._This_variant_has_been_reported_in_numerous_individuals_and_families_affected_with_Lynch_syndrome,_and_is_considered_a_founder_mutation_in_the_Ashkenazi_Jewish_population_(PMID:_12732731,_21155762,_20028993,_24440087,_23990280,_25430799,_20007843,_26544533)._This_variant_is_also_known_as_3956_3959delAAGC_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89488)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.3980_3983dup	MSH6	frameshift_variant	100980	1	NA	NA	-	-	-	-	184998	182191	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48033769_48033772dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	1553333738	-	Ambry_Genetics|Color|Invitae|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|GeneDx|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2017-11-01|2017-11-13|2017-04-05|0000-00-00|2017-11-09|2018-03-23	2020-02-26|2018-11-06|2017-10-05|2015-11-19|2019-01-29|2019-03-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline	SCV000214983|SCV000905461|SCV000218896|SCV000257290|SCV000568734|SCV000967756	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colon_cancer|not_provided|not_provided|Lynch_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_inserts_4_nucleotides_in_exon_9_of_the_MSH6_mRNA_(c.3980_3983dupATCA),_causing_a_frameshift_at_codon_1330._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_MSH6_mRNA_(p.Leu1330Valfs*12)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_31_amino_acids_of_the_MSH6_protein._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_colorectal_cancer_or_endometrial_cancer_(PMID:_20028993)._A_different_variant_(c.3984_3987dup),_leading_to_the_same_protein_effect_(p.Leu1330Valfs*12),_is_a_known_Lynch_syndrome_founder_mutation_in_the_Ashkenazi_Jewish_population._This_variant_has_been_shown_to_abolish_MSH6_expression_and_cause_tumor_microsatellite_instability_(PMID:_19851887)._It_has_also_been_reported_in_individuals_affected_with_constitutional_mismatch_repair_deficiency_syndrome_(PMID:_24440087),_and_segregated_with_disease_in_a_family_affected_with_colorectal_cancer_(PMID:_14520694)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_duplication_of_four_nucleotides_in_MSH6_is_denoted_c.3980_3983dupATCA_at_the_cDNA_level_and_p.Leu1330ValfsX12_(L1330VfsX12)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_duplicated_in_brackets,_is_ATGA[dupATCA]GTCA._The_duplication_causes_a_frameshift_which_changes_a_Leucine_to_a_Valine_at_codon_1330,_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_as_the_last_31_amino_acids_are_replaced_with_11_incorrect_amino_acids._MSH6_c.3980_3983dupATCA_has_been_observed_in_at_least_one_individual_with_a_personal_history_of_colorectal_or_endometrial_cancer_(Baglietto_2010)._In_addition,_an_adjacent_duplication_event_resulting_in_the_same_frameshift_effect,_MSH6_c.3984_3987dupGTCA,_has_been_reported_in_association_with_Lynch_syndrome_and_was_observed_in_trans_with_another_pathogenic_MSH6_variant_in_at_least_one_family_with_constitutional_mismatch_repair_deficiency_syndrome_(Goldberg_2010,_Raskin_2011,_Bakry_2014)._Based_on_currently_available_evidence,_we_consider_MSH6_c.3980_3983dupATCA_to_be_pathogenic.|The_p.Leu1330fs_variant_in_MSH6_has_been_reported_in_at_least_1_individual_with_Lynch_syndrome-associated_cancers_(Baglietto_2010)._Additionally,_another_varian_t_at_this_position_(c.3984_3987dupGTCA)_leading_to_the_same_frameshift_has_been_described_as_an_Ashkenazi_Jewish_founder_variant,_and_has_been_shown_to_cause_lo_ss_of_expression_of_MSH6_protein_(Goldberg_2010)._This_variant_has_also_been_rep_orted_by_other_clinical_laboratories_in_ClinVar_(Variation_ID_184998)_and_has_be_en_identified_in_1/109482_European_chromosomes_by_gnomAD_(http://gnomad.broadins_titute.org)._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_p_rotein?s_amino_acid_sequence_beginning_at_position_1330_and_leads_to_a_premature_termination_codon_12_amino_acids_downstream._Although_this_termination_codon_oc_curs_within_the_last_exon_and_is_more_likely_to_escape_nonsense_mediated_decay_(_NMD),_the_available_evidence_from_the_other_Ashkenazi_Jewish_founder_variant_sho_ws_that_the_variant_ultimately_leads_to_loss_of_function._Heterozygous_loss_of_f_unction_of_the_MSH6_gene_is_an_established_disease_mechanism_in_individuals_with_Lynch_syndrome._In_summary,_this_variant_meets_criteria_to_be_classified_as_pat_hogenic_for_Lynch_syndrome_in_an_autosomal_dominant_manner_based_upon_the_predic_ted_impact_to_the_protein_and_the_presence_of_an_established_pathogenic_variant_with_the_same_amino_acid_change._ACMG/AMP_Criteria_applied:_PS1:_PVS1_Strong,_PM_2.
NM_000179.2:c.4001+12_4001+15dup	MSH6	splice_donor_variant	100152	22	15414	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.4002-3_4005del	MSH6	splice_acceptor_variant,coding_sequence_variant,intron_variant	99870	4	15078	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.4002-3_4006del	MSH6	splice_acceptor_variant,coding_sequence_variant,intron_variant	99870	9	15078	17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000249.3:c.546-1G>C	MLH1	splice_acceptor_variant	102568	1	NA	NA	-	-	-	-	644548	651064	Hereditary_nonpolyposis_colon_cancer	-	Orphanet:ORPHA443090	-	NC_000003.11:g.37053310G>C	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MLH1:4292	SO:0001574|splice_acceptor_variant	1	-	-	Invitae	Likely_pathogenic	2018-08-16	2019-03-28	_single_submitter	germline	SCV000938112	Hereditary_nonpolyposis_colon_cancer	This_sequence_change_affects_an_acceptor_splice_site_in_intron_6_of_the_MLH1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MLH1-related_disease._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_MLH1_are_known_to_be_pathogenic_(PMID:_15713769,_24362816)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_000249.3:c.588del	MLH1	frameshift_variant	102660	1	NA	NA	-	-	-	-	90287	95761	Hereditary_cancer-predisposing_syndrome|Lynch_syndrome	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144	-	NC_000003.11:g.37053353del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.588del	-	MLH1:4292	SO:0001623|5_prime_UTR_variant	1	63751653	-	Sinai_Health_System|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2013-09-05|0000-00-00|2018-09-20	2013-12-18|2017-04-19|2020-02-26	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000106785|SCV000592363|SCV000669516	Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000249.3:c.1039-7_1040del	MLH1	splice_acceptor_variant,coding_sequence_variant,intron_variant	52280	9	12666	1	-	-	-	-	801955	790387	Lynch_syndrome_II	-	OMIM:609310	-	NC_000003.11:g.37067121_37067129del	_single_submitter	Uncertain_significance	-	-	Deletion	SO:0000159	-	-	MLH1:4292	SO:0001574|splice_acceptor_variant	0	-	-	Mendelics	Uncertain_significance	2019-05-28	2019-10-22	_single_submitter	unknown	SCV001136399	Lynch_syndrome_II	
NM_000249.3:c.1039-4_1040del	MLH1	splice_acceptor_variant,coding_sequence_variant,intron_variant	68786	7	13338	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000249.3:c.1410-2A>G	MLH1	splice_acceptor_variant	102706	3	NA	NA	-	-	-	-	455386	452453	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_II	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333991,OMIM:609310	-	NC_000003.11:g.37070273A>G	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MLH1:4292	SO:0001574|splice_acceptor_variant	1	746536721	-	Invitae|Mendelics|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2017-10-30|2019-05-28|2019-12-06	2018-04-02|2019-10-22|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline	SCV000625062|SCV001136413|SCV001171717	Hereditary_nonpolyposis_colon_cancer|Lynch_syndrome_II|Hereditary_cancer-predisposing_syndrome	This_sequence_change_affects_an_acceptor_splice_site_in_intron_12_of_the_MLH1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_a_MLH1-related_disease._In_summary,_donor_and_acceptor_splice_site_variants_are_typically_loss-of-function_(PMID:_16199547),_and_loss-of-function_variants_in_MLH1_are_known_to_be_pathogenic_(PMID:_15713769,_24362816)._However,_without_additional_functional_and/or_genetic_data,_this_variant_has_been_classified_as_Likely_Pathogenic.||Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity
NM_000249.3:c.1896+1G>T	MLH1	splice_donor_variant	102678	1	NA	NA	-	-	-	-	89926	95400	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000003.11:g.37089175G>T	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1896+1G>T	-	MLH1:4292	SO:0001627|intron_variant	1	267607867	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|GeneDx|Invitae|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2019-06-21|2018-08-10|2018-06-21|2017-02-24	2019-06-21|2019-01-29|2018-08-29|2020-02-26	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000106401|SCV000568570|SCV000543560|SCV001174121	Lynch_syndrome|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome	Interrupts_canonical_donor_splice_site|This_variant_is_denoted_MLH1_c.1896+1G>T_or_IVS16+1G>T_and_consists_of_a_G>T_nucleotide_substitution_at_the_+1_position_of_intron_16_of_the_MLH1_gene._This_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_identified_in_several_individuals_suspected_of_having_Lynch_syndrome,_including_two_whose_tumors_displayed_microsatellite_instability_(MSI-H),_with_one_also_exhibiting_loss_of_MLH1_protein_expression_on_immunohistochemistry_(IHC)_(Nilbert_1999,_Wahlberg_2002,_Mangold_2005,_Dymerska_2010,_Bonadona_2011)._Based_on_the_currently_available_information,_we_consider_MLH1_c.1896+1G>T_to_be_a_likely_pathogenic_variant.|This_sequence_change_affects_a_donor_splice_site_in_intron_16_of_the_MLH1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_affected_with_Lynch_syndrome_(PMID:Â¬â€ 10533476,Â¬â€ 15849733,Â¬â€ 21642682).Â¬â€ This_variant_is_also_described_as_aÂ¬â€ GAGgtg->GAGttgÂ¬â€ changeÂ¬â€ in_the_splice_donor_siteÂ¬â€ in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89926)._A_different_variant_affecting_this_nucleotide_(c.1896+1G>A)_has_been_determined_to_be_pathogenic_(PMID:_12067992,_Invitae)._This_suggests_that_this_nucleotide_is_important_for_normal_RNA_splicing,_and_that_other_variants_at_this_position_may_also_be_pathogenic._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_MLH1_are_known_to_be_pathogenic_(PMID:_15713769,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation
NM_000249.3:c.1897-2A>G	MLH1	splice_acceptor_variant	102638	1	NA	NA	-	-	-	-	89932	95406	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Muir-Torré_syndrome|Lynch_syndrome|Lynch_syndrome_II|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1321489,OMIM:158320,Orphanet:ORPHA587,SNOMED_CT:403824007|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1333991,OMIM:609310|MedGen:CN517202	-	NC_000003.11:g.37090006A>G	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1897-2A>G	-	MLH1:4292	SO:0001627|intron_variant	1	267607871	-	Fulgent_Genetics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic	2019-06-21|2016-05-24|2018-05-17|2018-07-03|2019-06-14|2018-09-30|2017-09-29|2018-10-31	2019-06-21|2018-01-25|2019-01-29|2018-08-29|2020-02-26|2018-11-06|2018-06-20|2018-11-14	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown	SCV000106407|SCV000696134|SCV000565163|SCV000625106|SCV000669547|SCV000908649|SCV000785594|SCV000893646	Lynch_syndrome|Lynch_syndrome|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_II|Turcot_syndrome/Muir-Torré_syndrome/Lynch_syndrome_II	Interrupts_canonical_donor_splice_site|Variant_summary:_The_MLH1_c.1897-2A>G_variant_involves_the_alteration_of_a_conserved_intronic_nucleotide._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._3/3_splice_prediction_tools_predict_loss_of_canonical_splicing_acceptor_site._ESEfinder_predicts_loss_of_binding_motifs_for_RNA_splicing_enhancers._This_variant_was_absent_in_121378_control_chromosomes,_and_has_been_shown_to_co-segregate_with_colon_cancer_in_one_family_(RAJKUMAR_MLH1&MSH2_Genetic_Testing_2004)._In_addition,_one_clinical_diagnostic_laboratory_classified_this_variant_as_likely_pathogenic._Taken_together,_this_variant_is_classified_as_likely_pathogenic.|This_variant_is_denoted_MLH1_c.1897-2A>G_or_IVS16-2A>G_and_consists_of_an_A>G_nucleotide_substitution_at_the_-2_position_of_intron_16_of_the_MLH1_gene._The_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_at_least_three_individuals_with_colorectal_cancer,_one_of_whom_had_a_tumor_displaying_microsatellite_instability_(Rajkumar_2004,_Pearlman_2017,_Yurgelun_2017)._We_consider_this_variant_to_be_likely_pathogenic.|This_sequence_change_affects_an_acceptor_splice_site_in_intron_16_of_the_MLH1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_affected_with_colorectal_cancer_(PMID:_28135145,_27978560,_15345113)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89932)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_MLH1_are_known_to_be_pathogenic_(PMID:_15713769,_24362816)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):RNA_Studies|||
NM_000249.3:c.1897-1G>A	MLH1	splice_acceptor_variant	102636	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000249.3:c.2080G>T	MLH1	stop_gained	102412	4	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006218.3:c.766G>T	PIK3CA	stop_gained	102212	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006218.3:c.2307T>A	PIK3CA	stop_gained	101892	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000038.5:c.70C>T	APC	stop_gained	102548	1	15420	0	5&5	1&1	rs145945630	Hereditary cancer-predisposing syndrome&Familial adenomatous polyposis 1	184702	182313	_hereditary|Familial_adenomatous_polyposis_1|not_specified|Familial_adenomatous_polyposis|not_provided	-	Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0006753,MeSH:D013274,MedGen:C0038356,OMIM:613659,SNOMED_CT:126824007|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0032580,Orphanet:ORPHA733,SNOMED_CT:72900001|MedGen:C1851124,OMIM:135290|MedGen:C2713442,OMIM:175100|MedGen:CN169374|MedGen:CN240755|MedGen:CN517202	-	NC_000005.9:g.112090657C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:9468	-	APC:324	SO:0001587|nonsense,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	145945630	-	Ambry_Genetics|Color|Invitae|Counsyl|GeneDx|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-24|2016-05-04|2018-12-11|2016-03-10|2018-06-01|2014-04-22|2018-11-20|2017-01-12|2018-10-31|2017-04-18	2020-02-26|2018-11-06|2019-03-28|2016-11-23|2019-01-29|2017-10-30|2019-04-24|2017-06-30|2018-11-14|2019-03-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline	SCV000214605|SCV000905870|SCV000282812|SCV000488376|SCV000568259|SCV000591013|SCV000918469|SCV000602530|SCV000894347|SCV000731596	_hereditary/Carcinoma_of_colon/Familial_adenomatous_polyposis_1/Neoplasm_of_stomach/Hepatocellular_carcinoma|Familial_multiple_polyposis_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg24*)_in_the_APC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs145945630,_ExAC_0.03%)._This_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_attenuated_familial_adenomatous_polyposis_(FAP)_(PMID:_18433509),_as_well_as_an_individual_with_suspected_Lynch_syndrome_(PMID:_25980754)._Deleterious_variants_in_the_5'_end_of_the_APC_gene_have_been_shown_to_be_associated_with_an_attenuated_phenotype_of_FAP,_since_alternative_translational_initiation_at_codon_184_may_result_in_a_partially_functional_APC_protein_(PMID:_12034871,_16461775,_18433509)._However,_this_has_not_been_experimentally_tested_for_this_particular_variant._In_the_literature,_exon_2_is_also_referred_to_as_exon_1_(PMID:_18433509)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_184702)._Loss-of-function_variants_in_APC_are_known_to_be_pathogenic_(PMID:_17963004,_20685668)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_APC_c.70C>T_at_the_cDNA_level_and_p.Arg24Ter_(R24X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Yurgelun_et_al._(2015)_reported_this_variant_in_an_individual_with_a_Lynch_syndrome-associated_cancer_and/or_colon_polyps_while_Kanter-Smoler_et_al._(2008)_reported_this_variant_in_an_individual_with_an_attenuated_polyposis_phenotype._It_is_considered_pathogenic.||Variant_summary:_APC_c.70C>T_(p.Arg24X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Some_truncating_mutations_in_the_5'_end_of_the_APC_gene_have_been_found_to_be_associated_with_an_attenuated_phenotype_of_familial_adenomatous_polyposis_coli_(AFAP),_as_it_was_demonstrated_that_a_downstream_in-frame_alternative_start_codon_(codon_184)_may_generate_a_partially_functional_protein_(see_e.g._PMID:_12034871)._However,_to_our_knowledge,_no_experimental_evidence_demonstrating_this_scenario_has_been_reported_for_the_variant_of_interest._The_variant_allele_was_found_at_a_frequency_of_1.8e-05_in_276948_control_chromosomes_(gnomAD)._c.70C>T_has_been_reported_in_the_literature_in_an_individual_affected_with_AFAP_(Kanter-Smoler_2008)_and_in_an_other_individual_affected_with_Lynch_syndrome-associated_cancer_and/or_polyps_(Yurgelun_2015)._These_data_indicate_that_the_variant_may_be_associated_with_disease._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic_(5x)/likely_pathogenic(1x)._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|||The_p.Arg24X_variant_in_APC_has_been_reported_in_1_individual_with_attenuated_FA_P_(AFAP)_and_1_individual_with_suspected_Lynch_syndrome_(Kanter-Smoler_2008,_Yur_gelun_2015)_and_has_also_been_reported_by_other_clinical_laboratories_in_ClinVar_(Variant_ID_184702)._It_has_been_identified_in_4/25788_Finnish_chromosomes_by_t_he_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs145945630)._Please_note_that_for_diseases_with_clinical_variability,_reduced_p_enetrance,_or_recessive_inheritance,_pathogenic_variants_may_be_present_at_a_low_frequency_in_the_general_population._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_24,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_APC_gene_is_an_established_disease_mechanism_in_individuals_with_FAP._However,_truncating_variants_in_the_5_'_end_of_the_APC_gene_have_typically_been_associated_with_AFAP_(Jasperson_2017)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_fami_lial_adenomatous_polyposis,_likely_in_the_attenuated_form,_in_an_autosomal_domin_ant_manner,_based_upon_predicted_impact_to_the_protein,_presence_in_affected_ind_ividuals,_and_low_frequency_in_the_general_population._ACMG/AMP_Criteria_applie_d:_PVS1,_PM2_supporting,_PS4_Moderate_(Richards_2015).
NM_000038.5:c.135+1G>A	APC	splice_donor_variant	102554	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000038.5:c.288T>A	APC	stop_gained	102734	1	NA	NA	5	1	rs376213437	not provided	181831	180167	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2713442,OMIM:175100|MedGen:CN240755|MedGen:CN517202	-	NC_000005.9:g.112102953T>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2844350	-	APC:324	SO:0001623|5_prime_UTR_variant	1	376213437	-	Sinai_Health_System|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2016-04-25|2018-04-11|2015-10-02|2018-11-08|2018-02-05	2019-01-29|2018-08-31|2017-10-30|2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000209561|SCV000887513|SCV000591022|SCV000647279|SCV001177888	not_provided|not_provided|Familial_adenomatous_polyposis|Familial_adenomatous_polyposis_1|Hereditary_cancer-predisposing_syndrome	This_pathogenic_variant_is_denoted_APC_c.288T>A_at_the_cDNA_level_and_p.Tyr96Ter_(Y96X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_a_Tyrosine_to_a_premature_stop_codon_(TAT>TAA)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_seven_Scottish_families_all_presenting_with_a_phenotype_suggestive_of_attenuated-FAP_(Ibrahim_2014)._Based_on_current_information,_we_consider_this_variant_to_be_pathogenic.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr96*)_in_the_APC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_with_colon_polyps_(PMID:_26681312)_and_in_7_families_with_attenuated_familial_adenomatous_polyposis_(AFAP)_(PMID:_24549056)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181831)._Using_a_modified_segregation_analysis_based_on_these_7_families,_the_relative_risk_of_colon_cancer_for_carriers_of_this_variant_was_estimated_to_be_30.78_(95%_CI_12.12-78.16)_(PMID:_24549056)._Two_different_variants_(c.288T>G,_c.287dupA)_giving_rise_to_the_same_protein_effect_observed_here_(p.Tyr96*)_have_been_reported_in_individuals_affected_with_or_suspected_of_having_familial_adenomatous_polyposis_(FAP)_(PMID:_20685668,_23159591)._Loss-of-function_variants_in_APC_are_known_to_be_pathogenic_(PMID:_20685668,_17963004)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000038.5:c.471G>A	APC	stop_gained	101300	1	NA	NA	-	-	-	-	411479	394398	Familial_adenomatous_polyposis_1|not_provided	-	OMIM:175100|MedGen:CN517202	-	NC_000005.9:g.112111374G>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	APC:324	SO:0001623|5_prime_UTR_variant	1	1060503328	-	Mayo_Clinic	Pathogenic|Pathogenic	2017-10-12|0000-00-00	2018-04-02|2017-10-31	_single_submitter|no_assertion_criteria_provided	germline|unknown	SCV000552658|SCV000691704	Familial_adenomatous_polyposis_1|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_157_(p.Trp157*)_of_the_APC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Truncating_variants_in_APC_are_known_to_be_pathogenic._This_particular_truncation_has_been_reported_in_the_literature_in_individuals_affected_with_familial_adenomatous_polyposis_(PMID:_20685668,_8381580)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000038.5:c.1530del	APC	frameshift_variant	102618	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.1119_1122del	PMS2	frameshift_variant	102710	2	NA	NA	-	-	-	-	642485	636266	Hereditary_nonpolyposis_colon_cancer	-	Orphanet:ORPHA443090	-	NC_000007.13:g.6029454_6029457TGAC[1]	_single_submitter	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	PMS2:5395	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	-	-	Invitae	Pathogenic	2018-11-29	2019-03-28	_single_submitter	germline	SCV000935442	Hereditary_nonpolyposis_colon_cancer	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln374Serfs*10)_in_the_PMS2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs757679199,_ExAC_0.003%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_PMS2-related_disease._Loss-of-function_variants_in_PMS2_are_known_to_be_pathogenic_(PMID:_21376568,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000535.6:c.1067del	PMS2	frameshift_variant	102682	1	NA	NA	-	-	-	-	140957	150671	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000007.13:g.6029510del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PMS2:5395	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	587781395	-	Ambry_Genetics|GeneDx	Pathogenic|Pathogenic	2015-03-07|2018-04-11	2020-02-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000183997|SCV000566328	Hereditary_cancer-predisposing_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_deletion_of_one_nucleotide_in_PMS2_is_denoted_c.1067delA_at_the_cDNA_level_and_p.Lys356ArgfsX4_(K356RfsX4)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_TTAA[delA]GACC._The_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_an_Arginine_at_codon_356,_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PMS2_c.1067delA_has_been_reported_in_at_least_three_individuals_with_colon_cancer,_two_of_whom_had_tumors_demonstrating_absence_of_PMS2_protein_expression_on_immunohistochemistry,_and_was_also_reported_in_at_least_one_individual_with_endometrial_and_breast_cancer_(Cragun_2014,_Goodenberger_2016,_Rosty_2016)._We_consider_this_variant_to_be_pathogenic.
NM_000535.6:c.1009dup	PMS2	frameshift_variant	102548	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.873del	PMS2	frameshift_variant	102716	1	NA	NA	-	-	-	-	585225	576260	Hereditary_nonpolyposis_colorectal_cancer_type_4	-	OMIM:614337	-	NC_000007.13:g.6035197del	_single_submitter	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	PMS2:5395	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	1261282733	-	Baylor_College_of_Medicine	Likely_pathogenic	2018-02-08	2018-06-14	_single_submitter	germline	SCV000840052	Hereditary_nonpolyposis_colorectal_cancer_type_4	_the_c.873delT_(p.Phe291Leufs*16)_variant_in_the_PMS2_gene_is_classified_as_likely_pathogenic.
NM_000535.6:c.861_864del	PMS2	frameshift_variant	102728	1	15428	1	-	-	-	-	91375	96850	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1838333,OMIM:614337|MedGen:CN517202	-	NC_000007.13:g.6035204_6035207CTGT[2]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.861_864del|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2844935	-	PMS2:5395	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	267608154	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Counsyl|Biochemical_Molecular_Genetic_Laboratory,King_Abdulaziz_Medical_City	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2016-06-07|2018-07-02|2019-04-11|2016-09-28|2018-03-13|0000-00-00|2018-05-09|2019-01-05|2018-03-12|2020-02-05	2013-12-18|2018-01-25|2018-08-20|2020-02-26|2017-10-26|2019-01-29|2017-10-31|2018-08-31|2019-03-28|2018-06-20|2020-02-12	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown|germline|germline|germline|unknown|germline|germline|unknown|germline	SCV000108390|SCV000697395|SCV000838188|SCV000276464|SCV000686247|SCV000490730|SCV000691976|SCV000888419|SCV000261051|SCV000786157|SCV001190842	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_nonpolyposis_colorectal_cancer_type_4|Turcot_syndrome	Coding_sequence_variation_resulting_in_a_stop_codon|Variant_summary:_The_PMS2_c.861_864delACAG_(p.Arg287Serfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_PMS2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.1021delA,_c.1831dupA._c.2186_2187delTC)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_2/120952_control_chromosomes_at_a_frequency_of_0.0000165,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_PMS2_variant_(0.0001136)._The_variant_has_been_reported_in_affected_individuals_in_the_literature,_with_absent_PMS2_protein_via_IHC_and_MSI-H_tumors._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_four_nucleotides_in_PMS2_is_denoted_c.861_864delACAG_at_the_cDNA_level_and_p.Arg287SerfsX19_(R287SfsX19)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_ACAG[ACAG]TTTTTC._The_deletion_causes_a_frameshift,_which_changes_an_Arginine_to_a_Serine_at_codon_287,_and_creates_a_premature_stop_codon_at_position_19_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PMS2_c.861_864delACAG_has_been_seen_in_an_individual_with_early_onset_rectal_cancer_(Senter_2008)_and_in_a_woman_with_early_onset_endometrial_cancer_with_loss_of_PMS2_staining_by_immunohistochemistry_(Moline_2013)._We_consider_this_variant_to_be_pathogenic.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg287Serfs*19)_in_the_PMS2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs267608154,_ExAC_0.01%)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_Lynch_syndrome-associated_cancers_(PMID:_18602922,_25980754,Â¬â€ 23612316),_and_pre-symptomatic_or_symptomatic_Lynch_syndrome_(PMID:_26110232,_27696107)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_91375)._Loss-of-function_variants_in_PMS2_are_known_to_be_pathogenic_(PMID:_21376568,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||
NM_000535.6:c.802dup	PMS2	frameshift_variant,splice_region_variant	101834	1	NA	NA	-	-	-	-	91369	96844	Hereditary_nonpolyposis_colon_cancer|Lynch_syndrome	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C1333990,Orphanet:ORPHA144	-	NC_000007.13:g.6036963dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.802dup	-	PMS2:5395	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	267608149	-	_Partners_HealthCare_Personalized_Medicine|Invitae	Pathogenic|Pathogenic|Pathogenic	2013-09-05|2017-12-14|2018-12-18	2013-12-18|2019-03-21|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000108384|SCV000966983|SCV000955610	Lynch_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon|The_p.Tyr268fs_variant_in_PMS2_has_been_reported_in_at_least_1_individual_with_P_MS2-associated_cancer_and_absence_of_PMS2_by_IHC_in_the_tumor_(Senter_2008,_Rost_y_2016)._It_was_also_identified_in_1/30264_South_Asian_and_1/110626_European_chr_omosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitut_e.org)._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protei_n?s_amino_acid_sequence_beginning_at_position_268_and_leads_to_a_premature_termi_nation_codon_31_amino_acids_downstream._This_alteration_is_then_predicted_to_lea_d_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_PMS2_ge_ne_is_an_established_disease_mechanism_in_Lynch_syndrome._In_addition,_this_vari_ant_was_classified_as_Pathogenic_on_September_5,_2013_by_the_ClinGen-approved_In_SIGHT_expert_panel_(ClinVar_SCV000108384.2)._In_summary,_this_variant_meets_crit_eria_to_be_classified_as_pathogenic_for_Lynch_syndrome_in_an_autosomal_dominant_based_upon_predicted_impact_on_protein._ACMG/AMP_Criteria_applied:_PVS1,_PM2,_PP_4.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr268Leufs*31)_in_the_PMS2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs267608149,_ExAC_0.007%)._This_variant_has_been_observed_in_an_individual_affected_with_colorectal_cancer_(PMID:Â¬â€ 18602922)._This_variant_is_also_known_as_c.802_803insT_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_91369)._Loss-of-function_variants_in_PMS2_are_known_to_be_pathogenic_(PMID:_21376568,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000535.6:c.741_742insGTGTGTGAAG	PMS2	frameshift_variant	102048	2	15054	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.736_740del	PMS2	frameshift_variant	102158	2	15218	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.706-1G>T	PMS2	splice_acceptor_variant	62394	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.706-1G>A	PMS2	splice_acceptor_variant	62394	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.706-2A>G	PMS2	splice_acceptor_variant	56760	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.697C>T	PMS2	stop_gained	102750	2	15422	1	5&5&5	3&1&1	rs587779343	Lynch syndrome&Hereditary cancer-predisposing syndrome&not provided	91362	96837	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000007.13:g.6038747G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.697C>T	-	PMS2:5395	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	587779343	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2017-05-05|2018-05-17|2017-02-13|2018-06-14|2018-12-18	2013-12-18|2018-01-25|2020-02-26|2017-10-26|2019-01-29|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000108375|SCV000697377|SCV000214344|SCV000686226|SCV000149610|SCV000551989	Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon|Variant_summary:_The_PMS2_c.697C>T_(p.Gln233X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_PMS2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.735dupG_[p.Pro246fsX3],_c.823C>T_[p.Gln275X],_and_c.1021delA_[p.Arg341fsX15])._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_the_large_control_database_ExAC_at_a_frequency_of_0.0000082_(1/121462_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_PMS2_variant_(0.0001136)._In_the_literature,_patients_and_families_with_colorectal_cancer_and_other_Lynch_syndrome-associated_cancers_have_been_identified_as_carriers_of_the_variant_and_include_supporting_molecular_data,_such_as_absence_of_PMS2_in_tumor_samples_(via_immunohistochemical_staining)_and_microsatellite_instability_(Niessen_GCC_2009:_van_der_Klift_HM_2016)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_PMS2_c.697C>T_at_the_cDNA_level_and_p.Gln233Ter_(Q233X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_with_a_personal_and/or_family_history_consistent_with_Lynch_syndrome_(Niessen_2009,_van_der_Klift_2016,_Rossi_2017)_and_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln233*)_in_the_PMS2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587779343,_ExAC_0.001%)._This_variant_has_been_observed_in_individualsÂ¬â€ affected_with_Lynch_syndrome_and_suspected_Lynch_syndrome_(PMID:_19132747,_20186688,_26110232,_25512458,_27435373)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_91362)._Loss-of-function_variants_in_PMS2_are_known_to_be_pathogenic_(PMID:_21376568,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000535.6:c.686_687del	PMS2	frameshift_variant	102746	1	NA	NA	-	-	-	-	411063	395972	Hereditary_nonpolyposis_colon_cancer	-	Orphanet:ORPHA443090	-	NC_000007.13:g.6038757_6038758AG[1]	_single_submitter	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	PMS2:5395	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	746766787	-	Invitae	Pathogenic	2017-02-08	2017-10-05	_single_submitter	germline	SCV000552024	Hereditary_nonpolyposis_colon_cancer	This_sequence_change_deletes_2_nucleotides_from_exon_6_of_the_PMS2_mRNA_(c.686_687delCT),_causing_a_frameshift_at_codon_229._This_creates_a_premature_translational_stop_signal_(p.Ser229Cysfs*19)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_PMS2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_Lynch_syndrome-related_cancer_and_homozygous_in_a_patient_with_constitutional_mismatch_repair_deficiency_(PMID:Â¬â€ 25430799,_26544533)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000535.6:c.613C>T	PMS2	stop_gained	102750	1	15422	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.564dup	PMS2	frameshift_variant	102742	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.400C>T	PMS2	stop_gained	102410	1	15424	0	5&5&5&5	0&3&1&1	rs63750871	Turcot syndrome&Lynch syndrome&Hereditary cancer-predisposing syndrome&not provided	9234	24273	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1838333,OMIM:614337|MedGen:CN517202	-	NC_000007.13:g.6042221G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:600259.0001|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.400C>T|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2831209	-	PMS2:5395	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	63750871	-	OMIM|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2004-05-01|2013-09-05|2017-10-20|2018-07-13|2018-03-02|2015-03-30|2017-06-29|2017-11-01|2018-10-23|2017-05-22|2017-09-19	2015-06-10|2013-12-18|2019-03-21|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2018-08-31|2019-03-28|2017-06-22|2018-06-14	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline	SCV000030036|SCV000108365|SCV000713220|SCV000918060|SCV000187198|SCV000686201|SCV000149604|SCV000889627|SCV000166386|SCV000677741|SCV000840047	Turcot_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4	|Coding_sequence_variation_resulting_in_a_stop_codon|The_p.Arg134X_variant_in_PMS2_has_been_reported_in_the_heterozygous_state_in_5_f_amilies_(6_individuals)_with_Lynch_syndrome-associated_cancers_(Parsons_1995,_No_rquist_2016,_Rosty_2016)_and_in_the_compound_heterozygous_state_in_2_families_(3_individuals)_with_constitutional_mismatch_repair_disease_(CMMRD:_De_Vos_2004,_L_avoine_2015)._In_vitro_functional_studies_provide_some_evidence_that_the_p.Arg13_4X_variant_may_decrease_mismatch_repair_function_resulting_in_microsatellite_ins_tability_(Parsons_1995,_Nicolaides_1998,_Gibson_2006)._This_variant_has_also_bee_n_identified_in_1/126384_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs63750871)._This_nonsense_var_iant_leads_to_a_premature_termination_codon_at_position_134,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_P_MS2_gene_is_an_established_disease_mechanism_in_Lynch_syndrome._In_addition,_thi_s_variant_was_classified_as_pathogenic_on_September_5,_2013_by_the_ClinGen-appro_ved_InSiGHT_expert_panel_(SCV000108365.2)._In_summary,_this_variant_meets_criter_ia_to_be_classified_as_pathogenic_for_Lynch_syndrome_in_an_autosomal_dominant_ma_nner,_based_upon_predicted_impact_on_the_protein,_presence_in_multiple_affected_individuals,_very_low_frequency_in_the_general_population_and_functional_evidenc_e.|Variant_summary:_PMS2_c.400C>T_(p.Arg134X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.697C>T,_p.Gln233X:_c.736_741delinsTGTGTGTGAAG,_p.Pro246fsX3)._The_variant_allele_was_found_at_a_frequency_of_8.2e-06_in_121392_control_chromosomes._c.400C>T_has_been_reported_in_the_literature_in_individuals_affected_with_Turcot_syndrome_who_carry_a_second_pathogenic_variant_(DeVos_2004)_and_in_patients_with_Lynch_Syndrome_and_colorectal_cancer_(Senter_2008,_Durno_2005)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._Additionally,_this_variant_was_found_to_have_a_dominant_negative_effect_in_hamster_fibroblast_cells_(Nicolaides_1998)_but_not_in_human_fibroblast_cells_(Yamada_2003)._However,_the_variant_was_found_to_abrogate_the_interaction_with_MLH1_(Nicolaides_1998),_a_known_pathogenic_mechanism._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_PMS2_c.400C>T_at_the_cDNA_level_and_p.Arg134Ter_(R134X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_the_homozygous_or_compound_heterozygous_state_in_at_least_three_young_individuals_with_constitutional_mismatch_repair_deficiency_(CMMR-D)_syndrome_and_a_history_of_caf?_au_lait_spots,_multiple_cancers,_and_constitutional_microsatellite_instability_(Hamilton_1995,_De_Vos_2004,_Daou_2015,_Lavoine_2015)._A_cell-line_derived_from_one_of_the_compound_heterozygous_patients_displayed_absent_mismatch_repair_(MMR)-activity_(Parsons_1995)._PMS2_Arg134Ter_has_also_been_observed_in_the_heterozygous_state_in_several_individuals_with_Lynch-related_tumors_showing_isolated_loss_of_PMS2_on_tumor_immunohistochemistry_(Senter_2008,_Vaughn_2013,_Rosty_2016)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg134*)_in_the_PMS2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs63750871,_ExAC_0.001%)._This_variant_has_been_reported_in_the_homozygous_state_and_in_trans_with_different_pathogenic_PMS2_variants_in_individuals_with_constitutional_mismatch_repair_deficiency_(CMMR-D)_(PMID:_25850602,_15077197,_26318770)._This_variant_has_also_been_reported_in_individuals_with_colorectal_cancer,_Lynch_syndrome_and_ovarian_cancer_(PMID:_18602922,_23012243,_26681312,_26895986)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_9234)._While_an_experimental_study_has_shown_that_this_truncating_variant_does_not_decrease_mismatch_repair_activity_in_a_human_fibroblast_cell_line_(PMID:_12714694),_two_additional_studies_in_patient-derived_cell_lines_and_a_hamster_cell_line_have_shown_that_cells_carrying_this_variant_have_impaired_mismatch_repair_activity_(PMID:_7632227,_9488480)._Loss-of-function_variants_in_PMS2_are_known_to_be_pathogenic_(PMID:_21376568,_24362816)._For_these_reasons,_this_change_has_been_classified_as_Pathogenic.||The_c.400C>T_(p.R134*)_variant_in_the_PMS2_gene_is_predicted_to_introduce_a_premature_translation_stop_codon._This_variant_has_been_reported_in_the_literature_in_multiple_individuals_with_constitutional_mismatch_repair_deficiency_syndrome_as_well_as_in_individuals_with_colorectal_cancer,_Lynch_syndrome_and_ovarian_cancer_(PMID:_15077197,_18602922,_23012243,_26681312,_26895986)._The_c.400C>T_(p.R134*)_variant_in_the_PMS2_gene_is_classified_as_pathogenic.
NM_000535.6:c.325dup	PMS2	frameshift_variant	100168	1	NA	NA	-	-	-	-	233300	233589	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838333,OMIM:614337|MedGen:CN517202	-	NC_000007.13:g.6043354dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	PMS2:5395	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	587781716	-	Baylor_College_of_Medicine	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-06|2017-11-22|2018-06-01|2018-10-15|2017-05-11	2020-02-26|2018-11-06|2018-08-29|2019-01-29|2018-06-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000277647|SCV000909678|SCV000625635|SCV000778899|SCV000840044	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colon_cancer|not_provided|Hereditary_nonpolyposis_colorectal_cancer_type_4	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous||This_sequence_change_inserts_1_nucleotide_in_exon_4_of_the_PMS2_mRNA_(c.325dupG),_causing_a_frameshift_at_codon_109._This_creates_a_premature_translational_stop_signal_(p.Glu109Glyfs*30)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_colorectal_cancer_and_in_a_family_affected_with_constitutional_mismatch_repair_deficiency_(PMID:_20205264,_21261604).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_233300)._Experimental_studies_have_shown_that_this_insertion_causes_out-of-frame_exon_skipping_in_a_minigene_assay_(PMID:_26247049)._Loss-of-function_variants_in_PMS2_are_known_to_be_pathogenic_(PMID:_21376568,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_duplication_of_one_nucleotide_in_PMS2_is_denoted_c.325dupG_at_the_cDNA_level_and_p.Glu109GlyfsX30_(E109GfsX30)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_CGGGGG[dupG]AAGC._The_duplication_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_a_Glycine_at_codon_109,_and_creates_a_premature_stop_codon_at_position_30_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay_(NMD)._This_variant_has_been_identified_in_multiple_individuals_with_a_personal_and/or_family_history_of_colon_cancer,_one_of_whom_was_diagnosed_with_an_early_onset_colorectal_tumor_that_demonstrated_absence_of_PMS2_on_immunohistochemistry_(IHC)_(Vaughn_2010,_Suerink_2015,_Goodenberger_2016)._It_has_also_been_reported_in_at_least_one_individual_with_constitutional_mismatch_repair_deficiency_(CMMR-D)_in_whom_a_second_PMS2_variant_had_been_identified_on_the_opposite_allele_(in_trans)_(Johannesma_2011)._Minigene_and_patient-derived_cell_line_RNA_analyses_suggest_this_variant_may_be_associated_with_a_shift_towards_expression_of_alternative_out-of-frame_transcripts_that_are_subjected_to_NMD_(van_der_Klift_2015)._We_consider_this_variant_to_be_pathogenic.|This_c.325dup_(p.Glu109Glyfs*30)_variant_has_been_reported_in_a_cohort_of_145_unrelated_patients_with_colorectal_cancer_[PMID_20205264]._This_variant_has_been_observed_in_3_heterozygous_individuals_from_the_ExAC_population_database_(http://exac.broadinstitute.org/variant/7-6043348-T-TC)._This_1bp_duplication_creates_a_frameshift_and_is_predicted_to_create_a_premature_stop_codon_30_amino_acid_downstream,_and_to_result_in_a_loss_of_function_of_the_PMS2_protein._This_variant_is_thus_classified_as_pathogenic.
NM_000535.6:c.250+2T>G	PMS2	splice_donor_variant	102262	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.164-1G>A	PMS2	splice_acceptor_variant	101630	2	NA	NA	-	-	-	-	484252	474770	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000007.13:g.6043690C>T	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PMS2:5395	SO:0001574|splice_acceptor_variant	1	763308607	-	Ambry_Genetics	Likely_pathogenic	2016-04-15	2020-02-26	_single_submitter	germline	SCV000670751	Hereditary_cancer-predisposing_syndrome	_2)_without_other_strong_(B-level)_evidence_supporting_pathogenicity:in_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Co-occurence_with_mutation_in_same_gene_(phase_unknown)
NM_000535.6:c.121G>T	PMS2	stop_gained	100434	1	NA	NA	-	-	-	-	219674	221737	Lynch_syndrome	-	Orphanet:ORPHA144	-	NC_000007.13:g.6045565C>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PMS2:5395	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	3209663	-	Invitae	Pathogenic	2016-01-31	2016-06-10	_single_submitter	germline	SCV000259681	Lynch_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_41_(p.Glu41*)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_sequence_change_has_not_been_reported_in_the_literature,_truncating_sequence_changes_in_PMS2_are_known_to_be_pathogenic_(PMID:_21376568,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_021930.5:c.42+1G>A	RINT1	splice_donor_variant	90848	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.103dup	RINT1	frameshift_variant	100428	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.165T>A	RINT1	stop_gained	102640	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.181G>T	RINT1	stop_gained	102626	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.449del	RINT1	frameshift_variant	102746	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.559_562dup	RINT1	frameshift_variant	102396	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.703del	RINT1	frameshift_variant	102716	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.740del	RINT1	frameshift_variant	102728	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.792_793del	RINT1	frameshift_variant	102738	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.796del	RINT1	frameshift_variant	102732	6	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.852_855del	RINT1	frameshift_variant	102704	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.989dup	RINT1	frameshift_variant	101098	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1066C>T	RINT1	stop_gained	102652	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1107+2dup	RINT1	splice_donor_variant	102464	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1333+1G>A	RINT1	splice_donor_variant	102652	8	NA	NA	-	-	-	-	547947	538391	Fulminant_hepatic_failure|INFANTILE_LIVER_FAILURE_SYNDROME_3|not_provided	-	Human_Phenotype_Ontology:HP:0004448,MedGen:CN237792|MedGen:CN262533,OMIM:618641|MedGen:CN517202	-	NC_000007.13:g.105190934G>A	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:610089.0001	-	RINT1:60561	SO:0001575|splice_donor_variant	9	375350359	-	Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Invitae|Working_Group:_Pediatric_metabolic_liver_diseases,University_Hospital_Heidelberg|OMIM	Uncertain_significance|Uncertain_significance|Pathogenic|Pathogenic	2017-02-09|2018-12-09|2019-01-14|2019-10-24	2018-02-28|2019-03-28|2019-01-16|2019-10-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided	paternal|germline|paternal|germline	SCV000782632|SCV000949740|SCV000864213|SCV000996529	not_provided|not_provided|Fulminant_hepatic_failure|INFANTILE_LIVER_FAILURE_SYNDROME_3	|This_sequence_change_affects_a_donor_splice_site_in_intron_9_of_the_RINT1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs375350359,_ExAC_0.01%),_and_has_an_allele_count_higher_than_expected_for_a_pathogenic_variant_(PMID:_28166811)._This_variant_has_been_observed_in_a_family_affected_with_breast_cancer_(PMID:Â¬â€ 25050558)._An_experimental_study_has_shown_that_this_variant_results_in_exon_9_skipping_(PMID:Â¬â€ 25050558)._The_current_clinical_and_genetic_evidence_is_not_sufficient_to_establish_whether_loss-of-function_variants_in_RINT1_cause_disease._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.||
NM_021930.5:c.1333+2dup	RINT1	splice_donor_variant	102652	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1471+2T>A	RINT1	splice_donor_variant	97278	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1501C>T	RINT1	stop_gained	102656	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1555C>T	RINT1	stop_gained	102692	2	15430	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1586del	RINT1	frameshift_variant	102664	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1603C>T	RINT1	stop_gained	102654	1	15430	1	-	-	-	-	657221	635424	not_provided	-	MedGen:CN517202	-	NC_000007.13:g.105195606C>T	_single_submitter	Uncertain_significance	-	-	single_nucleotide_variant	SO:0001483	-	-	RINT1:60561	SO:0001587|nonsense	1	-	-	Invitae	Uncertain_significance	2018-08-03	2019-03-28	_single_submitter	germline	SCV000954161	not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg535*)_in_the_RINT1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs764298491,_ExAC_0.006%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_RINT1-related_disease._The_current_clinical_and_genetic_evidence_is_not_sufficient_to_establish_whether_loss-of-function_variants_in_RINT1_cause_disease._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.
NM_021930.5:c.1672-1G>C	RINT1	splice_acceptor_variant	101346	1	15398	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1738C>T	RINT1	stop_gained	102698	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1773_1776dup	RINT1	frameshift_variant	102708	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1840del	RINT1	frameshift_variant	102704	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1887-2A>C	RINT1	splice_acceptor_variant	94606	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1909_1912del	RINT1	frameshift_variant	100826	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1966C>T	RINT1	stop_gained	102720	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.2067+6_2067+9del	RINT1	splice_donor_variant,coding_sequence_variant	102572	4	15436	0	-	-	-	-	410784	395991	not_specified	-	MedGen:CN169374	-	NC_000007.13:g.105205906_105205909TAAG[1]	_single_submitter	Uncertain_significance	-	-	Microsatellite	SO:0000289	-	-	RINT1:60561|EFCAB10:100130771	SO:0001575|splice_donor_variant,SO:0001624|3_prime_UTR_variant,SO:0001627|intron_variant	1	761799563	-	Invitae	Uncertain_significance	2016-09-29	2017-03-14	_single_submitter	germline	SCV000551648	not_specified	This_sequence_change_deletes_4_nucleotides_in_intron_13_of_the_RINT1_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_RINT1_protein._This_variant_is_present_in_population_databases_(rs761799563,_ExAC_0.02%)_but_has_not_been_reported_in_the_literature_in_individuals_with_a_RINT1-related_disease._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_alter_RNA_splicing,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_this_is_a_rare_intronic_change_with_uncertain_impact_on_splicing._It_has_been_classified_as_a_Variant_of_Uncertain_Significance.
NM_021930.5:c.2068-1G>C	RINT1	splice_acceptor_variant	102420	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.2186+1G>A	RINT1	splice_donor_variant	101862	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002485.4:c.2234+2T>G	NBN	splice_donor_variant	102130	1	NA	NA	-	-	-	-	185026	182827	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90949252A>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001575|splice_donor_variant	1	142301194	-	Ambry_Genetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx|Invitae	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-05-15|2017-05-08|2018-11-29|2018-06-05	2020-02-26|2017-08-01|2019-01-29|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000215014|SCV000601686|SCV000618013|SCV000758226	_normal_intelligence_and_immunodeficiency	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity||This_variant_is_denoted_NBN_c.2234+2T>G_or_IVS15+2T>G_and_consists_of_a_T>G_nucleotide_substitution_at_the_+2_position_of_intron_15_of_the_NBN_gene._This_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_was_identified_in_at_least_one_individual_referred_for_hereditary_cancer_testing_(LaDuca_2017)._Based_on_the_currently_available_evidence,_we_consider_NBN_c.2234+2T>G_to_be_a_likely_pathogenic_variant.|This_sequence_change_affects_a_donor_splice_site_in_the_last_intron_(intron_15)_of_the_NBN_gene._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_likely_alters_RNA_splicing_and_results_in_a_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs142301194,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185026)._Nucleotide_substitutions_within_the_consensus_splice_site_are_a_relatively_common_cause_of_aberrant_splicing_(PMID:_17576681,_9536098)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Aberrant_splicing_by_this_variant_is_expected_to_disrupt_a_portion_of_the_C-terminal_region_of_the_NBN_protein_containing_the_ATM_interaction_domain_(residues_734-754),_which_is_important_for_activating_ATM_in_DNA_repair_process_(PMID:_21035407,_15964794,_15758953,_15048089)._Experimental_studies_have_shown_that_while_cells_from_knockout_mice_lacking_exon_15_recapitulating_the_possible_splicing_defect_by_this_variant_preserve_checkpoint_function,_sensitivity_to_radiation,_and_chromosomal_stability,_the_cells_have_a_severely_disrupted_apoptotic_function_through_abnormal_ATM_interaction_(PMID:_17429352)._This_suggests_that_disruption_of_this_region_of_the_NBN_protein_is_causative_of_disease._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_002485.4:c.2140C>T	NBN	stop_gained	102568	5	NA	NA	5&5&5	1&1&1	rs730881864	not provided&Microcephaly, normal intelligence and immunodeficiency&Hereditary cancer-predisposing syndrome	182737	180279	_normal_intelligence_and_immunodeficiency|not_provided	-	Human_Phenotype_Ontology:HP:0001915,MedGen:C0002874,OMIM:609135,Orphanet:ORPHA182040,SNOMED_CT:306058006|MedGen:C0023449,OMIM:613065,Orphanet:ORPHA513,SNOMED_CT:91857003|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90955525G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001587|nonsense	1	730881864	-	Fulgent_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2018-09-14|2018-12-27|2017-12-28|2018-02-09|2018-12-07|2015-02-23|2018-08-01|2017-05-18	2019-01-29|2019-03-28|2018-07-10|2019-04-24|2020-02-26|2017-10-26|2018-08-08|2017-05-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|unknown	SCV000211472|SCV000260258|SCV000796710|SCV000917855|SCV000273524|SCV000685755|SCV000821749|SCV000611218	not_provided|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency/Aplastic_anemia/Acute_lymphoid_leukemia	This_variant_is_denoted_NBN_c.2140C>T_at_the_cDNA_level_and_p.Arg714Ter_(R714X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_at_least_one_individual_with_early_onset_breast_cancer_(Jian_2017)_and_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg714*)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs730881864,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182737)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_NBN_c.2140C>T_(p.Arg714X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_2.4e-05_in_246018_control_chromosomes_in_gnomAD._This_frequency_is_not_higher_than_expected_for_a_pathogenic_variant_in_NBN_causing_Nijmegen_Breakage_Syndrome_(2.4e-05_vs_2.50E-03),_allowing_no_conclusion_about_variant_significance._The_c.2140C>T_variant_has_been_reported_in_the_literature_in_individuals_affected_with_cancer_(Susswein_2015,_Jian_2017)._These_data_indicate_that_the_variant_may_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic/likely_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||
NM_002485.4:c.2071-2A>C	NBN	splice_acceptor_variant	102568	1	NA	NA	-	-	-	-	530763	524290	_normal_intelligence_and_immunodeficiency	-	MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009	-	NC_000008.10:g.90955596T>G	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001574|splice_acceptor_variant	1	775397477	-	Invitae	Likely_pathogenic	2017-12-29	2018-04-02	_single_submitter	germline	SCV000758219	_normal_intelligence_and_immunodeficiency	This_sequence_change_affects_an_acceptor_splice_site_in_intron_13_of_the_NBN_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs775397477,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_002485.4:c.2030_2037dup	NBN	frameshift_variant	102386	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002485.4:c.1741C>T	NBN	stop_gained	102536	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002485.4:c.1651dup	NBN	frameshift_variant	102506	1	NA	NA	-	-	-	-	234246	233641	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90965672dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	NBN:4683	SO:0001589|frameshift_variant	1	766044684	-	Ambry_Genetics|Invitae|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic	2019-01-31|2018-09-24|2019-05-17	2020-02-26|2019-03-28|2020-03-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000278787|SCV000552998|SCV001134496	_normal_intelligence_and_immunodeficiency|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg551Lysfs*5)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234246)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_002485.4:c.1640del	NBN	frameshift_variant	102532	1	NA	NA	-	-	-	-	371069	357663	_normal_intelligence_and_immunodeficiency	-	MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009	-	NC_000008.10:g.90965677del	_single_submitter	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	NBN:4683	SO:0001587|nonsense	0	776417262	-	Counsyl	Likely_pathogenic	2016-06-21	2016-11-23	_single_submitter	unknown	SCV000486538	_normal_intelligence_and_immunodeficiency	
NM_002485.4:c.1474C>T	NBN	stop_gained	102300	1	NA	NA	5	1	rs587782130	Hereditary cancer-predisposing syndrome	141946	151660	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90965843G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001587|nonsense	1	587782130	-	Ambry_Genetics|Color|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-04-19|2016-09-27|2016-05-16|2018-11-07	2020-02-26|2017-12-21|2019-01-29|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000185559|SCV000690664|SCV000570348|SCV000634229	_normal_intelligence_and_immunodeficiency	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_variant_is_denoted_NBN_c.1474C>T_at_the_cDNA_level_and_p.Gln492Ter_(Q492X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln492*)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141946)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002485.4:c.1142del	NBN	frameshift_variant	102098	3	NA	NA	-	-	-	-	141731	151445	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90967767del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:602667.0005|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2840924	-	NBN:4683	SO:0001589|frameshift_variant	1	587781969	-	OMIM|Invitae|GeneReviews|Counsyl|Ambry_Genetics|Color|GeneDx|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|not_provided|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	1998-05-01|2019-01-01|0000-00-00|2017-05-16|2018-05-29|2016-06-15|2018-05-29|2017-06-01|2017-10-22	2016-10-11|2019-03-28|2017-02-02|2017-06-22|2020-02-26|2017-10-26|2019-01-29|2019-07-12|2018-08-31	no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline	SCV000027557|SCV000287446|SCV000494637|SCV000678049|SCV000185206|SCV000685695|SCV000279248|SCV000609313|SCV000889542	Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Pro381Glnfs*23)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781969,_ExAC_0.005%)._This_variant_has_been_reported_in_individuals_affected_with_Nijmegen_breakage_syndrome_(PMID:_9590180,_10799436,_12621246),_as_well_as_breast_and/or_ovarian_cancer_(PMID:_22006311,_24549055,_26315354)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141731)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_is_denoted_NBN_c.1142delC_at_the_cDNA_level_and_p.Pro381GlnfsX23_(P381QfsX23)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_AGGC[delC]AAAAG._The_deletion_causes_a_frameshift,_which_changes_a_Proline_to_a_Glutamine_at_codon_381,_and_creates_a_premature_stop_codon_at_position_23_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._NBN_c.1142delC_has_been_observed_with_a_pathogenic_founder_variant_in_individuals_with_Nijmegen_Breakage_syndrome_(Varon_1998,_Bakhshi_2003)_and_in_individuals_with_a_personal_history_of_breast_and/or_ovarian_cancer_(Walsh_2011,_Ramus_2015,_Desmond_2015)._We_consider_this_variant_to_be_pathogenic.||
NM_002485.4:c.995-2A>G	NBN	splice_acceptor_variant	102660	1	NA	NA	-	-	-	-	232050	233673	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90971084T>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001574|splice_acceptor_variant	1	876659521	-	Ambry_Genetics|Color|Invitae|Counsyl|GeneDx	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-06-03|2018-06-18|2018-11-22|2017-03-03|2017-08-24	2020-02-26|2018-11-06|2019-03-28|2018-07-10|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline	SCV000276088|SCV000685842|SCV000287490|SCV000790071|SCV000565310	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|not_provided	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(B-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_affects_an_acceptor_splice_site_in_intron_8_of_the_NBN_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observedÂ¬â€ in_an_individual_affected_with_ovarian_cancer_(PMID:_26315354)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_232050)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||This_variant_is_denoted_NBN_c.995-2A>G_or_IVS8-2A>G_and_consists_of_an_A>G_nucleotide_substitution_at_the_-2_position_of_intron_8_of_the_NBN_gene._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_at_least_one_individual_with_ovarian_cancer_(Ramus_2015)._Based_on_the_currently_available_information,_we_consider_NBN_c.995-2A>G_to_be_a_likely_pathogenic_variant.
NM_002485.4:c.808_809del	NBN	frameshift_variant	102664	1	15426	1	-	-	-	-	185833	182868	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90982679_90982680AC[2]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2852592	-	NBN:4683	SO:0001589|frameshift_variant	1	786202490	-	Ambry_Genetics|Color|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-09-18|2017-03-10|2018-10-03|2018-10-29|2019-02-20	2020-02-26|2017-10-26|2019-03-28|2019-01-29|2020-03-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000216053|SCV000685829|SCV000260006|SCV000569057|SCV001134521	_normal_intelligence_and_immunodeficiency|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val270Cysfs*2)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185833)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_two_nucleotides_in_NBN_is_denoted_c.808_809delGT_at_the_cDNA_level_and_p.Val270CysfsX2_(V270CfsX2)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GTGT[delGT]TGTT._The_deletion_causes_a_frameshift,_which_changes_a_Valine_to_a_Cysteine_at_codon_270_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._NBN_c.808_809delGT,_also_described_as_NBN_c.804delGT_using_alternate_nomenclature,_has_been_reported_in_an_individual_with_breast_cancer_as_well_as_in_an_unaffected_control_individual_in_an_ovarian_cancer_case-control_meta-analysis_(Damiola_2014,_Ramus_2015)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_002485.4:c.698_701del	NBN	frameshift_variant,splice_region_variant	102064	1	NA	NA	-	-	-	-	127878	133335	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90983404_90983407del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:602667.0002|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2844349	-	NBN:4683	SO:0001589|frameshift_variant	1	587780100	-	_University_of_Chicago|Invitae|GeneReviews|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-12|2016-07-26|1998-05-01|2015-03-05|2018-12-18|2017-02-02|2018-08-03|2018-07-23|2018-04-11	2020-02-26|2017-10-26|2016-06-24|2015-09-15|2019-03-28|2017-02-02|2019-04-24|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000213967|SCV000685816|SCV000027554|SCV000248142|SCV000261243|SCV000494629|SCV000917863|SCV000149713|SCV000889556	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys233Serfs*5)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780100,_ExAC_0.01%)._This_variant_has_been_observed_inÂ¬â€ individuals_affected_with_Nijmegen_breakage_syndrome_(NBS),_and_breast/ovarian_cancer_(PMID:_9590180,_15474156,_26315354,_26534844)._This_variant_is_also_known_as_698del4_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127878)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_NBN_c.698_701delAACA_(p.Lys233SerfsX5)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_2e-05_in_252006_control_chromosomes_(gnomAD)._The_variant,_c.698_701delAACA,_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_and_Nijmegen_Breakage_Syndrome_(Varon_1998,_Gass_2017,_Ramus_2015,_Li_2015,_Susswein_2016)._These_data_indicate_that_the_variant_may_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_deletion_of_four_nucleotides_in_NBN_is_denoted_c.698_701delAACA_at_the_cDNA_level_and_p.Lys233SerfsX5_(K233SfsX5)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GCCA[delAACA]Ggta,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._The_deletion_causes_a_frameshift,_changing_a_Lysine_to_a_Serine_at_codon_233,_and_creates_a_premature_stop_codon_at_position_5_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_published_as_NBN_or_NBS1_698del4,_has_been_reported_in_families_with_Nijmegen_Breakage_Syndrome_as_well_as_in_women_with_breast_and_ovarian_cancer_(Varon_1998,_Meyer_2004,_Ramus_2015,_Li_2016,_Gass_2017),_and_is_considered_pathogenic.|
NM_002485.4:c.657_661del	NBN	frameshift_variant	102412	36	15420	8	-	-	-	-	6940	21979	Microcephaly|Lissencephaly|Ovarian_Neoplasms|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Breast-ovarian_cancer,_familial_1|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0000252,MedGen:C4551563|Human_Phenotype_Ontology:HP:0001339,MedGen:C0266463,Orphanet:ORPHA48471,SNOMED_CT:204036008|MeSH:D010051,MedGen:CN236629|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000008.10:g.90983445_90983449del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2747637|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2207620|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana:CMGVARID00342|OMIM_Allelic_Variant:602667.0001	-	NBN:4683	SO:0001589|frameshift_variant	1	587776650	-	OMIM|Invitae|Genetic_Services_Laboratory,_University_of_Chicago|Miami_Human_Genetics,University_of_Miami_Miller_School_of_Medicine|GeneReviews|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Baylor_Genetics|OMIM|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|GeneKor_MSA|GeneDx|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2008-10-15|2019-01-10|2015-03-04|2015-11-16|2017-02-02|2015-06-13|2015-11-25|2018-07-02|0000-00-00|2008-10-15|2018-08-06|2015-11-20|2015-02-05|2018-08-01|2018-12-24|2017-02-20|2018-03-16|2015-10-06|2018-12-01|2018-11-20	2016-10-11|2019-03-28|2015-09-15|2015-11-24|2017-02-02|2017-06-22|2018-01-25|2018-08-20|2019-09-27|2016-10-11|2020-02-26|2016-03-03|2016-07-05|2018-08-08|2019-01-29|2018-01-29|2018-08-31|2016-11-12|2019-02-22|2019-08-05	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|unknown|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000027552|SCV000218835|SCV000248141|SCV000256868|SCV000494627|SCV000678042|SCV000697978|SCV000838310|SCV001163582|SCV000027553|SCV000183792|SCV000266100|SCV000292133|SCV000821748|SCV000149712|SCV000806448|SCV000889554|SCV000492771|SCV000924010|SCV001160103	Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Lissencephaly/Microcephaly|Ovarian_Neoplasms|not_specified	|This_sequence_change_deletes_5_nucleotides_from_exon_6_of_the_NBN_mRNA_(c.657_661delACAAA),_causing_a_frameshift_at_codon_219._This_creates_a_premature_translational_stop_signal_and_would_generally_be_expected_to_result_in_an_absent_or_disrupted_protein_product._However,_experimental_studies_have_shown_that_this_deletion_introduces_two_in-frame_start_codons_downstream_of_the_frameshift,_which_can_initiate_protein_translation_and_generate_two_truncated_NBN_proteins_of_similar_length_that_maintain_partial_functionality_(PMID:_11279524)._This_variant_is_present_in_population_databases_(rs587776650,_ExAC_0.03%)._This_is_the_most_common_variant_reported_in_individuals_affected_with_Nijmegen_breakage_syndrome,_and_is_considered_to_be_a_founder_mutation_in_the_Slavic_population_(PMID:_9590180)._It_is_also_known_as_657del5_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_6940)._Heterozygous_carriers_may_have_increased_risk_for_several_types_of_cancers_including_breast,_lymphoma,_prostate,_melanoma,_medulloblastoma_and_others_(PMID:_15185344,_14973119,_18606567,_19908051,_24113799)._In_a_large_meta-analysis_involving_15,184_cases_and_54,081_controls_from_21_studies,_this_variant_was_found_to_increase_overall_cancer_risk_in_heterozygous_carriers_by_close_to_three-fold_(PMID:_24113799)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||The_NBN_c.657_661delACAAA_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_an_Asparagine_at_codon_219,_and_creates_a_premature_stop_codon_at_position_16_of_the_new_reading_frame._NBN_657del5_has_been_described_as_a_pathogenic_founder_variant_of_Slavic_and_Eastern_European_origin_and_is_the_most_common_pathogenic_variant_in_patients_with_the_related_autosomal_recessive_condition_called_Nijmegen_Breakage_syndrome_(Varon_1998)._An_in_vitro_study_conducted_by_Lins_et_al._(2009)_found_that_there_was_some_selective_loss_of_the_mutant_allele_associated_with_this_deletion,_but_much_less_than_would_be_expected_for_mRNA_eliminated_by_nonsense-mediated_decay_(NMD)._In_addition,_RT-PCR_analysis_revealed_no_significant_difference_in_NMD_rate_between_the_mutant_and_wild-type_mRNA,_suggesting_that_NMD_is_not_the_mechanism_by_which_this_variant_exerts_its_effect_(Lins_2009)._This_variable_mRNA_expression_and_degradation_may_explain_the_range_of_cancer_risks_that_have_been_observed_in_association_with_this_pathogenic_variant.|||||The_NBN_c.657_661delACAAA:_p.Lys219fs_variant_(rs587776650),_also_known_as_657del5,_is_reported_in_the_literature_as_the_most_common_pathogenic_variant_and_a_founder_mutation_in_the_Slavic_population_in_individuals_affected_with_Nijmegen_breakage_syndrome_(Varon_1998)._Heterozygous_carriers_are_also_reported_to_have_an_increased_risk_for_various_cancers,_including_breast_cancer,_prostate_cancer,_colorectal_cancer,_lymphoma,_melanoma,_and_medulloblastoma_(Ciara_2010,_Gao_2013,_Steffen_2004)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_6940),_and_is_found_in_the_non-Finnish_European_population_with_an_allele_frequency_of_0.040%_(52/128,774_alleles)_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_deleting_5_nucleotides,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._However,_functional_studies_show_two_in-frame_start_codons_created_by_the_frameshift_that_can_generate_truncated_NBN_proteins_with_partial_functionality_(Lins_2009,_Maser_2001)._Based_on_available_information,_the_p.Lys219fs_variant_is_considered_to_be_pathogenic._References:_Ciara_E_et_al._Heterozygous_germ-line_mutations_in_the_NBN_gene_predispose_to_medulloblastoma_in_pediatric_patients._Acta_Neuropathol._2010_Mar:119(3):325-34._Gao_P_et_al._Functional_variants_in_NBS1_and_cancer_risk:_evidence_from_a_meta-analysis_of_60_publications_with_111_individual_studies._Mutagenesis._2013_Nov:28(6):683-97._Lins_S_et_al._Clinical_variability_and_expression_of_the_NBN_c.657del5_allele_in_Nijmegen_Breakage_Syndrome._Gene._2009_Nov_1:447(1):12-7._Maser_RS_et_al._An_alternative_mode_of_translation_permits_production_of_a_variant_NBS1_protein_from_the_common_Nijmegen_breakage_syndrome_allele._Nat_Genet._2001_Apr:27(4):417-21._Steffen_J_et_al._Increased_cancer_risk_of_heterozygotes_with_NBS1_germline_mutations_in_Poland._Int_J_Cancer._2004_Aug_10:111(1):67-71._Varon_R_et_al._Nibrin,_a_novel_DNA_double-strand_break_repair_protein,_is_mutated_in_Nijmegen_breakage_syndrome._Cell._1998_May_1:93(3):467-76.
NM_002485.4:c.585-2A>G	NBN	splice_acceptor_variant	101774	1	NA	NA	-	-	-	-	577667	568199	_normal_intelligence_and_immunodeficiency	-	MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009	-	NC_000008.10:g.90983520T>C	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001574|splice_acceptor_variant	1	772005832	-	Invitae	Likely_pathogenic	2018-04-24	2018-08-29	_single_submitter	germline	SCV000829234	_normal_intelligence_and_immunodeficiency	This_sequence_change_affects_an_acceptor_splice_site_in_intron_5_of_the_NBN_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs772005832,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_002485.4:c.481-2A>T	NBN	splice_acceptor_variant	102496	1	NA	NA	-	-	-	-	451148	444308	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90990553T>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001574|splice_acceptor_variant	1	751567476	-	GeneDx|Ambry_Genetics|Color|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-11-19|2019-07-19|2018-08-23|2018-12-27|2018-03-12	2019-01-29|2020-02-26|2018-11-06|2019-03-28|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000619808|SCV000662681|SCV000690722|SCV000836601|SCV000919849	not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency	This_variant_is_denoted_NBN_c.481-2A>T_or_IVS4-2A>T_and_consists_of_an_A>T_nucleotide_substitutionat_the_-2_position_of_intron_4_of_the_NBN_gene._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_tocause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNAdecay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature.Based_on_the_currently_available_information,_we_consider_NBN_c.481-2A>T_to_be_a_likely_pathogenic_variant|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity||This_sequence_change_affects_an_acceptor_splice_site_in_intron_4_of_the_NBN_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs751567476,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_451148)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|Variant_summary:_NBN_c.481-2A>T_is_located_in_a_canonical_splice-site_and_is_predicted_to_affect_mRNA_splicing_resulting_in_a_significantly_altered_protein_due_to_either_exon_skipping,_shortening,_or_inclusion_of_intronic_material._Several_computational_tools_predict_a_significant_impact_on_normal_splicing:_Five_predict_the_variant_abolishes_a_3'_acceptor_site._However,_these_predictions_have_yet_to_be_confirmed_by_functional_studies._The_variant_allele_was_found_at_a_frequency_of_1.2e-05_in_245872_control_chromosomes._This_frequency_is_not_higher_than_expected_for_a_pathogenic_variant_in_NBN_causing_Nijmegen_Breakage_Syndrome_(1.2e-05_vs_0.0025),_allowing_no_conclusion_about_variant_significance._To_our_knowledge,_no_occurrence_of_c.481-2A>T_in_individuals_affected_with_Nijmegen_Breakage_Syndrome_and_no_experimental_evidence_demonstrating_its_impact_on_protein_function_have_been_reported._Three_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation,_and_all_classified_the_variant_as_likely_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic.
NM_002485.4:c.480+1G>A	NBN	splice_donor_variant	102622	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002485.4:c.407dup	NBN	frameshift_variant	102636	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002485.4:c.306del	NBN	frameshift_variant	102654	1	NA	NA	-	-	-	-	140828	150542	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90993619del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	NBN:4683	SO:0001589|frameshift_variant	1	587781305	-	Ambry_Genetics|Color|GeneDx|Counsyl	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2013-02-04|2015-07-08|2015-05-15|2017-08-18	2020-02-26|2018-11-06|2019-01-29|2018-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown	SCV000172919|SCV000905479|SCV000566606|SCV000793520	_normal_intelligence_and_immunodeficiency	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_in_NBN_is_denoted_c.306delT_at_the_cDNA_level_and_p.Phe102LeufsX7_(F102LfsX7)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_TGTT[T]GGAA._The_deletion_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Leucine_at_codon_102,_and_creates_a_premature_stop_codon_at_position_7_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._NBN_c.306delT_has_been_observed_in_an_individual_referred_for_clinical_testing_due_to_personal_and/or_family_history_of_cancer_(LaDuca_2014)._we_consider_this_variant_to_be_pathogenic.|
NM_002485.4:c.265C>T	NBN	stop_gained	102700	1	NA	NA	-	-	-	-	370213	357670	_normal_intelligence_and_immunodeficiency	-	MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009	-	NC_000008.10:g.90993658G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001587|nonsense	1	1057516320	-	Counsyl|Invitae	Likely_pathogenic|Pathogenic	2015-12-15|2018-08-31	2016-11-23|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline	SCV000485466|SCV000758178	Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg89*)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_370213)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002485.4:c.211_212insGA	NBN	frameshift_variant	102640	1	NA	NA	-	-	-	-	216086	212647	_normal_intelligence_and_immunodeficiency	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009	-	NC_000008.10:g.90993712_90993713insCT	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Insertion	SO:0000667	-	-	NBN:4683	SO:0001623|5_prime_UTR_variant	1	762664474	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2016-08-16|2018-03-12	2017-03-14|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000253873|SCV001175176	_normal_intelligence_and_immunodeficiency|Hereditary_cancer-predisposing_syndrome	This_sequence_change_inserts_2_nucleotides_in_exon_3_of_the_NBN_mRNA_(c.211_212insGA),_causing_a_frameshift_at_codon_71._This_creates_a_premature_translational_stop_signal_(p.Asn71Argfs*22)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_002485.4:c.181_182del	NBN	frameshift_variant	102596	1	NA	NA	-	-	-	-	186540	182903	_normal_intelligence_and_immunodeficiency	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009	-	NC_000008.10:g.90993742_90993743del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	NBN:4683	SO:0001623|5_prime_UTR_variant	1	768378152	-	Ambry_Genetics|Color|Counsyl|Invitae	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2019-01-25|2017-09-17|2018-02-15|2018-12-19	2020-02-26|2017-12-21|2018-07-10|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline	SCV000216923|SCV000690677|SCV000797828|SCV000960999	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asp61*)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs768378152,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186540)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002485.4:c.156_157del	NBN	frameshift_variant	102698	4	NA	NA	-	-	-	-	371121	357674	_normal_intelligence_and_immunodeficiency|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0023449,OMIM:613065,Orphanet:ORPHA513,SNOMED_CT:91857003|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90994966_90994967del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	NBN:4683	SO:0001623|5_prime_UTR_variant	1	767454740	-	_University_of_Chicago|Color|Ambry_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2016-07-07|2018-10-23|2018-07-02|2018-07-23|2016-09-12|2016-04-25|2018-12-29|2016-04-11	2016-11-23|2019-03-28|2018-08-20|2019-01-29|2017-07-05|2017-12-21|2020-02-26|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|unknown|germline|germline|germline|germline|germline	SCV000486614|SCV000553052|SCV000838320|SCV000568560|SCV000595917|SCV000690667|SCV001172585|SCV000697948	Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|not_provided|Acute_lymphoid_leukemia|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser53Cysfs*9)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs767454740,_ExAC_0.001%)._This_variant_has_been_observed_in_an_individual_affected_with_hereditary_breast_and/or_ovarian_cancer_(PMID:_24549055).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_371121)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_deletion_of_two_nucleotides_in_NBN_is_denoted_c.156_157delTT_at_the_cDNA_level_and_p.Ser53CysfsX9_(S53CfsX9)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ACTT[delTT]CTGT._The_deletion_causes_a_frameshift_which_changes_a_Serine_to_a_Cysteine_at_codon_53,_and_creates_a_premature_stop_codon_at_position_9_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._NBN_c.156_157delTT_has_been_observed_in_at_least_one_individual_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_(CastÃ©ra_2014)._Based_on_the_currently_available_information,_we_consider_this_deletion_to_be_a_likely_pathogenic_variant.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|Variant_summary:_The_variant_of_interest_causes_a_frameshift_mutation_resulting_in_a_predicted_truncated_NBN_protein,_a_mechanism_for_disease._The_variant_of_interest_was_observed_in_the_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_1/121384,_which_does_not_exceed_the_predicted_maximum_expected_allele_frequency_for_a_pathogenic_NBN_variant_of_1/8000_for_HBOC._The_variant_of_interest_has_been_reported_in_an_affected_individual_via_a_publication_that_consisted_of_a_cohort_of_HBOC_individuals._The_variant_of_interest_has_not_been_reported_in_clinical_laboratories_or_databases._Therefore,_taking_all_available_lines_of_evidence_into_consideration,_the_variant_of_interest_is_classified_as_Likely_Pathogenic.
NM_002485.4:c.127C>T	NBN	stop_gained	102704	3	NA	NA	5	1	rs200287925	Hereditary cancer-predisposing syndrome	142203	151917	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90994994G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001623|5_prime_UTR_variant	1	200287925	-	_Partners_HealthCare_Personalized_Medicine|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-12-05|2016-12-09|2016-04-05|2018-12-23|2018-04-18|2018-05-11	2020-02-26|2017-10-26|2016-11-23|2019-03-28|2019-03-21|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline	SCV000186143|SCV000685707|SCV000486041|SCV000634213|SCV000966851|SCV000577161	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg43*)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs200287925,_ExAC_0.03%)._This_variant_has_been_reported_in_an_individual_undergoing_hereditary_cancer_testing_(PMID:_24763289),_and_an_individual_affected_with_triple_negative_breast_cancer_(PMID:_26976419)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142203)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Arg43X_variant_in_NBN_has_been_not_been_reported_in_individuals_with_Nijme_gen_breakage_syndrome._However,_it_has_reported_in_1_individual_with_hereditary_cancer_and_two_individuals_with_breast_cancer_(LaDuca_2014,_Tung_2016,_Thompson_2016)_and_has_been_reported_in_ClinVar_(Variation_ID:_142203)._The_variant_has_b_een_identified_in_4/22288_Finnish_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org/:_dbSNP_rs200287925)._Although_this_v_ariant_has_been_seen_in_the_general_population,_its_frequency_is_low_enough_to_b_e_consistent_with_a_recessive_carrier_frequency._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_43_which_is_predicted_to_lead_to_a_tru_ncated_or_absent_protein._Loss_of_function_of_the_NBS_gene_is_an_established_dis_ease_mechanism_in_Nijmegen_breakage_syndrome._In_summary,_although_additional_st_udies_are_required_to_fully_establish_its_clinical_significance,_the_p.Arg43X_va_riant_is_likely_pathogenic_for_Nijmegen_breakage_syndrome._in_an_autosomal_reces_sive_manner_based_upon_predicted_impact_to_the_protein_and_absence_from_controls_,._ACMG/AMP_Criteria_applied:_PVS1:_PM2.|This_pathogenic_variant_is_denoted_NBN_c.127C>T_at_the_cDNA_level_and_p.Arg43Ter_(R43X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_at_least_three_breast_cancer_patients_(Damiola_2014,_Thompson_2016,_Tung_2016)_and_is_considered_pathogenic.
NM_002485.4:c.123del	NBN	frameshift_variant	102708	1	NA	NA	-	-	-	-	141631	151345	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90994998del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	NBN:4683	SO:0001623|5_prime_UTR_variant	1	587781891	-	Ambry_Genetics|Color|Invitae|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-03-22|2017-03-13|2018-07-01|2017-12-27	2020-02-26|2017-10-26|2018-08-29|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000185067|SCV000685705|SCV000553077|SCV000569358	_normal_intelligence_and_immunodeficiency|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser42Alafs*7)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_one_nucleotide_in_NBN_is_denoted_c.123delC_at_the_cDNA_level_and_p.Ser42AlafsX7_(S42AfsX7)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_CGAT[C]AGCC._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_an_Alanine_at_codon_42,_and_creates_a_premature_stop_codon_at_position_7_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.
NM_002485.4:c.114del	NBN	frameshift_variant	102704	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002485.4:c.88_89del	NBN	frameshift_variant	102708	1	NA	NA	-	-	-	-	141398	151112	_normal_intelligence_and_immunodeficiency	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009	-	NC_000008.10:g.90995035_90995036del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	NBN:4683	SO:0001623|5_prime_UTR_variant	1	587781718	-	Ambry_Genetics|Counsyl	Pathogenic|Likely_pathogenic	2014-02-27|2016-02-03	2020-02-26|2016-11-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown	SCV000184720|SCV000485727	_normal_intelligence_and_immunodeficiency	_nonsense)|
NM_002485.4:c.60del	NBN	frameshift_variant	102682	2	NA	NA	-	-	-	-	545793	536346	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90995061del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	NBN:4683	SO:0001623|5_prime_UTR_variant	1	758708229	-	GeneDx|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2017-06-08|2018-10-01|2018-11-13	2019-01-29|2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000779067|SCV000955504|SCV001186992	_normal_intelligence_and_immunodeficiency|Hereditary_cancer-predisposing_syndrome	This_deletion_of_one_nucleotide_in_NBN_is_denoted_c.60delT_at_the_cDNA_level_and_p.Gly21AlafsX14_(G21AfsX14)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_TGAC[delT]GGCG._The_deletion_causes_a_frameshift_which_changes_a_Glycine_to_an_Alanine_at_codon_21,_and_creates_a_premature_stop_codon_at_position_14_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gly21Alafs*14)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs758708229,_ExAC_0.003%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_545793)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_002485.4:c.38-2A>G	NBN	splice_acceptor_variant	102528	1	NA	NA	-	-	-	-	630225	619307	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000008.10:g.90995085T>C	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001574|splice_acceptor_variant	1	771475965	-	Color|Ambry_Genetics	Uncertain_significance|Likely_pathogenic	2018-10-08|2018-12-26	2018-11-06|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000909729|SCV001182831	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_000136.2:c.1387_1388del	FANCC	frameshift_variant	102652	1	NA	NA	-	-	-	-	182468	180333	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97869494_97869495AG[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Microsatellite	SO:0000289	-	-	FANCC:2176|AOPEP:84909	SO:0001589|frameshift_variant	1	730881710	-	GeneDx|Counsyl|Invitae|Ambry_Genetics	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2014-09-08|2018-01-19|2018-10-26|2019-06-13	2019-01-29|2018-07-10|2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline	SCV000211034|SCV000797239|SCV000937595|SCV001171507	_complementation_group_C|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	This_deletion_of_2_nucleotides_in_FANCC_is_denoted_c.1387_1388delTC_at_the_cDNA_level_and_p.Ala464ProfsX53_(A464PfsX53)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CCTC[TC]AGCC._The_deletion_causes_a_frameshift,_which_changes_an_Alanine_to_a_Proline_at_codon_464,_and_creates_a_premature_stop_codon_at_position_53_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._we_consider_this_variant_to_be_pathogenic.FANCC_has_been_only_recently_described_in_association_with_cancer_predisposition_and_the_risks_are_not_well_understood._Based_on_available_data,_the_presence_of_a_FANCC_mutation_may_confer_an_increased_risk_for_female_breast_cancer_(Thompson_2012,_Berwick_2007)._Berwick_et_al._(2007)_identified_33_female_FANCC_mutation_carriers:_all_grandmothers_of_known_Fanconi_Anemia_patients._In_this_group_of_women_the_observed_cases_of_breast_cancer_(n
NM_000136.2:c.1302dup	FANCC	frameshift_variant	102532	1	15424	1	-	-	-	-	182467	180336	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97873772dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	FANCC:2176|AOPEP:84909	SO:0001589|frameshift_variant	1	730881709	-	GeneDx|Invitae|Counsyl	Pathogenic|Pathogenic|Likely_pathogenic	2014-07-31|2016-12-28|2015-04-24	2019-01-29|2017-03-14|2019-08-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown	SCV000211033|SCV000261171|SCV001132391	_complementation_group_C	This_duplication_of_one_nucleotide_is_denoted_FANCC_c.1302dupT_at_the_cDNA_level_and_p.Gly435TrpfsX83_(G435WfsX83)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_duplicated_in_brackets,_is_GTGA[T]GGGA._The_duplication_causes_a_frameshift,_which_changes_a_Glycine_to_a_Tryptophan_at_codon_435,_and_creates_a_premature_stop_codon_at_position_83_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._we_consider_this_variant_to_be_pathogenic._FANCC_has_been_only_recently_described_in_association_with_cancer_predisposition_and_the_risks_are_not_well_understood._Based_on_available_data,_the_presence_of_a_FANCC_mutation_may_confer_an_increased_risk_for_female_breast_cancer_(Thompson_2012,_Berwick_2007)._Berwick_et_al._(2007)_identified_33_female_FANCC_mutation_carriers:_all_grandmothers_of_known_Fanconi_Anemia_patients._In_this_group_of_women_the_observed_cases_of_breast_cancer_(n
NM_000136.2:c.1257dup	FANCC	frameshift_variant	102706	1	NA	NA	-	-	-	-	545768	536353	Fanconi_anemia|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:CN517202	-	NC_000009.11:g.97873822dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	FANCC:2176|AOPEP:84909	SO:0001589|frameshift_variant	1	765551897	-	GeneDx|Invitae	Likely_pathogenic|Pathogenic	2017-02-16|2018-10-05	2019-01-29|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000779024|SCV000965355	not_provided|Fanconi_anemia	This_duplication_of_one_nucleotide_in_FANCC_is_denoted_c.1257dupC_at_the_cDNA_level_and_p.Thr420HisfsX15_(T420HfsX15)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_ACCCCC[dupC]ACGG._The_duplication_causes_a_frameshift_which_changes_a_Threonine_to_a_Histidine_at_codon_420,_and_creates_a_premature_stop_codon_at_position_15_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Based_on_the_currently_available_information,_we_consider_this_duplication_to_be_a_likely_pathogenic_variant.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Thr420Hisfs*15)_in_the_FANCC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs776037287,_ExAC_0.01%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_FANCC-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 545768)._Loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000136.2:c.1162G>T	FANCC	stop_gained	102666	1	15428	0	-	-	-	-	218427	215407	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97873912C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001587|nonsense	1	371897078	-	The_Children's_Hospital_of_Philadelphia|GeneDx|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Invitae|Ambry_Genetics	Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2015-07-15|2017-08-17|2015-11-25|2018-10-04|2017-09-06|2019-02-14	2015-08-10|2019-01-29|2019-08-05|2019-04-24|2018-04-02|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|unknown|germline|germline|germline	SCV000257631|SCV000779409|SCV000485348|SCV000919323|SCV000626233|SCV001170204	not_provided|not_provided|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	|This_variant_is_denoted_FANCC_c.1162G>T_at_the_cDNA_level_and_p.Gly388Ter_(G388X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glycine_to_a_premature_stop_codon_(GGA>TGA)_,_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_likely_pathogenic.||Variant_summary:_FANCC_c.1162G>T_(p.Gly388X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_p.Arg548X)._The_variant_allele_was_found_at_a_frequency_of_1.1e-05_in_277132_control_chromosomes._c.1162G>T_has_been_reported_in_the_literature_in_individuals_affected_with_and_pancreatic_cancer_and_AML_(Hu_2018,_Lu_2015)._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic/likely_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gly388*)_in_the_FANCC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_FANCC-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_218427)._Loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000136.2:c.1072+2T>A	FANCC	splice_donor_variant	102714	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000136.2:c.1069C>T	FANCC	stop_gained	102706	1	NA	NA	-	-	-	-	419252	407740	_complementation_group_C|not_provided	-	OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97879600G>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001587|nonsense	1	759900071	-	GeneDx|Counsyl	Pathogenic|Likely_pathogenic	2016-11-04|2014-01-02	2019-01-29|2019-08-05	_single_submitter|no_assertion_criteria_provided	germline|unknown	SCV000566937|SCV001132389	_complementation_group_C	This_variant_is_denoted_FANCC_c.1069C>T_at_the_cDNA_level_and_p.Gln357Ter_(Q357X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_with_another_FANCC_nonsense_variant_in_an_individual_reported_to_have_Fanconi_Anemia_(Nicchia_2015)_and_is_considered_to_be_pathogenic.|
NM_000136.2:c.996+1G>T	FANCC	splice_donor_variant	102742	1	15430	2	-	-	-	-	265137	259928	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97887367C>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001575|splice_donor_variant	1	370510954	-	GeneDx|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Invitae|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-07-31|2016-02-08|2016-04-29|2016-09-23|2019-09-28	2019-01-29|2019-08-05|2018-01-25|2017-03-14|2020-02-26	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline	SCV000321625|SCV000485754|SCV000695440|SCV000549917|SCV000673335	not_provided|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_FANCC_c.996+1G>T_or_IVS10+1G>T_and_consists_of_a_G>T_nucleotide_substitution_at_the_+1_position_of_intron_10_of_the_FANCC_gene._The_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature._Based_on_currently_available_evidence,_we_consider_FANCC_c.996+1G>T_to_be_a_likely_pathogenic_variant.||Variant_summary:_The_c.996+1G>A_in_a_FANCC_gene_is_a_splice-site_variant_that_alters_a_conserved_nucleotide._Mutation_taster_predicts_this_variant_to_be_disease-causing._5/5_in_silico_tools_via_Alamut_predict_this_variant_to_disrupt_a_canonical_donor_sequence,_however_these_predictions_have_yet_to_be_confirmed_by_functional_assay._The_variant_is_present_in_control_dataset_of_ExAC_at_a_low_frequency_of_0.0000165_(2/121274chrs_tested)_which_does_not_exceed_the_estimated_maximum_allele_frequency_for_a_pathogenic_allele_in_this_gene_(0.00177)._The_variant_has_not,_to_our_knowledge,_been_reported_in_affected_individuals_via_publications_and/or_reputable_databases/clinical_laboratories._Taken_together,_the_variant_was_classified_as_Likely_Pathogenic_until_additional_information_becomes_available.|This_sequence_change_affects_a_donor_splice_site_in_intron_10._It_is_expected_to_disrupt_mRNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_a_FANCC-related_disease._In_summary,_donor_and_acceptor_splice_site_variants_are_typically_loss-of-function_(PMID:_16199547),_and_loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_PMID:_17924555)._However,_without_additional_functional_and/or_genetic_data,_this_variant_has_been_classified_as_Likely_Pathogenic.|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity
NM_000136.2:c.946C>T	FANCC	stop_gained	102754	1	NA	NA	-	-	-	-	485554	474964	Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000009.11:g.97887418G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001587|nonsense	1	776529713	-	Ambry_Genetics|Invitae	Pathogenic|Pathogenic	2017-08-08|2018-12-28	2020-02-26|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000673351|SCV000959103	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln316*)_in_the_FANCC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs776529713,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_FANCC-related_conditions._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 485554)._Loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000136.2:c.844-1G>C	FANCC	splice_acceptor_variant	102708	2	NA	NA	-	-	-	-	189053	186792	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97888864C>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001574|splice_acceptor_variant	1	774209201	-	Children's_Mercy_Hospital_and_Clinics|GeneDx|Invitae|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2014-11-12|2017-12-18|2015-09-29|2018-01-02|2018-10-03|2018-08-08	2015-03-11|2019-04-24|2016-05-19|2019-01-29|2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|germline	SCV000220870|SCV000917334|SCV000281409|SCV000517421|SCV000549969|SCV001178923	Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|not_provided|not_provided|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	|Variant_summary:_The_FANCC_c.844-1G>C_variant_involves_the_alteration_of_a_conserved_intronic_nucleotide_and_5/5_splice_prediction_tools_predict_the_variant_to_abolish_a_cannonical_splice_acceptor_site._However,_these_predictions_have_yet_to_be_confirmed_by_functional_studies._This_variant_was_found_in_2/246200_control_chromosomes_(gnomAD)_at_a_frequency_of_0.0000081,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_FANCC_variant_(0.0017678)._The_variant_has_been_reported,_to_our_knowledge,_in_one_publication_citing_two_affected_individuals_(Ameziane_2008)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_likely_pathogenic/pathogenic._Taken_together,_this_variant_is_classified_as_likely_pathogenic.||This_pathogenic_variant_is_denoted_FANCC_c.844-1G>C_or_IVS8-1G>C_and_consists_of_a_G>C_nucleotide_substitution_at_the_-1_position_of_intron_8_of_the_FANCC_gene._The_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_the_compound_heterozygous_state_with_other_truncating_FANCC_variants_in_at_least_two_individuals_with_Fanconi_Anemia_(Ameziane_2008)._We_consider_FANCC_c.844-1G>C_to_be_pathogenic.|This_sequence_change_affects_an_acceptor_splice_site_in_intron_8_of_the_FANCC_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs774209201,_ExAC_0.002%)._This_variant_has_been_observed_inÂ¬â€ compound_heterozygosity_with_two_different_pathogenic_FANCC_variants_in_two_patients_with_suspected_Fanconi_anemia_(PMID:_17924555)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_189053)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation
NM_000136.2:c.843+1G>A	FANCC	splice_donor_variant	102728	2	15430	0	-	-	-	-	127547	133004	_complementation_group_C	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C3468041,OMIM:227645	-	NC_000009.11:g.97897627C>T	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001575|splice_donor_variant	1	587779909	-	Invitae|Counsyl	Likely_pathogenic|Likely_pathogenic	2015-08-29|2016-01-27	2016-01-06|2019-08-05	_single_submitter|no_assertion_criteria_provided	germline|unknown	SCV000260307|SCV000485681	_complementation_group_C	This_sequence_change_affects_a_donor_splice_site_in_intron_8._It_is_expected_to_disrupt_mRNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_truncating_variants_in_FANCC_are_known_to_be_pathogenic._(PMID:_17924555,_15695377)_In_summary,_this_is_a_rare_consensus_splice_site_sequence_change_which_is_expected_to_disrupt_gene_function,_but_in_the_absence_of_disease_segregation_or_functional_studies,_this_variant_has_been_classified_as_Likely_Pathogenic|
NM_000136.2:c.808A>T	FANCC	stop_gained	102740	1	NA	NA	-	-	-	-	420449	407750	_complementation_group_C|not_provided	-	OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97897663T>A	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001587|nonsense	1	776054094	-	GeneDx|Counsyl	Likely_pathogenic|Likely_pathogenic	2016-05-31|2016-11-11	2019-01-29|2019-08-05	_single_submitter|no_assertion_criteria_provided	germline|unknown	SCV000569290|SCV001132189	_complementation_group_C	This_variant_is_denoted_FANCC_c.808A>T_at_the_cDNA_level_and_p.Arg270Ter_(R270X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(AGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_likely_pathogenic.|
NM_000136.2:c.553C>T	FANCC	stop_gained	102690	11	15428	3	5&5	0&1	rs121917783	Fanconi anemia, complementation group C&not provided	12044	27083	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97912338G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:613899.0002	-	FANCC:2176	SO:0001587|nonsense	1	121917783	-	_ClinGen|Invitae|Natera_Inc|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic	2015-06-15|2017-04-03|0000-00-00|2018-07-26|0000-00-00|2018-12-12|2019-05-20|2018-04-26	2015-06-15|2018-01-25|2019-09-27|2019-01-29|2017-08-22|2019-03-28|2019-06-10|2020-02-26	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline	SCV000033064|SCV000695434|SCV001163624|SCV000149265|SCV000607026|SCV000549970|SCV001190681|SCV000673288	Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|not_provided|not_provided|Fanconi_anemia|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	|Variant_summary:_The_FANCC_c.553C>T_(p.Arg185X)_variant_involves_the_alteration_of_a_non-conserved_nucleotide,_resulting_in_a_nonsense_codon._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_the_large_control_database_ExAC_at_a_frequency_of_0.0000414_(5/120748_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_FANCC_variant_(0.0017678)._Several_reports_in_the_literature_have_detected_the_variant_among_individuals_diagnosed_with_a_variety_of_cancers,_including_2_families_where_the_variant_segregated_with_disease_in_4_individuals_(Verlander_AJHG_1994)._Functional_studies_have_revealed_that_the_variant_causes_partial_skip_of_exon_6_and_is_predicted_to_result_in_frameshit_in_cell_culture_via_cDNA_analysis_(Palagyi_MC_2010)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||This_variant_is_denoted_FANCC_c.553C>T_at_the_cDNA_level_and_p.Arg185Ter_(R185X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._In_addition_to_the_predicted_nonsense_variant,_RNA_analyses_have_demonstrated_that_this_variant_causes_partial_skipping_of_exon_7,_previously_reported_as_exon_6_using_alternate_nomenclature_(Gibson_1993,_Belanger_2013)._This_variant_has_been_reported_in_the_homozygous_and_compound_heterozygous_states_in_individuals_with_Fanconi_anemia_(Gibson_1993,_Tsangaris_2011,_Gille_2012)._This_variant_has_also_been_identified_in_the_heterozygous_state_in_two_sisters_with_breast_cancer,_who_also_had_a_family_history_of_breast_cancer_and_melanoma_(Thompson_2012),_and_in_an_individual_with_prostate_cancer_who_also_carried_a_BRCA2_truncating_variant_(Annala_2017)._We_consider_this_variant_to_be_pathogenic.|GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_185_(p.Arg185*)_of_the_FANCC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs121917783,_ExAC_0.008%)._This_variant_has_been_observed_as_homozygous_and_as_compound_heterozygous_in_individuals_with_Fanconi_anemia_(PMID:_7689011,_22778927,Â¬â€ 8128956,Â¬â€ 17924555,Â¬â€ 23613520)._In_addition,_this_variant_has_been_observed_in_several_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_23028338,Â¬â€ 26681312).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12044)._This_nonsense_variant_has_been_reported_to_cause_exon_6_skipping_in_a_portion_of_transcripts_by_mRNA_analysis,_resulting_in_a_prematurely_truncated_protein_(p.Met153Asnfs*23)_(PMID:_7689011,Â¬â€ 20509860)._Loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous
NM_000136.2:c.535C>T	FANCC	stop_gained	102640	1	NA	NA	4	1	rs769039987	not provided	235535	237216	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97912356G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176	SO:0001587|nonsense	1	769039987	-	Center_for_Pediatric_Genomic_Medicine,Children's_Mercy_Hospital_and_Clinics|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Invitae|Counsyl|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2016-04-29|2016-09-02|2018-06-04|2018-01-18|2014-11-19|2018-12-31	2016-05-19|2019-01-29|2018-09-19|2018-08-29|2019-08-05|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline	SCV000281191|SCV000568699|SCV000861684|SCV000833067|SCV001132390|SCV001185918	_complementation_group_C|Hereditary_cancer-predisposing_syndrome	|This_variant_is_denoted_FANCC_c.535C>T_at_the_cDNA_level_and_p.Arg179Ter_(R179X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_was_identified_in_a_mother_and_daughter_with_ovarian_and_breast_cancer_respectively,_but_was_absent_in_a_second_daughter_who_also_had_breast_cancer_(Thompson_2012)._Based_on_currently_available_information,_we_consider_this_variant_to_be_likely_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg179*)_in_the_FANCC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs769039987,_ExAC_0.003%)._This_variant_has_been_reported_in_a_family_affected_with_familial_breast_cancer_and_ovarian_cancer,_however,_there_is_insufficient_evidence_to_conclude_whether_this_variant_segregates_with_disease_or_not_(PMID:_23028338)._It_has_also_been_observed_in_an_individual_who_underwent_reproductive_carrier-testing_(PMID:_26990548)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_235535)._Loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000136.2:c.500del	FANCC	frameshift_variant	102654	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000136.2:c.489_490del	FANCC	frameshift_variant	102642	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000136.2:c.455dup	FANCC	frameshift_variant,splice_region_variant	102442	2	15430	2	-	-	-	-	409657	396906	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97934324dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	FANCC:2176	SO:0001589|frameshift_variant	1	774170058	-	Invitae|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America|Counsyl|Baylor_Genetics|Ambry_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2017-10-24|2015-03-25|2016-05-13|2015-06-03|0000-00-00|2019-03-21	2018-04-02|2019-01-29|2018-01-25|2019-08-05|2019-09-27|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline	SCV000549961|SCV000566026|SCV000695431|SCV001132187|SCV001163629|SCV001184463	Fanconi_anemia|not_provided|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn152Lysfs*9)_in_the_FANCC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs774170058,_ExAC_0.005%)._This_variant_has_been_reported_in_an_individual_affected_with_Fanconi_anemia_(PMID:_16429406)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_409657)._Loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_duplication_of_one_nucleotide_in_FANCC_is_denoted_c.455dupA_at_the_cDNA_level_and_p.Asn152LysfsX9_(N152KfsX9)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_TAAAAA[A]TGTGAG._The_duplication_causes_a_frameshift,_which_changes_an_Asparagine_to_a_Lysine_at_codon_152,_and_creates_a_premature_stop_codon_at_position_9_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._FANCC_c.455dupA,_previously_reported_as_FANCC_455_456dupA_and_450_451insA,_has_been_observed_in_individuals_with_Fanconi_Anemia_(Yates_2006,_Ameziane_2008)._we_consider_this_variant_to_be_pathogenic._FANCC_has_been_only_recently_described_in_association_with_cancer_predisposition_and_the_risks_are_not_well_understood._Based_on_available_data,_the_presence_of_a_FANCC_mutation_may_confer_an_increased_risk_for_female_breast_cancer_(Thompson_2012,_Berwick_2007)._Berwick_et_al._(2007)_identified_33_female_FANCC_mutation_carriers:_all_grandmothers_of_known_Fanconi_Anemia_patients._In_this_group_of_women_the_observed_cases_of_breast_cancer_(n
NM_000136.2:c.348dup	FANCC	frameshift_variant	102278	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000136.2:c.293_296del	FANCC	frameshift_variant	102544	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000136.2:c.265dup	FANCC	frameshift_variant	102320	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000136.2:c.166-2A>G	FANCC	splice_acceptor_variant	102052	1	NA	NA	-	-	-	-	135543	139282	not_specified	-	MedGen:CN169374	-	NC_000009.11:g.98009800T>C	no_assertion_provided	not_provided	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176	SO:0001574|splice_acceptor_variant	1	587777945	-	ITMI	not_provided	2013-09-19	2014-05-29	no_assertion_provided	germline	SCV000083954	not_specified	
NM_000136.2:c.67del	FANCC	frameshift_variant	102526	28	15434	3	-	-	-	-	12049	27088	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.98011509del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:613899.0007	-	FANCC:2176	SO:0001589|frameshift_variant	1	104886459	-	Children's_Mercy_Hospital_and_Clinics|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2001-09-01|2016-09-22|2015-06-14|2016-09-02|0000-00-00|0000-00-00|2018-07-16|2015-02-11|2018-12-30|2019-02-25	2019-11-07|2016-09-27|2019-08-05|2018-01-25|2019-09-27|2011-04-26|2019-01-29|2016-05-19|2019-03-28|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000033069|SCV000057810|SCV000677956|SCV000695436|SCV001163261|SCV000090447|SCV000149267|SCV000280699|SCV000549966|SCV001187905	Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|not_provided|not_provided|not_provided|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	|||Variant_summary:_The_FANCC_c.67delG_(p.Asp23Ilefs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_FANCC_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_8/121184_control_chromosomes_at_a_frequency_of_0.000066,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_FANCC_variant_(0.0017678)._The_variant_is_a_common_disease_variant_reported_in_numerous_affected_individuals_in_the_literature_in_the_homozygous_and_compound_heterozygous_state._It_has_been_reported_that_individuals_homozygous_for_the_variant_have_milder_phenotypes._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||The_pathogenic_FANCC_c.67delG_deletion_causes_a_frameshift,_which_changes_an_Aspartic_Acid_to_an_Isoleucine_at_codon_23,_and_creates_a_premature_stop_codon_at_position_23_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._FANCC_c.67delG,_previously_reported_as_322delG,_has_been_reported_as_a_founder_variant_in_the_Dutch_population_with_approximately_50%_of_Dutch_individuals_with_Fanconi_Anemia_being_homozygous_for_this_deletion_(Whitney_1993,_de_Vries_2012,_Gille_2012)._Of_note,_the_Fanconi_Anemia_patients_that_are_homozygous_or_compound_heterozygous_for_this_deletion_tend_to_have_a_mild_presentation_(Verlander_1994,_de_Vries_2012,_Gille_2012)._This_variant_has_also_been_reported_in_the_heterozygous_state_in_at_least_three_individuals_with_breast_cancer_(Berwick_2007,_Thompson_2012)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asp23Ilefs*23)_in_the_FANCC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs104886459,_ExAC_0.01%)._This_variant_is_a_known_common_cause_of_Fanconi_anemia,_and_is_a_recurrent_variant_in_affected_individuals_of_Dutch_ancestry_(PMID:Â¬â€ 22778927,Â¬â€ 22701786,Â¬â€ 8128956,Â¬â€ 9207444,Â¬â€ 11110674,Â¬â€ 20301575)._In_addition,_this_variant_has_been_reported_in_the_heterozygous_state_in_individuals_affected_with_breast_cancer_(PMID:Â¬â€ 17909071,Â¬â€ 23028338)._This_variant_is_also_known_as_322delG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12049)._Experimental_studies_have_shown_that_cells_carrying_this_variant_express_an_N_terminal-truncated_isoform_of_the_FANCC_protein,_due_to_re-initiation_of_translation_at_a_methionine_(Met55)_downstream_of_the_premature_translational_stop_signal_(PMID:_27133164,_8639804)._While_this_variant_rescues_inflammatory_cytokine-induced_cell_death_in_vitro_as_efficiently_as_wild-type_protein,_it_impairs_FANCC-mediated_nuclear_DNA_damage_repair_and_therefore_acts_as_a_loss-of-function_variant_(PMID:_27133164,_8639804)._Loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation
NM_000136.2:c.66G>A	FANCC	stop_gained	102456	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000136.2:c.37C>T	FANCC	stop_gained	102324	1	NA	NA	5	1	rs121917784	not provided	12046	27085	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.98011537G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:613899.0004	-	FANCC:2176	SO:0001587|nonsense	1	121917784	-	OMIM|GeneReviews|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Baylor_Genetics|GeneDx|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1993-09-11|2016-09-22|2014-05-27|2018-02-15|0000-00-00|2018-04-04|2018-08-10|2018-04-21	2015-06-15|2016-09-27|2015-03-11|2019-04-24|2019-09-27|2019-01-29|2019-03-28|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline	SCV000033066|SCV000057807|SCV000220353|SCV000917333|SCV001163262|SCV000149260|SCV000549951|SCV001182762	Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|not_provided|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	|||Variant_summary:_FANCC_c.37C>T_(p.Gln13X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.65G>A,_p.Trp22X:_c.553C>T,_p.Arg185X:_c.1642C>T,_p.Arg548X)._The_variant_allele_was_found_at_a_frequency_of_8.1e-06_in_245648_control_chromosomes_(gnomAD)._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_FANCC_causing_Fanconi_Anemia_Group_C_(8.1e-06_vs_1.80E-03),_allowing_no_conclusion_about_variant_significance._c.37C>T_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Fanconi_Anemia_Group_C_(De_Rocco_2014,_Gillio_1997,_Susswein_2015)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Three_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.||This_pathogenic_variant_is_denoted_FANCC_c.37C>T_at_the_cDNA_level_and_p.Gln13Ter_(Q13X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG)._This_variant_has_been_reported_in_the_homozygous_and_compound_heterozygous_state_in_individuals_with_Fanconi_Anemia_(Murer-Orlando_1993,_Verlander_1994,_Gillio_1997,_Nicchia_2015)_and_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Thus,_we_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_13_(p.Gln13*)_of_the_FANCC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Truncating_variants_in_FANCC_are_known_to_be_pathogenic._This_particular_truncation_has_been_reported_in_the_literature_as_homozygous_or_with_other_FANCC_pathogenic_variants_in_individuals_affected_with_Fanconi_anemia_(PMID:_8103176,_9207444,_8128956,_26740942)._This_variant_is_also_known_as_c.292C>T_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation
NM_000314.4:c.50_51del	PTEN	frameshift_variant	102754	1	NA	NA	-	-	-	-	141654	151368	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	-	NC_000010.10:g.89624276_89624277del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	PTEN:5728	SO:0001623|5_prime_UTR_variant	1	587781912	-	Ambry_Genetics|GeneDx|Invitae|ClinGen_PTEN_Variant_Curation_Expert_Panel	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-04-24|2015-01-19|2018-05-08|2017-10-18	2020-02-26|2019-01-29|2018-08-29|2018-10-11	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel	germline|germline|germline|germline	SCV000185099|SCV000565441|SCV000827782|SCV000840481	Hereditary_cancer-predisposing_syndrome|not_provided|PTEN_hamartoma_tumor_syndrome|PTEN_hamartoma_tumor_syndrome	|This_deletion_of_2_nucleotides_in_PTEN_is_denoted_c.50_51delAA_at_the_cDNA_level_and_p.Gln17ArgfsX26_(Q17RfsX26)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TATC[AA]GAGG._The_deletion_causes_a_frameshift,_which_changes_a_Glutamine_to_an_Arginine_at_codon_17,_and_creates_a_premature_stop_codon_at_position_26_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._we_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln17Argfs*26)_in_the_PTEN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781912,_ExAC_0.001%)._This_variant_has_been_observed_in_an_individual_affected_with_a_personal_and/or_family_history_of_cancer,_as_well_as_in_a_family_affected_with_Cowden_syndrome_(PMID:_Â¬â€ 24763289,Â¬â€ 20223021)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141654)._Loss-of-function_variants_in_PTEN_are_known_to_be_pathogenic_(PMID:_9467011,_21194675)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|PTEN_c.50_51delAA_(p.Q17RfsX26)_meets_criteria_to_be_classified_as_pathogenic_for_PTEN_Hamartoma_Tumor_syndrome_in_an_autosomal_dominant_manner_using_modified_ACMG_criteria_(Mester_et_al._2018:_manuscript_in_preparation)._Please_see_a_summary_of_the_rules_and_criteria_codes_in_the_'PTEN_ACMG_Specifications_Summary'_document_(assertion_method_column)._PVS1:_Null_variant_predicted_to_result_in_nonsense-mediated_decay_or_causing_truncation/frameshift_at_or_5'_to_c.1121_(NM_000314.4)._PM2:_Present_at_extremely_low_(<0.00001,_0.001%)_allele_frequency_in_the_gnomAD_cohort._(PMID_27535533)._PS4_P:_Proband(s)_with_phenotype_specificity_score_of_1-1.5._(PMID_20223021)
NM_000314.4:c.217G>T	PTEN	stop_gained	101972	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000314.4:c.388C>T	PTEN	stop_gained	102660	1	NA	NA	5&5&5&5&5&5	0&0&0&1&1&1	rs121909224	Cowden syndrome 1&Bannayan-Riley-Ruvalcaba syndrome&Macrocephaly/autism syndrome&not provided&Hereditary cancer-predisposing syndrome&PTEN hamartoma tumor syndrome	7819	22858	Neoplasm_of_brain|Ovarian_Neoplasms|Hereditary_cancer-predisposing_syndrome|Macrocephaly/autism_syndrome|PTEN_hamartoma_tumor_syndrome|Cowden_syndrome_1|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|MeSH:D010051,MedGen:CN236629|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1854416,OMIM:605309,Orphanet:ORPHA210548|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN072330,OMIM:158350|MedGen:CN169374|MedGen:CN517202	-	NC_000010.10:g.89692904C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2174|Herman_Laboratory,Nationwide_Children's_Hospital:PTENv2017-16|HGMD:CM971273|OMIM_Allelic_Variant:601728.0007|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2843913	-	PTEN:5728	SO:0001623|5_prime_UTR_variant	43	121909224	-	OMIM|Pathway_Genomics|Counsyl|OMIM|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Invitae|Herman_Laboratory,Nationwide_Children's_Hospital|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Database_of_Curated_Mutations_(DoCM)|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|Database_of_Curated_Mutations_(DoCM)|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2007-03-15|2014-07-24|2016-10-13|2007-03-15|2018-12-14|0000-00-00|2019-08-26|2018-05-22|2018-12-21|2017-03-01|2018-04-02|2014-10-02|2018-12-01|2015-07-14|2017-02-09	2018-06-28|2014-08-08|2016-11-23|2018-06-28|2019-01-29|2017-10-31|2020-03-06|2020-02-26|2019-03-28|2017-05-24|2019-03-21|2016-07-18|2019-02-22|2016-07-18|2017-06-30	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|unknown|germline|germline|germline|paternal|germline|somatic|somatic|somatic|germline	SCV000028470|SCV000189986|SCV000489500|SCV000028472|SCV000222110|SCV000692010|SCV001134775|SCV000187267|SCV000253832|SCV000579271|SCV000967757|SCV000504381|SCV000923927|SCV000504380|SCV000604969	Cowden_syndrome_1|Cowden_syndrome_1|Cowden_syndrome_1|Macrocephaly/autism_syndrome|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|PTEN_hamartoma_tumor_syndrome|PTEN_hamartoma_tumor_syndrome|Ovarian_Neoplasms|Ovarian_Neoplasms|Neoplasm_of_brain|not_specified	||||This_A>G_nucleotide_substitution_results_in_the_replacement_of_an_Arginine_codon_(AGG)_with_a_Glycine_codon_(GGG)_at_amino_acid_position_14,_and_is_denoted_c.40A>G_at_the_cDNA_level_or_p.R14G_at_the_protein_level._The_novel_R14G_missense_change_has_not_been_published_as_a_germline_pathogenic_variant,_nor_has_it_been_reported_as_a_benign_polymorphism_to_our_knowledge._However,_the_R14G_amino_acid_substitution_has_previously_been_reported_as_a_somatic_change_in_two_colon_tumors_and_one_kidney_tumor_among_other_tumor_types_according_to_the_Catalogue_of_Somatic_Mutations_in_Cancer._The_NHLBI_ESP_Exome_Sequencing_Project_reports_R14G_was_not_observed_in_approximately_6500_samples_from_individuals_of_European_and_African_American_backgrounds,_indicating_it_is_not_a_common_benign_variant_in_these_populations._The_R14G_variant_is_a_non-conservative_substitution_as_a_positively-charged_Arginine_residue_is_replaced_by_a_neutral_Glycine_residue_at_a_position_that_is_evolutionarily_well-conserved._This_amino_acid_substitution_is_located_within_the_phosphatase_tensin-type_domain,_a_known_functional_domain._missense_pathogenic_variants_in_nearby_positions_have_been_reported_in_the_literature,_according_to_HGMD_(K13E,_R15S,_D22G)._Therefore,_R14G_is_a_strong_candidate_for_a_disease-causing_mutation_likely_associated_with_a_PTEN-related_disorder:_however_the_possibility_that_it_is_a_benign_variant_cannot_be_excluded.||The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg130*)_in_the_PTEN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs121909224,_ExAC_0.006%)._This_variant_has_been_observed_in_several_individuals_affected_with_PTEN_hamartoma_tumor_syndrome_(PMID:_9259288,_21956414,_22266152,_23470840,_16773562,_24345843,_28655553)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_7819)._Loss-of-function_variants_in_PTEN_are_known_to_be_pathogenic_(PMID:_9467011,_21194675)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Arg130X_variant_in_PTEN_has_been_reported_in_at_least_10_individuals_with_Cowden_syndrome_(a_sub-type_of_PTEN_hamartoma_tumor_syndrome)_and_segregated_wit_h_disease_in_at_least_5_affected_relatives_from_2_families_(Nelen_1997,_Marsh_19_98,_Zori_1998,_Kubo_2000,_Ngeow_2011)._This_variant_has_been_identified_in_3/246_154_total_chromosomes_in_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad._broadinstitute.org:_dbSNP_rs121909224)_and_in_ClinVar_(Variation_ID#_7819)._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_130,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_func_tion_of_the_PTEN_gene_is_an_established_disease_mechanism_in_PTEN_hamartoma_tumo_r_syndrome._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogen_ic_for_PTEN_hamartoma_tumor_syndrome_in_an_autosomal_dominant_manner._ACMG/AMP_C_riteria_applied_PVS1:_PS4:_PP1_Moderate.||||
NM_000314.4:c.733C>T	PTEN	stop_gained	102722	1	NA	NA	5	1	rs786202918	Hereditary cancer-predisposing syndrome	186396	183044	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN517202	-	NC_000010.10:g.89717708C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:5068|Herman_Laboratory,Nationwide_Children's_Hospital:PTENv2017-32	-	PTEN:5728	SO:0001587|nonsense	1	786202918	-	Ambry_Genetics|Herman_Laboratory,Nationwide_Children's_Hospital|Invitae|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-26|2017-03-01|2017-02-15|2017-06-29	2020-02-26|2017-05-24|2017-10-05|2018-10-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline	SCV000216743|SCV000579287|SCV000645615|SCV000884426	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|PTEN_hamartoma_tumor_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_245_(p.Gln245*)_of_the_PTEN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_PTEN_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_a_family_affected_with_Cowden_disease_(PMID:_9467011)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000314.4:c.802-2_808del	PTEN	splice_acceptor_variant,coding_sequence_variant	92242	7	14742	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000314.4:c.802-2_816del	PTEN	splice_acceptor_variant,coding_sequence_variant	92242	7	14742	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000314.4:c.802-2A>T	PTEN	splice_acceptor_variant	74802	1	10752	1	-	-	-	-	142423	152137	Hereditary_cancer-predisposing_syndrome|PTEN_hamartoma_tumor_syndrome|Cowden_syndrome_1|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1959582,OMIM:601728,Orphanet:ORPHA306498|MedGen:CN072330,OMIM:158350|MedGen:CN517202	-	NC_000010.10:g.89720649A>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PTEN:5728	SO:0001574|splice_acceptor_variant	1	587782455	-	Cleveland_Clinic_Genomic_Medicine_Institute|ClinGen_PTEN_Variant_Curation_Expert_Panel	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-11-04|2014-02-28|2017-05-26|2017-10-18	2020-02-26|2019-01-29|2017-05-27|2018-10-11	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|reviewed_by_expert_panel	germline|germline|germline|germline	SCV000186522|SCV000222230|SCV000579242|SCV000840462	Hereditary_cancer-predisposing_syndrome|not_provided|Cowden_syndrome_1|PTEN_hamartoma_tumor_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:RNA_Studies:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|The_c.802-2_A>T_destroys_the_canonical_splice_acceptor_site_in_intron_7,_and_is_expected_to_cause_abnormal_gene_splicing._Although_this_mutation_has_not_been_reported_previously_to_our_knowledge,_its_presence_is_consistent_with_the_diagnosis_of_a_PTEN-related_disorder._This_mutation_destroys_the_canonical_splice_acceptor_site_in_intron_7,_and_is_expected_to_cause_abnormal_gene_splicing._The_variant_is_found_in_PTEN-HEREDIC_panel(s).||PTEN_c.802-2A>T_(IVS7-2A>T)_meets_criteria_to_be_classified_as_pathogenic_for_PTEN_Hamartoma_Tumor_syndrome_in_an_autosomal_dominant_manner_using_modified_ACMG_criteria_(Mester_et_al._2018:_manuscript_in_preparation)._Please_see_a_summary_of_the_rules_and_criteria_codes_in_the_'PTEN_ACMG_Specifications_Summary'_document_(assertion_method_column)._PVS1:_Null_variant_predicted_to_result_in_nonsense-mediated_decay_or_causing_truncation/frameshift_at_or_5'_to_c.1121_(NM_000314.4)._PM2:_Absent_in_large_sequenced_populations_(PMID_27535533)._PS4_P:_Proband(s)_with_phenotype_specificity_score_of_1-1.5._(Internal_laboratory_contributor(s),_SCV000222230.9)
NM_000051.3:c.15dup	ATM	frameshift_variant	102690	1	NA	NA	-	-	-	-	234089	233882	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108098366dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472	SO:0001587|nonsense	1	876660842	-	Ambry_Genetics|GeneDx	Pathogenic|Pathogenic	2018-05-22|2016-10-26	2020-02-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000278590|SCV000572144	Hereditary_cancer-predisposing_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_duplication_of_one_nucleotide_is_denoted_ATM_c.15dupT_at_the_cDNA_level_and_p.Asn6Ter_(N6X)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_braces,_is_TACT[T]AATG._The_duplication_creates_a_nonsense_variant,_which_changes_an_Asparagine_to_a_premature_stop_codon._Although_this_variant_has_not_been_previously_reported_to_our_knowledge,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay,_and_is_considered_pathogenic.
NM_000051.3:c.50_51del	ATM	frameshift_variant	102676	1	NA	NA	-	-	-	-	662558	639369	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108098401_108098402del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	-	-	Invitae	Pathogenic	2018-08-28	2019-03-28	_single_submitter	germline	SCV000960928	Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.His17Argfs*2)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs775561876,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.67C>T	ATM	stop_gained	102676	1	NA	NA	5	1	rs746235533	Hereditary cancer-predisposing syndrome	232248	233887	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108098418C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	746235533	-	Ambry_Genetics|Color|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-03-01|2018-02-14|2018-03-12|2018-11-02	2020-02-26|2018-11-06|2019-01-29|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000276332|SCV000913525|SCV000680683|SCV000748724	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_ATM_c.67C>T_at_the_cDNA_level_and_p.Arg23Ter_(R23X)_at_the_protein_level._Thesubstitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_ispredicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay.This_variant_has_been_observed_in_at_least_one_individual_with_mantle_cell_lymphoma_and_one_individual_with_gastriccancer_(Camacho_2002,_Huang_2015)._We_consider_this_variant_to_be_pathogenic|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg23*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs746235533,_ExAC_0.006%)._This_variant_has_been_reported_in_an_individual_affected_with_mantle_cell_lymphoma_(PMID:_11756177)_and_in_an_individual_affected_with_gastric_cancer._(PMID:_26506520)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_232248)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.70A>T	ATM	stop_gained,splice_region_variant	102678	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.103C>T	ATM	stop_gained	102646	2	NA	NA	5&5	1&1	rs55861249	Ataxia-telangiectasia syndrome&not provided	3025	18064	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108098533C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:607585.0008	-	ATM:472	SO:0001587|nonsense	1	55861249	-	OMIM|Genetic_Services_Laboratory,_University_of_Chicago|GeneReviews|Counsyl|Invitae|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1996-12-01|2014-06-27|2016-10-27|2016-07-18|2018-11-15|2018-07-02|2018-05-09|2018-07-22|2015-11-20|2017-02-21|2018-02-19|2018-05-25|2017-05-18	2015-07-16|2015-09-15|2016-10-27|2016-11-23|2019-03-28|2018-08-20|2019-04-24|2020-02-26|2016-03-03|2017-10-26|2019-01-29|2018-09-19|2017-05-23	no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|germline|unknown	SCV000023322|SCV000246611|SCV000328289|SCV000485098|SCV000826949|SCV000838465|SCV000916531|SCV000185123|SCV000266013|SCV000681949|SCV000293091|SCV000854897|SCV000611163	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	||||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_35_(p.Arg35*)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs55861249,_ExAC_0.009%)._This_variant_has_been_reported_as_a_common_variant_in_individuals_of_North_African_Jewish_descent_affected_with_ataxia_telangiectasia_(A-T)_(PMID:_8968760),_as_well_as_in_individuals_of_other_ethnicities_affected_with_A-T_(PMID:_21665257)_and_in_an_individual_affected_with_breast_cancer_(PMID:_26845104).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_3025)._Experimental_studies_using_A-T_patients'_cells_that_are_homozygous_for_this_variant_have_shown_that_they_are_more_sensitive_to_radiation-induced_damage_compared_to_normal_cells_(PMID:_15101044,_17699107),_a_result_consistent_with_an_absent_or_truncated_ATM_protein_(PMID:_8968760,_12637545_)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_Variant_summary:_The_ATM_c.103C>T_(p.Arg35X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.513C>G,_p.Tyr171X:_c.790delT,_p.Tyr264fsX12:_c.1027_1030delGAAA,_p.Glu343fsX2)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_8/246618_control_chromosomes_at_a_frequency_of_0.0000324,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_ATM_variant_(0.0039528)._The_variant_was_reported_in_numerous_affected_individuals_in_the_literature,_and_is_known_as_a_North_African_Jewish_founder_mutation._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Other_strong_data_supporting_pathogenic_classification|||This_pathogenic_variant_is_denoted_ATM_c.103C>T_at_the_cDNA_level_and_p.Arg35Ter_(R35X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_was_observed_in_32/33_defective_ATM_alleles_in_Jewish_A-T_families_of_North_African_origin_(Gilad_1996)._In_addition,_the_mutation_was_shown_to_be_functionally_abnormal,_inducing_aberrant_splicing_(Xiong_2014)_and_exhibiting_defects_in_a_cell_line_after_exposure_to_ionizing_radiation_(GutiÃ©rrez-EnrÃ­quez_2004)._It_is_considered_pathogenic.||
NM_000051.3:c.237del	ATM	frameshift_variant	102354	1	NA	NA	-	-	-	-	181874	180381	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108099956del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	730881303	-	GeneDx|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2018-04-20|2018-06-16|2017-03-03|2018-05-10|2017-07-31	2018-06-26|2018-08-29|2018-01-25|2020-02-26|2017-12-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000209620|SCV000622324|SCV000694219|SCV000660499|SCV000687382	not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_deletion_of_one_nucleotide_in_ATM_is_denoted_c.237delA_at_the_cDNA_level_and_p.Lys79AsnfsX37_(K79NfsX37)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_CAAA[delA]CCAA._The_deletion_causes_a_frameshift_which_changes_a_Lysine_to_an_Asparagine_at_codon_79,_and_creates_a_premature_stop_codon_at_position_37_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.237delA_was_identified_in_at_least_one_individual_with_ovarian_cancer_(Susswein_2016)._We_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys79Asnfs*37)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_ovarian_cancer_(PMID:_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181874)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_ATM_c.237delA_(p.Lys79Asnfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Tyr171X,_p.Arg2993X,_p.Lys2756X,_etc.)._This_variant_is_absent_in_114158_control_chromosomes_from_ExAC._This_variant_has_previously_been_reported_in_one_A-T_patient_in_compound_heterozygous_state_with_p.Tyr124Ter_(Minto_et_al._2017:_a_conference_meeting_abstract)_and_in_one_ovarian_cancer_patient_(Susswein_2015)._One_clinical_diagnostic_laboratory_has_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_likely_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_000051.3:c.381del	ATM	frameshift_variant	102594	1	NA	NA	-	-	-	-	141546	151260	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108106446del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:148232|Illumina_Clinical_Services_Laboratory,Illumina:1415920	-	ATM:472	SO:0001589|frameshift_variant	1	587781831	-	Ambry_Genetics|Color|GeneDx|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Blueprint_Genetics|Invitae|Counsyl|Illumina_Clinical_Services_Laboratory,Illumina|Biochemical_Molecular_Genetic_Laboratory,King_Abdulaziz_Medical_City	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-23|2017-08-11|2018-08-29|2017-06-13|2017-06-06|2018-12-26|2017-05-18|2018-08-14|2019-09-26	2020-02-26|2017-12-21|2019-01-29|2018-10-10|2019-05-08|2019-03-28|2018-07-10|2019-02-01|2019-09-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000184949|SCV000687504|SCV000566915|SCV000602573|SCV000927283|SCV000748771|SCV000791538|SCV000915496|SCV001133023	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_is_denoted_ATM_c.381delA_at_the_cDNA_level_and_p.Val128Ter_(V128X)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ATAC[delA]GTGA._The_deletion_creates_a_nonsense_variant,_which_changes_a_Valine_to_a_premature_stop_codon_(GTG>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.381delA,_previously_reported_as_380delA,_has_been_observed_in_the_homozygous_state_and_compound_heterozygous_state_in_individuals_with_Ataxia_telangiectasia_(Neubauer_2002,_Babaei_2005,_Broccoletti_2011)._This_variant_is_considered_pathogenic.|The_c.381delA_variant_has_been_previously_reported_in_association_with_ataxia_telangiectasia_in_multiple_unrelated_families_(Mitui_2005,_and_Babaei_2005)._The_c.381delA_variant_creates_a_frameshift_in_the_ATM_protein_at_codon_128_in_exon_5_which_results_in_a_premature_termination_codon_and_is_predicted_to_result_in_a_truncated_or_absent_protein_product._It_is_absent_from_general_population_databases_such_as_1000_Genomes,_NHLBI_GO_Exome_Sequencing_Project_(ESP)_,_and_the_Exome_Aggregation_Consortium_(ExAC)_browser_but_has_been_reported_to_ClinVar_(Variation_ID:_141546)._Based_on_these_observations,_the_c.381delA_variant_has_been_classified_as_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val128*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_to_co-occur_with_different_pathogenic_ATM_variants_in_individuals_affected_with_ataxia-telangiectasia_(A-T)_(PMID:_16266405,_15843990,_25502423,_25614872_)._This_variant_is_also_known_as_c.380delA_and_c.381_381delA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141546)._Experimental_studies_in_heterozygous_cell_lines_have_suggested_that_this_sequence_change_leads_to_reduced_ATM_protein_following_exposure_to_radiation_(PMID:_14970866)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_ATM_c.381delA_(p.Val128Ter)_variant_is_a_stop-gained_variant_predicted_to_result_in_premature_termination_of_the_protein._Across_a_selection_of_the_available_literature,_the_p.Val128Ter_variant_has_been_found_in_at_least_six_individuals_with_ataxia-telangiectasia,_all_in_a_compound_heterozygous_state_(Babaei_et_al._2005:_Mitui_et_al._2005:_Quarantelli_et_al._2013:_Podralska_et_al._2014)._Control_data_are_not_available_for_this_variant,_which_is_reported_at_a_frequency_of_0.000009_in_the_European_(non-Finnish)_population_of_the_Genome_Aggregation_Database._Based_on_the_collective_evidence_and_the_potential_impact_of_frameshift_variants,_the_p.Val128Ter_variant_is_classified_as_pathogenic_for_ataxia-telangiectasia._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|
NM_000051.3:c.392C>G	ATM	stop_gained	102612	1	NA	NA	-	-	-	-	545994	536377	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108106457C>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	1363726955	-	GeneDx|Ambry_Genetics	Likely_pathogenic|Pathogenic	2017-04-07|2019-10-29	2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000779467|SCV001183079	not_provided|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_ATM_c.392C>G_at_the_cDNA_level_and_p.Ser131Ter_(S131X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_likely_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.478_482del	ATM	frameshift_variant	102650	1	NA	NA	-	-	-	-	185501	183094	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108106543_108106547del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	587780624	-	Invitae|Counsyl|Ambry_Genetics|Color|GeneDx	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-14|2015-05-12|2018-05-31|2016-09-19|2016-10-17	2019-03-28|2017-06-22|2020-02-26|2017-10-26|2017-11-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline	SCV000166110|SCV000678112|SCV000215630|SCV000682221|SCV000564607	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	This_sequence_change_deletes_5_nucleotides_from_exon_5_of_the_ATM_mRNA_(c.478_482delTCTCA),_causing_a_frameshift_at_codon_160._This_creates_a_premature_translational_stop_signal_(p.Ser160Alafs*23)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individual(s)_with_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_(PMID:_26270727)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185501)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_5_nucleotides_in_ATM_is_denoted_c.478_482delTCTCA_at_the_cDNA_level_and_p.Ser160AlafsX23_(S160AfsX23)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AATA[delTCTCA]GCAA._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_an_Alanine_at_codon_160,_and_creates_a_premature_stop_codon_at_position_23_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature_as_a_germline_variant,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.497-3_498del	ATM	splice_acceptor_variant,coding_sequence_variant,intron_variant	56892	4	15318	0	-	-	-	-	802721	791028	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108114677_108114681del	_single_submitter	Uncertain_significance	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001574|splice_acceptor_variant	0	-	-	Mendelics	Uncertain_significance	2019-05-28	2019-10-22	_single_submitter	unknown	SCV001138429	Ataxia-telangiectasia_syndrome	
NM_000051.3:c.497-2A>G	ATM	splice_acceptor_variant	56432	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.497-1G>A	ATM	splice_acceptor_variant	56430	1	NA	NA	-	-	-	-	375250	361945	-	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	NC_000011.9:g.108114679G>A	no_interpretation_for_the_single_variant	-	-	424841:Uncertain_significance	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001574|splice_acceptor_variant	1	778624615	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.540del	ATM	frameshift_variant	99872	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.666_678del	ATM	frameshift_variant	102492	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.790del	ATM	frameshift_variant	102458	1	NA	NA	-	-	-	-	141742	151456	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108115642del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	587781978	-	Children's_Hospital_of_Philadelphia|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-23|2017-08-26|2018-07-25|2016-05-05|2017-05-02|2018-07-30	2020-02-26|2017-12-21|2019-03-28|2017-01-23|2018-01-25|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000185227|SCV000687801|SCV000283066|SCV000536866|SCV000694362|SCV000293219	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr264Ilefs*12)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs774609577,_ExAC_0.001%)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_9887333,_12673797,_12815592,_22213089,_15928302),_and_with_breast_or_ovarian_cancer_(PMID:_16832357,_24549055)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141742)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_ATM_c.790delT_(p.Tyr264Ilefs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.1027_1030delGAAA_[p.Glu343fs)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._The_variant_has_been_identified_in_numerous_patients_affected_with_ataxia_telangiectasia_and/or_breast_cancer_and_has_not_been_observed_in_healthy_individuals_(e.g.,_Renwick_2006:_Buzin_2003:_Castera_2014)._In_addition,_a_functional_study_revealed_that_a_patient_carrying_the_variant_of_interest_and_a_second_truncating_ATM_variant_(c.1563_1564delAG_[p.Glu522fs])_had_no_detectable_ATM_expression_or_kinase_activity_(Verhagen_HM_2012),_suggesting_the_variant_is_a_functional_null_allele._This_variant_is_absent_in_the_large_control_database_ExAC_(0/122508_control_chromosomes)._Multiple_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_deletion_of_one_nucleotide_in_ATM_is_denoted_c.790delT_at_the_cDNA_level_and_p.Tyr264IlefsX12_(Y264IfsX12)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GCTT[delT]ATAT._The_deletion_causes_a_frameshift,_which_changes_a_Tyrosine_to_an_Isoleucine_at_codon_264,_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._It_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_pathogenic_variant_has_been_reported_in_several_individuals_with_a_clinical_diagnosis_of_Ataxia-telangiectasia_(A-T)_and_in_individuals_with_personal_and/or_family_history_of_breast,_ovarian,_or_prostate_cancer_(Sandoval_1999,_Li_2000,_Mitui_2003,_Buzin_2003,_Thompson_2005,_Renwick_2006,_Castera_2014,_Pritchard_2016,_Decker_2017,_Kraus_2017)._Furthermore,_Verhagen_et_al._(2012)_studied_this_variant_in_a_patient_with_A-T_who_also_carried_another_truncating_variant_and_reported_absence_of_the_ATM_protein_in_this_individual._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.802C>T	ATM	stop_gained	102520	1	NA	NA	4&5	1&1	rs557012154	Ataxia-telangiectasia syndrome&Hereditary cancer-predisposing syndrome	188961	186798	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108115654C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	557012154	-	Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Invitae|Ambry_Genetics|GeneDx	Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2014-09-10|2016-09-26|2018-12-08|2018-07-06|2018-08-01	2015-03-11|2018-01-25|2019-03-28|2020-02-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline	SCV000220682|SCV000694369|SCV000749006|SCV000278020|SCV000617365	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|Variant_summary:_The_ATM_c.802C>T_(p.Gln268X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay_(NMD),_which_are_commonly_known_mechanisms_for_disease._If_this_variant_escapes_NMD,_this_variant_will_be_expected_to_truncate_the_catalytic_and_FAT_domains_and_armadillo-type_fold_(InterPro)._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Trp393X,_p.Gln1017X_etc.)._This_variant_was_found_in_2/125724_control_chromosomes_at_a_frequency_of_0.0000159,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_ATM_variant_(0.0039528)._In_literature,_this_variant_has_been_reported_in_two_patients_with_Ataxia-Telangiectasia_in_compound_heterozygous_with_another_variant_(Teraoka_1999,_Buzin_2003)._Functional_analysis_using_nested-PCR_cDNAs_of_a_cell_line_containing_this_variant_showed_missplicing_of_exon_9_(Teraoka_1999)._The_effect_was_the_partial_skipping_of_the_exon._Multiple_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_likely_pathogenic/pathogenic._Taken_together,_this_variant_is_classified_as_Likely_Pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln268*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs557012154,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_10330348,_12552559)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_188961)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_variant_is_denoted_ATM_c.802C>T_at_the_cDNA_level_and_p.Gln268Ter_(Q268X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA)_._In_addition,_ATM_Gln268Ter_has_also_been_reported_to_result_in_skipping_of_exon_7,_also_defined_as_exon_9_using_alternate_exon_numbering_(Teraoka_1999)._Both_ATM_Gln268Ter_and_skipping_of_exon_7_are_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_Gln268Ter_has_been_reported_in_the_compound_heterozygous_state_with_a_second_ATM_variant_in_several_individuals_with_A-T_(Buzin_2003,_Carranza_2017)._Based_on_currently_available_evidence,_we_consider_ATM_Gln268Ter_to_be_pathogenic.
NM_000051.3:c.824del	ATM	frameshift_variant	102478	2	NA	NA	-	-	-	-	220121	222029	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108115676del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001587|nonsense	9	864622389	-	Children's_Hospital_of_Philadelphia|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2018-10-13|2016-02-21|2018-07-19	2019-03-28|2017-01-23|2020-02-26	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|paternal|germline	SCV000260428|SCV000536863|SCV000273809	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu275*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_as_homozygous,_and_in_combination_with_another_ATM_variant,_in_families_affected_with_ataxia-telangiectasia_(PMID:_9463314,_9887333)._It_has_also_been_observed_in_an_individual_with_breast_cancer_(PMID:_27599564)._It_is_also_known_as_822delT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_220121)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.850C>T	ATM	stop_gained	102408	1	NA	NA	-	-	-	-	429069	421065	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.108115702C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	757782702	-	Ambry_Genetics|Color	Pathogenic|Pathogenic	2019-03-12|2017-11-09	2020-02-26|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000581449|SCV000913535	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)|
NM_000051.3:c.902-1G>T	ATM	splice_acceptor_variant	102322	1	NA	NA	-	-	-	-	418911	408054	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108117690G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001574|splice_acceptor_variant	1	1064793518	-	GeneDx|Ambry_Genetics|Color|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-07|2019-05-06|2017-11-17|2018-09-11	2019-01-29|2020-02-26|2018-11-06|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000566311|SCV000581462|SCV000911165|SCV000812959	not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome	This_pathogenic_variant_is_denoted_ATM_c.902-1G>T_or_IVS7-1G>T_and_consists_of_a_G>T_nucleotide_substitution_at_the_-1_position_of_intron_7_of_the_ATM_gene._The_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._Also_published_as_IVS9-1G>T_using_alternate_exon_numbering,_this_variant_has_been_observed_in_the_compound_heterozygous_state_in_a_case_of_Ataxia-Telangiectasia_(Teraoka_1999)._It_has_also_been_observed_in_an_individual_with_family_history_of_pancreatic_cancer_(Barnes_2017)._Based_on_currently_available_evidence,_we_consider_ATM_c.902-1G>T_to_be_pathogenic.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Functionally-validated_splicing_mutation||This_sequence_change_affects_an_acceptor_splice_site_in_intron_7_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_ataxia-telangiectasia_in_whom_it_co-occurs_with_a_second_pathogenic_ATM_variant_(PMID:_10330348)._This_variant_is_also_known_as_ISV9-1G>T_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_418911)._An_experimental_study_using_a_B-lymphoblastoid_cell_line_derived_from_an_affected_individual_showed_that_this_sequence_change_results_in_aberrant_splicing_(PMID:_10330348)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.943_944del	ATM	frameshift_variant	102432	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.980del	ATM	frameshift_variant	102538	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.992del	ATM	frameshift_variant	102584	1	NA	NA	-	-	-	-	407696	397791	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108117781del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	1060501684	-	Invitae	Pathogenic	2017-08-31	2018-04-02	_single_submitter	germline	SCV000547092	Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys331Serfs*15)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.1027_1030del	ATM	frameshift_variant	102534	2	NA	NA	-	-	-	-	135731	139443	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108117816_108117819del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	587780612	-	Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Vantari_Genetics|Color|GeneDx|Athena_Diagnostics_Inc	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-30|2014-03-10|2016-05-09|2019-04-05|2015-10-26|2015-10-29|2018-03-23|2018-03-31	2019-03-28|2015-03-11|2018-01-25|2020-02-26|2016-03-29|2017-10-26|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline|germline|germline	SCV000166073|SCV000220152|SCV000694167|SCV000184719|SCV000266988|SCV000681947|SCV000293429|SCV000840912	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu343Ilefs*2)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780612,_ExAC_0.005%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_10330348,_10817650,_12552559,_22213089,_21792198)_and_idiopathic_perifoveal_telangiectasia_(PMID:_18502988)._It_is_also_known_as_1024delAAAG,_1027_1030delAAAG,_and_1027del4_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141397)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_ATM_c.1027_1030delGAAA_(p.Glu343Ilefs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Trp393X,_p.Gln1017X,_p.Arg1466X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_is_absent_in_121026_control_chromosomes_but_has_been_reported_in_numerous_affected_individuals_in_the_literature._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|||This_deletion_of_4_nucleotides_in_ATM_is_denoted_c.1027_1030delGAAA_at_the_cDNA_level_and_p.Glu343IlefsX2_(E343IfsX2)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CAAA[delGAAA]ATTT._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_an_Isoleucine_at_codon_343,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.1027_1030delGAAA_,_also_published_as_ATM_c.1024delAAAG_by_alternate_nomenclature,_has_been_observed_in_individuals_with_ataxia_telangiectasia_who_harbor_a_second_ATM_variant,_and_corresponding_functional_studies_have_found_absent_or_reduced_levels_of_ATM_protein_expression_(Teraoka_1999,_Becker-Catania_2000,_Verhagen_2007,_Reiman_2011,_Verhagen_2012)._This_variant_has_also_been_reported_in_an_individual_with_a_personal_and_family_history_of_breast_cancer_(Desmond_2015),_and_in_at_least_two_individuals_with_idiopathic_perifoveal_telangiectasia_(Barbazetto_2008)._We_consider_this_variant_to_be_pathogenic.|
NM_000051.3:c.1139_1142dup	ATM	frameshift_variant	102652	2	NA	NA	-	-	-	-	280044	264571	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108119733_108119736dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472	SO:0001589|frameshift_variant	1	886041340	-	GeneDx|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2016-07-18|2018-12-20|2016-08-24|2019-03-28	2017-11-28|2019-03-28|2018-01-25|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000329804|SCV000546710|SCV000694172|SCV000581441	not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_duplication_of_four_nucleotides_in_ATM_is_denoted_c.1139_1142dupACAG_at_the_cDNA_level_and_p.Ser381ArgfsX27_(S381RfsX27)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_duplicated_in_brackets,_is_GATT[dupACAG]TGTC._The_duplication_causes_a_frameshift_which_changes_a_Serine_to_an_Arginine_at_codon_381,_and_creates_a_premature_stop_codon_at_position_27_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.1139_1142dupACAG,_published_as_c.1141insGACA_using_alternate_nomenclature,_has_been_observed_in_the_compound_heterozygous_state_in_at_least_one_patient_with_ataxia-telangiectasia_(Hacia_1998)._Based_on_the_currently_available_information,_we_consider_this_duplication_to_be_a_likely_pathogenic_variant.|This_sequence_change_inserts_4_nucleotides_in_exon_9_of_the_ATM_mRNA_(c.1139_1142dupACAG),_causing_a_frameshift_at_codon_381._This_creates_a_premature_translational_stop_signal_(p.Ser381Argfs*27)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_compound_heterozygous_state_in_an_individual_affected_with_ataxia-telangiectasia_(A-T)_(PMID:_9872980)._This_variant_is_also_known_as_1141insGACA_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_ATM_c.1139_1142dupACAG_(p.Ser381Argfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Trp393X,_p.Gln1017X,_p.Arg1466X,_p.Tyr2755fs)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_absent_in_121144_control_chromosomes,_but_has_been_cited_in_at_least_one_AT_patients_in_the_literature._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_000051.3:c.1201C>T	ATM	stop_gained	102588	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.1236-2_1243del	ATM	splice_acceptor_variant,coding_sequence_variant	100270	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.1236-2A>T	ATM	splice_acceptor_variant	72952	6	7212	3	-	-	-	-	375249	361947	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	Ataxia-telangiectasia_syndrome	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	NC_000011.9:g.108121426A>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	424841:Uncertain_significance	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001574|splice_acceptor_variant	1	80159221	-	_Manipal_Hospital|Ambry_Genetics|Mendelics	Uncertain_significance|Pathogenic|Uncertain_significance	0000-00-00|2013-06-25|2019-05-28	2016-12-30|2020-02-26|2019-10-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown	SCV000494066|SCV000581437|SCV001138451	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome	_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|
NM_000051.3:c.1236-1G>T	ATM	splice_acceptor_variant	90648	2	11644	0	-	-	-	-	802735	791042	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108121427G>T	_single_submitter	Uncertain_significance	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001574|splice_acceptor_variant	0	-	-	Mendelics	Uncertain_significance	2019-05-28	2019-10-22	_single_submitter	unknown	SCV001138453	Ataxia-telangiectasia_syndrome	
NM_000051.3:c.1245_1246insTTTTT	ATM	frameshift_variant	99784	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.1245_1246insTTTTTTTTTT	ATM	frameshift_variant	99784	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.1369C>T	ATM	stop_gained	102694	1	15412	0	5	1	rs749036865	Ataxia-telangiectasia syndrome	219999	222036	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108121561C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	749036865	-	Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-07-03|2016-09-12|2018-12-21|2017-07-17|2018-10-31	2017-10-05|2016-11-23|2020-02-26|2017-12-21|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|unknown	SCV000260212|SCV000486954|SCV000581476|SCV000687305|SCV000893171	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg457*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_particular_variant_has_been_reported_in_patients_affected_with_ataxia-telangiectasia_and_breast_cancer_(PMID:_17910737,_25428789,_26098866)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_219999)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||
NM_000051.3:c.1402_1403del	ATM	frameshift_variant	102704	3	15412	1	-	-	-	-	140889	150603	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108121594_108121595del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	587781347	-	Ambry_Genetics|Color|Counsyl|Invitae|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2012-11-19|2016-12-05|2015-01-28|2018-12-21|2019-01-04	2020-02-26|2017-10-26|2015-03-11|2019-03-28|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline	SCV000183842|SCV000681977|SCV000221096|SCV000260603|SCV000292779	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys468Glufs*18)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781347,_ExAC_0.03%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_24733792,_26094658),_as_well_as_in_the_homozygous_or_compound_heterozygous_state_in_individuals_with_ataxia-telangiectasia_(A-T)_(PMID:_9792409,_12552559,_23322442,_22649200,_20308662)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140889)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_two_nucleotides_in_ATM_is_denoted_c.1402_1403delAA_at_the_cDNA_level_and_p.Lys468GlufsX18_(K468EfsX18)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AGAC[delAA]GAGG._The_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_a_Glutamic_Acid_at_codon_468,_and_creates_a_premature_stop_codon_at_position_18_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.1402_1403delAA,_previously_reported_as_1403delAA_or_1787delAA,_has_been_observed_in_individuals_with_breast_cancer_(Kurian_2014,_Aloraifi_2015)_and_in_the_homozygous_or_compound_heterozygous_state_in_several_families_with_Ataxia-telangiectasia_(Broeks_1998,_Buzin_2003,_Carney_2012,_Jeddane_2013,_Huang_2013,_Chen_2013)._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.1476dup	ATM	frameshift_variant	102608	1	NA	NA	-	-	-	-	819288	810249	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.108121668dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472	SO:0001589|frameshift_variant	1	-	-	Ambry_Genetics	Pathogenic	2019-11-27	2020-02-26	_single_submitter	germline	SCV001172064	Hereditary_cancer-predisposing_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_000051.3:c.1501C>T	ATM	stop_gained	102618	1	NA	NA	-	-	-	-	524245	525915	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108121693C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	1281817400	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2018-01-17|2019-06-18	2018-08-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000748757|SCV001172283	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln501*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_000051.3:c.1564_1565del	ATM	frameshift_variant	102512	8	NA	NA	-	-	-	-	127340	132797	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108121754_108121755GA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	ATM:472	SO:0001589|frameshift_variant	1	587779817	-	Ambry_Genetics|Color|GeneKor_MSA|Invitae|Counsyl|GeneReviews|Integrated_Genetics/Laboratory_Corporation_of_America|Institute_of_Human_Genetics,Klinikum_rechts_der_Isar|GeneDx|Center_for_Pediatric_Genomic_Medicine,Children's_Mercy_Hospital_and_Clinics|Athena_Diagnostics_Inc|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-13|2017-03-31|2018-08-01|2018-12-31|2014-06-03|2016-10-27|2018-07-09|2019-02-21|2018-07-25|2017-08-29|2019-07-05|2017-01-30	2020-02-26|2017-10-26|2018-08-08|2019-03-28|2015-03-11|2016-10-27|2019-04-24|2020-01-21|2019-01-29|2017-10-05|2019-09-25|2018-06-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000185620|SCV000681982|SCV000821698|SCV000219160|SCV000220368|SCV000328297|SCV000918549|SCV001150019|SCV000149053|SCV000610563|SCV001143097|SCV000839878	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|not_provided|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_deletes_2_nucleotides_from_exon_10_of_the_ATM_mRNA_(c.1564_1565delGA),_causing_a_frameshift_at_codon_522._This_creates_a_premature_translational_stop_signal_(p.Glu522Ilefs*43)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs751357509,_ExAC_0.009%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_9463314,_10817650,_9000145,_12497634,_21965147,_10330348),_including_five_homozygous_individuals_(PMID:_10817650,_10330348),_and_an_individual_with_breast_cancer_(PMID:_27083775)._This_variant_is_also_known_as_1561delAG,_521Å’Ã®AG,_1563_1564delAG,_1563delAG,_c.1564_1565delAG_and_c.1561_1562delAG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127340)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_ATM_c.1564_1565delGA_(p.Glu522IlefsX43)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_5.3e-05_in_246034_control_chromosomes_(gnomAD)._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_ATM_causing_Ataxia-Telangiectasia_(5.3e-05_vs_0.004),_allowing_no_conclusion_about_variant_significance._The_variant,_c.1564_1565delGA,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Ataxia-Telangiectasia_(Demuth_2011,_Stankovic_1998,_Sandoval_199)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_ClinVar_submission_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cites_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.||The_ATM_c.1564_1565delGA_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_an_Isoleucine_at_codon_522,_and_creates_a_premature_stop_codon_at_position_43_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.1564_1565delGA,_also_reported_as_c.1563_1564delAG_and_c.1561_1562delAG,_has_been_observed_in_individuals_with_recessively_inherited_Ataxia-telangiectasia_and_in_patients_with_breast_cancer,_gastric_cancer,_and_an_unspecified_Lynch_syndrome-related_cancer_and/or_polyps_(Byrd_1996,_Demuth_2011,_Verhagen_2012,_Driessen_2013,_Huang_2015,_Hansford_2015,_Yurgelun_2015,_Mansfield_2016)._We_consider_this_variant_to_be_pathogenic.||The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|This_c.1564_1565del_(p.Glu522Ilefs*43)_has_previously_been_reported_a_patient_with_ataxia_telangiectasia_[p.R521fs_in_PMID_8789452]._It_has_also_been_reported_in_patients_with_gastric_cancer_and_suspected_lynch_syndrome_[c.1561_1562del,_p.R521fs_in_PMID_26506520]._This_c.1564_1565del_(p.Glu522Ilefs*43)_variant_been_observed_in_6_heterozygous_individuals_in_the_ExAC_population_database_(http://exac.broadinstitute.org/variant/11-108121752-CAG-C)._It_is_thus_interpreted_as_a_likely_pathogenic_variant.
NM_000051.3:c.1607+1G>T	ATM	splice_donor_variant	102182	1	NA	NA	-	-	-	-	220555	222042	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108121800G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001575|splice_donor_variant	1	772926890	-	Invitae|Counsyl|GeneDx|Ambry_Genetics	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2015-10-13|2015-11-16|2017-11-29|2019-07-18	2016-01-06|2016-11-23|2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline	SCV000261188|SCV000485314|SCV000293070|SCV000667940	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome	This_sequence_change_affects_a_donor_splice_site_in_intron_10._Experimental_studies_have_shown_that_this_nucleotide_change_disrupts_mRNA_splicing_and_leads_to_a_loss_of_ATM_protein_(PMID:_9450906,_9443866,_23454770)._Truncating_variants_in_ATM_are_known_to_be_pathogenic._This_particular_truncation_has_been_reported_in_multiple_patients_with_with_ataxia_telangiectasia,_including_one_homozygous_individual_(PMID:_9450906,_9443866,_19691550)._This_variant_is_also_known_as_IVS12+1G>T_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_ATM_c.1607+1G>T_or_IVS10+1G>T_and_consists_of_a_G>T_nucleotide_substitution_at_the_+1_position_of_intron_10_of_the_ATM_gene._The_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant,_previously_reported_as_IVS12+1G>T_using_alternate_exon_numbering,_has_been_reported_in_both_the_homozygous_state_and_compound_heterozygous_state_in_multiple_individuals_with_Ataxia-telangiectasia_(Gilad_1998,_Telatar_1998,_Magliozzi_2006,_Chessa_2009)._Based_on_current_evidence,_we_consider_ATM_c.1607+1G>T_to_be_pathogenic.|Functionally-validated_splicing_mutation_:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)
NM_000051.3:c.1799_1802+5del	ATM	splice_donor_variant,coding_sequence_variant,intron_variant	101798	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.1898+2T>G	ATM	splice_donor_variant	101964	1	NA	NA	-	-	-	-	141939	151653	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108123641T>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001575|splice_donor_variant	1	587782124	-	Ambry_Genetics|Color|GeneDx|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Invitae	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-10-23|2015-01-17|2018-11-13|2018-07-01|2018-12-21	2020-02-26|2017-10-26|2019-01-29|2019-07-12|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000185548|SCV000682012|SCV000293075|SCV000892002|SCV000546808	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Ataxia-telangiectasia_syndrome	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||This_variant_is_denoted_ATM_c.1898+2T>G_or_IVS12+2T>G_and_consists_of_a_T>G_nucleotide_substitution_at_the_+2_position_of_intron_12_of_the_ATM_gene._This_variant_destroys_a_canonical_splice_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant,_also_reported_as_ATM_IVS14+2T>G,_has_been_reported_in_the_compound_heterozygous_state_in_individuals_with_Ataxia-telangiectasia,_one_of_whom_also_developed_pancreatic_cancer_(Stankovic_1998,_Mitui_2005,_Verhagen_2007,_Cavalieri_2008,_Davis_2013)._Cell_lines_from_two_of_these_individuals_demonstrated_radiosensitivity_and_absence_of_ATM_protein_expression_and_kinase_activity_(Mitui_2005,_Driessen_2013)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||This_sequence_change_affects_a_donor_splice_site_in_intron_12_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_affected_with_both_classical_and_atypical_ataxia-telangiectasia_(A-T)_(PMID:_9463314,_16266405,_23566627,_24090759),_including_an_individual_in_whom_a_pathogenic_variant_was_detected_on_the_opposite_chromosome_(in_trans)_(PMID:_16266405)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._This_variant_has_also_been_reported_in_an_additional_individual_affected_with_breast_cancer_(PMID:_10677309)._This_variant_is_also_known_as_IVS14+2T>G_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141939)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.2012_2013dup	ATM	frameshift_variant	102678	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.2023C>T	ATM	stop_gained	102676	3	NA	NA	5&4	1&1	rs777849257	Hereditary cancer-predisposing syndrome&not provided	231933	234014	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108124665C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	777849257	-	Ambry_Genetics|GeneDx|Counsyl|Invitae	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-02-07|2018-03-20|2016-11-01|2018-12-05	2020-02-26|2019-01-29|2016-11-23|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline	SCV000275934|SCV000322534|SCV000487230|SCV000829660	Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_variant_is_denoted_ATM_c.2023C>T_at_the_cDNA_level_and_p.Gln675Ter_(Q675X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln675*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs777849257,_ExAC_0.004%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_231933)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.2131_2132dup	ATM	frameshift_variant	102092	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.2192dup	ATM	stop_gained,frameshift_variant	102628	1	NA	NA	-	-	-	-	633063	621329	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108127009dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472	SO:0001587|nonsense	1	1478081526	-	Integrated_Genetics/Laboratory_Corporation_of_America|Invitae|Ambry_Genetics	Likely_pathogenic|Pathogenic|Pathogenic	2018-12-14|2018-12-26|2019-08-16	2019-04-24|2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000918580|SCV000964405|SCV001175426	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	Variant_summary:_ATM_c.2192dupA_(p.Tyr731X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.3049C>T_(p.Gln1017X),_c.3372C>G_(p.Tyr1124X),_c.3663G>A_(p.Trp1221X))._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_246020_control_chromosomes_(gnomAD)._c.2192dupA_has_been_reported_in_the_literature_in_individuals_affected_with_Ataxia-Telangiectasia_and_Breast_Cancer_(Nunziato_2019,_Magliozzi_2006,_Saviozzi_2003)._These_data_indicate_that_the_variant_may_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._No_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar._However,_a_ClinVar_submission_from_a_clinical_diagnostic_laboratory_(evaluation_after_2014)_exists_for_a_different_variant_(ATM_c.2193C>A)_which_causes_the_same_protein_alteration_(p.Tyr731*)_as_the_variant_reported_here:_the_specific_variant_is_cited_in_ClinVar_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr731*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_an_individual_affected_withÂ¬â€ ataxia_telangiectasiaÂ¬â€ (PMID:Â¬â€ 12655570)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_000051.3:c.2201_2202insC	ATM	frameshift_variant	102632	1	NA	NA	-	-	-	-	524414	526100	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108127018_108127019insC	_single_submitter	Pathogenic	-	-	Insertion	SO:0000667	-	-	ATM:472	SO:0001589|frameshift_variant	1	1459299108	-	Invitae	Pathogenic	2017-11-14	2018-04-02	_single_submitter	germline	SCV000749079	Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ile735Asnfs*3)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.2284_2285del	ATM	frameshift_variant	102706	2	NA	NA	-	-	-	-	141325	151039	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108128239_108128240CT[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Microsatellite	SO:0000289	-	-	ATM:472	SO:0001589|frameshift_variant	1	587781658	-	_University_of_Chicago|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2019-02-01|2016-12-05|2018-12-25|2016-10-27|2016-03-01|2016-12-30|2019-01-07	2020-02-26|2017-10-26|2019-03-28|2016-10-27|2016-11-23|2017-07-05|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline	SCV000184612|SCV000682047|SCV000282894|SCV000328299|SCV000485904|SCV000593514|SCV000567457	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu762Valfs*2)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_8789452,_8845835,_21792198,_9463314,_27484032)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141325)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||This_deletion_of_2_nucleotides_in_ATM_is_denoted_c.2284_2285delCT_at_the_cDNA_level_and_p.Leu762ValfsX2_(L762VfsX2)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CACT[delCT]GTTT._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_a_Valine_at_codon_762,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Also_published_as_ATM_c.2284delCT_and_c.2282_2283del_using_alternate_nomenclature,_this_variant_has_been_reported_in_the_homozygous_or_compound_heterozygous_state_in_individuals_with_a_clinical_diagnosis_of_Ataxia-Telangiectasia_and_an_infant_with_severe_primary_immunodeficiency_(Gilad_1996,_Stankovic_1998,_Exley_2011,_Reiman_2011,_Yu_2016)._It_has_also_been_observed_in_the_single_heterozygous_state_in_at_least_one_individual_with_breast_or_ovarian_cancer_as_well_as_in_a_child_with_acute_lymphoblastic_leukemia_(ALL)_(Liberzon_2004,_Thompson_2016)._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.2413C>T	ATM	stop_gained	102660	2	NA	NA	5&5	1&1	rs780619951	Ataxia-telangiectasia syndrome&Hereditary cancer-predisposing syndrome	216021	212851	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108129749C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	780619951	-	Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-31|2016-03-22|2018-07-02|2018-10-02|2017-02-13|2018-06-22|2018-10-31	2019-03-28|2016-11-23|2018-08-20|2020-02-26|2017-10-26|2019-01-29|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|unknown|germline|germline|germline|unknown	SCV000253738|SCV000486043|SCV000838504|SCV000275927|SCV000682052|SCV000577402|SCV000893176	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_805_(p.Arg805*)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs780619951,_ExAC_0.05%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_9043869,_19691550,16941484,12815592,_15843990),_as_well_as_an_individual_with_a_personal_or_family_history_of_breast_or_ovarian_cancer_(PMID:_24549055)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_216021)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_variant_is_denoted_ATM_c.2413C>T_at_the_cDNA_level_and_p.Arg805Ter_(R805X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_the_compound_heterozygous_state_with_other_disease-causing_ATM_variants_in_multiple_individuals_with_Ataxia_telangiectasia_and_in_the_heterozygous_state_in_individuals_with_breast_cancer_(Chessa_2009,_Lin_2010,_Ng_2016,_Decker_2017)._We_consider_this_variant_to_be_pathogenic.|
NM_000051.3:c.2465T>G	ATM	stop_gained,splice_region_variant	102494	1	NA	NA	-	-	-	-	821323	810320	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.108129801T>G	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	-	-	Ambry_Genetics	Pathogenic	2018-09-17	2020-02-26	_single_submitter	germline	SCV001176474	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000051.3:c.2502dup	ATM	frameshift_variant	102702	1	NA	NA	-	-	-	-	127351	132808	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108137933dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472	SO:0001589|frameshift_variant	1	587779822	-	Ambry_Genetics|Color|GeneDx|Counsyl|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-11-24|2016-07-20|2018-10-01|2016-09-16|2018-10-26	2020-02-26|2017-10-26|2019-01-29|2016-11-23|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline	SCV000187199|SCV000682060|SCV000149065|SCV000486972|SCV000748965	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_one_nucleotide_in_ATM_is_denoted_c.2502dupA_at_the_cDNA_level_and_p.Val835SerfsX7_(V835SfsX7)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_GAGA[dupA]GTAG._The_duplication_causes_a_frameshift_which_changes_a_Valine_to_a_Serine_at_codon_835,_and_creates_a_premature_stop_codon_at_position_7_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.2502dupA,_also_reported_as_ATM_2502insA,_has_been_observed_in_both_the_homozygous_and_compound_heterozygous_state_in_individuals_with_Ataxia-telengiectasia_(Telatar_1998,_Sandoval_1999,_Chessa_2009)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val835Serfs*7)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_and_families_with_ataxia-telangiectasia_(PMID:_9443866,_19691550,_15843990)._It_has_also_been_reported_in_individuals_with_breast_cancer_and_melanoma_(PMID:_26681312,_26023681)._This_variant_is_also_known_as_2502insA,_c.2502_2503insA_p.(Val835fs),_and_2503_2504insA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127351)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.2508dup	ATM	frameshift_variant	102708	1	NA	NA	-	-	-	-	646712	639446	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108137939dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472	SO:0001589|frameshift_variant	1	-	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2018-10-11|2019-04-15	2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000940810|SCV001176634	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser837Ilefs*5)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs770396940,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_000051.3:c.2554C>T	ATM	stop_gained	102710	2	15418	1	-	-	-	-	407450	397861	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108137985C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	758081262	-	Fulgent_Genetics|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2018-12-29|2018-10-31|2019-03-06	2019-03-28|2018-11-14|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline	SCV000546653|SCV000893177|SCV001176806	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln852*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_affected_with_ataxia_telangiectasia_(PMID:_22130802,_26098866),_prostate_cancer_(PMID:Â¬â€ 28825054),_gastric_cancer_(PMID:_26098866),_and_chronic_lymphocytic_leukemia_(PMID:_24172824).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_407450)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.2638+2T>C	ATM	splice_donor_variant	102662	1	NA	NA	-	-	-	-	127357	132814	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108138071T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001575|splice_donor_variant	1	587779826	-	Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|GeneDx|PreventionGenetics,PreventionGenetics|Invitae|Counsyl	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2019-01-08|2015-11-20|2018-08-22|2018-06-05|2017-10-27|2018-09-23|2017-09-06	2020-02-26|2016-03-03|2018-11-06|2019-01-29|2018-01-29|2019-03-28|2018-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown	SCV000214719|SCV000266015|SCV000682067|SCV000149071|SCV000805523|SCV000547102|SCV000794012	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|||This_pathogenic_variant_is_denoted_ATM_c.2638+2T>C_or_IVS17+2T>C_and_consists_of_a_T>C_nucleotide_substitution_at_the_+2_position_of_intron_17_of_the_ATM_gene._The_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_an_individual_with_melanoma,_thyroid_cancer,_kidney_cancer,_and_polyps_who_was_undergoing_hereditary_cancer_multigene_panel_testing_(Shirts_2016)._Additionally,_a_different_nucleotide_change_at_the_same_position,_ATM_c.2638+2T>G,_reported_as_IVS19+2T>G_using_alternate_exon_numbering,_was_observed_in_trans_with_ATM_Val2716Ala_in_four_adult_sisters_with_atypical_ataxia-telangiectasia_(MÃ©neret_2014)._Based_on_the_current_evidence,_we_consider_ATM_c.2638+2T>C_to_be_pathogenic.||This_sequence_change_affects_a_donor_splice_site_in_intron_17_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_an_individual_affected_with_breast_cancer_(PMID:_26681312),_and_an_individual_affected_with_melanoma,_thyroid_and_kidney_cancer_(PMID:_26845104)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127357)._A_different_variant_affecting_this_nucleotide_(c.2638+2T>G,_also_known_as_VS19+2T>G)_has_been_determined_to_be_pathogenic_(PMID:_25122203)._This_suggests_that_this_nucleotide_is_important_for_normal_RNA_splicing,_and_that_other_variants_at_this_position_may_also_be_pathogenic._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.2690del	ATM	frameshift_variant	102662	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.2693T>G	ATM	stop_gained	102682	1	NA	NA	-	-	-	-	453426	460892	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108139191T>G	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	770610463	-	Invitae	Pathogenic	2017-06-28	2017-10-05	_single_submitter	germline	SCV000622349	Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_898_(p.Leu898*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.2734C>T	ATM	stop_gained	102696	1	NA	NA	-	-	-	-	490490	484230	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.108139232C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	764409952	-	Color	Pathogenic	2017-10-02	2017-12-21	_single_submitter	germline	SCV000687414	Hereditary_cancer-predisposing_syndrome	
NM_000051.3:c.2880del	ATM	frameshift_variant	102714	1	NA	NA	-	-	-	-	181871	180429	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108141832del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	730881300	-	Ambry_Genetics|Color|Counsyl|Invitae|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2017-06-08|2017-10-16|2016-08-30|2018-09-07|2018-11-15	2020-02-26|2018-11-06|2016-11-23|2019-03-28|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline	SCV000581448|SCV000905170|SCV000486873|SCV000622373|SCV000209616	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu961Cysfs*10)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs758561876,_ExAC_0.001%)._This_variant_has_been_observed_inÂ¬â€ individuals_affected_with_ataxia-telangiectasia_(PMID:_10980530,_17376192),_and_in_heterozygous_individuals_with_breast_and_pancreatic_cancers_(PMID:_26681312,Â¬â€ 26483394)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181871)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_pathogenic_variant_is_denoted_ATM_c.2880delC_at_the_cDNA_level_and_p.Leu961CysfsX10_(L961CfsX10)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ACCC[delC]TTGC._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_a_Cysteine_at_codon_961_and_creates_a_premature_stop_codon_at_position_10_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.2880delC_has_been_reported_in_a_compound_heterozygous_state_in_individuals_with_ataxia_telangiectasia_(Laake_2000,_Stray-Pedersen_2004),_as_well_as_in_an_individual_with_pancreatic_cancer_(Hu_2016)._We_therefore_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.2921+1G>A	ATM	splice_donor_variant	102674	4	NA	NA	-	-	-	-	141182	150896	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN517202	-	NC_000011.9:g.108141874G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:110979	-	ATM:472	SO:0001575|splice_donor_variant	1	587781558	-	Ambry_Genetics|Color|Counsyl|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Research_and_Development,Genoox|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-06-07|2015-01-19|2014-04-03|2018-12-30|2017-01-19|2018-11-26|0000-00-00|2016-08-29|2018-10-31	2020-02-26|2017-01-26|2015-03-11|2019-03-28|2018-01-25|2019-01-29|2019-03-28|2017-06-30|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|unknown|germline|unknown	SCV000184358|SCV000537641|SCV000220222|SCV000546716|SCV000694238|SCV000278817|SCV000916301|SCV000602557|SCV000893178	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|not_specified|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|||This_sequence_change_affects_a_donor_splice_site_in_intron_19_of_the_ATM_gene._It_is_expected_to_disrupt_mRNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781558,_ExAC_0.01%)._This_variant_has_been_observed_in_multiple_individuals_affected_with_ataxia-telangiectasia_(PMID:_8845835,_11298136,_12815592,_23322442,Â¬â€ 12673797)._In_two_individuals_this_variant_was_found_in_the_homozygous_state,_while_in_four_individuals_it_was_found_as_compound_heterozygous_with_a_second_pathogenic_ATM_variant._It_is_also_known_as_IVS21+1G>A_and_2839del83_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141182)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_ATM_c.2921+1G>A_variant_involves_the_alteration_of_a_conserved_intronic_nucleotide,_which_4/5_splice_prediction_tools_predict_a_significant_impact_on_normal_splicing_and_ESE_finder_predicts_the_removal_of_an_ESE_binding_site._The_variant_of_interest_was_observed_in_the_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_3/121072_(1/40355),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_ATM_variant_of_1/252_for_Ataxia-Telangiectasia._Multiple_publications_cite_the_variant_in_A-T_patients_that_were_homozygous_or_compound_heterozygous._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_ATM_c.2921+1G>A_or_IVS19+1G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_+1_position_of_intron_19_of_the_ATM_gene._The_variant,_also_reported_as_IVS21+1G>A_using_alternate_nomenclature_and_exon_numbering,_destroys_a_canonical_splice_donor_site_and_has_been_shown_to_result_in_exonic_skipping,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product_(Garcia-Perez_2001)._This_variant_has_been_reported_in_patients_with_classic_ataxia-telangiectasia_in_both_the_homozygous_and_compound_heterozygous_states_and_in_at_least_one_individual_with_endometrial_cancer_(Gilad_1996,_Garcia-Perez_2001,_Mitui_2003,_Jeddane_2013,_Ring_2016)._We_consider_this_variant_to_be_pathogenic.|||
NM_000051.3:c.2958_2961del	ATM	frameshift_variant	102648	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.3078-1G>A	ATM	splice_acceptor_variant	102544	2	NA	NA	-	-	-	-	231277	234071	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108143258G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001574|splice_acceptor_variant	1	750663117	-	Ambry_Genetics|Color|Counsyl|Invitae|GeneDx	Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2017-12-08|2018-09-14|2016-03-31|2018-11-28|2017-08-03	2020-02-26|2018-11-06|2016-11-23|2019-03-28|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline	SCV000275071|SCV000687450|SCV000486113|SCV000622387|SCV000568319	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Functionally-validated_splicing_mutation:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|||This_sequence_change_affects_an_acceptor_splice_site_in_intron_20_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_ataxia-telangiectasia,_who_also_had_a_second_truncating_variant_in_trans_in_the_ATM_gene_(PMID:_10234507)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_231277)._Experimental_studies_have_shown_that_this_sequence_change_can_result_in_the_out-of-frame_skipping_of_exon_21_(PMID:_10234507)._Due_to_alternative_exon_numbering,_exon_21_is_also_known_as_exon_23_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_pathogenic_variant_is_denoted_ATM_c.3078-1G>A_or_IVS20-1G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_-1_position_of_intron_20_of_the_ATM_gene._This_variant_destroys_a_canonical_splice_acceptor_site_and_has_been_shown_to_cause_abnormal_gene_splicing._Also_defined_as_IVS22-1G>A_using_alternate_nomenclature,_this_variant_was_reported_in_the_compound_heterozygous_state_in_an_individual_with_ataxia-telangiectasia_and_RT-PCR_analysis_demonstrated_that_this_variant_causes_skipping_of_the_subsequent_exon_(Izatt_1999)._This_disruption_would_be_predicted_to_lead_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.3214G>T	ATM	stop_gained	102662	1	NA	NA	-	-	-	-	407699	397887	Ovarian_Neoplasms|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108143509G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	1060501687	-	University_Hospital_Cologne|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-02-15|2016-05-24|2018-12-01|2018-05-18	2017-10-05|2019-01-29|2019-02-22|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000547097|SCV000566921|SCV000923762|SCV001180623	Ataxia-telangiectasia_syndrome|not_provided|Ovarian_Neoplasms|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1072_(p.Glu1072*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_9443866)_and_pancreatic_cancer_(PMID:_22585167)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_pathogenic_variant_is_denoted_ATM_c.3214G>T_at_the_cDNA_level_and_p.Glu1072Ter_(E1072X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_published_in_the_compound_heterozygous_state_in_at_least_three_cases_of_Ataxia-Telangiectasia_(Telatar_1998,_Mitui_2005,_Soukupova_2011),_and_in_the_heterozygous_state_in_a_case_of_familial_pancreatic_cancer_(Roberts_2012)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.3281del	ATM	frameshift_variant	102442	1	NA	NA	-	-	-	-	581217	565223	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108143576del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	776516754	-	Invitae	Pathogenic	2018-05-24	2018-08-29	_single_submitter	germline	SCV000833953	Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn1094Ilefs*15)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs776516754,_ExAC_0.01%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.3372C>G	ATM	stop_gained	102350	1	NA	NA	5&5	1&1	rs587779833	Hereditary cancer-predisposing syndrome&not provided	127371	132828	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108150305C>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	587779833	-	Fulgent_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-24|2017-12-24|2014-11-19|2018-12-06|2017-10-31|2017-09-13|2017-05-18	2020-02-26|2018-11-06|2015-03-11|2019-03-28|2019-04-24|2019-01-29|2017-05-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|unknown	SCV000186133|SCV000911665|SCV000220895|SCV000282930|SCV000916541|SCV000149085|SCV000611164	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr1124*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_10330348,_10817650),_and_an_individual_with_breast_and_lung_cancer_(PMID:_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127371)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_ATM_c.3372C>G_(p.Tyr1124X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._This_variant_was_found_in_1/245674_control_chromosomes_(gnomAD)_at_a_frequency_of_0.0000041,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_ATM_variant_(0.0010005)._Multiple_publications_have_cited_the_variant_in_affected_individuals_diagnosed_with_breast_cancer_or_Ataxia-Telangiectasia._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_variant_is_denoted_ATM_c.3372C>G_at_the_cDNA_level_and_p.Tyr1124Ter_(Y1124X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAG)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_Tyr1124Ter_has_been_observed_in_the_homozygous_state_in_at_least_one_individual_with_Ataxia-Telangiectasia_(Li_2000)._We_consider_this_variant_to_be_pathogenic.|
NM_000051.3:c.3475del	ATM	frameshift_variant	102666	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.3802del	ATM	frameshift_variant	102552	5	15422	1	-	-	-	-	127374	132831	Ovarian_Neoplasms|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108155009del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001587|nonsense	1	587779834	-	University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-04-01|2015-07-13|2018-12-04|2016-03-18|2018-07-02|2018-07-03|2018-11-06|2016-01-20|2018-12-01	2020-02-26|2017-10-26|2019-03-28|2016-11-23|2018-08-20|2019-04-24|2019-01-29|2018-08-31|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|unknown|unknown|germline|germline|germline|germline	SCV000184776|SCV000682163|SCV000253740|SCV000485724|SCV000838526|SCV000916584|SCV000149088|SCV000840935|SCV000923763	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|Ovarian_Neoplasms	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val1268*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs765158119,_ExAC_0.009%)._This_variant_has_been_reported_in_individuals_with_ataxia-telangiectasia_(A-T)_as_homozygous_(PMID:_9887333,_10864201)_or_compound_heterozygous_with_other_pathogenic_ATM_variants_(PMID:_9887333,_8755918,_25614872,_10330348,_25077176,_12815592,_23585524)._It_has_been_described_as_an_A-T_founder_mutation_in_families_from_the_British_Isles_(PMID:_9463314)._In_addition,_it_has_been_reported_in_individuals_with_breast_cancer_(PMID:_11606401,_18384426,_21787400,_16832357)_and_pancreatic_cancer_(PMID:_22585167)._This_variant_is_also_known_as_c.3801delG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127374)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_ATM_c.3802delG_(p.Val1268X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_p.Arg1466X_and_p.Ser1905fsX25)._The_variant_allele_was_found_at_a_frequency_of_4e-05_in_276948_control_chromosomes_(gnomAD)._This_frequency_is_not_higher_than_expected_for_a_pathogenic_variant_in_ATM_causing_Ataxia-Telangiectasia_(4e-05_vs_0.004),_allowing_no_conclusion_about_variant_significance._c.3802delG_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Ataxia-Telangiectasia_as_both_a_homozygous_and_compound_heterozygous_allele,_indicating_the_variant_is_very_likely_to_be_associated_with_disease._At_least_one_publication_reports_functional_data_indicating_the_variant_significantly_impairs_protein_expression_and_kinase_activity_in_patient_cells_(Carranza_2017)._Five_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_and_all_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_ATM_c.3802delG_at_the_cDNA_level_and_p.Val1268Ter_(V1268X)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_TGAG[delG]TGAA._The_deletion_creates_a_nonsense_variant,_changing_a_Valine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_ATM_c.3801delG_using_alternate_nomenclature,_has_been_observed_in_patients_with_breast_and/or_pancreatic_cancer_in_the_heterozygous_state_and_has_also_been_observed_in_multiple_patients_with_ataxia_telangiectasia_in_both_the_compound_heterozygous_and_homozygous_state_(McConville_1996,_Dork_2001,_Delia_2000,_Campbell_2003,_Brunet_2008,_Tavtigian_2009,_Goldgar_2011,_Roberts_2012)._We_consider_ATM_c.3802delG_to_be_pathogenic.||
NM_000051.3:c.3894dup	ATM	frameshift_variant	102578	1	NA	NA	-	-	-	-	141534	151248	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108155101dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472	SO:0001589|frameshift_variant	1	587781823	-	Ambry_Genetics|Color|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-05-23|2017-12-11|2016-01-10|2018-09-14|2017-06-27	2020-02-26|2018-11-06|2016-06-10|2019-04-24|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000184933|SCV000905172|SCV000282945|SCV000918564|SCV000329805	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_inserts_1_nucleotide_in_exon_26_of_the_ATM_mRNA_(c.3894dupT),_causing_a_frameshift_at_codon_1299._This_creates_a_premature_translational_stop_signal_(p.Ala1299Cysfs*3)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Truncating_variants_in_ATM_are_known_to_be_pathogenic._This_particular_truncation_has_been_reported_in_individuals_affected_with_AtaxiaTelangiectasia_(PMID:_10330348,_12815592,_19691550)._This_variant_is_also_known_as_c.3894_3895insT_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_ATM_c.3894dupT_(p.Ala1299CysfsX3)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_8.1e-06_in_246054_control_chromosomes_(gnomAD)._c.3894dupT_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Ataxia-Telangiectasia_(Chessa_2009,_Micol_2011)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Three_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_duplication_of_one_nucleotide_in_ATM_is_denoted_c.3894dupT_at_the_cDNA_level_and_p.Ala1299CysfsX3_(A1299CfsX3)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_braces,_is_ATTT[T]GCCT._The_duplication_causes_a_frameshift,_which_changes_an_Alanine_to_a_Cysteine_at_codon_1299,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.3894dupT,_also_known_as_ATM_3894insT_and_c.3894_3895insT,_has_been_observed_in_the_homozygous_and_compound_heterozygous_states_in_individuals_with_ataxia-telangiectasia_(Teraoka_1999,_Mitui_2003,_Chessa_2009)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.3993+1G>A	ATM	splice_donor_variant	102222	4	NA	NA	-	-	-	-	141447	151161	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108155201G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001575|splice_donor_variant	1	200196781	-	Ambry_Genetics|Color|Invitae|Counsyl|GeneDx	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-07-25|2018-08-13|2018-12-05|2017-06-14|2017-12-12	2020-02-26|2018-11-06|2019-03-28|2017-06-22|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline	SCV000184785|SCV000687508|SCV000282950|SCV000678090|SCV000515987	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_affects_a_donor_splice_site_in_intron_26_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs200196781,_ExAC_0.005%)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_a_pathogenic_variant_in_multiple_individuals_affected_with_ataxia-telangiectasia_(PMID:Â¬â€ 10980530,Â¬â€ 12815592)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._This_variant_is_also_known_as_IVS28+1G>A_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141447)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_ATM_c.3993+1G>A_or_IVS26+1G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_+1_position_of_intron_26_of_the_ATM_gene._This_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant,_also_defined_as_IVS28+1G>A_by_alternate_nomenclature,_has_been_reported_in_association_with_ataxia_telangiectasia_(Laake_2000,_Mitui_2003,_Coutinho_2004,_Cavaciuti_2005)_and_was_co-observed_with_a_CHEK2_pathogenic_variant_in_a_patient_with_bilateral_breast_cancer_(Tung_2016)._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.3994-2A>G	ATM	splice_acceptor_variant	100034	4	NA	NA	-	-	-	-	142167	151881	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108158325A>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001574|splice_acceptor_variant	1	587782276	-	Ambry_Genetics|Color|Invitae	Pathogenic|Likely_pathogenic|Likely_pathogenic	2019-04-18|2018-09-24|2018-11-16	2020-02-26|2018-11-06|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000186065|SCV000904688|SCV000253669	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome	Other_strong_data_supporting_pathogenic_classification||This_sequence_change_affects_an_acceptor_splice_site_in_intron_26_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587782276,_ExAC_0.006%)._This_variant_has_been_reported_in_an_individual_with_a_personal_history_of_breast_cancer_and_family_history_of_pancreatic_cancer_(PMID:_28956312)_and_in_an_individual_undergoing_hereditary_cancer_multi-gene_panel_testing_for_which_clinical_information_was_not_provided_(PMID:_24763289)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142167)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_000051.3:c.4373del	ATM	frameshift_variant	102610	1	NA	NA	-	-	-	-	141315	151029	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108160465del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	587781653	-	Baylor_College_of_Medicine	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-18|2018-03-09|2016-07-11|2018-09-17|2017-10-30	2020-02-26|2018-11-06|2019-01-29|2019-03-28|2018-06-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000184596|SCV000905173|SCV000209619|SCV000546761|SCV000839885	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_in_ATM_is_denoted_c.4373delG_at_the_cDNA_level_and_p.Gly1458GlufsX15_(G1458EfsX15)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_TTAG[G]AGGA._The_deletion_causes_a_frameshift,_which_changes_a_Glycine_to_a_Glutamic_Acid_at_codon_1458,_and_creates_a_premature_stop_codon_at_position_15_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.4373delG_has_been_observed_in_multiple_patients_with_Ataxia-Telangiectasia_and_has_been_associated_with_absent_ATM_protein_expression_and_no_residual_ATM_protein_activity_in_an_affected_compound_heterozygote_(Teraoka_1999,_Li_2000,_Carney_2012)._We_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gly1458Glufs*15)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_10330348,_22649200)_and_in_an_individual_affected_with_prostate_cancer_(PMID:_27433846)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_c.4373delG_frame_shift_variant_is_predicted_to_yield_loss_of_function_transcripts/proteins_of_ATM_gene,_which_is_one_of_mechanisms_causing_Ataxia-telangiectasia._This_variant_is_extremely_rare_in_general_population_(1_in_246014_by_gnomad)_and_observed_in_multiple_ataxia-telangiectasia_patients_(PMID:10330348,_22649200)._It_has_been_also_observed_in_other_clinical_labs_and_reported_as_a_pathogenic._Based_on_the_above_evidences,_we_interpret_this_variant_as_pathogenic.
NM_000051.3:c.4396C>T	ATM	stop_gained	102546	1	NA	NA	5	1	rs730881369	Ataxia-telangiectasia syndrome	236716	240964	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108160488C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	730881369	-	Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-10|2016-01-22|2017-11-19|2018-07-02|2015-01-23|2017-12-11|2018-02-19|2018-10-31	2019-03-28|2018-01-25|2018-07-10|2018-08-20|2017-01-26|2020-02-26|2019-01-29|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|unknown|germline|germline|germline|unknown	SCV000282958|SCV000694281|SCV000795828|SCV000838539|SCV000537651|SCV000581466|SCV000779350|SCV000893179	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1466_(p.Arg1466*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs730881369,_ExAC_0.006%)._This_variant_has_been_reported_in_many_individuals_affected_with_ataxia-telangiectasia_(PMID:_10425038,_12552559,_19691550,_22213089,_22527104,_26439923)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_236716)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_variant_is_denoted_ATM_c.4396C>T_at_the_cDNA_level_and_p.Arg1466Ter_(R1466X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_the_homozygous_or_compound_heterozygous_state_in_several_individuals_with_Ataxia-telangiectasia_and_in_the_heterozygous_state_in_at_least_one_individual_with_familial_breast_cancer_(Chessa_2009,_Snape_2012,_Chen_2015)._Based_on_current_evidence,_we_consider_this_variant_to_be_pathogenic.|
NM_000051.3:c.4493T>G	ATM	stop_gained	102630	1	NA	NA	-	-	-	-	453523	460976	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108163402T>G	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	1329359780	-	Invitae	Pathogenic	2017-07-26	2017-10-05	_single_submitter	germline	SCV000622506	Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1498_(p.Leu1498*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.4525_4526insAGTA	ATM	stop_gained,frameshift_variant	102632	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.4611_4611+9del	ATM	splice_donor_variant,coding_sequence_variant,intron_variant	102548	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.4612-3_4616del	ATM	splice_acceptor_variant,coding_sequence_variant,intron_variant	76100	1	NA	NA	-	-	-	-	631464	619393	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.108164037_108164044del	_single_submitter	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001574|splice_acceptor_variant	1	773012957	-	Color	Likely_pathogenic	2018-09-18	2018-11-06	_single_submitter	germline	SCV000913945	Hereditary_cancer-predisposing_syndrome	
NM_000051.3:c.4668T>G	ATM	stop_gained	102256	3	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.4776+2_4776+13del	ATM	splice_donor_variant,intron_variant	101962	1	NA	NA	-	-	-	-	420098	408160	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108164206_108164217del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001575|splice_donor_variant	1	762838462	-	GeneDx|Invitae|Color	Likely_pathogenic|Pathogenic|Likely_pathogenic	2015-11-13|2017-05-08|2018-09-04	2019-01-29|2017-10-05|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000568671|SCV000622530|SCV000687568	not_provided|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_ATM_c.4776+2_4776+13del12_or_IVS31+2_IVS31+13del12_and_consists_of_a_deletion_of_12_nucleotides_from_the_+2_to_+13_positions_of_intron_31._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_GAGg[del12]catc,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._This_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._However,_in_the_absence_of_RNA_or_functional_studies,_the_actual_effect_of_this_variant_is_unknown._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature._Based_on_the_currently_available_information,_we_consider_ATM_c.4776+2_4776+13del12_to_be_likely_pathogenic.|This_sequence_change_affects_a_donor_splice_site_in_intron_31_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_a_ATM-related_disease._Two_different_variants_affecting_this_same_splice_donor_site_(c.4776+2T>C_and_c.4776+2T>A)_have_been_determined_to_be_pathogenic_(PMID:_9497252,_9600235)._This_suggests_that_this_nucleotide_is_important_for_normal_RNA_splicing,_and_that_other_variants_at_this_position_may_also_be_pathogenic._Intron_31_is_also_referred_to_as_intron_33_in_the_literature_and_these_variants_are_also_known_as_IVS33+2T>C,_IVS33+2T>A,_and_4612del165_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.4909+1G>A	ATM	splice_donor_variant	102626	1	NA	NA	-	-	-	-	478991	476084	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108165787G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001575|splice_donor_variant	1	756987454	-	Ambry_Genetics|Invitae	Pathogenic|Pathogenic	2017-04-03|2017-10-20	2020-02-26|2018-04-02	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000660621|SCV000748956	Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_splicing_assay_data_in_support_of_pathogenicity:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|This_sequence_change_affects_a_donor_splice_site_in_intron_32_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs756987454,_ExAC_0.001%)._This_variant_has_been_reported_as_homozygous_in_two_apparently_unrelated_individuals_affected_with_ataxia-telangiectasia,_and_as_heterozygous_in_an_individual_affected_with_breast_cancer_(PMID:_9887333,_26534844)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.5188C>T	ATM	stop_gained	102448	2	NA	NA	-	-	-	-	189054	186800	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108172385C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	764389018	-	Counsyl|Invitae|Ambry_Genetics|Color|GeneDx	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2014-11-11|2018-10-17|2019-03-27|2016-12-21|2018-02-12	2015-03-11|2019-03-28|2020-02-26|2017-10-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline	SCV000220872|SCV000261713|SCV000665457|SCV000682254|SCV000779352	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg1730*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs764389018,_ExAC_0.001%)._This_variant_has_been_observed_in_several_individuals_affected_with_ataxia-telangiectasia_(PMID:_10425038,_12815592,_21792198,_22213089)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_189054)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_variant_is_denoted_ATM_c.5188C>T_at_the_cDNA_level_and_p.Arg1730Ter_(R1730X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_the_homozygous_or_compound_heterozygous_state_in_several_individuals_with_Ataxia-telangiectasia_(Mitui_2003,_Mitui_2005,_Carranza_2017,_van_Os_2017)_and_is_considered_pathogenic.
NM_000051.3:c.5290del	ATM	frameshift_variant	102448	2	NA	NA	-	-	-	-	127405	132862	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108172487del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	587779846	-	Ambry_Genetics|Color|Counsyl|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-12-17|2016-05-02|2014-12-04|2018-12-31|2018-08-03|2018-09-21	2020-02-26|2017-10-26|2015-03-11|2019-03-28|2019-04-24|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline	SCV000183971|SCV000682261|SCV000220935|SCV000253739|SCV000916586|SCV000149119	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu1764Tyrfs*12)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587779846,_ExAC_0.002%)._This_variant_has_been_reported_in_several_individuals_affected_with_ataxia-telangiectasia_and_breast_cancer_(PMID:_10330348,_10425038,_12552559,_16832357,_26681312,_22649200)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127405)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_ATM_c.5290delC_(p.Leu1764TyrfsX12)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.5712dupA/p.Ser1905fsX25,_c.5908C>T/p.Gln1970X)._The_variant_allele_was_found_at_a_frequency_of_8.3e-06_in_121178_control_chromosomes._c.5290delC_has_been_reported_in_the_literature_in_individuals_affected_with_Ataxia-Telangiectasia_(Castellvi-Bev_1999,_Sun_2002,_Thompson_2005)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._At_least_one_publication_reports_experimental_evidence_evaluating_an_impact_on_protein_function._The_most_pronounced_variant_effect_results_in_<10%_of_normal_activity._Three_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_deletion_of_one_nucleotide_in_ATM_is_denoted_c.5290delC_at_the_cDNA_level_and_p.Leu1764TyrfsX12_(L1764YfsX12)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_CTAT[delC]TACA._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_a_Tyrosine_at_codon_1764_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.5290delC_has_been_reported_in_individuals_with_ataxia_telangiectasia,_as_well_in_individuals_with_breast_or_lung_cancer_(Castellvi-Bel_1999,_Teraoka_1999,_Sun_2002,_Renwick_2006,_Lu_2015,_Maxwell_2016,_Decker_2017,_Parry_2017)._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.5443del	ATM	frameshift_variant	102450	1	NA	NA	-	-	-	-	236738	240985	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108173703del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	878853522	-	Invitae	Pathogenic	2016-02-08	2016-06-10	_single_submitter	germline	SCV000282992	Ataxia-telangiectasia_syndrome	This_sequence_change_deletes_one_nucleotide_in_exon_36_of_the_ATM_mRNA_(c.5443delG),_causing_a_frameshift_at_codon_1815._This_creates_a_premature_translational_stop_signal_(p.Asp1815Thrfs*13)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_truncating_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_10817650,_19781682)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.5554C>T	ATM	stop_gained	102410	1	NA	NA	-	-	-	-	370611	357913	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108175459C>T	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	0	754562056	-	Counsyl	Likely_pathogenic	2016-03-10	2016-11-23	_single_submitter	unknown	SCV000485972	Ataxia-telangiectasia_syndrome	
NM_000051.3:c.5623C>T	ATM	stop_gained	102100	2	NA	NA	5	1	rs376603775	not provided	245815	244622	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108175528C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	376603775	-	_University_of_Cambridge|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-07|2018-09-28|2017-11-07|2018-01-26|2018-12-31	2019-01-29|2020-02-26|2018-11-06|2018-04-23|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000292957|SCV000581455|SCV000913964|SCV000992201|SCV000622605	not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome	This_pathogenic_variant_is_denoted_ATM_c.5623C>T_at_the_cDNA_level_and_p.Arg1875Ter_(R1875X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_association_with_breast_cancer_and,_in_the_homozygous_state,_Ataxia-telangiectasia_(A-T)_(Gilad_1998,_Teraoka_1999,_Goldgar_2011,_Keimling_2011)._In_addition,_cell_lines_from_two_patients_with_A-T_were_used_to_show_that_this_variant_results_in_no_ATM_protein_expression,_defective_phosphorylation_of_downstream_target_genes,_and_a_damaging_effect_on_double_strand_break_repair_function_similar_to_a_BRCA1_pathogenic_variant_(Keimling_2011)._This_variant_is_considered_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg1875*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs376603775,_ExAC_0.003%)._This_variant_has_been_observed_in_an_individual_affected_with_breast_cancer_(PMID:_26976419),_and_in_the_homozygous_or_compound_heterozygous_state_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_9450906,_10873394,_21792198,_27980538)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_245815)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.5692C>T	ATM	stop_gained	102524	1	NA	NA	-	-	-	-	482526	475938	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108178641C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2310584	-	ATM:472	SO:0001587|nonsense	1	775036118	-	Ambry_Genetics|Color|Counsyl|Invitae|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-09-06|2017-04-10|2017-12-08|2018-10-29|2019-05-22	2020-02-26|2017-12-21|2018-07-10|2019-03-28|2019-08-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline	SCV000667807|SCV000687636|SCV000796269|SCV000956854|SCV001158445	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg1898*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs775036118,_ExAC_0.006%)._This_variant_has_been_observed_in_individuals_affected_with_ataxia-telangiectasia_and_breast_cancerÂ¬â€ (PMID:Â¬â€ 17124347,Â¬â€ 25077176,Â¬â€ 23454770,Â¬â€ 25374739,Â¬â€ 23322442,Â¬â€ 28724667)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 482526)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.5712dup	ATM	frameshift_variant	102582	1	NA	NA	-	-	-	-	141416	151130	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108178661dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472	SO:0001589|frameshift_variant	1	587781730	-	Ambry_Genetics|Color|Counsyl|Invitae|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-02-26|2017-05-11|2014-03-07|2018-12-10|2018-07-02|2018-04-09|2018-12-18	2020-02-26|2017-10-26|2015-03-11|2019-03-28|2018-08-20|2019-04-24|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|unknown|germline|germline	SCV000184741|SCV000682282|SCV000220146|SCV000547052|SCV000838556|SCV000916572|SCV000209623	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_inserts_1_nucleotide_in_exon_38_of_the_ATM_mRNA_(c.5712dupA),_causing_a_frameshift_at_codon_1905._This_creates_a_premature_translational_stop_signal_(p.Ser1905Ilefs*25)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_8845835,_10873394,_16266405,_10817650)_and_in_an_individual_affected_with_pancreatic_cancer_(PMID:_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141416)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_ATM_c.5712dupA_(p.Ser1905IlefsX25)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_8.1e-06_in_245942_control_chromosomes_(gnomAD)._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_ATM_causing_Ataxia-Telangiectasia_(8.1e-06_vs_4.00e-03),_allowing_no_conclusion_about_variant_significance._The_variant,_c.5712dupA,_has_been_reported_in_the_literature_in_individuals_affected_with_Ataxia-Telangiectasia,_breast,_and_pancreatic_cancer_(Susswein_2016,_Tung_2015,_Gilad_1996)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_duplication_of_one_nucleotide_in_ATM_is_denoted_c.5712dupA_at_the_cDNA_level_and_p.Ser1905IlefsX25_(S1905IfsX25)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_braces,_is_TAAAAA[A]TCAC._The_duplication_causes_a_frameshift,_which_changes_a_Serine_to_an_Isoleucine_at_codon_1905,_and_creates_a_premature_stop_codon_at_position_25_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.5712dupA_has_been_observed_in_the_compound_heterozygous_state_with_another_ATM_pathogenic_variant_in_at_least_three_individuals_with_ataxia-telangiectasia_(Gilad_1996,_Becker-Catania_2000,_Mitui_2005)._It_has_also_been_observed_in_at_least_two_individuals_undergoing_hereditary_cancer_multigene_testing_(LaDuca_2014,_Tung_2015)._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.5763-2A>C	ATM	splice_acceptor_variant	102414	1	NA	NA	-	-	-	-	232005	234226	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.108180885A>C	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	876659489	-	Ambry_Genetics	Likely_pathogenic	2015-06-01	2020-02-26	_single_submitter	germline	SCV000276023	Hereditary_cancer-predisposing_syndrome	_2)_without_other_strong_(B-level)_evidence_supporting_pathogenicity
NM_000051.3:c.5932G>T	ATM	stop_gained	102582	5	NA	NA	5&5&5	1&1&1	rs587779852	Hereditary cancer-predisposing syndrome&Ataxia-telangiectasia syndrome&not provided	127414	132871	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108183151G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587779852	-	Ambry_Genetics|Color|Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|PreventionGenetics,PreventionGenetics|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-17|2016-02-09|2018-12-22|2016-03-11|2017-07-14|2018-05-30|2016-03-02|2017-05-18	2020-02-26|2017-01-26|2019-03-28|2016-11-23|2018-01-25|2019-01-29|2018-01-29|2017-05-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|unknown	SCV000172771|SCV000537636|SCV000260557|SCV000485199|SCV000694312|SCV000149128|SCV000805589|SCV000611165	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1978_(p.Glu1978*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587779852,_ExAC_0.01%)._This_variant_has_been_reported_in_several_individuals_affected_with_ataxia-telangiectasia_and_breast_cancer_(PMID:_15880721,_16266405,_17124347,_18807267,_19691550,_25614872,_18497957)._It_has_been_found_to_be_a_prevalent_ATM_mutation_in_Eastern_Europe_(PMID:_15880721,_16266405,_18807267)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127414)._Experimental_studies_indicate_that_this_nonsense_change_may_lead_to_the_out-of-frame_skipping_of_exon_40_(PMID:_10330348,_24451234),_although_the_clinical_significance_of_these_findings_is_unknown._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_ATM_c.5932G>T_(p.Glu1978X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.7327C>T_[p.Arg2443X],_c.7517_7520delGAGA_[p.Arg2506fsX3],_and_c.7913G>A_[p.Trp2638X])._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_the_control_database_ExAC_and_control_cohorts_reported_in_the_literature_at_a_frequency_of_0.0000779_(10/128320_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_ATM_variant_(0.0039528)._The_variant_has_been_found_in_homozygosity_and_compound_heterozygosity_in_numerous_patients_and_families_with_ataxia-telangiectasia_(Podralska_MGGM_2014:_Birrell_HM_2005)._Additionally,_a_large_case-control_study_showed_that_the_variant_is_enriched_in_heterozygous_breast_cancer_patients_in_Eastern_European_populations_(Odds_Ratio_
NM_000051.3:c.5979_5983del	ATM	frameshift_variant	102556	2	NA	NA	-	-	-	-	233016	234239	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108183198_108183202del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	876660134	-	Ambry_Genetics|Color|GeneKor_MSA|Invitae|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2016-10-20|2016-04-25|2018-08-01|2017-08-15|2017-07-19	2020-02-26|2017-10-26|2018-08-08|2018-04-02|2018-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000277309|SCV000682293|SCV000821701|SCV000547057|SCV000792875	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser1993Argfs*23)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_reported_in_the_literature_in_several_individuals_affected_with_ataxia-telangectasia_(PMID:_8845835,_17124347,_17910737,_19691550,_23454770)._This_variant_is_also_known_as_5979del5_or_5979delTAAAG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_233016)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.6082C>T	ATM	stop_gained	102708	1	NA	NA	5	1	rs876659454	Hereditary cancer-predisposing syndrome	231947	234244	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108186625C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	876659454	-	Ambry_Genetics|Color|Counsyl|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-04-08|2018-07-02|2017-03-15|2018-07-27	2020-02-26|2018-11-06|2018-07-10|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline	SCV000275951|SCV000913986|SCV000790314|SCV000834925	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln2028*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_as_homozygous_in_an_individual_affected_with_ataxia-telangiectasia_(PMID:_12552559,_22213089).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_231947)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.6198+1G>A	ATM	splice_donor_variant	102474	1	NA	NA	-	-	-	-	221911	223599	Hereditary_breast_and_ovarian_cancer_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108186841G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	778031266	-	Ambry_Genetics|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Dr._Peter_K._Rogan_Lab,Western_University|GeneDx|Counsyl	Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic	2015-06-05|2018-01-26|2015-12-22|2017-03-09|2017-07-25	2020-02-26|2018-04-23|2015-12-22|2019-01-29|2018-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|unknown	SCV000276351|SCV000992203|SCV000262588|SCV000617371|SCV000793009	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|Ataxia-telangiectasia_syndrome	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbSNP,_ESP,_1000_Genomes):in_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(B-level)_evidence_supporting_pathogenicity|Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|Sequenced_patient_with_familial_breast_cancer|The_c.6198+1G>A_variant_in_the_ATM_gene_has_been_reported_previously_in_at_least_two_individuals_with_hereditary_breast_and_ovarian_cancer_and_has_also_been_reported_along_with_another_ATM_variant_in_at_least_two_individuals_reported_to_have_ataxia-telangiectasia_(Stankovic_et_al.,_1998:_Reiman_et_al.,_2011:_Exley_et_al.,_2011:_Caminsky_et_al.,_2016)._This_splice_site_variant_destroys_the_canonical_splice_donor_site_in_intron_42_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._The_c.6198+1G>A_variant_is_not_observed_at_a_significant_frequency_in_large_population_cohorts_(Lek_et_al.,_2016:_1000_Genomes_Consortium_et_al.,_2015:_Exome_Variant_Server)._We_interpret_c.6198+1G>A_as_a_likely_pathogenic_variant.|
NM_000051.3:c.6228del	ATM	frameshift_variant	102698	1	NA	NA	-	-	-	-	186516	183348	_susceptibility_to|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3469522|MedGen:CN517202	-	NC_000011.9:g.108188129del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	786203008	-	Ambry_Genetics|Color|Invitae|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Genetic_Services_Laboratory,_University_of_Chicago	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-02-07|2015-12-28|2018-12-11|2018-08-23|2018-01-26|2017-04-05	2020-02-26|2017-10-26|2019-03-28|2019-01-29|2018-09-19|2017-07-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000216895|SCV000682314|SCV000260167|SCV000292791|SCV000703277|SCV000593511	_susceptibility_to	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu2077Phefs*5)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_ataxia-telangiectasia_(PMID:_10817650)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186516)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_one_nucleotide_in_ATM_is_denoted_c.6228delT_at_the_cDNA_level_and_p.Leu2077PhefsX5_(L2077FfsX5)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ATAT[delT]CTTT._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_a_Phenylalanine_at_codon_2077,_and_creates_a_premature_stop_codon_at_position_5_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.6228delT_has_been_reported_in_individuals_with_breast_and/or_pancreatic_cancer,_as_well_as_in_a_patient_with_ataxia_telangiectasia_(Li_2000,_Frey_2015,_Shindo_2017)._We_consider_this_variant_to_be_pathogenic.||
NM_000051.3:c.6404_6405insTT	ATM	frameshift_variant	101102	1	15426	0	-	-	-	-	220763	222101	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108190737_108190738insTT	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Insertion	SO:0000667	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587782554	-	Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Color|Ambry_Genetics	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-14|2016-08-24|2018-09-24|2017-02-22|2015-01-20|2018-09-29	2018-08-29|2016-11-23|2019-04-24|2019-01-29|2017-12-21|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline	SCV000261563|SCV000486857|SCV000916597|SCV000292474|SCV000687694|SCV001187382	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg2136*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587782554,_ExAC_0.002%)._This_variant_has_been_reported_in_the_literature_in_individuals_with_ataxia-telangiectasia_(PMID:_8659541,_9463314,_21792198)_and_an_individual_with_breast_cancer_(PMID:_25428789)._This_variant_is_also_known_as_6404insTT_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_220763)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_ATM_c.6404_6405insTT_(p.Arg2136X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_7.3e-06_in_275474_control_chromosomes_(gnomAD)._The_variant,_c.6404_6405insTT,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Ataxia-Telangiectasia_(Micol_2011,_Telatar_1996)_and_breast_cancer_(Churpek_2015)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic/likely_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_insertion_of_2_nucleotides_is_denoted_ATM_c.6404_6405insTT_at_the_cDNA_level_and_p.Arg2136Ter_(R2136X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_inserted_in_brackets,_is_CTCT[insTT]AAGA._The_insertion_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.6404_6405insTT,_previously_reported_as_6404insTT_using_alternate_nomenclature,_has_been_observed_in_several_individuals_with_Ataxia-telangiectasia_(Telatar_1996,_Stankovic_1998,_Reiman_2011)_as_well_as_in_affected_individuals_undergoing_evaluation_for_hereditary_breast_or_ovarian_cancer_(Churpek_2015,_Thompson_2016)._This_variant_is_considered_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.6635_6636del	ATM	frameshift_variant	102562	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.6650_6657del	ATM	frameshift_variant	102544	1	NA	NA	-	-	-	-	219963	222104	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108196114_108196121del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	864622326	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2015-08-26|2017-05-15	2016-01-06|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000260159|SCV000278202	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_deletes_8_nucleotides_from_exon_46_of_the_ATM_mRNA_(c.6650_6657delTTTTAGTT),_causing_a_frameshift_at_codon_2217._This_creates_a_premature_translational_stop_signal_(p.Phe2217Serfs*29)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_truncating_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_10817650,_19781682)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.6677dup	ATM	frameshift_variant	102536	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.6908dup	ATM	frameshift_variant	102584	2	NA	NA	-	-	-	-	453647	461099	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108196885dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	773570504	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2017-05-22|2016-06-02	2017-10-05|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000622696|SCV000660620	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_inserts_1_nucleotide_in_exon_47_of_the_ATM_mRNA_(c.6908dupA),_causing_a_frameshift_at_codon_2304._This_creates_a_premature_translational_stop_signal_(p.Glu2304Glyfs*69)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_two_families_affected_with_classical_ataxia-telangiectasia_and_in_two_individuals_from_a_single_family_affected_with_variant_ataxia-telangiectasia,_as_well_as,_in_three_individuals_from_a_single_family_affected_with_breast_cancer_(PMID:_11897822,_1935770).Â¬â€ This_variant_is_also_known_as_6903insA_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.6976-2A>C	ATM	splice_acceptor_variant	102190	1	NA	NA	-	-	-	-	142355	152069	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108198370A>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587782403	-	Ambry_Genetics|Color|GeneDx|Invitae|Counsyl	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-06-19|2018-08-28|2018-05-07|2018-10-31|2016-07-05	2020-02-26|2018-11-06|2019-01-29|2019-03-28|2016-11-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000186419|SCV000687745|SCV000209635|SCV000283030|SCV000486609	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_variant_is_denoted_ATM_c.6976-2A>C_or_IVS47-2A>C_and_consists_of_an_A>C_nucleotide_substitution_at_the_-2_position_of_intron_47_of_the_ATM_gene._Using_alternate_intron_numbering,_this_variant_would_be_defined_as_ATM_IVS49-2A>C._The_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_observed_in_at_least_two_individuals_with_breast_cancer_(Decker_2017)._Based_on_the_currently_available_information,_we_consider_ATM_c.6976-2A>C_to_be_a_likely_pathogenic_variant.|This_sequence_change_affects_an_acceptor_splice_site_in_intron_47._It_is_expected_to_disrupt_mRNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_has_been_reported_in_an_individual_with_polyposis_and_colon_cancer_(PMID:_26681312)._In_summary,_donor_and_acceptor_splice_site_variants_are_typically_loss-of-function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_18321536)._However,_without_additional_functional_and/or_genetic_data,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_000051.3:c.7000_7003del	ATM	frameshift_variant	102408	1	NA	NA	-	-	-	-	187035	183374	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108198392_108198395TACA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Microsatellite	SO:0000289	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	786203421	-	Ambry_Genetics|Color|Invitae|Counsyl	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2019-03-14|2018-06-11|2018-12-12|2015-12-15	2020-02-26|2018-11-06|2019-03-28|2016-11-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown	SCV000217530|SCV000905174|SCV000283031|SCV000485465	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr2334Glnfs*4)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs763554569,_ExAC_0.01%)._This_variant_has_been_reported_in_an_individual_affected_with_prostate_cancer_(PMID:_27433846)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_187035)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571))._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.6997dup	ATM	frameshift_variant	102410	2	15428	1	-	-	-	-	140818	150532	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108198393dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587781299	-	_University_of_Washington|Color|Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Blueprint_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-04|2015-11-20|2015-09-03|2018-12-16|2015-08-25|2018-06-04|2018-08-22|2018-05-21	2020-02-26|2016-03-03|2017-10-26|2019-03-28|2017-06-22|2019-04-24|2019-01-29|2019-05-08	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline	SCV000172903|SCV000266020|SCV000682383|SCV000260039|SCV000678163|SCV000916577|SCV000292478|SCV000927694	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Thr2333Asnfs*40)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_with_ataxia-telangiectasia_(PMID:_9463314),_and_in_several_individuals_affected_with_breast_cancer_(PMID:_21787400,_26845104)._It_has_also_been_reported_in_an_individual_with_colorectal_cancer_(PMID:_23585368)._It_is_also_known_as_6996_6997insA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140818)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_ATM_c.6997dupA_(p.Thr2333AsnfsX40)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_8.1e-06_in_245820_control_chromosomes._c.6997dupA_has_been_reported_in_the_literature_in_individuals_affected_with_Ataxia-Telangiectasia_(Stankovic_1998,_Li_2000,_Exley_2011)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._At_least_one_publication_reports_experimental_evidence_evaluating_an_impact_on_protein_function,_demonstrating_the_lack_of_ATM_protein_and_ATM_kinase_activity_in_LCLs_derived_from_a_patient_who_had_the_variant_of_interest_in_compound_heterozygosity_with_an_other_truncating_ATM_variant_(Exley_2011)._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic_(5x)_or_likely_pathogenic_(1x)._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_duplication_of_one_nucleotide_in_ATM_is_denoted_c.6997dupA_at_the_cDNA_level_and_p.Thr2333AsnfsX40_(T2333NfsX40)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_ACTT[dupA]CATA._The_duplication_causes_a_frameshift,_which_changes_a_Threonine_to_an_Asparagine_at_codon_2333,_and_creates_a_premature_stop_codon_at_position_40_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.6997dupA,_previously_reported_as_6997insA,_has_been_observed_in_association_with_breast_cancer,_colorectal_cancer,_and_Ataxia-telangiectasia_(Stankovic_1998,_Thompson_2005,_Goldgar_2011,_Smith_2013)._We_consider_this_variant_to_be_pathogenic.|
NM_000051.3:c.7072C>T	ATM	stop_gained	102318	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.7096G>T	ATM	stop_gained	102684	1	NA	NA	5&4	1&1	rs587781672	Hereditary cancer-predisposing syndrome&Ataxia-telangiectasia syndrome	141344	151058	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108199754G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587781672	-	Ambry_Genetics|Counsyl|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2017-07-10|2014-06-05|2018-09-06|2018-11-23	2020-02-26|2015-03-11|2019-03-28|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline	SCV000184646|SCV000220379|SCV000829074|SCV000918577	Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu2366*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_ataxia-telangiectasia_(PMID:Â¬â€ 18321536)._Additionally,_the_variant_has_been_reported_in_an_individual_affected_with_hereditary_breast_cancer_(PMID:_25330149)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141344)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_ATM_c.7096G>T_(p.Glu2366X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_246208_control_chromosomes._c.7096G>T_has_been_reported_in_the_literature_in_a_compound_heterozygous_individual_affected_with_Ataxia-Telangiectasia_(Du_2008)_and_in_a_heterozygous_individual_affected_with_Breast_Cancer_(Cybulski_2015)._At_least_two_publications_reported_experimental_evidence_evaluating_an_impact_on_protein_function,_demonstrating_the_lack_of_protein,_no_ATM-dependent_kinase_activity_and_increased_radiosensitivity_in_a_patient_derived_lymphoblastoid_cell_line_that_carried_the_variant_together_with_another_truncating_ATM_variant_(Du_2013,_Nakamura_2014)._Two_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation,_and_both_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_000051.3:c.7327C>T	ATM	stop_gained	102452	1	NA	NA	5	1	rs121434220	Hereditary cancer-predisposing syndrome	3036	18075	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108200960C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:607585.0019	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	121434220	-	PreventionGenetics	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1999-01-01|2014-07-19|2018-10-13|2017-02-02|2019-03-29|2016-07-01|2018-11-06|2017-07-14	2016-09-16|2015-03-11|2019-03-28|2018-01-25|2020-02-26|2017-12-21|2019-01-29|2018-01-29	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline|germline|germline	SCV000023333|SCV000220525|SCV000260860|SCV000694350|SCV000273030|SCV000687767|SCV000566496|SCV000805612	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg2443*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_8808599,_10817650,_9887333,_21833744,_14586414),_and_individuals_with_prostate,_breast,_and_pancreatic_cancer_(PMID:_24556621,_26822949,_26483394)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_3036)._Experimental_studies_in_heterozygous_cell_lines_have_shown_that_this_nonsense_change_causes_reduced_ATM_protein_and_mRNA_expression,_and_increased_sensitivity_to_radiation_(PMID:_15101044,_14970866)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_ATM_c.7327C>T_(p.Arg2443X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._This_prediction_has_been_confirmed_by_one_study_showing_that_the_ATM_protein_is_absent_in_cells_from_a_patient_who_carries_the_variant_of_interest_and_a_frameshift_variant_(Prodosmo_2013)._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.7517_7520delGAGA,_c.8264_8268delATAAG)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_has_been_reported_in_multiple_AT_patients_and_is_absent_in_119996_control_chromosomes._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic/likely_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous||This_pathogenic_variant_is_denoted_ATM_c.7327C>T_at_the_cDNA_level_and_p.Arg2443Ter_(R2443X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_the_homozygous_and_compound_heterozygous_states_in_multiple_individuals_with_ataxia-telangiectasia_(Sandoval_1999,_Bernstein_2003,_Anheim_2010,_Tariq_2018)_and_in_the_heterozygous_state_in_individuals_with_breast,_pancreatic,_and/or_prostate_cancer_(Leongamornlert_2014,_Hu_2016,_Lhota_2016)._We_consider_this_variant_to_be_pathogenic.|
NM_000051.3:c.7495_7498del	ATM	frameshift_variant	102520	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.7517_7520del	ATM	splice_acceptor_variant,coding_sequence_variant	102354	1	NA	NA	-	-	-	-	141647	151361	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108202170_108202171GA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva:21_May_2017	-	ATM:472|C11orf65:160140	SO:0001574|splice_acceptor_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	9	587781905	-	Ambry_Genetics|Color|GeneDx|GeneReviews|Counsyl|Invitae|Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-01-12|2017-06-22|2017-04-26|2016-10-27|2015-12-23|2019-01-05|2016-09-12|2016-02-15	2020-02-26|2017-12-21|2019-01-29|2016-10-27|2016-11-23|2019-03-28|2017-05-19|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|paternal|germline	SCV000185088|SCV000687776|SCV000292954|SCV000328284|SCV000485200|SCV000546740|SCV000598151|SCV000694356	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_four_nucleotides_in_ATM_is_denoted_c.7517_7520delGAGA_at_the_cDNA_level_and_p.Arg2506ThrfsX3_(R2506TfsX3)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TAGA[delGAGA]CGGA._The_deletion_causes_a_frameshift,_which_changes_an_Arginine_to_a_Threonine_at_codon_2506,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.7517_7520delGAGA,_previously_reported_as_ATM_7517del4,_has_been_observed_in_numerous_patients_with_classic_ataxia-telangiectasia_in_both_the_homozygous_and_compound_heterozygous_state_and_is_considered_an_Italian_pathogenic_founder_variant_(Gilad_1996,_Coutinho_2004,_Cavalieri_2006,_Magliozzi_2006,_Chessa_2009,_Demuth_2011)._We_consider_this_variant_to_be_pathogenic.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg2506Thrfs*3)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_8845835,_19691550,_17124347,_16941484,_21965147,_12815592)._This_variant_is_also_known_as_7517del4_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141647)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_heterozygous_variant_in_the_ATM_gene_(autosomal_recessive_transmission),_inherited_from_the_father,_was_present_in_a_female_patient_who_also_harbours_a_second_variant_in_the_same_gene_inherited_by_the_mother_(compound_heterozygosity).|Variant_summary:_Variant_results_in_a_frameshift_mutation_altering_the_3050_amino_acid_long_ATM_beginning_at_position_2506_and_leading_to_a_premature_termination_codon_3_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Mutation_taster_predicts_the_variant_to_be_disease_causing._It_is_absent_from_the_large_and_broad_cohorts_of_the_ExAC_project_but_while_it_was_reported_in_several_ATM_patients_in_either_compound_heterozygosity_or_homozygosity_indicating_pathogenicity._The_reported_patients_are_predominantly_of_Italian_origin_and_the_variant_is_considered_to_be_one_of_the_most_common_Italian_AT_mutation_(Cavalieri_Hum_Mutat_2006,_Chessa_Human_Genetics_2009)._Furthermore,_a_clinical_laboratory_classifies_variant_as_Pathogenic_via_ClinVar_(without_evidence_to_independently_evaluate)._Truncating_mutations_are_known_mechanisms_of_AT_and_truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.8264_8268delATAAG/p.Tyr2755fs),_and_considering_the_additional_supporting_information,_the_variant_shows_strong_indications_for_pathogenicity,_and_therefore,_it_is_classified_as_pathogenic.
NM_000051.3:c.7629_7629+4del	ATM	splice_donor_variant,coding_sequence_variant	102448	1	NA	NA	-	-	-	-	232873	234329	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108202284_108202288del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472|C11orf65:160140	SO:0001575|splice_donor_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	876660041	-	Ambry_Genetics|Invitae|Counsyl	Pathogenic|Pathogenic|Likely_pathogenic	2018-02-15|2018-11-09|2017-04-10	2020-02-26|2019-03-28|2018-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown	SCV000277129|SCV000546896|SCV000790805	Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|This_sequence_change_affects_the_donor_splice_site_in_intron_51_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs751497695,_ExAC_0.002%)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_a_pathogenic_variant_in_an_individual_affected_with_ataxia_telangiectasia_(PMID:Â¬â€ 10980530)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 232873)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.7629+2T>C	ATM	splice_donor_variant	101894	1	NA	NA	-	-	-	-	186579	183401	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108202286T>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001575|splice_donor_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	786203059	-	Fulgent_Genetics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-10-29|2018-09-21|2015-12-09|2018-11-02|2018-10-31	2020-02-26|2018-11-06|2019-01-29|2019-03-28|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000216973|SCV000537623|SCV000293660|SCV000826093|SCV000893186	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_variant_is_denoted_ATM_c.7629+2T>C_or_IVS51+2T>C_and_consists_of_a_T>C_nucleotide_substitution_at_the_+2_position_of_intron_51_of_the_ATM_gene._This_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature._Based_on_the_currently_available_information,_we_consider_ATM_c.7629+2T>C_to_be_a_likely_pathogenic_variant.|This_sequence_change_affects_a_donor_splice_site_in_intron_51_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186579)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_000051.3:c.7630-2A>C	ATM	splice_acceptor_variant	102490	1	15416	1	-	-	-	-	127447	132904	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108202604A>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587779866	-	Ambry_Genetics|Color|GeneKor_MSA|Invitae|Counsyl|Mendelics|Baylor_Genetics|GeneDx|PreventionGenetics,PreventionGenetics|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-07-17|2015-01-23|2018-08-01|2018-12-31|2015-12-04|2018-07-02|0000-00-00|2018-10-18|2016-03-25|2017-05-18	2020-02-26|2017-01-26|2018-08-08|2019-03-28|2016-11-23|2018-08-20|2019-09-27|2019-01-29|2018-01-29|2017-05-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|unknown|germline|germline|germline|unknown	SCV000183992|SCV000537667|SCV000821703|SCV000260235|SCV000485386|SCV000838594|SCV001163273|SCV000149162|SCV000805615|SCV000611168	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|||This_sequence_change_affects_an_acceptor_splice_site_in_intron_51_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587779866,_ExAC_0.003%)._This_variant_has_been_reported_in_several_individuals_affected_with_ataxia-telangiectasia_in_both_the_compound_heterozygous_and_homozygous_states_(PMID:_9887333,_25374739,_21833744,_9443866)._It_has_also_been_observed_in_individuals_with_breast_cancer_(PMID:_26681312)._This_variant_is_known_as_IVS51-2A>C_and_IVS53-2A>C_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127447)._An_experimental_study_using_lymphoblastoid_cell_lines_derived_from_affected_individuals_showed_that_this_variant_results_in_two_aberrant_forms_of_the_ATM_transcript,_one_in_which_exon_52_is_skipped_and_another_in_which_the_first_11_nucleotides_of_exon_52_are_skipped_(PMID:_9887333)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||This_pathogenic_variant_is_denoted_ATM_c.7630-2A>C_or_IVS51-2A>C_and_consists_of_an_A>C_nucleotide_substitution_at_the_-2_position_of_intron_51_of_the_ATM_gene._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_splicing_of_exon_52:_however,_the_skipping_of_exon_52_is_predicted_to_be_in-frame._Even_though_this_variant_is_predicted_to_result_in_an_in-frame_transcript,_this_single_exon_deletion_would_result_in_the_loss_of_53_residues,_some_of_which_are_located_within_the_FAT_domain_(Stracker_2013)._This_variant,_also_denoted_as_IVS53-2A>C_and_IVS54-2A>C_using_alternate_exon_numbering,_has_been_observed_in_several_individuals_with_ataxia_telangiectasia_in_the_homozygous_and_compound_heterozygous_state_and_has_been_reported_as_a_founder_variant_identified_in_individuals_of_Polish_descent_(Telatar_1998,_Sandoval_1999,_Teraoka_1999,_Li_2000,_Mitui_2005,_Soukupova_2011,_Nespoli_2013,_Podralska_2014)._Furthermore,_this_variant_was_studied_by_Sandoval_et_al._(1999)_in_the_homozygous_state,_and_was_found_to_cause_exon_skipping_in_patient_RNA_and_did_not_produce_any_detectable_ATM_protein._We_therefore_consider_this_variant_to_be_pathogenic.||
NM_000051.3:c.7777C>T	ATM	stop_gained	102316	1	NA	NA	-	-	-	-	490708	484437	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108202753C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	781215442	-	Color|Invitae	Pathogenic|Pathogenic	2017-09-29|2018-12-04	2017-12-21|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000687788|SCV000749015	Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln2593*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs781215442,_ExAC_0.002%)._This_variant_has_been_reported_in_two_brothers_affected_with_prostate_cancer_and_colon_cancer_(PMID:_24556621),_and_an_individual_affected_with_breast_cancer_(PMID:_28779002).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 490708)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.7792C>T	ATM	stop_gained	102088	2	NA	NA	4	1	rs138941496	not provided	265383	259971	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108203492C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	138941496	-	Fulgent_Genetics	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2016-05-12|2019-04-09|2017-11-25|2018-09-19|2018-10-31	2019-01-29|2020-02-26|2018-11-06|2019-03-28|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000322214|SCV000668152|SCV000904736|SCV000834275|SCV000893857	not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	This_variant_is_denoted_ATM_c.7792C>T_at_the_cDNA_level_and_p.Arg2598Ter_(R2598X)_at_the_proteinlevel._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNAdecay._This_variant_has_been_observed_in_at_least_three_ataxia-telangiectasia_patients,_2_of_whom_were_identified_tocarry_a_second_ATM_truncating_variant_(Wright_1996,_Mitui_2003,_Lin_2015)._We_consider_this_variant_to_be_likelypathogenic|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg2598*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs138941496,_ExAC_0.002%)._This_variant_has_been_reportedÂ¬â€ in_several_individuals_affected_withÂ¬â€ ataxia-telangiectasia_(PMID:_8808599,_12815592,_10864201,Â¬â€ 26677768)Â¬â€ and_observed_on_the_opposite_chromosome_(in_trans)_from_other_pathogenic_variants_in_most_of_the_affected_individuals_(PMID:_12815592,_10864201,Â¬â€ 26677768)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_265383)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.7886_7890del	ATM	frameshift_variant	102420	1	NA	NA	-	-	-	-	230200	234341	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108203581_108203585TATTA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	OMIM_Allelic_Variant:607585.0015	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	1450394308	-	OMIM|GeneReviews|Counsyl|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Ambry_Genetics|Color|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1998-04-01|2016-10-27|2016-10-19|2018-12-17|2017-05-25|2018-07-02|2018-10-04|2017-02-15|2018-10-22	2016-09-16|2016-10-27|2016-11-23|2019-03-28|2018-01-25|2018-08-20|2020-02-26|2017-10-26|2019-01-29	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|unknown|germline|germline|germline	SCV000023329|SCV000328270|SCV000486550|SCV000547031|SCV000694361|SCV000838601|SCV000273655|SCV000682440|SCV000568334	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|||This_sequence_change_deletes_5_nucleotides_in_exon_53_of_the_ATM_mRNA_(c.7886_7890delTATTA),_causing_a_frameshift_at_codon_2629._This_creates_a_premature_translational_stop_signal_(p.Ile2629Serfs*25)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_as_homozygous_or_compound_heterozygous_in_individuals_with_ataxia-telangiectasia_(PMID:_12815592,Â¬â€ 23322442,Â¬â€ 8845835,_23946315,_9600235)._This_variant_has_also_been_reported_in_individuals_with_breast_cancer_and/or_ovarian_cancer_(PMID:_21787400,_26436112)._This_variant_is_also_known_as_7883del5,_7884_7888del5,_c.7878_7882delTTATA_and_c.7886_7890del._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_ATM_c.7886_7890delTATTA_(p.Ile2629Serfs)_variant_(also_known_as_7878del5,_7883del5_and_7884_7888del5)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Lys2756X,_p.Arg2763X,_p.Arg2993X,_etc.)._This_variant_is_absent_in_120872_control_chromosomes_from_ExAC._This_variant_has_been_reported_in_several_A-T_patients/families_across_multiple_countries_in_homozygous_state_as_well_as_in_compound_heterozygous_state_with_other_pathogenic/likely_pathogenic_variants_(Gilad_1996,_Telatar_1996,_Sasaki_1998,_Stankovic_1998,_Exley_2011,_Mitui_2003,_Jeddane_2013,_Charlesworth_2013)._Cosegregation_of_this_variant_with_disease_have_also_been_reported_from_a_family_(Charlesworth_2013)._It_has_also_been_found_in_a_breast_cancer_patient_(Hirotsu_2015),_which_is_consistent_with_the_fact_that_pathogenic_variants_in_ATM_gene_are_known_to_confer_elevated_risk_of_breast_cancer_in_a_heterozygous_state._In_a_compound_heterozygous_patient_that_carried_this_variant_and_3802delG,_no_ATM_kinase_activity_and_ATM_protein_expression_was_observed_in_lymphoblastoid_cell_line_derived_from_the_patient,_strongly_supporting_its_predicted_outcome_(Exley_2011)._Multiple_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_five_nucleotides_in_ATM_is_denoted_c.7886_7890delTATTA_at_the_cDNA_level_and_p.Ile2629SerfsX25_(I2629SfsX25)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ATTA[delTATTA]GCAA._The_deletion_causes_a_frameshift_which_changes_an_Isoleucine_to_a_Serine_at_codon_2629,_and_creates_a_premature_stop_codon_at_position_25_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.7886_7890delTATTA,_previously_reported_as_7883del5,_7884_7888del5,_7878del5,_and_7886_7889del5,_has_been_observed_in_both_the_homozygous_and_compound_heterozygous_state_in_patients_with_Ataxia-telangiectasia_and_in_at_least_one_individual_with_breast_cancer_(Gilad_1996,_Ejima_1998,_Mitui_2003,_Exley_2011,_Goldgar_2011,_Charlesworth_2013,_Jeddane_2013)._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.7921C>T	ATM	stop_gained	102400	1	NA	NA	-	-	-	-	481287	475884	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108203621C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	769523686	-	Ambry_Genetics|Invitae|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic	2018-04-02|2018-04-06|2018-02-19	2020-02-26|2018-08-29|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000665592|SCV000748966|SCV000779506	Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln2641*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs769523686,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_variant_is_denoted_ATM_c.7921C>T_at_the_cDNA_level_and_p.Gln2641Ter_(Q2641X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature_as_a_pathogenic_or_benign_germline_variant,_it_is_considered_likely_pathogenic.
NM_000051.3:c.7927_7927+1insAAACA	ATM	frameshift_variant,splice_region_variant	102346	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.8152-1G>A	ATM	splice_acceptor_variant	102350	1	NA	NA	-	-	-	-	451773	444717	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108206571G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	1398616877	-	GeneDx|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic	2017-09-01|2018-12-06	2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000620518|SCV000660743	not_provided|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_ATM_c.8152-1G>A_or_IVS55-1G>A_and_consists_of_a_G>A_nucleotide_substitutionat_the_-1_position_of_intron_55_of_the_ATM_gene._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predictedto_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNAdecay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature.Based_on_the_currently_available_information,_we_consider_ATM_c.8152-1G>A_to_be_a_likely_pathogenic_variant|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity
NM_000051.3:c.8185C>T	ATM	stop_gained	102414	1	NA	NA	5	1	rs587781967	Hereditary cancer-predisposing syndrome	141726	151440	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108206605C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587781967	-	Ambry_Genetics|Color|Counsyl|Invitae|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2018-10-09|2017-11-17|2016-06-23|2018-01-11|2016-07-07	2020-02-26|2018-11-06|2016-11-23|2018-08-29|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline	SCV000185198|SCV000911669|SCV000486531|SCV000835581|SCV000779355	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln2729*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781967,_ExAC_0.002%)._This_variant_has_been_reported_to_be_homozygous_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_12815592,_24789685)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141726)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_variant_is_denoted_ATM_c.8185C>T_at_the_cDNA_level_and_p.Gln2729Ter_(Q2729X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_the_homozygous_state_in_an_individual_with_classic_ataxia-telangiectasia_(Mitui_2003)._This_variant_is_considered_pathogenic.
NM_000051.3:c.8266A>T	ATM	stop_gained,splice_region_variant	102238	4	15420	1	5&5	1&1	rs371638537	Hereditary cancer-predisposing syndrome&not provided	135780	139492	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108206686A>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	17	371638537	-	Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Baylor_Genetics|Ambry_Genetics|Color|GeneDx	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-05|2014-03-04|2016-08-11|2017-09-01|2019-05-07|2016-02-25|2018-12-24	2019-03-28|2015-03-11|2018-01-25|2017-10-16|2020-02-26|2017-10-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|maternal|germline|germline|germline	SCV000166144|SCV000220141|SCV000694375|SCV000807217|SCV000172765|SCV000682472|SCV000209653	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_2756_(p.Lys2756*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs371638537,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(A-T)_(PMID:_10330348,_12552559,_8659541,_9463314),_chronic_lymphocytic_leukemia_(PMID:_11756185,_21933854),_medulloblastoma_(PMID:_28007021),_pancreatic_cancer_(PMID:_22585167),_breast_cancer_and_prostate_cancer_(PMID:_26094658,_25503501,_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_135780)._Experimental_studies_have_shown_that_reprogrammed_A-T_cells_carrying_this_variant_exhibit_partially_disrupted_ATM_protein_function,_such_as_defective_repair_of_DNA_double-strand_breaks_and_repressed_phosphorylation_of_ATM_substrates_(PMID:_25032865)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_ATM_c.8266A>T_(p.Lys2756X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.8264_8268delATAAG/p.Tyr2755fsX12)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_1/118602_control_chromosomes_at_a_frequency_of_0.0000084,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_ATM_variant_(0.0039528)._This_variant_has_been_reported_in_multiple_patients_with_AT_and_different_types_of_cancers._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic/likely_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_mutation_has_been_previously_reported_as_disease-causing_and_was_found_once_in_our_laboratory_in_trans_with_a_deleterious_intronic_mutation_in_a_7-month-old_female_with_immune_deficiency,_hearing_loss,_and_skin_lesion.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_ATM_c.8266A>T_at_the_cDNA_level_and_p.Lys2756Ter_(K2756X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_a_Lysine_to_a_premature_stop_codon_(AAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_association_with_ataxia-telangiectasia,_chronic_lymphocytic_leukemia,_colorectal_cancer,_and_familial_pancreatic_cancer_(Telatar_1996,_Stankovic_1998,_Teraoka_1999,_Yuille_2002,_Buzin_2003,_Kato_2006,_Du_2008,_Skowronska_2012,_Roberts_2012,_Schrader_2015,_Vanderver_2016)._ATM_Lys2756Ter_has_also_been_observed_in_individuals_with_familial_breast_cancer_and_prostate_cancer_(Maxwell_2014,_Desmond_2015,_Pritzlaff_2017)._We_therefore_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.8281_8284del	ATM	frameshift_variant	102660	1	NA	NA	-	-	-	-	639719	639653	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108213959_108213960TC[1]	_single_submitter	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	-	-	Invitae	Pathogenic	2018-08-13	2019-03-28	_single_submitter	germline	SCV000931899	Ataxia-telangiectasia_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln2762Glufs*43)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs775899653,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.8292_8293del	ATM	frameshift_variant	102668	1	15428	1	-	-	-	-	245989	244647	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108213972_108213973del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	879254036	-	GeneDx|Invitae|Mendelics|Ambry_Genetics	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-10-09|2018-12-03|2018-07-02|2016-11-25	2019-01-29|2019-03-28|2018-08-20|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline	SCV000293246|SCV000547148|SCV000838613|SCV000665273	not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_deletion_of_2_nucleotides_in_ATM_is_denoted_c.8292_8293delTG_at_the_cDNA_level_and_p.Ser2764ArgfsX4_(S2764RfsX4)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_GAAG[TG]GTGT._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_an_Arginine_at_codon_2764,_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Based_on_the_currently_available_information,_we_consider_this_deletion_to_be_a_likely_pathogenic_variant.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser2764Argfs*4)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_245989)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.8303_8306del	ATM	frameshift_variant	102670	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.8307G>A	ATM	stop_gained	102668	1	NA	NA	-	-	-	-	189104	186804	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108213987G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	778269655	-	Counsyl|Invitae|Color|Ambry_Genetics	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2014-12-23|2018-11-28|2016-11-28|2017-02-24	2015-03-11|2019-03-28|2017-10-26|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline	SCV000220986|SCV000260922|SCV000682476|SCV001189935	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Trp2769*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs778269655,_ExAC_0.01%)._This_variant_has_been_observed_in_an_individual_affected_withÂ¬â€ ataxia-telangiectasia_(PMID:_8845835)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_189104)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_000051.3:c.8395_8404del	ATM	frameshift_variant	102564	3	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.8418+5_8418+8del	ATM	splice_donor_variant,intron_variant	102418	1	15416	1	-	-	-	-	181866	180519	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108214099_108214102GTGA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	730881295	-	Children's_Hospital_of_Philadelphia|GeneDx|Athena_Diagnostics_Inc	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-08-06|2015-02-02|2018-12-27|2016-04-05|2018-08-14|2018-09-27	2020-02-26|2017-10-26|2019-03-28|2017-01-23|2019-01-29|2019-09-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000215050|SCV000682483|SCV000261443|SCV000536753|SCV000209610|SCV001143122	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided	Functionally-validated_splicing_mutation:RNA_Studies:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_four_nucleotide_deletion_falls_in_intron_57_of_the_ATM_mRNA._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_ATM_protein._This_sequence_change_affects_a_highly_conserved_nucleotide_near_the_donor_splice_site._This_variant_is_present_in_population_databases_(rs769139997,_ExAC_0.001%)._This_variant_has_been_reported_as_compound_heterozygous_with_other_ATM_variants_in_several_individuals_affected_with_ataxia-telangiectasia_(PMID:_9872980,_10817650,_12552559,Â¬â€ 28008555),_and_as_heterozygous_in_individuals_affected_with_breast_and_prostate_cancer_(PMID:Â¬â€ 26681312,_27433846)._This_variant_is_also_known_as_c.8269delta150,_8418+1delGTGA,_IVS59+1del4,_and_IVS59+5_IVS59+8delGTGA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181866)._Experimental_studies_have_shown_that_this_deletion_causes_skipping_of_exon_57_(known_as_exon_59_in_the_literature),_resulting_in_a_shortened_mRNA_transcript_(PMID:_8808599)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_ATM_c.8418+5_8418+8delGTGA_or_IVS57+5_IVS57+8delGTGA_and_consists_of_a_deletion_of_four_nucleotides_at_the_+5_to_+8_position_of_intron_57_of_the_ATM_gene._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TGgtga[delgtga]cacc,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._RT-PCR_analysis_in_patient_cells_demonstrated_that_this_variant,_previously_published_as_ATM_IVS59+5_IVS59+8delGTGA,_IVS59+1del4,_8418+1delGTGA,_or_8269del150,_results_in_exon_skipping_(Gilad_1996)._This_variant_has_been_observed_in_multiple_Ataxia-telangiectasia_patients_as_well_as_individuals_with_breast_or_prostate_cancer_(Wright_1996,_Hacia_1998,_Li_2000,_Buzin_2003,_Pritchard_2016,_Pritzlaff_2017)._Based_on_the_currently_available_information,_we_consider_ATM_c.8418+5_8418+8delGTGA_to_be_pathogenic.|The_best_available_variant_frequency_is_uninformative_because_it_is_below_the_disease_allele_frequency._Found_in_at_least_one_symptomatic_patient._Predicted_to_negatively_affect_a_known_splice_site._Occurs_in_three_or_more_cases_with_a_recessive_pathogenic_variant_in_the_same_gene._Damaging_to_protein_function(s)_relevant_to_disease_mechanism.
NM_000051.3:c.8418+1G>A	ATM	splice_donor_variant	102412	1	NA	NA	-	-	-	-	370640	357925	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108214099G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	766533795	-	Counsyl|Invitae	Likely_pathogenic|Likely_pathogenic	2016-03-14|2018-11-05	2016-11-23|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline	SCV000486007|SCV000547055	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	|This_sequence_change_affects_a_donor_splice_site_in_intron_57_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs766533795,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_370640)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_000051.3:c.8549T>A	ATM	stop_gained	102468	1	NA	NA	5	1	rs876658716	Hereditary cancer-predisposing syndrome	230697	234385	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108216600T>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	876658716	-	Ambry_Genetics|Color|GeneDx|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2019-03-14|2017-06-02|2017-10-06|2018-12-12|2018-02-09	2020-02-26|2017-10-26|2019-01-29|2019-03-28|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000274337|SCV000682495|SCV000617954|SCV000622827|SCV000916549	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_ATM_c.8549T>A_at_the_cDNA_level_and_p.Leu2850Ter_(L2850X)_at_the_proteinlevel._The_substitution_creates_a_nonsense_variant,_which_changes_a_Leucine_to_a_premature_stop_codon_(TTG>TAG),and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNAdecay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_pathogenic|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu2850*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_ATM-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_230697)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_ATM_c.8549T>A_(p.Leu2850X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._A_truncation_downstream_of_this_position,_c.8977C>T_(p.Arg2993X)_have_been_classified_as_pathogenic_by_our_laboratory._To_our_knowledge,_no_occurrence_of_c.8549T>A_in_individuals_affected_with_Ataxia-Telangiectasia_and_no_experimental_evidence_demonstrating_its_impact_on_protein_function_have_been_reported._Multiple_clinical_diagnostic_laboratories_via_ClinVar_(evaluation_after_2014)_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic.
NM_000051.3:c.8655dup	ATM	frameshift_variant	101958	5	NA	NA	-	-	-	-	420694	408254	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108218076dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	753961188	-	GeneDx|Ambry_Genetics|Color|Invitae|Baylor_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-09|2018-06-12|2016-02-23|2018-12-25|0000-00-00	2019-01-29|2020-02-26|2017-10-26|2019-03-28|2019-09-27	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000569631|SCV000672647|SCV000682508|SCV000818306|SCV001163275	not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	This_duplication_of_one_nucleotide_in_ATM_is_denoted_c.8655dupT_at_the_cDNA_level_and_p.Val2886CysfsX10_(V2886CfsX10)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_AACT[dupT]GTAC._The_duplication_causes_a_frameshift_which_changes_a_Valine_to_a_Cysteine_at_codon_2886,_and_creates_a_premature_stop_codon_at_position_10_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.8655dupT,_also_described_as_c.8653_8654insT_using_alternate_nomenclature,_has_been_reported_in_the_compound_heterozygous_state_with_an_ATM_nonsense_variant_in_a_child_with_clinical_features_of_Ataxia-telangiectasia_(Barbaro_2017)._Based_on_currently_available_evidence,_we_consider_this_to_be_a_pathogenic_variant.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val2886Cysfs*10)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs753961188,_ExAC_0.008%)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_other_pathogenic_variant_in_an_individual_affected_with_ataxia-telangiectasia_(PMID:_27873105)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease.Â¬â€ This_variant_is_also_known_asÂ¬â€ c.8653_8654insTÂ¬â€ in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 420694)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.8786+1G>A	ATM	splice_donor_variant	102722	2	NA	NA	-	-	-	-	127463	132920	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Malignant_Glioma|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0555198|MedGen:CN517202	-	NC_000011.9:g.108224608G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	17174393	-	GeneDx|PreventionGenetics,PreventionGenetics|Counsyl|Invitae|GeneReviews|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-10-27|2016-11-22|2014-08-22|2018-12-24|2016-10-27|2018-03-26|2018-12-20|2017-05-25|2017-02-13|2018-10-31	2019-01-29|2018-01-29|2015-03-11|2019-03-28|2016-10-27|2019-04-24|2020-02-26|2017-10-26|2018-12-04|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline|germline|unknown	SCV000149178|SCV000805632|SCV000220622|SCV000283091|SCV000328305|SCV000918527|SCV000273800|SCV000682516|SCV000891075|SCV000893858	not_provided|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Malignant_Glioma|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	This_variant_is_denoted_ATM_c.8786+1G>A_or_IVS60+1G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_+1_position_of_intron_60_of_the_ATM_gene._The_variant,_also_reported_as_ATM_c.8672del115_and_IVS62+1G>A_using_alternate_nomenclature_and_exon_numbering,_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_association_with_recessively_inherited_Ataxia-Telangiectasia_(Wright_1996,_Stankovic_1998,_Telatar_1998,_Teraoka_1999,_Laake_2000,_Li_2000,_GarcÃ­a-PÃ©rez_2001,_Buzin_2003,_Reiman_2011),_and_is_considered_pathogenic.|||This_sequence_change_affects_a_donor_splice_site_in_intron_60_of_the_ATM_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs17174393,_ExAC_0.003%)._This_variant_has_been_reported_in_individuals_with_ataxia_telangiectasia_(PMID:_8808599,_10330348,_8659541,_10980530,_9463314,_11298136,_10817650,_21459046,_21792198)_and_individuals_with_a_family_history_of_breast_cancer_(PMID:_21445571)._This_variant_is_also_known_as_IVS62+1G>A_and_c.8672del115_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127463)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_ATM_c.8786+1G>A_is_located_in_a_canonical_splice-site_and_is_predicted_to_affect_mRNA_splicing_resulting_in_a_significantly_altered_protein_due_to_either_exon_skipping,_shortening,_or_inclusion_of_intronic_material._Several_computational_tools_predict_a_significant_impact_on_normal_splicing:_Five_predict_the_variant_abolishes_a_5_splicing_donor_site._Multiple_publications,_Laake_2000_and_Stankovic_1998,_functionally_assessed_the_variant_and_found_it_to_affect_mRNA_splicing._The_variant_was_observed_with_an_allele_frequency_of_1.2e-05_in_246218_control_chromosomes_(gnomAD)._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_ATM_causing_Ataxia-Telangiectasia_(1.2e-05_vs_0.004),_allowing_no_conclusion_about_variant_significance._The_variant,_c.8786+1G>A,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Ataxia-Telangiectasia_(Laake_2000,_Stankovic_1998)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._Multiple_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|||
NM_000051.3:c.8833_8834del	ATM	frameshift_variant	102698	1	NA	NA	-	-	-	-	186546	183460	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108225582_108225583CT[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	786203030	-	Ambry_Genetics|Color|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-04-05|2017-06-06|2017-10-16|2018-11-16	2020-02-26|2018-11-06|2019-01-29|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000216930|SCV000903221|SCV000568343|SCV000828136	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_deletion_of_two_nucleotides_in_ATM_is_denoted_c.8833_8834delCT_at_the_cDNA_level_and_p.Leu2945ValfsX10_(L2945VfsX10)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AACT[delCT]GTTA._The_deletion_causes_a_frameshift_which_changes_a_Leucine_to_a_Valine_at_codon_2945,_and_creates_a_premature_stop_codon_at_position_10_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.8833_8834delCT_has_been_observed_in_at_least_three_individuals_with_Ataxia-telangiectasia_and_one_individual_with_breast_cancer_(Telatar_1996,_Li_2000,_Magliozzi_2006,_Prodosmo_2016)._We_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu2945Valfs*10)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasiaÂ¬â€ (PMID:_8659541,_17124347,_10817650)_and_breast_cancer_(PMID:_27599564,Â¬â€ 29271107)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 186546)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000051.3:c.8876_8879del	ATM	frameshift_variant	102686	1	NA	NA	-	-	-	-	189140	186805	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108235834_108235837del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	786204726	-	Counsyl|Invitae|GeneDx|Ambry_Genetics|Color	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-01-21|2018-01-02|2017-02-06|2019-02-03|2018-03-09	2015-03-11|2018-04-02|2019-01-29|2020-02-26|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline	SCV000221056|SCV000283096|SCV000293443|SCV000581454|SCV000903724	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asp2959Glyfs*3)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs770704493,_ExAC_0.009%)._This_This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_12815592)._This_variant_is_also_known_as_8875_8878delGACT_and_8874_8877delTGAC_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_189140)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_four_nucleotides_in_ATM_is_denoted_c.8876_8879delACTG_at_the_cDNA_level_and_p.Asp2959GlyfsX3_(D2959GfsX3)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TTTG[delACTG]GACC._The_deletion_causes_a_frameshift_which_changes_an_Aspartic_Acid_to_a_Glycine_at_codon_2959,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._ATM_c.8876_8879delACTG,_also_reported_as_c.8874_8877delTGAC_using_alternate_nomenclature,_has_been_reported_in_at_least_two_individuals_with_Ataxia-telangiectasia_(A-T),_including_once_in_the_compound_heterozygous_state_with_an_ATM_nonsense_variant_and_once_in_the_homozygous_state_(Mitui_2003,_Carranza_2016)._In_addition,_a_cell_line_derived_from_the_homozygous_A-T_patient_was_evaluated,_revealing_the_absence_of_ATM_protein_expression_and_intermediate_radiosensitivity_(Carranza_2016)._Based_on_current_evidence_we_consider_ATM_c.8876_8879delACTG_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_000051.3:c.8977C>T	ATM	stop_gained	102670	2	NA	NA	5	1	rs770641163	Hereditary cancer-predisposing syndrome	186330	183467	Hereditary_breast_and_ovarian_cancer_syndrome|Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108235935C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	770641163	-	Ambry_Genetics|Color|GeneKor_MSA|Counsyl|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Dr._Peter_K._Rogan_Lab,Western_University|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-04-13|2017-10-02|2018-08-01|2014-11-24|2018-12-20|2016-10-14|2018-11-24|2015-12-22|2017-05-18	2020-02-26|2017-12-21|2018-08-08|2015-03-11|2019-03-28|2018-01-25|2019-01-29|2015-12-22|2017-05-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|unknown|unknown	SCV000216664|SCV000687865|SCV000821704|SCV000220908|SCV000283099|SCV000694387|SCV000490415|SCV000262587|SCV000611169	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Structural_Evidence||||This_sequence_change_results_in_a_premature_translational_stop_signal_at_codon_2993_(p.Arg2993*)_located_within_the_last_15_codons_of_the_penultimate_exon_in_the_ATM_mRNA._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_create_a_truncated_ATM_protein._This_variant_is_present_in_population_databases_(rs770641163,_ExAC_0.003%)._This_variant_has_been_reported_as_homozygous_and_in_trans_with_second_pathogenic_ATM_variants_in_several_individuals_affected_with_ataxia-telangiectasia_(A-T)_(PMID:_12815592,_23322442,_17124347,_16238588,_20840352)._It_has_also_been_reported_in_an_individual_with_chronic_lymphocytic_leukemia_(PMID:_21933854)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186330)._An_experimental_study_showed_loss_of_kinase_activity_in_cells_derived_from_a_homozygous_A-T_patient_carrying_this_variant_(PMID:_23774824)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_ATM_c.8977C>T_(p.Arg2993X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_ATM_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_2/121398_control_chromosomes_at_a_frequency_of_0.0000165,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_ATM_variant_(0.0010005)._The_variant_has_been_reported_in_publications_in_affected_individuals_both_in_the_homozygous_and_compound_heterozygous_state._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_variant_is_denoted_ATM_c.8977C>T_at_the_cDNA_level_and_p.Arg2993Ter_(R2993X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_lead_to_protein_truncation._This_variant_has_been_reported_in_both_the_homozygous_and_compound_heterozygous_state_in_multiple_patients_with_ataxia_telangiectasia_(Li_2000,_Sun_2002,_Mitui_2003,_Claret_Teruel_2005,_Magliozzi_2006,_Chessa_2009,_Carranza_2017),_and_in_at_least_one_individual_with_breast_cancer_(Caminsky_2016)._The_disrupted_region_at_the_end_of_the_gene_is_located_the_FATC_domain_(Stracker_2013)._We_consider_ATM_Arg2993Ter_to_be_pathogenic.|Sequenced_patient_with_familial_breast_cancer|
NM_003002.3:c.296del	SDHD	frameshift_variant	102746	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_003002.3:c.314+2C>G	SDHD	splice_donor_variant	102740	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.67+2T>C	BRCA2	splice_donor_variant	102306	1	NA	NA	-	-	-	-	52163	66831	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32890666T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Geisinger_Health_System:ADMI00075	-	BRCA2:675	SO:0001575|splice_donor_variant	9	81002885	-	Invitae|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Genologica_Medica|Geisinger_Autism_and_Developmental_Medicine_Institute,Geisinger_Health_System|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-17|2004-02-20|2015-10-02|2016-10-27|2017-01-01|2017-10-04|2018-10-11	2019-03-28|2014-03-28|2016-10-28|2016-11-23|2017-03-15|2018-03-27|2020-03-06	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|paternal|germline	SCV000073037|SCV000146096|SCV000327503|SCV000489568|SCV000577942|SCV000804388|SCV001133872	Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided	This_sequence_change_affects_a_donor_splice_site_in_intron_2_of_the_BRCA2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_and_a_family_affected_with_breast/ovarian_cancer_(PMID:_12955716,_22798144)._This_variant_is_also_known_as_IVS2+2T>C_and_295+2T>C_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52163)._Experimental_studies_have_shown_that_this_intronic_change_disrupts_splicing_and_results_in_an_mRNA_product_with_exon_2_skipped_(PMID:_22505045)._Exon_2_contains_the_translational_start_site_of_BRCA2._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||This_variant_was_identified_in_a_3_year_old_male_with_autism_spectrum_disorder,_global_developmental_delay,_hypotonia,_and_plagiocephaly,_as_a_secondary_finding._It_was_inherited_from_a_healthy_father_who's_family_history_includes_several_females_with_breast_cancer._This_variant_has_been_reported_in_the_literature_and_in_ClinVar_as_a_pathogenic_variant,_due_to_association_with_hereditary_breast/ovarian_cancer._The_variant_alters_a_canonical_splice_site.|The_variant_disrupts_a_canonical_splice_site,_and_is_therefore_predicted_to_significantly_disrupt_the_protein_structure._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_000059.3:c.68-2A>G	BRCA2	splice_acceptor_variant	101556	1	NA	NA	-	-	-	-	187538	183616	_familial_2	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32893212A>G	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001574|splice_acceptor_variant	1	769152395	-	Ambry_Genetics|Invitae|Mendelics|Mendelics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-03-07|2018-12-26|2018-07-02|2019-05-28	2020-02-26|2019-03-28|2018-08-20|2019-10-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|unknown	SCV000218118|SCV000831230|SCV000838719|SCV001138940	_familial_2	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|This_sequence_change_affects_an_acceptor_splice_site_in_intron_2_of_the_BRCA2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs769152395,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRCA2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_187538)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||
NM_000059.3:c.317-2A>G	BRCA2	splice_acceptor_variant	102028	1	NA	NA	-	-	-	-	432106	426043	not_provided	-	MedGen:CN517202	-	NC_000013.10:g.32899211A>G	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001574|splice_acceptor_variant	1	1477341630	-	GeneDx	Likely_pathogenic	2016-03-03	2017-11-28	_single_submitter	germline	SCV000589790	not_provided	The_c.317-2A>G_variant_in_the_BRCA2_gene_has_not_been_published_previously,_to_our_knowledge._The_c.317-2A>G_variant_destroys_the_canonical_splice_acceptor_site_in_intron_3._It_is_predicted_to_cause_abnormal_gene_splicing,_either_leading_to_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay,_or_to_an_abnormal_protein_product_if_the_message_is_used_for_protein_translation._Loss_of_function_variants,_including_splice_site_variants,_are_known_to_be_pathogenic_in_this_gene_associated_with_hereditary_breast_and_ovarian_cancer_syndrome_(Stenson_et_al.,_2014)._Based_on_the_ACMG_recommendations,_c.317-2A>G_is_interpreted_as_an_expected_pathogenic_sequence_change.
NM_000059.3:c.632-2A>G	BRCA2	splice_acceptor_variant	99500	1	NA	NA	-	-	-	-	52063	66731	_familial_2|not_provided	-	OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32903578A>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001574|splice_acceptor_variant	1	397507842	-	_c/o_University_of_Cambridge|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)	Pathogenic|Pathogenic|Pathogenic	2016-02-18|2015-10-02|2019-06-18	2019-01-29|2016-10-28|2019-07-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel	germline|germline|germline	SCV000279216|SCV000327393|SCV001161655	not_provided|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2	This_variant_is_denoted_BRCA2_c.632-2A>G_or_IVS7-2A>G_and_consists_of_an_A>G_nucleotide_substitution_at_the_-2_position_of_intron_7_of_the_BRCA2_gene._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA2_860-2A>G._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_was_reported_in_a_male_with_breast_cancer_and_via_RNA_analysis_was_found_to_cause_exonic_skipping_and_create_a_premature_stop_codon_(Ottini_2009)._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.||IARC_class_based_on_posterior_probability_from_multifactorial_likelihood_analysis,_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_000059.3:c.658_659del	BRCA2	frameshift_variant	100182	4	15416	0	-	-	-	-	9342	24381	Medulloblastoma|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_1|Glioma_susceptibility_3|Wilms_tumor_1|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:C2676676,OMIM:604370|MedGen:C2751641,OMIM:613029|MedGen:CN033288,OMIM:194070|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32903606_32903607del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:113557|Breast_Cancer_Information_Core__(BRCA2):886&base_change%3Ddel_GT|OMIM_Allelic_Variant:600185.0027	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359604	-	OMIM|OMIM|OMIM|OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Ambry_Genetics|Color|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Baylor_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2007-01-01|2007-01-01|2007-01-01|2007-01-01|2014-01-04|2002-05-29|2014-11-03|2015-02-04|2016-04-22|2015-10-02|2014-07-10|2015-10-06|0000-00-00|2015-09-21|2018-12-28|2016-04-18|2014-01-31|2015-04-17|2017-01-24|2019-02-22|2016-12-27|2014-09-03|2018-11-09|2016-08-15|2015-11-20|2017-02-23|2016-12-04|2018-09-13	2017-11-28|2017-11-28|2017-11-28|2017-11-28|2015-12-29|2014-03-28|2016-04-21|2015-03-11|2016-06-09|2016-10-28|2017-07-06|2017-10-18|2018-04-04|2018-04-09|2019-03-28|2016-11-14|2017-08-04|2019-03-21|2017-07-13|2020-03-06|2018-03-09|2018-01-29|2020-02-26|2017-12-21|2016-03-03|2017-02-23|2018-07-18|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000030150|SCV000030151|SCV000030152|SCV000030153|SCV000054244|SCV000147427|SCV000195951|SCV000221117|SCV000282430|SCV000327465|SCV000584073|SCV000605688|SCV000733216|SCV000744390|SCV000073001|SCV000494408|SCV000587560|SCV000605780|SCV000108633|SCV000296738|SCV000778635|SCV000805748|SCV000186913|SCV000292146|SCV000266043|SCV000540998|SCV000863725|SCV000883510	Fanconi_anemia,_complementation_group_D1|Wilms_tumor_1|Glioma_susceptibility_3|Medulloblastoma|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_1|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer|not_specified	||||||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val220Ilefs*4)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs768580992,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_affected_with_hereditary_breast_and_ovarian_cancer_(PMID:_9667259,_22923021,_23767878,_24504028),_and_Fanconi_anemia_(PMID:_26657402)._This_variant_is_also_known_as_886delGT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_9342)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_c.658_659delGT_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein,_which_is_a_commonly_known_mechanism_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(c.755_758delACAG,_p.Asp252fsX24:_c.771_775delTCAAA,_p.Asn257fsX17:_c.778_779delGA,_p.Glu260fsX15)._The_variant_was_observed_in_the_large_and_broad_cohorts_of_the_ExAC_project_at_an_allele_frequency_of_0.006%_which_does_not_exceed_the_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_BRCA2_(0.075%)._The_variant_has_been_reported_in_numerous_affected_individuals_in_the_literature,_including_2_siblings_affected_with_Fanconi_anemia_who_also_carried_a_second_pathogenic_BRCA2_variant_(Svojgr_2016)._Mutliple_reputable_clinical_labs_have_classified_the_variant_as_Pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||The_p.Val220fs_variant_in_BRCA2_has_been_identified_in_>50_individuals_with_BRCA_2-associated_cancers_(Frank_1998,_Berzina_2013,_Breast_Cancer_Information_Core_(_BIC)_database)_and_in_3_compound_heterozygous_individuals_with_Fanconi_anemia_(O_ffit_2003,_Hirsch_2004,_Reid_2005)._This_variant_has_been_identified_in_4/51064_of_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.b_roadinstitute.org:_dbSNP_rs80359604)._This_variant_is_predicted_to_cause_a_frame_shift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_220_and_leads_to_a_premature_termination_codon_4_amino_acids_downstream._This_altera_tion_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._In_summary,_thi_s_variant_meets_our_criteria_to_be_classified_as_pathogenic_for_hereditary_breas_t_and_ovarian_cancer_in_an_autosomal_dominant_manner_based_on_the_low_frequency_in_controls_and_the_predicted_impact_to_the_protein.|This_pathogenic_variant_is_denoted_BRCA2_c.658_659delGT_at_the_cDNA_level_and_p.Val220IlefsX4_(V220IfsX4)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AACT[delGT]ATTT._The_deletion_causes_a_frameshift,_which_changes_a_Valine_to_an_Isoleucine_at_codon_220,_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.658_659delGT,_previously_reported_as_886delGT_using_alternate_nomenclature,_has_been_reported_in_multiple_individuals_from_hereditary_breast_and_ovarian_cancer_families_(Frank_1998,_Jakubowska_2003,_Machado_2007,_Berzina_2013,_Cunningham_2014,_de_Juan_2015)_and_has_been_observed_in_the_compound_heterozygous_state_with_a_second_pathogenic_BRCA2_variant_in_patients_with_Fanconi_anemia_(Alter_2007,_Miele_2015)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||||The_BRCA2_c.658_659delGT:_p.Val220fs_variant_(rs80359604),_also_known_as_886delGT,_has_been_reported_in_multiple_individuals_with_hereditary_breast_and_ovarian_cancer_syndrome_(Cunningham_2014,_de_Juan_2015,_Frank_1998),_and_in_patients_with_Fancomi_anemia_when_found_in-trans_with_another_pathogenic_variant_(Hirsch_2004,_Svojgr_2016)._It_is_listed_as_pathogenic_in_ClinVar_(Variation_ID:_9342),_and_observed_in_the_Genome_Aggregation_Database_at_an_overall_frequency_of_0.004%_(12/270878_alleles)._This_variant_introduces_a_frameshift_by_deleting_2_nucleotides,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_available_information,_this_variant_is_considered_pathogenic._REFERENCES_Cunningham_J_et_al._Clinical_characteristics_of_ovarian_cancer_classified_by_BRCA1,_BRCA2,_and_RAD51C_status._Sci_Rep._2014:_4:4026._de_Juan_I_et_al._BRCA1_and_BRCA2_mutations_in_males_with_familial_breast_and_ovarian_cancer_syndrome._Results_of_a_Spanish_multicenter_study._Fam_Cancer._2015:_14(4):505-13._Frank_T_et_al._Sequence_analysis_of_BRCA1_and_BRCA2:_correlation_of_mutations_with_family_history_and_ovarian_cancer_risk._J_Clin_Oncol._1998:16(7):2417-25._Hirsch_B_et_al._Association_of_biallelic_BRCA2/FANCD1_mutations_with_spontaneous_chromosomal_instability_and_solid_tumors_of_childhood._Blood._2004:_103(7):2554-9._Svojgr_K_et_al._Fanconi_anemia_with_biallelic_FANCD1/BRCA2_mutations_-_Case_report_of_a_family_with_three_affected_children._Eur_J_Med_Genet._2016:_59(3):152-7.
NM_000059.3:c.755_758del	BRCA2	frameshift_variant	102448	2	NA	NA	-	-	-	-	38103	46659	_familial_2|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32905125_32905128ACAG[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:170363|Breast_Cancer_Information_Core__(BRCA2):983&base_change%3Ddel_ACAG	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359659	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Integrated_Genetics/Laboratory_Corporation_of_America|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-12-21|2002-05-29|2014-11-03|2016-04-22|2015-10-02|2016-04-15|2018-08-13|2019-05-03|2017-06-15|2018-09-10|2015-01-07|2018-12-20|2014-01-31|2017-04-20|2016-07-15|2017-06-18	2013-12-30|2014-03-28|2016-04-21|2016-06-09|2016-10-28|2016-11-23|2019-01-29|2020-03-06|2018-10-10|2020-02-26|2016-07-05|2019-03-28|2017-08-04|2017-08-04|2018-01-25|2018-04-30	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054292|SCV000147675|SCV000195952|SCV000282444|SCV000327681|SCV000488483|SCV000210706|SCV000296717|SCV000885106|SCV000213386|SCV000292156|SCV000073258|SCV000587567|SCV000588071|SCV000695064|SCV000219290	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast_and/or_ovarian_cancer	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_pathogenic_deletion_of_four_nucleotides_in_BRCA2_is_denoted_c.755_758delACAG_at_the_cDNA_level_and_p.Asp252ValfsX24_(D252VfsX24)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ACAG[delACAG]TGAA._The_deletion_causes_a_frameshift,_which_changes_an_Aspartic_Acid_to_a_Valine_at_codon_252,_and_creates_a_premature_stop_codon_at_position_24_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.755_758delACAG,_also_reported_as_982del4_or_983del4_using_alternate_nomenclature,_has_been_published_in_association_with_breast_and_ovarian_cancer_(Tavtigian_1996,_Evans_2008,_Borg_2010,_Kang_2015,_Cao_2016,_Yang_2017)_and_is_considered_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient_in_literature,_and_not_found_in_general_population_data.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asp252Valfs*24)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast,_ovarian,_and_prostate_cancer_(PMID:_8589730,_24549055,_17636422,_23569316,_20104584,_18489799)._In_the_literature,_this_variant_is_also_known_as_982del4_and_983_986del4._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_38103)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_c.755_758delACAG_(p.Asp252Valfs)_variant_in_BRCA2_gene_is_a_frame_shift_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._The_variant_is_absent_from_the_large_control_population_dataset_of_ExAC,_but_has_been_reported_in_multiple_affected_individuals_and_segregated_with_the_disease_in_at_several_families_(Gayther,_1999)._In_addition,_multiple_clinical_diagnostic_centers_classify_variant_as_Pathogenic._Taken_together,_the_variant_was_classified_as_Pathogenic.|
NM_000059.3:c.956dup	BRCA2	frameshift_variant	96808	1	NA	NA	-	-	-	-	52870	67538	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32906571dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Breast_Cancer_Information_Core__(BRCA2):1184&base_change%3Dins_A|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto:291304	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359770	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|Ambry_Genetics|Color|GeneDx|Baylor_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-31|2014-01-31|2017-02-27|2018-01-22|2012-10-24|2000-06-12|2016-02-11|2016-09-08|2015-10-02|2017-06-01|2018-05-03|2017-07-05|2017-12-19|2017-02-23	2019-03-28|2017-08-04|2019-03-21|2019-04-24|2013-12-30|2014-03-28|2016-07-18|2016-09-13|2016-10-28|2017-06-21|2020-02-26|2017-12-21|2019-01-29|2017-02-23	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000073870|SCV000587575|SCV000605815|SCV000916906|SCV000108842|SCV000145794|SCV000296572|SCV000300375|SCV000328155|SCV000579479|SCV000217360|SCV000689207|SCV000278836|SCV000541001	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn319Lysfs*8)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs756186207,_ExAC_0.01%)._This_variant_has_been_reported_in_breast_cancer_patients_(PMID:_12920083,Â¬â€ 28724667)._This_variant_is_also_referred_to_as_c.951dupA_and_c.1179insAÂ¬â€ in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 52870)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Asn319fs_variant_in_BRCA2_has_been_reported_in_1_Caucasian_individual_with_breast_cancer_(Ozcelik_2003)._It_has_also_been_identified_in_1/8618_of_East_A_sian_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadins_titute.org:_dbSNP_rs80359770)._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_319_and_lea_ds_to_a_premature_termination_codon_8_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_f_unction_of_the_BRCA2_gene_is_an_established_disease_mechanism_in_breast_cancer._In_addition,_this_variant_was_classified_as_Pathogenic_on_Sept_8,_2016_by_the_Cl_inGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000300375.2)._In_summary,_this_va_riant_meets_criteria_to_be_classified_as_pathogenic_for_breast_cancer_in_an_auto_somal_dominant_manner_based_upon_the_predicted_impact_to_the_protein.|Variant_summary:_BRCA2_c.956dupA_(p.Asn319LysfsX8)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._***)._The_variant_was_absent_in_225112_control_chromosomes._c.956dupA_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Nine_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic/likely_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.956dupA_at_the_cDNA_level_and_p.Asn319LysfsX8_(N319KfsX8)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_CAAAAA[A]TCTA._The_duplication_causes_a_frameshift,_which_changes_an_Asparagine_to_a_Lysine_at_codon_319,_and_creates_a_premature_stop_codon_at_position_8_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.956dupA,_previously_reported_as_1179insA_and_1184insA,_has_been_observed_patients_with_Hereditary_Breast_and_Ovarian_Cancer_syndrome_(Ozcelik_2003,_Thirthagiri_2008)._We_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.994dup	BRCA2	frameshift_variant	96708	1	NA	NA	-	-	-	-	52925	67593	_familial_2|Neuroendocrine_tumor_of_pancreas	-	MedGen:C2675520,OMIM:612555|MedGen:C4305467,SNOMED_CT:717919005	-	NC_000013.10:g.32906609dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359777	-	_c/o_University_of_Cambridge|3DMed_Clinical_Laboratory_Inc	Pathogenic|Pathogenic|Pathogenic	2016-09-08|2015-10-02|2017-11-20	2016-09-13|2016-10-28|2018-06-19	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000300379|SCV000328179|SCV000804014	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Neuroendocrine_tumor_of_pancreas	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||
NM_000059.3:c.1189_1190insTTAG	BRCA2	frameshift_variant	102336	1	NA	NA	-	-	-	-	51080	65748	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32906804_32906805insTTAG	reviewed_by_expert_panel	Pathogenic	-	-	Insertion	SO:0000667	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	397515635	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-29|2014-01-31|2017-04-20|2016-12-23|2017-01-19|2019-04-04|2017-03-24|2015-08-21|2016-10-18|2015-10-02|2016-10-10|2017-11-10|2015-08-21	2019-03-28|2017-08-04|2017-08-04|2019-03-21|2018-01-25|2020-02-26|2017-12-21|2016-07-18|2016-10-18|2016-10-28|2016-11-23|2018-01-29|2018-08-31	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000071768|SCV000587582|SCV000588077|SCV000605807|SCV000694518|SCV000186246|SCV000688698|SCV000296621|SCV000323962|SCV000326510|SCV000489480|SCV000805648|SCV000887751	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided	This_sequence_change_inserts_4_nucleotides_in_exon_10_of_the_BRCA2_mRNA_(c.1189_1190insTTAG),_causing_a_frameshift_at_codon_397._This_creates_a_premature_translational_stop_signal_(p.Gln397Leufs*25)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_or_ovarian_cancer_(PMID:_16644204,_22006311,_26787237,_26681312).Â¬â€ This_variant_is_also_known_as_1417insTTAG_and_1418insTTAG_in_the_literature._For_these_reasons,_this_sequence_change_has_been_classified_as_Pathogenic.|||The_p.Gln397fs_variant_in_BRCA2_has_been_reported_in_at_least_5_individuals_with_BRCA2-associated_cancers_(Lalloo_2006,_Walsh_2011,_Susswein_2015,_Breast_Cancer_Information_Core_(BIC)_database),_and_was_absent_from_large_population_studies._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_ami_no_acid_sequence_beginning_at_position_397_and_leads_to_a_premature_termination_codon_25_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_disease_mechanism_in_hereditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_variant_was_classified_as_Pathogenic_on_October_18,_2016_by_t_he_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000323962.1)._In_summary,_th_is_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosoma_l_dominant_manner.|Variant_summary:_The_BRCA2_c.1189_1190insTTAG_(p.Gln397Leufs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.1257delT/p.Cys419fs)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_is_absent_in_120790_control_chromosomes._This_variant_has_been_reported_in_multiple_affected_individuals._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||
NM_000059.3:c.1238del	BRCA2	frameshift_variant	102256	1	NA	NA	-	-	-	-	37731	46287	_familial_2|BRCA2-Related_Disorders|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN239275|MedGen:CN517202	-	NC_000013.10:g.32906853del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Illumina:708230	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359271	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Illumina_Clinical_Services_Laboratory,Illumina	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2014-01-06|2002-05-29|2016-04-22|2015-10-02|2018-02-22|2014-11-22|2014-01-31|2017-04-21|2017-04-13|2019-01-13	2015-08-20|2014-03-28|2016-06-09|2016-10-28|2020-02-26|2018-11-06|2017-08-04|2018-01-25|2019-01-29|2019-02-01	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053917|SCV000145838|SCV000282354|SCV000326523|SCV000187038|SCV000903392|SCV000587586|SCV000694524|SCV000210712|SCV000914619	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|BRCA2-Related_Disorders	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||Variant_summary:_The_BRCA2_c.1238delT_(p.Leu413Hisfs)_variant_(alternatively_also_known_as_1466delT)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Ser1630X,_p.Tyr1739X,_p.Asn1747X)._This_variant_is_absent_in_120730_control_chromosomes_from_ExAC._This_variant_has_been_reported_in_several_HBOC_patients/families_in_literature_and_clinical_databases._In_addition,_several_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_Pathogenic.|This_deletion_of_one_nucleotide_in_BRCA2_is_denoted_c.1238delT_at_the_cDNA_level_and_p.Leu413HisfsX17_(L413HfsX17)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ACCCC[delT]ATTG._The_deletion_causes_a_frameshift_which_changes_a_Leucine_to_a_Histidine_at_codon_413,_and_creates_a_premature_stop_codon_at_position_17_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.1238delT,_also_known_as_1466delT_using_alternate_nomenclature,_has_been_reported_in_at_least_three_individuals_with_breast_cancer_(Capalbo_2006,_Giannini_2006,_Caux-Moncoutier_2011)._We_consider_this_variant_to_be_pathogenic.|The_BRCA2_c.1238delT_(p.Leu413HisfsTer17)_variant_results_in_a_frameshift,_and_is_predicted_to_result_in_premature_termination_of_the_protein._The_p.Leu413HisfsTer17_has_been_reported_in_eight_studies_in_which_it_has_been_identified_in_a_heterozygous_state_in_at_least_11_individuals_with_hereditary_cancer,_either_breast_cancer,_breast_cancer_and_ovarian_cancer_or_ovarian_cancer_alone_(Capalbo_et_al._2006:_Giannini_et_al._2006:_Caux-Moncoutier_et_al._2011:_Concolino_et_al.2014:_Coppa_et_al._2014:_Minucci_2015:_Manie_et_al._2016:_Palmero_et_al._2018)._The_variant_is_reported_at_a_frequency_of_0.000009_in_the_European_(non-Finnish)_population_from_the_Genome_Aggregation_Database_but_this_is_based_on_one_allele_in_a_region_of_good_sequencing_coverage,_so_the_variant_is_presumed_to_be_rare._Although_the_c.3201+1G>C_variant_has_not_been_reported_in_the_literature_in_individuals_with_Fanconi_anemia,_it_cannot_be_ruled_out_of_causing_this_condition_based_on_allele_frequency_in_consideration_of_condition_penetrance_and_prevalence_estimates._Based_on_the_evidence_and_the_potential_impact_of_frameshift_variants,_the_BRCA2_p.Leu413HisfsTer17_variant_is_classified_as_pathogenic_for_hereditary_breast_and_ovarian_cancer._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_000059.3:c.1672del	BRCA2	frameshift_variant	102606	1	NA	NA	-	-	-	-	51172	65840	_familial_2	-	OMIM:612555	-	NC_000013.10:g.32907287del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	397507601	-	_c/o_University_of_Cambridge	Pathogenic|Pathogenic	2016-09-08|2015-10-02	2016-09-13|2016-10-28	_single_submitter	germline|germline	SCV000300454|SCV000326588	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|
NM_000059.3:c.1755_1759del	BRCA2	frameshift_variant	102312	1	NA	NA	-	-	-	-	37754	46310	_familial_2|BRCA2-Related_Disorders|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN239275|MedGen:CN517202	-	NC_000013.10:g.32907370_32907374del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:96464|Breast_Cancer_Information_Core__(BRCA2):1983&base_change%3Ddel_GAAAA|Illumina_Clinical_Services_Laboratory,Illumina:917721|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2403312	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359302	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Illumina_Clinical_Services_Laboratory,Illumina	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-12-12|2002-05-29|2016-09-08|2015-10-02|2016-08-22|2018-12-30|2014-01-31|2019-02-26|2019-04-26|2015-10-08|2019-01-09|2015-02-17|2017-07-18|2018-10-18	2015-08-20|2014-03-28|2016-09-13|2016-10-28|2016-11-23|2019-03-28|2017-08-04|2019-09-24|2020-02-26|2016-07-05|2019-01-29|2018-08-31|2018-10-10|2019-02-01	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053940|SCV000145926|SCV000300459|SCV000326603|SCV000489106|SCV000071887|SCV000587607|SCV000916840|SCV000185985|SCV000292147|SCV000108599|SCV000296726|SCV000885084|SCV000914620	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|BRCA2-Related_Disorders	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys585Asnfs*3)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_15131399,_16284991,_20616022,_19620486,_25186627),_and_in_individuals_with_breast,_pancreatic,_and_fallopian_tube_cancer_(PMID:_26681312)._This_variant_is_also_known_as_1983del5_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37754)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRCA2_c.1755_1759delGAAAA_(p.Lys585AsnfsX3)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.1763_1766delATAA,_p.Asn588fsX25:_c.1796_1800delCTTAT,_p.Ser599X:_c.1800T>A,_p.Tyr600X)._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_245304_control_chromosomes_(gnomAD)._c.1755_1759delGAAAA_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_breast_and/or_ovarian_cancer,_fallopian_tube_cancer_and_pancreatic_cancer_(Susswein_2016,_Senter_2014,_Pal_2005,_Lubinski_2004)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._Nine_ClinVar_submissions_from_clinical_diagnostic_laboratories_and_reputable_databases_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_five_nucleotides_in_BRCA2_is_denoted_c.1755_1759delGAAAA_at_the_cDNA_level_and_p.Lys585AsnfsX3_(K585NfsX3)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GAAAAA[delGAAAA]CAAA._The_deletion_causes_a_frameshift_which_changes_a_Lysine_to_an_Asparagine_at_codon_585,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.1755_1759delGAAAA,_also_known_as_1983del5_using_alternative_nomenclature,_has_been_reported_in_individuals_with_a_personal_and/or_family_history_of_breast,_ovarian,_and_pancreatic_cancer_(Lubinski_2004,_Pal_2005,_Couch_2007,_Watson_2009,_Senter_2014)._We_consider_this_variant_to_be_pathogenic.||The_BRCA2_c.1755_1759del,_p.Lys585fs_variant_(rs80359302)_has_been_reported_in_a_family_with_breast_and/or_ovarian_cancer_(Lubinski_2004)._It_is_listed_in_ClinVar_as_pathogenic_(Variation_ID:_37754),_and_observed_in_the_general_population_databases_at_a_very_low_frequency_(1/245304_alleles:_Genome_Aggregation_Database)._The_variant_introduces_a_frameshift,_and_is_predicted_to_result_in_a_truncated_protein_or_an_absent_transcript._Based_on_the_above_information,_the_variant_is_classified_as_pathogenic._REFERENCES_Link_to_ClinVar_database_for_c.1755_1759del:_https://www.ncbi.nlm.nih.gov/clinvar/variation/37754/_Lubinski_J_et_al._Cancer_variation_associated_with_the_position_of_the_mutation_in_the_BRCA2_gene._Fam_Cancer._2004:3(1):1-10.|The_BRCA2_c.1755_1759delGAAAA_(p.Lys585AsnfsTer3)_variant,_also_known_as_1983del5_results_in_a_frameshift_and_is_predicted_to_result_in_premature_termination_of_the_protein._The_p.Lys585AsnfsTer3_variant_has_been_reported_in_at_least_three_studies_in_which_it_is_found_in_a_heterozygous_state_in_a_total_of_eight_patients_diagnosed_with_breast,_ovarian/fallopian_tube,_pancreatic,_or_other_cancers_(Lubinski_et_al._2004:_Pal_et_al._2005:_Susswein_et_al._2016)._The_p.Lys585AsnfsTer3_variant_is_reported_at_a_frequency_of_0.000009_in_the_European_(non-Finnish)_population_of_the_Genome_Aggregation_Database_though_this_is_based_on_one_allele_in_a_region_of_good_sequence_coverage_so_the_variant_is_presumed_to_be_rare._Hall_et_al._(2016)_developed_a_mouse_model_of_pancreatic_acinar_cell_carcinoma_and_determined_that_it_was_homozygous_for_the_BRCA2_p.Lys585AsnfsTer3_variant._Immunohistochemical_staining_of_tissues_from_this_mouse_model_revealed_that_the_mutated_BRCA2_protein_was_not_localized_to_the_nucleus,_but_was_instead_only_expressed_in_the_cytoplasm,_as_compared_to_normal_tissues_where_BRCA2_was_localized_to_both_the_nucleus_and_cytoplasm._This_variant_has_not_been_reported_in_the_literature_in_association_with_Fanconi_anemia,_and_this_variant_could_not_be_ruled_out_of_causing_this_disease_based_on_based_on_the_variant_frequency,_disease_prevalence,_disease_penetrance,_and_inheritance_mode._Due_to_the_potential_impact_of_frameshift_variants,_the_p.Lys585AsnfsTer3_variant_is_classified_as_pathogenic_for_BRCA2-related_disorders.
NM_000059.3:c.1796_1800del	BRCA2	frameshift_variant	100302	1	NA	NA	-	-	-	-	37756	46312	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32907411_32907415del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):2022&base_change%3Ddel_ATTTT|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2482972|Breast_Cancer_Information_Core__(BRCA2):2024&base_change%3Ddel_TTTAT	-	BRCA2:675	SO:0001587|nonsense	1	276174813	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-05-02|2002-05-29|2016-04-22|2015-11-11|2015-10-02|2017-03-20|2017-05-25|2018-11-19|2015-11-11|2018-09-14|2017-01-23|2018-11-20|2015-04-08|2017-01-10	2015-12-29|2014-03-28|2016-06-09|2016-07-18|2016-10-28|2017-06-22|2018-06-14|2019-01-29|2018-08-31|2020-02-26|2017-10-26|2019-03-28|2017-04-19|2018-01-25	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053942|SCV000145940|SCV000282361|SCV000296660|SCV000326611|SCV000677720|SCV000839921|SCV000210716|SCV000887761|SCV000184811|SCV000683449|SCV000071900|SCV000591768|SCV000694563	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||The_c.1796_1800del_(p.Ser599*)_variant_in_the_BRCA2_gene_has_been_detected_multiple_patients_with_breast_cancer_[reported_as_2022del5_in_PMID_8988179]._This_variant_creates_a_premature_stop_codon_at_amino_acid_position_599_of_the_BRCA2_protein._This_variant_is_thus_predicted_to_result_in_a_loss_of_function_of_the_protein._This_variant_has_not_been_observed_in_the_ExAC_population_database._This_variant_thus_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_BRCA2_c.1796_1800delCTTAT_at_the_cDNA_level_and_p.Ser599Ter_(S599X)_at_the_protein_level._The_normal_sequence_with_the_bases_that_are_deleted_in_brackets_is_ACAT[delCTTAT]AAAG._The_substitution_creates_a_nonsense_variant,_changing_a_Serine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_denoted_2024del5_using_alternate_nomenclature,_has_been_reported_in_association_with_breast_cancer,_often_in_individuals_of_Greek_descent_(Ladopoulou_2002,_Bayraktar_2012,_Koumpis_2011)._We_consider_this_variant_to_be_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser599*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_22009639,_8988179,_24549055,_22085629,_22798144)._This_variant_is_also_known_as_c.1796delCTTAT_and_2024del5_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 37756)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_BRCA2_c.1796_1800delCTTAT_(p.Ser599Terfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_was_not_observed_in_controls_(ExAC,_1000_Gs,_or_ESP)_and_has_been_reported_in_multiple_affected_individuals_via_publications._In_addition,_multiple_clinical_diagnostic_laboratories/databases_cite_the_variant_as_pathogenic._Therefore,_the_variant_of_interest_has_been_classified_as_Pathogenic.
NM_000059.3:c.1813del	BRCA2	frameshift_variant	95590	2	NA	NA	-	-	-	-	37763	46319	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32907428del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):2041&base_change%3Ddel_A|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2563195|Breast_Cancer_Information_Core__(BRCA2):2034&base_change%3Ddel_A	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359306	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-10-22|2002-05-29|2016-04-22|2015-10-02|2018-09-10|2015-08-21|2018-06-27|2015-10-16|2018-12-11|2014-01-31|2017-04-20|2016-10-13|2018-07-02	2015-08-20|2014-03-28|2016-06-09|2016-10-28|2019-01-29|2018-08-31|2020-02-26|2016-07-05|2019-03-28|2017-08-04|2017-08-04|2018-01-25|2018-08-20	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown	SCV000053949|SCV000145952|SCV000282362|SCV000326618|SCV000210717|SCV000296624|SCV000187256|SCV000292131|SCV000071909|SCV000587613|SCV000588079|SCV000694570|SCV000838763	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_deletion_of_one_nucleotide_is_denoted_BRCA2_c.1813delA_at_the_cDNA_level_and_p.Ile605TyrfsX9_(I605YfsX9)_at_the_protein_level._This_deletion_is_also_known_as_BRCA2_2041delA_using_alternate_nomenclature._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GAAAAAAA[delA]TACC._The_deletion_causes_a_frameshift,_which_changes_an_Isoleucine_to_a_Tyrosine_at_codon_605,_and_creates_a_premature_stop_codon_at_position_9_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.1813delA_has_been_reported_in_association_with_hereditary_breast_and/or_ovarian_cancer_(Bergthorsson_2001,_Spearman_2008,_Sugano_2008,_Hirasawa_2017,_Dudley_2018)._We_consider_this_variant_to_be_pathogenic.||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ile605Tyrfs*9)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_with_breast_and/or_ovarian_cancer_(PMID:_11389159,Â¬â€ 19016756,_24549055,_20104584,_23704984,_18824701)._It_has_also_been_reported_in_an_individual_with_prostate_cancer_(PMID:_23035815)._This_variant_is_also_known_as_2041delA_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37763)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA2_c.1813delA_(p.Ile605Tyrfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.1813dupA_(p.Ile605fs),_c.1832C>A_(p.Ser611X),_and_c.1842dupT_(p.Asn615X))._The_variant_of_interest_was_not_found_in_the_large,_broad_control_population,_ExAC_(115908_chrs_tested)._Multiple_publications_have_cited_the_variant_in_affected_individuals,_along_with_multiple_reputable_databases/clinical_diagnostic_laboratories_have_cited_the_variant_as_pathogenic._Therefore,_the_variant_of_interest_has_been_classified_as_Pathogenic.|
NM_000059.3:c.2319del	BRCA2	frameshift_variant	102420	1	NA	NA	-	-	-	-	254500	248934	_familial_2	-	OMIM:612555	-	NC_000013.10:g.32910811del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	774808238	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)	Pathogenic	2016-09-08	2016-09-13	reviewed_by_expert_panel	germline	SCV000300507	_familial_2	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.
NM_000059.3:c.2330dup	BRCA2	frameshift_variant	102406	1	NA	NA	-	-	-	-	91775	97252	_familial_2|Breast_and/or_ovarian_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32910822dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Breast_Cancer_Information_Core__(BRCA2):2558&base_change%3Dins_A|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2569333|OMIM_Allelic_Variant:600185.0026	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359328	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2003-01-01|2011-12-12|2002-05-29|2014-11-03|2016-09-08|2015-10-02|2017-04-14|2018-08-20|2015-09-04|2018-06-22|2015-06-11|2018-12-06|2014-01-31|2017-04-20|2014-04-23|2018-12-04|2015-10-28|2017-07-07	2012-11-09|2013-06-26|2014-03-28|2016-04-21|2016-09-13|2016-10-28|2017-06-22|2019-01-29|2018-08-31|2020-02-26|2017-10-26|2019-03-28|2017-08-04|2017-08-04|2017-04-19|2019-04-24|2018-07-18|2018-04-30	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000030149|SCV000109486|SCV000146031|SCV000195969|SCV000300509|SCV000326691|SCV000677671|SCV000210721|SCV000296622|SCV000214529|SCV000683480|SCV000259811|SCV000587629|SCV000588083|SCV000591801|SCV000919031|SCV000863670|SCV000902194	Malignant_tumor_of_prostate|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_pathogenic_variant_is_denoted_BRCA2_c.2330dupA_at_the_cDNA_level_and_p.Asp777GlufsX11_(D777EfsX11)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_AAGG[dupA]TGTT._The_duplication_causes_a_frameshift,_which_changes_an_Aspartic_Acid_to_a_Glutamic_Acid_at_codon_777,_and_creates_a_premature_stop_codon_at_position_11_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.2330dupA,_previously_reported_as_2558insA_using_alternate_nomenclature,_has_been_observed_in_association_with_breast,_ovarian,_prostate,_and_pancreatic_cancer_(Al-Saffer_2002,_Edwards_2010,_Song_2014,_George_2017,_Lowery_2018)._We_therefore_consider_this_variant_to_be_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asp777Glufs*11)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_with_prostate_cancer_(PMID:_12474142),_fallopian_tube_carcinoma_(PMID:_11812938),_and_ovarian_cancer_(PMID:_24728189,_12414830)._This_variant_is_also_known_as_2558insA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_91775)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_BRCA2_c.2330dupA_(p.Asp777GlufsX11)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.2368G>T/p.Glu790X,_c.2400_2401delTA/p.Asn801fsX3)._The_variant_allele_was_found_at_a_frequency_of_8e-06_in_248882_control_chromosomes_(gnomAD_and_publication_data)._c.2330dupA_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_and_other_tumor_phenotypes._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported_(Edwards_2003,_Oros_2004,_Alsop_2012,_Song_2014,_George_2016)._Nine_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.||
NM_000059.3:c.2588dup	BRCA2	frameshift_variant	96002	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.2653_2656del	BRCA2	frameshift_variant	96450	1	NA	NA	-	-	-	-	51322	65990	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32911145_32911148del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):2881&base_change%3Ddel_GACA	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359340	-	Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-05-29|2016-09-08|2015-10-02|2018-07-11|2017-11-13|2018-04-18|2014-01-31|2012-12-03	2014-03-28|2016-09-13|2016-10-28|2020-02-26|2018-11-06|2019-01-29|2017-08-04|2017-04-19	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000146084|SCV000300546|SCV000326741|SCV000213400|SCV000903288|SCV000568460|SCV000587639|SCV000591815	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_four_nucleotides_in_BRCA2_is_denoted_c.2653_2656delGACA_at_the_cDNA_level_and_p.Asp885MetfsX9_(D885MfsX9)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CTCA[delGACA]ATGA._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA2_2881_2884delGACA._The_deletion_causes_a_frameshift_which_changes_an_Aspartic_Acid_to_a_Methionine_at_codon_885,_and_creates_a_premature_stop_codon_at_position_9_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.2653_2656delGACA_has_been_observed_in_at_least_two_individuals_referred_for_hereditary_cancer_testing_(Lecarpentier_2012)._We_consider_this_variant_to_be_pathogenic.||
NM_000059.3:c.2808_2811del	BRCA2	frameshift_variant	102406	2	NA	NA	-	-	-	-	9322	24361	Neoplasm_of_the_breast|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_1|Breast_and/or_ovarian_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:C2676676,OMIM:604370|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32911300_32911303del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):3034&base_change%3Ddel_AAAC|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:111500|OMIM_Allelic_Variant:600185.0016|Breast_Cancer_Information_Core__(BRCA2):3036&base_change%3Ddel_ACAA|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2436329|OMIM_Allelic_Variant:600185.0006	-	BRCA2:675	SO:0001589|frameshift_variant	3	80359351	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Division_Human_Genetics,Medical_University_Innsbruck|Counsyl|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Center_of_Medical_Genetics_and_Primary_Health_Care|Mendelics|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|GenomeConnect,_ClinGen|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Laboratory_of_Molecular_Diagnosis_of_Cancer,West_China_Hospital,_Sichuan_University|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Baylor_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1995-12-21|2013-07-29|2013-02-20|2015-02-11|2014-07-04|2016-04-21|2016-04-22|2015-10-02|2017-01-01|2015-07-01|0000-00-00|2015-09-21|2018-05-22|0000-00-00|2019-05-28|2019-01-09|2015-11-13|2014-01-31|2017-04-20|2012-05-06|0000-00-00|2017-08-07|2018-07-02|2018-11-21|2015-04-05|2018-11-16|2019-06-23|2017-11-01|2017-12-13|2018-01-24|2015-11-20|2015-11-01|0000-00-00|2017-02-23|2016-03-29	2015-04-23|2015-12-29|2014-03-28|2015-02-11|2015-03-11|2016-04-21|2016-06-09|2016-10-28|2017-03-15|2017-10-18|2018-04-04|2018-04-09|2018-06-14|2019-08-31|2019-10-22|2019-03-28|2019-03-21|2017-08-04|2017-08-04|2017-04-19|2017-08-22|2018-01-25|2018-08-20|2020-02-26|2016-07-05|2019-01-29|2020-03-06|2017-11-21|2018-03-09|2018-10-10|2016-03-03|2016-02-27|2016-12-06|2017-02-23|2018-07-18	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000030128|SCV000053988|SCV000146117|SCV000212014|SCV000220481|SCV000267754|SCV000282373|SCV000326768|SCV000577950|SCV000605665|SCV000733240|SCV000744430|SCV000839926|SCV000987243|SCV001139044|SCV000072077|SCV000271324|SCV000587644|SCV000588085|SCV000591826|SCV000607364|SCV000694631|SCV000838778|SCV000186032|SCV000292132|SCV000210725|SCV000296702|SCV000296818|SCV000778656|SCV000885087|SCV000266039|SCV000265905|SCV000492474|SCV000541011|SCV000863579	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|Breast-ovarian_cancer,_familial_1|Neoplasm_of_the_breast|Neoplasm_of_the_breast|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer	||||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||The_c.2808_2811delACAA_(p.Ala938Profs*21)_frameshift_variant_in_BRCA2_is_predicted_to_introduce_a_premature_translation_termination_codon._It_has_been_reported_in_multiple_unrelated_patients_with_breast,_ovarian_or_prostate_cancer_[PMID_8524414,_22144684,_21952622,_22006311,_21324516]._This_variant_is_classified_as_pathogenic.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ala938Profs*21)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80359351,_ExAC_0.003%)._This_variant_has_been_reported_in_individuals_affected_with_female_breast_cancer,_male_breast_cancer,_ovarian_cancer,_prostate_cancer,_and_pancreatic_cancer_(PMID:_9585613,_21952622,_12955716,_23929434)._In_the_literature,_this_variant_is_also_known_as_2807del4,_3034del4,_3036del4,_3034delAAAC,_3036delACAA,_and_3036_3039del4._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_9322)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Ala938fs_variant_in_BRCA2_is_a_well-established_pathogenic_variant_for_her_editary_breast_and_ovarian_cancer_(HBOC)_and_is_one_of_the_most_common_germline_mutations_in_non-Ashkenazi_Jewish_individuals_with_breast_cancer_(Gao_2000,_Diez_2003,_Janavicius_2010,_Caputo_2012,_Kwong_2012,_Infante_2013)._This_variant_has_also_been_identified_in_one_male_with_prostate_cancer_and_5_males_with_breast_c_ancer_(Edwards_2010,_de_Juan_2015)._Furthermore,_this_variant_was_identified_in_2/66388_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://e_xac.broadinstitute.org:_dbSNP_rs80359351)._The_p.Ala938fs_variant_is_predicted_t_o_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_a_t_position_938_and_leads_to_a_premature_termination_codon_21_amino_acids_downstr_eam._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_disease_mecha_nism_for_HBOC._In_summary,_this_variant_meets_our_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_predicted_imp_act_to_the_protein_and_prevalence_in_affected_individuals.||||GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.|Variant_summary:_The_BRCA2_c.2808_2811delACAA_(p.Ala938Profs)_variant_(legacy_names:_3036del4_and_3036delACAA)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._This_variant_is_absent_in_120732_control_chromosomes_from_ExAC._This_variant_is_known_to_be_a_one_of_the_most_common_pathogenic_variants_in_non-Ashkenazi_Caucasians_(Diez_2003,_Caputo_2012,_Hall_2009,_Infante_2013)._Several_clinical_diagnostic_laboratories/reputable_databases_in_ClinVar_have_classified_this_variant_as_pathogenic._Therefore,_this_variant_is_classified_as_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_BRCA2_c.2808_2811delACAA_at_the_cDNA_level_and_p.Ala938ProfsX21_(A938PfsX21)_at_the_protein_level,_and_is_also_known_as_3034del4,_3036del4,_or_3036_3039delACAA_using_alternate_nomenclature._The_normal_sequence_with_the_bases_that_are_deleted_in_brackets_is_ATAA[delACAA]GCAA._The_deletion_causes_a_frameshift,_changing_an_Alanine_to_a_Proline_at_codon_938_and_creating_a_premature_stop_codon_at_position_21_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.2808_2811delACAA_has_been_reported_in_association_with_familial_and_early-onset_breast_and/or_ovarian_cancer_(Wooster_1995,_Salazar_2006,_Walsh_2011,_Zhang_2011,_de_Juan_2015),_in_individuals_with_prostate_cancer_(Kote-Jarai_2011,_Edwards_2010),_and_as_a_recurrent_variant_in_Western_European_and_Hispanic_populations_(Diez_2003,_Janavicius_2010,_Caputo_2012,_Ossa_2016)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|||The_BRCA2_c.2808_2811delACAA_variant_(rs80359351)_is_reported_in_the_literature_in_individuals_affected_with_familial_breast,_ovarian_and_prostate_cancers_(Edwards_2010,_Kote-Jarai_2011,_Walsh_2011,_Wooster_1995,_Zhang_2011),_and_has_been_described_as_a_founder_variant_in_Western_Europeans_(Caputo_2012)._This_variant_is_reported_as_pathogenic_23_times_in_ClinVar_(Variation_ID:_9322)_and_is_seen_in_the_general_population_at_a_low_overall_frequency_of_0.001%_(3/245804_alleles)_in_the_Genome_Aggregation_Database._This_variant_deletes_4_nucleotides_causing_a_frameshift,_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_the_above_information,_this_variant_is_considered_pathogenic._References:_Caputo_S_et_al._(2012)_Description_and_analysis_of_genetic_variants_in_French_hereditary_breast_and_ovarian_cancer_families_recorded_in_the_UMD-BRCA1/BRCA2_databases._Nucleic_Acids_Res._40(Database_issue):D992-1002._Edwards_SM_et_al._(2010)_Prostate_cancer_in_BRCA2_germline_mutation_carriers_is_associated_with_poorer_prognosis._Br_J_Cancer._103(6):918-24._Kote-Jarai_Z_et_al._(2011)_BRCA2_is_a_moderate_penetrance_gene_contributing_to_young-onset_prostate_cancer:_implications_for_genetic_testing_in_prostate_cancer_patients._Br_J_Cancer._105(8):1230-4._Walsh_T_et_al._(2011)_Mutations_in_12_genes_for_inherited_ovarian,_fallopian_tube,_and_peritoneal_carcinoma_identified_by_massively_parallel_sequencing._Proc_Natl_Acad_Sci_U_S_A._108(44):18032-7._Wooster_R_et_al._(1995)_Identification_of_the_breast_cancer_susceptibility_gene_BRCA2._Nature._378(6559):789-92._Zhang_S_et_al._(2011)_Frequencies_of_BRCA1_and_BRCA2_mutations_among_1,342_unselected_patients_with_invasive_ovarian_cancer._Gynecol_Oncol._121(2):353-7.|||||
NM_000059.3:c.2830A>T	BRCA2	stop_gained	102360	1	15436	0	5&5&5	3&2&1	rs80358533	Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&not provided	51355	66023	Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32911322A>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80358533	-	Baylor_Genetics|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|Biochemical_Molecular_Genetic_Laboratory,King_Abdulaziz_Medical_City	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-02-23|2006-11-27|2002-05-29|2016-09-08|2015-10-02|2015-07-01|2015-08-11|0000-00-00|2015-09-21|2018-09-28|2015-06-15|2018-06-28|2015-03-04|2014-01-31|2016-12-13|2018-07-02|2018-12-01|2020-02-05	2017-02-23|2013-06-26|2014-03-28|2016-09-13|2016-10-28|2017-10-18|2017-06-22|2018-04-04|2018-04-09|2020-02-26|2016-07-05|2019-01-29|2017-08-01|2017-08-04|2018-01-25|2018-08-20|2019-02-22|2020-02-12	criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000540994|SCV000109084|SCV000146122|SCV000300563|SCV000326771|SCV000605671|SCV000677672|SCV000733241|SCV000744431|SCV000186031|SCV000292148|SCV000210293|SCV000296716|SCV000587645|SCV000694634|SCV000838779|SCV000923785|SCV001190805	Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Ovarian_Neoplasms|Fanconi_anemia,_complementation_group_D1	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_BRCA2_c.2830A>T_at_the_cDNA_level_and_p.Lys944Ter_(K944X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Lysine_to_a_premature_stop_codon_(AAA>TAA)_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_BRCA2_3058A>T_by_alternate_nomenclature,_has_been_reported_in_multiple_individuals_with_personal_and/or_family_history_of_breast,_ovarian,_and/or_pancreatic_cancer_(Hakansson_1997,_Peto_1999,_Capalbo_2006,_Thomassen_2008,_Borg_2010,_Blay_2013,_Lucas_2014)._Additionally,_Ruud_et_al._(2001)_reported_a_patient_with_Fanconi_anemia_who_passed_away_following_a_diagnosis_of_medulloblastoma_and_resultant_chemotherapy_toxicity._Follow-up_studies_on_archived_tissue_by_Bodd_et_al._(2010)_revealed_compound_heterozygosity_for_BRCA2_Lys944Ter,_present_in_her_mother_who_had_a_family_history_of_breast_and_ovarian_cancer,_and_a_BRCA2_missense_variant,_present_in_her_father._We_consider_this_variant_to_be_pathogenic.|||Variant_summary:_The_BRCA2_c.2830A>T_(p.Lys944X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_and_other_laboratories_(e.g._c.2287delC,_c.2400_2401delTA,_c.2808delA,_etc.)._This_variant_is_absent_in_120672_control_chromosomes_from_ExAC._This_variant_is_widely_reported_as_a_pathogenic_variant_in_literature_and_clinical_databases_and_has_been_reported_in_several_HBOC_patients/families,_including_evidence_of_cosegregation._In_addition,_this_variant_has_also_been_reported_in_a_patient_with_Fanconi_Anemia_(Bodd_2010)._Several_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_Pathogenic.|||
NM_000059.3:c.3103G>T	BRCA2	stop_gained	101954	1	NA	NA	5&5&5&5	1&3&1&1	rs80358556	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&not provided	51400	66068	_familial_2|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN517202	-	NC_000013.10:g.32911595G>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:126358	-	BRCA2:675	SO:0001587|nonsense	1	80358556	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Ambry_Genetics|Color|True_Health_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-26|2014-01-31|2017-07-24|2013-12-03|2004-02-20|2016-04-22|2015-10-02|2016-09-06|2019-12-11|2019-04-16|2016-10-11|2017-12-01|2018-11-21|2015-11-28|2016-10-12	2019-03-28|2017-08-04|2018-01-25|2015-12-29|2014-03-28|2016-06-09|2016-10-28|2016-11-23|2020-03-06|2020-02-26|2017-10-26|2018-03-08|2019-01-29|2018-08-31|2017-06-30	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline	SCV000072132|SCV000587656|SCV000694667|SCV000109089|SCV000146170|SCV000282375|SCV000326813|SCV000489204|SCV001192816|SCV000186034|SCV000683526|SCV000787927|SCV000210304|SCV000296718|SCV000602807	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_specified	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu1035*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_several_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_17688236,_26681312,_26296701,_16912212),_as_well_as_an_individual_with_glioblastoma_(PMID:_26787237)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_51400)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_BRCA2_c.3103G>T_(p.Glu1035X)_variant_(legacy_name_3331G>T)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Gln1063X,_p.Gln1129X,_and_p.Arg2520X)._This_variant_is_absent_in_120800_control_chromosomes_from_ExAC._This_variant_has_been_reported_in_several_HBOC_patients_in_literature_(Malone_2006,_Ramus_2007,_Conner_2014,_Tung_2015,_Ellingson_2015,_Susswein_2015,_Meric-Bernstam_2016)._In_addition,_several_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_variant_is_denoted_BRCA2_c.3103G>T_at_the_cDNA_level_and_p.Glu1035Ter_(E1035X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_BRCA2_3331G>T_using_alternate_nomenclature,_has_been_observed_in_multiple_individuals_and_families_with_Hereditary_Breast_and_Ovarian_Cancer_syndrome_(Ramus_2007,_Ellingson_2015)_and_is_considered_pathogenic.||
NM_000059.3:c.3170_3174del	BRCA2	frameshift_variant	101322	3	NA	NA	-	-	-	-	37826	46382	_familial_2|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32911662_32911666del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):3398&base_change%3Ddel_AGAAA|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2442770	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359373	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Invitae|Cancer_Genetics_and_Genomics_Laboratory,British_Columbia_Cancer_Agency|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-01-31|2004-02-20|2016-09-08|2015-10-02|2016-08-23|2017-05-25|2019-01-05|2017-04-18|2014-01-31|2017-04-20|2014-02-11|2018-08-13|2019-04-10|2015-03-06|2018-10-03|2015-04-30|2015-10-02|2017-09-06	2015-12-29|2014-03-28|2016-09-13|2016-10-28|2016-11-23|2018-06-14|2019-03-28|2017-08-04|2017-08-04|2017-08-04|2017-04-19|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2018-08-31|2018-07-18|2018-04-30	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054012|SCV000146184|SCV000300594|SCV000326827|SCV000489135|SCV000839918|SCV000072154|SCV000586939|SCV000587662|SCV000588089|SCV000591849|SCV000918996|SCV000186021|SCV000683533|SCV000278845|SCV000296698|SCV000863676|SCV000901105	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||The_c.3170_3174del_(p.Lys1057Thrfs*8)_variant_in_the_BRCA2_gene_has_been_detected_in_one_family_from_a_cohort_of_cancer_patients_[PMID_15131399,_reported_as_3398delAAAAG]_and_a_cohort_of_patients_with_prostate_cancer_[PMID_27433846]._The_variant_was_also_reported_in_11_patients_in_the_Breast_Cancer_Information_Core_database._This_5_bp_deletion_in_exon_11_results_in_a_frameshift_and_the_creation_of_a_premature_stop_codon._This_variant_is_thus_predicted_to_result_in_a_loss_of_function_of_the_protein._This_variant_has_been_detected_in_three_individuals_in_the_ExAC_database_(http://exac.broadinstitute.org/variant/13-32911658-CAAAAG-C)._This_variant_thus_classified_as_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys1057Thrfs*8)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs781096360,_ExAC_0.005%)._This_variant_has_been_reported_as_recurrent_in_French_Canadian_individuals_and_families_with_breast,_ovarian,_and_pancreatic_cancer_(PMID:_15131399,_15382066,_16539696,_25864590,_20694749,_23621881)._It_has_also_been_reported_in_individuals_with_breast_and_prostate_cancer_from_other_populations_(PMID:_25863477,_26296701,_27433846)._This_variant_is_also_known_as_3398delAAAAG_and_3398del5_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37826)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||Variant_summary:_BRCA2_c.3170_3174delAGAAA_(p.Lys1057ThrfsX8)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_1.2e-05_in_241872_control_chromosomes_(gnomAD)._c.3170_3174delAGAAA_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Lubinski_2004,_Oros_2004,_de_Juan_Jimenez_2013,_Ghadirian_2013)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Ten_ClinVar_submissions_from_other_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_deletion_of_five_nucleotides_in_BRCA2_is_denoted_c.3170_3174delAGAAA_at_the_cDNA_level_and_p.Lys1057ThrfsX8_(K1057TfsX8)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CAAA[delAGAAA]CTGA._The_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_a_Threonine_at_codon_1057,_and_creates_a_premature_stop_codon_at_position_8_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.3170_3174delAGAAA,_previously_reported_as_BRCA2_3398del5,_has_been_observed_in_families_with_hereditary_breast_and_ovarian_cancer_and_is_considered_a_French_Canadian_pathogenic_founder_variant_(Lubinski_2004,_Oros_2006,_Janavicius_2010,_de_Juan_Jimenez_2013,_Andrei_2015,_Belanger_2015,_Pritchard_2016)._We_consider_this_variant_to_be_pathogenic.|||
NM_000059.3:c.3500_3501del	BRCA2	frameshift_variant	102236	1	NA	NA	-	-	-	-	51478	66146	_familial_2|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32911992_32911993del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):3728&base_change%3Ddel_TA	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359387	-	_c/o_University_of_Cambridge|Counsyl|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2004-02-20|2016-09-08|2015-10-02|2017-04-11|2018-08-01|2017-03-16|2019-01-17	2014-03-28|2016-09-13|2016-10-28|2017-06-22|2020-02-26|2018-11-06|2020-03-06	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline	SCV000146245|SCV000300642|SCV000326876|SCV000677675|SCV000277539|SCV000906899|SCV001133759	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_000059.3:c.3545_3546del	BRCA2	frameshift_variant	102326	5	NA	NA	-	-	-	-	37846	46402	_familial_2|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D030342,MedGen:C0950123|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32912037_32912038del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2447084|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:175398|Breast_Cancer_Information_Core__(BRCA2):3773&base_change%3Ddel_TT	-	BRCA2:675	SO:0001587|nonsense	1	80359388	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Division_Human_Genetics,Medical_University_Innsbruck|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Invitae|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Ambry_Genetics|Color|Ambry_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-05-01|2002-05-29|2014-01-31|2015-02-11|2016-04-22|2015-10-02|2015-07-01|2018-12-04|2017-02-28|2014-10-30|2016-10-04|2017-06-09|2018-11-30|2015-03-30|2017-11-01|2017-08-04|2018-11-21|2016-03-02|2014-06-05|2016-04-07|2017-10-12	2015-08-20|2014-03-28|2014-05-01|2015-02-11|2016-06-09|2016-10-28|2017-10-18|2019-03-28|2017-08-28|2017-04-19|2019-03-21|2018-01-25|2019-01-29|2018-08-31|2017-11-21|2018-10-10|2020-02-26|2017-10-26|2018-02-08|2018-07-18|2018-04-30	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054032|SCV000146255|SCV000154067|SCV000212017|SCV000282379|SCV000326880|SCV000605663|SCV000072232|SCV000219328|SCV000591867|SCV000605795|SCV000694703|SCV000108612|SCV000296692|SCV000693564|SCV000883490|SCV000186023|SCV000683566|SCV000262830|SCV000863678|SCV000902197	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Inborn_genetic_diseases|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Phe1182*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs748852670,_ExAC_0.006%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_15131399,_24156927,_25884701,_20104584)._This_variant_is_also_known_as_3772delTT,_c.3773delTT,_and_p.Phe1182Terfs_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37846)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||The_p.Phe1182X_variant_in_BRCA2_has_been_reported_in_>15_individuals_with_BRCA2-_associated_cancers_(Breast_Cancer_Information_Core_(BIC)_database,_Lubinski_2004_,_Borg_2010,_Tea_2014,_Belanger_2015,_Polsler_2016)._It_has_also_been_identified_in_4/66684_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http_://exac.broadinstitute.org:_dbSNP_rs80359388):_however,_this_frequency_is_low_en_ough_to_be_consistent_with_the_frequency_of_hereditary_breast_and_ovarian_cancer_(HBOC)_in_the_general_population._This_variant_creates_a_premature_termination_codon_at_position_1182,_which_is_predicted_to_lead_to_a_truncated_or_absent_prot_ein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_disease_m_echanism_in_HBOC._Furthermore,_the_p.Phe1182X_variant_was_classified_as_Pathogen_ic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000_282379.1)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogeni_c_for_HBOC_in_an_autosomal_dominant_manner.|Variant_summary:_The_c.3545_3546delTT_(p.Phe1182X)_variant_in_BRCA2_gene_is_a_2-bp_deletion_that_creates_a_nonsense_variant_at_codon_1182._This_change_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_or_nonsense-mediated_mRNA_decay._The_variant_is_present_at_a_low_frequency_in_large_control_population_dataset_of_ExAC_at_a_frequency_0.000033_(4/121246_chrs_tested),_which_does_not_exceed_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_variant_(0.00075)._The_variant_has_been_reported_in_numerous_affected_individuals_via_published_reports_and_cited_by_reputable_databases/clinical_laboratories_as_Pathogenic._Taking_together,_the_variant_was_classified_as_Pathogenic.|This_deletion_of_two_nucleotides_is_denoted_BRCA2_c.3545_3546delTT_at_the_cDNA_level_and_p.Phe1182Ter_(F1182X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CAAT[delTT]GAAG._The_deletion_creates_a_nonsense_variant,_which_changes_a_Phenylalanine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.3545_3546delTT,_previously_reported_as_3772delTT_or_3773delTT_using_alternate_nomenclature,_has_been_reported_in_multiple_individuals_with_a_personal_and/or_family_history_of_breast,_ovarian,_and/or_pancreatic_cancer_(Lubinski_2004,_Cavallone_2010,_Tea_2014,_Belanger_2015,_Shindo_2017),_and_in_the_compound_heterozygous_state_in_at_least_one_patient_with_Fanconi_Anemia_(Malric_2015)._We_consider_this_variant_to_be_pathogenic.|||The_BRCA2_c.3545_3546delTT:_p.Phe1182Ter_variant_(rs80359388),_also_known_as_3772delTT_and_3773delTT,_has_been_reported_in_several_individuals_and_families_with_breast_and/or_ovarian_cancer_(Belanger_2015,_Borg_2010,_Lubinski_2004,_Tea_2014)._It_is_reported_in_ClinVar_as_pathogenic_(Variation_ID:_37846),_and_observed_in_the_general_population_with_an_overall_allele_frequency_of_0.002_percent_(5/245740_alleles)_in_the_Genome_Aggregation_Database._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_absent_transcript._Taken_together,_c.3545_3546delTT_is_considered_pathogenic._REFERENCES_Link_to_ClinVar_database_for_c.3545_3546delTT:_https://www.ncbi.nlm.nih.gov/clinvar/variation/37846/_Belanger_MH_et_al._A_targeted_analysis_identifies_a_high_frequency_of_BRCA1_and_BRCA2_mutation_carriers_in_women_with_ovarian_cancer_from_a_founder_population._J_Ovarian_Res._2015_Mar_27:8:1._Borg_A_et_al._Characterization_of_BRCA1_and_BRCA2_deleterious_mutations_and_variants_of_unknown_clinical_significance_in_unilateral_and_bilateral_breast_cancer:_the_WECARE_study._Hum_Mutat._2010_Mar:31(3):E1200-40._Lubinski_J_et_al._Cancer_variation_associated_with_the_position_of_the_mutation_in_the_BRCA2_gene._Fam_Cancer._2004:3(1):1-10._Tea_MK_et_al._Central_European_BRCA2_mutation_carriers:_birth_cohort_status_correlates_with_onset_of_breast_cancer._Maturitas._2014_Jan:77(1):68-72.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||Lines_of_evidence_used_in_support_of_classification:_POSITIVE:_Relevant_Alteration(s)_Detected||
NM_000059.3:c.3599_3600del	BRCA2	frameshift_variant	102508	3	NA	NA	-	-	-	-	51493	66161	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32912091_32912092del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):3826&base_change%3Ddel_TG|Breast_Cancer_Information_Core__(BRCA2):3827&base_change%3Ddel_GT|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2830172	-	BRCA2:675	SO:0001587|nonsense	1	80359391	-	GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-11|2016-08-11|2017-11-30|2002-05-29|2016-09-08|2015-10-02|2016-01-15|2014-10-10|2019-05-06|2017-03-29|2018-11-02|2014-01-31|2013-11-15|2018-05-22	2019-01-29|2018-08-31|2018-03-09|2014-03-28|2016-09-13|2016-10-28|2016-11-23|2018-04-17|2020-02-26|2018-11-06|2019-03-28|2017-08-04|2017-04-19|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000210737|SCV000600557|SCV000778665|SCV000146265|SCV000300648|SCV000326886|SCV000488173|SCV000743287|SCV000213406|SCV000903412|SCV000072243|SCV000587675|SCV000591871|SCV000916858	not_provided|not_provided|not_provided|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	This_pathogenic_variant_is_denoted_BRCA2_c.3599_3600delGT_at_the_cDNA_level_and_p.Cys1200Ter_(C1200X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GACT[delGT]AACA._The_deletion_creates_a_nonsense_variant,_changing_a_Cysteine_to_a_premature_stop_codon_(TGT>TAA)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_BRCA2_3827delGT_or_C1200fs*1_using_alternate_nomenclature,_has_been_reported_in_association_with_hereditary_breast_and_ovarian_cancer_and_is_thought_to_be_a_pathogenic_founder_variant_in_the_Philippines_and_other_Asian_countries_(De_Leon_Matsuda_2002,_Liede_2002,_Song_2014,_Kang_2015,_Nielsen_2016)._We_consider_this_variant_to_be_pathogenic||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Cys1200*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80359391,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_with_breast_cancer,_ovarian_cancer,_and_Fanconi_anemia_(PMID:_24504028,_16683254,_25863477,_15645491,_24728189)._This_variant_is_also_known_as_3827delGT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_51493)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_BRCA2_c.3599_3600delGT_(p.Cys1200X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_p.Phe1216fsX2_and_p.Leu1227fsX5)._The_variant_allele_was_found_at_a_frequency_of_2e-05_in_249126_control_chromosomes._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_BRCA2_causing_Hereditary_Breast_and_Ovarian_Cancer_(2e-05_vs_0.00075),_allowing_no_conclusion_about_variant_significance._The_variant,_c.3599_3600delGT,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer,_indicating_that_the_variant_is_very_likely_to_be_associated_with_disease_(Song_2014,_Hamann_2003._Kim_2012,_Kang_2015)._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Seven_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_and_all_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_000059.3:c.3683dup	BRCA2	frameshift_variant	102058	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.3708dup	BRCA2	frameshift_variant	101782	1	NA	NA	-	-	-	-	91805	97282	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32912200dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	34575057	-	Sharing_Clinical_Reports_Project_(SCRP)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|GeneDx|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-11-10|2016-09-08|2015-10-02|2018-03-13|2014-01-31|2018-07-30	2013-06-26|2016-09-13|2016-10-28|2019-01-29|2017-08-04|2019-03-28	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000109516|SCV000300656|SCV000326900|SCV000210731|SCV000587678|SCV000836751	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.3708dupA_at_the_cDNA_level_and_p.Ala1237SerfsX6_(A1237SfsX6)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_CAAAA[dupA]GCTG._The_duplication_causes_a_frameshift_which_changes_an_Alanine_to_a_Serine_at_codon_1237,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.3708dupA,_also_known_as_3936dupA_using_alternate_nomenclature,_has_been_reported_in_association_with_hereditary_breast_and_ovarian_cancer_(Meisel_2017)_and_is_considered_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ala1237Serfs*6)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_an_individual_with_a_family_history_indicative_of_hereditary_breast_or_ovarian_cancer_(PMID:_28324225)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_91805)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000059.3:c.3785C>G	BRCA2	stop_gained	99704	1	NA	NA	5&5	3&1	rs80358620	Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome	51525	66193	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32912277C>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80358620	-	Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Sharing_Clinical_Reports_Project_(SCRP)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Ambry_Genetics|True_Health_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-10|2018-05-29|0000-00-00|2016-04-22|2012-04-30|2015-10-02|2018-04-02|2019-05-23|2019-01-07|2018-04-09|2018-11-26|2019-02-22	2019-03-28|2019-04-24|2014-03-28|2016-06-09|2015-03-23|2016-10-28|2018-06-20|2019-08-02|2020-02-26|2018-06-26|2019-01-29|2020-03-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|reviewed_by_expert_panel|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline	SCV000072279|SCV000916867|SCV000146297|SCV000282383|SCV000297522|SCV000326915|SCV000786273|SCV000993559|SCV000183819|SCV000805241|SCV000566129|SCV001133771	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser1262*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80358620,_ExAC_0.002%)._This_particular_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_ovarian_cancer_(PMID:_24728189)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_51525)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_BRCA2_c.3785C>G_(p.Ser1262X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_p.Val1283fsX2_and_p.Lys1289fsX3)._The_variant_allele_was_found_at_a_frequency_of_8.4e-06_in_118690_control_chromosomes._c.3785C>G_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Five_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_and_all_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_BRCA2_c.3785C>G_at_the_cDNA_level_and_p.Ser1262Ter_(S1262X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_4013C>G._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Loughrey_2008,_de_Juan_Jim?nez_2013,_Song_2014)._We_consider_this_variant_to_be_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_000059.3:c.3847_3848del	BRCA2	frameshift_variant	86556	9	15398	0	-	-	-	-	37859	46415	_familial_2|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32912339_32912340del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2269717|Breast_Cancer_Information_Core__(BRCA2):4075&base_change%3Ddel_GT|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2437522	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359405	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Division_Human_Genetics,Medical_University_Innsbruck|Counsyl|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Baylor_Genetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-05-31|2002-05-29|2015-02-11|2014-08-25|2016-04-21|2016-04-22|2015-10-02|2016-09-23|0000-00-00|2014-10-10|2015-09-21|2017-04-04|2019-02-21|2019-04-12|2019-01-09|2016-02-08|2014-01-31|0000-00-00|2015-06-22|2018-05-29|2016-06-15|2014-09-16|2017-02-23|2019-05-02|2017-11-01|2017-05-30|2017-03-07|2018-12-01|2019-05-06	2015-08-20|2014-03-28|2015-02-11|2015-03-11|2016-04-21|2016-06-09|2016-10-28|2017-10-18|2018-04-04|2018-04-17|2018-04-09|2018-06-14|2019-08-02|2019-09-13|2019-03-28|2019-03-21|2017-08-04|2017-04-19|2018-01-25|2020-02-26|2017-10-26|2015-02-05|2017-02-23|2020-03-06|2017-11-21|2018-09-19|2018-04-30|2019-02-22|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054045|SCV000146307|SCV000212018|SCV000220629|SCV000267761|SCV000282384|SCV000326923|SCV000605697|SCV000733250|SCV000743291|SCV000744446|SCV000839910|SCV000993558|SCV001132517|SCV000072293|SCV000271326|SCV000587682|SCV000591878|SCV000694724|SCV000186025|SCV000683584|SCV000210739|SCV000541010|SCV000296700|SCV000693565|SCV000708829|SCV000902200|SCV000923787|SCV001160398	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_provided|not_provided|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms|not_specified	|||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||The_c.3847_3848del_(p.Val1283Lysfs*2)_variant_has_been_detected_in_several_patients_and_families_with_breast_and/or_ovarian_cancer_[PMID_8589730,_22752604,_24504028,_22006311,_21324516,_sometimes_reported_as_4075delGT],_colorectal_cancer_[PMID_24814045]_and_prostate_cancer_[PMID_21952622]._This_variant_has_been_reported_in_11_heterozygous_individuals_from_the_ExAC_population_database_(http://exac.broadinstitute.org/variant/13-32912337-CTG-C)._This_2_bp_deletion_is_located_in_exon_11,_and_leads_to_the_creation_of_a_frameshift_and_a_premature_stop_codon_at_amino_acid_position._This_variant_is_expected_to_result_in_a_loss_of_function_of_the_protein_and_is_thus_classified_as_pathogenic._This_pathogenic_variant_in_the_BRCA2_gene_is_also_considered_medically_actionable_[ACMG59,_PMID_27854360]|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val1283Lysfs*2)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs746229647,_ExAC_0.02%)._This_variant_has_been_reported_in_several_individuals_and_families_affected_with_breast,_ovarian,_and_prostate_cancer_(PMID:_8589730,_21324516,_23199084,_21952622)._It_was_also_shown_to_segregate_with_disease_in_a_family_with_colorectal_and_other_cancers_(PMID:_24814045)._This_variant_is_also_known_as_4075delGT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37859)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Val1283fs_variant_in_BRCA2_has_been_reported_in_>35_individuals_with_BRCA2_-associated_cancers_(Wang_2012,_Breast_Cancer_Information_Core_(BIC)_database)._This_variant_has_also_been_identified_in_11/50346_European_chromosomes_by_the_Ex_ome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs803594_05):_however,_this_frequency_is_low_enough_to_be_consistent_with_the_frequency_o_f_hereditary_breast_and_ovarian_cancer_(HBOC)_in_the_general_population._This_va_riant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1283_and_leads_to_a_premature_termination_codon_2_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncate_d_or_absent_protein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_estab_lished_disease_mechanism_for_HBOC._In_summary,_this_variant_meets_our_criteria_t_o_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upo_n_the_predicted_impact_to_the_protein.|||Variant_summary:_This_frameshift_variant_leads_to_premature_truncation_at_exon_11._In_ExAC,_it_has_been_observed_at_allele_frequency_of_11/94102_chromosomes._This_frequency_is_lower_than_the_maximal_expected_allele_frequency_for_a_pathogenic_BRCA2_variant_based_on_the_disease_prevalence_of_HBOC._It_has_been_recurrently_observed_in_patients_with_HBOC._This_supports_that_the_11_individuals_with_this_variant_in_ExAC_are_very_likely_to_represent_as_subclinical_cases_and/or_reduced_penetrance._Multiple_labs_(via_ClinVar)_classify_the_variant_as_pathogenic._Therefore,_based_on_the_variant's_nature_and_location,_and_population_and_patient_data,_this_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_BRCA2_c.3847_3848delGT_at_the_cDNA_level_and_p.Val1283LysfsX2_(V1283KfsX2)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AACT{delGT}AAGT._The_deletion_causes_a_frameshift,_which_changes_a_Valine_to_a_Lysine_at_codon_1283_in_exon_11,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_mutation_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.3847_3848delGT,_previously_reported_as_4075delGT,_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Tavtigian_1996)._BRCA2_c.3847_3848delGT_is_also_a_common_mutation_in_Norwegian_and_Danish_populations_(Janavicius_2010)._We_therefore_consider_this_mutation_to_be_pathogenic._and_is_indicative_of_Hereditary_Breast_and_Ovarian_Cancer_(HBOC)_syndrome,_an_autosomal_dominant_condition_that_predisposes_to_breast_and_ovarian_cancer_as_well_as_other_cancers._The_predominant_BRCA2-related_cancer_risks_for_women_who_have_not_been_diagnosed_with_cancer_have_been_estimated_as_41%_-_84%_lifetime_risk_for_breast_cancer_and_11%_-_27%_lifetime_risk_for_ovarian_cancer_(Ford_1998,_Risch_2006)._BRCA2_mutations_have_also_been_reported_in_women_with_fallopian_tube_carcinoma,_primary_peritoneal_carcinoma,_and_uterine_serous_carcinoma_(Levine_2003,_Biron-Shental_2006)._Women_with_BRCA1/2_mutations_also_have_an_increased_risk_for_contralateral_breast_cancer._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_under_age_40_have_a_21-31%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_63%_risk_to_develop_a_second_breast_cancer_within_25_years._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_between_ages_40_and_50_have_an_11-13%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_44-49%_risk_within_25_years._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_after_age_50_have_an_8%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_20%_risk_within_25_years_(Graeser_2009)._Other_cancer_risks_associated_with_a_BRCA2_mutation_include_up_to_a_7%_risk_for_pancreatic_cancer_(Ozcelik_1997,_The_Breast_Cancer_Linkage_Consortium_1999),_up_to_a_34%_risk_for_prostate_cancer_in_male_carriers_(Thompson_2001),_and_up_to_a_7%_risk_for_male_breast_cancer_(Liede_2004)._The_variant_is_found_in_BRCA,HIRISK-BR-HEREDIC,BR-OV-HEREDIC_panel(s).||The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|||||The_BRCA2_c.3847_3848delGT:_p.Val1283fs_variant_(rs746229647),_also_known_as_4075delGT,_is_published_in_the_medical_literature_in_individuals_with_several_types_of_cancer_and_families_with_HBOC_(Borg_2010,_Garre_2015,_Susswein_2016,_Wojcik_2016)._The_variant_is_classified_as_pathogenic_in_the_ClinVar_database_(Variation_ID:_37859)_and_is_absent_from_general_population_databases_(1000_Genomes_Project,_Exome_Variant_Server,_and_Genome_Aggregation_Database),_indicating_it_is_not_a_common_polymorphism._This_variant_deletes_two_nucleotides,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Borg_A_et_al._Characterization_of_BRCA1_and_BRCA2_deleterious_mutations_and_variants_of_unknown_clinical_significance_in_unilateral_and_bilateral_breast_cancer:_the_WECARE_study._Hum_Mutat._2010_Mar:31(3):E1200-40._Garre_P_et_al._BRCA2_gene:_a_candidate_for_clinical_testing_in_familial_colorectal_cancer_type_X._Clin_Genet._2015_Jun:87(6):582-7._Susswein_LR_et_al._Pathogenic_and_likely_pathogenic_variant_prevalence_among_the_first_10,000_patients_referred_for_next-generation_cancer_panel_testing._Genet_Med._2016_Aug:18(8):823-32._Wojcik_P_et_al._Recurrent_mutations_of_BRCA1,_BRCA2_and_PALB2_in_the_population_of_breast_and_ovarian_cancer_patients_in_Southern_Poland._Hered_Cancer_Clin_Pract._2016_Feb_3:14:5.
NM_000059.3:c.3860del	BRCA2	frameshift_variant	82472	2	NA	NA	-	-	-	-	51545	66213	_familial_2|Tumor_susceptibility_linked_to_germline_BAP1_mutations|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:C3280492,OMIM:614327|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32912352del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):4082&base_change%3Ddel_A|Breast_Cancer_Information_Core__(BRCA2):4088&base_change%3Ddel_A	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359406	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Department_of_Medical_Genetics,Oslo_University_Hospital|Counsyl|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Baylor_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-14|2014-01-31|2010-05-25|2004-11-25|2016-09-08|2015-10-02|2017-01-01|2015-07-01|2017-01-20|2013-07-15|2017-03-16|2017-06-15|2017-05-24|2015-07-23|2017-02-23|2010-01-19	2019-03-28|2017-08-04|2013-06-26|2014-03-28|2016-09-13|2016-10-28|2017-03-15|2017-10-18|2017-06-22|2020-02-26|2017-10-26|2019-01-29|2017-08-01|2016-05-09|2017-02-23|2018-07-18	criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000072301|SCV000587685|SCV000109113|SCV000146317|SCV000300674|SCV000326927|SCV000577952|SCV000605632|SCV000677676|SCV000186537|SCV000683586|SCV000210740|SCV000600567|SCV000277411|SCV000541004|SCV000863680	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Tumor_susceptibility_linked_to_germline_BAP1_mutations|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn1287Ilefs*6)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_several_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_11857748,_24156927,_23199084,_12942367,_27393621,_12955716)._This_variant_has_also_been_reported_as_4082delA_and_4088delA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_51545)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_BRCA2_c.3860delA_at_the_cDNA_level_and_p.Asn1287IlefsX6_(N1287IfsX6)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_GAAAAAA[A]TAAT._The_deletion_causes_a_frameshift,_which_changes_an_Asparagine_to_an_Isoleucine_at_codon_1287,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.3860delA,_previously_reported_as_BRCA2_4088delA_using_alternate_nomenclature,_has_been_reported_in_association_with_familial_breast_and/or_ovarian_cancer_(Llort_2002,_Perkowska_2003,_Papi_2009,_Janavicius_2010,_Tea_2014,_Kim_2016)._We_therefore_consider_this_variant_to_be_pathogenic.||||
NM_000059.3:c.4258del	BRCA2	frameshift_variant	100580	2	NA	NA	-	-	-	-	51617	66285	_familial_2|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN517202	-	NC_000013.10:g.32912750del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:198193|Breast_Cancer_Information_Core__(BRCA2):4486&base_change%3Ddel_G	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359436	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Ambry_Genetics|Color|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|GeneDx|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-04-17|2002-05-29|2014-10-20|2016-09-08|2015-10-02|2015-07-01|2018-11-19|2017-02-07|2014-01-31|2017-07-05|2018-08-06	2013-06-26|2014-03-28|2015-03-11|2016-09-13|2016-10-28|2017-10-18|2020-02-26|2018-11-06|2017-08-04|2019-01-29|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline	SCV000109119|SCV000146396|SCV000220817|SCV000300729|SCV000326996|SCV000605650|SCV000216175|SCV000906907|SCV000587706|SCV000778951|SCV000883495	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_specified	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_deletion_of_one_nucleotide_in_BRCA2_is_denoted_c.4258delG_at_the_cDNA_level_and_p.Asp1420IlefsX28_(D1420IfsX28)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_TAAAA[delG]ATTT._The_deletion_causes_a_frameshift_which_changes_an_Aspartic_Acid_to_an_Isoleucine_at_codon_1420,_and_creates_a_premature_stop_codon_at_position_28_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.4258delG_has_been_observed_in_association_with_breast_cancer_and_is_known_to_be_a_pathogenic_founder_variant_in_the_Swedish_population_(Hakansson_1997,_Haraldsson_1998,_Loman_2001,_Janavicius_2010)._We_consider_this_variant_to_be_pathogenic.|The_BRCA2_c.4258delG:_p.Asp1420fs_variant_(rs80359436),_also_known_as_4486delG,_is_reported_in_the_literature_in_families_with_breast_cancer_(Hakansson_1997,_Winter_2016),_and_is_commonly_found_in_the_Swedish_population_(Janavicius_2010)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_51617),_and_is_observed_in_the_general_population_with_a_low_overall_allele_frequency_of_0.0008%_(2/240284_alleles)_in_the_Genome_Aggregation_Database._This_variant_deletes_a_single_nucleotide_causing_a_frameshift,_and_is_predicted_to_result_in_a_truncated_protein_or_absent_transcript._Based_on_the_above_information,_this_variant_is_considered_pathogenic._REFERENCES_Hakansson_S_et_al._Moderate_frequency_of_BRCA1_and_BRCA2_germ-line_mutations_in_Scandinavian_familial_breast_cancer._Am_J_Hum_Genet._1997_May:60(5):1068-78._Janavicius_R._Founder_BRCA1/2_mutations_in_the_Europe:_implications_for_hereditary_breast-ovarian_cancer_prevention_and_control._EPMA_J._2010_Sep:1(3):397-412._Winter_C_et_al._Targeted_sequencing_of_BRCA1_and_BRCA2_across_a_large_unselected_breast_cancer_cohort_suggests_that_one-third_of_mutations_are_somatic._Ann_Oncol._2016_Aug:27(8):1532-8.
NM_000059.3:c.4284dup	BRCA2	frameshift_variant	100604	1	NA	NA	-	-	-	-	37892	46448	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32912776dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Breast_Cancer_Information_Core__(BRCA2):4512&base_change%3Dins_T|Breast_Cancer_Information_Core__(BRCA2):4510&base_change%3Dins_T|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2408080|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto:289090	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359439	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|GeneKor_MSA|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-10-30|2002-05-29|2014-12-29|2016-09-08|2015-10-02|2018-01-30|2018-11-15|2016-02-08|2014-01-31|2016-07-21|2017-11-01|2017-03-07|2019-04-16|2015-07-21|2019-01-17|2015-02-20	2015-12-29|2014-03-28|2015-03-11|2016-09-13|2016-10-28|2018-06-14|2019-03-28|2019-03-21|2017-08-04|2017-04-19|2017-11-21|2018-01-25|2020-02-26|2016-07-05|2019-01-29|2018-08-31	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054078|SCV000146401|SCV000220993|SCV000300733|SCV000327007|SCV000839927|SCV000072400|SCV000271327|SCV000587708|SCV000591899|SCV000693567|SCV000694762|SCV000184901|SCV000292168|SCV000210748|SCV000296728	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_c.4284_4285insT_(p.Gln1429Serfs*9)_variant_in_the_BRCA2_gene_has_been_reported_in_multiple_breast_cancer_and_ovarian_cancer_patient_[PMID:_21120943,_22085629,_24728189]_while_only_observed_once_in_general_population_according_to_gnomad_database._This_variant_is_predicted_to_cause_loss_of_function_of_normal_protein_through_mRNA_decay_or_producing_a_truncated_protein,_which_is_a_known_disease_mechanism_for_this_gene._Based_on_the_current_evidences,_this_c.4284_4285insT_(p.Gln1429Serfs*9)_variant_in_the_BRCA2_gene_is_classified_as_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln1429Serfs*9)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_11179017,_20373018,_22085629,_24156927,_24728189)._This_variant_is_also_known_as_4510insT_and_4512insT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37892)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Gln1429fs_variant_in_BRCA2_has_been_reported_in_>10_individuals_with_BRCA2_-associated_cancers_(Risch_2001,_Zuradelli_2010,_Zhang_2011,_Koumpis_2011,_Caux-_Moncoutier_2011,_Song_2014,_Breast_Cancer_Information_Core_(BIC)_database)_and_w_as_absent_from_large_population_studies._This_variant_is_predicted_to_cause_a_fr_ameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1_429_and_leads_to_a_premature_termination_codon_9_amino_acids_downstream._This_al_teration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygou_s_loss_of_function_of_the_BRCA2_gene_is_an_established_disease_mechanism_in_here_ditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_variant_was_classifie_d_as_Pathogenic_on_Sep_8,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(Clin_Var_SCV000300733.2)._In_summary,_this_variant_meets_our_criteria_to_be_classifie_d_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner.||||Variant_summary:_The_BRCA2_c.4284dupT_(p.Gln1429Serfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.4398_4402delACATT_[p.Leu1466fs)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_is_absent_from_the_large_control_population_database_ExAC_(0/122560_control_chromosomes)._Several_publications_have_identified_the_variant_in_affected_individuals._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_have_cited_this_variant_in_patients_and_have_classified_it_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.4284dupT_at_the_cDNA_level_and_p.Gln1429SerfsX9_(Q1429SfsX9)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_ATTTTT[dupT]CAGA._The_duplication_causes_a_frameshift,_which_changes_a_Glutamine_to_a_Serine_at_codon_1429,_and_creates_a_premature_stop_codon_at_position_9_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.4284dupT,_previously_reported_as_4510insT_or_4512insT_using_alternate_nomenclature,_has_been_observed_in_association_with_breast_and_ovarian_cancer_(Risch_2001,_Zuradelli_2010,_Koumpis_2011,_Song_2014,_Tea_2014)._We_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.4398_4402del	BRCA2	frameshift_variant	101190	1	NA	NA	-	-	-	-	51640	66308	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32912890_32912894del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):4626&base_change%3Ddel_ACATT|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2483424	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359444	-	Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-18|2015-06-16|2019-07-02|2012-05-01|2002-05-29|2014-11-03|2016-04-22|2015-11-18|2015-10-02|2016-08-30|2019-05-01|2017-05-22|2018-04-26|2015-11-18	2019-03-28|2017-04-19|2019-09-24|2013-12-30|2014-03-28|2016-04-21|2016-06-09|2016-07-18|2016-10-28|2016-11-23|2020-02-26|2017-10-26|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline	SCV000072417|SCV000591902|SCV000694767|SCV000115178|SCV000146417|SCV000195984|SCV000282391|SCV000296657|SCV000327023|SCV000489178|SCV000186008|SCV000683615|SCV000210749|SCV000887815	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu1466Phefs*2)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs755956766,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_breast,_ovarian,_and_prostate_cancer_(PMID:_17700570,_24504028,_26681312,_27831900,_24728189,Â¬â€ 27406733)._This_variant_is_also_known_as_4625_4629delACATT_and_1465_1467del_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_51640)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRCA2_c.4398_4402delACATT_(p.Leu1466PhefsX2)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory._The_variant_allele_was_found_at_a_frequency_of_4e-06_in_249696_control_chromosomes._c.4398_4402delACATT_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Breast_and_Ovarian_Cancer_(Alsop_2012,_Song_2014,_George_2016,_Susswein_2016,_Rebbeck_2018)_and_prostate_cancer_(Agalliu_2007)._One_publication,_George_2016)._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Nine_ClinVar_submissions_including_one_expert_panel,_ENIGMA,_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_deletion_of_five_nucleotides_in_BRCA2_is_denoted_c.4398_4402delACATT_at_the_cDNA_level_and_p.Leu1466PhefsX2_(L1466FfsX2)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AATT[delACATT]CTGA._The_deletion_causes_a_frameshift_which_changes_a_Leucine_to_a_Phenylalanine_at_codon_1466_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.4398_4402delACATT,_previously_reported_as_4625_4629delACATT_and_1465_1467del_using_alternate_nomenclature,_has_been_observed_in_individuals_with_ovarian_and_prostate_cancer_(Agalliu_2007,_Cunningham_2014,_Song_2014,_Natarajan_2016)._We_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.4415_4418del	BRCA2	frameshift_variant	101702	1	NA	NA	-	-	-	-	37902	46458	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32912903_32912906AGAA[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2455804	-	BRCA2:675	SO:0001589|frameshift_variant	1	397507333	-	Sharing_Clinical_Reports_Project_(SCRP)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Color|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-05-01|2016-09-08|2015-10-02|2016-11-14|2018-10-07|2014-01-31|2018-04-02|2018-07-02|2015-04-20|2018-02-15|2018-12-27	2013-12-30|2016-09-13|2016-10-28|2016-11-23|2019-03-28|2017-08-04|2019-04-24|2019-01-29|2018-08-31|2018-11-06|2020-02-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000054088|SCV000300744|SCV000327030|SCV000489707|SCV000072423|SCV000587712|SCV000918980|SCV000279255|SCV000296683|SCV000903714|SCV001184189	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_deletes_4_nucleotides_from_exon_11_of_the_BRCA2_mRNA_(c.4415_4418delAGAA),_causing_a_frameshift_at_codon_1472._This_creates_a_premature_translational_stop_signal_(p.Lys1472Thrfs*6)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer_and/or_ovarian_cancer_(PMID:_24010542,_26681682,_15918047,_15131399)._This_variant_has_also_been_reported_in_an_individual_with_colorectal_cancer_(PMID:_28195393)._This_variant_is_also_known_as_4643del4_or_4643delAGAA_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRCA2_c.4415_4418delAGAA_(p.Lys1472ThrfsX6)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_243794_control_chromosomes_(gnomAD_and_publications)._c.4415_4418delAGAA_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Lubinski_2004,_Pietschmann_2005,_Konstantopoulou_2014,_Eccles_2016)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_deletion_of_four_nucleotides_in_BRCA2_is_denoted_c.4415_4418delAGAA_at_the_cDNA_level_and_p.Lys1472ThrfsX6_(K1472TfsX6)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AGAA[delAGAA]CAAA._The_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_a_Threonine_at_codon_1472,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.4415_4418delAGAA,_previously_reported_as_BRCA2_4643del4_and_4643delAGAA_using_alternate_nomenclature,_has_been_observed_in_individuals_with_familial_or_early-onset_breast_cancer_(Pietschmann_2005,_Konstantopoulou_2014,_Eccles_2016)._We_consider_this_variant_to_be_pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation
NM_000059.3:c.4414_4415del	BRCA2	frameshift_variant	101720	1	NA	NA	-	-	-	-	37901	46457	_familial_2	-	OMIM:612555	-	NC_000013.10:g.32912906_32912907del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	397507332	-	_c/o_University_of_Cambridge	Pathogenic|Pathogenic|Pathogenic	2009-08-12|2016-09-08|2015-10-02	2012-08-22|2016-09-13|2016-10-28	_single_submitter	germline|germline|germline	SCV000054087|SCV000300743|SCV000327029	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|
NM_000059.3:c.4478_4481del	BRCA2	frameshift_variant	102094	4	NA	NA	-	-	-	-	51653	66321	_familial_2|Diffuse_intrinsic_pontine_glioma|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:C2986658|MedGen:CN169374|MedGen:CN517202	-	NC_000013.10:g.32912966_32912969AAAG[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:141381|Breast_Cancer_Information_Core__(BRCA2):4706&base_change%3Ddel_AAAG|Breast_Cancer_Information_Core__(BRCA2):4705&base_change%3Ddel_GAAA|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2831670	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359454	-	GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Integrated_Genetics/Laboratory_Corporation_of_America|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-17|2016-10-12|2013-02-20|2002-05-29|2014-09-04|2016-04-22|2015-10-02|2018-05-30|2016-12-01|2018-12-21|2014-01-31|2017-04-20|2016-05-04|2016-11-30|2017-06-09	2019-01-29|2018-08-31|2015-12-29|2014-03-28|2015-03-11|2016-06-09|2016-10-28|2020-02-26|2017-10-26|2019-03-28|2017-08-04|2017-08-04|2018-01-25|2017-06-30|2018-08-09	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000210810|SCV000600589|SCV000109124|SCV000146433|SCV000220668|SCV000282393|SCV000327042|SCV000186011|SCV000683623|SCV000072434|SCV000587714|SCV000588092|SCV000694775|SCV000602836|SCV000853214	not_provided|not_provided|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_specified|Diffuse_intrinsic_pontine_glioma	This_pathogenic_variant_is_denoted_BRCA2_c.4478_4481delAAAG_at_the_cDNA_level_and_p.Glu1493ValfsX10_(E1493VfsX10)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AAAG[delAAAG]TGTC._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_a_Valine_at_codon_1493,_and_creates_a_premature_stop_codon_at_position_10_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.4478_4481delAAAG,_previously_reported_as_4706_4709delAAAG,_4706del4,_or_4705del4_using_alternate_nomenclature,_has_been_observed_in_association_with_hereditary_breast_and_ovarian_cancer_(Tavtigian_1996,_Meindl_2002,_Ginsburg_2011,_Zhang_2011,_Kim_2012,_Dudley_2018)_as_well_as_early-onset_prostate_cancer_(Kote-Jarai_2011)._We_consider_this_variant_to_be_pathogenic.|||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu1493Valfs*10)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_and_families_affected_with_female_breast_and_ovarian_cancer,_male_breast_cancer,_and_prostate_cancer_(PMID:_8589730,_21324516,_22798144,_21952622,_15131399,_11179017,_20927582)._This_variant_is_also_known_as_4706del4_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_51653)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA2_variant,_c.4478_4481delAAAG_(p.Glu1493Valfs),_causes_a_frameshift_resulting_in_a_premature_stop_codon,_a_known_mechanism_for_disease,_as_these_types_of_variants_are_predicted_to_cause_transcript_degradation_through_nonsense_mediated_decay_or_produce_a_truncated_protein._The_variant_of_interest_was_not_observed_in_controls_(ExAC,_1000_Gs,_or_ESP)_and_has_been_reported_in_multiple_affected_individuals_via_publications._In_addition,_multiple_reputable_clinical_laboratories/databases_cite_the_variant_with_a_classification_of_pathogenic._Therefore,_the_variant_of_interest_is_classified_as_Pathogenic.||This_is_a_frameshift_alteration_in_which_four_nucleotides_are_deleted_(coding_nucleotides_4478_through_4481)_and_is_predicted_to_change_a_Glutamic_Acid_to_a_Valine_at_amino_acid_codon_1493,_shift_the_reading_frame_and_result_in_a_premature_stop_codon_10_amino_acids_downstream._Classification_criteria:_PVS1,_PM2,_PP1.
NM_000059.3:c.4593dup	BRCA2	frameshift_variant	102236	1	NA	NA	-	-	-	-	51681	66349	_familial_2	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32913085dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	397507731	-	_c/o_University_of_Cambridge|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-11-28|2016-09-08|2015-10-02|2018-12-13	2013-06-26|2016-09-13|2016-10-28|2020-02-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000109534|SCV000300770|SCV000327058|SCV001184522	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000059.3:c.4631dup	BRCA2	frameshift_variant	102338	1	15406	1	-	-	-	-	37912	46468	_familial_2|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32913123dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2220274|Breast_Cancer_Information_Core__(BRCA2):4859&base_change%3Dins_A	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359460	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2007-08-15|2003-12-23|2016-09-08|2015-10-02|2018-08-07|2014-01-31|2018-02-19|2018-06-11|2015-04-07|2019-08-23|2017-11-15|2017-04-23|2019-01-04	2012-07-24|2014-03-28|2016-09-13|2016-10-28|2019-03-28|2017-08-04|2019-04-24|2020-02-26|2018-11-06|2020-03-06|2019-01-29|2018-04-30|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054098|SCV000146458|SCV000300774|SCV000327062|SCV000072469|SCV000587718|SCV000916854|SCV000187408|SCV000911166|SCV000296705|SCV000329608|SCV000901110|SCV001158114	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Breast_and/or_ovarian_cancer|not_specified	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn1544Lysfs*4)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs771851449,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_breast/ovarian_cancer,_and_an_individual_undergoing_testing_for_Lynch_syndrome_Â¬â€ (PMID:_17688236,_23683081,_25980754,_24728189)._This_variant_is_also_known_as_4859insA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37912)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRCA2_c.4631dupA_(p.Asn1544LysfsX4)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_was_absent_in_245418_control_chromosomes_(gnomAD)._The_c.4631dupA_variant_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Multiple_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_classify_the_variant_as_pathogenic,_in_addition,_multiple_reliable_databases_also_classify_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.4631dupA_at_the_cDNA_level_and_p.Asn1544LysfsX4_(N1544KfsX4)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_braces,_is_GAAAA[A]CCTT._The_duplication_causes_a_frameshift,_which_changes_an_Asparagine_to_a_Lysine_at_codon_1544,_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.4631dupA,_previously_published_as_BRCA2_4859dupA_using_alternate_nomenclature,_has_been_reported_in_association_with_Hereditary_Breast_Ovarian_Cancer_Syndrome_(Ramus_2007,_Blay_2013)._We_consider_this_variant_to_be_pathogenic.||The_BRCA2_c.4631dupA:_p.Asn1544fs_variant_(rs80359460)_is_reported_in_the_literature_in_multiple_individuals_affected_with_breast_and/or_ovarian_cancer_(Blay_2013,_Ramus_2007,_Song_2014,_Yurgelun_2015)._This_variant_is_found_on_only_two_chromosomes_in_the_Genome_Aggregation_Database,_indicating_it_is_not_a_common_polymorphism,_and_it_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_37912)._This_variant_causes_a_frameshift_by_inserting_a_single_nucleotide,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Blay_P_et_al._Mutational_analysis_of_BRCA1_and_BRCA2_in_hereditary_breast_and_ovarian_cancer_families_from_Asturias_(Northern_Spain)._BMC_Cancer._2013_May_17:13:243._Ramus_SJ_et_al._Contribution_of_BRCA1_and_BRCA2_mutations_to_inherited_ovarian_cancer._Hum_Mutat._2007_Dec:28(12):1207-15._Song_H_et_al._The_contribution_of_deleterious_germline_mutations_in_BRCA1,_BRCA2_and_the_mismatch_repair_genes_to_ovarian_cancer_in_the_population._Hum_Mol_Genet._2014_Sep_1:23(17):4703-9._Yurgelun_MB_et_al._Identification_of_a_Variety_of_Mutations_in_Cancer_Predisposition_Genes_in_Patients_With_Suspected_Lynch_Syndrome._Gastroenterology._2015_Sep:149(3):604-13.e20.
NM_000059.3:c.4808dup	BRCA2	frameshift_variant	102234	2	NA	NA	-	-	-	-	51719	66387	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32913300dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Breast_Cancer_Information_Core__(BRCA2):5036&base_change%3Dins_A	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359466	-	Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-06-20|2016-09-08|2019-01-11|2019-01-22|2017-06-16	2014-03-28|2016-09-13|2019-01-29|2019-09-24|2020-02-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000146485|SCV000300785|SCV000329821|SCV000918869|SCV001184908	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.4808dupA_at_the_cDNA_level_and_p.Asn1603LysfsX6_(N1603KfsX6)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_TAAAA[dupA]CCTT._The_duplication_causes_a_frameshift_which_changes_an_Asparagine_to_a_Lysine_at_codon_1603,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.4808dupA,_also_defined_as_5036dupA_and_5032insA_by_alternate_nomenclature,_has_been_reported_in_at_least_one_family_with_hereditary_breast_and_ovarian_cancer_(Gayther_1997)._We_consider_this_variant_to_be_pathogenic.|Variant_summary:_BRCA2_c.4808dupA_(p.Asn1603LysfsX6)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.4876_4877delAA,_p.Asn1626fsX12:_c.4936_4939delGAAA,_p.Glu1646fsX23:_c.4965C>G,_p.Tyr1655X)._The_variant_allele_was_found_at_a_frequency_of_8.2e-06_in_245372_control_chromosomes_(gnomAD)._c.4808dupA_has_been_reported_in_the_literature_in_a_family_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Gayther_1997)._Two_ClinVar_submissions_from_a_clinical_diagnostic_laboratory_and_a_reputable_database_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000059.3:c.4821_4822del	BRCA2	frameshift_variant	102218	2	NA	NA	-	-	-	-	254541	248975	_familial_2	-	OMIM:612555	-	NC_000013.10:g.32913313_32913314del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	769017108	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)	Pathogenic	2016-09-08	2016-09-13	reviewed_by_expert_panel	germline	SCV000300787	_familial_2	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.
NM_000059.3:c.4829_4830del	BRCA2	frameshift_variant	102218	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.4859T>G	BRCA2	stop_gained	102174	1	NA	NA	5	3	rs80358710	Breast-ovarian cancer, familial 2	51730	66398	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32913351T>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80358710	-	Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-05-29|2016-09-08|2015-10-02|2014-01-31|2016-10-05	2014-03-28|2016-09-13|2016-10-28|2017-08-04|2019-01-29	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000146496|SCV000300793|SCV000327098|SCV000587728|SCV000779374	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_variant_is_denoted_BRCA2_c.4859T>G_at_the_cDNA_level_and_p.Leu1620Ter_(L1620X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_has_been_published_as_BRCA2_c.5087T>G._The_substitution_creates_a_nonsense_variant,_which_changes_a_Leucine_to_a_premature_stop_codon_(TTA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_with_ovarian_cancer_and_is_considered_pathogenic_(Risch_2006,_Zhang_2011).
NM_000059.3:c.4876_4877del	BRCA2	frameshift_variant	102096	2	NA	NA	-	-	-	-	37929	46485	_familial_2|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32913368_32913369del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):5104&base_change%3Ddel_AA	-	BRCA2:675	SO:0001589|frameshift_variant	17	80359470	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|GenomeConnect,_ClinGen|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-06-04|2002-05-29|2016-04-21|2016-04-22|2015-10-02|2016-07-06|2018-12-28|2014-01-31|2016-10-04|2017-06-27|0000-00-00|2018-09-19|2017-03-01|2018-04-26|2019-05-17|2015-08-12	2015-08-20|2014-03-28|2016-04-21|2016-06-09|2016-10-28|2016-11-23|2019-03-28|2017-08-04|2019-03-21|2018-01-25|2018-03-13|2020-02-26|2017-10-26|2019-01-29|2020-03-06|2018-04-30	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|maternal|germline|germline|germline|germline|germline	SCV000054115|SCV000146498|SCV000267772|SCV000282396|SCV000327099|SCV000488854|SCV000072523|SCV000587729|SCV000605802|SCV000694809|SCV000840192|SCV000186009|SCV000683659|SCV000210757|SCV000296684|SCV000219343	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Breast_and/or_ovarian_cancer	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn1626Serfs*12)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_with_breast,_ovarian,_and_prostate_cancer_(PMID:_11179017,_21952622,_24556621,_23524863,_26787237,_28008555)._This_variant_is_also_known_as_c.4874_4875delAA,_4877delAA,_5102delAA,_and_5104delAA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37929)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Asn1626fs_variant_in_BRCA2_has_been_reported_in_>20_individuals_with_BRCA2_-associated_cancers_(Risch_2001,_Kote-Jarai_2011,_Gonzalez-Garay_2013,_Leongamor_nlert_2014,_Meric-Bernstam_2016,_Breast_Cancer_Information_Core_(BIC)_database)_and_was_absent_from_large_population_studies._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_posit_ion_1626_and_leads_to_a_premature_termination_codon_12_amino_acids_downstream._T_his_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heter_ozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_disease_mechanism_i_n_individuals_with_hereditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_thi_s_variant_was_classified_as_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000282396.1)._In_summary,_the_p.Asn1626fs_varia_nt_meets_our_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_do_minant_manner.|Variant_summary:_The_BRCA2_c.4876_4877delAA_(p.Asn1626Serfs)_variant_(alternatively_also_known_as_5102delAA)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Val1814X,_p.Lys1872X,_p.Cys1885X,_etc.)._This_variant_is_absent_in_122720_control_chromosomes_(including_ExAC)._This_variant_has_been_reported_in_several_HBOC_patients_in_literature_and_clinical_databases._It_has_also_been_reported_in_patients_with_prostate_cancer_(Kote-Jarai_2011)._In_addition,_several_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_two_nucleotides_in_BRCA2_is_denoted_c.4876_4877delAA_at_the_cDNA_level_and_p.Asn1626SerfsX12_(N1626SfsX12)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA2_5102delAA_or_5104delAA._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TGAA[delAA]TCTC._The_deletion_causes_a_frameshift,_which_changes_an_Asparagine_to_a_Serine_at_codon_1626_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.4876_4877delAA_has_been_reported_in_association_with_breast,_ovarian_and_prostate_cancer,_as_well_as_melanoma_(Risch_2001,_Walsh_2011,_Leongamornlert_2014,_Meric-Bernstam_2016)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|
NM_000059.3:c.4889C>G	BRCA2	stop_gained	101896	1	NA	NA	5&5&5&5	1&3&1&1	rs80358711	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&not provided	51732	66400	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32913381C>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80358711	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Ambry_Genetics|Color|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|GeneKor_MSA	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-07|2014-01-31|2016-10-04|2011-02-08|2002-05-29|2015-08-21|2016-09-08|2015-10-02|2017-01-04|2018-12-24|2015-04-06|2016-11-04|2019-01-16|2017-11-01	2019-03-28|2017-08-04|2019-03-21|2015-08-20|2014-03-28|2016-07-18|2016-09-13|2016-10-28|2017-06-22|2020-02-26|2017-01-26|2018-09-19|2019-01-29|2017-11-21	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline	SCV000072525|SCV000587730|SCV000605799|SCV000109137|SCV000146499|SCV000296626|SCV000300794|SCV000327100|SCV000677680|SCV000186010|SCV000537669|SCV000225188|SCV000321464|SCV000693568	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1630_(p.Ser1630*)_of_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_families_and_individuals_affected_with_breast_cancer_(PMID:Â¬â€ 12920083,Â¬â€ 22762150,Â¬â€ 17624602).Â¬â€ This_variant_is_also_known_as_5117C>G_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Ser1630X_variant_in_BRCA2_has_been_reported_in_at_least_15_individuals_wit_h_BRCA2-associated_cancers_(Castera_2014,_Castro_2013,_Lecarpentier_2012,_Ozceli_k_2003,_Zugazagoitia_2014,_Breast_Cancer_Information_Core_database,_www.research_.nhgri.nih.gov/bic/)._This_variant_has_been_identified_in_2/65832_European_chrom_osomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org_:_dbSNP_rs80358711)._This_frequency_is_low_enough_to_be_consistent_with_the_freq_uency_of_hereditary_breast_and_ovarian_cancer_(HBOC)_in_the_general_population._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_1630,_w_hich_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_disease_mechanism_in_HBOC._In_addi_tion,_this_variant_was_classified_as_Pathogenic_on_September_8,_2016_by_the_Clin_Gen-approved_ENIGMA_expert_panel_(ClinVar_SCV000300794.2)._In_summary,_this_vari_ant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_domin_ant_manner_based_upon_the_predicted_impact_to_the_protein.||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_pathogenic_variant_is_denoted_BRCA2_c.4889C>G_at_the_cDNA_level_and_p.Ser1630Ter_(S1630X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_BRCA2_5117C>G_using_alternate_nomenclature,_has_been_reported_in_individuals_and_families_with_breast_and/or_ovarian_cancer_(Ozcelik_2003,_Claus_2005,_Malone_2006,_Rodriguez_2012,_Castera_2014,_Zugazagoitia_2014,_Pellegrino_2016)._We_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.5073dup	BRCA2	frameshift_variant	96262	3	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.5110_5113del	BRCA2	frameshift_variant	96718	1	NA	NA	-	-	-	-	246151	244852	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32913598_32913601AGAA[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	BRCA2:675	SO:0001587|nonsense	1	879254123	-	_c/o_University_of_Cambridge|Counsyl|Invitae|Color|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-11-17|2016-10-18|2015-10-02|2017-01-03|2018-08-20|2018-05-21|2018-02-14	2019-01-29|2016-10-18|2016-10-28|2017-06-22|2019-03-28|2018-11-06|2020-02-26	criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline	SCV000293579|SCV000324297|SCV000327131|SCV000677844|SCV000549606|SCV000912075|SCV001185464	not_provided|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_deletion_of_4_nucleotides_is_denoted_BRCA2_c.5110_5113delAGAA_at_the_cDNA_level_and_p.Arg1704Ter_(R1704X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_AGAA[AGAA]TAAA._The_deletion_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.5110_5113delAGAA_has_been_observed_in_a_cohort_of_individuals_with_advanced_stage_cancer_diagnoses_(Schrader_2015)._This_variant_is_considered_pathogenic.|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg1704*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_thyroid_carcinoma_(PMID:_26556299)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_246151)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000059.3:c.5213_5216del	BRCA2	frameshift_variant	101492	1	NA	NA	-	-	-	-	37951	46507	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32913705_32913708del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2829415|Breast_Cancer_Information_Core__(BRCA2):5441&base_change%3Ddel_CTTA	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359493	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Mendelics|Ambry_Genetics|Color|GeneDx|GeneKor_MSA|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-08-06|2000-06-12|2016-06-10|2016-09-08|2015-10-02|2017-01-01|0000-00-00|2015-09-21|2018-09-11|2014-01-31|2018-07-02|2018-06-25|2016-06-14|2018-10-16|2017-11-01|2016-06-10	2012-08-22|2014-03-28|2016-07-18|2016-09-13|2016-10-28|2017-03-15|2018-04-04|2018-04-09|2019-03-28|2017-08-04|2018-08-20|2020-02-26|2016-07-05|2019-01-29|2017-11-21|2018-08-31	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline	SCV000054137|SCV000146567|SCV000296495|SCV000300845|SCV000327171|SCV000577955|SCV000733263|SCV000744465|SCV000072622|SCV000587749|SCV000838808|SCV000273746|SCV000292170|SCV000568472|SCV000693571|SCV000887845	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Thr1738Ilefs*2)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs753870552,_ExAC_0.002%)._This_variant_has_been_reported_inÂ¬â€ several_individuals_with_breast_and_ovarian_cancer_(PMID:_11920643,_24504028,_16683254,_19949876,_24156927,_26659639,_27831900)._This_variant_is_also_known_as_5439delTACT_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37951)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_four_nucleotides_in_BRCA2_is_denoted_c.5213_5216delCTTA_at_the_cDNA_level_and_p.Thr1738IlefsX2_(T1738IfsX2)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GATA[CTTA]TTTA._The_deletion_causes_a_frameshift_which_changes_a_Threonine_to_an_Isoleucine_at_codon_1738,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.5213_5216delCTTA,_also_published_as_5439delTACT,_5441_5444delCTTA_and_5441del4_using_alternate_nomenclature,_has_been_reported_in_association_with_breast_and/or_ovarian_cancer_(Montagna_2002,_van_der_Hout_2006,_Song_2014,_Tea_2014,_Francies_2015)._We_consider_this_variant_to_be_pathogenic.||
NM_000059.3:c.5217_5223del	BRCA2	frameshift_variant	101646	1	NA	NA	-	-	-	-	51822	66490	_familial_2|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN517202	-	NC_000013.10:g.32913709_32913715del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:148473|Breast_Cancer_Information_Core__(BRCA2):5445&base_change%3Ddel_TTTAAGT	-	BRCA2:675	SO:0001587|nonsense	1	80359496	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-05|2014-01-31|2013-08-28|2017-01-19|2013-03-06|2002-05-29|2016-04-22|2015-10-02|2015-07-01|2018-04-27|2019-02-23|2015-07-29|2019-01-07|2015-08-12|2017-02-01	2019-03-28|2017-08-04|2017-04-19|2018-01-25|2015-08-20|2014-03-28|2016-06-09|2016-10-28|2017-10-18|2018-06-14|2020-02-26|2016-07-05|2019-01-29|2017-08-01|2017-06-30	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000072626|SCV000587750|SCV000591951|SCV000694844|SCV000109147|SCV000146571|SCV000282401|SCV000327177|SCV000605664|SCV000839913|SCV000186007|SCV000292159|SCV000278858|SCV000296636|SCV000602857	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_specified	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr1739*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80359496,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_and_ovarian_cancer_(PMID:_10717622,_26350514)._This_variant_is_also_known_as_5445del7_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_51822)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA2_c.5217_5223delTTTAAGT_(p.Tyr1739X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._This_variant_was_found_in_1/121342_control_chromosomes_at_a_frequency_of_0.0000082,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._Multiple_publications_have_cited_the_variant_in_affected_individulas,_along_with_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_c.5217_5223del_(p.Tyr1739*)_variant_in_exon_11_of_the_BRCA2_gene_is_a_deletion_of_seven_nucleotides_and_is_predicted_to_cause_loss_of_function_of_normal_protein_through_mRNA_decay_or_producing_a_truncated_protein,_which_is_a_known_disease_mechanism_for_this_gene._This_particular_variant_(also_published_as_c.5445del7)_has_been_reported_in_multiple_hereditary_breast_and_ovarian_cancer_patients_(PMID:_10717622,_26350514)._The_c.5217_5223del_variant_in_the_BRCA2_gene_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_seven_nucleotides_in_BRCA2_is_denoted_c.5217_5223delTTTAAGT_at_the_cDNA_level_and_p.Tyr1739Ter_(Y1739X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CTTA[delTTTAAGT]AACA._This_deletion_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAT>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_published_as_BRCA2_5445del7,_has_been_reported_in_multiple_Hereditary_Breast_and_Ovarian_Cancer_syndrome_families_(Malone_2000,_Scottish/Northern_Irish_BRCA1/BRCA2_Consortium_2003,_H?berg-Vetti_2016)._We_consider_this_deletion_to_be_pathogenic.||
NM_000059.3:c.5290_5291del	BRCA2	frameshift_variant	102140	1	NA	NA	-	-	-	-	37956	46512	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32913778_32913779TC[2]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2837733|Breast_Cancer_Information_Core__(BRCA2):5518&base_change%3Ddel_TC	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359503	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-09-09|2004-02-20|2016-09-08|2015-10-02|2016-05-12|2019-01-07|2014-01-31|2019-01-29|2017-08-07|2017-07-05|2018-01-16|2017-05-10	2012-10-30|2014-03-28|2016-09-13|2016-10-28|2016-11-23|2019-03-28|2017-08-04|2019-09-24|2020-02-26|2017-12-21|2019-01-29|2018-08-31	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000054142|SCV000146592|SCV000300857|SCV000327194|SCV000488636|SCV000072642|SCV000587758|SCV000694855|SCV000274228|SCV000688926|SCV000566976|SCV000600637	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser1764Lysfs*3)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observedÂ¬â€ in_the_literature_in_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancers_(PMID:_11972384,_23479189,_24504028).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 37956)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRCA2_c.5290_5291delTC_(p.Ser1764LysfsX3)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.5614A>T/p.Lys1872X,_c.5624delA/p.Lys1875fsX34)._The_variant_was_absent_in_247964_control_chromosomes._c.5290_5291delTC_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Reedy_2002,_Cunningham_2014,_Jimenez_2013,_Lubinski_2004,_Li_2018)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Eight_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_2_nucleotides_in_BRCA2_is_denoted_c.5290_5291delTC_at_the_cDNA_level_and_p.Ser1764LysfsX3_(S1764KfsX3)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TCTC[delTC]AAAAAAT._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_a_Lysine_at_codon_1764,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.5290_5291delTC,_also_published_as_5518delTC_and_5514delTC_using_alternate_nomenclature,_has_been_reported_in_association_with_Hereditary_Breast_and_Ovarian_Cancer_(Reedy_2002,_Kauff_2003,_Lubinski_2004,_Song_2014)._We_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.5576_5579del	BRCA2	frameshift_variant	100602	1	NA	NA	-	-	-	-	37975	46531	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32914068_32914071del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):5804&base_change%3Ddel_TTAA|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:111621|Breast_Cancer_Information_Core__(BRCA2):5803&base_change%3Ddel_ATTA|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2461852	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359520	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Department_of_Medical_Genetics,Oslo_University_Hospital|Counsyl|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|PreventionGenetics,PreventionGenetics|GenomeConnect,_ClinGen|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic	2012-05-01|2002-05-29|2016-04-22|2015-10-02|2017-01-01|2017-01-10|2015-08-25|2019-01-05|2014-01-31|2017-04-20|2014-08-20|2016-10-28|2016-04-25|2019-01-07|2016-02-22|2018-09-12|2019-05-17|2017-05-08|2017-12-14|0000-00-00|2009-03-10	2015-08-20|2014-03-28|2016-06-09|2016-10-28|2017-03-15|2017-10-18|2017-06-22|2019-03-28|2017-08-04|2017-08-04|2017-04-19|2019-03-21|2018-01-25|2020-02-26|2016-07-05|2019-01-29|2020-03-06|2018-10-10|2018-01-29|2017-08-22|2018-07-18	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline	SCV000054161|SCV000146636|SCV000282408|SCV000327232|SCV000577957|SCV000605703|SCV000677685|SCV000072697|SCV000587774|SCV000588101|SCV000591975|SCV000605790|SCV000694882|SCV000186048|SCV000292136|SCV000210767|SCV000296678|SCV000602738|SCV000805726|SCV000607032|SCV000863704	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|Fanconi_anemia,_complementation_group_D1/Hereditary_breast_and_ovarian_cancer_syndrome|Breast_and/or_ovarian_cancer	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ile1859Lysfs*3)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs770318608,_ExAC_0.02%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_23633455,_8705994,_22160602,_22217648,_23683081)._This_variant_is_also_known_as_5803delATTA,_5804del4,_and_5574_5577delAATT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37975)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||The_p.Ile1859fs_variant_in_BRCA2_has_been_reported_in_>35_individuals_with_BRCA2_-associated_cancers_(Saghir_2015,_Kim_2016,_Breast_Cancer_Information_Core_datab_ase)._It_has_also_been_identified_in_2/10144_African_chromosomes_by_the_Exome_Ag_gregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs80359520):_h_owever,_this_frequency_is_low_enough_to_be_consistent_with_the_frequency_of_here_ditary_breast_and_ovarian_cancer_(HBOC)_in_the_general_population._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequen_ce_beginning_at_position_1859_and_leads_to_a_premature_termination_codon_3_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_a_bsent_protein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_disease_mechanism_in_HBOC._In_addition,_this_variant_was_classified_as_Pathogen_ic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000_282408.1)._In_summary,_this_variant_meets_our_criteria_to_be_classified_as_patho_genic_for_HBOC_in_an_autosomal_dominant_manner.|Variant_summary:_The_c.5576_5579delTTAA_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein,_which_is_a_commonly_known_mechanism_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(c.5585_5588delTGAA,_c.5603_5606delACAG,_c.5616_5620delAGTAA)._The_variant_was_observed_in_the_large_and_broad_cohorts_of_the_ExAC_project_at_an_allele_frequency_of_0.003%_which_does_not_exceed_the_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_BRCA2_(0.075%)._The_variant_has_been_cited_in_numerous_affected_individuals_via_the_literature_and_databases,_and_has_been_classified_by_multiple_reputable_databases_and_clinical_labs_as_pathogenic._Taken_together,_this_variant_has_been_classified_as_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_four_nucleotides_in_BRCA2_is_denoted_c.5576_5579delTTAA_at_the_cDNA_level_and_p.Ile1859LysfsX3_(I1859KfsX3)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ACAA[delTTAA]AAAAG._This_deletion,_also_known_as_5802del4_or_5804del4_using_alternate_nomenclature,_causes_a_frameshift,_which_changes_an_Isoleucine_to_a_Lysine_at_codon_1859,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.5576_5579delTTAA_has_been_reported_as_a_recurrent_pathogenic_variant_in_breast_and/or_ovarian_cancer_families_and_is_suggested_to_be_a_pathogenic_founder_variant_in_Asian_populations_(Ikeda_2001,_Sugano_2008,_Wang_2012,_Kang_2015,_Kim_2016,_Eoh_2017,_Pritzlaff_2017)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|The_BRCA2_c.5576_5579delTTAA:p.Ile1859fs_variant_(also_known_as_5802del_and_5803del)_has_been_described_in_the_literature_in_individuals_and_families_with_breast_and_ovarian_cancer_(Foster_1996,_George_2013,_Schneegans_2012)._The_variant_is_listed_in_the_dbSNP_variant_database_(rs80359521)_but_is_not_listed_in_the_general_population-based_databases_(1000_Genomes_Project,_Exome_Variant_Server,_Exome_Aggregation_Consortium)._This_variant_deletes_four_nucleotides_and_creates_a_frameshift,_which_is_predicted_to_result_in_a_truncated_protein_or_absent_transcript._Taken_together,_this_variant_is_considered_pathogenic._References:_Foster_KA_et_al._Somatic_and_germline_mutations_of_the_BRCA2_gene_in_sporadic_ovarian_cancer._Cancer_Res._1996_56(16):3622-5._George_J_et_al._Nonequivalent_gene_expression_and_copy_number_alterations_in_high-grade_serous_ovarian_cancers_with_BRCA1_and_BRCA2_mutations._Clin_Cancer_Res._2013_19(13):3474-84._Schneegans_SM_et_al._Validation_of_three_BRCA1/2_mutation-carrier_probability_models_Myriad,_BRCAPRO_and_BOADICEA_in_a_population-based_series_of_183_German_families._Fam_Cancer._2012_11(2):181-8.||GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.|
NM_000059.3:c.5621_5624del	BRCA2	frameshift_variant	101478	1	NA	NA	-	-	-	-	37980	46536	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32914113_32914116del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):5849&base_change%3Ddel_TTAA	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359526	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2010-06-01|2002-05-29|2016-01-25|2016-09-08|2015-10-02|2019-02-09|2016-04-15|2018-07-03|2018-12-10|2014-10-08|2014-01-31|0000-00-00	2013-12-30|2014-03-28|2016-07-18|2016-09-13|2016-10-28|2020-02-26|2017-10-26|2019-01-29|2019-03-28|2016-11-14|2017-08-04|2017-04-19	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054166|SCV000146647|SCV000296575|SCV000300907|SCV000327247|SCV000186045|SCV000683716|SCV000278863|SCV000072711|SCV000494294|SCV000587782|SCV000591978	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_4_nucleotides_is_denoted_BRCA2_c.5621_5624delTTAA_at_the_cDNA_level_and_p.Ile1874ArgfsX34_(I1874RfsX34)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GTAA[delTTAA]GGAA._The_deletion_causes_a_frameshift,_which_changes_an_Isoleucine_to_an_Arginine_at_codon_1874,_and_creates_a_premature_stop_codon_at_position_34_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_5621_5624delTTAA,_previously_reported_as_5849del4_using_alternate_nomenclature,_has_been_observed_in_association_with_breast_and/or_ovarian_cancer_(Serova_1997,_Tai_2007,_Litton_2012)._We_therefore_consider_this_variant_to_be_pathogenic.|This_sequence_change_deletes_4_nucleotides_from_exon_11_of_the_BRCA2_mRNA_(c.5621_5624delTTAA),_causing_a_frameshift_at_codon_1874._This_creates_a_premature_translational_stop_signal_(p.Ile1874Argfs*34)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer_(PMID:_9042907,_10449599,_19620486,_219131812,_26681312,_18042939)._This_variant_is_also_known_as_5849del4_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 37980)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||
NM_000059.3:c.5645C>A	BRCA2	stop_gained	101972	3	NA	NA	5&5&5&5&5	3&1&1&1&1	rs80358785	Breast-ovarian cancer, familial 2&not provided&Hereditary cancer-predisposing syndrome&Hereditary breast and ovarian cancer syndrome&Breast cancer	37984	46540	_familial_2|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32914137C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2273423	-	BRCA2:675	SO:0001587|nonsense	1	80358785	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Division_Human_Genetics,Medical_University_Innsbruck|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Laboratory_of_Molecular_Diagnosis_of_Cancer,West_China_Hospital,_Sichuan_University|GeneKor_MSA|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-08-19|2002-05-29|2015-02-11|2016-04-22|2015-10-02|2015-07-01|0000-00-00|2014-10-08|2015-09-21|2018-05-15|2017-04-03|2019-03-12|2017-02-21|2018-12-26|2014-01-31|2016-05-31|2018-01-17|2015-11-01|2017-11-01|2004-02-13|2017-03-17|2018-12-01|2019-03-26	2013-12-30|2014-03-28|2015-02-11|2016-06-09|2016-10-28|2017-10-18|2018-04-04|2018-04-17|2018-04-09|2019-01-29|2018-08-31|2020-02-26|2017-10-26|2019-03-28|2017-08-04|2018-01-25|2019-03-21|2016-02-27|2017-11-21|2018-07-18|2018-04-30|2019-02-22|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054170|SCV000146653|SCV000212022|SCV000282410|SCV000327251|SCV000605680|SCV000733269|SCV000743309|SCV000744472|SCV000210359|SCV000600653|SCV000186044|SCV000683721|SCV000072718|SCV000587784|SCV000694888|SCV000967739|SCV000265907|SCV000693572|SCV000863707|SCV000902206|SCV000923792|SCV001160441	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Neoplasm_of_the_breast|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms|not_specified	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||This_pathogenic_variant_is_denoted_BRCA2_c.5645C>A_at_the_cDNA_level_and_p.Ser1882Ter_(S1882X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_a_Serine_to_a_premature_stop_codon_(TCA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_BRCA2_5873C>A_using_alternate_nomenclature,_has_been_reported_in_multiple_individuals_and_families_with_breast_and/or_ovarian_cancer_as_well_as_in_two_siblings_with_with_Fanconi_Anemia_and_is_considered_pathogenic_(De_Benedetti_1998,_Reid_2005,_Weren_2016,_Zhong_2016,_Takahashi_2017).||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser1882*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80358785,_ExAC_0.01%)._This_variant_has_been_reported_in_several_individuals_and_families_affected_with_breast,_ovarian_and_prostate_cancer_(PMID:_22144684,_22535016,_22666503,_21952622,_15024741)._This_variant_is_also_known_as_5873C>A_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37984)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_sequence_change_has_been_classified_as_Pathogenic.||Variant_summary:_The_BRCA2_c.5645C>A_(p.Ser1882X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_was_observed_in_the_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_3/120628_(1/40160,_0.0000249),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_BRCA2_variant_of_1/1333_(0.0007503)._In_addition,_it_needs_to_be_noted_that_these_three_occurrences_need_to_be_cautiously_considered_due_to_the_fact_that_the_ExAC_cohort_contains_individuals_that_could_harbor_a_BRCA2_phenotype._However,_multiple_affected_individuals_have_been_reported_via_publications,_along_with_numerous_reputable_databases/clinical_laboratories_citing_the_variant_as_pathogenic._Therefore,_the_variant_of_interest_has_been_classified_as_Pathogenic.|The_p.Ser1882X_variant_in_BRCA2_has_been_reported_in_>60_individuals_with_BRCA2-_associated_cancers_and_segregated_with_disease_in_2_affected_relatives_from_2_fa_milies_(Caputo_2012,_De_Silva_2017,_Heidemann2012,_Rebbeck_2016,_Reid_2005)._Thi_s_variant_has_also_been_identified_in_1/17202_East_Asian_and_2/110946_European_c_hromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstit_ute.org:_dbSNP_rs80358785)._This_nonsense_variant_leads_to_a_premature_terminati_on_codon_at_position_1882,_which_is_predicted_to_lead_to_a_truncated_or_absent_p_rotein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_diseas_e_mechanism_in_hereditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_va_riant_was_classified_as_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENI_GMA_expert_panel_(ClinVar_SCV000282410.1)._In_summary,_this_variant_meets_criter_ia_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_predicted_impact_to_the_protein,_absence_in_the_general_population_and_pre_sence_in_multiple_affected_individuals._ACMG/AMP_Criteria_applied:_PVS1:_PS4:_PM_2_(Richards_2015).||||||The_BRCA2_c.5645C>A:_p.Ser1882Ter_variant_(rs80358785),_also_known_as_5873C>A,_is_reported_in_several_individuals_with_hereditary_breast_and_ovarian_cancer_syndrome_and_is_described_as_a_founder_mutation_in_the_Eastern_European_population_(Caputo_2012,_Heramb_2018,_Meisel_2017,_Momozawa_2018)._It_has_also_been_reported_in_two_brothers_with_Wilms_tumor_and_brain_tumors,_who_also_carry_an_additional_truncating_variant_in_trans_(Reid_2005)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_37984)._It_is_found_in_the_general_population_with_a_low_overall_allele_frequency_of_0.002%_(4/249416_alleles)_in_the_Genome_Aggregation_Database._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Caputo_S_et_al._Description_and_analysis_of_genetic_variants_in_French_hereditary_breast_and_ovarian_cancer_families_recorded_in_the_UMD-BRCA1/BRCA2_databases._Nucleic_Acids_Res._2012_Jan:40(Database_issue):D992-1002._Heramb_C_et_al._BRCA1_and_BRCA2_mutation_spectrum_-_an_update_on_mutation_distribution_in_a_large_cancer_genetics_clinic_in_Norway._Hered_Cancer_Clin_Pract._2018_Jan_10:16:3._Meisel_C_et_al._Spectrum_of_genetic_variants_of_BRCA1_and_BRCA2_in_a_German_single_center_study._Arch_Gynecol_Obstet._2017_May:295(5):1227-1238._Momozawa_Y_et_al._Germline_pathogenic_variants_of_11_breast_cancer_genes_in_7,051_Japanese_patients_and_11,241_controls._Nat_Commun._2018_Oct_4:9(1):4083._Reid_S_et_al._Biallelic_BRCA2_mutations_are_associated_with_multiple_malignancies_in_childhood_including_familial_Wilms_tumour._J_Med_Genet._2005_Feb:42(2):147-51.
NM_000059.3:c.5682C>G	BRCA2	stop_gained	102204	1	NA	NA	5&5&5&5&5	3&1&1&0&1	rs41293497	Breast-ovarian cancer, familial 2&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&Ovarian cancer&not provided	37989	46545	Tracheoesophageal_fistula|Medulloblastoma|Malignant_tumor_of_prostate|Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Ovarian_cancer|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Glioma_susceptibility_3|Pancreatic_cancer_2|Wilms_tumor_1|Breast_and/or_ovarian_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0002575,MedGen:C1861028,OMIM:189960|Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1140680,Orphanet:ORPHA213500|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:C2751641,OMIM:613029|MedGen:C3150546,OMIM:613347|MedGen:CN033288,OMIM:194070|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32914174C>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	41293497	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Fulgent_Genetics,Fulgent_Genetics|Department_of_Medical_Genetics,Oslo_University_Hospital|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Cancer_Genetics_and_Genomics_Laboratory,British_Columbia_Cancer_Agency|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Ambry_Genetics|Color|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|CSER__CC_NCGL,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Fulgent_Genetics,Fulgent_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-07-19|2002-05-29|2016-04-22|2015-10-02|2015-10-27|2015-07-01|2015-09-29|0000-00-00|2014-10-08|2015-09-21|2018-12-13|2016-06-14|2017-04-18|2014-01-31|2017-04-20|2012-08-13|2019-01-17|2016-05-17|2018-01-26|2014-06-01|2018-05-18|2019-03-28|2017-05-18|2015-11-23|2018-12-01	2015-12-29|2014-03-28|2016-06-09|2016-10-28|2017-04-18|2017-10-18|2017-06-22|2018-04-04|2018-04-17|2018-04-09|2019-03-28|2016-11-14|2017-08-04|2017-08-04|2017-08-04|2017-04-19|2020-02-26|2017-10-26|2018-04-23|2014-08-28|2019-01-29|2020-03-06|2017-05-23|2018-07-18|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000054175|SCV000146669|SCV000282412|SCV000327264|SCV000575740|SCV000605682|SCV000677688|SCV000733270|SCV000743310|SCV000744473|SCV000072732|SCV000494385|SCV000586962|SCV000587792|SCV000588102|SCV000591987|SCV000186051|SCV000683723|SCV000992212|SCV000190123|SCV000210363|SCV000296756|SCV000611178|SCV000863710|SCV000923793	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ovarian_cancer|not_provided|not_provided|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_2/Fanconi_anemia,_complementation_group_D1/Medulloblastoma/Wilms_tumor_1/Malignant_tumor_of_prostate/Pancreatic_cancer_2/Glioma_susceptibility_3/Tracheoesophageal_fistula|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr1894*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ovarian_cancer,_breast_cancer,_prostate_cancer,_and_Fanconi_anemia_(PMID:_11179017,_15070707,_16168118,_18042939,_20736950)._This_variant_is_also_known_as_5910C>G_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37989)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_BRCA2_c.5682C>G_(p.Tyr1894X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.6644_6647delACTC,_c.6682dupG,_c.6997_6998delGT,_etc.)._This_variant_is_absent_in_120576_control_chromosomes_from_ExAC._This_variant_is_a_recurrent_pathogenic_mutation_found_in_several_HBOC_patients/families_and_in_individuals_undergoing_BRCA1/2_clinical_testing._In_compound_heterozygous_with_another_variant,_it_has_also_been_reported_to_cause_Fanconi_Anemia._Several_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_a_Disease_Variant_(or_Pathogenic).|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.||This_pathogenic_variant_is_denoted_BRCA2_c.5682C>G_at_the_cDNA_level_and_p.Tyr1894Ter_(Y1894X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAG)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_5910C>G_using_alternate_nomenclature,_has_been_observed_in_association_with_hereditary_breast,_ovarian,_and_prostate_cancer_(Risch_2001,_Pohlreich_2005,_Edwards_2010,_Tea_2014,_Cini_2016,_Fernandes_2016,_Kim_2016)._We_consider_this_variant_to_be_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient_in_the_literature,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|||
NM_000059.3:c.5754_5755del	BRCA2	frameshift_variant	102426	1	NA	NA	-	-	-	-	51929	66597	_familial_2	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32914246_32914247del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	397507803	-	_c/o_University_of_Cambridge|Color	Pathogenic|Pathogenic|Pathogenic	2016-09-08|2015-10-02|2017-07-05	2016-09-13|2016-10-28|2017-12-21	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000300925|SCV000327276|SCV000688945	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||
NM_000059.3:c.5773C>T	BRCA2	stop_gained	102400	1	NA	NA	5	3	rs80358806	Breast-ovarian cancer, familial 2	51933	66601	_familial_2	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32914265C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80358806	-	Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2003-12-23|2016-09-08|2014-01-31|2014-05-13|2017-03-28	2014-03-28|2016-09-13|2017-08-04|2017-04-19|2017-10-26	no_assertion_criteria_provided|reviewed_by_expert_panel|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000146695|SCV000300928|SCV000587797|SCV000592001|SCV000683733	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||
NM_000059.3:c.5782G>T	BRCA2	stop_gained	102382	1	NA	NA	5&5&5	3&0&1	rs56253082	Breast-ovarian cancer, familial 2&Hereditary breast and ovarian cancer syndrome&Familial cancer of breast	37996	46552	_familial_2	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32914274G>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	56253082	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Color|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-05-01|1999-04-13|2016-09-08|2015-10-02|2018-01-31|2014-01-31|2015-04-04|2018-04-23	2013-12-30|2014-03-28|2016-09-13|2016-10-28|2018-08-29|2017-08-04|2017-12-21|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000054183|SCV000146698|SCV000300933|SCV000327280|SCV000072767|SCV000587799|SCV000688950|SCV001186557	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu1928*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_a_male_patient_affected_with_breast_cancer,_who_had_a_family_history_of_breast_cancer_(PMID:_15519522)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37996)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000059.3:c.5828del	BRCA2	frameshift_variant	102464	2	NA	NA	-	-	-	-	37999	46555	_familial_2|not_provided	-	MeSH:D030342,MedGen:C0950123|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32914320del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):6056&base_change%3Ddel_C	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359541	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Genetic_Services_Laboratory,_University_of_Chicago|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|Color|Ambry_Genetics|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-07-17|2002-05-29|2015-01-23|2016-09-08|2015-10-02|2016-10-24|2015-11-11|2017-07-12|2017-11-20|2018-03-30|2018-12-10|2014-01-31|2016-05-03|2014-06-06	2014-07-28|2014-03-28|2015-09-15|2016-09-13|2016-10-28|2019-01-29|2017-08-01|2017-08-08|2018-11-06|2020-02-26|2019-03-28|2017-08-04|2018-01-25|2018-02-08	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054186|SCV000146707|SCV000246807|SCV000300937|SCV000327291|SCV000210771|SCV000296592|SCV000679719|SCV000905018|SCV001186609|SCV000072779|SCV000587803|SCV000694905|SCV000186291	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Inborn_genetic_diseases	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_deletion_of_one_nucleotide_in_BRCA2_is_denoted_c.5828delC_at_the_cDNA_level_and_p.Ser1943LeufsX20_(S1943LfsX20)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GTTT[delC]TAAA._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_a_Leucine_at_codon_1943,_and_creates_a_premature_stop_codon_at_position_20_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.5828delC,_also_reported_as_6056delC_using_alternate_nomenclature,_has_been_observed_in_association_with_breast_and/or_ovarian_cancer_(Palma_2008,_Finkelman_2012)._We_consider_this_variant_to_be_pathogenic.||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser1943Leufs*20)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_18703817,_22430266),_and_prostate_cancer_(PMID:_26681312)._This_variant_is_also_known_as_6056delC_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37999)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_BRCA2_c.5828delC_variant_results_in_frameshift_and_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_is_a_commonly_known_mechanism_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Ser1970X,_p.Ser1982fs)._Mutation_Taster_predicts_damaging_outcome_for_this_variant._This_variant_was_not_found_in_122374_control_chromosomes,_but_has_been_cited_in_multiple_cancer_patients_in_the_literature,_including_breast/ovarian_and_prostate_cancers._In_addition,_clinical_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_was_classified_as_pathogenic.|Lines_of_evidence_used_in_support_of_classification:_UNCERTAIN:_Alteration(s)_of_Uncertain_Clinical_Significance_Detected
NM_000059.3:c.5857G>T	BRCA2	stop_gained	102510	1	NA	NA	5&5&5&5	1&3&2&2	rs80358814	not provided&Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&Hereditary breast and ovarian cancer syndrome	51952	66620	Tracheoesophageal_fistula|Medulloblastoma|Malignant_tumor_of_prostate|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Glioma_susceptibility_3|Pancreatic_cancer_2|Wilms_tumor_1|not_specified|Breast_and/or_ovarian_cancer|BRCA2-Related_Disorders|not_provided	-	Human_Phenotype_Ontology:HP:0002575,MedGen:C1861028,OMIM:189960|Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:C2751641,OMIM:613029|MedGen:C3150546,OMIM:613347|MedGen:CN033288,OMIM:194070|MedGen:CN169374|MedGen:CN221562|MedGen:CN239275|MedGen:CN517202	-	NC_000013.10:g.32914349G>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2251952|Illumina_Clinical_Services_Laboratory,Illumina:779121	-	BRCA2:675	SO:0001587|nonsense	1	80358814	-	GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Ambry_Genetics|Color|Invitae|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Illumina_Clinical_Services_Laboratory,Illumina|Fulgent_Genetics,Fulgent_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-08|2015-10-10|2011-03-15|2002-05-29|2016-04-21|2015-10-10|2016-09-08|2015-10-02|0000-00-00|2015-09-21|2018-05-23|2015-07-15|2018-12-27|2017-03-08|2016-02-08|2014-01-31|2017-04-20|2013-11-18|2016-04-11|2017-04-28|2017-05-18|2015-10-28|2017-03-08|2019-02-21	2019-01-29|2018-08-31|2015-12-29|2014-03-28|2016-04-21|2016-07-18|2016-09-13|2016-10-28|2018-04-04|2018-04-09|2020-02-26|2016-07-05|2019-03-28|2017-08-28|2019-03-21|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2019-02-01|2017-05-23|2018-07-18|2018-04-30|2019-08-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline	SCV000210373|SCV000889081|SCV000109160|SCV000146715|SCV000267789|SCV000296600|SCV000300944|SCV000327300|SCV000733274|SCV000744478|SCV000186047|SCV000292172|SCV000072788|SCV000219366|SCV000271331|SCV000587805|SCV000588104|SCV000592006|SCV000694907|SCV000383727|SCV000611179|SCV000863713|SCV000902208|SCV001160340	not_provided|not_provided|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|BRCA2-Related_Disorders|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_2/Fanconi_anemia,_complementation_group_D1/Medulloblastoma/Wilms_tumor_1/Malignant_tumor_of_prostate/Pancreatic_cancer_2/Glioma_susceptibility_3/Tracheoesophageal_fistula|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer|not_specified	This_pathogenic_variant_is_denoted_BRCA2_c.5857G>T_at_the_cDNA_level_and_p.Glu1953Ter_(E1953X)_at_the_protein_level._This_variant_is_also_known_as_BRCA2_6085G>T_using_alternate_nomenclature._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_as_a_French_Canadian_founder_pathogenic_variant_in_multiple_hereditary_or_early-onset_breast_and/or_ovarian_cancer_families_as_well_as_in_association_with_familial_prostate_cancer_(Serova-Sinilnikova_1997,_Frank_1998,_Tonin_1998,_Oros_2004,_Zhang_2011,_Taherian_2013,_Belanger_2015)_and_is_considered_pathogenic.||||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1953_(p.Glu1953*)_of_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80358814,_ExAC_0.002%)._This_variant_has_been_observed_in_individuals_and_families_affected_with_breast,_ovarian,_and_prostate_cancer_(PMID:_9150172,_9792861,_16683254,_23318356,_28008555)._ItÂ¬â€ is_recognized_as_a_common_cause_of_breast_and_ovarian_cancer_in_the_French_Canadian_population_(PMID:_15382066,_23621881)._This_variant_is_also_known_as_6085G>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 51952)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Glu1953X_variant_in_BRCA2_has_been_reported_in_>35_individuals_with_BRCA2-_associated_cancers_(Serova-Sinilnikova_1997,_Ghadirian_2009,_Janavicius_2010,_Ta_herian_2013,_Breast_Cancer_Information_Core_(BIC)_database)._This_variant_has_be_en_identified_in_1/66642_European_chromosomes_by_the_Exome_Aggregation_Consortiu_m_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs80358814)._This_frequency_is_lo_w_enough_to_be_consistent_with_the_frequency_of_hereditary_breast_and_ovarian_ca_ncer_(HBOC)_in_the_general_population._This_nonsense_variant_leads_to_a_prematur_e_termination_codon_at_position_1953,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_BRCA2_function_is_an_established_disease_mechanism_for_HBOC._In_summary,_this_variant_meets_our_criteria_to_be_classifie_d_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_predicte_d_impact_to_the_protein.||||Variant_summary:_The_c.5857G>T_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein,_which_is_a_commonly_known_mechanism_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(c.5864C>A,_p.Ser1955X:_c.5909C>A,_p.Ser1970X:_c.5946delT,_p.Ser1982fsX22)._The_variant_was_observed_in_the_large_and_broad_cohorts_of_the_ExAC_project_at_an_allele_frequency_of_0.0008%_which_does_not_exceed_the_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_BRCA2_(0.075%)._The_variant_has_been_reported_in_numerous_families_and_affected_individuals_in_the_literature,_mainly_of_French_Canadian_descent,_and_has_been_reported_as_pathogenic_by_multiple_reputable_clinical_labs_and_databases._Taken_together,_this_variant_has_been_classified_as_a_Pathogenic.|The_BRCA2_c.5857G>T_(p.Glu1953Ter)_variant_is_a_stop-gained_variant_that_is_predicted_to_result_in_a_premature_termination_of_the_protein._The_p.Glu1953Ter_variant_has_been_reported_in_at_least_seven_studies_in_individuals_with_breast,_ovarian_or_prostate_cancer_in_which_it_is_found_in_a_heterozygous_state_in_at_least_44_patients._The_variant_is_a_common_cause_of_breast_and_ovarian_cancer_in_the_French_Canadian_population_(Serova-Sinilnikova_et_al._1997:_Tonin_et_al._1998:_Oros_et_al._2004:_van_der_Hout_et_al._2006:_Cavallone_et_al._2010:_Taherian_et_al._2014:_Ghadirian_et_al._2014)._Control_data_are_unavailable_from_these_studies_for_this_variant,_which_is_reported_at_a_frequency_of_0.00001_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._This_frequency_is_based_on_one_allele_only_in_a_region_of_good_sequence_coverage_so_the_variant_is_presumed_to_be_rare._Although_the_p.Glu1953Ter_variant_has_not_been_reported_in_any_cases_of_Fanconi_anemia,_it_is_generally_accepted_that_pathogenic_variants_in_the_BRCA2_gene_also_confer_carrier_status_for_Fanconi_anemia._Due_to_the_potential_impact_of_stop-gained_variants_and_the_supporting_evidence,_the_p.Glu1953Ter_variant_is_classified_as_pathogenic_for_BRCA2-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.||||The_BRCA2_c.5857G>T:_p.Glu1953Ter_variant_(rs80358814),_also_reported_as_6085G>T,_has_been_described_in_multiple_individuals_affected_with_hereditary_breast_and_ovarian_cancer_(HBOC),_including_prostate_and_male_breast_cancers_(Pritzlaff_2017,_Serova-Sinilnikova_1997,_Taherian_2013,_Tonin_1998,_van_der_Hout_2006)_and_is_a_common_cause_of_HBOC_in_the_French_Canadian_population_(Ghadirian_2014,_Oros_2004)._It_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_51952)_and_is_observed_on_only_2_alleles_in_the_Genome_Aggregation_Database,_indicating_it_is_not_a_common_polymorphism._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_pathogenic._REFERENCES_Ghadirian_P_et_al._Screening_for_BRCA1_and_BRCA2_mutations_among_French-Canadian_breast_cancer_cases_attending_an_outpatient_clinic_in_Montreal._Clin_Genet._2014_Jan:85(1):31-5._Oros_K_et_al._Significant_proportion_of_breast_and/or_ovarian_cancer_families_of_French_Canadian_descent_harbor_1_of_5_BRCA1_and_BRCA2_mutations._Int_J_Cancer._2004_Nov_10:112(3):411-9._Pritzlaff_M_et_al._Male_breast_cancer_in_a_multi-gene_panel_testing_cohort:_insights_and_unexpected_results._Breast_Cancer_Res_Treat._2017_Feb:161(3):575-586._Serova-Sinilnikova_O_et_al._BRCA2_mutations_in_hereditary_breast_and_ovarian_cancer_in_France._Am_J_Hum_Genet._1997_May:60(5):1236-9._Taherian_N_et_al._Familial_prostate_cancer:_the_damage_done_and_lessons_learnt._Nat_Rev_Urol._2013_Feb:10(2):116-22._Tonin_P_et_al._Founder_BRCA1_and_BRCA2_mutations_in_French_Canadian_breast_and_ovarian_cancer_families._Am_J_Hum_Genet._1998_Nov:63(5):1341-51._van_der_Hout_A_et_al._A_DGGE_system_for_comprehensive_mutation_screening_of_BRCA1_and_BRCA2:_application_in_a_Dutch_cancer_clinic_setting._Hum_Mutat._2006_Jul:27(7):654-66.
NM_000059.3:c.5864C>A	BRCA2	stop_gained	102510	1	15430	0	5&5&5&5	1&3&1&1	rs80358815	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&not provided	51954	66622	_familial_2|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32914356C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:149213	-	BRCA2:675	SO:0001587|nonsense	1	80358815	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-22|2014-01-31|2017-04-20|2015-06-08|2016-08-22|2012-07-06|2002-05-29|2014-10-28|2016-04-22|2015-10-30|2015-10-02|0000-00-00|2017-07-28|2018-10-31|2017-11-22|2018-04-20|2017-12-13|2017-02-23|2014-10-13	2019-03-28|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2015-08-20|2014-03-28|2015-03-11|2016-06-09|2016-07-18|2016-10-28|2018-04-04|2018-04-17|2020-02-26|2018-11-06|2019-01-29|2018-03-09|2017-06-30|2018-07-18	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000072790|SCV000587807|SCV000588105|SCV000592009|SCV000694908|SCV000109161|SCV000146718|SCV000220841|SCV000282416|SCV000296595|SCV000327303|SCV000733275|SCV000743314|SCV000213414|SCV000903519|SCV000278865|SCV000778692|SCV000602868|SCV000863714	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_specified|Breast_and/or_ovarian_cancer	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser1955*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80358815,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_11802209,_15131399,_16683254,_24504028,_24728189,_26586665),_as_well_as_prostate_cancer_and_pancreatic_cancer_(PMID:_26483394,_27433846)._This_variant_is_also_known_as_6092C>A_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_51954)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_The_BRCA2_c.5864C>A_(p.Ser1955X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.5909C>A/p.S1970X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_1/124064_control_chromosomes_at_a_frequency_of_0.0000081,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._Variant_was_found_to_co-segregate_in_multiple_HBOC_families._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_BRCA2_c.5864C>A_at_the_cDNA_level_and_p.Ser1955Ter_(S1955X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA2_6092C>A._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_breast,_ovarian,_and_prostate_cancer_patients_(Meindl_2002,_Lubinski_2004,_Cunningham_2014,_Pritchard_2016,_Barnes_2017)._We_consider_this_variant_to_be_pathogenic.|||
NM_000059.3:c.5946del	BRCA2	frameshift_variant	102460	7	15420	3	-	-	-	-	9325	24364	Neoplasm_of_the_breast|Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Pancreatic_cancer_2|not_specified|Breast_and/or_ovarian_cancer|BRCA2-Related_Disorders|not_provided|Hereditary_Cancer_Syndrome	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:C3150546,OMIM:613347|MedGen:CN169374|MedGen:CN221562|MedGen:CN239275|MedGen:CN517202|MedGen:CN882908	-	NC_000013.10:g.32914438del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:21724|Breast_Cancer_Information_Core__(BRCA2):6174&base_change%3Ddel_T|OMIM_Allelic_Variant:600185.0009|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2386465|Illumina_Clinical_Services_Laboratory,Illumina:776850|OMIM_Allelic_Variant:600185.0005	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359550	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Pathway_Genomics|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Centro_de_Genética_y_Biología_Molecular,_Universidad_de_San_Martín_de_Porres|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Fulgent_Genetics,Fulgent_Genetics|Genetic_Services_Laboratory,_University_of_Chicago|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Equipe_Genetique_des_Anomalies_du_Developpement,_Université_de_Bourgogne|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|OMIM|OMIM|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Invitae|Curoverse|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America|GeneReviews|Bioscientia_Institut_fuer_Medizinische_Diagnostik_GmbH,Sonic_Healthcare|Baylor_Genetics|Ambry_Genetics|Color|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|True_Health_Diagnostics|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Gharavi_Laboratory,Columbia_University|Illumina_Clinical_Services_Laboratory,Illumina|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|Rady_Children's_Institute_for_Genomic_Medicine,_Rady_Children's_Hospital_San_Diego|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|risk_factor|Pathogenic|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|pathologic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1995-12-21|2013-01-15|2002-05-29|2014-04-07|2014-07-24|2014-11-03|2015-06-10|2016-04-22|2015-10-02|2016-02-12|2016-05-16|2015-07-01|0000-00-00|2015-09-21|2017-11-07|2017-05-24|2016-09-12|2016-09-12|2012-07-13|2019-01-11|2015-08-01|2014-01-31|2015-07-28|2017-03-31|2018-07-02|2019-05-01|2013-09-26|0000-00-00|2017-02-23|2018-09-20|2015-03-09|2017-07-12|2017-09-27|2018-11-19|2017-02-03|2019-03-30|2017-11-01|2017-01-27|2016-03-03|2018-09-16|2017-04-28|0000-00-00|2017-10-19|2018-12-01|2018-08-14|2018-11-20	2015-04-23|2015-12-29|2014-03-28|2014-05-01|2014-08-08|2016-04-21|2016-02-23|2016-06-09|2016-10-28|2017-04-18|2017-07-05|2017-10-18|2018-04-04|2018-04-09|2018-02-06|2018-06-14|2016-09-12|2016-09-12|0000-00-00|2019-03-28|2015-08-24|2017-08-04|2017-04-19|2019-03-21|2018-08-20|2019-09-24|2013-04-30|2016-12-07|2017-02-23|2020-02-26|2016-07-05|2017-08-08|2018-03-08|2019-01-29|2018-09-19|2020-03-06|2017-11-21|2018-03-09|2018-01-29|2018-09-24|2019-02-01|2016-12-06|2018-04-30|2019-02-22|2019-09-20|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|not_applicable|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|not_provided|not_provided|germline|germline|germline|germline|germline|germline|unknown|germline|not_provided|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline	SCV000030127|SCV000054198|SCV000146737|SCV000154098|SCV000189906|SCV000195993|SCV000263344|SCV000282418|SCV000327312|SCV000575747|SCV000593749|SCV000605651|SCV000733276|SCV000744479|SCV000803796|SCV000839905|SCV000030132|SCV000030133|SCV000043218|SCV000072813|SCV000245334|SCV000587812|SCV000592016|SCV000605785|SCV000838826|SCV000918979|SCV000086654|SCV000484936|SCV000540997|SCV000184420|SCV000292121|SCV000679720|SCV000787938|SCV000108631|SCV000225181|SCV000296747|SCV000693574|SCV000778694|SCV000805732|SCV000809465|SCV000383728|SCV000492446|SCV000219371|SCV000923794|SCV000996186|SCV000602754	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Pancreatic_cancer_2|Fanconi_anemia,_complementation_group_D1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|not_provided|not_provided|BRCA2-Related_Disorders|Neoplasm_of_the_breast|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms|Hereditary_Cancer_Syndrome|not_specified	|||||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||||The_c.5946del_(p.Ser1982Argfs*22)_variant_has_been_detected_in_a_multiple_patients_with_breast_and_ovarian_cancer_[reported_as_c.6174del_in_PMID_8673091,_23633455,_22006311,_21324516,_22430266]._The_variant_was_also_detected_in_patients_with_prostate_cancer_[PMID_19188187,_20736950]_and_pancreatic_ductal_adenocarcinoma_[PMID_23658460]._This_variant_is_associated_with_a_cancer_risk_of_50-43%_and_18-20%_risk_for_breast_and_ovarian_cancer_respectively_by_age_70_[PMID_9145676,15994883]._In_vitro_assays_showed_that_this_variant_leads_to_a_loss_of_function_of_the_protein_[PMID_15695382]._This_variant_has_been_reported_in_32_non-Finnish_Europeans_from_the_ExAC_database_(http://exac.broadinstitute.org/variant/13-32914437-GT-G)._This_c.5946del_(p.Ser1982Argfs*22)_variant_occurs_at_high_frequency_in_the_Ashkenazi_Jewish_population_and_is_considered_a_founder_mutation_in_this_population._This_variant_is_thus_classified_as_pathogenic.[leduc,_2017-03-07]|||Converted_during_submission_to_Pathogenic.|This_sequence_change_deletes_1_nucleotide_from_exon_11_of_the_BRCA2_mRNA_(c.5946delT),_causing_a_frameshift_at_codon_1982._This_creates_a_premature_translational_stop_signal_(p.Ser1982Argfs*22)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_pathogenic_variant_is_a_common_cause_of_breast_and_ovarian_cancer_in_the_Ashkenazi_Jewish_population_(PMID:_9042909,_22430266),_and_has_been_reported_in_individuals_of_other_ethnicities_(PMID:_8758903,_10417300)._In_the_literature,_this_variant_is_also_known_as_6174delT._This_variant_has_been_associated_with_a_43%_to_55%_risk_of_breast_cancer_by_age_70,_and_a_20%_to_37%_risk_of_ovarian_cancer_by_age_70_(PMID:_15994883,_22430266)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Frameshifts_in_BRCA2_are_considered_pathogenic,_and_this_is_a_BRCA2_Ser1982Arg_frameshift_variant_in_exon_11|||The_p.Ser1982fs_variant_in_BRCA2_is_a_founder_mutation_in_the_Ashkenazi_Jewish_p_opulation_(Finkelman_2012)_and_has_been_identified_in_>500_individuals_of_variou_s_ethnicities_with_BRCA2-associated_cancers_(Breast_Cancer_Information_Core_(BIC_)_database:_https://research.nhgri.nih.gov/projects/bic/)._It_has_also_been_iden_tified_in_0.6%_(59/10151)_Ashkenazi_Jewish_chromosomes_and_10/126512_European_ch_romosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitu_te.org:_dbSNP_rs80359550)._This_variant_is_predicted_to_cause_a_frameshift,_whic_h_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1982_and_leads_to_a_premature_termination_codon_22_amino_acids_downstream._This_alteration_is_t_hen_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_fun_ction_of_the_BRCA2_gene_is_an_established_disease_mechanism_in_individuals_with_hereditary_breast_and_ovarian_cancer_(HBOC)._Additionally,_this_variant_was_clas_sified_as_pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_pan_el_(ClinVar_SCV000282418.1)._In_summary,_the_p.Ser1982fs_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_up_on_the_predicted_impact_to_the_protein_and_presence_in_multiple_affected_individ_uals._ACMG/AMP_Criteria_applied_(Richards_2015):_PVS1,_PS4_Strong.||Variant_summary:_BRCA2_c.5946delT_(p.Ser1982ArgfsX22)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_0.0002765_in_282088_control_chromosomes_(gnomAD),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)_and_was_predominantly_observed_in_the_Ashkenazi_Jewish_subpopulation._This_variant_is_a_well-established_Ashkenazi_Jewish_founder_mutation._The_variant,_c.5946delT,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Abeliovich_1997,_Friedman_1998)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._At_least_one_publication_reports_experimental_evidence_evaluating_an_impact_on_protein_function_(Wu_2005)._Multiple_ClinVar_submissions_after_2014_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Converted_during_submission_to_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_pathogenic_variant_is_denoted_BRCA2_c.5946delT_at_the_cDNA_level_and_p.Ser1982ArgfsX22_(S1982RfsX22)_at_the_protein_level_and_is_also_known_as_6174delT_using_alternate_nomenclature._The_normal_sequence_with_the_base_that_is_deleted_in_brackets_is_CAAG[delT]GGAA._The_deletion_causes_a_frameshift,_changing_a_Serine_to_an_Arginine_at_codon_1982,_and_creating_a_premature_stop_codon_at_position_22_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_either_through_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.5946delT_is_known_to_be_a_pathogenic_founder_variant_in_the_Ashkenazi_Jewish_population_(Oddoux_1996).||The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|||||The_BRCA2_c.5946delT_(p.Ser1982ArgfsTer22)_variant,_more_commonly_known_as_c.6174delT,_results_in_a_frameshift_and_premature_termination_of_the_protein._The_p.Ser1982ArgfsTer22_variant_is_a_well-described_founder_variant_in_the_BRCA2_gene_that_is_prevalent_in_the_Ashkenazi_Jewish_and_Icelandic_populations,_with_a_carrier_frequency_of_~1.5%_(Roa_et_al._1996:_Neuhausen_et_al._1996)._The_variant_has_been_shown_to_occur_in_approximately_eight_percent_of_women_diagnosed_with_breast_cancer_before_the_age_of_42_years_(Neuhausen_et_al._1996:_Oddoux_et_al._1996:_Petrucelli_et_al._2010:_Finkelman_et_al._2012)._By_the_age_of_70,_43%_of_individuals_who_carry_this_variant_are_predicted_to_develop_breast_cancer_and_20%_are_predicted_to_develop_ovarian_cancer_(Struewing_et_al._1997:_King_et_al._2003)._Across_a_selection_of_the_literature,_the_p.Ser1982ArgfsTer22_variant_has_been_identified_in_55_of_1,272_(4%)_individuals_with_breast_cancer,_44_of_382_(11.5%)_individuals_with_ovarian_cancer,_and_at_least_118_of_9,658_(1.2%)_Ashkenazi_Jewish_individuals_from_the_general_population_(Couch_et_al._1996:_Roa_et_al._1996:_Neuhausen_et_al._1996:_Oddoux_et_al._1996:_Struewing_et_al._1997:_Satagopan_et_al._2002:_King_et_al._2003)._Additionally,_the_p.Ser1982ArgfsTer22_variant_has_been_identified_in_a_compound_heterozygous_state_in_four_individuals,_including_two_cousins,_with_Fanconi_anemia_and_brain_tumors_from_three_different_Ashkenazi_Jewish_families_(Offit_et_al._2003:_Alter_et_al._2007)._The_p.Ser1982ArgfsTer22_variant_was_absent_from_at_least_1,726_non-Ashkenazi_Jewish_controls_and_is_reported_at_a_frequency_of_0.00048_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Functional_studies_demonstrated_decreased_cell_viability_and_survival_in_carriers_of_the_p.Ser1982ArgfsTer22_variant_(Wu_et_al._2005)._The_variant_protein_was_shown_to_be_localized_in_the_cytoplasm_and_not_in_the_nucleus._The_p.Ser1982ArgfsTer22_variant_is_predicted_to_result_in_truncation_of_approximately_41%_of_the_BRCA2_protein,_which_would_remove_two_signals_required_for_nuclear_localization_and_represents_a_likely_mode_of_pathogenicity_for_the_variant_(Spain_et_al._1999)._In_a_study_in_mouse_embryonic_stem_cells,_the_p.Ser1982ArgfsTer22_variant_failed_to_rescue_the_loss_of_endogenous_BRCA2_(Kuznetsov_et_al._2008)._Based_on_the_collective_evidence,_the_p.Ser1982ArgfsTer22_variant_is_classified_as_pathogenic_for_BRCA2-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.||||This_variant_is_also_known_as_c.6174delT_using_alternate_nomenclature._This_variant_is_known_as_a_founder_mutation_in_the_Ashkenazi_Jewish_population_(PMID:_20301425)_and_has_been_previously_reported_as_a_heterozygous_change_in_multiple_individuals_with_a_personal_or_family_history_of_breast_and/or_ovarian_cancer,_among_other_types_of_cancer_(PMID:_20301425,_29084914,_29433453,_2644092,_29321669,_28767289)._Based_on_the_available_evidence,_the_c.5946delT_(p.Ser1982ArgfsTer22)_variant_is_classified_as_pathogenic.|The_BRCA2_c.5946delT:_p.Ser1982fs_variant_(also_known_as_6174delT)_creates_a_frameshift_and_is_predicted_to_result_in_a_truncated_protein_or_absent_transcript._This_variant_is_known_to_be_a_pathogenic_founder_variant_in_the_Ashkenazi_Jewish_population_(Abeliovich_1997,_Couch_1996,_Finkelman_2012),_and_has_been_associated_with_hereditary_breast_and_ovarian_cancer_syndrome_(see_ClinVar_and_references_therein)._References:_Link_to_ClinVar_database_for_BRCA2_c.5946delT:_https://www.ncbi.nlm.nih.gov/clinvar/variation/9325/_Abeliovich_D_et_al._The_founder_mutations_185delAG_and_5382insC_in_BRCA1_and_6174delT_in_BRCA2_appear_in_60%_of_ovarian_cancer_and_30%_of_early-onset_breast_cancer_patients_among_Ashkenazi_women._Am_J_Hum_Genet._1997_Mar:60(3):505-14._Couch_FJ_et_al._BRCA2_germline_mutations_in_male_breast_cancer_cases_and_breast_cancer_families._Nat_Genet._1996_May:13(1):123-5._Finkelman_BS_et_al._Breast_and_ovarian_cancer_risk_and_risk_reduction_in_Jewish_BRCA1/2_mutation_carriers._J_Clin_Oncol._2012_Apr_20:30(12):1321-8.
NM_000059.3:c.5978T>G	BRCA2	stop_gained	102358	1	NA	NA	5	3	rs768242833	Breast-ovarian cancer, familial 2	254570	249004	_familial_2	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32914470T>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	768242833	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto	Pathogenic|Pathogenic	2016-09-08|2014-01-31	2016-09-13|2017-08-04	reviewed_by_expert_panel|no_assertion_criteria_provided	germline|germline	SCV000300961|SCV000587815	_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|
NM_000059.3:c.6065C>G	BRCA2	stop_gained	102464	1	NA	NA	5&5	3&1	rs80358843	Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome	51998	66666	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32914557C>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80358843	-	Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|GeneDx|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2004-02-20|2016-09-08|2015-10-02|2019-03-02|2018-09-10|0000-00-00|2019-02-21	2014-03-28|2016-09-13|2016-10-28|2020-02-26|2019-01-29|2017-04-19|2019-09-24	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000146757|SCV000300975|SCV000327343|SCV000278494|SCV000512374|SCV000592026|SCV000694933	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_pathogenic_variant_is_denoted_BRCA2_c.6065C>G_at_the_cDNA_level_and_p.Ser2022Ter_(S2022X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_BRCA2_6293C>G_using_alternate_nomenclature,_has_been_observed_in_association_with_breast_cancer_(Loman_2000,_Staff_2001,_Jonsson_2005,_Nik-Zainal_2012,_Winter_2016,_Davies_2017),_and_is_considered_pathogenic.||Variant_summary:_BRCA2_c.6065C>G_(p.Ser2022X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.6079dupA,_p.Arg2027fsX22:_c.6270_6271delTA:_p.His2090fsX9:_c.6275_6276delTT,_p.Leu2092fsX7)._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_245756_control_chromosomes_(gnomAD)._c.6065C>G_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(e.g._Loman_2000,_Bosdet_2013,_Lin_2019)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_other_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_000059.3:c.6079dup	BRCA2	frameshift_variant	102484	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.6267del	BRCA2	frameshift_variant	100592	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.6269del	BRCA2	frameshift_variant	100448	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.6275_6276del	BRCA2	frameshift_variant	100264	5	15420	1	-	-	-	-	9318	24357	_familial_2|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32914767_32914768del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2209640|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:51021|Breast_Cancer_Information_Core__(BRCA2):6503&base_change%3Ddel_TT|OMIM_Allelic_Variant:600185.0002	-	BRCA2:675	SO:0001589|frameshift_variant	1	11571658	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Pathway_Genomics|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Invitae|Cancer_Genetics_and_Genomics_Laboratory,British_Columbia_Cancer_Agency|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2001-01-01|2013-10-16|2002-05-29|2014-02-18|2014-07-24|2016-04-22|2015-10-02|2017-01-01|0000-00-00|2015-09-21|2017-10-12|2018-12-28|2017-04-18|2014-01-31|2017-04-20|2013-08-12|2016-07-22|2018-11-12|2015-04-06|2018-01-26|2019-01-04|2018-05-25|2019-05-04|2018-05-21|2015-08-18|2018-11-28	2020-01-14|2015-12-29|2014-03-28|2014-05-01|2014-08-08|2016-06-09|2016-10-28|2017-03-15|2018-04-04|2018-04-09|2018-06-14|2019-03-28|2017-08-04|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2020-02-26|2016-07-05|2018-04-23|2019-01-29|2018-09-19|2020-03-06|2018-10-10|2018-07-18|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000030124|SCV000054219|SCV000146807|SCV000154072|SCV000189898|SCV000282422|SCV000327378|SCV000577963|SCV000733279|SCV000744484|SCV000839912|SCV000072897|SCV000586966|SCV000587833|SCV000588108|SCV000592039|SCV000694953|SCV000185959|SCV000292149|SCV000992213|SCV000210777|SCV000225153|SCV000296690|SCV000883475|SCV000863721|SCV001160127	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|Breast_and/or_ovarian_cancer|not_specified	|||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||This_c.6275_6276del_(p.Leu2092Profs*7)_variant_in_exon_11_of_the_BRCA2_gene_is_a_deletion_of_2_nucleotides_and_is_predicted_to_cause_loss_of_function_of_normal_protein_through_mRNA_decay_or_producing_a_truncated_protein,_which_is_a_known_disease_mechanism_for_this_gene._This_particular_variant_(also_known_as_6503delTT)_has_been_reported_in_multiple_individuals_affected_with_breast,_ovarian,_and_prostate_cancer_(PMID:_8524414,_22009639,_21324516,_22006311,_20736950,_23199084)._The_c.6275_6276del_(p.Leu2092Profs*7)_variant_in_BRCA2_gene_is_classified_as_pathogenic_(Atteeq_Rehman_10-12-2017).|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu2092Profs*7)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs11571658,_ExAC_0.009%)._This_variant_has_been_reported_in_individuals_affected_with_breast,_ovarian,_and_prostate_cancer_(PMID:_8524414,_22009639,_21324516,_22006311,_20736950,_23199084),_and_has_been_proposed_to_be_a_European_founder_variant_(PMID:_23199084)._This_variant_is_also_known_as_6503delTT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_9318)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||Variant_summary:_The_BRCA2_c.6275_6276delTT_(p.Leu2092Profs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.p.N2135fs)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_2/120912_control_chromosomes_at_a_frequency_of_0.0000165,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._This_variant_has_been_reported_in_numerous_Br/Ov_cancer_patients._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|This_deletion_of_two_nucleotides_in_BRCA2_is_denoted_c.6275_6276delTT_at_the_cDNA_level_and_p.Leu2092ProfsX7_(L2092PfsX7)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AGTC[delTT]CACT._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_a_Proline_at_codon_2092,_and_creates_a_premature_stop_codon_at_position_7_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.6275_6276delTT,_previously_reported_as_BRCA2_6503delTT,_has_been_observed_in_numerous_families_with_Hereditary_Breast_and_Ovarian_Cancer_(Wooster_1995,_Edwards_2010,_Walsh_2011,_Zhang_2011,_Bayraktar_2012,_Higgs_2015)._We_consider_this_variant_to_be_pathogenic.||The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_multiple_symptomatic_patients,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|The_BRCA2_c.6275_6276delTT:_p.Leu2092fs_variant_(rs11571658),_also_known_as_6503delTT_for_traditional_nomenclature,_is_reported_in_individuals_with_breast,_ovarian,_or_prostate_cancer_(Bayraktar_2012,_de_Juan_2015,_Edwards_2010,_Walsh_2011,_Wooster_1995,_Zhang_2011)._This_variant_is_reported_multiple_times_in_ClinVar_(Variation_ID:_9318),_and_found_in_the_general_population_with_a_low_overall_allele_frequency_of_0.003%_(9/269698_alleles)_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_deleting_2_nucleotides,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Bayraktar_S_et_al._Predictive_factors_for_BRCA1/BRCA2_mutations_in_women_with_ductal_carcinoma_in_situ._Cancer._2012_Mar_15:118(6):1515-22._de_Juan_I_et_al._BRCA1_and_BRCA2_mutations_in_males_with_familial_breast_and_ovarian_cancer_syndrome._Results_of_a_Spanish_multicenter_study._Fam_Cancer._2015_Dec:14(4):505-13._Edwards_SM_et_al._Prostate_cancer_in_BRCA2_germline_mutation_carriers_is_associated_with_poorer_prognosis._Br_J_Cancer._2010_Sep_7:103(6):918-24._Walsh_T_et_al._Mutations_in_12_genes_for_inherited_ovarian,_fallopian_tube,_and_peritoneal_carcinoma_identified_by_massively_parallel_sequencing._Proc_Natl_Acad_Sci_U_S_A._2011_Nov_1:108(44):18032-7._Wooster_R_et_al._Identification_of_the_breast_cancer_susceptibility_gene_BRCA2._Nature._1995_Dec_21-28:378(6559):789-92._Zhang_S_et_al._Frequencies_of_BRCA1_and_BRCA2_mutations_among_1,342_unselected_patients_with_invasive_ovarian_cancer._Gynecol_Oncol._2011_May_1:121(2):353-7.||The_BRCA2_c.6275_6276delTT:_p.Leu2092fs_variant_(rs11571658),_also_known_as_6503delTT_in_traditional_nomenclature,_is_reported_in_multiple_individuals_affected_with_breast,_ovarian,_or_prostate_cancer_(Bayraktar_2012,_de_Juan_2015,_Edwards_2010,_Walsh_2011,_Wooster_1995,_Zhang_2011)._This_variant_is_reported_as_pathogenic_by_numerous_laboratories_in_ClinVar_(Variation_ID:_9318),_and_it_is_found_in_the_general_population_with_a_low_overall_allele_frequency_of_0.004%_(10/274924_alleles)_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_deleting_two_nucleotides,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Bayraktar_S_et_al._Predictive_factors_for_BRCA1/BRCA2_mutations_in_women_with_ductal_carcinoma_in_situ._Cancer._2012_Mar_15:118(6):1515-22._de_Juan_I_et_al._BRCA1_and_BRCA2_mutations_in_males_with_familial_breast_and_ovarian_cancer_syndrome._Results_of_a_Spanish_multicenter_study._Fam_Cancer._2015_Dec:14(4):505-13._Edwards_SM_et_al._Prostate_cancer_in_BRCA2_germline_mutation_carriers_is_associated_with_poorer_prognosis._Br_J_Cancer._2010_Sep_7:103(6):918-24._Walsh_T_et_al._Mutations_in_12_genes_for_inherited_ovarian,_fallopian_tube,_and_peritoneal_carcinoma_identified_by_massively_parallel_sequencing._Proc_Natl_Acad_Sci_U_S_A._2011_Nov_1:108(44):18032-7._Wooster_R_et_al._Identification_of_the_breast_cancer_susceptibility_gene_BRCA2._Nature._1995_Dec_21-28:378(6559):789-92._Zhang_S_et_al._Frequencies_of_BRCA1_and_BRCA2_mutations_among_1,342_unselected_patients_with_invasive_ovarian_cancer._Gynecol_Oncol._2011_May_1:121(2):353-7.
NM_000059.3:c.6466_6469del	BRCA2	frameshift_variant	96356	1	NA	NA	-	-	-	-	252446	246842	_familial_2|Breast_and/or_ovarian_cancer	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN221562	-	NC_000013.10:g.32914954_32914955TC[2]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359596	-	GeneKor_MSA|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Invitae|Ambry_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-11-01|2016-09-08|2015-10-02|2014-01-31|2012-11-15|2017-12-20|2017-06-27|2012-07-06	2017-11-21|2016-09-13|2016-10-28|2017-08-04|2017-04-19|2018-04-02|2020-02-26|2018-07-18	criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline	SCV000296827|SCV000301055|SCV000327436|SCV000587850|SCV000592054|SCV000759003|SCV000666164|SCV000863724	Familial_cancer_of_breast|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Breast_and/or_ovarian_cancer	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser2156Asnfs*11)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs748536459,_ExAC_0.002%)._This_variant_has_been_reported_in_an_individual_in_the_Leiden_Open-source_Variation_Database_(PMID:_21520333).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_252446)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_000059.3:c.6535_6536insA	BRCA2	frameshift_variant	100556	1	NA	NA	-	-	-	-	38050	46606	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32915027_32915028insA	reviewed_by_expert_panel	Pathogenic	-	-	Insertion	SO:0000667	Breast_Cancer_Information_Core__(BRCA2):6763&base_change%3Dins_A	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359601	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2009-04-15|2002-05-29|2016-04-22|2015-10-02|2014-01-31|2018-03-02|2018-01-26|2018-02-26	2012-10-30|2014-03-28|2016-06-09|2016-10-28|2017-08-04|2018-08-31|2018-04-23|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000054239|SCV000146880|SCV000282429|SCV000327456|SCV000587856|SCV000889102|SCV000992215|SCV001187558	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000059.3:c.6757_6758del	BRCA2	frameshift_variant	102664	1	NA	NA	-	-	-	-	52177	66845	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32915247_32915248CT[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA2):6985&base_change%3Ddel_CT|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2846640	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359623	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Sharing_Clinical_Reports_Project_(SCRP)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-09-09|2014-01-31|2018-02-05|2004-02-20|2010-01-13|2016-09-08|2015-10-02|2019-01-02|2018-02-10|2018-12-18|2018-06-28	2019-03-28|2017-08-04|2019-04-24|2014-03-28|2015-08-20|2016-09-13|2016-10-28|2020-02-26|2018-11-06|2019-01-29|2018-08-31	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000073054|SCV000587868|SCV000918813|SCV000146924|SCV000297548|SCV000301104|SCV000327515|SCV000213420|SCV000906927|SCV000617470|SCV000887888	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_deletes_2_nucleotides_from_exon_11_of_the_BRCA2_mRNA_(c.6757_6758delCT),_causing_a_frameshift_at_codon_2253._This_creates_a_premature_translational_stop_signal_(p.Leu2253Phefs*7)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Truncating_variants_in_BRCA2_are_known_to_be_pathogenic._This_particular_truncation_has_been_reported_in_the_literature_in_an_individual_affected_with_breast_and_ovarian_cancer_(PMID:_11606101)._This_variant_has_also_been_reported_as_6985delCT_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRCA2_c.6757_6758delCT_(p.Leu2253PhefsX7)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._p.Arg2318X,_p.Gln2342fsX17)._The_variant_was_absent_in_121130_control_chromosomes._c.6757_6758delCT_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_and_prostate_cancer_(Bosdet_2013,_Euhus_2002,_Schorge_2001,_Lubinski_2004,_Pritchard_2016)._These_data_indicate_that_the_variant_is_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Five_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_two_nucleotides_in_BRCA2_is_denoted_c.6757_6758delCT_at_the_cDNA_level_and_p.Leu2253PhefsX7_(L2253FfsX7)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TTCT[delCT]TTTTA._The_deletion_causes_a_frameshift_which_changes_a_Leucine_to_a_Phenylalanine_at_codon_2253,_and_creates_a_premature_stop_codon_at_position_7_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.6757_6758delCT,_also_denoted_6985delCT_using_alternate_nomenclature,_has_been_reported_in_association_with_hereditary_breast_and_ovarian_cancer_(Schorge_2001,_Lubinski_2004,_Pritchard_2016)._We_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.6841+1G>A	BRCA2	splice_donor_variant	102192	1	NA	NA	-	-	-	-	658498	652821	Hereditary_breast_and_ovarian_cancer_syndrome	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145	-	NC_000013.10:g.32915334G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001575|splice_donor_variant	1	-	-	_Partners_HealthCare_Personalized_Medicine	Likely_pathogenic|Likely_pathogenic	2018-07-18|2018-07-31	2019-03-28|2019-03-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000955782|SCV000966919	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	This_sequence_change_affects_a_donor_splice_site_in_intron_11_of_the_BRCA2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs773863936,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_in_the_Leiden_Open-source_Variation_Database_(PMID:_21520333)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|The_c.6841+1G>A_variant_in_BRCA2_has_not_been_previously_reported_in_individuals_with_hereditary_breast_and_ovarian_cancer_(HBOC)_but_has_been_identified_in_1/1_11520_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gn_omad.broadinstitute.org:_dbSNP_rs773863936)._The_c.6841+1G>A_variant_occurs_in_t_he_invariant_region_(+/-_1,2)_of_the_splice_consensus_sequence_and_is_predicted_to_cause_altered_splicing_leading_to_an_abnormal_or_absent_protein._In_vitro_fun_ctional_splicing_studies_have_shown_that_a_different_variant_at_the_same_nucleot_ide_position_(c.6841+1G>C)_causes_aberrant_splicing_that_leads_to_in_frame_skipp_ing_in_a_critical_region_of_exon_11_(Baert_2018),_suggesting_that_variants_at_th_is_position_are_likely_to_disrupt_RNA_splicing._In_summary,_although_additional_studies_are_required_to_fully_establish_its_clinical_significance,_the_c.6841+1_G>A_variant_is_likely_pathogenic._ACMG/AMP_Criteria_Applied:_PM2,_PM4,_PM5,_PP3.
NM_000059.3:c.6859_6863del	BRCA2	frameshift_variant	100974	1	NA	NA	-	-	-	-	91461	96938	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32918712_32918716del	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	398122568	-	Sharing_Clinical_Reports_Project_(SCRP)|GeneDx|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Uncertain_significance	2008-08-13|2015-05-04|2019-01-07|2019-12-18	2015-08-20|2019-01-29|2019-03-28|2020-02-26	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000108775|SCV000566500|SCV000939823|SCV001187981	_familial_2|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome	|This_deletion_of_5_nucleotides_in_BRCA2_is_denoted_c.6859_6863delAGAAA_at_the_cDNA_level_and_p.Arg2287LeufsX4_(R2287LfsX4)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_CAAA[AGAAA]CTTA._The_deletion_causes_a_frameshift,_which_changes_an_Arginine_to_a_Leucine_at_codon_2287,_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_This_variant,_also_known_as_BRCA2_7087_7091delAGAAA_using_alternate_nomenclature,_has_not,_to_our_knowledge,_been_reported_in_the_literature,_the_adjacent_mutation_BRCA2_c.6856delAAAAG,_which_also_results_in_a_frameshift_at_this_residue_(p.Arg2287LeufsX4),_has_been_reported_in_at_least_one_individual_with_early-onset_prostate_cancer_(Edwards_2003,_2010)._we_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg2287Leufs*4)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_at_least_one_individual_affected_with_prostate_cancer_(PMID:Â¬â€ 12474142,Â¬â€ 20043088).Â¬â€ This_variant_is_also_known_asÂ¬â€ 7084delAAAAG_andÂ¬â€ 6856delAAAAGÂ¬â€ in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 91461)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Insufficient_evidence
NM_000059.3:c.7069_7070del	BRCA2	frameshift_variant	102484	6	15432	1	-	-	-	-	38082	46638	_familial_2|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN517202	-	NC_000013.10:g.32929059_32929060del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2221732|Breast_Cancer_Information_Core__(BRCA2):7297&base_change%3Ddel_CT|Geisinger_Autism_and_Developmental_Medicine_Institute,Geisinger_Health_System:ADMI00115|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:174397	-	BRCA2:675	SO:0001589|frameshift_variant	17	80359636	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Genologica_Medica|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Geisinger_Autism_and_Developmental_Medicine_Institute,Geisinger_Health_System|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Ambry_Genetics|Color|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-04-23|2002-05-29|2014-11-03|2016-04-22|2015-10-02|2016-02-04|2017-01-01|2015-07-01|0000-00-00|2015-09-21|2017-06-11|2018-07-25|2019-04-30|2017-07-27|2019-01-09|2015-04-07|2018-12-26|2015-12-15|2014-01-31|2014-06-23|2017-08-07|2018-07-02|2019-01-14	2015-12-29|2014-03-28|2016-04-21|2016-06-09|2016-10-28|2016-11-23|2017-03-15|2017-10-18|2018-04-04|2018-04-09|2018-03-27|2019-01-29|2020-03-06|2018-10-10|2020-02-26|2016-07-05|2019-03-28|2019-03-21|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|maternal|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline	SCV000054271|SCV000147015|SCV000196001|SCV000282439|SCV000327588|SCV000488257|SCV000577969|SCV000605676|SCV000733293|SCV000744510|SCV000804428|SCV000210786|SCV000296725|SCV000885109|SCV000185962|SCV000292173|SCV000073149|SCV000271332|SCV000587883|SCV000592097|SCV000695036|SCV000838849|SCV001160239	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_specified	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||||This_6_year_old_male_with_global_developmental_delays_(at-risk_for_mild_intellectual_disability),_ADHD,_disruptive_behavior,_and_mild_overgrowth_was_found_to_carry_a_maternally_inherited_2_bp_deletion_in_the_BRCA2_gene._The_c.7069_7070delCT_pathogenic_variant_in_the_BRCA2_gene,_previously_reported_as_7297delCT_using_alternate_nomenclature,_has_been_published_in_association_with_early-onset_breast_cancer,_ovarian_cancer,_and_prostate_cancer_(Garvin_et_al.,_1997:_Zhang_et_al.,_2011:_Cunningham_et_al.,_2014:_Song_et_al.,_2014:_Ellingson_et_al.,_2015:_Decker_et_al.,_2016)._The_deletion_causes_a_frameshift_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Given_that_this_is_an_adult-onset_condition,_the_patient_is_not_expected_to_be_affected_at_this_time._The_patient's_mother_has_not_been_formally_evaluated_in_the_oncology_setting,_so_her_current_status_is_unknown.|This_pathogenic_variant_is_denoted_BRCA2_c.7069_7070delCT_at_the_cDNA_level_and_p.Leu2357ValfsX2_(L2357VfsX2)_at_the_protein_level._The_normal_sequence_with_the_bases_that_are_deleted_in_brackets_is_ATTT[delCT]GTCT._The_deletion_causes_a_frameshift,_changing_a_Leucine_to_a_Valine_at_codon_2357,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.7069_7070delCT,_previously_reported_as_7297delCT_using_alternate_nomenclature,_has_been_published_in_association_with_early-onset_breast_cancer,_ovarian_cancer,_and_prostate_cancer_(Garvin_1997,_Zhang_2011,_Cunningham_2014,_Song_2014,_Ellingson_2015,_Decker_2016)._We_therefore_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu2357Valfs*2)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs756538291,_ExAC_0.006%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_9429140,_21324516,_24504028,_24728189)._This_variant_is_also_known_as_7297delCT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_38082)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Leu2357fs_variant_in_BRCA2_has_been_identified_in_>30_individuals_with_BRC_A2-associated_cancers_(Garvin_1997,_Spearman_2008,_Borg_2010,_Caux-Moncoutier_20_11,_Zhang_2011,_Breast_Cancer_Information_Core_(BIC)_database)._This_variant_has_also_been_identified_in_4/66706_European_chromosomes_by_the_Exome_Aggregation_C_onsortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs80359636)._Please_note_that_this_frequency_is_low_enough_to_be_consistent_with_the_frequency_of_heredit_ary_breast_and_ovarian_cancer_(HBOC)_in_the_general_population._This_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_2357_and_leads_to_a_premature_termination_codon_2_amino_ac_ids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_abse_nt_protein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_di_sease_mechanism_in_individuals_with_HBOC._In_addition,_this_variant_was_classifi_ed_as_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(_ClinVar_SCV000282439.1)._In_summary,_this_variant_meets_criteria_to_be_classifie_d_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_predicte_d_impact_to_the_protein.|||Variant_summary:_The_BRCA2_c.7069_7070delCT_(p.Leu2357Valfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.7133C>G_[p.Ser2378X],_c.7180A>T_[p.Arg2394X],_and_c.7360delA_[p.Ile2454fs)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_the_large_control_database_ExAC_at_a_frequency_of_0.000033_(4/121100_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._The_variant_has_been_identified_in_numerous_patients_in_published_reports_(e.g.,_Thomassen_Acta_Oncol_2008)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||The_BRCA2_c.7069_7070delCT,_p.Leu2357fs_variant_(rs80359636),_also_known_as_7297delCT,_has_been_reported_in_multiple_individuals_with_early_onset_breast_or_ovarian_cancer_(Caux-Moncoutier_2011,_Cunningham_2014,_Garvin_1997,_Zhang_2011)._It_is_listed_as_pathogenic_in_ClinVar_(Variation_ID:_38082),_and_observed_7_times_in_the_Genome_Aggregation_Database_(7/276822_alleles)._The_variant_introduces_a_frameshift,_and_is_predicted_to_result_in_a_truncated_protein_or_an_absent_transcript._Based_on_the_above_information,_the_variant_is_classified_as_pathogenic._References:_Caux-Moncoutier_V_et_al._EMMA,_a_cost-_and_time-effective_diagnostic_method_for_simultaneous_detection_of_point_mutations_and_large-scale_genomic_rearrangements:_application_to_BRCA1_and_BRCA2_in_1,525_patients._Hum_Mutat._2011:_32(3):325-34._Cunningham_J_et_al._Clinical_characteristics_of_ovarian_cancer_classified_by_BRCA1,_BRCA2,_and_RAD51C_status._Sci_Rep._2014:_4:4026._Garvin_A_et_al._BRCA1_and_BRCA2_mutation_analysis_in_86_early_onset_breast/ovarian_cancer_patients._J_Med_Genet._1997:_34(12):990-5._Zhang_S_et_al._Frequencies_of_BRCA1_and_BRCA2_mutations_among_1,342_unselected_patients_with_invasive_ovarian_cancer._Gynecol_Oncol._2011:_121(2):353-7.
NM_000059.3:c.7147dup	BRCA2	frameshift_variant	102574	1	NA	NA	-	-	-	-	236897	241703	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32929137dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	878853599	-	_c/o_University_of_Cambridge|GeneDx	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-12|2016-10-13|2016-09-08|2015-10-02|2016-12-12	2019-03-28|2018-01-25|2016-09-13|2016-10-28|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000283309|SCV000695045|SCV000301135|SCV000327597|SCV000779006	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr2383Leufs*9)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_reported_in_individuals_in_the_Leiden_Open-source_Variation_Database_(PMID:_21520333)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_236897)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_This_c.7147dupT_variant_in_BRCA2_gene_leads_to_that_results_in_the_loss_of_the_1023_amino_acids_of_BRCA2_(~70%)._This_change_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_or_nonsense-mediated_mRNA_decay._The_variant_is_absent_from_the_control_dataset_of_ExAC_and_has_not,_to_our_knowledge,_been_reported_in_affected_individuals_via_published_reports._Lastly,_the_variant_has_been_cited_as_Pathogenic_by_a_reputable_database/clinical_laboratory._Taking_together,_the_variant_was_classified_as_Likely_Pathogenic.|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.7147dupT_at_the_cDNA_level_and_p.Tyr2383LeufsX9_(Y2383LfsX9)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_ATTT[dupT]ATCA._The_duplication_causes_a_frameshift_which_changes_a_Tyrosine_to_a_Leucine_at_codon_2383,_and_creates_a_premature_stop_codon_at_position_9_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.
NM_000059.3:c.7419_7420del	BRCA2	frameshift_variant	102452	1	NA	NA	-	-	-	-	38095	46651	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32929407_32929408TG[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA2):7647&base_change%3Ddel_TG	-	BRCA2:675	SO:0001587|nonsense	1	80359651	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2009-01-15|2004-02-20|2016-04-22|2015-10-02|0000-00-00|2015-09-21|2014-01-31|2017-11-09|2017-05-01	2012-06-13|2014-03-28|2016-06-09|2016-10-28|2018-04-04|2018-04-09|2017-08-04|2019-04-24|2017-08-01	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054284|SCV000147079|SCV000282442|SCV000327653|SCV000733299|SCV000744517|SCV000587892|SCV000916925|SCV000600746	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||Variant_summary:_The_BRCA2_c.7419_7420delTG_(p.Cys2473X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._This_variant_was_found_in_1/245822_control_chromosomes_(gnomAD)_at_a_frequency_of_0.0000041,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._Multiple_publications_have_cited_the_variant_in_affected_individuals_and_indicate_the_variant_is_a_Dutch_founder_mutation._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|
NM_000059.3:c.7435+2T>A	BRCA2	splice_donor_variant	102196	1	NA	NA	-	-	-	-	581485	566076	Hereditary_breast_and_ovarian_cancer_syndrome	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145	-	NC_000013.10:g.32929427T>A	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001575|splice_donor_variant	1	1434072252	-	Invitae	Likely_pathogenic	2018-03-28	2018-08-29	_single_submitter	germline	SCV000834313	Hereditary_breast_and_ovarian_cancer_syndrome	This_sequence_change_affects_a_donor_splice_site_in_intron_14_of_the_BRCA2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRCA2-related_disease._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_000059.3:c.7558C>T	BRCA2	stop_gained	102574	1	NA	NA	5&5&5&5&5&5	2&3&0&2&1&1	rs80358981	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 2&Breast cancer&Hereditary cancer-predisposing syndrome&Breast-ovarian cancer, familial 1&not provided	52353	67021	Neoplasm_of_the_breast|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_1|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000013.10:g.32930687C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:94751	-	BRCA2:675	SO:0001587|nonsense	1	80358981	-	Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|CSER__CC_NCGL,_University_of_Washington|Ambry_Genetics|Color|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-28|2015-07-30|2014-01-31|2017-04-20|2015-04-08|2016-09-15|2013-03-14|2002-05-29|2016-04-22|2015-10-02|2016-08-16|2015-07-01|0000-00-00|2015-09-21|2018-01-14|2014-06-01|2019-07-26|2015-03-09|2015-11-20|2018-07-03|2015-02-12|2018-07-03	2019-03-28|2019-03-21|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2015-12-29|2014-03-28|2016-06-09|2016-10-28|2016-11-23|2017-10-18|2018-04-04|2018-04-09|2018-06-14|2014-08-28|2020-02-26|2016-07-05|2016-03-03|2019-01-29|2018-08-31|2019-08-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000073257|SCV000271333|SCV000587899|SCV000588114|SCV000592123|SCV000695078|SCV000109202|SCV000147121|SCV000282445|SCV000327682|SCV000489082|SCV000605679|SCV000733301|SCV000744521|SCV000839930|SCV000190124|SCV000213082|SCV000292167|SCV000266045|SCV000278874|SCV000296742|SCV000602766	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Neoplasm_of_the_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|not_specified	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg2520*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80358981,_ExAC_0.005%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_9150154,_14981104,_21990299,_22009639,_23242139,_24959366,_25863477,_20104584,_16284991),_and_an_individual_with_pancreatic_cancer_(PMID:_24959366)._This_variant_is_also_known_as_7786C>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52353)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Arg2520X_variant_in_BRCA2_has_been_reported_in_>40_individuals_with_BRCA2-_associated_cancers_(Hakansson_1997,_Bayraktar_2012,_Castera_2014,_Schultheis_201_4,_Breast_Cancer_Information_Core_(BIC)_database),_and_segregated_with_associate_d_cancers_in_2_affected_relatives_from_1_family._This_variant_has_also_been_iden_tified_in_3/66376_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC_,_http://exac.broadinstitute.org:_dbSNP_rs80358981)._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_2520,_which_is_predicted_to_lead_t_o_a_truncated_or_absent_protein._Heterozygous_loss_of_BRCA2_function_is_an_estab_lished_disease_mechanism_in_hereditary_breast_and_ovarian_cancer_(HBOC)._In_summ_ary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_a_utosomal_dominant_manner_based_on_the_low_frequency_in_controls,_presence_in_aff_ected_individuals,_and_predicted_impact_to_the_protein.||||Variant_summary:_The_BRCA2_c.7558C>T_(p.Arg2520X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._If_a_protein_product_is_made,_it_is_predicted_to_truncate_the_helical_domain,_nucleic_acid-binding/OB-fold_domain,_tower_domain,_and_oligonucleotide/oligosaccharide-binding_1_domain_(via_InterPro)._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.7721G>A/p.Trp2574X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_3/120748_control_chromosomes_at_a_frequency_of_0.0000248,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._This_variant_has_been_reported_in_many_HBOC_patients_in_the_literature._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||This_c.7558C>T_(p.Arg2520*)_variant_in_exon_15_of_the_BRCA2_gene_creates_a_premature_translation_termination_codon_and_is_predicted_to_result_in_loss_of_function_through_nonsense-mediated_mRNA_decay_or_by_producing_a_truncated_protein,_which_is_a_known_disease_mechanism_for_this_gene._This_variant_has_been_reported_in_multiple_hereditary_breast_and_ovarian_cancer_patients_(PMID:_9150154,_21990299,_22009639,_24959366,_25863477,_16284991,_25525159)_and_an_individual_with_pancreatic_cancer_(PMID:_24959366)._The_c.7558C>T_(p.Arg2520*)_variant_in_the_BRCA2_gene_is_classified_as_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_pathogenic_variant_is_denoted_BRCA2_c.7558C>T_at_the_cDNA_level_and_p.Arg2520Ter_(R2520X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_published_as_BRCA2_7786C>T_using_alternate_nomenclature,_has_been_reported_in_multiple_individuals_with_breast,_ovarian,_and/or_pancreatic_cancer,_many_with_family_histories_of_breast_and/or_ovarian_cancer_(Hakansson_1997,_Malander_2004,_Pal_2005,_Yang_2011,_Bayraktar_2012,_Schultheis_2014,_Nakamura_2015,_Wong-Brown_2015,_Kwong_2016)._We_consider_this_variant_to_be_pathogenic.||The_BRCA2_c.7558C>T:_p.Arg2520Ter_variant_(rs80358981)_has_been_described_in_individuals_with_breast,_ovarian,_pancreatic,_prostate_and_testicular_cancer_(Hakansson_1997,_Yang_2011,_Schultheis_2014)._It_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_52353)_and_observed_in_the_general_population_at_a_low_overall_frequency_of_0.0016%_(4/245940_alleles)_in_the_Genome_Aggregation_Database._This_variant_introduces_a_premature_termination_codon,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_pathogenic._References:_Hakansson_S_et_al._Moderate_frequency_of_BRCA1_and_BRCA2_germ-line_mutations_in_Scandinavian_familial_breast_cancer._Am_J_Hum_Genet._1997:60(5):1068-78._Schultheis_A_et_al._Squamous_Cell_Carcinoma_of_the_Pancreas_in_a_Patient_with_Germline_BRCA2_Mutation-Response_to_Neoadjuvant_Radiochemotherapy._Case_Rep_Oncol_Med._2014:2014:860532._Yang_D_et_al._Association_of_BRCA1_and_BRCA2_mutations_with_survival,_chemotherapy_sensitivity,_and_gene_mutator_phenotype_in_patients_with_ovarian_cancer._JAMA._2011:306(14):1557-65.
NM_000059.3:c.7673_7674dup	BRCA2	frameshift_variant	102592	1	NA	NA	-	-	-	-	254610	249044	_familial_2	-	OMIM:612555	-	NC_000013.10:g.32931932_32931933AG[3]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359672	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)	Pathogenic	2016-09-08	2016-09-13	reviewed_by_expert_panel	germline	SCV000301188	_familial_2	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.
NM_000059.3:c.7757G>A	BRCA2	stop_gained	102710	2	NA	NA	5&5&5&5	1&3&1&1	rs80359003	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&not provided	52401	67069	_familial_2|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32932018G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80359003	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-22|2014-01-31|2017-04-20|2013-04-05|2016-09-20|2013-04-11|2004-02-20|2016-04-22|2015-10-02|2018-07-26|2016-07-11|2018-09-13|2016-07-01|2015-07-13	2019-03-28|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2015-08-20|2014-03-28|2016-06-09|2016-10-28|2020-02-26|2017-01-26|2019-01-29|2018-08-31|2018-07-18	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000073315|SCV000587905|SCV000588116|SCV000592139|SCV000695098|SCV000109208|SCV000147172|SCV000282448|SCV000327724|SCV000186017|SCV000537635|SCV000278876|SCV000600767|SCV000863742	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Breast_and/or_ovarian_cancer	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_2586_(p.Trp2586*)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_families_and_individuals_with_hereditary_breast_and_ovarian_cancer_(PMID:_11802209,_16528604,_23633455,_12673801)_and_in_individuals_with_prostate_cancer_(PMID:_23569316,_23035815,_25485004)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_The_BRCA2_c.7757G>A_(p.Trp2586X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._If_a_protein_product_is_made,_it_is_predicted_to_truncate_the_tower_domain,_Nucleic_acid-binding,_OB-fold_domain,_helical_domain,_and_oligonucleotide/_oligosaccharide-binding_3_(InterPro)._Truncations_at_this_position_or_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.7758G>A/p.Trp2586X,_p.Arg2645fsX3,_p.Arg2892fsX14,_etc.)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_absent_in_121352_control_chromosomes,_but_has_been_reported_in_multiple_HBOC_and_prostate_cancer_patients_in_the_literature._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_BRCA2_c.7757G>A_at_the_cDNA_level_and_p.Trp2586Ter_(W2586X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tryptophan_to_a_premature_stop_codon_(TGG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_published_as_BRCA2_7985G>A_using_alternate_nomenclature,_has_been_reported_in_association_with_breast,_ovarian,_and_prostate_cancer_(Perkowska_2003,_Jonsson_2005,_George_2013,_Walker_2014),_and_is_considered_pathogenic.||
NM_000059.3:c.7805+1G>A	BRCA2	splice_donor_variant	102622	1	NA	NA	-	-	-	-	52410	67078	_familial_2	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32932067G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA2):8033+1&base_change%3DG_to_A	-	BRCA2:675	SO:0001575|splice_donor_variant	1	81002809	-	_c/o_University_of_Cambridge|Invitae|GeneKor_MSA|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2008-02-13|2003-12-23|2015-10-02|2016-08-16|2017-11-01|2018-08-07|2018-09-19	2013-08-08|2014-03-28|2016-10-28|2017-03-14|2017-11-21|2020-02-26|2018-11-06	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000109209|SCV000147184|SCV000327732|SCV000073326|SCV000296831|SCV000665944|SCV000906942	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|||This_sequence_change_affects_a_donor_splice_site_in_intron_16_of_the_BRCA2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_a_BRCA2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52410)._In_summary,_donor_and_acceptor_splice_site_variants_are_typically_truncating_(PMID:_16199547),_and_truncating_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._However,_without_additional_functional_and/or_genetic_data,_this_variant_has_been_classified_as_Likely_Pathogenic.||Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Functionally-validated_splicing_mutation|
NM_000059.3:c.7933A>T	BRCA2	stop_gained	102590	1	NA	NA	-	-	-	-	267043	261441	_familial_2	-	OMIM:612555	-	NC_000013.10:g.32936787A>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	876658889	-	_c/o_University_of_Cambridge	Pathogenic|Pathogenic	2016-10-18|2015-10-02	2016-10-18|2016-10-28	_single_submitter	germline|germline	SCV000324601|SCV000327766	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|
NM_000059.3:c.7977-1G>C	BRCA2	splice_acceptor_variant	101866	1	15422	1	-	-	-	-	38132	46688	_familial_2|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN517202	-	NC_000013.10:g.32937315G>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA2):8205-1&base_change%3DG_to_C	-	BRCA2:675	SO:0001574|splice_acceptor_variant	1	81002874	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Fulgent_Genetics,Fulgent_Genetics|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-05-01|2002-05-29|2015-10-02|2016-05-24|2015-10-22|2019-06-18|2018-12-28|2014-01-31|2018-01-15|2019-04-26|2015-04-08|2017-08-30|2016-04-02|2016-02-17	2013-12-30|2014-03-28|2016-10-28|2016-11-23|2017-04-18|2019-07-23|2019-03-28|2017-08-04|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2018-08-31|2017-06-30	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054321|SCV000147237|SCV000327781|SCV000488695|SCV000575741|SCV001161565|SCV000073381|SCV000587925|SCV000919024|SCV000213004|SCV000683926|SCV000568489|SCV000889145|SCV000602775	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_specified	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_000059.3:c.8463dup	BRCA2	frameshift_variant	102690	1	NA	NA	-	-	-	-	52596	67264	_familial_2	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32944670dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	397507988	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2016-09-08|2015-10-02|2014-01-31|2017-12-03	2016-09-13|2016-10-28|2017-08-04|2018-11-06	reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000301279|SCV000327896|SCV000587954|SCV000906580	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||
NM_000059.3:c.8537_8538del	BRCA2	frameshift_variant	102456	2	NA	NA	-	-	-	-	9328	24367	_familial_2|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32945138_32945139AG[2]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA2):8765&base_change%3Ddel_AG|OMIM_Allelic_Variant:600185.0012|Breast_Cancer_Information_Core__(BRCA2):8761&base_change%3Ddel_AG	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359714	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Pathway_Genomics|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1998-07-01|2013-04-22|2002-05-29|2014-07-24|2016-09-08|2015-10-02|2016-09-16|2018-12-30|2016-02-08|2014-01-31|2017-04-20|2013-11-14|2017-10-23|2018-12-06|2015-04-06|2018-12-13|2015-07-14|2017-09-04|2016-05-11	2016-09-09|2015-12-29|2014-03-28|2014-08-08|2016-09-13|2016-10-28|2016-11-23|2019-03-28|2019-03-21|2017-08-04|2017-08-04|2017-04-19|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2017-08-01|2018-04-30|2018-07-18	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000030136|SCV000054357|SCV000147396|SCV000189901|SCV000301287|SCV000327919|SCV000489211|SCV000073563|SCV000271336|SCV000587959|SCV000588121|SCV000592208|SCV000916958|SCV000186015|SCV000683979|SCV000210795|SCV000296650|SCV000219410|SCV000863619	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu2846Glyfs*22)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80359714,_ExAC_0.001%)._This_variant_is_clearly_defined_as_a_breast_and/or_ovarian_cancer_causative_allele_(PMID:_8673090,_21324516,_22401979)._It_is_a_common_cause_of_cancer_in_individuals_of_French_Canadian_(PMID:_15382066,_9792861,_27603373),_Yemenite_Jewish_(PMID:_9634522,_11512557),_and_Northern_Sardinian_(PMID:_19619314,_17640379)_ancestry._This_variant_is_also_known_as_8765delAG_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 9328)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Glu2846fs_variant_in_BRCA2_is_a_well-established_pathogenic_founder_varian_t_for_several_populations,_including_French_Canadians,_Jewish-Yemenites,_and_Nor_thern_Sardinian_(Tonin_1998,_Lerer_1998,_Ferla_2007)._This_variant_has_been_ide_ntified_in_1/66688_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExA_C,_http://exac.broadinstitute.org:_dbSNP_rs80359716)._This_frequency_is_low_enou_gh_to_be_consistent_with_the_frequency_of_hereditary_breast_and_ovarian_cancer_(_HBOC)_in_the_general_population._This_variant_is_predicted_to_cause_a_frameshift_,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_2846_and_leads_to_a_premature_termination_codon_22_amino_acids_downstream._This_alteratio_n_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_BRCA2_function_is_an_established_disease_mechanism_in_HBOC._In_summary,_this_variant_meets_our_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosom_al_dominant_manner.||||Variant_summary:_The_BRCA2_c.8537_8538delAG_(p.Glu2846GlyfsX22)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.8546delA_[p.Lys2849fsX14]_and_c.8575delC_[p.Gln2859fsX4])._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_3/245884_control_chromosomes_at_a_frequency_of_0.0000122,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._The_variant_has_been_reported_in_many_HBOC_patients_and_families,_including_76_patients_from_the_BIC_database._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_BRCA2_c.8537_8538delAG_at_the_cDNA_level_and_p.Glu2846GlyfsX22_(E2846GfsX22)_at_the_protein_level._This_deletion_is_also_known_as_BRCA2_c.8535delAG_or_8765delAG_using_alternate_nomenclature._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AGAG[delAG]GAAG._The_deletion_causes_a_frameshift,_changing_a_Glutamic_Acid_to_a_Glycine_at_codon_2846,_and_creating_a_premature_stop_codon_at_position_22_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.8537_8538delAG_has_been_reported_as_a_common_pathogenic_variant_associated_with_hereditary_breast/ovarian_cancer_in_the_French_Canadian,_Sardinian,_and_Czech_populations_(Foretova_2010,_Janavicius_2010,_Ghadirian_2014)._We_consider_this_variant_to_be_pathogenic.|||
NM_000059.3:c.9016_9017del	BRCA2	frameshift_variant	102132	1	NA	NA	-	-	-	-	52727	67395	_familial_2	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32953949_32953950del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):9244&base_change%3Ddel_TA|Breast_Cancer_Information_Core__(BRCA2):9243&base_change%3Ddel_AT	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359739	-	_c/o_University_of_Cambridge|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-02-26|2003-12-23|2016-09-08|2015-10-02|2019-02-20	2013-12-30|2014-03-28|2016-09-13|2016-10-28|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000115226|SCV000147513|SCV000301334|SCV000328023|SCV001179919	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000059.3:c.9054_9055del	BRCA2	frameshift_variant	102112	1	NA	NA	-	-	-	-	52734	67402	_familial_2	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32953987_32953988del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):9282&base_change%3Ddel_TA	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359743	-	_c/o_University_of_Cambridge|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2001-02-16|2016-09-08|2015-10-02|2016-01-21	2014-03-28|2016-09-13|2016-10-28|2020-02-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000147522|SCV000301342|SCV000328036|SCV000668531	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000059.3:c.9097dup	BRCA2	frameshift_variant	99852	2	NA	NA	-	-	-	-	38208	46764	Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_1|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:C2676676,OMIM:604370|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32954030dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRCA2:675	SO:0001589|frameshift_variant	3	397507419	-	Sharing_Clinical_Reports_Project_(SCRP)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Center_of_Medical_Genetics_and_Primary_Health_Care|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneKor_MSA|Bioscientia_Institut_fuer_Medizinische_Diagnostik_GmbH,Sonic_Healthcare|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-03-01|2016-04-21|2016-04-22|2015-10-02|2016-02-18|0000-00-00|2018-09-05|2019-06-12|2019-03-18|2016-07-20|2018-12-14|2014-01-31|2013-05-22|2016-10-28|2017-06-23|2018-07-02|2015-11-20|2018-08-01|2018-09-27|2013-06-08|2018-12-01	2015-12-29|2016-04-21|2016-06-09|2016-10-28|2016-11-23|2019-08-31|2019-01-29|2020-03-06|2020-02-26|2017-10-26|2019-03-28|2017-08-04|2017-04-19|2019-03-21|2018-01-25|2018-08-20|2016-03-03|2018-08-08|2019-03-13|2018-07-18|2019-02-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|somatic	SCV000054399|SCV000196022|SCV000282467|SCV000328046|SCV000488294|SCV000987249|SCV000210799|SCV000296658|SCV000185303|SCV000684022|SCV000073724|SCV000587986|SCV000592254|SCV000605794|SCV000695208|SCV000838892|SCV000266049|SCV000693591|SCV000925778|SCV000863757|SCV000923938	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.9097dupA_at_the_cDNA_level_and_p.Thr3033AsnfsX11_(T3033NfsX11)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_CAAAAAAA[dupA]CTCA._The_duplication_causes_a_frameshift,_which_changes_a_Threonine_to_an_Asparagine_at_codon_3033,_and_creates_a_premature_stop_codon_at_position_11_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.9097dupA,_previously_reported_as_c.9097_9098insA,_9325insA,_and_9317insA_using_alternate_nomenclature,_has_been_observed_in_association_with_breast,_ovarian_and_pancreatic_cancer,_and_in_the_compound_heterozygous_state_in_an_individual_with_Fanconi_Anemia_(Serova-Sinilnikova_1997,_Kopic_2011,_Kwong_2012,_Holter_2015)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_not_found_in_general_population_data.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Functionally-validated_splicing_mutation_:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Thr3033Asnfs*11)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer,_pancreatic_cancer,_and_Fanconi_anemia_(PMID:_22970155,_9150172,_25940717,_21138478)._This_variant_is_also_known_as_c.9097_9098insA,_9325insA_and_9317insA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_38208)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||The_p.Thr3033fs_variant_in_BRCA2_has_been_reported_in_>20_individuals_with_BRCA2_-associated_cancers_(Serova-Sinilnikova_1997,_Kopic_2011,_Kwong_2012,_Holter_201_5,_Wong-Brown_2015,_Breast_Cancer_Information_Core_(BIC)_database)._This_variant_has_been_identified_in_0.02%_(10/62160)_of_European_chromosomes_by_the_Exome_Ag_gregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs754205122)._This_frequency_is_low_enough_to_be_consistent_with_the_frequency_of_hereditary_b_reast_and_ovarian_cancer_(HBOC)_in_the_general_population._This_variant_is_predi_cted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_begin_ning_at_position_3033_and_leads_to_a_premature_termination_codon_11_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_p_rotein._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_diseas_e_mechanism_in_hereditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_va_riant_was_classified_as_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENI_GMA_expert_panel_(ClinVar_SCV000282467.1)._In_summary,_this_variant_meets_our_cr_iteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner.|||||||
NM_000059.3:c.9127G>T	BRCA2	stop_gained	102426	1	NA	NA	5&5	3&1	rs398122610	Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome	91517	96994	_familial_2	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32954153G>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	398122610	-	Sharing_Clinical_Reports_Project_(SCRP)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2008-03-28|2016-09-08|2015-10-02|2015-07-01|2017-04-26	2013-06-26|2016-09-13|2016-10-28|2017-10-18|2020-02-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000108831|SCV000301354|SCV000328064|SCV000605643|SCV000185308	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000059.3:c.9253dup	BRCA2	frameshift_variant	101812	1	NA	NA	-	-	-	-	38225	46781	_familial_2|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32954279dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Breast_Cancer_Information_Core__(BRCA2):9481&base_change%3Dins_A|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2451241	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359752	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Fulgent_Genetics,Fulgent_Genetics|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|GeneDx|Gharavi_Laboratory,Columbia_University|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Integrated_Genetics/Laboratory_Corporation_of_America|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-12-11|2002-05-29|2014-06-16|2015-04-15|2016-09-08|2015-10-02|2015-10-23|2015-07-01|0000-00-00|2015-09-21|2018-04-27|2018-12-26|2018-09-16|2015-04-15|2018-05-29|2015-11-23|2018-10-20|2014-01-31|2017-04-20|2016-11-02|2018-12-01	2015-08-20|2014-03-28|2015-03-11|2016-07-18|2016-09-13|2016-10-28|2017-04-18|2017-10-18|2018-04-04|2018-04-09|2018-06-14|2019-01-29|2018-09-24|2018-08-31|2020-02-26|2016-07-05|2019-03-28|2017-08-04|2017-08-04|2018-01-25|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054416|SCV000147581|SCV000220419|SCV000296685|SCV000301365|SCV000328084|SCV000575733|SCV000605645|SCV000733335|SCV000744559|SCV000839929|SCV000210800|SCV000809461|SCV000889181|SCV000185673|SCV000292174|SCV000073773|SCV000587992|SCV000588127|SCV000695224|SCV000923799	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Ovarian_Neoplasms	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||The_c.9246_9247dupA_(p.Thr3085Asnfs*26)_frameshift_variant_in_BRCA2_has_been_reported_in_multiple_unrelated_patients_with_breast,_ovarian_or_prostate_cancer_[PMID_11389159,_16455195,_16683254,_21952622,22798144,_25330149]._Based_on_the_current_evidence,_this_variant_is_classified_as_pathogenic|This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.9253dupA_at_the_cDNA_level_and_p.Thr3085AsnfsX26_(T3085NfsX26)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_duplicated_in_braces,_is_GAAAAAA[A]CAGG._The_duplication_causes_a_frameshift,_which_changes_a_Threonine_to_an_Asparagine_at_codon_3085,_and_creates_a_premature_stop_codon_at_position_26_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.9253dupA,_also_known_as_BRCA2_9481insA,_9481dupA_and_9474insA_using_alternate_nomenclature,_has_been_observed_in_association_with_breast,_ovarian_and_prostate_cancer_(Montagna_2002,_Spearman_2008,_Borg_2010,_Kote-Jarai_2011,_Kim_2012,_Castro_2013,_Kang_2015,_Pal_2015)._We_consider_this_variant_to_be_pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Thr3085Asnfs*26)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_particular_variant_has_been_reported_in_individuals_and_families_affected_withÂ¬â€ breast,_ovarian,_and_prostate_cancerÂ¬â€ (PMID:_11389159,_16455195,_16683254,_19656164,_21952622,_22798144,_23569316,_25330149).Â¬â€ This_variant_is_also_known_as_9474insA,_9481insA,_9253insA,_and_c.9253_9254insA_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:38225)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA2_c.9253dupA_(p.Thr3085Asnfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.9294C>G/p.Tyr3098X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_is_absent_in_120176_control_chromosomes._This_variant_has_been_reported_in_multiple_Br/Ov_cancer_patients,_with_evidence_of_co-segregation_of_variant_with_disease._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|
NM_000059.3:c.9382C>T	BRCA2	stop_gained	102656	1	15426	0	5&5&5&5&5	1&3&1&1&1	rs80359212	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&not provided&Breast cancer	52826	67494	Medulloblastoma|Malignant_tumor_of_prostate|Neoplasm_of_the_breast|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Glioma_susceptibility_3|Pancreatic_cancer_2|Wilms_tumor_1|Breast_and/or_ovarian_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:C2751641,OMIM:613029|MedGen:C3150546,OMIM:613347|MedGen:CN033288,OMIM:194070|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32968951C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	HGMD:CM014328	-	BRCA2:675	SO:0001587|nonsense	1	80359212	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|GenomeConnect,_ClinGen|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Division_Human_Genetics,Medical_University_Innsbruck|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|Department_of_Medical_Genetics,Oslo_University_Hospital|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Ambry_Genetics|Color|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Laboratory_of_Molecular_Diagnosis_of_Cancer,West_China_Hospital,_Sichuan_University|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Baylor_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-27|2014-01-31|2017-04-20|2012-02-09|2017-08-14|2018-07-02|0000-00-00|2013-01-23|2002-05-29|2015-02-11|2016-04-21|2016-04-22|2015-10-02|2017-01-01|2017-07-19|2015-07-01|2015-07-28|0000-00-00|2014-10-08|2015-09-21|2018-02-06|2018-11-27|2016-05-17|2014-04-15|2018-07-30|2015-10-17|2015-11-01|0000-00-00|2017-02-23|2008-07-17|2017-08-17|2018-10-31	2019-03-28|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2018-03-13|2015-08-20|2014-03-28|2015-02-11|2016-04-21|2016-06-09|2016-10-28|2017-03-15|2017-07-24|2017-10-18|2017-06-22|2018-04-04|2018-04-17|2018-04-09|2018-06-14|2020-02-26|2017-10-26|2018-09-19|2019-01-29|2018-08-31|2016-02-27|2016-12-06|2017-02-23|2018-07-18|2018-04-30|2018-11-14	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown	SCV000073820|SCV000588001|SCV000588129|SCV000592281|SCV000695236|SCV000838903|SCV000840274|SCV000109267|SCV000147627|SCV000212034|SCV000267830|SCV000282472|SCV000328122|SCV000577977|SCV000584011|SCV000605659|SCV000677708|SCV000733337|SCV000743366|SCV000744563|SCV000839931|SCV000185978|SCV000684059|SCV000202307|SCV000210506|SCV000296605|SCV000265916|SCV000492448|SCV000540993|SCV000863763|SCV000902219|SCV000894009	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Neoplasm_of_the_breast|Neoplasm_of_the_breast|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_2/Fanconi_anemia,_complementation_group_D1/Medulloblastoma/Wilms_tumor_1/Malignant_tumor_of_prostate/Pancreatic_cancer_2/Glioma_susceptibility_3	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg3128*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80359212,_ExAC_0.02%)._This_variant_has_been_reported_in_multiple_individuals_and_families_with_breast_cancer_(PMID:_10978364,_24156927,_16683254,_24916970,_15168169,_11400546,_16905680),_an_individual_with_ovarian_cancer_(PMID:_24728189),_and_individuals_with_prostate_cancer_(PMID:_24556621,_20736950)._This_variant_is_also_known_as_9610C>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52826)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_The_BRCA2_c.9382C>T_(p.Arg3128X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.9403delC_[p.Leu3135fsX28],_c.9435_9436delGT_[p.Ser3147fsX2],_and_c.9672dupA_[p.Tyr3225fsX30])._This_variant_was_found_in_the_large_control_database_ExAC_at_a_frequency_of_0.0000165_(2/121360_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._The_variant_has_been_reported_in_multiple_affected_individuals_and_was_shown_to_segregate_with_the_disease_in_multiple_HBOC_families._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.|||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||||||This_c.9382C>T_(p.R3128*)_missense_variant_is_predicted_to_result_in_a_premature_stop_codon_and_has_been_reported_in_multiple_individuals_with_breast,_ovarian,_and_prostate_cancer_(PMID:_10978364,_24156927,_16683254,_24916970,_15168169,_11400546,_16905680,_24728189,_24556621,_20736950)._Therefore,_the_c.9382C>T_(p.R3128*)_variant_in_the_BRCA2_gene_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_pathogenic_variant_is_denoted_BRCA2_c.9382C>T_at_the_cDNA_level_and_p.Arg3128Ter_(R3128X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_is_also_defined_as_BRCA2_9610C>T._The_substitution_creates_a_nonsense_variant,_changing_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_Arg3128Ter_has_been_reported_in_multiple_families_with_breast,_ovarian,_and/or_prostate_cancer_(Plaschke_2000,_Simard_2007,_Vogel_2007,_Sugano_2008,_Edwards_2010,_Leongamornlert_2014,_Peixoto_2015,_Rosenthal_2015,_Kwong_2016)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|||||||
NM_000059.3:c.9435_9436del	BRCA2	frameshift_variant	102658	1	NA	NA	-	-	-	-	38240	46796	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_1|BRCA2-Related_Disorders|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:C2676676,OMIM:604370|MedGen:CN239275|MedGen:CN517202	-	NC_000013.10:g.32969002_32969003GT[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Illumina:1324162	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359763	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Illumina_Clinical_Services_Laboratory,Illumina	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-10-10|2002-05-29|2016-09-08|2015-10-02|2015-11-18|2018-06-18|2016-04-21|2018-12-21|2014-01-31|0000-00-00|2017-11-24|2015-11-20|2018-04-18|2017-04-28|2018-08-15	2015-08-20|2014-03-28|2016-09-13|2016-10-28|2016-11-23|2020-02-26|2017-12-21|2019-03-28|2017-08-04|2017-04-19|2019-04-24|2016-03-03|2019-01-29|2017-08-01|2019-02-01	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054431|SCV000147636|SCV000301391|SCV000328134|SCV000487799|SCV000185976|SCV000689196|SCV000259805|SCV000588006|SCV000592288|SCV000918909|SCV000266053|SCV000108648|SCV000600861|SCV000914621	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|BRCA2-Related_Disorders	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser3147Cysfs*2)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_8673090,_22798144,_18489799,_21913181),_ovarian_cancer_(PMID:_24504028),_and_an_individual_with_male_breast_cancer_and_melanoma_(PMID:_28008555)._This_variant_is_also_known_as_9433delGT,_9663delGT_and_3144_3145del_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_38240)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_c.9435_9436delGT_(p.Ser3147CysfsX2)_variant_in_BRCA2_gene_is_a_frameshift_change_that_results_in_the_loss_of_the_~271_amino_acids_of_brca2_protein_(~10%)._This_change_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_or_nonsense-mediated_mRNA_decay._In_addition,_truncations_downstream_of_this_position_have_been_classified_as_pathogenic/likely_pathogenic_by_our_laboratory_(e.g._p.Arg3268fsX9,_p.Lys3263fsX12,_p.Tyr3308X,_etc)._The_variant_is_present_at_a_low_frequency_in_the_large_control_population_datasets_of_gnomAD_(0.000004:_1/246128_chrs_tested)._The_c.9435_9436delGT_has_been_reported_in_multiple_affected_individuals_with_personal_and_family_history_of_BrC_via_published_report._Lastly,_it_is_cited_as_Pathogenic_by_reputable_databases/clinical_laboratories._Taking_together,_the_variant_was_classified_as_Pathogenic.||This_deletion_of_two_nucleotides_in_BRCA2_is_denoted_c.9435_9436delGT_at_the_cDNA_level_and_p.Ser3147CysfsX2_(S3147CfsX2)_at_the_protein_level._This_deletion_is_also_known_as_BRCA2_9433delGT,_9663_9664delGT_and_9663delGT_using_alternate_nomenclature._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CTGT[delGT]TTTC._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_a_Cysteine_at_codon_3147,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.9435_9436delGT_has_been_observed_in_familial_breast_and_ovarian_cancer_cases_(Phelan_1996,_Kim_2012,_Cunningham_2014,_Hong_2016)_and_is_considered_pathogenic.||The_BRCA2_c.9435_9436delGT_(p.Ser3147CysfsTer2)_variant_is_a_frameshift_variant_that_is_predicted_to_cause_premature_truncation_of_the_protein._The_p.Ser3147CysfsTer2_variant_has_been_found_in_a_heterozygous_state_in_at_least_four_patients_with_hereditary_breast_and_ovarian_cancer_(HBOC),_including_in_one_male_with_breast_cancer,_in_two_individuals_with_breast_and/or_ovarian_cancer_and_in_one_individual_with_ovarian_cancer_(Kim_et_al._2012:_Litton_et_al._2012:_Cunningham_et_al._2014:_Pritzlaff_et_al._2017)._The_variant_was_also_identified_in_a_heterozygous_state_in_three_at-risk_individuals_with_a_family_history_of_early-onset_breast_and_ovarian_cancer_(Lubinski_et_al._2004:_Machackova_et_al._2008:_Bellacosa_et_al._2010)._This_variant_has_not_been_described_in_the_literature_in_patients_with_Fanconi_anemia_(FA),_however,_it_is_generally_accepted_that_heterozygous_variants_pathogenic_for_HBOC_confer_carrier_status_for_FA._Control_data_are_unavailable_for_this_variant_which_is_reported_at_a_frequency_of_0.000009_in_the_European_(non-Finnish)_population_of_the_Genome_Aggregation_Database_but_this_is_based_on_one_allele_in_a_region_of_good_sequence_coverage_so_the_variant_is_presumed_to_be_rare._Based_on_the_evidence_and_the_potential_impact_of_frameshift_variants,_the_p.Ser3147CysfsTer2_variant_is_classified_as_pathogenic_for_BRCA2-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_000059.3:c.9502-2A>C	BRCA2	splice_acceptor_variant	102550	1	NA	NA	-	-	-	-	52858	67526	_familial_2|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32971033A>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA2):9730-2&base_change%3DA_to_C	-	BRCA2:675	SO:0001574|splice_acceptor_variant	1	81002868	-	_c/o_University_of_Cambridge|Ambry_Genetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2003-12-23|2015-10-02|2016-02-10|2017-04-04	2014-03-28|2016-10-28|2020-02-26|2017-08-01	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000147657|SCV000328148|SCV000185979|SCV000600864	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|not_provided	||Functionally-validated_splicing_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|
NM_000059.3:c.9580_9581del	BRCA2	frameshift_variant	102692	1	NA	NA	-	-	-	-	38249	46805	_familial_2|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32971113_32971114del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):9808&base_change%3Ddel_CC	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359771	-	_c/o_University_of_Cambridge|GeneDx|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2007-06-20|1999-06-21|2016-09-08|2015-10-02|2016-11-28|2016-07-05|2016-08-18	2012-06-20|2014-03-28|2016-09-13|2016-10-28|2019-01-29|2020-02-26|2017-10-26	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000054440|SCV000147667|SCV000301404|SCV000328157|SCV000564803|SCV000665945|SCV000684074	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_deletion_of_two_nucleotides_in_BRCA2_is_denoted_c.9580_9581delCC_at_the_cDNA_level_and_p.Pro3194AsnfsX2_(P3194NfsX2)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CACC[delCC]AACT._The_deletion_causes_a_frameshift,_which_changes_a_Proline_to_an_Asparagine_at_codon_3194,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.9580_9581delCC,_previously_reported_as_9808delCC,_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Hakansson_1997)._We_consider_this_variant_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_005163.2:c.1260+1G>C	AKT1	splice_donor_variant	102694	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_005163.2:c.949del	AKT1	frameshift_variant	102556	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_005163.2:c.647_648del	AKT1	frameshift_variant	100716	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_005163.2:c.175+1G>A	AKT1	splice_donor_variant	102320	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.34dup	FAN1	frameshift_variant	99550	3	15288	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.34del	FAN1	frameshift_variant	99550	3	15288	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.32_35del	FAN1	frameshift_variant	100874	2	15432	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.74_75del	FAN1	frameshift_variant	102374	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.162T>A	FAN1	stop_gained	102686	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.256_257del	FAN1	frameshift_variant	102716	3	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.352A>T	FAN1	stop_gained	102704	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.372_375dup	FAN1	frameshift_variant	102682	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.406del	FAN1	frameshift_variant	102692	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.506C>G	FAN1	stop_gained	102566	2	15426	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.523G>T	FAN1	stop_gained	102556	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.560_561del	FAN1	frameshift_variant	102512	7	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.706_709del	FAN1	frameshift_variant	102684	2	15432	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.724C>T	FAN1	stop_gained	102714	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.840del	FAN1	frameshift_variant	102696	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.885del	FAN1	frameshift_variant	102698	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.922_923del	FAN1	frameshift_variant	102690	24	15434	3	-	-	-	-	421580	409204	not_provided	-	MedGen:CN517202	-	NC_000015.9:g.31197788_31197789del	_single_submitter	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	FAN1:22909	SO:0001589|frameshift_variant	1	774499986	-	GeneDx	Likely_pathogenic	2016-06-30	2019-01-29	_single_submitter	germline	SCV000570837	not_provided	The_c.922_923delGT_variant_in_the_FAN1_gene_has_not_been_reported_previously_as_a_pathogenic_variant_nor_as_a_benign_variant,_to_our_knowledge._This_variant_causes_a_frameshift_starting_with_codon_Valine_308,_changes_this_amino_acid_to_a_Cysteine_residue,_and_creates_a_premature_Stop_codon_at_position_5_of_the_new_reading_frame,_denoted_p.Val308CysfsX5._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_either_through_protein_truncation_or_nonsense-mediated_mRNA_decay._Population_data_reported_for_the_c.922_923delGT_variant_by_the_NHLBI_Exome_Sequencing_Project_are_unreliable_due_to_the_number_of_reported_homozygous_individuals_(44/6500)_exceeding_that_which_would_be_expected_according_to_Hardy-Weinberg_equilibrium._The_c.922_923delGT_variant_is_a_strong_candidate_for_a_pathogenic_variant,_however_the_possibility_it_may_be_a_rare_benign_variant_cannot_be_excluded.
NM_014967.4:c.929C>G	FAN1	stop_gained	102652	16	15428	16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.1121dup	FAN1	stop_gained,frameshift_variant	102706	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.1122C>G	FAN1	stop_gained	102690	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.1217_1221del	FAN1	frameshift_variant	100622	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.1275_1279dup	FAN1	frameshift_variant	102060	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.1741C>T	FAN1	stop_gained	102746	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.1811+1G>A	FAN1	splice_donor_variant	102470	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.1811+1G>T	FAN1	splice_donor_variant	102470	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2090_2091del	FAN1	frameshift_variant	102568	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2116C>T	FAN1	stop_gained	102724	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2128C>T	FAN1	stop_gained	102706	8	15428	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2245C>T	FAN1	stop_gained	102692	5	15400	2	5	0	rs387907279	Interstitial nephritis, karyomegalic	37097	45772	_karyomegalic	-	MedGen:C3553774,OMIM:614817,Orphanet:ORPHA401996	-	NC_000015.9:g.31217402C>T	no_assertion_criteria_provided	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:613534.0004	-	FAN1:22909|MTMR10:54893	SO:0001587|nonsense	1	387907279	-	OMIM	Pathogenic	2012-07-08	2016-08-10	no_assertion_criteria_provided	germline	SCV000053405	_karyomegalic	
NM_014967.4:c.2260C>T	FAN1	stop_gained	102730	2	15410	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2489-1G>C	FAN1	splice_acceptor_variant	102314	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2590C>T	FAN1	stop_gained,splice_region_variant	102730	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2593-1G>C	FAN1	splice_acceptor_variant	100922	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2616del	FAN1	frameshift_variant	101922	8	NA	NA	-	-	-	-	437429	430985	_karyomegalic	-	MedGen:C3553774,OMIM:614817,Orphanet:ORPHA401996	-	NC_000015.9:g.31221429del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva:19_May_2017|OMIM_Allelic_Variant:613534.0005	-	FAN1:22909|MTMR10:54893	SO:0001589|frameshift_variant	1	750056424	-	OMIM|Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva	Pathogenic|Pathogenic	2012-07-08|2016-09-21	2016-08-10|2017-05-19	_single_submitter	germline|germline	SCV000053406|SCV000598149	Interstitial_nephritis,_karyomegalic|Interstitial_nephritis,_karyomegalic	|
NM_014967.4:c.2774_2775del	FAN1	frameshift_variant	99472	5	15412	3	-	-	-	-	37100	45775	_karyomegalic	-	MedGen:C3553774,OMIM:614817,Orphanet:ORPHA401996	-	NC_000015.9:g.31221587_31221588del	no_assertion_criteria_provided	Pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:613534.0007	-	FAN1:22909|MTMR10:54893	SO:0001589|frameshift_variant	1	765970053	-	OMIM	Pathogenic	2012-07-08	2015-08-11	no_assertion_criteria_provided	germline	SCV000053408	_karyomegalic	
NM_014967.4:c.2854C>T	FAN1	stop_gained	102256	10	15436	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2860dup	FAN1	frameshift_variant	102328	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2863C>T	FAN1	stop_gained	102308	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.*3+1G>A	FAN1	splice_donor_variant	100630	15	15416	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002528.6:c.807G>A	NTHL1	stop_gained	102446	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002528.6:c.806G>A	NTHL1	stop_gained	102460	2	NA	NA	-	-	-	-	639573	643981	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.2090143C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	-	-	NTHL1:4913	SO:0001587|nonsense	1	-	-	Invitae|Ambry_Genetics	Uncertain_significance|Likely_pathogenic	2018-10-11|2019-07-26	2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000931691|SCV001189643	not_provided|Hereditary_cancer-predisposing_syndrome	This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_NTHL1_gene_(p.Trp269*)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_delete_the_last_44_amino_acids_of_the_NTHL1_protein._This_variant_is_present_in_population_databases_(rs753029097,_ExAC_0.003%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_disease._Experimental_studies_and_prediction_algorithms_are_not_available_for_this_variant,_and_the_functional_significance_of_the_deleted_amino_acids_is_currently_unknown._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_data_supporting_pathogenic_classification:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)_:Structural_Evidence
NM_002528.6:c.709+1G>A	NTHL1	splice_donor_variant	102048	1	NA	NA	-	-	-	-	218092	214746	Familial_adenomatous_polyposis_3|not_provided	-	MedGen:C4225157,OMIM:616415,Orphanet:ORPHA454840|MedGen:CN517202	-	NC_000016.9:g.2093567C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:602656.0002	-	NTHL1:4913	SO:0001575|splice_donor_variant	1	372946560	-	OMIM|Invitae	Pathogenic|Pathogenic	2015-11-12|2018-10-09	2016-08-11|2019-03-28	_single_submitter	unknown|germline	SCV000257324|SCV000947161	Familial_adenomatous_polyposis_3|not_provided	|This_sequence_change_affects_a_donor_splice_site_in_intron_4_of_the_NTHL1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs372946560,_ExAC_0.002%)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_another_pathogenic_variant_in_an_individual_affected_with_multiple_primary_tumors_including_multiple_colorectal_adenomas_(PMID:Â¬â€ 26559593)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_218092)._Experimental_studies_have_shown_that_this_sequence_change_disrupts_normal_mRNA_splicing_(PMID:Â¬â€ 26559593)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002528.6:c.550-1G>A	NTHL1	splice_acceptor_variant	102168	7	NA	NA	-	-	-	-	665971	652700	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.2093728C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NTHL1:4913	SO:0001574|splice_acceptor_variant	1	-	-	Invitae|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic	2018-12-22|2019-12-11	2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000965262|SCV001186169	not_provided|Hereditary_cancer-predisposing_syndrome	This_sequence_change_affects_an_acceptor_splice_site_in_intron_3_of_the_NTHL1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs779757251,_ExAC_0.009%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_disease._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_splicing_assay_data_in_support_of_pathogenicity:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_002528.6:c.457C>T	NTHL1	stop_gained	101114	1	NA	NA	-	-	-	-	647096	644037	not_provided	-	MedGen:CN517202	-	NC_000016.9:g.2094723G>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NTHL1:4913	SO:0001627|intron_variant	1	-	-	Invitae	Pathogenic	2019-01-01	2019-03-28	_single_submitter	germline	SCV000941300	not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg153*)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs374489979,_ExAC_0.01%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_conditions._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002528.6:c.433C>T	NTHL1	stop_gained	102042	1	NA	NA	-	-	-	-	652003	644042	not_provided	-	MedGen:CN517202	-	NC_000016.9:g.2094747G>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NTHL1:4913	SO:0001627|intron_variant	1	-	-	Invitae	Pathogenic	2018-12-07	2019-03-28	_single_submitter	germline	SCV000947527	not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln145*)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_conditions._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002528.6:c.390C>A	NTHL1	stop_gained	96108	4	15418	2	-	-	-	-	644578	644049	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.2094790G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NTHL1:4913	SO:0001627|intron_variant	1	-	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2019-01-05|2019-01-23	2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000938148|SCV001183030	not_provided|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr130*)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs371328106,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_disease._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_002528.6:c.380_383dup	NTHL1	frameshift_variant	96118	1	NA	NA	-	-	-	-	644885	644051	not_provided	-	MedGen:CN517202	-	NC_000016.9:g.2094798_2094801dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	NTHL1:4913	SO:0001627|intron_variant	1	-	-	Invitae	Pathogenic	2018-08-10	2019-03-28	_single_submitter	germline	SCV000938510	not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg129Thrfs*42)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs759955745,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_disease._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002528.6:c.374dup	NTHL1	frameshift_variant	102234	4	NA	NA	-	-	-	-	660624	644056	not_provided	-	MedGen:CN517202	-	NC_000016.9:g.2096139dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	NTHL1:4913	SO:0001627|intron_variant	1	-	-	Invitae	Pathogenic	2018-12-14	2019-03-28	_single_submitter	germline	SCV000958445	not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val127Glyfs*43)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs763525759,_ExAC_0.05%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_conditions._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002528.6:c.283C>T	NTHL1	stop_gained	102742	1	NA	NA	-	-	-	-	652924	644070	not_provided	-	MedGen:CN517202	-	NC_000016.9:g.2096224G>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NTHL1:4913	SO:0001627|intron_variant	1	-	-	Invitae	Pathogenic	2018-08-14	2019-03-28	_single_submitter	germline	SCV000948708	not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln95*)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs201671098,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_disease._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002528.6:c.268C>T	NTHL1	stop_gained	102736	210	15402	25	5	0	rs150766139	Familial adenomatous polyposis 3	192319	190112	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C4225157,OMIM:616415,Orphanet:ORPHA454840|MedGen:CN517202	-	NC_000016.9:g.2096239G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:602656.0001	-	NTHL1:4913	SO:0001627|intron_variant	1	150766139	-	OMIM|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Invitae|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Ambry_Genetics	Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-06-01|2017-01-13|2019-01-04|2019-01-08|2018-01-26|2018-10-17	2016-08-11|2018-09-19|2019-01-29|2019-03-28|2018-04-23|2020-02-26	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|germline	SCV000223893|SCV000705556|SCV000779405|SCV000957470|SCV000992218|SCV001177246	Familial_adenomatous_polyposis_3|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	||This_pathogenic_variant_is_denoted_NTHL1_c.268C>T_at_the_cDNA_level_and_p.Gln90Ter_(Q90X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glycine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_several_individuals_with_colorectal_cancer_and/or_adenomas_(Dallosso_2008,_Rivera_2015,_Timofeeva_2015,_Weren_2015)._Weren_et_al._(2015)_identified_NTHL1_Gln90Ter_in_the_homozygous_state_in_7_individuals_from_three_families_with_a_history_of_multiple_colorectal_adenomas_and/or_colorectal_cancer._Additionally,_Rivera_et_al._(2015)_identified_NTHL1_Gln90Ter_in_the_compound_heterozygous_state_with_a_canonical_splice_variant,_confirmed_to_be_in_trans_through_familial_testing,_in_an_individual_with_colon_cancer,_multiple_colorectal_adenomas,_and_other_neoplasms._Lastly,_other_studies_identified_NTHL1_Gln90Ter_in_the_homozygous_or_compound_heterozygous_state_in_several_unrelated_individuals_with_colorectal_adenomas_and_colorectal_cancer_(Chubb_2016,_Belhadj_2017,_Broderick_2017)._Based_on_currently_available_information,_we_consider_NTHL1_Gln90Ter_to_be_pathogenic._Of_note,_NTHL1-Associated_Polyposis_(NAP)_is_a_recessive_condition_associated_with_two_pathogenic_variants_on_opposite_chromosomes_in_NTHL1._Although_this_variant_is_considered_pathogenic,_a_second_pathogenic_variant,_as_would_be_required_for_expression_of_the_recessive_condition_NAP,_was_not_detected_in_this_individual._We_cannot_exclude_the_possibility_that_this_patient_harbors_a_second_disease-causing_NTHL1_pathogenic_variant_that_is_undetectable_by_this_test._NTHL1_has_only_recently_been_described_in_association_with_cancer_predisposition_and_the_risks_are_not_well_understood._Based_on_available_data,_the_presence_of_two_pathogenic_variants_in_NTHL1_is_indicative_of_NTHL1-Associated_Polyposis_(NAP),_an_autosomal_recessive_condition_that_may_confer_an_increased_risk_for_colorectal_cancer_and_polyps._Although_the_development_of_colorectal_cancer_and_attenuated_polyposis_appears_to_be_the_predominant_feature_of_NAP,_multiple_case_reports_have_described_individuals_with_NAP_to_have_developed_multiple_extracolonic_neoplasms,_including_breast,_endometrial,_bladder,_and_skin_cancers_as_well_as_several_benign_findings_(Rivera_2015,_Weren_2015,_Belhadj_2017)._The_National_Comprehensive_Cancer_Network_has_management_guidelines_for_individuals_with_two_pathogenic_variants_in_NTHL1_(NCCN).|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln90*)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs150766139,_ExAC_0.4%)._This_variant_has_been_observed_as_homozygous,_and_on_the_opposite_chromosome_(in_trans)_from_a_likely_pathogenic_variant,_in_many_individuals_affected_with_multiple_adenomatous_polyps_and_often_colorectal_cancer_(PMID:Â¬â€ 25938944,_27720914,Â¬â€ 26559593)._These_findings_are_consistent_with_autosomal_recessive_inheritance,_and_suggest_that_this_variant_contributes_to_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_192319)._Experimental_studies_have_shown_that_deletion_of_the_N-terminal_92_amino_acids_of_the_NTHL1_protein_results_in_complete_loss_of_its_activity_(PMID:_12144783)._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_002528.6:c.235dup	NTHL1	frameshift_variant	102730	1	NA	NA	-	-	-	-	545885	536453	not_provided	-	MedGen:CN517202	-	NC_000016.9:g.2096276dup	_single_submitter	Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	NTHL1:4913	SO:0001627|intron_variant	1	745671590	-	GeneDx	Likely_pathogenic	2018-03-07	2019-01-29	_single_submitter	germline	SCV000779220	not_provided	This_duplication_of_one_nucleotide_in_NTHL1_is_denoted_c.235dupG_at_the_cDNA_level_and_p.Ala79GlyfsX2_(A79GfsX2)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_AGGGG[dupG]CTGA._The_duplication_causes_a_frameshift_which_changes_an_Alanine_to_a_Glycine_at_codon_79,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Based_on_currently_available_evidence,_we_consider_this_duplication_to_be_a_likely_pathogenic_variant._Of_note,_NTHL1-Associated_Polyposis_(NAP)_is_a_recessive_condition_associated_with_two_pathogenic_variants_on_opposite_chromosomes_in_NTHL1.
NM_002528.6:c.188_189del	NTHL1	frameshift_variant	102560	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002528.6:c.139+1G>A	NTHL1	splice_donor_variant	77098	3	15400	1	-	-	-	-	656884	653223	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C4225157,OMIM:616415,Orphanet:ORPHA454840|MedGen:CN517202	-	NC_000016.9:g.2097709C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NTHL1:4913	SO:0001575|splice_donor_variant	1	-	-	Invitae|Mendelics|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-12-19|2019-05-28|2018-08-29	2019-03-28|2019-10-22|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline	SCV000953759|SCV001139732|SCV001171643	not_provided|Familial_adenomatous_polyposis_3|Hereditary_cancer-predisposing_syndrome	This_sequence_change_affects_a_donor_splice_site_in_intron_1_of_the_NTHL1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs749908882,_ExAC_0.04%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_disease._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_splicing_assay_data_in_support_of_pathogenicity
NM_024675.3:c.3324C>G	PALB2	stop_gained	102732	1	NA	NA	-	-	-	-	460990	466111	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000016.9:g.23619211G>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	1218512317	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2017-04-07|2018-06-21	2017-10-05|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000633423|SCV001181411	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_last_exon_of_the_PALB2_mRNA_at_codon_1108_(p.Tyr1108*)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_delete_the_last_80_amino_acids_of_the_PALB2_protein._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_breast_cancer_(PMID:_25330149)._This_variant_is_expected_to_delete_a_large_portion_of_the_WD40_domain_of_PALB2,_which_is_involved_in_the_PALB2/BRCA2_interaction._X-ray_crystallography_analysis_of_the_PALB2_protein_suggests_that_the_p.Tyr1183*_alteration,_also_located_in_the_last_exon_of_the_protein_but_downstream_of_p.Tyr1108*,_will_destabilize_the_PALB2_protein_leading_to_its_degradation_(PMID:_19609323)._Based_on_these_data,_p.Tyr1108*_is_also_expected_to_result_in_PALB2_protein_destabilization._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_024675.3:c.3256C>T	PALB2	stop_gained	102750	4	NA	NA	5&5	1&1	rs587776527	Hereditary cancer-predisposing syndrome&not provided	126729	132239	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Pancreatic_cancer_3|PALB2-Related_Disorders|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150547,OMIM:613348|MedGen:CN239408|MedGen:CN517202	-	NC_000016.9:g.23619279G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:1659081|OMIM_Allelic_Variant:610355.0010	-	PALB2:79728	SO:0001587|nonsense	1	587776527	-	OMIM|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Ambry_Genetics|Color|Invitae|Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|GeneDx|Illumina_Clinical_Services_Laboratory,Illumina	risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2009-04-10|2015-11-20|2019-03-22|2017-04-03|2018-12-14|2015-06-01|2018-10-30|2018-04-25	2019-04-19|2016-03-03|2020-02-26|2017-10-26|2019-03-28|2015-08-13|2019-01-29|2019-02-01	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000021464|SCV000266108|SCV000538169|SCV000686021|SCV000218669|SCV000267973|SCV000211531|SCV000914709	Pancreatic_cancer_3|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|PALB2-Related_Disorders	||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg1086*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observedÂ¬â€ in_the_literature_in_individuals_affected_with_pancreatic_cancer_(PMID:_19264984,_23561644,_25356972),_breast_cancer_(PMID:_26283626,_26845104),_and_ovarian_cancer_(PMID:_26315354)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126729)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_PALB2_c.3256C>T_at_the_cDNA_level_and_p.Arg1086Ter_(R1086X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_families_presenting_with_breast,_ovarian_and/or_pancreatic_cancers_(Jones_2009,_Grant_2013,_Norquist_2015,_Ramus_2015,_Thompson_2015,_Frey_2017,_Zhang_2017),_and_is_considered_pathogenic.|The_PALB2_c.3256C>T_(p.Arg1086Ter)_variant_is_a_stop-gained_variant_that_is_predicted_to_result_in_premature_termination_of_the_protein._Across_a_selection_of_the_available_literature,_it_has_been_reported_in_a_heterozygous_state_in_at_least_eleven_individuals_with_cancer,_including_five_with_pancreatic_cancer,_three_with_breast_cancer_(one_bilateral),_and_one_with_ovarian_cancer_(Jones_et_al._2009:_Grant_et_al._2013:_Thompson_et_al._2015:_Zhen_et_al._2015:_Norquist_et_al._2016:_Susswein_et_al._2016:_Sun_et_al._2017)._Five_of_these_individuals_had_a_family_history_of_cancer._Although_the_p.Arg1086Ter_variant_has_not_been_reported_in_the_literature_in_individuals_with_Fanconi_anemia,_it_cannot_be_ruled_out_of_causing_this_condition_based_on_allele_frequency_in_consideration_of_condition_penetrance_and_prevalence_estimates._Control_data_are_unavailable_for_this_variant,_which_is_reported_at_a_frequency_of_0.000036_in_the_European_(non-Finnish)_population_of_the_Genome_Aggregation_Database._Based_on_the_available_evidence,_the_p.Arg1086Ter_variant_is_classified_as_pathogenic_for_PALB2-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_024675.3:c.3247_3248insT	PALB2	frameshift_variant	102750	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_024675.3:c.3116del	PALB2	frameshift_variant,splice_region_variant	102080	3	NA	NA	-	-	-	-	126715	132225	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_N|Pancreatic_cancer_3|Breast_cancer,_susceptibility_to|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1835817,OMIM:610832|MedGen:C3150547,OMIM:613348|MedGen:C3469522|MedGen:CN517202	-	NC_000016.9:g.23625411del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:610355.0009|OMIM_Allelic_Variant:610355.0005	-	PALB2:79728	SO:0001589|frameshift_variant	1	180177133	-	OMIM|Invitae|Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|Counsyl|OMIM|OMIM|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|GeneDx	risk_factor|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2007-02-01|2018-12-31|2015-06-01|2016-06-21|2007-02-01|2009-04-10|2018-10-09|2015-11-20|2015-02-24|2018-01-26|2017-12-29	2012-04-17|2019-03-28|2015-08-13|2016-11-23|2012-04-17|2019-04-19|2020-02-26|2016-03-03|2017-12-21|2018-04-23|2019-01-29	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000021459|SCV000260801|SCV000267972|SCV000488804|SCV000021458|SCV000021463|SCV000186091|SCV000266106|SCV000690900|SCV000992219|SCV000293156	Breast_cancer,_susceptibility_to|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Fanconi_anemia,_complementation_group_N|Pancreatic_cancer_3|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn1039Ilefs*2)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_affected_with_Fanconi_anemia,_breast_cancer,_pancreatic_cancer,_and_stomach_cancer_(PMID:_17200671,_17200668,Â¬â€ 19264984,Â¬â€ 20412113,_25452441,_26845104)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126715)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|This_deletion_of_one_nucleotide_in_PALB2_is_denoted_c.3116delA_at_the_cDNA_level_and_p.Asn1039IlefsX2_(N1039IfsX2)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_agGA[delA]TTTA,_where_the_capital_letters_are_exonic_and_lowercase_letters_are_intronic._The_deletion_causes_a_frameshift,_which_changes_an_Asparagine_to_an_Isoleucine_at_codon_1039,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.3116delA_has_been_observed,_in_the_compound_heterozygous_state,_in_an_individual_with_Fanconi_Anemia_and_a_history_of_neuroblastoma_and_acute_myeloid_leukemia_(Reid_2007)._Additionally,_this_variant_has_been_seen_in_association_with_familial_breast_and_pancreatic_cancer_(Rahman_2007,_Jones_2009,_Slater_2010,_Antoniou_2014,_Thompson_2015)._We_consider_this_variant_to_be_pathogenic.
NM_024675.3:c.3113G>A	PALB2	stop_gained,splice_region_variant	102692	13	15426	1	5&5	2&1	rs180177132	Hereditary cancer-predisposing syndrome&not provided	126711	132221	_susceptibility_to|PALB2-Related_Disorders|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3469522|MedGen:CN239408|MedGen:CN517202	-	NC_000016.9:g.23632683C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:702353	-	PALB2:79728	SO:0001587|nonsense	1	180177132	-	Invitae|Pathway_Genomics|Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|OMIM|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|Illumina_Clinical_Services_Laboratory,Illumina	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-07|2014-11-06|2015-06-01|2016-03-18|2017-04-03|2019-10-23|2015-11-20|2015-02-09|2018-01-26|2013-02-28|2018-12-11|2018-03-06|2015-08-11|2017-05-08|2018-09-19	2019-03-28|2015-01-12|2015-08-13|2016-11-23|2018-06-14|2020-02-26|2016-03-03|2016-07-05|2018-04-23|2019-04-19|2019-01-29|2018-09-19|2018-08-31|2018-01-25|2019-02-01	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000166660|SCV000207350|SCV000267971|SCV000488411|SCV000840027|SCV000183829|SCV000266105|SCV000292142|SCV000992220|SCV000190693|SCV000150005|SCV000225072|SCV000601775|SCV000699583|SCV000914711	_susceptibility_to|not_provided|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|PALB2-Related_Disorders	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1038_(p.Trp1038*)_of_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_individuals_and_families_affected_with_breast_cancer,_with_evidence_of_co-segregation_with_disease_(PMID:_17200668,_21182766,_21285249,_23471749).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126711)._This_variant_also_falls_in_the_last_nucleotide_of_the_exon,_which_is_part_of_the_consensus_splice_site._Experimental_studies_have_shown_that_this_variant_causes_altered_splicing,_creating_different_PALB2_transcripts_in_lymphoblastoid_cells_derived_from_individuals_with_breast_cancer_(PMID:_21285249,_23448497)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||This_c.3113G>A_(p.Trp1038*)_variant_has_previously_been_reported_in_16_(out_of_4,178_total)_patients_with_breast_cancer_[PMID_17200668,_21285249,_25575445,_23448497,_26283626,_21409391,_23471749]._The_cumulative_risk_for_carrier_of_this_variant_was_estimated_as_91%_by_age_70_with_a_median_age_of_onset_of_42_years_old_reported_in_an_Australian_population_[PMID_23471749]._This_c.3113G>A_is_located_in_exon_10_of_the_PALB2_gene_at_the_exon/intron_junction_with_intron_10._Transcripts_analysis_showed_that_this_variant_not_only_produces_a_stop_codon_at_amino_acid_position_1038_but_also_produces_two_additional_PALB2_transcripts_including_an_alternative_splicing_and_a_complete_deletion_of_exon_10,_all_three_leading_to_a_loss_of_function_of_the_protein_[PMID_23471749]._The_c.3113G>A_(p.Trp1038*)_variant_has_been_observed_in_two_Europeans_and_one_African_individual_at_the_heterozygous_state_in_the_ExAC_population_database_(http://exac.broadinstitute.org/variant/16-23632683-C-T)._It_is_thus_interpreted_as_a_pathogenic_variant.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Last_nucleotide_of_exon|||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.||This_pathogenic_variant_is_denoted_PALB2_c.3113G>A_at_the_cDNA_level_and_p.Trp1038Ter_(W1038X)_at_the_protein_level._This_is_a_nonsense_variant,_changing_a_Tryptophan_to_a_premature_stop_codon._In_an_mRNA-based_assay,_Casadei_et_al._(2011)_showed_that_the_expected_transcript,_an_immediate_stop_codon,_was_not_the_only_aberrant_transcript_produced_by_this_variant._Two_other_alternate_transcripts,_an_in-frame_deletion_of_exon_10_and_an_out-of-frame_deletion_of_31_base_pairs_in_exon_10,_were_also_identified_and_are_a_result_of_the_proximity_of_the_variant_to_the_splice_donor_site._Additionally,_Teo_et_al._(2013)_confirmed_the_presence_of_these_two_alternate_transcripts_but_failed_to_identify_the_expected_nonsense_transcript_in_an_mRNA-based_assay._The_in-frame_deletion_of_exon_10_is_located_within_a_region_of_interaction_with_BRCA2_which_is_thought_to_be_important_to_PALB2_protein_function,_and_both_the_expected_transcript_and_the_deletion_of_31_base_pairs_are_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay_(Casadei_2011,_Teo_2013)._This_variant_has_been_reported_in_several_individuals_with_a_personal_and/or_family_history_of_breast_cancer_(Rahman_2007,_Southey_2010,_Wong_2011,_Teo_2013,_Southey_2016,_Winship_2016)_and_is_considered_a_pathogenic_founder_variant_in_the_British_population_(Hartley_2014)._PALB2_Trp1038Ter_has_been_associated_with_a_significantly_increased_risk_for_breast_cancer_in_a_large,_multi-center_case-control_analysis_(Southey_2016)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||||The_PALB2_c.3113G>A_(p.Trp1038Ter)_variant_is_a_stop-gained_variant_that_is_predicted_to_result_in_a_premature_termination_of_the_protein._Across_a_selection_of_the_available_literature,_the_c.3113G>A_(p.Trp1038Ter)_variant_has_been_identified_in_a_heterozygous_state_in_at_least_21_probands_from_13_unrelated_families_(Rahman_et_al._2007:_Southey_et_al._2010:_Teo_et_al._2013:_Hartley_et_al._2014)._Affected_individuals_were_found_to_have_a_variety_of_cancers_including_breast,_ovarian,_and_pancreatic._The_p.Trp1038Ter_variant_was_absent_from_1724_healthy_control_subjects_and_is_reported_at_a_frequency_of_0.000125_in_the_African_population_of_the_Genome_Aggregation_Database._Experimental_studies_on_RNA_isolated_from_patient_derived_lymphoblastoid_cell_lines_have_shown_that_the_p.Trp1038Ter_variant_caused_altered_splicing_(Casadei_et_al._2011:_Teo_et_al._2013)._Although_this_variant_has_not_been_reported_in_any_probands_with_Fanconi_anemia,_it_is_known_that_PALB2_heterozygous_variants_can_also_confer_carrier_status_for_Fanconi_anemia._Due_to_the_potential_impact_of_stop-gained_variants_and_the_evidence_from_the_literature,_this_variant_is_classified_as_pathogenic_for_PALB2-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_024675.3:c.2931dup	PALB2	frameshift_variant	102744	1	NA	NA	-	-	-	-	142591	152305	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Tumor_susceptibility_linked_to_germline_BAP1_mutations|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3280492,OMIM:614327|MedGen:CN517202	-	NC_000016.9:g.23634355dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2841237	-	PALB2:79728	SO:0001589|frameshift_variant	1	587782570	-	Ambry_Genetics|Invitae|Ambry_Genetics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2016-09-09|2018-02-14|2015-08-26|2018-05-07|2017-11-06	2020-02-26|2018-08-29|2016-05-09|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000186845|SCV000253939|SCV000278023|SCV000293382|SCV000889591	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Tumor_susceptibility_linked_to_germline_BAP1_mutations|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_inserts_1_nucleotide_in_exon_9_of_the_PALB2_mRNA_(c.2931dupA),_causing_a_frameshift_at_codon_978._This_creates_a_premature_translational_stop_signal_(p.Val978Serfs*2)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Truncating_variants_in_PALB2_are_known_to_be_pathogenic._This_particular_truncation_has_been_reported_in_an_individual_undergoing_testing_for_hereditary_cancer_syndromes_(PMID:_24763289)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142591)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_duplication_of_one_nucleotide_in_PALB2_is_denoted_c.2931dupA_at_the_cDNA_level_and_p.Val978SerfsX2_(V978SfsX2)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_GGCT[dupA]GTTA._The_duplication_causes_a_frameshift,_which_changes_a_Valine_to_a_Serine_at_codon_978,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.2931dupA_has_been_reported_in_at_least_one_individual_who_had_multi-gene_panel_testing_due_to_a_personal_and/or_family_history_suggestive_of_a_hereditary_cancer_syndrome_(Laduca_2014)._We_consider_this_variant_to_be_pathogenic.|
NM_024675.3:c.2748+1G>T	PALB2	splice_donor_variant	102740	1	NA	NA	-	-	-	-	186035	184183	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23637556C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001575|splice_donor_variant	1	753153576	-	Baylor_College_of_Medicine	Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2019-08-15|2015-07-10|2018-07-30|2018-02-25	2020-02-26|2019-01-29|2019-03-28|2018-06-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000216287|SCV000567121|SCV000757190|SCV000840035	Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|This_pathogenic_variant_is_denoted_PALB2_c.2748+1G>T_or_IVS7+1G>T_and_consists_of_a_G>T_nucleotide_substitution_at_the_+1_position_of_intron_7_of_the_PALB2_gene._The_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature._Based_on_the_current_evidence,_we_consider_PALB2_c.2748+1G>T_to_be_pathogenic.|This_sequence_change_affects_a_donor_splice_site_in_intron_7_of_the_PALB2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs753153576,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_PALB2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186035)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|The_c.2748+1G>T_variant_in_the_PALB2_gene_is_predicted_to_disrupt_a_canonical_splice_donor_site_and_thus_alter_mRNA_splicing._This_variant_is_extremely_rare_in_the_general_population._This_c.2748+1G>T_variant_in_the_PALB2_gene_is_classified_as_likely_pathogenic.
NM_024675.3:c.2727_2728del	PALB2	frameshift_variant	102746	1	NA	NA	-	-	-	-	182742	180718	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23637578_23637579del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2831390	-	PALB2:79728	SO:0001589|frameshift_variant	1	730881869	-	Baylor_College_of_Medicine|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-23|2018-01-11|2018-12-24|2018-02-24|2018-05-17|2018-07-11	2020-02-26|2018-11-06|2019-03-28|2018-06-14|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000275628|SCV000903745|SCV000290847|SCV000840036|SCV000211479|SCV000601769	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Thr911Leufs*16)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer_(PMID:_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182742)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_c.2727_2728delTT_(p.Thr911Leufs*16)_frameshift_variant_in_the_PALB2_gene_is_predicted_to_introduce_a_premature_translation_termination_codon._This_variant_has_been_reported_in_two_unrelated_breast_cancer_patients_(PMID_26681312_and_28724667)._Moreover,_four_independent_genetic_diagnostic_laboratories_have_categorized_this_variant_as_pathogenic/likely_pathogenic_(ClinVar_database)._Mono-allelic_loss_of_function_variants_in_the_PALB2_gene_have_been_associated_with_susceptibility_to_breast_cancer_and_pancreatic_cancer._Bi-allelic_loss_of_function_variants_in_this_gene_are_associated_with_Fanconi_anemia,_complementation_group_N_(OMIM_610832)._This_variant_in_the_PALB2_gene_is_classified_as_pathogenic.|This_deletion_of_two_nucleotides_in_PALB2_is_denoted_c.2727_2728delTT_at_the_cDNA_level_and_p.Thr911LeufsX16_(T911LfsX16)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AACT[delTT]ATAC._The_deletion_causes_a_frameshift_which_changes_a_Threonine_to_a_Leucine_at_codon_911,_and_creates_a_premature_stop_codon_at_position_16_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.2727_2728delTT_has_been_observed_in_individuals_with_pancreatic_or_breast_cancer_(Sun_2017,_Lowery_2018)._Based_on_the_currently_available_information,_we_consider_this_deletion_to_be_a_pathogenic_variant.|
NM_024675.3:c.2386G>T	PALB2	stop_gained	102726	1	15430	0	5&5	1&1	rs180177112	Hereditary cancer-predisposing syndrome&not provided	126649	132159	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23641089C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	180177112	-	Invitae|Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|Counsyl|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|PreventionGenetics,PreventionGenetics	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-12|2015-06-01|2016-04-20|2019-01-10|2015-02-23|2018-05-16|2017-04-13|2017-05-01	2019-03-28|2015-08-13|2016-11-23|2020-02-26|2017-10-26|2019-01-29|2017-08-01|2018-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline	SCV000218974|SCV000267967|SCV000488542|SCV000183831|SCV000685947|SCV000292656|SCV000601759|SCV000807087	Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gly796*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_multiple_individuals_with_breast_cancer_(PMID:_17200668,_23935381,_24549055,_25099575,_24415441)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126649)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_25099575,_17200668)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_PALB2_c.2386G>T_at_the_cDNA_level_and_p.Gly796Ter_(G796X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glycine_to_a_premature_stop_codon_(GGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_association_with_breast_cancer_(Rahman_2007,_Casadei_2011,_Fernandes_2014)_and_is_considered_pathogenic.||
NM_024675.3:c.2323C>T	PALB2	stop_gained	102742	1	NA	NA	5&5	1&1	rs180177111	Familial cancer of breast&Hereditary cancer-predisposing syndrome	126646	132156	_susceptibility_to|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3469522|MedGen:CN517202	-	NC_000016.9:g.23641152G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:610355.0012	-	PALB2:79728	SO:0001587|nonsense	1	180177111	-	Invitae|Counsyl|OMIM|Ambry_Genetics|Color|GeneDx	Pathogenic|Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic	2018-12-21|2015-05-01|2007-01-01|2017-03-29|2018-04-25|2015-08-12	2019-03-28|2017-06-22|2019-04-19|2020-02-26|2018-11-06|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline	SCV000218806|SCV000677768|SCV000190686|SCV000215584|SCV000905027|SCV000490685	_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln775*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_with_breast_cancer_(PMID:_23302520,_23341105,_19863560,_18053174)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126646)._Experimental_in_vitro_studies_have_shown_that_this_nonsense_variant_results_in_defective_DNA_repair_(PMID:_24485656)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_PALB2_c.2323C>T_at_the_cDNA_level_and_p.Gln775Ter_(Q775X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_as_a_French_Canadian_founder_pathogenic_variant_and_has_been_observed_in_multiple_women_with_a_personal_and/or_family_history_of_hereditary_breast_and_ovarian_cancer_(Catucci_2014,_Tischkowitz_2013,_Ghadirian_2009,_Foulkes_2007)_and_is_considered_pathogenic.
NM_024675.3:c.2267_2283dup	PALB2	frameshift_variant	102748	1	NA	NA	-	-	-	-	245890	244957	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23641200_23641216dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	755471995	-	GeneDx|Ambry_Genetics|Color|Invitae	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-10-12|2018-06-01|2017-05-05|2018-08-29	2017-11-28|2020-02-26|2017-12-21|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000293073|SCV000538149|SCV000690836|SCV000550696	not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	This_duplication_of_17_nucleotides_in_PALB2_is_denoted_c.2267_2283dup17_at_the_cDNA_level_and_p.His762AlafsX8_(H762AfsX8)_at_the_protein_level._The_surrounding_sequence_is_TGCT[dup17]CATT._The_duplication_causes_a_frameshift,_which_changes_a_Histidine_to_an_Alanine_at_codon_762,_and_creates_a_premature_stop_codon_at_position_8_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_likely_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.His762Alafs*8)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_PALB2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_245890)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_024675.3:c.2257C>T	PALB2	stop_gained	102746	4	NA	NA	5&5	1&1	rs180177110	Hereditary cancer-predisposing syndrome&not provided	142403	152117	Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23641218G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	180177110	-	Ambry_Genetics|Color|GeneKor_MSA|Mendelics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-14|2015-02-16|2018-08-01|2018-07-02|2018-09-25|2016-04-30|2018-12-26|2017-04-25|2017-06-03|2017-01-06	2020-02-26|2017-10-26|2018-08-08|2018-08-20|2019-01-29|2018-08-31|2019-03-28|2017-06-22|2018-06-14|2019-03-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|unknown|germline|germline	SCV000186491|SCV000685936|SCV000821752|SCV000839023|SCV000293386|SCV000888367|SCV000550814|SCV000677769|SCV000840034|SCV000731344	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_breast_and_ovarian_cancer_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_variant_is_denoted_PALB2_c.2257C>T_at_the_cDNA_level_and_p.Arg753Ter_(R753X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_Arg753Ter_has_been_reported_in_individuals_with_personal_and/or_family_histories_of_breast,_ovarian_and/or_pancreatic_cancer_(Jones_2009,_Papi_2010,_Hellebrand_2011,_Tung_2015,_Bunnell_2016,_Kim_2016,_Crawford_2017)._This_variant_has_also_been_reported_in_the_compound_heterozygous_state_with_another_PALB2_truncating_variant_in_an_individual_with_Fanconi_anemia_(Reid_2007)._We_therefore_consider_PALB2_Arg753Ter_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg753*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs180177110,_ExAC_0.01%)._This_variant_has_been_observed_in_individuals_affected_with_breast_cancer_(PMID:_21618343,_19763884,_20852946,Â¬â€ 25452441,_25186627)_and_Fanconi_anemia_(PMID:_17200671)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142403)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_c.2257C>T_(p.Arg753*)_variant_in_the_PALB2_gene_has_been_detected_in_a_cohort_of_818_breast_cancer_patients_[PMID_21618343]._The_proband_was_diagnosed_with_breast_cancer_at_33_years_old._The_variant_was_inherited_from_the_mother_who_also_had_breast_cancer_at_66_years_old._The_maternal_grandmother_also_had_breast_cancer_at_43_years_old_but_the_PALB2_status_was_unavailable._The_variant_was_also_detected_in_a_cohort_of_235_Korean_patients_with_hereditary_breast_cancer_[PMID_27783279]._This_c.2257C>T_(p.Arg753*)_variant_has_also_been_reported_in_a_compound_heterozygous_patient_with_Fanconi_Anemia_N_[PMID_17200671]._This_c.2257C>T_(p.Arg753*)_change_has_been_observed_in_6_heterozygous_individual_in_GnomAD_(http://gnomad.broadinstitute.org/variant/16-23641217-C-T)._The_c.2257C>T_change_creates_a_stop_codon_at_amino_acid_position_753_of_the_PALB2_protein_and_is_thus_predicted_to_lead_to_a_loss_of_function_of_the_PALB2_protein._This_c.2257C>T_(p.Arg753*)_variant_is_thus_classified_as_pathogenic.|The_p.Arg753X_variant_in_PALB2_has_been_reported_in_4_individuals_with_hereditar_y_breast_cancer_(Papi_2010,_Hellebrand_2011,_Kim_2016)_and_segregated_with_disea_se_in_two_affected_relatives_from_2_families_(Papi_2010,_Hellebrand_2011)._It_ha_s_also_been_reported_in_at_least_one_individual_with_pancreatic_cancer_(Jones_20_09)_and_one_with_Fanconi_Anemia,_who_also_carried_a_second_pathogenic_variant_in_PALB2,_further_supporting_pathogenicity_(Reid_2007)._This_variant_has_been_iden_tified_in_1/10406_of_African_chromosomes_by_the_Exome_Aggregation_Consortium_(Ex_AC,_http://exac.broadinstitute.org:_dbSNP_rs180177110)._This_nonsense_variant_le_ads_to_a_premature_termination_codon_at_position_753,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_breast_cancer_in_an_autosomal_dominant_manner_base_d_upon_the_impact_of_the_variant_to_the_protein.
NM_024675.3:c.2167_2168del	PALB2	frameshift_variant	102750	2	NA	NA	-	-	-	-	136132	139844	Neoplasm_of_the_breast|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Cancer_of_the_pancreas|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0346647|MedGen:CN517202	-	NC_000016.9:g.23641307_23641308del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2832420	-	PALB2:79728	SO:0001589|frameshift_variant	1	587776416	-	Invitae|Counsyl|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|SNPedia|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|3DMed_Clinical_Laboratory_Inc|3DMed_Clinical_Laboratory_Inc	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-17|2016-01-15|2018-12-31|2015-11-20|2014-12-23|0000-00-00|2019-01-07|2016-11-24|2015-12-14|2016-11-28|2018-03-03|2018-03-03	2019-03-28|2016-11-23|2020-02-26|2016-03-03|2017-10-26|2014-08-20|2019-01-29|2018-08-31|2018-01-25|2019-03-21|2018-06-19|2018-06-19	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000166650|SCV000488150|SCV000184167|SCV000266103|SCV000685926|SCV000188552|SCV000292651|SCV000601752|SCV000699555|SCV000712659|SCV000804053|SCV000804054	Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Neoplasm_of_the_breast|Cancer_of_the_pancreas	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Met723Valfs*21)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_and_families_affected_with_breast_and_ovarian_cancer_(PMID:_24556926,_25099575,_24448499)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_136132)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_25099575,_17200668)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification|||Converted_during_submission_to_Pathogenic.|This_deletion_of_two_nucleotides_in_PALB2_is_denoted_c.2167_2168delAT_at_the_cDNA_level_and_p.Met723ValfsX21_(M723VfsX21)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AGAC[delAT]GTGT._The_deletion_causes_a_frameshift_which_changes_a_Methionine_to_a_Valine_at_codon_723,_and_creates_a_premature_stop_codon_at_position_21_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.2167_2168delAT_has_been_published_as_a_loss_of_function_variant_and_has_been_reported_in_individuals_with_hereditary_breast_or_ovarian_cancer_(Antoniou_2014,_Catucci_2014,_Catucci_2016,_Crawford_2017)._We_consider_this_variant_to_be_pathogenic.||Variant_summary:_This_c.2167_2168delAT_variant_causes_a_frameshift,_which_alters_the_proteins_amino_acid_sequence_beginning_at_position_723_and_leads_to_a_premature_termination_codon_20_amino_acid_downstream._It_is_predicted_to_cause_a_truncated_or_absent_PALB2_protein._Mutation_taster_predicts_this_variant_to_be_disease-causing._The_variant_was_observed_in_the_large_and_broad_cohorts_of_the_ExAC_project_with_an_allele_frequency_of_0.0066%_(8/121410_chr)._This_frequency_does_not_exceed_the_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_PALB2_(0.016%)._This_variant_has_been_reported_in_multiple_BrC_pts,_and_it_has_been_classified_as_pathogenic_by_multiple_clinical_labs_(via_ClinVar)._Taken_together,_this_variant_has_been_classified_as_a_Pathogenic.|The_p.Met723fs_variant_in_PALB2_has_been_reported_in_at_least_9_individuals_with_hereditary_breast_cancer_and_in_1_individual_with_ovarian_cancer_(Antoniou_2014_,_Kanchi_2014,_Catucci_2014,_Catucci_2016)_and_segregated_with_disease_in_9_affe_cted_relatives_(including_2_with_other_PALB2-associated_cancers)_from_2_families_(Catucci_2016)._Additionally,_this_variant_has_been_identified_in_6/11578_of_La_tino_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadins_titute.org:_dbSNP_rs587776416)._The_p.Met723fs_variant_is_predicted_to_cause_a_f_rameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_723_and_leads_to_a_premature_termination_codon_21_amino_acids_downstream._This_a_lteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._In_summary_,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_hereditary_brea_st_cancer_in_an_autosomal_dominant_manner_based_upon_segregation_studies_and_the_predicted_impact_to_the_protein.||
NM_024675.3:c.2108T>G	PALB2	stop_gained	102744	1	NA	NA	5	1	rs752592662	Hereditary cancer-predisposing syndrome	233463	235246	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000016.9:g.23641367A>C	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	752592662	-	Ambry_Genetics	Pathogenic	2017-10-04	2020-02-26	_single_submitter	germline	SCV000277837	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_024675.3:c.2074C>T	PALB2	stop_gained	102744	1	NA	NA	5	0	rs587776415	not provided	143966	153696	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23641401G>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	587776415	-	SNPedia|Ambry_Genetics	pathogenic|Pathogenic	0000-00-00|2017-08-28	2014-08-20|2020-02-26	_single_submitter	germline|germline	SCV000188551|SCV000666915	not_provided|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_024675.3:c.2006del	PALB2	frameshift_variant	102724	1	NA	NA	-	-	-	-	134994	138733	Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	-	SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN517202	-	NC_000016.9:g.23641469del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	587778584	-	ITMI|Ambry_Genetics|GeneDx	not_provided|Pathogenic|Pathogenic	2013-09-19|2018-06-26|2014-06-23	2014-05-29|2020-02-26|2019-01-29	no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000085952|SCV000274713|SCV000211474	not_specified|Hereditary_cancer-predisposing_syndrome|not_provided	|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_pathogenic_variant_is_denoted_PALB2_c.2006delA_at_the_cDNA_level_and_p.Glu669GlyfsX3_(E669GfsX3)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ATGG[A]GGAC._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_a_Glycine_at_codon_669,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_previously_reported,_it_is_considered_pathogenic.
NM_024675.3:c.1919C>A	PALB2	stop_gained	102500	1	NA	NA	5	1	rs760094988	Hereditary cancer-predisposing syndrome	231394	235256	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23641556G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	760094988	-	Ambry_Genetics|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic	2019-03-06|2017-01-20|2018-12-26	2020-02-26|2019-01-29|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000275230|SCV000568069|SCV000633314	Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_pathogenic_variant_is_denoted_PALB2_c.1919C>A_at_the_cDNA_level_and_p.Ser640Ter_(S640X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_a_woman_with_a_personal_history_of_early-onset_breast_cancer_and_a_family_history_of_breast_and_prostate_cancer_(Vietri_2015)._We_therefore_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser640*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs760094988,_ExAC_0.001%)._This_variant_has_been_observed_in_an_individual_affected_with_breast_cancer_(PMID:Â¬â€ 25666743)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_231394)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_024675.3:c.1685-2A>G	PALB2	splice_acceptor_variant	95268	1	NA	NA	-	-	-	-	449968	445546	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23641792T>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001574|splice_acceptor_variant	1	754660432	-	GeneDx|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic	2018-05-16|2019-06-28	2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000618466|SCV000665096	not_provided|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_PALB2_c.1685-2A>G_or_IVS4-2A>G_and_consists_of_an_A>G_nucleotidesubstitution_at_the_-2_position_of_intron_4_of_the_PALB2_gene._This_variant_destroys_a_canonical_splice_acceptor_site_andis_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_at_least_one_individual_witha_personal_and_family_history_of_breast_and/or_ovarian_cancer_(Li_2016)._Based_on_the_currently_available_information,we_consider_PALB2_c.1685-2A>G_to_be_a_likely_pathogenic_variant|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_024675.3:c.1671_1674del	PALB2	frameshift_variant	101858	1	NA	NA	-	-	-	-	410108	401050	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000016.9:g.23646194_23646197ATAA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	1060502734	-	Invitae|Mendelics|Mendelics|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-09|2019-05-28|2018-07-02|2018-08-08	2019-03-28|2019-10-22|2018-08-20|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|unknown|germline	SCV000550604|SCV001140029|SCV000839032|SCV001173143	Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_deletes_4_nucleotides_from_exon_4_of_the_PALB2_mRNA_(c.1671_1674delTATT),_causing_a_frameshift_at_codon_558._This_creates_a_premature_translational_stop_signal_(p.Ile558Lysfs*2)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer_(PMID:Â¬â€ 27779110)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_410108)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_sequence_change_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_024675.3:c.1665dup	PALB2	frameshift_variant	102324	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_024675.3:c.1616_1617dup	PALB2	frameshift_variant	102744	1	NA	NA	-	-	-	-	186949	184234	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000016.9:g.23646250_23646251dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	786203346	-	Ambry_Genetics|Invitae	Pathogenic|Pathogenic	2017-07-07|2018-11-19	2020-02-26|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000217421|SCV000955645	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn540Leufs*22)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_PALB2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186949)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_024675.3:c.1592del	PALB2	frameshift_variant	102744	1	15436	0	-	-	-	-	126609	132119	_susceptibility_to|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3469522|MedGen:CN517202	-	NC_000016.9:g.23646278del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:610355.0006	-	PALB2:79728	SO:0001589|frameshift_variant	1	180177102	-	_University_of_Washington|Color|GeneDx	risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2007-03-15|2018-12-18|2017-04-04|2018-08-17|2015-11-20|2017-01-26|2017-07-13	2012-04-17|2019-03-28|2017-06-22|2020-02-26|2016-03-03|2018-11-06|2019-01-29	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline	SCV000021460|SCV000261895|SCV000677784|SCV000187568|SCV000266102|SCV000911953|SCV000211469	_susceptibility_to|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|This_sequence_change_deletes_one_nucleotide_in_exon_4_of_the_PALB2_mRNA_(c.1592delT),_causing_a_frameshift_at_codon_531._This_creates_a_premature_translational_stop_signal_(p.Leu531Cysfs*30)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_an_individual_affected_with_breast_cancer_(PMID:_22241545)._It_has_also_been_reported_as_a_common_cause_of_breast_and_ovarian_cancer_in_the_Finnish_population_(PMID:_17287723,_18628482,_19383810)._Experimental_studies_using_carrier_lymphoblastoid_cell_lines_have_shown_that_although_this_variant_does_not_lead_to_nonsense_mediated_decay,_the_resultant_truncated_PALB2_protein_is_unstable,_with_only_10%_being_retained_(PMID:_24153426)._Also,_this_variant_protein_showed_a_reduced_ability_to_bind_BRCA2_and_failed_to_support_homologous_recombination_or_to_restore_crosslink_repair_in_PALB2-knockdown_cells_(PMID:_17287723,_26640152)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_deletion_of_one_nucleotide_is_denoted_PALB2_c.1592delT_at_the_cDNA_level_and_p.Leu531CysfsX30_(L531CfsX30)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_CTTT[delT]GCCA._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_a_Cysteine_at_codon_531,_and_creates_a_premature_stop_codon_at_position_30_of_the_new_reading_frame._The_transcribed_message_was_shown_to_escape_nonsense_mediated_decay,_and_instead_results_in_a_truncated_protein_that_is_highly_unstable_and_functionally_abnormal_(Nikkil?_2013)._In_addition,_this_variant_has_been_shown_to_be_deficient_in_BRCA2_binding_capacity,_homologous_recombination,_and_crosslink_repair,_and_to_increase_error-prone_double_stranded_break_repair_(Erkko_2007,_Obermeier_2015)._PALB2_1592delT_has_been_observed_in_at_least_one_individual_with_serous_ovarian_cancer,_it_is_associated_with_hereditary_breast_cancer_and_is_considered_to_be_a_Finnish_pathogenic_founder_variant,_present_in_about_1%_of_the_population_(Erkko_2007,_Erkko_2008,_Heikkinen_2009,_Haanpaa_2013,_Nikkil?_2013,_Sokolenko_2015,_Kotsopoulos_2017)._We_consider_this_variant_to_be_pathogenic.
NM_024675.3:c.1317del	PALB2	frameshift_variant	102018	1	NA	NA	-	-	-	-	126598	132108	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23646552del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	515726067	-	Invitae|Counsyl|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-02|2016-08-18|2019-04-05|2015-06-09|2018-09-11|2016-09-26	2019-03-28|2016-11-23|2020-02-26|2017-10-26|2019-01-29|2017-08-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline	SCV000253935|SCV000489097|SCV000184298|SCV000685871|SCV000211468|SCV000601727	Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Phe440Leufs*12)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_and_a_single_family_affected_with_breast_cancer_(PMID:_25619955,_25186627,_26681312,_20852946)._This_variant_is_also_known_as_1517delG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126598)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_deletion_of_one_nucleotide_in_PALB2_is_denoted_c.1317delG_at_the_cDNA_level_and_p.Phe440LeufsX12_(F440LfsX12)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_AAGG[delG]TTTA._The_deletion_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Leucine_at_codon_440,_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.1317delG,_previously_reported_as_c.1517delG,_has_been_observed_in_at_least_three_women_with_a_history_of_breast_cancer_(Balia_2010,_Sokolenko_2015,_Tung_2015)._We_consider_this_variant_to_be_pathogenic.|
NM_024675.3:c.1240C>T	PALB2	stop_gained	102360	1	NA	NA	5&5&5	1&1&1	rs180177100	Hereditary cancer-predisposing syndrome&Familial cancer of breast&not provided	128117	133574	_complementation_group_N|Pancreatic_cancer_3|not_provided	-	Human_Phenotype_Ontology:HP:0002575,MedGen:C1861028,OMIM:189960|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1835817,OMIM:610832|MedGen:C3150547,OMIM:613348|MedGen:CN517202	-	NC_000016.9:g.23646627G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	180177100	-	Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-02-19|2015-03-04|2018-07-02|2018-12-19|2016-07-26|2018-08-21|2016-05-13|2017-05-18|2017-07-03	2020-02-26|2017-10-26|2018-08-20|2019-03-28|2016-11-23|2019-01-29|2017-08-01|2017-05-23|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|unknown|germline|germline|unknown|germline	SCV000186556|SCV000685862|SCV000839042|SCV000166641|SCV000488968|SCV000149973|SCV000601725|SCV000611291|SCV000699526	_complementation_group_N/Pancreatic_cancer_3/Tracheoesophageal_fistula|Hereditary_breast_and_ovarian_cancer_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg414*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_or_ovarian_cancer_(PMID:_21285249,_21165770,_21618343,_22692731,_24136930,_24448499)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128117)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_PALB2_c.1240C>T_at_the_cDNA_level_and_p.Arg414Ter_(R414X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_multiple_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_(Casadei_2011,_Hellebrand_2011,_Kanchi_2014,_Norquist_2016,_Sahasrabudhe_2017)._PALB2_Arg414Ter_was_also_identified_in_a_familial_pancreatic_cancer_kindred_(Slater_2010)._This_variant_is_considered_pathogenic.|||Variant_summary:_The_PALB2_c.1240C>T_(p.Arg414X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_PALB2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.2167_2168delAT,_p.Met723fsX21:_c.2920_2921delAA,_p.Lys974fsX5:_c.3113G>A,_p.Trp1038X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_is_absent_in_122690_control_chromosomes._The_variant_has_been_reported_in_numerous_HBOC_patients_in_the_literature._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.
NM_024675.3:c.1140_1143del	PALB2	frameshift_variant	102544	2	NA	NA	-	-	-	-	492149	484855	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000016.9:g.23646724_23646727del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	1257545151	-	Color|Mendelics|Ambry_Genetics|Invitae|Mendelics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-04-10|2018-07-02|2019-05-14|2018-12-14|2019-05-28	2017-12-21|2018-08-20|2020-02-26|2019-03-28|2019-10-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|unknown	SCV000690769|SCV000839046|SCV001178514|SCV000757355|SCV001140043	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast	||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser380Argfs*43)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer_(PMID:_28423363).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 492149)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_024675.3:c.1120_1123del	PALB2	frameshift_variant	102586	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_024675.3:c.1059_1075del	PALB2	frameshift_variant	102636	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_024675.3:c.886del	PALB2	frameshift_variant	102662	1	NA	NA	-	-	-	-	143979	153709	Familial_cancer_of_breast|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:CN517202	-	NC_000016.9:g.23646987del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001587|nonsense	1	-	-	SNPedia|Invitae	pathogenic|Pathogenic	0000-00-00|2018-07-17	2014-08-20|2019-03-28	_single_submitter	germline|germline	SCV000188567|SCV000962955	not_provided|Familial_cancer_of_breast	Converted_during_submission_to_Pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Met296*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_affected_with_breast_cancer_(PMID:Â¬â€ 25099575,Â¬â€ 28779002)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_143979)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_024675.3:c.758dup	PALB2	frameshift_variant	102676	3	NA	NA	-	-	-	-	126769	132279	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23647109dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2721657	-	PALB2:79728	SO:0001589|frameshift_variant	1	515726126	-	Peter_MacCallum_Cancer_Centre|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-13|2015-06-01|2016-02-10|2017-10-04|2018-12-26|2014-12-08|2018-12-30|2017-07-13	2019-03-28|2015-08-13|2016-11-23|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline	SCV000253947|SCV000267963|SCV000488259|SCV000919931|SCV000185051|SCV000686074|SCV000211484|SCV000601797	Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser254Ilefs*3)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs756660214,_ExAC_0.01%)._This_variant_has_been_observed_inÂ¬â€ individuals_affected_with_breast_and_ovarian_cancer_(PMID:_21932393,_22692731,_23110154,_26283626,_23824750,_24448499,_24870022)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126769)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_PALB2_c.758dupT_(p.Ser254IlefsX3)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_PALB2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.1240C>T,_p.Arg414X:_c.2167_2168delAT,_p.Met723fsX21:_c.2920_2921delAA,_p.Lys974fsX5:_c.3113G>A,_p.Trp1038X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_6/246460_control_chromosomes_(gnomAD_and_Zheng_2012)_at_a_frequency_of_0.0000243,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_PALB2_variant_(0.0001563)._This_variant_has_been_reported_in_multiple_HBOC_patients_(Wong-Brown_2014,_Churpek_2015,_Lerner-Ellis_2017,_Pern_2012,_Thompson_2016)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_duplication_of_one_nucleotide_in_PALB2_is_denoted_PALB2_c.758dupT_at_the_cDNA_level_and_p.Ser254IlefsX3_(S254IfsX3)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_ACTC[dupT]ATCA._The_duplication_causes_a_frameshift,_which_changes_a_Serine_to_an_Isoleucine_at_codon_254,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.758dupT_has_been_reported_in_association_with_familial_breast_cancer,_including_triple_negative_and_bilateral_disease,_and_has_also_been_identified_in_individuals_with_melanoma_and_ovarian_cancer_(Pern_2012,_Zheng_2012,_Kanchi_2014,_Wong-Brown_2014,_Churpek_2015,_Thompson_2015)._We_consider_this_variant_to_be_pathogenic.|
NM_024675.3:c.757_758del	PALB2	frameshift_variant	102676	1	NA	NA	-	-	-	-	126768	132278	_complementation_group_N|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1835817,OMIM:610832|MedGen:CN517202	-	NC_000016.9:g.23647109_23647110AG[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	180177092	-	PALB2_database|Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Genetic_Services_Laboratory,_University_of_Chicago|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|GeneKor_MSA|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-07-16|2019-01-07|2016-11-09|2018-08-03|2015-03-04|2019-04-19|2015-11-20|2014-12-08|2018-08-01|2018-10-09|2017-04-17|2018-12-01	2013-09-12|2019-03-28|2016-11-23|2019-04-24|2015-09-15|2020-02-26|2016-03-03|2017-10-26|2018-08-08|2019-01-29|2017-08-01|2019-02-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000148607|SCV000253946|SCV000489689|SCV000917956|SCV000248444|SCV000186591|SCV000266113|SCV000686073|SCV000821762|SCV000150021|SCV000601796|SCV000924011	_complementation_group_N|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Ovarian_Neoplasms	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu253Ilefs*3)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs180177092,_ExAC_0.001%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_21285249,_22006311,_26845104),_and_an_individual_affected_with_breast_cancer_and/or_ovarian_cancer_(PMID:_26898890)._It_was_also_reported_to_co-occur_with_a_second_pathogenic_PALB2_variant_in_an_individual_affected_with_Fanconi_anemia_(PMID:_17200671)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126768)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_PALB2_c.757_758delCT_(p.Leu253IlefsX3)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.1240C>T/p.Arg414X,_c.2167_2168delAT/p.Met723fsX21)._The_variant_allele_was_found_at_a_frequency_of_8.2e-06_in_123596_control_chromosomes._c.757_758delCT_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_in_heterozygous_state_and_one_individual_with_Fanconi_anemia_in_compound_heterozygous_state_(Walsh_2011,_Casedei_2011,_Tung_2015)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._Seven_ClinVar_submissions_from_other_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification||||This_deletion_of_two_nucleotides_is_denoted_PALB2_c.757_758delCT_at_the_cDNA_level_and_p.Leu253IlefsX3_(L253IfsX3)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GACT[delCT]ATCA._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_an_Isoleucine_at_codon_253,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.757_758delCT_has_been_observed_in_individuals_with_breast,_peritoneal,_or_pancreatic_cancer,_some_of_whom_also_had_a_family_history_of_breast_and/or_ovarian_cancer_(Jones_2009,_Casadei_2011,_Tung_2014,_Caminsky_2016,_Shirts_2016)._Additionally,_this_variant_has_also_been_reported,_in_the_compound_heterozygous_state,_in_an_individual_with_Fanconi_anemia_and_a_family_history_of_breast_cancer_(Reid_2007)._We_consider_this_variant_to_be_pathogenic.||
NM_024675.3:c.726_727insTTAGGTCTGTAGA	PALB2	stop_gained,frameshift_variant	102612	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_024675.3:c.712A>T	PALB2	stop_gained	102590	1	NA	NA	-	-	-	-	826857	812821	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000016.9:g.23647155T>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	-	-	Ambry_Genetics	Pathogenic	2018-12-28	2020-02-26	_single_submitter	germline	SCV001188381	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_024675.3:c.654del	PALB2	frameshift_variant	102670	1	NA	NA	-	-	-	-	141372	151086	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000016.9:g.23647214del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	587781697	-	Ambry_Genetics|Color|Invitae	Pathogenic|Pathogenic|Pathogenic	2016-09-13|2015-01-31|2017-12-05	2020-02-26|2016-07-05|2018-04-02	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000184681|SCV000292143|SCV000757371	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asp219Thrfs*4)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_PALB2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141372)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_024675.3:c.509_510del	PALB2	frameshift_variant	102716	5	NA	NA	-	-	-	-	126757	132267	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_specified|PALB2-Related_Disorders|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN239408|MedGen:CN517202	-	NC_000016.9:g.23647358_23647359del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:177557|Illumina_Clinical_Services_Laboratory,Illumina:614668|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2780922	-	PALB2:79728	SO:0001589|frameshift_variant	1	515726123	-	PALB2_database|Invitae|Pathway_Genomics|Counsyl|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|GeneKor_MSA|Mendelics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Illumina_Clinical_Services_Laboratory,Illumina|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-07-16|2018-12-28|2014-11-06|2016-11-02|2018-10-19|2015-11-20|2015-02-24|2018-08-01|2018-07-02|2018-08-22|2016-04-30|2017-04-27|2018-07-23	2013-09-12|2019-03-28|2015-01-12|2016-11-23|2020-02-26|2016-03-03|2017-10-26|2018-08-08|2018-08-20|2019-01-29|2018-08-31|2019-02-01|2019-08-05	no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline	SCV000148593|SCV000166665|SCV000207352|SCV000489643|SCV000185544|SCV000266111|SCV000686065|SCV000821754|SCV000839054|SCV000211483|SCV000601792|SCV000396132|SCV001157357	Pancreatic_cancer_3|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|PALB2-Related_Disorders|not_specified	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg170Ilefs*14)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs515726124,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_with_breast,_ovarian,_and_pancreatic_cancer_(PMID:_20122277,_20412113,_21285249,_24061862,_25959805,_25330149,_27106063,_27038244,_26083025)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126757)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_25099575,_17200668)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification|||||This_deletion_of_two_nucleotides_is_denoted_PALB2_c.509_510delGA_at_the_cDNA_level_and_p.Arg170IlefsX14_(R170IfsX14)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CTCA[delGA]TTGT._The_deletion_causes_a_frameshift,_which_changes_an_Arginine_to_an_Isoleucine_at_codon_170,_and_creates_a_premature_stop_codon_at_position_14_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.509_510delGA,_previously_reported_as_509delAG_or_508_9delAG,_has_been_reported_in_association_with_familial_breast_and_pancreatic_cancers_and_is_a_recurrent_pathogenic_variant_in_Central_and_Eastern_European_populations_(Dansonka-Mieszkowska_2010,_Slater_2010,_Casadei_2011,_Noskowicz_2014,_Cybulski_2015,_Wojcik_2016,_Kluska_2017)._In_addition,_in_vitro_assays_by_Pauty_et._al._2017_demonstrated_that_this_variant_failed_to_form_DNA_damage-induced_foci,_failed_to_stimulate_RAD51,_and_only_weakly_bound_DNA_at_high_concentrations._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||The_PALB2_c.509_510delGA_(p.Arg170IlefsTer14)_variant_results_in_frameshift_and_is_predicted_to_result_in_premature_truncation_of_the_protein._The_p.Arg170IlefsTer14_variant_is_reported_in_at_least_six_studies_in_which_it_is_found_in_a_heterozygous_state_in_a_total_of_23_breast_cancer_patients,_two_ovarian_cancer_patients_and_one_pancreatic_cancer_patient_(Dansonka-Mieszkowska_et_al._2010:_Slater_et_al._2010:_Casadei_et_al._2011:_Bogdanova_et_al._2011:_Adank_et_al._2011:_Noskowicz_et_al._2014)._This_variant_has_not_been_reported_in_individuals_with_Fanconi_anemia._The_p.Arg170IlefsTer14_variant_was_found_in_a_heterozygous_state_in_one_of_5097_controls_and_is_reported_at_a_frequency_of_0.00010_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._The_variant_creates_a_premature_stop_codon_which_shortens_the_PALB2_protein_to_182_amino_acids_from_1186_amino_acids._This_removes_the_C-terminal_domain_which_contains_the_WD40_repeats_necessary_for_BRCA2/PALB2_complex_formation._Other_deletion_variants_that_remove_the_C-terminal_domain_of_the_PALB2_protein_have_been_shown_to_have_highly_reduced_BRCA2_binding_capacity_and_be_defective_in_the_repair_of_ds_breaks_and_mitomyocin_C-induced_damages._To_date,_all_PALB2_variants_detected_in_families_with_breast_cancer_or_Fanconi_anemia_have_been_frameshift_or_nonsense_changes_leading_to_a_truncated_protein._Based_on_the_evidence_and_the_potential_impact_of_frameshift_variants,_the_p.Arg170IlefsTer14_variant_is_classified_as_pathogenic_for_PALB2-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|The_PALB2_c.509_510delGA:_p.Arg170fs_variant_(rs515726124)_is_a_recurrent_alteration_in_individuals_with_breast_cancer_(Casadel_2011,_Cybulski_2015,_Cybulski_2015b,_Dansonka-Mieszkowska_2010,_Kluska_2017,_Noskowicz_2014),_and_is_significantly_enriched_in_affected_individuals_compared_to_the_healthy_population_(Cybulski_2015)._This_variant_is_reported_as_pathogenic_in_ClinVar_(Variation_ID:_126757),_and_found_in_the_general_population_with_a_low_overall_allele_frequency_of_0.003%_(8/246222_alleles)_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_deleting_2_nucleotides,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Casadel_S_et_al._Contribution_of_inherited_mutations_in_the_BRCA2-interacting_protein_PALB2_to_familial_breast_cancer._Cancer_Res._2011:_71(6):2222-9._Cybulski_C_et_al._Clinical_outcomes_in_women_with_breast_cancer_and_a_PALB2_mutation:_a_prospective_cohort_analysis._Lancet_Oncol._2015:_16(6):638-44._Cybulski_C_et_al._Mutations_predisposing_to_breast_cancer_in_12_candidate_genes_in_breast_cancer_patients_from_Poland._Clin_Genet._2015b:_88(4):366-70._Dansonka-Mieszkowska_A_et_al._A_novel_germline_PALB2_deletion_in_Polish_breast_and_ovarian_cancer_patients._BMC_Med_Genet._2010:_11:20._Kluska_A_et_al._PALB2_mutations_in_BRCA1/2-mutation_negative_breast_and_ovarian_cancer_patients_from_Poland._BMC_Med_Genomics._2017:_10(1):14._Noskowicz_M_et_al._Prevalence_of_PALB2_mutation_c.509_510delGA_in_unselected_breast_cancer_patients_from_Central_and_Eastern_Europe._Fam_Cancer._2014:_13(2):137-42.
NM_024675.3:c.424A>T	PALB2	stop_gained	102672	1	NA	NA	5	1	rs587782005	Hereditary cancer-predisposing syndrome	141779	151493	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23647443T>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	587782005	-	Ambry_Genetics|Color|GeneDx|Invitae|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-11|2017-07-16|2018-02-23|2018-11-05|2018-02-06	2020-02-26|2017-12-21|2019-01-29|2019-03-28|2018-06-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000185284|SCV000690930|SCV000490683|SCV000550632|SCV000786003	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_PALB2_c.424A>T_at_the_cDNA_level_and_p.Lys142Ter_(K142X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Lysine_to_a_premature_stop_codon_(AAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys142*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587782005,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_PALB2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141779)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_25099575,_17200668)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_024675.3:c.395del	PALB2	frameshift_variant	102538	2	NA	NA	-	-	-	-	126748	132258	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000016.9:g.23647472del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	180177085	-	PALB2_database|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2012-07-16|2018-04-25|2018-06-05	2013-09-12|2018-08-29|2020-02-26	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000148583|SCV000828995|SCV001183152	_complementation_group_N|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val132Alafs*45)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs180177085,_ExAC_0.003%)._This_variant_has_been_reported_in_an_individual_affected_with_Fanconi_anemia_(PMID:Â¬â€ 17200671)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126748)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_024675.3:c.196C>T	PALB2	stop_gained	102740	2	NA	NA	5&5	1&1	rs180177083	Hereditary cancer-predisposing syndrome&not provided	126629	132139	Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23649186G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	180177083	-	Peter_MacCallum_Cancer_Centre|Counsyl|Ambry_Genetics|Color|True_Health_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-30|2015-06-01|2015-12-07|2018-08-06|2015-02-17|2018-04-09|2018-08-24|2017-01-31|2016-04-01	2019-03-28|2015-08-13|2016-11-23|2020-02-26|2017-10-26|2018-06-26|2019-01-29|2017-08-01|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000253937|SCV000267959|SCV000487889|SCV000213579|SCV000685912|SCV000805276|SCV000292642|SCV000601747|SCV000699549	Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln66*)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_families_affected_with_breast_and_ovarian_cancer_(PMID:_21285249,_21409391,_23448497,_26534844)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126629)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_variant_is_denoted_PALB2_c.196C>T_at_the_cDNA_level_and_p.Gln66Ter_(Q66X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_familial_breast_cancer_patients_and_is_considered_pathogenic_(Casadei_2011,_Wong_2011,_Teo_2013,_Antoniou_2014,_Thompson_2015).||Variant_Summary:_The_variant_of_interest_causes_nonsense_mutation_involving_a_conserved_nucleotide_predicted_to_cause_a_truncated_PALB2_protein,_a_known_disease_mechanism_for_HBOC._The_variant_of_interest_was_not_observed_in_controls_(ExAC,_1000_Gs_or_ESP),_but_has_been_reported_in_multiple_affected_individuals_(primarily_from_Australia)_via_publications_and_reputable_databases/clinical_laboratories_cite_the_variant_with_a_classification_of_pathogenic._Therefore,_taking_all_available_lines_of_evidence_into_consideration,_the_variant_of_interest_is_classified_as_Pathogenic.
NM_024675.3:c.178C>T	PALB2	stop_gained	102742	1	NA	NA	-	-	-	-	265704	260110	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23649204G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001587|nonsense	1	886039747	-	GeneDx|Ambry_Genetics	Likely_pathogenic|Pathogenic	2016-08-29|2019-12-02	2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000322700|SCV001173708	not_provided|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_PALB2_c.178C>T_at_the_cDNA_level_and_p.Gln60Ter_(Q60X)_at_the_protein_level.The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_andis_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNAdecay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_likelypathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_024675.3:c.172_175del	PALB2	frameshift_variant	102738	6	15430	1	-	-	-	-	126623	132133	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Pancreatic_cancer_3|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150547,OMIM:613348|MedGen:CN517202	-	NC_000016.9:g.23649207_23649210ACAA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Microsatellite	SO:0000289	OMIM_Allelic_Variant:610355.0007	-	PALB2:79728	SO:0001589|frameshift_variant	1	180177143	-	Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|Invitae|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|OMIM|Ambry_Genetics|Color|GeneKor_MSA|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-06-01|2018-12-27|2017-08-15|2018-04-27|2009-04-10|2019-03-22|2015-02-18|2018-08-01|2018-10-18|2017-02-24|2016-12-09	2015-08-13|2019-03-28|2018-06-20|2018-06-14|2012-04-17|2020-02-26|2017-10-26|2018-08-08|2019-01-29|2017-08-01|2018-09-19	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000267958|SCV000290814|SCV000785469|SCV000840029|SCV000021461|SCV000172718|SCV000685897|SCV000821755|SCV000149982|SCV000601740|SCV000704184	Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Pancreatic_cancer_3|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln60Argfs*7)_in_the_PALB2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_observed_in_multiple_individuals_affected_with_pancreatic_cancer_(PMID:_19264984,_27038244),_breast_cancer_(PMID:_25959805,_21285249,_22310028,_21618343,_24136930,_27616075),_and_ovarian_cancer_(PMID:_22310028).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126623)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||A_heterozygous_c.172_17del_(p.Gln60Argfs*7)_pathogenic_variant_in_the_PALB2_gene_was_detected_in_this_individual._This_variant_has_been_previously_described_as_disease-causing_in_pancreatic,_breast_and_ovarian_cancer_(PMID:_19264984,_27038244,_25959805,_21285249,_21285249,_22310028,_22310028)._Therefore,_we_consider_this_variant_to_be_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_pathogenic_variant_is_denoted_PALB2_c.172_175delTTGT_at_the_cDNA_level_and_p.Gln60ArgfsX7_(Q60RfsX7)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TTGT[delTTGT]CTCA._The_deletion_causes_a_frameshift,_changing_a_Glutamine_to_an_Arginine_at_codon_60,_and_creates_a_premature_stop_codon_at_position_7_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_described_as_a_recurrent_variant_in_Polish_and_Czech_populations_and_has_been_reported_in_several_individuals_with_personal_and/or_family_history_of_breast_or_pancreatic_cancer_(Jones_2009,_Casadei_2011,_Hellebrand_2011,_Janatova_2013,_Thompson_2015,_Kraus_2016,_Lener_2016,_Pritzlaff_2016,_Kluska_2017),_with_one_case-control_study_finding_this_variant_to_be_present_at_a_significantly_higher_frequency_in_women_with_breast_cancer_as_compared_to_unaffected_controls_(OR
NM_024675.3:c.162del	PALB2	frameshift_variant	102742	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000546.5:c.796G>T	TP53	stop_gained	101478	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000546.5:c.475_476dup	TP53	frameshift_variant	102604	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000546.5:c.376-2dup	TP53	splice_acceptor_variant	101276	1	NA	NA	-	-	-	-	185593	185393	Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.7578556dup	criteria_provided,_multiple_submitters,_no_conflicts	Uncertain_significance	-	-	Duplication	SO:1000035	-	-	TP53:7157	SO:0001623|5_prime_UTR_variant	1	751253294	-	Ambry_Genetics|Color|GeneKor_MSA|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2019-08-29|2018-03-16|2018-08-01|2018-12-04|2016-08-29|2019-02-05	2020-02-26|2018-11-06|2018-08-08|2019-03-28|2017-11-28|2020-03-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000215739|SCV000691592|SCV000822206|SCV000285192|SCV000293780|SCV000602270	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|not_specified|not_provided	Insufficient_or_conflicting_evidence|||This_sequence_change_falls_in_intron_4_of_the_TP53_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_TP53_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_TP53-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185593)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|This_variant_is_denoted_TP53_c.376-2dupA_or_IVS4-2dupA_and_consists_of_a_duplication_of_one_nucleotide_at_the_-2_position_in_intron_4_of_the_T53_gene._The_normal_sequence,_with_the_base_that_is_duplicated_in_braces,_is_ctac{a}gTAC,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._The_adenine_(A)_nucleotide_that_is_duplicated_is_conserved_across_species_and_is_part_of_the_canonical_splice_acceptor_site._Multiple_in_silico_models_predict_this_variant_to_cause_a_reduction_in_use_of_this_natural_splice_acceptor_site,_and_to_possibly_cause_abnormal_gene_splicing._However,_in_the_absence_of_RNA_or_functional_studies,_the_actual_effect_of_this_variant_is_unknown._TP53_c.376-2dupA_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_indicating_it_is_not_a_common_benign_variant_in_these_populations._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature_as_pathogenic_or_benign._Based_on_currently_available_information,_we_consider_TP53_c.376-2dupA_to_be_a_variant_of_uncertain_significance.|
NM_007294.3:c.5468-1G>T	BRCA1	splice_acceptor_variant	101890	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007294.3:c.5391del	BRCA1	frameshift_variant	102724	1	NA	NA	-	-	-	-	254469	249074	_familial_1	-	OMIM:604370	-	NC_000017.10:g.41201153del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	774988515	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)	Pathogenic	2016-09-08	2016-09-13	reviewed_by_expert_panel	germline	SCV000300254	_familial_1	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.
NM_007294.3:c.5333-2A>C	BRCA1	splice_acceptor_variant	102702	1	NA	NA	-	-	-	-	55535	70202	_familial_1	-	OMIM:604370	-	NC_000017.10:g.41201213T>G	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001627|intron_variant	1	397509264	-	_c/o_University_of_Cambridge	Pathogenic	2015-10-02	2016-10-28	_single_submitter	germline	SCV000326278	_familial_1	
NM_007294.3:c.5266dup	BRCA1	frameshift_variant	102752	12	15432	5	-	-	-	-	17677	32716	Pancreatic_cancer,_susceptibility_to|Neoplasm_of_the_breast|Neoplasm_of_ovary|Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Porokeratosis_punctata_palmaris_et_plantaris|Breast-ovarian_cancer,_familial_1|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	.|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1867982,OMIM:175860|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41209082dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto:287572|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:148363|Breast_Cancer_Information_Core__(BRCA1):5382&base_change%3Dins_C|OMIM_Allelic_Variant:113705.0018	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80357906	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Pathway_Genomics|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Division_Human_Genetics,Medical_University_Innsbruck|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Genetic_Services_Laboratory,_University_of_Chicago|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Mendelics|OMIM|GeneReviews|GeneDx|Bioscientia_Institut_fuer_Medizinische_Diagnostik_GmbH,Sonic_Healthcare|Baylor_Genetics|Invitae|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|GeneKor_MSA|Integrated_Genetics/Laboratory_Corporation_of_America|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Mendelics|Ambry_Genetics|Color|True_Health_Diagnostics|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GenomeConnect,_ClinGen|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|risk_factor|pathologic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2008-10-15|2014-04-08|2002-05-29|2014-07-24|2014-11-03|2015-02-11|2014-07-07|2016-04-22|2015-10-02|2015-07-01|2017-01-01|2015-12-10|2016-05-16|0000-00-00|2014-10-10|2015-09-21|2017-05-25|2019-05-28|2008-10-15|2013-09-26|2014-10-09|0000-00-00|2017-02-23|2019-01-01|2017-02-02|2016-12-02|2018-08-01|2016-04-22|2017-02-14|2014-01-31|2016-08-30|2018-07-02|2019-01-14|2014-11-19|2018-04-27|2016-12-30|2014-11-07|2019-05-20|0000-00-00|2016-12-21|2016-10-31|0000-00-00|2014-05-29|2017-07-21|2016-07-07|2017-05-25|2018-12-01|2018-12-27	2018-08-17|2015-12-29|2014-03-28|2014-08-08|2016-04-21|2015-02-11|2015-03-11|2016-06-09|2016-10-28|2017-04-17|2017-03-15|2017-07-06|2017-07-05|2018-04-04|2018-04-17|2018-04-09|2018-06-14|2019-10-22|2018-08-17|2013-04-30|2015-02-05|2016-12-07|2017-02-23|2019-03-28|2017-08-28|2019-03-21|2018-08-08|2016-11-14|2017-02-16|2017-08-04|2017-04-19|2018-08-20|2020-02-26|2016-07-05|2018-06-26|2017-07-13|2016-11-03|2020-03-06|2017-08-22|2018-03-09|2018-01-29|2016-12-06|2016-11-12|2017-07-24|2018-07-18|2018-04-30|2019-02-22|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|unknown|unknown|not_provided|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|unknown|germline|germline|germline|germline|germline	SCV000039534|SCV000053833|SCV000145419|SCV000189885|SCV000195938|SCV000212010|SCV000220482|SCV000282341|SCV000326231|SCV000564336|SCV000577937|SCV000584072|SCV000593675|SCV000733591|SCV000743374|SCV000744589|SCV000839893|SCV001140476|SCV000053476|SCV000086949|SCV000210056|SCV000484933|SCV000540940|SCV000076906|SCV000219263|SCV000271320|SCV000296781|SCV000494397|SCV000576438|SCV000587484|SCV000591601|SCV000839212|SCV000186302|SCV000292125|SCV000805234|SCV000209886|SCV000226938|SCV000296309|SCV000607156|SCV000778733|SCV000806969|SCV000492476|SCV000493028|SCV000584019|SCV000863608|SCV000901129|SCV000923779|SCV001159310	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Pancreatic_cancer,_susceptibility_to|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|not_provided|Neoplasm_of_the_breast|Neoplasm_of_ovary|Porokeratosis_punctata_palmaris_et_plantaris|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms|not_specified	|||||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||||||The_c.5266dup_(p.Gln1756Profs*74)_variant_in_the_BRCA1_gene_has_been_detected_multiple_patients_with_breast_cancer_and/or_ovarian_cancer_[PMID_7894492,_26718727,_20569256,_21503673,_23232912,_26666763,_22430266,_19359128,_20730485,_22032251,_21324516,_among_others,_referred_as_5382C_in_some_publications],_pancreatic_cancer_[PMID_24737347,_26440929]_and_prostate_cancer_[PMID_27433846_]._This_variant_is_a_founder_mutation_in_the_Ashkenazi_Jewish_population_and_is_found_with_a_high_prevalence_in_Poland_and_Eastern_Europe_[PMID_20569256,_20345474,_20507347]._The_estimated_risk_for_carriers_of_this_variant_was_89%_for_breast_cancer_and_42%_for_ovarian_cancer_by_age_70_[PMID_22430266]._This_one_bp_duplication_in_exon_19_results_in_a_frameshift_and_the_creation_of_a_premature_stop_codon._This_variant_is_thus_predicted_to_result_in_a_loss_of_function_of_the_protein._This_variant_has_been_detected_in_19_individuals_from_the_ExAC_database_(http://exac.broadinstitute.org/variant/17-41209079-T-TG)._This_variant_thus_classified_as_pathogenic.|||Converted_during_submission_to_Pathogenic.|This_insertion_of_one_nucleotide_is_denoted_BRCA1_c.5266insC_(a.k.a_c.5266dupC)_at_the_cDNA_level_and_p.Gln1756ProfsX74_(Q1756PfsX74)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_TCCC{insC}AGGA._The_inserton_causes_a_frameshift,_which_changes_a_Glutamine_to_a_Proline_at_codon_1756_in_exon_19,_and_creates_a_premature_stop_codon_at_position_74_of_the_new_reading_frame._This_mutation_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._BRCA1_c.5266_5267insC_(a.k.a_5266dupC),_also_known_as_5382insC_or_5385insC_using_alternate_nomenclature,_is_a_common_founder_mutation_in_the_Ashkenazi_Jewish_population_(Roa_1996)._We_consider_this_mutation_to_be_pathogenic._and_is_indicative_of_Hereditary_Breast_and_Ovarian_Cancer_(HBOC),_an_autosomal_dominant_condition_that_predisposes_to_early_onset_breast_cancer,_ovarian_and_fallopian_tube_cancer,_as_well_as_other_cancers._Breast_and_ovarian_cancer_are_the_predominant_BRCA1-related_cancers_that_unaffected_female_mutation_carriers_are_at_risk_to_develop._The_lifetime_risk_for_breast_cancer_is_estimated_to_be_57_to_84%_and_the_lifetime_risk_for_ovarian_cancer_is_estimated_to_be_24_to_54%_(Antoniou_2003,_Chen_2007,_Ford_1998)._BRCA1_mutations_have_also_been_reported_in_women_with_fallopian_tube_carcinoma,_primary_peritoneal_carcinoma,_and_uterine_serous_carcinoma_(Levine_2003,_Pennington_2013)._Graeser_et_al._(2009)_found_that_women_who_harbor_pathogenic_BRCA1_or_2_mutations_have_an_increased_risk_for_contralateral_breast_cancer_that_is_dependent_on_age_at_initial_diagnosis._It_is_estimated_that_the_risk_to_develop_a_second_breast_cancer_within_10_years_of_the_first_diagnosis_if_initially_diagnosed_less_than_age_40_years_of_age_is_21_to_31%,_between_the_ages_of_40_and_50_is_11_to_13%_and_after_the_age_of_50_is_8%._Additionally,_it_is_estimated_that_the_risk_to_develop_a_second_breast_cancer_within_25_years_of_their_first_diagnosis_if_initially_diagnosed_less_than_40_years_of_age_is_63%,_between_the_ages_of_40_and_50_is_44_to_49%_and_after_the_age_of_50_is_20%._Other_cancer_risks_associated_with_a_BRCA1_pathogenic_variant_include_approximately_a_20%_risk_for_prostate_cancer_in_male_carriers_(Thompson_2002),_a_4%_risk_for_male_breast_cancer_(Liede_2004),_and_an_estimated_1_to_3%_risk_for_pancreatic_cancer_in_both_men_and_women_(Brose_2002,_Thompson_2002)._The_variant_is_found_in_BRCA-AJ,BRCA1-BRCA2,BR-OV-HEREDIC,HEREDICANCER,ENDOM-HEREDIC,HIRISK-BR-HEREDIC_panel(s).|||This_sequence_change_inserts_1_nucleotide_in_exon_19_of_the_BRCA1_mRNA_(c.5266dupC),_causing_a_frameshift_at_codon_1756._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_BRCA1_mRNA_(p.Gln1756Profs*74)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_final_73_amino_acids_of_the_protein,_which_includes_the_C-terminal_BRCT_domain._This_pathogenic_variant_is_a_common_cause_of_breast_and_ovarian_cancer_in_the_Ashkenazi_Jewish_population_(PMID:_9042909,_22430266),_and_has_been_reported_in_individuals_from_other_ethnicitiesÂ¬â€ (PMID:_22185575).Â¬â€ This_variant_is_also_known_as_5382insC_and_5385insC_in_the_literature._This_variant_has_been_associated_with_a_67%_to_89%_risk_of_breast_cancer_by_age_70,_and_a_33%_to_42%_risk_of_ovarian_cancer_by_age_70_(PMID:_15994883,_22430266)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Gln1756fs_variant_in_BRCA1_(also_referred_to_as_p.Gln1777fs)_is_a_founder_variant_in_the_Ashkenazi_Jewish_population_and_has_been_reported_in_>1000_indivi_duals_with_BRCA1-associated_cancers_(Abeliovich_1997,_Elwad_2011,_Breast_Cancer_Information_Core_(BIC)_database)._This_variant_has_also_been_identified_in_22/10_152_Ashkenazi_Jewish_and_20/126734_European_chromosomes_by_the_Genome_Aggregatio_n_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs397507247)._This_v_ariant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1756_and_leads_to_a_premature_termination_codon_74_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_trunca_ted_or_absent_protein._Heterozygous_loss_of_function_of_the_BRCA1_gene_is_an_est_ablished_disease_mechanism_in_hereditary_breast_and_ovarian_cancer_(HBOC)._Furth_ermore,_the_p.Gln1756fs_variant_was_classified_as_Pathogenic_on_April_22,_2016_b_y_the_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000282341.1)._In_summary,_the_p.Gln1756fs_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_predicted_impact_to_the_protein_a_nd_presence_in_affected_individuals._ACMG/AMP_Criteria_applied:_PS4,_PVS1_(Richa_rds_2015).||Variant_summary:_The_BRCA1_c.5266dupC_variant_results_in_a_frameshift,_which_alters_the_protein's_amino_acid_sequence_beginning_at_position_1756_and_leads_to_a_premature_termination_codon_73_amino_acids_downstream._It_is_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_non-sense_meditated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(such_as_c.5387C>A/p.Ser1796X,_c.5417delC/Pro1806fsX28,_etc)._Mutation_Taster_predicts_a_damaging_outcome_for_this_variant,_and_functional_studies_have_shown_HR_activity_is_significantly_impaired_by_this_variant_(Bouwman_BRCA1_Cancer_Discovery_2013)._BRCA1_c.5266dupC_was_found_in_19/121412_control_chromosomes_at_a_frequency_of_0.0001565,_which_does_not_exceed_maximal_expected_frequency_of_a_pathogenic_BRCA1_allele_(0.0010005)._The_variant_has_been_cited_in_hundreds_of_HBOC_patients_and_is_reported_as_a_known_common_founder_mutation_in_the_literature._Additionally,_this_variant_has_been_classified_by_multiple_clinical_labs_and_databases_as_pathogenic._Taken_together,_this_variant_was_classified_as_disease_variant/pathogenic.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_duplication_of_one_nucleotide_is_denoted_BRCA1_c.5266dupC_at_the_cDNA_level_and_p.Gln1756ProfsX74_(Q1756PfsX74)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_ATCC[dupC]AGGA._The_duplication_causes_a_frameshift,_which_changes_a_Glutamine_to_a_Proline_at_codon_1756,_and_creates_a_premature_stop_codon_at_position_74_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._BRCA1_c.5266dupC,_also_known_as_5382insC_or_5385insC_using_alternate_nomenclature,_is_a_common_founder_variant_in_the_Ashkenazi_Jewish_population_(Roa_1996)._We_consider_this_variant_to_be_pathogenic.||The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.|||||||||The_BRCA1_c.5266dupC:_p.Gln1756fs_variant_(rs397507247),_also_known_as_5382insC,_has_been_described_in_individuals_and_families_with_hereditary_breast_and_ovarian_cancer,_peritoneal_cancer,_and_pancreatic_cancer_and_is_a_known_pathogenic_founder_variant_(Bogdanova_2010,_Elsakov_2010,_Heidemann_2012,_Simard_1994,_Uglanitsa_2010,_Zhang_2011)._This_variant_is_reported_as_pathogenic_in_ClinVar_(Variation_ID:_17677)._It_is_found_in_the_general_population_with_an_overall_allele_frequency_of_0.02%_(51/282892_alleles)_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_duplicating_a_single_nucleotide,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Bogdanova_NV_et_al._High_frequency_and_allele-specific_differences_of_BRCA1_founder_mutations_in_breast_cancer_and_ovarian_cancer_patients_from_Belarus._Clin_Genet._2010_78(4):364-72._Elsakov_P_et_al._The_contribution_of_founder_mutations_in_BRCA1_to_breast_and_ovarian_cancer_in_Lithuania._Clin_Genet._2010_78(4):373-6._Heidemann_S_et_al._Double_heterozygosity_for_mutations_in_BRCA1_and_BRCA2_in_German_breast_cancer_patients:_implications_on_test_strategies_and_clinical_management._Breast_Cancer_Res_Treat._2012_134(3):1229-39._Simard_J_et_al._Common_origins_of_BRCA1_mutations_in_Canadian_breast_and_ovarian_cancer_families._Nat_Genet._1994_8(4):392-8._Uglanitsa_N_et_al._The_contribution_of_founder_mutations_in_BRCA1_to_breast_cancer_in_Belarus._Clin_Genet._2010_78(4):377-80._Zhang_S_et_al._Frequencies_of_BRCA1_and_BRCA2_mutations_among_1,342_unselected_patients_with_invasive_ovarian_cancer._Gynecol_Oncol._2011_121(2):353-7.
NM_007294.3:c.5194-2A>G	BRCA1	splice_acceptor_variant	102742	1	NA	NA	-	-	-	-	37647	46203	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41209154T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA1):5313-2&base_change%3DA_to_G	-	BRCA1:672	SO:0001574|splice_acceptor_variant	1	80358069	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-04-11|1999-06-21|2015-11-20|2015-10-02|2018-05-29|2018-07-15|2018-12-31|2014-01-31|2013-02-17|2016-02-29	2012-07-24|2014-03-28|2016-03-03|2016-10-28|2020-02-26|2018-11-06|2019-01-29|2017-08-04|2017-04-19|2018-01-25	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053828|SCV000145388|SCV000266034|SCV000326210|SCV000186915|SCV000683270|SCV000322128|SCV000587477|SCV000591591|SCV000699220	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	||||Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Other_strong_data_supporting_pathogenic_classification||This_variant_is_denoted_BRCA1_c.5194-2A>G_or_IVS18-2A>G_and_consists_of_a_A>G_nucleotide_substitution_at_the_-2_position_of_intron_18_of_the_BRCA1_gene._Using_alternate_nomenclature,_this_variant_has_been_previously_published_as_BRCA1_5313-2A>G_and_IVS19-2A>G._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_individuals_with_breast_cancer_and/or_clinical_features_of_Hereditary_Breast/Ovarian_Cancer_syndrome_(Esteban-Cardenosa_2004,_Shirts_2016,_Park_2017)._Based_on_the_currently_available_information,_we_consider_BRCA1_c.5194-2A>G_to_be_a_likely_pathogenic_variant.|||
NM_007294.3:c.5080G>T	BRCA1	stop_gained	102588	1	NA	NA	5&5&5	1&3&1	rs80356896	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 1&not provided	55387	70054	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41215963C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80356896	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|GeneDx|Color|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-14|2014-01-31|2006-11-05|2002-05-29|2016-09-08|2015-10-02|0000-00-00|2015-09-21|2015-03-17|2016-10-11|2019-03-27	2019-03-28|2017-08-04|2013-06-26|2014-03-28|2016-09-13|2016-10-28|2018-04-04|2018-04-09|2019-01-29|2017-10-26|2020-02-26	criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000076793|SCV000587458|SCV000109396|SCV000145303|SCV000300196|SCV000326151|SCV000733600|SCV000744601|SCV000321439|SCV000683251|SCV001185403	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu1694*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_patients_affected_with_breast_and/or_ovarian_cancer_(PMID:Â¬â€ 9333265,Â¬â€ 9497265)._In_the_literature,_this_variant_is_also_known_as_5199G>T._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_55387)._In_addition,_experimental_studies_have_demonstrated_that_this_nonsense_variant_leads_to_the_skipping_of_exon_17_(also_called_exon_18_in_the_literature)_during_mRNA_splicing_and_results_in_the_in-frame_deletion_of_26_amino_acids_(p.Asp1692_Phe1717del)_from_the_BRCA1_protein._The_deletion_of_these_amino_acids_disrupts_the_conserved_BRCT_protein_domain_and_is_expected_to_be_deleteriousÂ¬â€ (PMID:_9497265)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||This_pathogenic_variant_is_denoted_BRCA1_c.5080G>T_at_the_cDNA_level_and_p.Glu1694Ter_(E1694X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAG>TAG)._BRCA1_c.5080G>T_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._However_in_vivo_and_in_vitro_assays_have_shown_that_this_mutation_results_in_complete_skipping_of_exon_17,_previously_described_as_exon_18_using_alternate_exon_numbering,_which_is_due_to_the_disruption_of_a_splicing_enhancer._The_complete_skipping_of_this_exon_results_in_an_in-frame_deletion_of_26_amino_acids:_however,_the_skipping_of_exon_17_results_in_disruption_of_the_first_BRCT_domain_making_it_unlikely_that_the_BRCA1_protein_can_remain_functional_(Perrin-Vidoz_2002,_Liu_2001,_Mazoyer_1998)._Additionally,_BRCA1_c.5080G>T,_also_published_as_5199G>T_using_alternate_nomenclature,_has_been_reported_in_several_individuals_with_Hereditary_Breast_and_Ovarian_Cancer_syndrome_(Shattuck-Eidens_1997,_Liu_2001,_Schoumacher_2001,_Meindl_2002,_Kim_2012)._Based_on_current_information,_we_consider_this_BRCA1_c.5080G>T_to_be_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Functionally-validated_splicing_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_007294.3:c.5068A>T	BRCA1	stop_gained	102684	1	NA	NA	5	3	rs397507239	Breast-ovarian cancer, familial 1	37626	46182	_familial_1	-	OMIM:604370	-	NC_000017.10:g.41219631T>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	397507239	-	_c/o_University_of_Cambridge|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2010-05-12|2016-09-08|2015-10-02|2017-11-28	2012-08-22|2016-09-13|2016-10-28|2018-06-20	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown	SCV000053807|SCV000300194|SCV000326129|SCV000785794	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||
NM_007294.3:c.4936del	BRCA1	frameshift_variant	102504	1	NA	NA	-	-	-	-	55322	69989	_familial_1|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41222997del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):5053&base_change%3Ddel_G|Breast_Cancer_Information_Core__(BRCA1):5055&base_change%3Ddel_G	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80357653	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-24|2014-01-31|1999-06-21|2016-04-22|2015-10-02|2017-06-30|2018-05-31|2018-05-23|2018-12-01	2019-03-28|2017-08-04|2014-03-28|2016-06-09|2016-10-28|2020-02-26|2018-11-06|2019-01-29|2019-02-22	criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000076712|SCV000587434|SCV000145215|SCV000282335|SCV000326067|SCV000185554|SCV000905199|SCV000293378|SCV000923990	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ovarian_Neoplasms	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val1646Serfs*12)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_inÂ¬â€ individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_11710890,_25476495)._This_variant_is_also_known_as_5055_delG:_Stop_1657_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_55322)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_in_BRCA1_is_denoted_c.4936delG_at_the_cDNA_level_and_p.Val1646SerfsX12_(V1646SfsX12)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_AAGG[G]TCAA._The_deletion_causes_a_frameshift,_which_changes_a_Valine_to_a_Serine_at_codon_1646,_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.4936delG,_also_published_as_5055delG_using_alternate_nomenclature,_has_been_published_in_association_with_hereditary_breast_and_ovarian_cancer_and_has_been_observed_in_individuals_of_Ashkenazi_Jewish_descent_(King_2001,_Yazici_2002,_Finkelman_2012,_Rosenthal_2014)._We_consider_this_variant_to_be_pathogenic.|
NM_007294.3:c.4745del	BRCA1	frameshift_variant	102636	1	NA	NA	-	-	-	-	55278	69945	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41223186del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):4864&base_change%3Ddel_A	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80357907	-	Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Department_of_Medical_Genetics,Oslo_University_Hospital|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto	Pathogenic|Pathogenic|Pathogenic|Pathogenic	1999-06-21|2016-09-08|2015-07-01|2014-01-31	2014-03-28|2016-09-13|2017-04-17|2017-08-04	_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline	SCV000145171|SCV000300157|SCV000564331|SCV000587426	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||
NM_007294.3:c.4689C>G	BRCA1	stop_gained	102146	1	NA	NA	5&5&5&5	3&2&1&1	rs80357433	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&not provided	37607	46163	_familial_1|not_specified|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41223242G>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:93567|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario:1777085	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80357433	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Department_of_Medical_Genetics,Oslo_University_Hospital|Genetic_Services_Laboratory,_University_of_Chicago|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Snyder_Lab,_Genetics_Department,Stanford_University|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneKor_MSA|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Baylor_Genetics|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-03-04|2002-05-29|2016-04-21|2016-04-22|2015-03-09|2015-10-02|2016-04-28|2015-07-01|2016-05-16|0000-00-00|2017-07-28|2015-09-21|2017-06-06|2017-01-01|2019-01-02|2014-01-31|0000-00-00|2016-05-03|2018-11-13|2016-05-02|2018-05-29|2015-05-14|2017-11-01|2016-03-03|2015-03-09|2017-02-23|2018-12-01|2019-05-13	2013-12-30|2014-03-28|2016-04-21|2016-06-09|2016-07-18|2016-10-28|2016-11-23|2017-04-17|2017-07-05|2018-04-04|2018-04-17|2018-04-09|2018-06-14|2018-10-29|2019-03-28|2017-08-04|2017-04-19|2018-01-25|2020-02-26|2017-10-26|2019-01-29|2018-09-19|2017-11-21|2018-01-29|2018-08-31|2017-02-23|2019-02-22|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053788|SCV000145160|SCV000267714|SCV000282332|SCV000296307|SCV000326033|SCV000488572|SCV000564327|SCV000593676|SCV000733607|SCV000743389|SCV000744610|SCV000839898|SCV000853089|SCV000076644|SCV000587421|SCV000591537|SCV000699164|SCV000186890|SCV000683206|SCV000210185|SCV000226313|SCV000693540|SCV000806958|SCV000888922|SCV000540932|SCV000923988|SCV001157089	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|Familial_cancer_of_breast|Ovarian_Neoplasms|not_specified	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||||||The_c.4689C>G_(p.Tyr1563*)_variant_in_the_BRCA1_gene_has_been_detected_multiple_patients_with_breast_cancer_and/or_ovarian_cancer_[PMID_8554067,_23110154]._This_variant_creates_a_premature_stop_codon_at_amino_acid_position_1563_of_the_BRCA1_protein._This_variant_is_thus_predicted_to_result_in_a_loss_of_function_of_the_protein._This_variant_has_not_been_observed_in_the_ExAC_population_database._This_variant_is_thus_classified_as_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr1563*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_hereditary_breast_and_ovarian_cancer_(PMID:_8554067,_23110154,_25066507,_20727672,_27167707)._This_variant_is_also_known_as_4808C>G_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37607)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA1_c.4689C>G_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein,_which_is_a_commonly_known_mechanism_for_disease._Mutation_taster_predicts_a_damaging_outcome_for_this_variant._The_variant_is_not_found_in_120204_control_chromosomes_and_it_was_reported_in_several_HBOC_spectrum_patients_via_publications_and_databases_suggesting_a_disease_causing_impact._Furthermore,_truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.:_p.Glu1725X,_p.Arg1751X,_p.Ser1796X,_p.Trp1815X,_p.Arg1835X)_indicating_pathogenicity._In_addition,_several_clinical_laboratories_and_reputable_databases_classified_this_variant_as_Pathogenic._Taken_together,_this_variant_was_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_BRCA1_c.4689C>G_at_the_cDNA_level_and_Tyr1563Ter_(Y1563X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_denoted_4808C>G_using_alternate_nomenclature,_has_been_reported_in_association_with_familial_breast_cancer_and/or_ovarian_cancer_and_is_considered_pathogenic_(Serova_1996,_Shih_2002,_Turkovic_2010,_Schneegans_2012,_Wong-Brown_2015).|||||||The_BRCA1_c.4689C>G:_p.Tyr1563Ter_variant_(rs80357433),_also_known_as_4808C>G,_is_reported_in_the_literature_in_multiple_individuals_and_families_affected_with_hereditary_breast_and_ovarian_cancer_(Pern_2012,_Rebbeck_2018,_Schneegans_2012,_Serova_1996)._This_variant_is_only_observed_on_one_allele_in_the_Genome_Aggregation_Database,_indicating_it_is_not_a_common_polymorphism._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Pern_F_et_al._Mutation_analysis_of_BRCA1,_BRCA2,_PALB2_and_BRD7_in_a_hospital-based_series_of_German_patients_with_triple-negative_breast_cancer._PLoS_One._2012:7(10):e47993._Rebbeck_TR_et_al._Mutational_spectrum_in_a_worldwide_study_of_29,700_families_with_BRCA1_or_BRCA2_mutations._Hum_Mutat._2018_May:39(5):593-620._Schneegans_SM_Validation_of_three_BRCA1/2_mutation-carrier_probability_models_Myriad,_BRCAPRO_and_BOADICEA_in_a_population-based_series_of_183_German_families._Fam_Cancer._2012_Jun:11(2):181-8._Serova_O_et_al._A_high_incidence_of_BRCA1_mutations_in_20_breast-ovarian_cancer_families._Am_J_Hum_Genet._1996_Jan:58(1):42-51.
NM_007294.3:c.4327C>T	BRCA1	stop_gained	102664	2	15428	0	5&5&5&5&5&5	3&2&1&0&1&1	rs41293455	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&Familial cancer of breast&not provided&not specified	17675	32714	Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_1|Pancreatic_cancer_4|FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:C3280442,OMIM:614320|MedGen:C4554406,OMIM:617883|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41234451G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:63140|Department_of_Pathology_and_Molecular_Medicine,Queen's_University:722777|OMIM_Allelic_Variant:113705.0016|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario:1775457	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	41293455	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Counsyl|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Genetic_Services_Laboratory,_University_of_Chicago|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|Baylor_Genetics|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|GeneKor_MSA|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1994-12-01|2013-11-14|2002-05-29|2014-10-02|2016-04-21|2016-04-22|2015-10-02|2017-01-01|2016-11-29|0000-00-00|2014-10-08|2015-09-21|2019-01-09|2014-01-31|2017-04-20|2013-06-21|2016-10-28|2016-08-15|2018-11-19|2016-06-15|0000-00-00|2017-02-23|2018-09-11|2018-05-25|2019-05-16|2016-11-28|2016-07-01|2019-02-21|2017-05-18|2017-08-14|2015-12-07|2018-10-31	2018-03-12|2015-08-20|2014-03-28|2015-03-11|2016-04-21|2016-06-09|2016-10-28|2017-03-15|2017-07-05|2018-04-04|2018-04-17|2018-04-09|2019-03-28|2017-08-04|2017-08-04|2017-04-19|2019-03-21|2018-01-25|2020-02-26|2017-01-26|2016-06-05|2017-02-23|2019-01-29|2018-09-19|2020-03-06|2018-03-09|2016-07-19|2019-08-05|2017-05-23|2018-04-30|2018-07-18|2018-11-14	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|germline|germline|unknown	SCV000039532|SCV000109372|SCV000145057|SCV000220762|SCV000267710|SCV000282327|SCV000325921|SCV000577931|SCV000593678|SCV000733611|SCV000743394|SCV000744615|SCV000076536|SCV000587391|SCV000588057|SCV000591505|SCV000605740|SCV000699132|SCV000186935|SCV000537634|SCV000280026|SCV000540934|SCV000210173|SCV000225648|SCV000296337|SCV000778740|SCV000296802|SCV000602710|SCV000611253|SCV000219242|SCV000863581|SCV000893445	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_provided|not_provided|not_provided|not_specified|not_specified|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_1/Pancreatic_cancer_4|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_1/Pancreatic_cancer_4/FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S	|||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg1443*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs41293455,_ExAC_0.02%)._This_variant_has_been_reported_in_many_individuals_with_hereditary_breast_and_ovarian_cancer_(PMID:_16030099,_23233716,_19656415,_22798144)._It_is_known_to_be_a_common_cause_of_disease_in_the_French_Canadian_population_(PMID:_15883839,_10422801,_20694749,_11250694)._This_variant_is_also_known_as_4446C>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_17675)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||The_p.Arg1443X_variant_in_BRCA1_has_been_previously_reported_in_>100_individuals_with_BRCA1-associated_cancers_(Vezina_2005,_Hall_2009)._It_has_also_been_identi_fied_in_1/6614_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_h_ttp://exac.broadinstitute.org:_dbSNP_rs41293455)._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_1443,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._In_addition,_functional_studies_provide_some_evide_nce_that_this_variant_results_in_a_truncated_protein_(Caligo_2009)._Heterozygous_loss_of_function_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_indiv_iduals_with_hereditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_varia_nt_was_classified_as_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000282327.1)._In_summary,_this_variant_meets_our_crite_ria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner.|Variant_summary:_The_c.4327C>T_(p.Arg1443X)_variant_in_BRCA1_gene_is_a_nonsense_mutation._The_mutation_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._The_variant_was_observed_in_the_large_and_broad_cohorts_of_the_ExAC_project_at_an_allele_frequency_of_0.000016_(2/121390_chrs_tested)._This_frequency_does_not_exceed_the_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_BRCA1_(0.001)._The_variant_has_been_reported_in_multiple_HBOC_families_and_was_shown_to_segregate_with_disease_phenotype._It_has_been_classified_as_pathogenic_by_multiple_reputable_databases/clinical_laboratories._Taken_together,_the_variant_was_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||||This_pathogenic_variant_is_denoted_BRCA1_c.4327C>T_at_the_cDNA_level_and_p.Arg1443Ter_(R1443X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_reported_as_BRCA1_4446C>T_using_alternate_nomenclature,_has_been_observed_in_multiple_families_with_early-onset_breast_and_ovarian_cancer_and_has_been_reported_as_a_recurrent_variant_in_the_French_Canadian_and_Hispanic_populations_(Castilla_1994,_Simard_2007,_Zhang_2011,_Weitzel_2013,_Cruz-Correa_2017)._We_consider_this_variant_to_be_pathogenic.||The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity._Occurs_in_a_single_case_with_an_otherwise_positive_result._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.|||The_BRCA1_c.4327C>T:_p.Arg1443Ter_variant_(rs41293455),_also_known_as_4446C>T_for_traditional_nomenclature,_is_reported_in_the_literature_in_multiple_individuals_with_hereditary_breast_and_ovarian_cancer_syndrome_(Castilla_1994,_de_Jonge_2017,_Rashid_2016,_Sun_2017,_Susswein_2016,_Zhang_2011)._This_variant_is_also_described_as_a_founder_variant_in_the_French_Canadian_population_(Cavallone_2010,_Neuhausen_2000,_Tonin_1999,_Vezina_2005)._It_is_reported_by_multiple_laboratories_in_ClinVar_(Variation_ID:_17675),_and_found_in_the_general_population_with_a_low_overall_allele_frequency_of_0.002%_(6/246148_alleles)_in_the_Genome_Aggregation_Database._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Castilla_LH_et_al._Mutations_in_the_BRCA1_gene_in_families_with_early-onset_breast_and_ovarian_cancer._Nat_Genet._1994_Dec:8(4):387-91._Cavallone_L_et_al._Comprehensive_BRCA1_and_BRCA2_mutation_analyses_and_review_of_French_Canadian_families_with_at_least_three_cases_of_breast_cancer._Fam_Cancer._2010_Dec:9(4):507-17._de_Jonge_MM_et_al._Linking_uterine_serous_carcinoma_to_BRCA1/2-associated_cancer_syndrome:_A_meta-analysis_and_case_report._Eur_J_Cancer._2017_Feb:72:215-225._Neuhausen_SL._Founder_populations_and_their_uses_for_breast_cancer_genetics._Breast_Cancer_Res._2000:2(2):77-81._Rashid_MU_et_al._High_prevalence_and_predominance_of_BRCA1_germline_mutations_in_Pakistani_triple-negative_breast_cancer_patients._BMC_Cancer._2016_Aug_23:16(1):673._Sun_J_et_al._Germline_Mutations_in_Cancer_Susceptibility_Genes_in_a_Large_Series_of_Unselected_Breast_Cancer_Patients._Clin_Cancer_Res._2017_Oct_15:23(20):6113-6119._Susswein_LR_et_al._Pathogenic_and_likely_pathogenic_variant_prevalence_among_the_first_10,000_patients_referred_for_next-generation_cancer_panel_testing._Genet_Med._2016_Aug:18(8):823-32._Tonin_PN_et_al._Founder_BRCA1_and_BRCA2_mutations_in_French_Canadian_ovarian_cancer_cases_unselected_for_family_history._Clin_Genet._1999_May:55(5):318-24._Vezina_H_et_al._Molecular_and_genealogical_characterization_of_the_R1443X_BRCA1_mutation_in_high-risk_French-Canadian_breast/ovarian_cancer_families._Hum_Genet._2005_Jul:117(2-3):119-32._Zhang_S_et_al._Frequencies_of_BRCA1_and_BRCA2_mutations_among_1,342_unselected_patients_with_invasive_ovarian_cancer._Gynecol_Oncol._2011_May_1:121(2):353-7.||||
NM_007294.3:c.4183C>T	BRCA1	stop_gained,splice_region_variant	99006	1	NA	NA	5&5&5	3&1&1	rs80357260	Breast-ovarian cancer, familial 1&Hereditary cancer-predisposing syndrome&not provided	55125	69792	_familial_1|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41242963G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80357260	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Division_Human_Genetics,Medical_University_Innsbruck|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Mendelics|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-09-17|2002-05-29|2015-02-11|2014-04-21|2016-04-22|2015-10-02|0000-00-00|2019-05-28|2019-04-05|2015-02-24|2018-04-19|2015-10-14|2014-01-31|2013-02-26|2016-05-11|2018-07-02|2013-08-09|2019-01-30	2013-06-26|2014-03-28|2015-02-11|2015-03-11|2016-06-09|2016-10-28|2018-04-04|2019-10-22|2020-02-26|2017-10-26|2019-01-29|2018-08-31|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2018-07-18|2019-02-11	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000109366|SCV000145005|SCV000212002|SCV000220260|SCV000282324|SCV000325875|SCV000733613|SCV001140532|SCV000213361|SCV000683156|SCV000210169|SCV000296397|SCV000587380|SCV000591497|SCV000699114|SCV000839239|SCV000863604|SCV000914330	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast_and/or_ovarian_cancer|Familial_cancer_of_breast	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_pathogenic_variant_is_denoted_BRCA1_c.4183C>T_at_the_cDNA_level_and_p.Gln1395Ter_(Q1395X)_at_the_protein_level._This_variant_is_also_known_as_BRCA1_4302C>T_using_alternate_nomenclature._The_substitution_creates_a_nonsense_variant,_changing_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_Gln1395Ter_has_been_reported_in_several_individuals_with_early-onset_and/or_familial_breast_or_ovarian_cancer_and_is_reported_to_be_a_pathogenic_founder_variant_in_the_Tyrol_region_of_Austria_(Langston_1996,_Sensi_2003,_Rashid_2006,_Singer_2014,_Polsler_2016)._We_consider_this_variant_to_be_pathogenic.||||Variant_summary:_The_BRCA1_c.4183C>T_(p.Gln1395X)_variant_causes_a_nonsense_mutation_in_exon_9_resulting_in_a_premature_termination_codon,_a_known_mechanism_for_disease,_as_these_types_of_variants_are_predicted_to_cause_transcript_degradation_through_nonsense_mediated_decay_or_produce_a_truncated_protein._The_variant_of_interest_was_not_observed_in_controls_(ExAC,_1000_Gs_or_ESP),_but_has_been_reported_in_multiple_affected_individuals_via_publications._In_addition,_multiple_reputable_databases/clinical_laboratories_cite_the_variant_as_pathogenic._Therefore,_taking_all_available_lines_of_evidence_into_consideration,_the_variant_of_interest_is_classified_as_Pathogenic.|||
NM_007294.3:c.4165_4166del	BRCA1	frameshift_variant	101090	1	NA	NA	-	-	-	-	55117	69784	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41242980_41242981CT[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA1):4284&base_change%3Ddel_AG	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80357572	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|GeneDx|Ambry_Genetics|GeneKor_MSA	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-11|2014-01-31|2012-07-03|2002-05-29|2016-04-08|2016-09-08|2015-10-02|0000-00-00|2015-09-21|2017-07-25|2019-10-24|2017-11-01	2019-03-28|2017-08-04|2013-08-08|2014-03-28|2016-07-18|2016-09-13|2016-10-28|2018-04-04|2018-04-09|2019-01-29|2020-02-26|2017-11-21	criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000076476|SCV000587378|SCV000109364|SCV000145001|SCV000296450|SCV000300085|SCV000325871|SCV000733614|SCV000744619|SCV000564739|SCV000607973|SCV000693533	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser1389*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80357572,_ExAC_0.002%)._This_variant_has_been_reported_in_the_literature_in_families_affected_with_breast_and_ovarian_cancer_(PMID:_8900426,_9760198,_10923033,_16683254)._This_variant_is_also_known_as_c.4282delAG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_55117)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||This_deletion_of_two_nucleotides_in_BRCA1_is_denoted_as_c.4165_4166delAG_at_the_cDNA_level_p.Ser1389Ter_(S1389X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TCAG[AG]TGAC._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_a_premature_stop_codon_(AGT>TGA)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_Ser1389Ter,_also_published_as_4282delAG,_has_been_reported_in_at_least_two_Hereditary_Breast_and_Ovarian_Cancer_syndrome_families_and_is_considered_pathogenic_(Dong_1998,_Pohlreich_2005).|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|
NM_007294.3:c.4096+1G>A	BRCA1	splice_donor_variant	102490	3	NA	NA	-	-	-	-	37565	46121	_familial_1|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41243451C>T	reviewed_by_expert_panel	Uncertain_significance	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA1):4215+1&base_change%3DG_to_A	-	BRCA1:672	SO:0001627|intron_variant	1	80358178	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Counsyl|Mendelics|GeneDx|Ambry_Genetics|Color|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|GeneKor_MSA|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Uncertain_significance	2012-02-13|2002-05-29|2015-09-24|2015-10-02|2018-04-12|2018-02-28|2019-05-28|2018-09-20|2019-10-17|2018-08-17|2018-11-20|2014-01-16|2018-08-01|2019-01-30|2014-04-23|2019-04-10	2013-06-26|2014-03-28|2016-07-18|2016-10-28|2018-05-21|2018-06-20|2019-10-22|2019-01-29|2020-02-26|2018-11-06|2019-03-28|2017-04-19|2018-08-08|2019-02-11|2018-07-18|2019-09-24	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053746|SCV000144971|SCV000296390|SCV000325845|SCV000783125|SCV000786121|SCV001140538|SCV000210164|SCV000213358|SCV000683149|SCV000076454|SCV000591488|SCV000693531|SCV000914331|SCV000863684|SCV000699108	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer|not_specified	||||Clinical_data_collected_by_the_ENIGMA_consortium_demonstrates_that_the_BRCA1_c.4096+1G>A_variant_may_not_exhibit_the_clinical_characteristics_of_a_standard_high-risk_pathogenic_BRCA1_variant_(Spurdle,_unpublished_data)._This_splice_site_variant_has_been_proven_to_result_in_production_of_naturally_occurring_in-frame_transcripts_delta11q_(Bonatti_et_al.,_2006_-_PMID:_17011978)_and_delta11_(Radice,_unpublished_data)._Since_no_clinically_relevant_domain_has_been_described_in_BRCA1_exon_11_(ENIGMA_rules),_the_splicing_alteration_is_compatible_with_the_clinical_data,_and_supports_Class-3_classification.|||This_variant_is_denoted_BRCA1_c.4096+1G>A_or_IVS10+1G>A,_and_consists_of_a_G>A_nucleotide_substitution_at_the_+1_position_of_intron_10_of_the_BRCA1_gene._This_variant,_previously_reported_as_IVS11+1G>A_using_alternate_nomenclature,_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing._Splicing_assays_have_demonstrated_that_this_variant_results_in_the_production_of_a_shortened_BRCA1_transcript_lacking_a_large_portion_of_exon_10,_previously_denoted_exon_11,_which_is_known_as_the_BRCA1_delta11q_isoform_(Bonatti_2006)._This_shortened_transcript_encodes_a_truncated_BRCA1_protein_that_lacks_the_nuclear_localization_signal_and_the_DNA_binding_domain_(Thakur_1997,_Narod_2004,_Borg_2010)._BRCA1_c.4096+1G>A_has_been_observed_in_individuals_with_breast,_ovarian,_or_prostate_cancer_(Bonatti_2006,_Manguoglu_2010,_Tung_2015,_Brianese_2017,_Ibrahim_2018),_and_RNA_studies_in_an_ovarian_cancer_patient_detected_both_normal_length_transcript_as_well_as_the_shortened_delta11q,_with_the_shortened_transcript_being_more_abundant_(Bonatti_2006)._The_delta_11q_isoform_has_also_been_observed_in_control_individuals_and_normal_tissue_(Thakur_1997,_Bonatti_2006,_Colombo_2014)._In_sum,_although_this_canonical_splice_variant_results_in_an_abnormal_protein_product_lacking_key_functional_domains,_the_impact_of_this_isoform_on_BRCA1_function_cannot_be_predicted._We_therefore_consider_this_variant_to_be_likely_pathogenic.|Other_strong_data_supporting_pathogenic_classification:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity||This_sequence_change_affects_a_donor_splice_site_in_intron_10._It_is_expected_to_disrupt_mRNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80358178,_ExAC_0.004%)._This_variant_has_been_reported_in_individuals_affected_with_ovarian_(PMID:_17011978)_and_breast_cancer_(PMID:_27328445,Â¬â€ 21156238,Â¬â€ 29116469).Â¬â€ This_variant_has_been_observed_in_an_individual_also_carrying_a_different_BRCA1_pathogenic_allele_(Invitae),_which_suggests_that_this_c.4096+1G>A_variant_may_not_be_the_primary_cause_of_disease._This_variant_is_also_known_as_IVS11+1G>A_and_c.4215+1G>A_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37565)._Experimental_studies_have_shown_that_this_sequence_change_alters_splicing_of_exon_10_(also_referred_to_as_exon_11_in_the_literature),_resulting_in_loss_of_the_full-length_transcript,_and_increased_expression_of_a_shorter_in-frame_transcript_that_lacks_a_large_portion_of_exon_10_(referred_to_as_del11q)_(PMID:_17011978)._This_alternative_in-frame_transcript_has_been_reported_to_occur_naturally_in_healthy_individuals_(PMID:_24569164),_and_functional_studies_suggest_that_protein_made_from_this_transcript_may_retain_residual_function_(PMID:_8972225,_11359908,_11431698,_16943438)._The_clinical_significance_of_these_findings_is_uncertain._A_different_variant_(c.4096+3A>G),_affecting_the_same_consensus_splice_site,_has_been_shown_to_result_in_the_increased_abundance_of_a_naturally_occurring_BRCA1_isoform_lacking_exon_10,_and_a_shortened_in-frame_splice_variant_that_removes_a_large_portion_of_this_exon_(PMID:_23239986)._The_shortened_splice_variants_may_retain_residual_function_(PMID:_8972225,_16943438,_11359908,_11431698)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||||Variant_summary:_BRCA1_c.4096+1G>A_is_located_in_a_canonical_splice-site_and_is_predicted_to_affect_mRNA_splicing_resulting_in_a_significantly_altered_protein_due_to_either_exon_skipping,_shortening,_or_inclusion_of_intronic_material._3/5_computational_tools_predict_this_variant_having_a_significant_impact_on_normal_splicing_and_abolishes_a_5'_splicing_donor_site._The_variant_allele_was_found_at_a_frequency_of_1.2e-05_in_245834_control_chromosomes_(gnomAD)._The_variant,_c.4096+1G>A,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_and_other_cancers_(Bonatti_2006,_Manguoglu_2010_and_Spugnesi_2016,_Rebbeck_2018,_Ibrahim_2018,_Susswein_2016)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._The_experimental_results_indicated_the_delta10q_was_more_abundant_than_the_full-length_transcript_and_there_was_a_quantitative_difference_between_proband_and_control,_with_the_patient_showing_a_reduced_amount_of_full-length_transcript_(Bonatti_2006)._Thus,_increased_amount_of_delta10q_coupled_with_decreased_amount_of_full-length_transcript_is_a_potential_disease_mechanism_due_to_this_variant._However,_the_ability_of_the_protein_product_derived_from_the_delta_10q_transcript_to_impact_BRCA1_function_was_not_demonstrated_in_this_study._The_isoform_delta10q_would_lack_Serine-Rich_domain_(InterPro)._Alternatively_spliced_BRCA1_isoforms_that_affect_exon_10_have_been_described_in_minor_amount_in_different_human_tissues_(PMIDs:_9010228,_24569164)_as_well,_and_mouse_studies_have_indicated_that_they_may_retain_some_residual_function_(PMIDs:_8972225,_11359908,_16943438)._Co-occurrences_with_pathogenic_variants_have_been_reported_in_UMD_(BRCA2_c.8249_8250delAG,_p.Lys2750AsnfsX13,_UMD_database)_and_ClinVar_(not_specified),_providing_supporting_evidence_for_a_benign_role._Eight_clinical_diagnostic_laboratories_and_one_expert_panel_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation_(2xVUS,_3xlikely_pathogenic,_3xpathogenic)._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_VUS-possibly_pathogenic.
NM_007294.3:c.4065_4068del	BRCA1	frameshift_variant	102530	1	NA	NA	-	-	-	-	17674	32713	_familial_1|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41243482_41243485del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Children's_Hospital_of_Eastern_Ontario:1776816|Breast_Cancer_Information_Core__(BRCA1):4184&base_change%3Ddel_TCAA	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	3	80357508	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|Baylor_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1994-12-01|2013-03-21|2002-05-29|2014-11-14|2016-04-22|2015-10-02|2015-11-20|2017-01-01|2017-07-21|0000-00-00|2017-05-31|2019-01-09|2017-02-01|2014-01-31|0000-00-00|2017-08-22|2018-07-02|2019-03-26|2015-04-13|2018-12-19|2019-03-20|2016-07-01|2017-02-23|2010-07-08	2018-03-12|2015-12-29|2014-03-28|2015-03-11|2016-06-09|2016-10-28|2017-04-17|2017-03-15|2017-07-24|2018-04-04|2018-04-09|2019-03-28|2017-08-28|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2020-02-26|2017-10-26|2019-01-29|2020-03-06|2016-07-19|2017-02-23|2018-07-18	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000039531|SCV000053742|SCV000144954|SCV000220878|SCV000282322|SCV000325829|SCV000564378|SCV000577930|SCV000584013|SCV000733615|SCV000744620|SCV000076444|SCV000219238|SCV000587372|SCV000591484|SCV000699105|SCV000839242|SCV000186942|SCV000683147|SCV000210049|SCV000296305|SCV000296801|SCV000540939|SCV000863590	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_specified|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn1355Lysfs*10)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80357508,_ExAC_0.006%)._This_variant_has_been_reported_in_multiple_individuals_and_families_affected_with_breast_and_ovarian_cancer_(PMID:_14757871,_8571953,_11802209,_21559243)._This_variant_is_also_known_as_4184del4_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_17674)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_The_BRCA1_c.4065_4068delTCAA_(p.Asn1355Lysfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.4117G>T,_p.Glu1373X:_c.4158_4162delCTCTC,_p.Ser1387fs)._This_variant_has_been_reported_in_numerous_HBOC_patients_with_positive_family_history_(e.g._Langston_1996,_Spitzer_2000,_Evans_2004,_Borg_2010)._This_variant_is_absent_in_121322_control_chromosomes,_suggesting_that_it_is_not_a_common,_benign_variant._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_four_nucleotides_in_BRCA1_is_denoted_c.4065_4068delTCAA_at_the_cDNA_level_and_p.Asn1355LysfsX10_(N1355KfsX10)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ATAA[delTCAA]GAAG._The_deletion_causes_a_frameshift,_which_changes_an_Asparagine_to_a_Lysine_at_codon_1355,_and_creates_a_premature_stop_codon_at_position_10_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_reported_as_BRCA1_4184del4_or_4184_4187delTCAA_using_alternate_nomenclature,_has_been_reported_in_association_with_hereditary_breast_cancer_and_in_multiple_individuals_with_breast,_ovarian,_or_prostate_cancer_(Friedman_1994,_Neuhausen_1996,_Liede_2002,_Meindl_2002,_Farooq_2011,_Couch_2015,_Bu_2016,_Chan_2018)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|||
NM_007294.3:c.4035del	BRCA1	frameshift_variant	102576	2	15428	7	-	-	-	-	37560	46116	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41243514del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Queen's_University:721148|OMIM_Allelic_Variant:113705.0030|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2610918|Breast_Cancer_Information_Core__(BRCA1):4154&base_change%3Ddel_A	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357711	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|GeneKor_MSA	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1996-03-01|2013-04-19|2002-05-29|2015-01-19|2016-04-22|2015-10-02|2015-07-01|2019-02-04|2018-12-20|2014-01-31|2017-04-20|2014-01-13|2016-10-04|2017-01-06|2019-01-07|2016-04-02|2019-04-29|2015-08-04|2018-08-01	2017-04-25|2015-08-20|2014-03-28|2015-03-11|2016-06-09|2016-10-28|2017-04-17|2019-08-02|2019-03-28|2017-08-04|2017-08-04|2017-04-19|2019-03-21|2018-01-25|2019-01-29|2018-08-31|2020-02-26|2017-10-26|2018-08-08	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000039547|SCV000053740|SCV000144938|SCV000221052|SCV000282321|SCV000325817|SCV000564320|SCV000993554|SCV000076426|SCV000587366|SCV000588051|SCV000591480|SCV000605754|SCV000699099|SCV000108672|SCV000296398|SCV000185517|SCV000683145|SCV000296800	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu1346Lysfs*20)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80357711,_ExAC_0.007%)._This_variant_is_a_known_common_cause_of_breast_and_ovarian_cancer_in_individuals_from_Eastern_Europe_(PMID:_23199084,_20569256,_20345474,_22032251)._In_addition,_this_variant_has_been_associated_with_a_higher_prevalence_of_ovarian_cancer_than_breast_cancer_(PMID:_22032251,_15591272)._This_variant_is_also_known_as_4153delA_and_4154delA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37560)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||The_p.Glu1346fs_variant_in_BRCA1_has_been_reported_in_>100_individuals_with_BRCA_1-associated_cancers_and_is_a_known_eastern_European_founder_mutation_(Janaviciu_s_2013,_Tihomirova_2014,_Breast_Cancer_Information_Core_(BIC)_database)._This_va_riant_has_been_identified_in_5/66724_European_chromosomes_by_the_Exome_Aggregati_on_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs80357711):_however,_this_frequency_is_low_enough_to_be_consistent_with_the_frequency_of_hereditary_breast_and_ovarian_cancer_(HBOC)_in_the_general_population._This_variant_is_pred_icted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_begi_nning_at_position_1346_and_leads_to_a_premature_termination_codon_20_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_BRCA1_gene_is_an_established_disea_se_mechanism_in_individuals_with_HBOC._In_addition,_this_variant_was_classified_as_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(Cli_nVar_SCV000282321.1)._In_summary,_the_p.Glu1346fs_variant_meet_criteria_to_be_cl_assified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner.|Variant_summary:_The_BRCA1_c.4035delA_(p.Glu1346Lysfs)_variant_(alternatively_also_known_as_c.4034delA,_4153delA_and_4154delA)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay_(NMD),_which_are_commonly_known_mechanisms_for_disease._If_this_variant_escapes_NMD,_it_is_expected_to_truncate_two_BCRT_domains_(InterPro)_that_are_known_to_be_critical_for_BRCA1_function._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_and_others_(e.g._p.Glu1373X,_p.Gln1395X,_p.Gln1408X,_etc.)._This_variant_was_found_in_7/123408_control_chromosomes_including_broad_and_large_populations_from_ExAC_at_a_frequency_of_0.0000567,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._This_variant_is_a_common_pathogenic_variant_that_causes_HBOC_and_has_also_been_reported_as_a_found_mutation_in_east_European_patients_(Bogdanova_2010,_Plakhins_2011)._In_a_survival_analysis_(Plakhins_2011)_from_HBOC_patients_from_Latvia,_the_mean_estimated_survival_time_during_a_20_year_follow-up_period_was_calculated_as_134_months_(95%_CI_
NM_007294.3:c.3999_4008del	BRCA1	frameshift_variant	102540	1	NA	NA	-	-	-	-	254448	249095	_familial_1	-	OMIM:604370	-	NC_000017.10:g.41243544_41243553del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	754792932	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)	Pathogenic	2016-09-08	2016-09-13	reviewed_by_expert_panel	germline	SCV000300053	_familial_1	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.
NM_007294.3:c.3770_3771del	BRCA1	frameshift_variant	102510	1	NA	NA	-	-	-	-	37546	46102	_familial_1|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1140680,Orphanet:ORPHA213500|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41243777_41243778CT[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA1):3888&base_change%3Ddel_GA|Breast_Cancer_Information_Core__(BRCA1):3889&base_change%3Ddel_AG|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2392874|OMIM_Allelic_Variant:113705.0028	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357579	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|3DMed_Clinical_Laboratory_Inc|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1999-08-01|2012-03-23|2002-05-29|2016-09-08|2015-10-02|2016-01-19|2015-07-01|2017-01-01|0000-00-00|2015-09-21|2018-12-21|2014-01-31|2018-08-16|2018-11-03|2016-07-30|2017-08-08|2015-08-22|2017-06-27|2018-12-01	2015-06-25|2013-12-30|2014-03-28|2016-09-13|2016-10-28|2016-11-23|2017-04-17|2017-03-15|2018-04-04|2018-04-09|2019-03-28|2017-08-04|2019-04-24|2020-02-26|2017-10-26|2017-11-28|2018-08-31|2018-06-19|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000039545|SCV000053726|SCV000144872|SCV000300013|SCV000325752|SCV000488193|SCV000564304|SCV000577929|SCV000733617|SCV000744624|SCV000076338|SCV000587347|SCV000918771|SCV000186869|SCV000683133|SCV000292519|SCV000296287|SCV000803957|SCV000923983	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Ovarian_cancer|Ovarian_Neoplasms	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||||This_sequence_change_deletes_2_nucleotides_from_exon_10_of_the_BRCA1_mRNA_(c.3770_3771delAG),_causing_a_frameshift_at_codon_1257._This_creates_a_premature_translational_stop_signal_(p.Glu1257Glyfs*9)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80357993,_ExAC_0.001%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_18627636,_23479189,_16683254,_17319787,_23683081)._It_is_also_known_as_3890_3891delAG_and_3889delAG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37546)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRCA1_c.3770_3771delAG_(p.Glu1257GlyfsX9)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_8.1e-06_in_245968_control_chromosomes_(gnomAD)._The_variant,_c.3770_3771delAG,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Takahashi_1995,_Judkins_2005,_Hansa_2012,_Thirthagiri_2008,_Sun_2017)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._11_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_two_nucleotides_in_BRCA1_is_denoted_c.3770_3771delAG_at_the_cDNA_level_and_p.Glu1257GlyfsX9_(E1257GfsX9)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ACAG[delAG]GAGA._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_a_Glycine_at_codon_1257,_and_creates_a_premature_stop_codon_at_position_9_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.3770_3771delAG,_previously_reported_as_3890_3891delAG,_3888delGA,_3889delAG,_and_1257del2,_has_been_observed_in_association_with_breast_and_ovarian_cancer_(Takahashi_1995,_Couch_1996,_Liede_2002,_Sakamoto_2016)_and_is_a_recurrent_pathogenic_variant_within_regions_of_Spain_(Esteban_CardeÃ±osa_2010,_de_Juan_Jimenez_2013)._We_consider_this_variant_to_be_pathogenic.|||
NM_007294.3:c.3756_3759del	BRCA1	frameshift_variant	102556	2	NA	NA	-	-	-	-	17673	32712	_familial_1|Breast_and/or_ovarian_cancer|breast_cancer|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN221562|MedGen:CN235590|MedGen:CN517202	-	NC_000017.10:g.41243790_41243793GACA[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA1):3875&base_change%3Ddel_GTCT|Breast_Cancer_Information_Core__(BRCA1):3874&base_change%3Ddel_TGTC|OMIM_Allelic_Variant:113705.0014	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357868	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Division_Human_Genetics,Medical_University_Innsbruck|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|GeneKor_MSA|Bioscientia_Institut_fuer_Medizinische_Diagnostik_GmbH,Sonic_Healthcare|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1994-12-01|2013-11-19|2002-05-29|2015-02-11|2014-11-24|2016-04-22|2015-10-02|2015-02-10|2017-01-01|0000-00-00|2015-09-21|2017-11-01|2019-06-25|2018-07-24|2019-05-30|2019-03-30|2016-06-14|2018-12-28|2014-01-31|0000-00-00|2016-04-22|2018-08-01|0000-00-00|2015-05-19|0000-00-00|2018-12-01	2018-03-12|2015-12-29|2014-03-28|2015-02-11|2015-03-11|2016-06-09|2016-10-28|2017-04-17|2017-03-15|2018-04-04|2018-04-09|2018-06-14|2019-08-01|2019-01-29|2020-03-06|2020-02-26|2016-07-05|2019-03-28|2017-08-04|2017-04-19|2018-01-25|2018-08-08|2016-12-07|2018-07-18|2019-04-01|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline	SCV000039530|SCV000053723|SCV000144861|SCV000212000|SCV000220913|SCV000282317|SCV000325742|SCV000564358|SCV000577928|SCV000733618|SCV000744625|SCV000839892|SCV000993437|SCV000210046|SCV000296325|SCV000186865|SCV000292139|SCV000076327|SCV000587342|SCV000591471|SCV000699069|SCV000296799|SCV000484932|SCV000863644|SCV000916304|SCV000923982	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer|breast_cancer|Ovarian_Neoplasms	|||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||The_c.3756_3759delGTCT_(p.Ser1253Argfs*10)_frame_shift_variant_is_predicted_to_yield_loss_of_function_transcripts/proteins_of_BRCA1_gene,_which_is_one_of_mechanisms_causing_BRCA1_defect_related_cancers._This_variant_is_extremely_rare_in_general_population_(4_in_246010_by_gnomad)_and_observed_in_multiple_breast/ovarian_cancer_patients_(PMID:78944991,_12947551,_21324516,_23633455,_24504028)._It_has_been_also_observed_in_other_clinical_labs_and_reported_as_pathogenic._Based_on_the_above_evidences,_we_interpret_this_variant_as_pathogenic.||This_deletion_of_four_nucleotides_in_BRCA1_is_denoted_c.3756_3759delGTCT_at_the_cDNA_level_and_p.Ser1253ArgfsX10_(S1253RfsX10)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GTCT[delGTCT]AAGA._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_an_Arginine_at_codon_1253,_and_creates_a_premature_stop_codon_at_position_10_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.3756_3759delGTCT,_also_denoted_3875del4_using_alternate_nomenclature,_has_been_published_in_association_with_breast_and_ovarian_cancers_(Castilla_1994,_Zhang_2011,_Alsop_2012,_Gaj_2012,_Ghiorzo_2012,_George_2013)._This_variant_is_also_a_well-described_pathogenic_founder_variant_in_the_French-Canadian_population_in_Quebec_(Janavicius_2010)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser1253Argfs*10)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80357868,_ExAC_0.004%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer,_and_pancreatic_cancer_(PMID:_7894491,_21324516,_23633455,_21989927)._This_variant_is_also_known_as_3875del4_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_17673)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA1_c.3756_3759delGTCT_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_a_commonly_known_mechanism_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Gln1756fs)._Mutation_Taster_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_3/121438_control_chromosomes_at_a_frequency_of_0.0000247,_which_does_not_exceed_maximal_expected_frequency_of_a_pathogenic_BRCA1_allele_(0.0010005)._The_variant_has_been_cited_in_multiple_HBOC_patients_in_the_literature._In_addition,_multiple_clinical_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_was_classified_as_pathogenic.||||The_p.Ser1253ArgfsX10_variant_has_been_identified_in_17_out_of_6280_proband_chromosomes_(frequency_0.003)_in_individuals_with_breast_and_ovarian_cancer_phenotype,_but_not_found_in_200_control_chromosomes_included_in_these_studies_(Turner_1999,_Langston_1996,_Castilla_1994,_Zhang_2011,_Gaj_2012)._It_is_also_listed_in_dbSNP_database_presented_?with_untested_allele?_(ID#:_rs80357868)_while_no_frequency_information_is_provided:_however,_this_variant_has_been_listed_27X_in_the_UMD_and_123X_in_the_BIC_database_as_a_clinically_significant_mutation._The_p.Ser1253ArgfsX10_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein's_amino_acid_sequence_beginning_at_codon_1253_and_leads_to_a_premature_stop_codon_10_codons_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_BRCA1_protein._Loss_of_function_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_familial_breast_and_ovarian_cancer_patients._In_summary,_based_on_the_above_information,_this_variant_is_classified_as_pathogenic.|
NM_007294.3:c.3748G>T	BRCA1	stop_gained	102524	1	NA	NA	5&5&5&5	3&1&1&1	rs28897686	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&not provided&Hereditary cancer-predisposing syndrome	17672	32711	_familial_1|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41243800C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Queen's_University:722481|OMIM_Allelic_Variant:113705.0013	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	28897686	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Baylor_Genetics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1994-12-01|2012-04-05|2002-05-29|2015-11-20|2016-09-08|2015-10-02|2015-06-17|0000-00-00|2014-10-08|2015-09-21|2018-12-28|2014-01-31|2017-04-20|2012-11-19|2016-05-23|2018-12-31|2019-07-06|2019-02-11|2016-12-19|2017-02-23|2017-01-11	2018-03-12|2013-12-30|2014-03-28|2016-03-03|2016-09-13|2016-10-28|2017-06-22|2018-04-04|2018-04-17|2018-04-09|2019-03-28|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2019-01-29|2020-03-06|2020-02-26|2017-10-26|2017-02-23|2017-06-30	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000039529|SCV000109357|SCV000144858|SCV000266030|SCV000300004|SCV000325737|SCV000677650|SCV000733619|SCV000743401|SCV000744626|SCV000076324|SCV000587340|SCV000588048|SCV000591470|SCV000699068|SCV000108671|SCV000296296|SCV000186866|SCV000683129|SCV000540952|SCV000602708	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|not_specified	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu1250*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs28897686,_ExAC_0.003%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_7894491,_12497638,_24504028,_24728189)._This_variant_is_also_known_as_3867G>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_17672)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_The_BRCA1_c.3748G>T_(p.Glu1250X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.3904G>T/p.Glu1302X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_2/121388_control_chromosomes_at_a_frequency_of_0.0000165,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._This_variant_has_been_reported_in_multiple_affected_individuals_and_functional_study_showed_variant_with_~10%_of_relative_HDR_activity_in_comparison_to_WT_BRCA1_(Lu_2015)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_BRCA1_c.3748G>T_at_the_cDNA_level_and_p.Glu1250Ter_(E1250X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA1_3867G>T._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_Glu1250Ter_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Castilla_1994,_Ahmad_2012,_Cunningham_2014,_Weren_2016)_and_is_considered_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||
NM_007294.3:c.3626del	BRCA1	frameshift_variant	102634	1	NA	NA	-	-	-	-	54943	69610	_familial_1	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41243923del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):3745&base_change%3Ddel_T|OMIM_Allelic_Variant:113705.0032	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357571	-	_c/o_University_of_Cambridge|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2000-10-01|1999-04-12|2016-09-08|2015-10-02|2019-03-18	2013-04-03|2014-03-28|2016-09-13|2016-10-28|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000039549|SCV000144816|SCV000299980|SCV000325705|SCV000665844	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_007294.3:c.3607C>T	BRCA1	stop_gained	102508	2	NA	NA	5&5&5&5&5&5	3&2&1&0&1&1	rs62625308	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&Breast cancer&not provided&Familial cancer of breast	17671	32710	_familial_1|Breast_and/or_ovarian_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1140680,Orphanet:ORPHA213500|MedGen:C2676676,OMIM:604370|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41243941G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario:1835977|OMIM_Allelic_Variant:113705.0012|Department_of_Pathology_and_Molecular_Medicine,Queen's_University:722389	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	3	62625308	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|CSER__CC_NCGL,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|Baylor_Genetics|3DMed_Clinical_Laboratory_Inc|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1994-12-01|2012-10-18|0000-00-00|2016-04-22|2015-10-02|2015-12-16|2016-04-11|0000-00-00|2015-09-21|2018-12-28|2014-01-31|2017-04-20|2013-06-25|2017-05-24|2019-08-13|2018-09-28|2016-07-25|2014-06-01|2018-10-02|2015-04-21|2018-08-01|2017-02-23|2017-02-16|2016-03-13|2013-12-20|2018-12-01	2018-03-12|2015-08-20|2014-03-28|2016-06-09|2016-10-28|2016-11-23|2017-04-17|2018-04-04|2018-04-09|2019-03-28|2017-08-04|2017-08-04|2017-04-19|2019-03-21|2019-09-24|2020-02-26|2017-01-26|2014-08-28|2019-01-29|2018-08-31|2018-08-08|2017-02-23|2018-06-19|2018-04-30|2018-07-18|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|somatic	SCV000039528|SCV000053711|SCV000144807|SCV000282311|SCV000325699|SCV000488004|SCV000564385|SCV000733624|SCV000744631|SCV000076264|SCV000587321|SCV000588046|SCV000591455|SCV000605742|SCV000918688|SCV000186873|SCV000537658|SCV000190087|SCV000210150|SCV000296328|SCV000296797|SCV000540941|SCV000803975|SCV000324835|SCV000863580|SCV000923944	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Neoplasm_of_the_breast|not_provided|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast|Ovarian_cancer|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg1203*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_and_families_affected_with_breast_and_ovarian_cancer,_and_has_been_reported_to_segregate_with_disease_in_a_family_(PMID:_7894493,_21324516,_22006311,_22752604,_24010542)._This_sequence_change_is_also_known_as_3726C>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_17671)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||The_p.Arg1203X_variant_in_BRCA1_has_been_reported_in_>40_individuals_with_BRCA1-_associated_cancers_(Friedman_1994,_Manguoglu_2003,_Walsh_2011,_Solano_2012,_Kim_2012,_Juwle_2012,_Couch_2015,_Breast_Cancer_Information_Core_(BIC)_database,_Sha_ring_Clinical_Reports_Project)._This_variant_has_been_identified_in_1/17194_East_Asian_and_2/111402_European_chromosomes_by_the_Genome_Aggregation_Database_(gno_mAD,_http://gnomad.broadinstitute.org:_dbSNP_rs62625308)._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_1203,_which_is_predicted_to_l_ead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_individuals_with_hereditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_variant_was_classified_as_Pathogeni_c_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV0002_82311.1)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner.|Variant_summary:_BRCA1_c.3607C>T_(p.Arg1203X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory._The_variant_allele_was_found_at_a_frequency_of_1.2e-05_in_251014_control_chromosomes._c.3607C>T_has_been_reported_in_the_literature_in_numerous_individuals_affected_with_hereditary_or_early-onset_breast_and/or_ovarian_cancer_(ie._Friedman_1994,_Meindl_2002,_Kim_2012,_Juwle_2012,_Solano_2013,_Stavropoulo_2013)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._16_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_(after_2014)._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_pathogenic_variant_is_denoted_BRCA1_c.3607C>T_at_the_cDNA_level_and_p.Arg1203Ter_(R1203X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_3726C>T_using_alternate_nomenclature,_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Friedman_1994,_Walsh_2011,_Zhang_2011)._We_therefore_consider_this_variant_to_be_pathogenic.|||||||
NM_007294.3:c.3485del	BRCA1	frameshift_variant	102670	1	NA	NA	-	-	-	-	37531	46087	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41244063del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):3604&base_change%3Ddel_A|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2831101	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357509	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Center_of_Medical_Genetics_and_Primary_Health_Care|Invitae|Curoverse|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Bioscientia_Institut_fuer_Medizinische_Diagnostik_GmbH,Sonic_Healthcare	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2014-04-16|2002-05-29|2016-09-08|2015-10-02|0000-00-00|2015-09-21|0000-00-00|2018-05-25|2015-08-01|2014-01-31|2017-01-27|2017-07-06|2018-12-05|2016-09-11|2018-11-21|2015-01-20|0000-00-00	2015-08-20|2014-03-28|2016-09-13|2016-10-28|2018-04-04|2018-04-09|2019-08-31|2018-08-29|2015-08-24|2017-08-04|2019-03-21|2018-01-25|2019-01-29|2018-08-31|2020-02-26|2017-12-21|2016-12-07	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053709|SCV000144775|SCV000299952|SCV000325669|SCV000733627|SCV000744634|SCV000987232|SCV000076226|SCV000245336|SCV000587316|SCV000605763|SCV000699038|SCV000210041|SCV000600335|SCV000273760|SCV000688438|SCV000484951	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||This_sequence_change_deletes_1_nucleotide_from_exon_10_of_the_BRCA1_mRNA_(c.3485delA),_causing_a_frameshift_at_codon_1162._This_creates_a_premature_translational_stop_signal_(p.Asp1162Valfs*48)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_9150151,_24010542,_16683254,_26681312,_25452441)._This_variant_is_also_known_as_3604delA,_c.3625delA,_and_3741delA_in_the_literature._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Frameshifts_in_BRCA1_are_considered_pathogenic,_and_this_is_a_BRCA1_Asp1162Val_frameshift_variant_in_exon_10||The_p.Asp1162fs_variant_in_BRCA1_has_been_reported_in_>30_individuals_with_BRCA1_-associated_cancers_(Peelen_1997,_Breast_Cancer_Information_Core_(BIC)_database)_and_was_absent_from_large_population_studies._This_variant_is_predicted_to_caus_e_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_posi_tion_1162_and_leads_to_a_premature_termination_codon_48_amino_acids_downstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_protein._Hete_rozygous_loss_of_function_of_function_of_the_BRCA1_gene_is_an_established_diseas_e_mechanism_in_hereditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_va_riant_was_classified_as_Pathogenic_on_September_8,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000299952.2)._In_summary,_the_p.Asp1162fs_varian_t_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominan_t_manner.|Variant_summary:_The_BRCA1_c.3485delA_(p.Asp1162Valfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.3582_3589delCCATACAC/_p.His1195fs)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_is_absent_in_121314_control_chromosomes._This_variant_has_been_reported_in_many_affected_individuals_and_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_deletion_of_one_nucleotide_in_BRCA1_is_denoted_c.3485delA_at_the_cDNA_level_and_p.Asp1162ValfsX48_(D1162VfsX48)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GAAG[delA]TACT._The_deletion_causes_a_frameshift,_which_changes_an_Aspartic_Acid_to_a_Valine_at_codon_1162,_and_creates_a_premature_stop_codon_at_position_48_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.3485delA,_also_reported_as_BRCA1_3604delA,_has_been_observed_in_several_hereditary_breast_and_ovarian_cancer_families_and_has_been_described_as_a_pathogenic_founder_variant_in_Finnish_and_Dutch_populations_(Peelen_1997,_Vehmanen_1997,_Syrjakoski_2000,_Janavicius_2010,_Brohet_2014)._We_consider_this_variant_to_be_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||
NM_007294.3:c.3400G>T	BRCA1	stop_gained	102528	1	NA	NA	5&5&5	3&1&1	rs80357018	Breast-ovarian cancer, familial 1&not provided&Hereditary breast and ovarian cancer syndrome	37529	46085	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41244148C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357018	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-12-07|2002-05-29|2016-04-22|2015-10-02|2015-07-09|2017-07-03|2016-11-10|2018-10-17|2014-01-31|2016-03-21|2018-01-17|2019-02-08|2017-09-26	2013-12-30|2014-03-28|2016-06-09|2016-10-28|2017-04-17|2019-01-29|2018-08-31|2019-03-28|2017-08-04|2018-01-25|2019-03-21|2020-02-26|2017-12-21	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053706|SCV000144751|SCV000282306|SCV000325649|SCV000564367|SCV000209892|SCV000600331|SCV000076191|SCV000587308|SCV000699029|SCV000966959|SCV000608082|SCV000688434	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_pathogenic_variant_is_denoted_BRCA1_c.3400G>T_at_the_cDNA_level_and_p.Glu1134Ter_(E1134X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_BRCA1_3519G>T_using_alternate_nomenclature,_has_been_reported_in_individuals_with_early-onset_and/or_familial_breast_and_ovarian_cancer_(Bergthorsson_2001,_Nedelcu_2002,_Pal_2005,_Couch_2015)_and_is_considered_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1134_(p.Glu1134*)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_and_ovarian_cancer_(PMID:_10644434,_16284991,_25452441,_27376475,_27836010,_26833046,_11389159)._This_variant_is_also_known_as_3519G>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37529)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_Summary:_The_variant_of_interest_causes_a_nonsense_mutation_involving_a_conserved_nucleotide_resulting_in_a_predicted_truncated_BRCA1_protein,_a_known_mechanism_for_disease._The_variant_of_interest_has_not_been_observed_in_controls,_but_has_been_reported_in_multiple_affected_individuals_via_publications._In_addition,_multiple_reputable_databases/clinical_laboratories_cite_the_variant_with_a_classification_of_pathogenic._Therefore,_taking_all_available_lines_of_evidence_into_consideration,_the_variant_of_interest_is_classified_as_Pathogenic.|The_p.Glu1134X_variant_in_BRCA1_has_been_reported_in_>20_individuals_with_BRCA1-_associated_cancers_(Wagner_1999,_Bergthorsson_2001,_Nedelcu_2002,_Pal_2005,_Couc_h_2015,_Rebbeck_2016,_Breast_Cancer_Information_Core_(BIC)_database:_https://res_earch.nhgri.nih.gov/bic/)_and_was_absent_from_large_population_studies._This_non_sense_variant_leads_to_a_premature_termination_codon_at_position_1134,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_functio_n_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_individuals_with_here_ditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_variant_was_classifie_d_as_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(C_linVar_SCV000282306.1)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_presence_in_m_ultiple_affected_individuals,_absence_in_the_general_population_and_predicted_im_pact_to_the_protein._ACMG/AMP_Criteria_applied:_PVS1:_PS4:_PM2_(Richards_2015).|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_007294.3:c.3143del	BRCA1	frameshift_variant	102346	1	NA	NA	-	-	-	-	266338	261765	_familial_1	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41244406del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	886040100	-	_c/o_University_of_Cambridge|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2016-10-18|2015-10-02|2018-07-09	2016-10-18|2016-10-28|2020-02-26	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000323568|SCV000325564|SCV000607975	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_007294.3:c.3115del	BRCA1	frameshift_variant	102424	1	NA	NA	-	-	-	-	266336	261767	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41244433del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	886040098	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto	Pathogenic|Pathogenic|Pathogenic	2016-10-18|2015-10-02|2014-01-31	2016-10-18|2016-10-28|2017-08-04	_single_submitter|no_assertion_criteria_provided	germline|germline|germline	SCV000323564|SCV000325560|SCV000587282	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||
NM_007294.3:c.3048_3052dup	BRCA1	frameshift_variant	102514	4	NA	NA	-	-	-	-	54763	69430	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41244497_41244501dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Breast_Cancer_Information_Core__(BRCA1):3166&base_change%3Dins_TGAGA|Breast_Cancer_Information_Core__(BRCA1):3171&base_change%3Dins_TGAGA|OMIM_Allelic_Variant:113705.0033|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2400676	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357856	-	OMIM|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Pathway_Genomics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2001-10-01|2002-05-29|2014-07-24|2015-02-12|2016-10-18|2015-10-02|2015-07-01|2018-07-16|2014-01-31|2015-10-22|2019-01-04|2015-06-08|2017-06-30|2015-02-12	2018-03-12|2014-03-28|2014-08-08|2016-07-18|2016-10-18|2016-10-28|2017-04-17|2019-03-28|2017-08-04|2017-04-19|2020-02-26|2017-10-26|2017-11-28|2018-08-31	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000039550|SCV000144624|SCV000189891|SCV000296295|SCV000323556|SCV000325544|SCV000564330|SCV000076072|SCV000587274|SCV000591422|SCV000186306|SCV000683084|SCV000210033|SCV000887657	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn1018Metfs*8)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_variant_is_present_in_population_databases_(rs80357856),_the_frequency_information_is_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_reported_as_the_most_common_cause_of_breast_and_ovarian_cancer_in_the_Western_Swedish_population_(PMID:_11781691,_15951958,_20151938),_although_it_has_also_been_reported_in_other_ethnicities_(PMID:_24504028)._This_variant_is_also_known_as_3171ins5_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_54763)._This_variant_has_been_associated_with_a_59-93%_risk_of_breast_or_ovarian_cancer_by_age_70_(PMID:_11576847)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_5_nucleotides_is_denoted_BRCA1_c.3048_3052dupTGAGA_at_the_cDNA_level_and_p.Asn1018MetfsX8_(N1018MfsX8)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_duplicated_in_braces,_is_GAAA[TGAGA]ACAT._The_duplication_causes_a_frameshift,_which_changes_an_Asparagine_to_a_Methionine_at_codon_1018,_and_creates_a_premature_stop_codon_at_position_8_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.3048_3052dupTGAGA,_previously_reported_as_3171ins5_or_3166ins5,_using_alternate_nomenclature_has_been_observed_in_multiple_families_with_breast,_ovarian_and_pancreatic_cancers_and_is_the_most_common_Swedish_founder_variant_(Shattuck-Eidens_1995,_Johannsson_1996,_Bergman_2001,_Cunningham_2014)._We_consider_this_variant_to_be_pathogenic.|
NM_007294.3:c.2836_2837del	BRCA1	frameshift_variant	102598	2	NA	NA	-	-	-	-	54696	69363	_familial_1	-	OMIM:604370	-	NC_000017.10:g.41244712_41244713del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	397509016	-	_c/o_University_of_Cambridge	Pathogenic|Pathogenic	2016-09-08|2015-10-02	2016-09-13|2016-10-28	_single_submitter	germline|germline	SCV000299843|SCV000325474	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|
NM_007294.3:c.2706_2707dup	BRCA1	frameshift_variant	102264	1	NA	NA	-	-	-	-	37483	46039	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41244841_41244842dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Breast_Cancer_Information_Core__(BRCA1):2826&base_change%3Dins_AT	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357717	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Rady_Children's_Institute_for_Genomic_Medicine,_Rady_Children's_Hospital_San_Diego|Ambry_Genetics|Invitae|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2010-03-31|2002-05-29|2015-09-02|2016-09-08|2015-10-02|2015-06-03|2018-11-19|2018-11-01|2018-11-20|2017-09-21	2012-06-20|2014-03-28|2016-07-18|2016-09-13|2016-10-28|2017-06-22|2019-09-20|2020-02-26|2019-03-28|2017-11-28	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline	SCV000053660|SCV000144518|SCV000296275|SCV000299816|SCV000325439|SCV000677646|SCV000996213|SCV000187285|SCV000549364|SCV000567213	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_frameshifting_variant_in_exon_10_of_24_introduces_a_premature_stop_codon_and_is_therefore_predicted_to_result_in_loss_of_normal_protein_function._This_variant_is_reported_as_a_pathogenic_variant_in_a_single_publication_(PMID:_28152038)_and_multiple_clinical_diagnostic_laboratories_in_ClinVar_have_classified_this_variant_as_a_pathogenic_change_for_hereditary_breast_and_ovarian_cancer_syndrome_(Variation_ID:_37483)._It_is_present_in_the_heterozygous_state_in_the_gnomAD_population_database_at_a_frequency_of_0.0008%_(2/250830)_and_thus_is_presumed_to_be_rare._Based_on_the_available_evidence,_the_c.2706_2707dup_(p.Cys903TyrfsTer98)_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Cys903Tyrfs*98)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRCA1-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37483)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_BRCA1_c.2706_2707dupAT_duplication_causes_a_frameshift,_which_changes_a_Cysteine_to_a_Tyrosine_at_codon903_in_exon_10,_and_creates_a_premature_stop_codon_at_position_98_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_functionthrough_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.
NM_007294.3:c.2475del	BRCA1	frameshift_variant	102364	1	NA	NA	-	-	-	-	37472	46028	_familial_1|not_specified|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41245073del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:173945|Breast_Cancer_Information_Core__(BRCA1):2594&base_change%3Ddel_C	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357970	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Counsyl|Invitae|Cancer_Genetics_and_Genomics_Laboratory,British_Columbia_Cancer_Agency|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-02-04|2002-05-29|2014-11-03|2016-04-22|2015-10-02|2015-07-21|2015-04-01|2018-12-27|2017-04-18|2014-01-31|2016-06-08|2018-11-15|2016-08-06|2018-06-07|2019-02-15|2018-12-01|2019-03-25	2013-12-30|2014-03-28|2016-04-21|2016-06-09|2016-10-28|2017-04-17|2017-06-22|2019-03-28|2017-08-04|2017-08-04|2018-01-25|2020-02-26|2017-10-26|2019-01-29|2020-03-06|2019-02-22|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053647|SCV000144450|SCV000195906|SCV000282281|SCV000325365|SCV000564368|SCV000677643|SCV000075863|SCV000586884|SCV000587221|SCV000698959|SCV000186327|SCV000683038|SCV000292513|SCV000296289|SCV000923975|SCV001157346	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Ovarian_Neoplasms|not_specified	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asp825Glufs*21)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_with_breast_cancer,_ovarian_cancer,_and_prostate_cancer_(PMID:_8595428,_22160602,_22516946,_24504028,_20104584,_24307375)._This_variant_is_a_well-known_disease_causing_variant_in_the_Scandinavian_population_(PMID:_23199084,_18465347,_23704984)._In_the_literature,_this_variant_is_also_known_as_2594delC._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37472)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA1_c.2475delC_(p.Asp825Glufs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.2515delC,_c.2679_2682delGAAA,_c.2681_2682delAA)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant_and_the_variant_is_absent_in_121366_control_chromosomes._The_variant_has_been_reported_in_numerous_affected_families_and_individuals_in_the_literature,_and_has_been_described_as_a_common_mutation_in_individuals_of_Scandinavian_ancestry._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_in_BRCA1_is_denoted_c.2475delC_at_the_cDNA_level_and_p.Asp825GlufsX21_(D825EfsX21)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ATGA[delC]ACAG._The_deletion_causes_a_frameshift,_which_changes_an_Aspartic_Acid_to_a_Glutamic_Acid_at_codon_825,_and_creates_a_premature_stop_codon_at_position_21_of_the_new_reading_frame._BRCA1_c.2475delC_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_known_as_BRCA1_2594delC_using_alternate_nomenclature,_has_been_published_in_association_with_breast,_ovarian,_and_prostate_cancer,_and_is_reported_as_a_recurrent_variant_in_Scandinavian_populations_(Plummer_1995,_Janavicius_2010,_Leongamornlert_2012,_Schneegans_2012,_Pennington_2013,_Cunningham_2014)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_not_found_in_general_population_data.||The_BRCA1_c.2475delC:_p.Asp825fs_variant_(rs80357970),_also_known_as_2594delC,_has_been_reported_in_multiple_unrelated_individuals_diagnosed_with_hereditary_breast_and_ovarian_cancer_syndrome_(Cunningham_2014,_Pennington_2013,_Schneegans_2012)._This_variant_is_classified_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_37472)._It_is_only_observed_on_one_allele_in_the_Genome_Aggregation_Database,_indicating_it_is_not_a_common_polymorphism._This_variant_causes_a_frameshift_by_deleting_a_single_nucleotide,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Cunningham_J_et_al._Clinical_characteristics_of_ovarian_cancer_classified_by_BRCA1,_BRCA2,_and_RAD51C_status._Sci_Rep._2014:_4:4026._Pennington_K_et_al._BRCA1,_TP53,_and_CHEK2_germline_mutations_in_uterine_serous_carcinoma._Cancer._2013:_119(2):332-8._Schneegans_S_et_al._Validation_of_three_BRCA1/2_mutation-carrier_probability_models_Myriad,_BRCAPRO_and_BOADICEA_in_a_population-based_series_of_183_German_families._Fam_Cancer._2012:_11(2):181-8.
NM_007294.3:c.2338C>T	BRCA1	stop_gained	102218	1	NA	NA	5&5&5	1&3&1	rs80356945	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 1&Hereditary cancer-predisposing syndrome	54540	69207	_familial_1|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41245210G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Queen's_University:721946	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80356945	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-01|2015-01-22|2017-04-20|0000-00-00|2016-10-28|2016-08-03|2012-10-15|2002-05-29|2014-01-10|2016-04-22|2015-10-02|0000-00-00|2014-10-08|2015-09-21|2019-03-14|2014-12-12|2015-08-14|2018-06-07|2018-12-01	2019-03-28|2017-08-04|2017-08-04|2017-04-19|2019-03-21|2018-01-25|2015-08-20|2014-03-28|2014-05-01|2016-06-09|2016-10-28|2018-04-04|2018-04-17|2018-04-09|2020-02-26|2017-10-26|2018-08-31|2019-01-29|2019-02-22	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000075818|SCV000587206|SCV000588039|SCV000591380|SCV000605748|SCV000698940|SCV000109315|SCV000144385|SCV000154010|SCV000282277|SCV000325327|SCV000733644|SCV000743417|SCV000744661|SCV000213341|SCV000683028|SCV000296375|SCV000490433|SCV000923974	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Ovarian_Neoplasms	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln780*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_and_families_affected_with_breast_and/or_ovarian_cancer_(PMID:_7663517,_9667259,_16683254,_21324516,_22006311,_22752604)._It_is_also_known_as_2457C>T,_Q780X_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_54540)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||The_p.Gln780X_variant_in_BRCA1_has_been_reported_in_>30_individuals_with_BRCA1-a_ssociated_cancers_(Hogervorst_1995,_Frank_1998,_Meindl_2002,_van_der_Hout_2006,_Walsh_2011,_Zhang_2011,_Juwle_2012,_Breast_Cancer_Information_Core_(BIC)_databas_e)._This_variant_was_absent_from_large_population_studies._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_780,_which_is_predicted_to_l_ead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_function_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_individuals_with_hereditary_breast_and_ovarian_cancer_(HBOC)._In_addition,_this_variant_was_classified_as_Pathogeni_c_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(ClinVar_SCV0002_82277.1)._In_summary,_this_variant_meets_our_criteria_to_be_classified_as_pathog_enic_for_HBOC_in_an_autosomal_dominant_manner.|Variant_summary:_The_BRCA1_c.2338C>T_(p.Gln780X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.2389G>T/p.Glu797X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_is_absent_in_121352_control_chromosomes._This_variant_has_been_reported_in_many_HBOC_patients._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_pathogenic_variant_is_denoted_BRCA1_c.2338C>T_at_the_cDNA_level_and_p.Gln780Ter_(Q780X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_published_as_BRCA1_2457C>T_using_alternate_nomenclature,_has_been_reported_in_association_with_breast_and/or_ovarian_cancer_(Friedman_1995,_Peelen_1997,_Frank_1998,_Walsh_2011,_Weren_2016)_and_is_considered_pathogenic.|
NM_007294.3:c.2269del	BRCA1	frameshift_variant	102530	1	NA	NA	-	-	-	-	37459	46015	_familial_1|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41245281del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):2388&base_change%3Ddel_G	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357583	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2009-12-14|2002-05-29|2016-04-22|2015-10-02|2018-07-09|2015-04-01|2018-11-14|2017-03-29|2014-01-31|2017-10-24	2012-06-20|2014-03-28|2016-06-09|2016-10-28|2020-02-26|2018-11-06|2019-01-29|2018-03-09|2017-08-04|2018-04-30	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000053634|SCV000144362|SCV000282276|SCV000325310|SCV000275788|SCV000911348|SCV000568420|SCV000778760|SCV000587204|SCV000901139	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Breast_and/or_ovarian_cancer	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_in_BRCA1_is_denoted_c.2269delG_at_the_cDNA_level_and_p.Val757PhefsX8_(V757FfsX8)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_AAGG[delG]TTTTG._The_deletion_causes_a_frameshift_which_changes_a_Valine_to_a_Phenylalanine_at_codon_757,_and_creates_a_premature_stop_codon_at_position_8_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.2269delG,_also_published_as_2388delG_using_alternate_nomenclature,_has_been_reported_in_patients_with_personal_and/or_family_histories_of_breast_and_ovarian_cancer_(Stoppa-Lyonnet_1997,_Rashid_2006,_Ramus_2007,_Stegel_2011,_Kang_2015,_Minucci_2015,_Kwong_2016)._We_consider_this_variant_to_be_pathogenic.|||
NM_007294.3:c.1961del	BRCA1	frameshift_variant	102326	1	15414	1	-	-	-	-	37438	45994	_familial_1|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1134719,SNOMED_CT:408643008|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41245594del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):2080&base_change%3Ddel_A|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario:1836007|Illumina_Clinical_Services_Laboratory,Illumina:630118|Department_of_Pathology_and_Molecular_Medicine,Queen's_University:721707|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2461080	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357522	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Division_Human_Genetics,Medical_University_Innsbruck|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Counsyl|Invitae|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|Illumina_Clinical_Services_Laboratory,Illumina|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|GeneKor_MSA|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|PreventionGenetics,PreventionGenetics|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|3DMed_Clinical_Laboratory_Inc	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2014-01-08|2002-05-29|2014-11-03|2015-02-11|2016-04-22|2015-10-02|2017-01-01|0000-00-00|2015-09-21|2017-06-27|2019-01-05|2016-02-16|2016-06-14|2014-01-31|2017-04-20|0000-00-00|2017-11-01|2016-06-06|2018-03-27|2017-04-03|2018-01-24|2015-04-24|2017-03-16|0000-00-00|2017-09-14	2015-12-29|2014-03-28|2016-04-21|2015-02-11|2016-06-09|2016-10-28|2017-03-15|2018-04-04|2018-04-09|2018-06-20|2019-03-28|2016-07-12|2016-10-18|2017-08-04|2017-08-04|2017-04-19|2017-11-21|2018-01-25|2020-02-26|2017-12-21|2019-01-29|2018-08-31|2018-01-29|2016-12-06|2018-06-19	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053612|SCV000144262|SCV000195897|SCV000211994|SCV000282269|SCV000325202|SCV000577925|SCV000733652|SCV000744670|SCV000785270|SCV000075673|SCV000324814|SCV000403071|SCV000587176|SCV000588035|SCV000591357|SCV000693514|SCV000698901|SCV000185656|SCV000688356|SCV000292510|SCV000296329|SCV000806905|SCV000492455|SCV000803967	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Neoplasm_of_the_breast|Infiltrating_duct_carcinoma_of_breast	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys654Serfs*47)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80357522,_ExAC_0.001%)._This_variant_has_been_reported_inÂ¬â€ individuals_affected_with_breast,_ovarian,_and_endometrial_cancer_(PMID:_7493024,_12955716,_17645508,_23633455,_26026974)._This_variant_is_also_known_as_2073delA_and_2080delA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37438)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Interpretation_was_last_updated_within_1_year_from_2/16/2016_10:54_AM|The_c.1961delA_(p.Lys654SerfsTer47)_variant_(also_commonly_referred_to_as_c.2080delA)_results_in_a_frameshift,_and_is_predicted_to_result_in_premature_termination_of_the_protein._Across_a_selection_of_the_available_literature,_the_p.Lys654SerfsTer47_variant_has_been_identified_in_a_heterozygous_state_in_29_cases_of_breast_or_ovarian_cancer_(Gayther_et_al._1995:_Risch_et_al._2001:_Curci_et_al._2002:_Diez_et_al._2003:_Martinez-Ferrandis_et_al._2003:_Ahn_et_al._2007:_Kwon_et_al._2008:_Iyevleva_et_al._2010:_Kim_et_al._2012:_Kang_et_al._2015:_de_Juan_Jiminez_et_al._2013:_George_et_al._2013:_Abugattas_et_al._2014:_Silva_et_al._2014)._The_variant_was_absent_from_100_controls_and_is_reported_at_a_frequency_of_0.00002_in_the_European_(Non-Finnish)_population_of_the_Exome_Aggregation_Consortium_Project_but_this_is_based_on_one_allele_so_the_variant_is_presumed_to_be_rare._Most_variants_in_the_BRCA1_gene_that_have_been_shown_to_be_associated_with_breast_and_ovarian_cancer_are_frameshift_variants_resulting_in_a_non-functional_protein._Based_on_the_potential_impact_of_frameshift_variants_and_the_available_evidence,_the_p.Lys654SerfsTer47_variant_is_classified_as_pathogenic_for_hereditary_breast_and_ovarian_cancer_syndrome.|||||Variant_summary:_The_BRCA1_c.1961delA_(p.Lys654Serfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.2001dupA,_c.2299delA)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_1/121294_control_chromosomes_at_a_frequency_of_0.0000082,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._This_variant_has_been_reported_in_numerous_HBOC_patients._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_in_BRCA1_is_denoted_c.1961delA_at_the_cDNA_level_and_p.Lys654SerfsX47_(K654SfsX47)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GAAAAAAA[delA]GTAC._The_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_a_Serine_at_codon_654,_and_creates_a_premature_stop_codon_at_position_47_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.1961delA,_previously_denoted_as_2073delA_and_2080delA_using_alternate_nomenclature,_has_been_reported_in_individuals_with_female_and_male_breast_cancer,_ovarian_cancer_(Gayther_1995,_Risch_2001,_Diez_2003,_Abugattas_2015,_Couch_2015,_de_Juan_2015,_Kang_2015)_and_as_a_recurrent_variant_in_individuals_of_Spanish_descent_with_breast_and/or_ovarian_cancer_(de_Juan_Jimenez_2013)._We_consider_this_variant_to_be_pathogenic.||||
NM_007294.3:c.1823_1826del	BRCA1	frameshift_variant	102516	1	NA	NA	-	-	-	-	54361	69028	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41245724_41245727del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):1942&base_change%3Ddel_AGAA|Breast_Cancer_Information_Core__(BRCA1):1492&base_change%3Ddel_AGAA|Breast_Cancer_Information_Core__(BRCA1):1940&base_change%3Ddel_AAAG	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357585	-	Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Sharing_Clinical_Reports_Project_(SCRP)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-11-27|2016-07-01|2002-05-29|2011-03-07|2015-01-15|2016-04-22|2015-11-17|2015-10-02|2015-07-31|2017-08-16|2017-03-20	2018-04-02|2018-01-25|2014-03-28|2014-03-06|2015-03-11|2016-06-09|2016-07-18|2016-10-28|2017-04-17|2020-02-26|2017-10-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000075611|SCV000698889|SCV000144194|SCV000189328|SCV000221028|SCV000282264|SCV000296320|SCV000325154|SCV000564370|SCV000186956|SCV000682988	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys608Ilefs*3)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_and_families_affected_with_breast_and_ovarian_cancer_(PMID:_10486320,_24728189,_25452441,_9333265,_24504028)._This_variant_is_also_known_as_1942del4_and_608_609del_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_54361)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_007294.3:c.1793T>G	BRCA1	stop_gained	102514	1	NA	NA	5&5	3&1	rs80357118	Breast-ovarian cancer, familial 1&Hereditary cancer-predisposing syndrome	54352	69019	_familial_1	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41245755A>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357118	-	Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-05-29|2016-09-08|2015-10-02|2015-07-01|2019-05-08	2014-03-28|2016-09-13|2016-10-28|2017-04-17|2020-02-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000144188|SCV000299649|SCV000325140|SCV000564346|SCV000213333	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_007294.3:c.1772del	BRCA1	frameshift_variant	102554	1	NA	NA	-	-	-	-	54346	69013	_familial_1	-	OMIM:604370	-	NC_000017.10:g.41245776del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):1891&base_change%3Ddel_T	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357901	-	_c/o_University_of_Cambridge	Pathogenic|Pathogenic|Pathogenic|Pathogenic	0000-00-00|2011-03-08|2016-09-08|2015-10-02	2014-03-28|2014-03-06|2016-09-13|2016-10-28	_single_submitter	germline|germline|germline|germline	SCV000144178|SCV000189327|SCV000299646|SCV000325136	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|
NM_007294.3:c.1687C>T	BRCA1	stop_gained	102246	6	NA	NA	5&5&5&5&5	3&1&1&1&1	rs80356898	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&not provided&Ovarian cancer	37426	45982	Breast_carcinoma|Neoplasm_of_ovary|Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Ovarian_cancer|Breast-ovarian_cancer,_familial_1|Pancreatic_cancer_4|FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S|Breast_and/or_ovarian_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0003002,MedGen:C0678222,Orphanet:ORPHA180257|Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1140680,Orphanet:ORPHA213500|MedGen:C2676676,OMIM:604370|MedGen:C3280442,OMIM:614320|MedGen:C4554406,OMIM:617883|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41245861G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80356898	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Division_Human_Genetics,Medical_University_Innsbruck|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|Fulgent_Genetics,Fulgent_Genetics|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|Bioscientia_Institut_fuer_Medizinische_Diagnostik_GmbH,Sonic_Healthcare	Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2014-01-13|0000-00-00|2014-11-03|2015-02-11|2016-04-22|2015-10-02|2015-07-01|2017-01-01|0000-00-00|2018-12-26|2014-01-31|0000-00-00|2017-08-14|2018-07-02|2017-07-07|2019-04-29|2015-04-07|2018-06-15|2015-05-18|2016-07-01|2014-02-17|2018-10-31|2016-05-13|2018-12-01|2018-11-23	2015-12-29|2014-03-28|2016-04-21|2015-02-11|2016-06-09|2016-10-28|2017-04-17|2017-03-15|2018-04-04|2019-03-28|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2019-03-21|2020-02-26|2017-01-26|2019-01-29|2018-08-31|2016-07-19|2016-11-12|2018-11-14|2018-04-30|2019-02-22|2019-03-13	no_assertion_criteria_provided|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline	SCV000053600|SCV000144157|SCV000195893|SCV000211992|SCV000282262|SCV000325122|SCV000564338|SCV000577923|SCV000733653|SCV000075572|SCV000587157|SCV000591346|SCV000698881|SCV000839281|SCV000966957|SCV000186952|SCV000537661|SCV000210108|SCV000296341|SCV000296792|SCV000492951|SCV000893451|SCV000902230|SCV000923775|SCV000925893	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Ovarian_cancer|Neoplasm_of_ovary/Breast_carcinoma|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_1/Pancreatic_cancer_4/FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms|Familial_cancer_of_breast	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln563*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80356898,_ExAC_0.008%)._This_variant_has_been_reported_in_many_individuals_with_breast,_ovarian,_and_pancreatic_cancer_(PMID:_23199084,_24312913,_21989927,_25330149,_25948282,_26852130)._This_variant_is_also_known_as_1806C>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37426)._Experimental_studies_have_confirmed_that_this_variant_results_in_the_loss_of_BRCA1_mRNA_and_protein_(PMID:_12393792)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA1_c.1687C>T_(p.Gln563X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._This_variant_was_found_in_5/121138_control_chromosomes_at_a_frequency_of_0.0000413,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._These_occurrences_need_to_be_cautiously_considered_due_to_the_cohort_could_harbor_individuals_with_a_BRCA1_phenotype._This_variant_has_been_reported_in_multiple_HBOC_patients_and_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||The_p.Gln563X_variant_in_BRCA1_(also_referred_to_as_1806C>T)_has_been_reported_i_n_>100_individuals_with_BRCA1-associated_cancers_(Shattuck-Eidens_1995,_Wagner_1_998,_Pohlreich_2003,_Foretova_2004,_Salazar_2006,_Krajc_2008,_Janav_2010,_Zurade_lli_2010,_Blay_2013,_Cunningham_2014,_Kluska_2015,_Cini_2016,_Breast_Cancer_Info_rmation_Core_(BIC)_database)._It_was_also_identified_in_5/66568_European_chromos_omes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs80356898):_however,_this_frequency_is_low_enough_to_be_consistent_with_t_he_frequency_of_hereditary_breast_and_ovarian_cancer_(HBOC)_in_the_general_popul_ation._This_nonsense_variant_leads_to_a_premature_termination_codon_at_position_563,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_l_oss_of_function_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_HBOC._F_urthermore,_this_variant_was_classified_as_Pathogenic_on_April_22,_2016_by_the_C_linGen-approved_ENIGMA_expert_panel_(ClinVar_SCV000282262.1)._In_summary,_this_v_ariant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_do_minant_manner.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_BRCA1_c.1687C>T_at_the_cDNA_level_and_p.Gln563Ter_(Q563X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG)._BRCA1_Gln563Ter_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_also_published_as_BRCA1_1806C>T_using_alternate_nomenclature,_has_been_reported_in_association_with_breast,_ovarian_and_pancreatic_cancer_and_is_considered_to_be_a_founder_pathogenic_variant_in_Sweden_and_other_European_countries_(Janavicius_2010,_Ghiorzo_2012,_Karami_2013,_Meisel_2017)._We_consider_this_variant_to_be_pathogenic.|||||||
NM_007294.3:c.1579_1580del	BRCA1	frameshift_variant	102234	1	NA	NA	-	-	-	-	96902	102805	_familial_1	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41245970_41245971del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	431825387	-	_c/o_University_of_Cambridge|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2007-06-22|2016-09-08|2015-10-02|2016-07-05|2017-10-16	2013-12-30|2016-09-13|2016-10-28|2020-02-26|2018-11-06	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000115097|SCV000299623|SCV000325102|SCV000607912|SCV000905206	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)|
NM_007294.3:c.1360_1361del	BRCA1	frameshift_variant	102406	2	NA	NA	-	-	-	-	37406	45962	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41246187_41246188CT[2]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2624642|Breast_Cancer_Information_Core__(BRCA1):1479&base_change%3Ddel_AG	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357969	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-05-01|2002-05-29|2016-09-08|2015-10-02|2015-01-01|2018-04-06|2017-02-12|2018-12-03|2017-07-17|2018-09-02|2014-01-31|2014-08-08|2016-12-09|2018-07-02	2013-12-30|2014-03-28|2016-09-13|2016-10-28|2017-04-17|2019-01-29|2018-08-31|2020-02-26|2017-12-21|2019-03-28|2017-08-04|2017-04-19|2018-01-25|2018-08-20	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown	SCV000053579|SCV000144066|SCV000299586|SCV000325047|SCV000564354|SCV000210012|SCV000600249|SCV000186893|SCV000688334|SCV000075453|SCV000587124|SCV000591325|SCV000698854|SCV000839286	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_variant_is_denoted_BRCA1_c.1360_1361delAGAG>-_at_the_cDNA_level_and_p.Ser454Ter_(S454X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(AGT>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_BRCA1_variant,_also_denoted_1479delAG_using_alternate_nomenclature,_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Ottini_2000,_Zhang_2011)_and_is_considered_pathogenic.||Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion):Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser454*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80357969,_ExAC_0.003%)._This_variant_has_been_observed_in_several_individuals_with_personal_or_family_history_of_breast_and/or_ovarian_cancer_(PMID:_10528853,_22874498,_26681312,_26219728)._This_variant_is_also_known_as_1479delAG_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37406)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA1_c.1360_1361delAG_(p.Ser454Terfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_was_observed_in_the_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_2/121340_(1/60670),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_BRCA1_variant_of_1/1000._The_variant_of_interest_was_reported_in_multiple_affected_individuals_via_publications._In_addition,_multiple_clinical_diagnostic_laboratories/databases_cite_the_variant_as_pathogenic._Therefore,_the_variant_of_interest_has_been_classified_as_Pathogenic.|
NM_007294.3:c.1082_1092del	BRCA1	frameshift_variant	102482	3	NA	NA	-	-	-	-	54122	68789	_familial_1|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41246458_41246468del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:119128|Breast_Cancer_Information_Core__(BRCA1):1201&base_change%3Ddel_11|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2841755	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80359880	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-08-14|2013-02-20|2016-04-21|2016-09-08|2015-10-02|2017-07-27|2018-03-21|2015-02-17|2018-03-06|2017-12-11|2014-01-31|2019-01-05	2013-06-26|2014-03-28|2016-04-21|2016-09-13|2016-10-28|2018-06-20|2020-02-26|2018-11-06|2019-01-29|2018-08-31|2017-08-04|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000109279|SCV000144001|SCV000267689|SCV000299536|SCV000324948|SCV000785418|SCV000216031|SCV000904685|SCV000322183|SCV000888831|SCV000587100|SCV000602678	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|not_specified	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_11_nucleotides_is_denoted_BRCA1_c.1082_1092del11_at_the_cDNA_level_and_p.Ser361Ter_(S361X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_TGCT[del11]AGAG._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TAG)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.1082_1092del11,_previously_reported_as_1201del11,_has_been_reported_in_several_kindreds_with_early-onset_breast_and/or_ovarian_cancer_diagnoses_and_is_thought_to_be_a_founder_variant_in_the_Swedish_population_(Shattuck-Eidens_1995,_Johannsson_1996,_Loman_2001,_Malander_2004,_Borg_2010)._We_consider_this_variant_to_be_pathogenic.|||The_BRCA1_c.1082_1092del11:_p.Ser361Ter_variant_(rs80359880),_also_known_as_1201del11,_is_reported_in_the_literature_in_multiple_individuals_affected_with_early-onset_breast_and/or_ovarian_cancer,_and_is_thought_to_be_a_founder_variant_in_Sweden_(Borg_2010,_Janavicius_2010,_Johannsson_1996,_Loman_2001,_Malander_2004,_Shattuck-Eidens_1995)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_54122),_and_is_only_observed_on_three_alleles_in_the_Genome_Aggregation_Database,_indicating_it_is_not_a_common_polymorphism._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Borg_A_et_al._Characterization_of_BRCA1_and_BRCA2_deleterious_mutations_and_variants_of_unknown_clinical_significance_in_unilateral_and_bilateral_breast_cancer:_the_WECARE_study._Hum_Mutat._2010_Mar:31(3):E1200-40._Janavicius_R_et_al._Founder_BRCA1/2_mutations_in_the_Europe:_implications_for_hereditary_breast-ovarian_cancer_prevention_and_control._EPMA_J._2010_Sep:1(3):397-412._Johannsson_O_et_al._Founding_BRCA1_mutations_in_hereditary_breast_and_ovarian_cancer_in_southern_Sweden._Am_J_Hum_Genet._1996_Mar:58(3):441-50._Loman_N_et_al._Family_history_of_breast_and_ovarian_cancers_and_BRCA1_and_BRCA2_mutations_in_a_population-based_series_of_early-onset_breast_cancer._J_Natl_Cancer_Inst._2001_Aug_15:93(16):1215-23._Malander_S_et_al._One_in_10_ovarian_cancer_patients_carry_germ_line_BRCA1_or_BRCA2_mutations:_results_of_a_prospective_study_in_Southern_Sweden._Eur_J_Cancer._2004_Feb:40(3):422-8._Shattuck-Eidens_D_et_al._A_collaborative_survey_of_80_mutations_in_the_BRCA1_breast_and_ovarian_cancer_susceptibility_gene._Implications_for_presymptomatic_testing_and_screening._JAMA._1995_273(7):535-41.
NM_007294.3:c.1054G>T	BRCA1	stop_gained	102592	1	NA	NA	5&5&5	3&1&1	rs80357472	Breast-ovarian cancer, familial 1&Hereditary cancer-predisposing syndrome&not provided	54108	68775	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41246494C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357472	-	_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-05-29|2016-09-08|2015-10-02|2018-04-19|2017-11-20|2018-12-28|2017-03-25|2018-10-19	2014-03-28|2016-09-13|2016-10-28|2020-02-26|2018-11-06|2019-01-29|2017-08-01|2019-04-24	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000143989|SCV000299527|SCV000324940|SCV000213330|SCV000904134|SCV000292508|SCV000600236|SCV000918783	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_BRCA1_c.1054G>T_at_the_cDNA_level_and_p.Glu352Ter_(E352X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_BRCA1_1173G>T_using_alternate_nomenclature,_has_been_reported_in_at_least_four_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_(Sekine_2001,_Simard_2007,_Thirthagiri_2008,_Belanger_2015)_and_is_considered_pathogenic.||Variant_summary:_BRCA1_c.1054G>T_(p.Glu352X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_was_absent_in_131808_control_chromosomes_(gnomAD)._c.1054G>T_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Nakamura_2013,_Thirthagiri_2008,_Simard_2007,_Sekine_2001,_Lang_2017,_Maxwell_2017)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_007294.3:c.929del	BRCA1	frameshift_variant	102646	1	NA	NA	-	-	-	-	37708	46264	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41246619del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):1048&base_change%3Ddel_A	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357844	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Ambry_Genetics|GeneDx|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-09-10|2002-05-29|2016-09-08|2015-10-02|2015-07-01|2019-01-28|2018-04-02|2014-01-31	2015-08-20|2014-03-28|2016-09-13|2016-10-28|2017-04-17|2020-02-26|2019-01-29|2017-08-04	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline	SCV000053894|SCV000143955|SCV000299507|SCV000326465|SCV000564311|SCV000187044|SCV000292505|SCV000587087	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_deletion_of_one_nucleotide_in_BRCA1_is_denoted_c.929delA_at_the_cDNA_level_and_p.Gln310ArgfsX4_(Q310RfsX4)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_AAAC[A]GCCT._The_deletion_causes_a_frameshift,_which_changes_a_Glutamine_to_an_Arginine_at_codon_310,_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_c.929delA,_previously_reported_as_BRCA1_1048delA,_has_been_observed_in_association_with_breast_and_ovarian_cancer_(Friedman_1995,_Zhang_2011,_Song_2014,_Couch_2015)._We_consider_this_variant_to_be_pathogenic.|
NM_007294.3:c.791_794del	BRCA1	frameshift_variant	101956	1	NA	NA	-	-	-	-	55705	70372	_familial_1|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41246754_41246757del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA1):910&base_change%3Ddel_GTTC	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357707	-	_c/o_University_of_Cambridge|Counsyl|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1999-12-30|2015-10-02|2017-08-18|2018-09-17|2017-11-02|2015-11-17	2014-03-28|2016-10-28|2018-06-20|2020-02-26|2017-12-21|2017-08-01	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline	SCV000145682|SCV000326411|SCV000785482|SCV000275396|SCV000688662|SCV000296336	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	_nonsense)||
NM_007294.3:c.594-2A>G	BRCA1	splice_acceptor_variant	102128	1	NA	NA	-	-	-	-	55644	70311	Familial_cancer_of_breast	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006	-	NC_000017.10:g.41247941T>C	no_assertion_provided	not_provided	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001574|splice_acceptor_variant	1	80358033	-	_National_Center_for_Biotechnology_Information_(NCBI)	not_provided	0000-00-00	2013-03-30	no_assertion_provided	germline	SCV000679635	Familial_cancer_of_breast	
NM_007294.3:c.514C>T	BRCA1	stop_gained	102732	1	NA	NA	5	3	rs80356947	Breast-ovarian cancer, familial 1	55420	70087	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41251825G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80356947	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-01-06|2013-03-25|2016-09-08|2015-10-02|2015-07-01|2017-07-21|2014-01-31	2013-06-26|2014-03-28|2016-09-13|2016-10-28|2017-04-17|2017-07-24|2017-08-04	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline	SCV000109405|SCV000145605|SCV000299470|SCV000326169|SCV000564306|SCV000584014|SCV000587059	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||
NM_007294.3:c.301+1G>C	BRCA1	splice_donor_variant	102574	1	NA	NA	-	-	-	-	267517	262987	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41256884C>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_benign(1),Likely_pathogenic(1),Pathogenic(1),Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001575|splice_donor_variant	1	587782173	-	_c/o_University_of_Cambridge|Ambry_Genetics|Color|Invitae	Pathogenic|Likely_pathogenic|Likely_benign|Uncertain_significance	2015-10-02|2019-05-31|2018-03-15|2018-03-27	2016-10-28|2020-02-26|2018-11-06|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000325525|SCV000608219|SCV000912053|SCV000834653	_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity||This_sequence_change_affects_a_donor_splice_site_in_intron_5_of_the_BRCA1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587782173,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_affected_with_BRCA1-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_267517)._An_experimental_study_has_shown_that_a_different_variant_(c.301+6T>C)Â¬â€ affecting_a_nucleotide_within_the_consensus_splice_site_of_the_intron_results_in_an_aberrant_transcript_encoding_an_in-frame_deletion_of_3_amino_acids_at_the_exon_5-6_junction_(referred_to_as_the_exon_6-7_junction)_(PMID:_21769658)._While_the_effect_of_this_variant_(c.301+1G>C)_has_not_been_assessed_experimentally,_algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_disrupts_the_consensus_splice_site_and_creates_a_cryptic_donor_splice_site_9_nucleotides_upstream,_leading_to_the_in-frame_loss_of_3_amino_acids.Â¬â€ This_is_similarly_predicted_and_experimentally_demonstrated_for_c.301+6T>C._These_data_suggest_that_an_upstream,_cryptic_donor_site_can_potentially_rescue_disruption_of_the_canonical_donor_site,_thereby_preserving_the_integrity_of_the_reading_frame._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.
NM_007294.3:c.301+1G>A	BRCA1	splice_donor_variant	102574	1	NA	NA	-	-	-	-	142004	151718	_familial_1|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41256884C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_benign(1),Likely_pathogenic(2),Pathogenic(1),Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001575|splice_donor_variant	1	587782173	-	Ambry_Genetics|Color|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Invitae	Likely_pathogenic|Likely_benign|Pathogenic|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance	2017-06-27|2017-09-12|2015-10-02|2017-05-04|2017-10-27|2017-05-22|2018-07-17	2020-02-26|2018-11-06|2016-10-28|2017-11-28|2018-08-31|2019-03-21|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000185671|SCV000912054|SCV000325524|SCV000577622|SCV000888880|SCV000605736|SCV000635877	_familial_1|not_provided|not_provided|not_specified|Hereditary_breast_and_ovarian_cancer_syndrome	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Deficient_protein_function_in_appropriate_functional_assay(s):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|||This_variant_is_denoted_BRCA1_c.301+1G>A_or_IVS5+1G>A_and_consists_of_a_G>A_nucleotidesubstitution_at_the_+1_position_of_intron_5_of_the_BRCA1_gene._This_variant_destroys_a_canonical_splice_donor_site_and_ispredicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsensemediatedmRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_inthe_literature._Based_on_the_currently_available_information,_we_consider_BRCA1_c.301+1G>A_to_be_a_likely_pathogenicvariant.||The_c.301+1G>A_variant_in_BRCA1_has_been_reported_in_1_Caucasian_woman_with_brea_st_cancer_who_also_carried_another_pathogenic_variant_in_BRCA2_(Rebbeck_2016)._T_his_variant_has_been_identified_in_1/111,504_European_chromosomes_by_the_genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org/:_dbSNP_rs5877821_73)._This_variant_occurs_in_the_invariant_region_(+/-_1,2)_of_the_splice_consens_us_sequence_and_variants_in_this_region_are_predicted_to_cause_altered_splicing_leading_to_an_abnormal_or_absent_protein._However,_in_vitro_functional_studies_f_or_another_variant_at_this_exon-intron_junction_(301+6T>C)_suggest_the_use_of_an_alternative_splice_donor_site_resulting_in_an_in-frame_deletion_of_three_amino_acids_(Thomassen_2012)._Please_note,_these_types_of_assays_may_not_accurately_re_present_biological_function._In_summary,_due_to_conflicting_and_insufficient_evi_dence,_the_clinical_significance_of_the_c.301+1G>A_variant_is_uncertain.|This_sequence_change_affects_a_donor_splice_site_in_intron_5_of_the_BRCA1_gene._This_variant_is_present_in_population_databases_(rs587782173,_ExAC_0.001%)._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer_(PMID:_27836010)._However,_in_that_individual_a_pathogenic_allele_was_also_identified_in_BRCA2,_which_suggests_that_this_c.301+1G>A_variant_was_not_the_primary_cause_of_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142004)._A_experimental_study_has_shown_that_a_different_variant_(c.301+6T>C)_results_in_an_aberrant_transcript_encoding_an_in-frame_deletion_of_3_amino_acids_at_the_exon_5-6_junction_(referred_to_as_the_exon_6-7_junction)_(PMID:_21769658)._While_the_effect_of_this_variant_(c.301+1G>A)_has_not_been_assessed_experimentally,_algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_disrupts_the_consensus_splice_site._However,_these_algorithms_also_detect_a_cryptic_donor_splice_site_9_nucleotides_upstream,_the_use_of_which_would_lead_to_the_in-frame_deletion_of_3_amino_acids._These_data_suggest_that_an_upstream,_cryptic_donor_site_can_potentially_rescue_disruption_of_the_canonical_donor_site,_thereby_preserving_the_integrity_of_the_reading_frame._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.
NM_007294.3:c.246del	BRCA1	frameshift_variant	102640	1	NA	NA	-	-	-	-	266264	262012	_familial_1	-	OMIM:604370	-	NC_000017.10:g.41256941del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	886040039	-	_c/o_University_of_Cambridge	Pathogenic|Pathogenic	2016-10-18|2015-10-02	2016-10-18|2016-10-28	_single_submitter	germline|germline	SCV000323460|SCV000325362	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|
NM_007294.3:c.135-1G>T	BRCA1	splice_acceptor_variant	101782	1	15422	1	-	-	-	-	37404	45960	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41258551C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA1):254-1&base_change%3DG_to_T	-	BRCA1:672	SO:0001574|splice_acceptor_variant	1	80358158	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-05-21|0000-00-00|2015-10-02|2015-11-12|2019-06-18|2018-12-21|2014-01-31|2016-05-20|2018-07-20|2018-01-01|2018-05-03|2015-07-17	2013-12-30|2014-03-28|2016-10-28|2017-06-22|2019-07-23|2019-03-28|2017-08-04|2018-01-25|2020-02-26|2018-11-06|2019-01-29|2018-08-31	no_assertion_criteria_provided|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053577|SCV000144430|SCV000325042|SCV000677633|SCV001161540|SCV000075448|SCV000587018|SCV000698850|SCV000186898|SCV000903751|SCV000292501|SCV000296367	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.81-1G>A	BRCA1	splice_acceptor_variant	102202	1	NA	NA	-	-	-	-	91668	97145	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41267797C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA1):200-1&base_change%3DG_to_A	-	BRCA1:672	SO:0001627|intron_variant	1	80358018	-	_c/o_University_of_Cambridge|Ambry_Genetics|Color|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2010-08-12|2004-02-20|2015-10-02|2018-07-24|2018-08-29|2018-10-15|2018-09-06|2018-12-24	2013-06-26|2014-03-28|2016-10-28|2020-02-26|2018-11-06|2019-03-28|2019-01-29|2020-03-06	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000108982|SCV000144224|SCV000326431|SCV000186928|SCV000688672|SCV000289845|SCV000567462|SCV001133649	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided	|||Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_sequence_change_affects_an_acceptor_splice_site_in_intron_2_of_the_BRCA1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80358018,_ExAC_0.002%)._This_variant_has_been_observed_in_an_individuals_affected_with_breast_cancer_(PMID:Â¬â€ 10644434)Â¬â€ and_ovarian_cancer_(PMID:Â¬â€ 22711857)._This_variant_is_also_known_asÂ¬â€ 200-1G>A_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_91668)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_variant_is_denoted_BRCA1_c.81-1G>A_or_IVS2-1G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_-1_position_of_intron_2_of_the_BRCA1_gene._Using_alternate_nomenclature,_this_variant_has_previously_been_published_as_BRCA1_200-1G>A._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_association_with_hereditary_breast_and_ovarian_cancer_syndrome_(Wagner_1999,_Alsop_2012,_Rebbeck_2018)._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.|The_variant_disrupts_a_canonical_splice_site,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_007294.3:c.68_69del	BRCA1	frameshift_variant	102356	11	15426	0	-	-	-	-	17662	32701	_familial_1|Pancreatic_cancer_4|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:C3280442,OMIM:614320|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41276045_41276046CT[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA1):185&base_change%3Ddel_AG|Department_of_Pathology_and_Molecular_Medicine,Queen's_University:723501|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:68587|Illumina_Clinical_Services_Laboratory,Illumina:678897|OMIM_Allelic_Variant:113705.0003|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:1981909	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	5	80357914	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Pathway_Genomics|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Counsyl|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|Genetic_Services_Laboratory,_University_of_Chicago|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genomic_Research_Center,_Shahid_Beheshti_University_of_Medical_Sciences|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|OMIM|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Illumina_Clinical_Services_Laboratory,Illumina|Cancer_Genetics_and_Genomics_Laboratory,British_Columbia_Cancer_Agency|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|GeneReviews|GeneDx|Baylor_Genetics|GeneKor_MSA|Ambry_Genetics|Color|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|risk_factor|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|pathologic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2008-10-01|2013-11-14|2002-05-29|2014-07-24|2014-11-03|2014-05-30|2015-11-20|2016-04-22|2015-10-02|2015-07-01|2017-01-01|2017-07-14|2016-12-02|0000-00-00|2017-12-03|2017-05-25|2019-01-22|2008-10-01|2012-07-13|2019-01-04|2016-01-19|2016-06-14|2017-04-18|2014-01-31|2017-04-20|0000-00-00|2017-08-10|2018-07-02|2013-09-26|2014-10-06|2017-02-23|2018-08-01|2019-02-13|2015-01-12|2018-05-23|2016-05-09|2018-11-19|2019-02-25|2016-11-29|2016-07-11|2016-06-22|2017-07-31|2018-12-01|2018-09-13	2018-08-17|2015-12-29|2014-03-28|2014-08-08|2016-04-21|2015-03-11|2016-03-03|2016-06-09|2016-10-28|2017-04-17|2017-03-15|2017-07-19|2017-07-05|2018-04-04|2017-12-03|2018-06-14|2019-08-02|2018-08-17|0000-00-00|2019-03-28|2019-03-21|2016-10-18|2017-08-04|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2013-04-30|2015-02-20|2017-02-23|2018-08-08|2020-02-26|2016-07-05|2018-05-23|2018-09-19|2019-01-29|2020-03-06|2018-03-09|2018-01-29|2018-07-18|2018-04-30|2019-02-22|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|inherited|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|not_provided|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline	SCV000039518|SCV000053880|SCV000144169|SCV000189887|SCV000195875|SCV000220360|SCV000266036|SCV000282348|SCV000326390|SCV000564332|SCV000577914|SCV000583605|SCV000593688|SCV000733684|SCV000746289|SCV000839891|SCV000993552|SCV000053475|SCV000043189|SCV000077108|SCV000271311|SCV000403078|SCV000586860|SCV000587006|SCV000588022|SCV000591232|SCV000699291|SCV000839317|SCV000086950|SCV000108687|SCV000540943|SCV000693502|SCV000186370|SCV000292122|SCV000803154|SCV000227400|SCV000278833|SCV000296272|SCV000778781|SCV000806982|SCV000863618|SCV000901065|SCV000923765|SCV000602669	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Pancreatic_cancer_4|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|Breast_and/or_ovarian_cancer|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms|not_specified	|||||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||||The_c.68_69del_(p.Glu23Valfs*17)_variant_in_the_BRCA1_gene_has_been_detected_multiple_patients_with_breast_cancer_and/or_ovarian_cancer_[PMID_14576434,_26718727,_21503673,_22430266,_23633455,_22752604,_referred_as_c.185delAG_in_some_publications]._This_variant_is_a_founder_mutation_in_Ashkenazi_Jews_with_a_frequency_of_about_1%_[PMID_14576434]._The_variant_has_also_been_detected_in_patients_with_prostate_[PMID_22516946]_and_pancreatic_cancer_[PMID_20711688,_24737347,_23658460,_26440929]._This_one_bp_deletion_in_exon_2_results_in_a_frameshift_and_the_creation_of_a_premature_stop_codon._Functional_in_vitro_assays_showed_that_this_variant_was_deleterious_[PMID_23867111]._This_variant_has_been_reported_in_31_individuals_from_the_ExAC_database_(http://exac.broadinstitute.org/variant/22-29091226-TA-T)._This_variant_is_thus_classified_as_pathogenic|||Converted_during_submission_to_Pathogenic.|This_sequence_change_deletes_two_nucleotides_from_exon_2_of_the_BRCA1_mRNA_(c.68_69delAG),_causing_a_frameshift_at_codon_23._This_creates_a_premature_translational_stop_signal_(p.Glu23Valfs*17)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_pathogenic_variant_is_a_known_common_cause_of_breast_and_ovarian_cancer_in_the_Ashkenazi_Jewish_population_(PMID:_9042909,_22430266),_although_it_has_been_observed_in_individuals_from_other_ethnicities_(PMID:_8651293,_8571953,_9921907)._This_variant_has_also_been_reported_in_individuals_affected_with_pancreatic_cancer_(PMID:_15994883,_22430266,_23658460,_24737347)._It_is_also_known_as_185delAG_or_187delAG_in_the_literature._This_variant_has_been_associated_with_a_64%_to_83%_risk_of_breast_cancer_by_age_70,_and_a_14%_to_58%_risk_of_ovarian_cancer_by_age_70_(PMID:_15994883,_22430266)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Glu23ValfsX17_variant_in_BRCA1_has_been_reported_in_numerous_individuals_w_ith_hereditary_breast_and_ovarian_cancer_(HBOC)_and_is_a_known_pathogenic_Ashken_azi_Jewish_founder_variant_(Struewing_1997,_Abeliovich_2013)._It_has_also_been_i_dentified_in_38/10150_Ashkenazi_Jewish_and_11/126308_European_chromosomes_by_gno_mAD_(http://gnomad.broadinstitute.org)._Please_note_that_this_frequency_is_low_e_nough_to_be_consistent_with_the_frequency_of_HBOC_in_the_general_population._Thi_s_frameshift_variant_is_predicted_to_alter_the_protein?s_amino_acid_sequence_beg_inning_at_position_23_and_lead_to_a_premature_termination_codon_17_amino_acids_d_ownstream._This_alteration_is_then_predicted_to_lead_to_a_truncated_or_absent_pr_otein._Heterozygous_loss_of_function_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_individuals_with_HBOC._Additionally,_this_variant_was_classified_a_s_Pathogenic_on_April_22,_2016_by_the_ClinGen-approved_ENIGMA_expert_panel_(Clin_Var_SCV000282348.1)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_predicted_im_pact_to_the_protein_and_presence_in_multiple_affected_individuals._ACMG/AMP_Crit_eria_applied:_PVS1,_PS4_strong.|The_c.68_69delAG_(p.Glu23ValfsTer17)_variant,_also_commonly_known_as_185delAG,_is_a_frameshift_variant_that_is_very_well_described_in_the_literature_as_one_of_the_most_frequent_variants_found_in_breast_cancer_(Shattuck-Eidens_et_al._1995:_Offit_et_al._1996)._It_was_first_identified_in_a_study_by_Simard_et_al._(1994)_in_index_cases_from_four_unrelated_Canadian_families_with_hereditary_breast_and_ovarian_cancer_(HBOC)._Wang_et_al._(2012)_conducted_a_meta-analysis_of_over_29_studies_published_between_2000_and_2010_and_determined_the_overall_frequency_of_the_p.Glu23ValfsTer17_variant_in_2128_breast_cancer_cases_to_be_0.072._The_variant_is_one_of_three_known_common_founder_germline_variants_primarily_found_in_individuals_of_Ashkenazi_Jewish_heritage_(Struewing_et_al._1997:_Abeliovich_et_al._1997:_Laitman_et_al._2013)_and_has_been_detected_in_20%_of_Ashkenazi_Jewish_women_diagnosed_with_breast_cancer_before_age_42_years_(Offit_et_al_1996)._In_the_Ashkenazi_Jewish_population,_the_variant_is_associated_with_a_risk_of_between_56%_and_83%_of_breast_cancer_and_of_between_14%_and_58%_risk_of_ovarian_cancer_by_the_age_of_70_(Struewing_et_al._1997:_Antoniou_et_al._2005:_Finkelman_et_al._2012)._The_variant_has_been_observed_in_individuals_of_other_ethnicities_(Wang_et_al._2012:_Laitman_et_al._2013)._The_variant_is_reported_at_a_frequency_of_0.00042_in_the_European_(Non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Based_on_the_available_evidence,_the_p.Glu23ValfsTer17_variant_is_classified_as_pathogenic_for_hereditary_breast_and_ovarian_cancer.|||||Variant_summary:_The_BRCA1_c.68_69delAG_(p.Glu23Valfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_is_one_of_the_most_common_Jewish_founder_mutations._Multiple_publications_have_cited_the_variant_in_affected_individuals._This_variant_was_found_in_29/120972_control_chromosomes_at_a_frequency_of_0.0002397,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||Converted_during_submission_to_Pathogenic.|This_mutation_is_caused_by_the_deletion_of_two_nucleotides_(AG)_in_BRCA1_exon_2,_and_is_denoted_c.68_69delAG_at_the_cDNA_level_using_current_HGVS_nomenclature,_or_Glu23ValfsX16_at_the_protein_level._The_mutation_is_also_known_as_BRCA1_185delAG_or_187delAG_and_is_a_founder_mutation_in_the_Ashkenazi_Jewish_population_(Struewing_1995)._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_acid_to_a_Valine_at_codon_23_and_creates_a_premature_stop_codon_at_position_16_of_the_new_reading_frame._This_mutation_is_predicted_to_cause_loss_of_normal_protein_function_either_through_protein_truncation_or_nonsense-mediated_mRNA_decay_and_is_indicative_of_Hereditary_Breast_and_Ovarian_Cancer_(HBOC)_syndrome,_an_autosomal_dominant_condition_that_predisposes_to_breast_and_ovarian_cancer_as_well_as_other_cancers._The_predominant_BRCA1-related_cancer_risks_for_women_who_have_not_been_diagnosed_with_cancer_have_been_estimated_to_be_57%_-_84%_lifetime_risk_for_breast_cancer_and_24%_-_54%_lifetime_risk_for_ovarian_cancer_(Antoniou_2003,_Chen_2007,_Ford_1998)._BRCA1_mutations_have_also_been_reported_in_women_with_fallopian_tube_carcinoma,_primary_peritoneal_carcinoma,_and_uterine_serous_carcinoma_(Levine_2003,_Pennington_2013)._Women_with_BRCA1/2_mutations_also_have_an_increased_risk_for_contralateral_breast_cancer._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_under_age_40_have_a_21-31%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_63%_risk_to_develop_a_second_breast_cancer_within_25_years._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_between_ages_40_and_50_have_an_11-13%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_44-49%_risk_within_25_years._Women_with_BRCA_mutations_whose_first_cancer_was_diagnosed_after_age_50_have_an_8%_risk_to_develop_a_second_breast_cancer_within_10_years_and_a_20%_risk_within_25_years_(Graeser_2009)._Other_cancer_risks_associated_with_a_BRCA1_mutation_include_approximately_3%_risk_for_pancreatic_cancer_(The_Breast_Cancer_Linkage_Consortium_1999),_a_20%_risk_for_prostate_cancer_(Thompson_2002),_and_4%_risk_for_male_breast_cancer_(Liede_2004)._The_variant_is_found_in_BR-OV-HEREDIC,BRCA1-BRCA2,BRCA-AJ,HIRISK-BR-HEREDIC,HEREDICANCER_panel(s).|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_deletion_of_two_nucleotides_is_denoted_BRCA1_c.68_69delAG_at_the_cDNA_level_and_p.Glu23ValfsX17_(E23VfsX17)_at_the_protein_level._The_variant_is_also_known_as_BRCA1_185delAG_or_187delAG_using_alternate_nomenclature_and_is_one_of_three_main_pathogenic_founder_variants_in_the_Ashkenazi_Jewish_population_(Struewing_1995)._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TTAG[delAG]TGTC._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_a_Valine_at_codon_23,_and_creates_a_premature_stop_codon_at_position_17_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.||||||The_BRCA1_c.68_69delAG:_p.Glu23fs_variant_(rs386833395),_also_known_as_187delAG,_is_described_in_the_literature_as_a_known_common_cause_of_breast_and_ovarian_cancer_in_the_Ashkenazi_Jewish_population,_but_is_also_observed_in_other_ethnic_populations_in_individuals_with_breast,_ovarian,_and_pancreatic_cancer_(see_link_to_HGMD_database_and_references_therein)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_17662),_and_is_found_in_the_general_population_with_an_overall_allele_frequency_of_0.02%_(58/282,442_alleles)_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_deleting_2_nucleotides,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_the_p.Glu23fs_variant_is_considered_to_be_pathogenic._References:_Link_to_HGMD_database_(CD951600):_https://portal.biobase-international.com/hgmd/pro/mut.php?acc
NM_007294.3:c.-3_4dup	BRCA1	frameshift_variant	102302	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_058216.2:c.80_99del	RAD51C	frameshift_variant	102748	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_058216.2:c.93del	RAD51C	frameshift_variant	102744	8	15432	0	-	-	-	-	182847	180903	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.56770097del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2855054|OMIM_Allelic_Variant:602774.0007|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2272795	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	730881942	-	OMIM|Ambry_Genetics|Color|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-08-15|2019-03-28|2014-12-18|2018-12-28|2019-01-10|2019-06-13|2017-06-02|2017-11-22|2019-04-07	2019-08-21|2020-02-26|2017-12-21|2019-03-28|2019-01-29|2020-03-06|2017-06-22|2018-01-25|2019-08-05	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000045557|SCV000215256|SCV000691291|SCV000259467|SCV000211643|SCV001134795|SCV000677786|SCV000699829|SCV001158330	Breast-ovarian_cancer,_familial_3|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|not_provided|not_provided|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O|Hereditary_breast_and_ovarian_cancer_syndrome|not_specified	|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Phe32Serfs*8)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs763897044,_ExAC_0.02%)._This_variant_has_been_reported_in_multiple_individuals_and_families_with_breast_and/or_ovarian_cancer_(PMID:_21616938),_and_an_individual_with_prostate_cancer_(PMID:_27433846)._This_variant_has_been_reported_as_a_putative_founder_mutation_for_breast_and/or_ovarian_cancer_risk_in_individual_of_Finnish_ancestry_(PMID:_21616938,_24800917)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182847)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_one_nucleotide_in_RAD51C_is_denoted_c.93delG_at_the_cDNA_level_and_p.Phe32SerfsX8_(F32SfsX8)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_CGGG[delG]TTCC._The_deletion_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Serine_at_codon_32,_and_creates_a_premature_stop_codon_at_position_8_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._RAD51C_c.93delG_has_been_reported_in_several_families_with_breast_and/or_ovarian_cancer,_in_at_least_one_individual_with_prostate_cancer,_and_has_been_described_as_a_Finnish_founder_pathogenic_variant_(Pelttari_2011,_Pritchard_2016)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_not_found_in_general_population_data.||Variant_summary:_The_RAD51C_c.93delG_(p.Phe32SerfsX8)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_RAD51C_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_15/250416_control_chromosomes_at_a_frequency_of_0.0000599,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_RAD51C_variant_(0.0000625)._This_variant_has_also_been_reported_in_multiple_families_and_individuals_with_breast_and/or_ovarian_cancer_and_based_on_haplotype_analysis_authors_concluded_that_it_is_likely_a_founder_mutation_in_the_Finnish_population_that_is_associated_with_moderate-to-high_risk_susceptibility_for_ovarian_cancer_(Pelttari_2011)._The_founder_effect_can_also_explain_the_higher_occurrence_of_the_variant_in_this_population_(gnomAD_5/22298_Finnish_European)._The_variant_was_also_found_in_a_patient_with_ovarian_cancer_in_a_different_population_(Susswein_2016)._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.97C>T_(p.Gln33X),_c.397C>T_(p.Gln133X),_c.577C>T_(p.Arg193X))._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|The_RAD51C_c.93delG:_p.Phe32fs_variant_(rs730881942)_is_reported_in_the_literature_in_individuals_with_breast_and/or_ovarian_cancer,_prostate_cancer,_soft_tissue_sarcoma,_or_hematologic_cancer_(Pelttari_2011,_Pritchard_2016,_Schrader_2016,_Susswein_2016)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_182847)._It_is_found_in_the_general_population_with_an_overall_allele_frequency_of_0.005%_(13/282860_alleles)_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_deleting_a_single_nucleotide,_so_it_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Pelttari_LM_et_al._RAD51C_is_a_susceptibility_gene_for_ovarian_cancer._Hum_Mol_Genet._2011_Aug_15:20(16):3278-88._Pritchard_CC_et_al._Inherited_DNA-Repair_Gene_Mutations_in_Men_with_Metastatic_Prostate_Cancer._N_Engl_J_Med._2016_Aug_4:375(5):443-53._Schrader_KA_et_al._Germline_Variants_in_Targeted_Tumor_Sequencing_Using_Matched_Normal_DNA._JAMA_Oncol._2016_Jan:2(1):104-11._Susswein_LR_et_al._Pathogenic_and_likely_pathogenic_variant_prevalence_among_the_first_10,000_patients_referred_for_next-generation_cancer_panel_testing._Genet_Med._2016_Aug:18(8):823-32.
NM_058216.2:c.97C>T	RAD51C	stop_gained	102746	2	NA	NA	5&5&5	1&1&1	rs587782528	Hereditary cancer-predisposing syndrome&Fanconi anemia, complementation group O&not provided	142534	152248	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56770101C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	587782528	-	Ambry_Genetics|Color|Invitae|Counsyl|GeneDx|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-06-22|2016-06-20|2018-12-27|2016-08-26|2017-06-23|2016-08-26|2016-08-08	2020-02-26|2017-01-26|2019-03-28|2016-11-23|2019-01-29|2016-11-23|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|unknown|germline	SCV000186754|SCV000537681|SCV000253965|SCV000489955|SCV000211638|SCV000489956|SCV000699813	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Fanconi_anemia,_complementation_group_O|not_provided|Breast-ovarian_cancer,_familial_3|Hereditary_breast_and_ovarian_cancer_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln33*)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587782528,_ExAC_0.01%)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_ovarian_cancer_and_endometrial_cancer_(PMID:_26261251,_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142534)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_RAD51C_c.97C>T_at_the_cDNA_level_and_p.Gln33Ter_(Q33X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_at_least_two_individuals_with_ovarian_cancer_(Song_2015)_and_is_considered_pathogenic.||Variant_summary:_The_RAD51C_c.97C>T_(p.Gln33X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_RAD51C_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_was_observed_in_the_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_1/126836,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_RAD51C_variant_of_1/16000._The_variant_of_interest_has_been_reported_in_an_affected_individual,_along_with_multiple_reputable_databases/clinical_laboratories_citing_the_variant_as_pathogenic._Therefore,_the_variant_of_interest_has_been_classified_as_Pathogenic.
NM_058216.2:c.145+2_145+3insTT	RAD51C	splice_donor_variant	102618	2	NA	NA	-	-	-	-	819250	815695	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000017.10:g.56770151_56770152insTT	_single_submitter	Uncertain_significance	-	-	Insertion	SO:0000667	-	-	RAD51C:5889	SO:0001575|splice_donor_variant	1	-	-	Ambry_Genetics	Uncertain_significance	2020-01-29	2020-02-26	_single_submitter	germline	SCV001171994	Hereditary_cancer-predisposing_syndrome	Insufficient_evidence
NM_058216.2:c.181_182del	RAD51C	frameshift_variant	102704	1	NA	NA	-	-	-	-	187716	185141	_complementation_group_O|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:CN517202	-	NC_000017.10:g.56772325_56772326CT[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	786203945	-	Ambry_Genetics|Invitae|GeneDx	Pathogenic|Pathogenic|Pathogenic	2019-01-16|2018-12-10|2018-05-22	2020-02-26|2019-03-28|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000218322|SCV000550223|SCV000779052	_complementation_group_O|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu61Alafs*11)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs754525165,_ExAC_0.006%)._This_variant_has_been_reported_in_an_individual_affected_with_prostate_cancer_(PMID:_27433846)._This_variant_is_also_known_as_c.179_180del_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_187716)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_two_nucleotides_in_RAD51C_is_denoted_c.181_182delCT_at_the_cDNA_level_and_p.Leu61AlafsX11_(L61AfsX11)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AACT[delCT]GCAA._The_deletion_causes_a_frameshift_which_changes_a_Leucine_to_an_Alanine_at_codon_61,_and_creates_a_premature_stop_codon_at_position_11_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._RAD51C_c.181_182delCT,_also_known_as_c.179_180del_by_alternate_nomenclature,_has_been_observed_in_at_least_one_prostate_cancer_patient_(Pritchard_2016)._We_consider_this_variant_to_be_pathogenic.
NM_058216.2:c.216_220del	RAD51C	frameshift_variant	102732	1	NA	NA	-	-	-	-	185920	185142	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000017.10:g.56772362_56772366del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	786202563	-	Ambry_Genetics	Pathogenic	2014-08-14	2020-02-26	_single_submitter	germline	SCV000216154	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_058216.2:c.224dup	RAD51C	stop_gained,frameshift_variant	102726	2	NA	NA	-	-	-	-	182844	180908	Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56772370dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	730881939	-	University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-09|2016-03-07|2018-12-13|2016-11-14|2018-12-13|2016-11-14|2018-04-09|2018-12-01	2020-02-26|2017-10-26|2019-03-28|2016-11-23|2019-01-29|2016-11-23|2019-04-24|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|unknown|germline|unknown|germline|germline	SCV000216856|SCV000686334|SCV000260045|SCV000490109|SCV000211640|SCV000490110|SCV000920115|SCV000924018	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Fanconi_anemia,_complementation_group_O|not_provided|Breast-ovarian_cancer,_familial_3|Hereditary_breast_and_ovarian_cancer_syndrome|Ovarian_Neoplasms	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr75*)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_20400964,_26848151,_22006311,_26681312)._This_variant_is_also_referred_to_as_c.224insA,_c.223_224insA,_and_224_225insA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182844)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_duplication_of_one_nucleotide_is_denoted_RAD51C_c.224dupA_at_the_cDNA_level_and_p.Tyr75Ter_(Y75X)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_AGAT[dupA]TGCT._The_duplication_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._RAD51C_c.224dupA,_also_reported_as_c.223_224insA_or_c.224_225insA,_has_been_observed_in_individuals_with_breast_or_ovarian_cancer,_with_studied_tumors_demonstrating_loss_of_heterozygosity_(Meindl_2010,_Walsh_2011,_Villalona-Calero_2016,_Wolf_2016)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||Variant_summary:_RAD51C_c.224dupA_(p.Tyr75X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_p.Gln133X_and_p.Arg193X)._The_variant_was_absent_in_246238_control_chromosomes._c.224dupA_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Five_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_and_all_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|
NM_058216.2:c.238G>T	RAD51C	stop_gained	102726	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_058216.2:c.498del	RAD51C	frameshift_variant	102738	1	NA	NA	-	-	-	-	480949	478844	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000017.10:g.56774147del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	RAD51C:5889	SO:0001589|frameshift_variant	1	746993675	-	Ambry_Genetics|Color	Pathogenic|Pathogenic	2017-03-10|2017-09-26	2020-02-26|2017-12-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000664925|SCV000691241	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)|
NM_058216.2:c.502A>T	RAD51C	stop_gained	102740	1	NA	NA	5&5	1&1	rs587781490	Hereditary cancer-predisposing syndrome&not provided	141095	150809	_complementation_group_O|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:CN517202	-	NC_000017.10:g.56774151A>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	RAD51C:5889	SO:0001587|nonsense	1	587781490	-	University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-05-23|2016-04-12|2018-12-06|2018-12-01	2020-02-26|2019-01-29|2019-03-28|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline	SCV000184224|SCV000211633|SCV000770066|SCV000924019	_complementation_group_O|Ovarian_Neoplasms	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|This_pathogenic_variant_is_denoted_RAD51C_c.502A>T_at_the_cDNA_level_and_p.Arg168Ter_(R168X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(AGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_at_least_three_breast_cancer_cases,_one_of_which_was_mosaic_(Lhota_2016,_Yablonski-Peretz_2016),_and_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg168*)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_26687385,_26822949)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141095)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_058216.2:c.525dup	RAD51C	frameshift_variant	102732	1	NA	NA	-	-	-	-	409827	402768	_complementation_group_O	-	MeSH:D010051,MedGen:CN236629|MedGen:C3150653,OMIM:613390	-	NC_000017.10:g.56774174dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	RAD51C:5889	SO:0001589|frameshift_variant	1	768793789	-	University_Hospital_Cologne	Pathogenic|Pathogenic	2018-11-28|2018-12-01	2019-03-28|2019-02-22	_single_submitter|no_assertion_criteria_provided	germline|germline	SCV000550170|SCV000923801	_complementation_group_O|Ovarian_Neoplasms	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Cys176Leufs*27)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs768793789,_ExAC_0.001%)._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer_and_non-Hodgkin_lymphoma_and_her_daughter_affected_with_ovarian_cancer_(PMID:_20400964)._This_variant_is_also_known_as_c.525_526insC_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 409827)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_058216.2:c.571+1G>A	RAD51C	splice_donor_variant	102724	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_058216.2:c.572-1G>T	RAD51C	splice_acceptor_variant	102630	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_058216.2:c.577C>T	RAD51C	stop_gained	102614	2	NA	NA	5&5&5	2&1&1	rs200293302	Hereditary cancer-predisposing syndrome&Fanconi anemia, complementation group O&not provided	140849	150563	RAD51C-Related_Disorders|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	.|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56780562C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:1351099	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	200293302	-	Ambry_Genetics|Color|Invitae|GeneDx|Counsyl|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Illumina_Clinical_Services_Laboratory,Illumina	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-16|2015-02-18|2018-12-13|2019-01-03|2017-02-13|2018-10-31|2017-07-14|2019-04-05	2020-02-26|2016-07-05|2019-03-28|2019-01-29|2017-06-22|2018-11-14|2018-01-25|2019-04-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|unknown|germline|germline	SCV000183755|SCV000292164|SCV000260761|SCV000211615|SCV000677771|SCV000893460|SCV000699816|SCV000914251	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|not_provided|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O|Hereditary_breast_and_ovarian_cancer_syndrome|RAD51C-Related_Disorders	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg193*)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs200293302,_ExAC_0.02%)._This_variant_has_been_observed_inÂ¬â€ individuals_affected_with_breast_cancer_and_ovarian_cancer_(PMID:_22538716,_22725699,_26261251,_25086635,_26740214)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140849)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_pathogenic_variant_is_denoted_RAD51C_c.577C>T_at_the_cDNA_level_and_p.Arg193Ter_(R193X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_multiple_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_and_is_considered_pathogenic_(Loveday_2012,_Coulet_2013,_Blanco_2014,_Norquist_2015,_Song_2015,_Tung_2016,_Jian_2017).|||Variant_summary:_The_RAD51C_c.577C>T_(p.Arg193X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_RAD51C_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._This_variant_was_found_in_5/120882_control_chromosomes_at_a_frequency_of_0.0000414,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_RAD51C_variant_(0.0000625)._Multiple_publications_have_cited_the_variant_in_affected_individuals,_including_a_family_that_the_variant_cosegregated_with_disease_(Blanco_2014)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|The_RAD51C_c.577C>T_(p.Arg193Ter)_variant_is_a_stop-gained_variant_predicted_to_result_in_premature_termination_of_the_protein._The_p.Arg193Ter_variant_has_been_reported_in_at_least_five_studies_in_which_it_is_found_in_a_heterozygous_state_in_seven_individuals_diagnosed_with_ovarian_cancer,_two_of_whom_are_related_(Loveday_et_al._2012:_Coulet_et_al._2013:_Blanco_et_al._2014:_Song_et_al._2015:_Jonson_et_al._2016)._The_p.Arg193Ter_variant_was_also_reported_in_a_heterozygous_state_in_two_unaffected_individuals_who_may_yet_be_too_young_to_develop_disease_(one_individual_was_25_years_old_and_the_other_is_of_unknown_age)._All_of_these_individuals_have_a_family_history_of_breast_and/or_ovarian_cancer_and_are_negative_for_variants_in_the_BRCA1_and_BRCA2_genes._The_p.Arg193Ter_variant_was_absent_from_3,928_controls_and_is_reported_at_a_frequency_of_0.00012_in_the_Latino_population_of_the_Genome_Aggregation_Database._Although_the_p.Arg193Ter_variant_has_not_been_reported_in_the_literature_in_individuals_with_Fanconi_anemia,_it_cannot_be_ruled_out_of_causing_this_condition_based_on_allele_frequency_in_consideration_of_disease_penetrance_and_prevalence_estimates._Based_on_the_collective_evidence_and_the_potential_impact_of_stop-gained_variants,_the_p.Arg193Ter_variant_is_classified_as_pathogenic_for_RAD51C-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_058216.2:c.706-2A>G	RAD51C	splice_acceptor_variant	102656	5	15420	1	-	-	-	-	128209	133666	Ovarian_Neoplasms|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56787218A>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	RAD51C:5889	SO:0001574|splice_acceptor_variant	17	587780259	-	Ambry_Genetics|Color|Invitae|Division_of_Human_Genetics,Children's_Hospital_of_Philadelphia|GeneDx|Laboratoire_de_Biologie_et_Génétique_du_Cancer,Centre_François_Baclesse|Counsyl|Fulgent_Genetics,Fulgent_Genetics|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2019-09-23|2016-02-10|2018-12-11|2016-08-16|2018-04-30|0000-00-00|2017-01-12|2018-10-31|2018-12-01	2020-02-26|2017-10-26|2019-03-28|2017-01-23|2019-01-29|2017-03-06|2017-06-22|2018-11-14|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|maternal|germline|germline|unknown|unknown|germline	SCV000186640|SCV000686377|SCV000291240|SCV000536783|SCV000150087|SCV000536677|SCV000677780|SCV000893462|SCV000923802	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Fanconi_anemia,_complementation_group_O|not_provided|Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O|Ovarian_Neoplasms	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Functionally-validated_splicing_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_affects_an_acceptor_splice_site_in_intron_4_of_the_RAD51C_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780259,_ExAC_0.003%)._This_variant_has_been_reported_in_the_literature_in_several_individuals_with_breast_and_ovarian_cancer_(PMID:_22006311,_22538716,_24549055,_25452441,_26261251,_26681312,Â¬â€ 29255180)._In_one_family,_it_was_reported_to_segregate_with_ovarian_cancer_in_two_individuals_(PMID:_24139550)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128209)._Experimental_studies_have_shown_that_this_sequence_change_disrupts_normal_mRNA_splicing_(PMID:_24139550,_22006311)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_RAD51C_c.706-2A>G_or_IVS4-2A>G_and_consists_of_an_A>G_nucleotide_substitution_at_the_-2_position_of_intron_4_of_the_RAD51C_gene._The_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_an_abnormal_protein_product._RAD51C_c.706-2A>G_was_shown_to_result_in_skipping_of_exon_5,_leading_to_the_in-frame_loss_of_44_amino_acids_(Golmard_2013),_and_RNAseq_analysis_performed_by_Davy_2017_et_al._revealed_several_splice_products,_the_most_predominant_of_which_was_exon_5_skipping,_followed_by_a_proportion_of_normal,_wild-type_transcript._This_variant_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Walsh_2011,_Loveday_2012,_Golmard_2013,_Couch_2015,_Song_2015,_Golmard_2017,_Harter_2017,_Kotoula_2017)._Based_on_the_current_evidence,_we_consider_this_variant_to_be_likely_pathogenic.||||
NM_058216.2:c.709C>T	RAD51C	stop_gained	102660	1	NA	NA	5&5	1&1	rs770637624	Hereditary cancer-predisposing syndrome&Fanconi anemia, complementation group O	186364	185160	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56787223C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2846799	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	770637624	-	Ambry_Genetics|Color|Invitae|Mendelics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Counsyl|Mendelics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-03-19|2015-11-06|2019-01-05|2019-05-28|2018-05-02|2018-07-12|2017-04-28|2018-07-02	2020-02-26|2017-01-26|2019-03-28|2019-10-22|2019-01-29|2018-08-31|2017-06-22|2018-08-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|unknown|unknown	SCV000216703|SCV000537645|SCV000291234|SCV001140719|SCV000567973|SCV000888602|SCV000677818|SCV000839333	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Fanconi_anemia,_complementation_group_O|not_provided|not_provided|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O|Hereditary_breast_and_ovarian_cancer_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg237*)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs770637624,_ExAC_0.001%)._This_variant_has_been_reported_in_an_individual_affected_with_thyroid_and_ovarian_cancer,_who_also_has_a_family_history_of_breast_and_ovarian_cancer_(PMID:_25086635)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186364)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_RAD51C_c.709C>T_at_the_cDNA_level_and_p.Arg237Ter_(R237X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_with_prostate_and_gastric_cancer,_as_well_as_in_at_least_two_families_with_breast_and/or_ovarian_cancer_(Blanco_2014,_Pritchard_2016,_Sahasrabudhe_2017,_Tavera-Tapia_2017)._We_consider_this_variant_to_be_pathogenic.|||
NM_058216.2:c.774del	RAD51C	frameshift_variant	102712	11	NA	NA	-	-	-	-	419188	410106	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56787288del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	754367349	-	GeneDx|Counsyl|Color|Ambry_Genetics|Invitae	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-04-24|2017-02-14|2017-09-29|2019-04-05|2018-11-01	2019-01-29|2017-06-22|2017-12-21|2020-02-26|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline	SCV000566828|SCV000677785|SCV000691266|SCV001189230|SCV000826564	not_provided|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O	This_deletion_of_one_nucleotide_in_RAD51C_is_denoted_c.774delT_at_the_cDNA_level_and_p.Thr259LeufsX4_(T259LfsX4)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_TTCG[delT]ACTC._The_deletion_causes_a_frameshift_which_changes_a_Threonine_to_a_Leucine_at_codon_259,_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._RAD51C_c.774delT_has_been_observed_in_multiple_women_with_personal_and_family_histories_of_breast_and/or_ovarian_cancer_and_has_been_suggested_to_be_a_recurrent_variant_in_the_Swedish_population_(Sopik_2014,_Osorio_2012,_Romero_2011,_Vuorela_2011,_Cunningham_2014,_Song_2015)._Based_on_the_currently_available_information,_we_consider_this_deletion_to_be_a_likely_pathogenic_variant.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Thr259Leufs*4)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs754367349,_ExAC_0.02%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:Â¬â€ 21537932,Â¬â€ 26261251)_and_an_individual_affected_with_ovarian_cancer_(PMID:Â¬â€ 21750962)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_419188)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_058216.2:c.821del	RAD51C	frameshift_variant	102700	1	NA	NA	-	-	-	-	480505	479018	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000017.10:g.56787335del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	1466185247	-	Ambry_Genetics|Color	Pathogenic|Pathogenic	2016-05-25|2015-06-01	2020-02-26|2017-12-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000663782|SCV000691271	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)|
NM_058216.2:c.837+1G>A	RAD51C	splice_donor_variant	102682	1	NA	NA	-	-	-	-	229854	236233	_familial_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56787352G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:602774.0008|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2854757	-	RAD51C:5889	SO:0001575|splice_donor_variant	1	760235677	-	OMIM|Ambry_Genetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	risk_factor|Pathogenic|Pathogenic	2011-08-15|2015-03-03|2019-05-30	2019-08-21|2020-02-26|2020-03-06	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000045558|SCV000273205|SCV001134790	_familial_3|Hereditary_cancer-predisposing_syndrome|not_provided	|Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion):Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|The_variant_disrupts_a_canonical_splice_site,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_058216.2:c.838-2A>T	RAD51C	splice_acceptor_variant	102584	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_058216.2:c.905-2_905-1del	RAD51C	splice_acceptor_variant	102652	1	NA	NA	-	-	-	-	141768	151482	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56801399_56801400del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	RAD51C:5889	SO:0001574|splice_acceptor_variant	1	587781995	-	Ambry_Genetics|Color|GeneDx|Invitae|Counsyl	Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2019-10-03|2018-09-05|2018-12-11|2018-12-29|2017-10-17	2020-02-26|2018-11-06|2019-01-29|2019-03-28|2018-06-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000185270|SCV000691288|SCV000293781|SCV000650029|SCV000785628	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity||This_variant_is_denoted_RAD51C_c.905-2_905-1delAG_and_consists_of_a_deletion_of_two_nucleotides_starting_at_the_-2_position_of_intron_6._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_tctc[delag]GGGA,_where_the_lowercase_letters_are_intronic_and_capital_are_exonic._This_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._RAD51C_c.905-2_905-1delAG_has_been_reported_in_a_patient_with_breast_cancer_and_another_with_a_personal_and_family_history_of_ovarian_cancer,_and_has_been_shown_by_RT-PCR_to_result_in_skipping_of_exon_7_(Song_2015,_Lhota_2016)._Based_on_the_currently_evidence,_we_consider_RAD51C_c.905-2_905-1delAG_to_be_pathogenic.|This_sequence_change_affects_an_acceptor_splice_site_in_intron_6_of_the_RAD51C_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781995,_ExAC_0.01%)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_ovarian_cancer_and_breast_cancer_(PMID:Â¬â€ 26261251,Â¬â€ 26822949)._This_variant_is_also_known_as_905-2delAG_and_c.905-2_1delAG_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141768)._Different_variants_affecting_this_acceptor_splice_site_(c.905-2A>G,_c.905-2A>C,_c.905-2delA)_have_been_determined_to_be_pathogenic_(PMID:_22725699,_26824983,_Invitae)._This_suggests_that_this_splice_site_is_important_for_normal_RNA_splicing,_and_that_other_variants_at_this_position_may_also_be_pathogenic._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_058216.2:c.942_948del	RAD51C	frameshift_variant	102646	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_058216.2:c.955C>T	RAD51C	stop_gained	102618	1	NA	NA	5&5	1&1	rs587781287	Hereditary cancer-predisposing syndrome&Fanconi anemia, complementation group O	140799	150513	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56801451C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	587781287	-	_University_of_Chicago	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-22|2015-07-17|2018-12-14|2016-12-05|2016-12-16	2020-02-26|2017-01-26|2019-03-28|2019-01-29|2017-07-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000172859|SCV000537646|SCV000291256|SCV000566619|SCV000596689	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|not_provided|Breast-ovarian_cancer,_familial_3	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_319_(p.Arg319*)_of_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_22538716,_25452441,_26261251)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_pathogenic_variant_is_denoted_RAD51C_c.955C>T_at_the_cDNA_level_and_p.Arg319Ter_(R319X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_at_least_on_individual_with_triple_negative_breast_cancer_and_four_individuals_with_ovarian_cancer,_including_three_with_a_family_history_of_breast_and/or_ovarian_cancer,_and_was_not_observed_in_2,772_unaffected_controls_(Loveday_2012,_Couch_2015,_Norquist_2015,_Song_2015)._RAD51C_Arg319Ter_is_considered_pathogenic.|
NM_032043.2:c.2765T>G	BRIP1	stop_gained	102670	3	NA	NA	5&5	1&1	rs587782410	Hereditary cancer-predisposing syndrome&not provided	142366	152080	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59763337A>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	587782410	-	Ambry_Genetics|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Counsyl|Counsyl|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2018-05-31|2018-05-23|2018-07-09|2018-02-26|2018-06-29|2016-08-02|2016-08-02|2018-12-18|2016-11-25	2020-02-26|2018-05-23|2018-11-06|2019-01-29|2018-08-31|2016-11-23|2016-11-23|2019-03-28|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown|germline|germline	SCV000186433|SCV000803167|SCV000903752|SCV000279375|SCV000887991|SCV000489911|SCV000489912|SCV000547327|SCV000699703	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Fanconi_anemia,_complementation_group_J|Neoplasm_of_ovary|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Hereditary_breast_and_ovarian_cancer_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_pathogenic_variant_is_denoted_BRIP1_c.2765T>G_at_the_cDNA_level_and_p.Leu922Ter_(L922X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Leucine_to_a_premature_stop_codon_(TTA>TGA)_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRIP1_Leu922Ter_has_been_reported_in_at_least_three_individuals_with_breast_cancer_(Couch_2015,_Easton_2016,_Weber-Lassalle_2018)._This_variant_is_considered_pathogenic.||||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_922_(p.Leu922*)_of_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_25452441,_26921362)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_BRIP1_c.2765T>G_(p.Leu922X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRIP1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_was_observed_in_the_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_1/121394,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_BRIP1_variant_of_1/16000._The_variant_has_been_reported_in_one_triple_negative_breast_cancer_case_as_well_as_a_high-risk_unaffected_control_(Couch_2015,_Ramus_2015)_via_publications._In_addition,_multiple_clinical_diagnostic_laboratories_cite_the_variant_as_pathogenic._However,_it_does_need_to_be_noted,_a_recent_publication_by_Easton_2016_(PMID:_26921362)_indicates_that_the_prevalence_of_truncating_variants_in_BRIP1_have_comparable_occurrences_in_controls_and_cases,_for_example,_p.Arg798Ter_was_observed_in_23_cases_and_18_controls,_suggesting_that_truncating_variants_may_not_be_associated_with_a_substantial_increase_in_breast_cancer_risk,_although_the_authors_do_state_BRIP1_screening_might_have_utility_for_ovarian_cancer_risk_prediction,_in_combination_with_other_risk_factors._Therefore,_the_variant_of_interest_has_been_classified_as_Likely_Pathogenic.
NM_032043.2:c.2732dup	BRIP1	frameshift_variant	102642	12	NA	NA	-	-	-	-	407818	402699	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59763370dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	752780954	-	Invitae|Ambry_Genetics|GeneDx	Pathogenic|Pathogenic|Pathogenic	2016-10-31|2017-02-03|2018-01-26	2017-03-14|2020-02-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000547279|SCV000668949|SCV000779191	_complementation_group_J|Hereditary_cancer-predisposing_syndrome|not_provided	This_sequence_change_inserts_1_nucleotide_in_exon_19_of_the_BRIP1_mRNA_(c.2732dupT),_causing_a_frameshift_at_codon_912._This_creates_a_premature_translational_stop_signal_(p.Thr912Aspfs*27)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_duplication_of_one_nucleotide_in_BRIP1_is_denoted_c.2732dupT_at_the_cDNA_level_and_p.Thr912AspfsX27_(T912DfsX27)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_GAAG[dupT]GACC._The_duplication_causes_a_frameshift_which_changes_a_Threonine_to_an_Aspartic_Acid_at_codon_912,_and_creates_a_premature_stop_codon_at_position_27_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.
NM_032043.2:c.2684_2687del	BRIP1	frameshift_variant	102632	2	15424	1	-	-	-	-	241642	242857	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59763417_59763420del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001587|nonsense	1	760551339	-	Invitae|GeneDx|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-30|2018-09-14|2018-09-14|2017-06-12	2019-03-28|2019-01-29|2020-02-26|2017-10-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000291016|SCV000569475|SCV000668876|SCV000684229	_complementation_group_J|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser895*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_observed_inÂ¬â€ an_individual_with_breast_cancer_(PMID:_25330149)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_241642)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_four_nucleotides_is_denoted_BRIP1_c.2684_2687delCCAT_at_the_cDNA_level_and_p.Ser895Ter_(S895X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GTAT[delCCAT]AAAG._The_deletion_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRIP1_c.2684_2687delCCAT_has_been_reported_in_individuals_with_personal_or_family_history_of_breast_and/or_ovarian_cancer_(Cybulski_2014,_Easton_2016,_Yurgelun_2018)._This_variant_is_considered_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_032043.2:c.2493-1G>A	BRIP1	splice_acceptor_variant	102532	1	NA	NA	-	-	-	-	418096	410126	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59770874C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001574|splice_acceptor_variant	1	786203451	-	GeneDx|Invitae	Pathogenic|Likely_pathogenic	2014-11-07|2018-05-11	2019-01-29|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000564814|SCV000822573	_complementation_group_J	This_pathogenic_variant_is_denoted_BRIP1_c.2493-1G>A_or_IVS17-1G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_-1_position_of_intron_17_of_the_BRIP1_gene._The_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature._BRIP1_has_been_only_recently_described_in_association_with_cancer_predisposition_and_the_risks_are_not_well_understood._The_presence_of_a_BRIP1_mutation_may_confer_an_increased_risk_for_female_breast_cancer_and_ovarian_cancer_based_on_currently_available_data_(Seal_2006,_Rafnar_2011,_Pennington_2014)._In_one_case-control_study,_truncating_BRIP1_mutations_were_identified_in_9_out_of_1,212_individuals_previously_diagnosed_with_breast_cancer,_from_BRCA-negative_families,_and_in_2_out_of_2,081_controls,_suggesting_an_increased_risk_for_breast_cancer_(OR_
NM_032043.2:c.2492+2T>C	BRIP1	splice_donor_variant	101866	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.2400C>G	BRIP1	stop_gained	101792	5	NA	NA	5&5&5	1&1&1	rs574552037	Hereditary cancer-predisposing syndrome&Familial cancer of breast&not provided	142343	152057	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59793404G>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	574552037	-	Ambry_Genetics|Color|Invitae|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-09|2016-09-27|2019-01-09|2018-02-14|2016-06-20	2020-02-26|2017-10-26|2019-03-28|2019-01-29|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000186395|SCV000684211|SCV000260437|SCV000210817|SCV000699692	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|not_provided|Fanconi_anemia,_complementation_group_J	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr800*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs574552037,_ExAC_0.005%)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_a_pathogenic_variant_in_an_individual_affected_with_Fanconi_anemia_type_J_(PMID:_16116424)._It_has_also_been_reported_in_an_individual_affected_with_ovarian_cancer_(PMID:_26315354)._This_variant_is_also_known_as_2541C>G_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142343)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_pathogenic_variant_is_denoted_BRIP1_c.2400C>G_at_the_cDNA_level_and_p.Tyr800Ter_(Y800X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_BRIP1_2541C>G_using_alternate_nomenclature,_has_been_observed_in_an_individual_with_peritoneal_cancer,_another_with_a_personal_history_of_ovarian_cancer_and_family_history_of_breast_and_ovarian_cancer,_and_was_also_reported_in_the_compound_heterozygous_state_with_a_second_truncating_BRIP1_variant_in_an_individual_with_Fanconi_anemia_(Norquist_2015,_Ramus_2015,_Levran_2005)._We_consider_this_variant_to_be_pathogenic.|Variant_summary:_The_BRIP1_c.2400C>G_(p.Tyr800X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRIP1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_3/120180_control_chromosomes_at_a_frequency_of_0.000025,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRIP1_variant_(0.0000625)._This_variant_has_been_reported_in_one_FA_patient_with_BRIP1_R798X_in_trans,_and_no_BRIP1_protein_was_detected_in_the_cells_extracts_from_individual_with_this_variant_(Levran_2005)._In_addition,_multiple_clinical_diagnostic_laboratories_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.
NM_032043.2:c.2392C>T	BRIP1	stop_gained	101098	28	15402	1	5&5&5&5&5	0&2&1&1&1	rs137852986	Fanconi anemia, complementation group J&Hereditary cancer-predisposing syndrome&Familial cancer of breast&Fanconi anemia, complementation group J&not provided	4738	19777	Tracheoesophageal_fistula|Neoplasm_of_the_breast|Neoplasm_of_ovary|Familial_cancer_of_breast|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_J|Breast_cancer,_early-onset|BRIP1-Related_Disorders|not_provided	-	Human_Phenotype_Ontology:HP:0002575,MedGen:C1861028,OMIM:189960|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:C4016951|MedGen:CN239206|MedGen:CN517202	-	NC_000017.10:g.59793412G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(2),Pathogenic(16),Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	Illumina_Clinical_Services_Laboratory,Illumina:449885|OMIM_Allelic_Variant:605882.0003|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2292684	-	BRIP1:83990	SO:0001587|nonsense	1	137852986	-	OMIM|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|GeneKor_MSA|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|PreventionGenetics,PreventionGenetics|Illumina_Clinical_Services_Laboratory,Illumina|Illumina_Clinical_Services_Laboratory,Illumina|Counsyl|Genetic_Services_Laboratory,_University_of_Chicago|Fulgent_Genetics,Fulgent_Genetics|Illumina_Clinical_Services_Laboratory,Illumina|Mendelics	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2005-09-01|2016-08-18|2020-02-14|2018-07-02|2019-05-04|2019-02-23|2015-11-20|2015-02-23|2018-08-01|2019-01-09|2018-07-30|2017-03-14|2015-10-30|2016-06-14|2016-06-14|2016-08-18|2017-03-13|2017-05-18|2019-04-05|2019-05-28	2019-04-19|2016-11-23|2020-02-18|2018-08-20|2019-08-05|2020-02-26|2016-03-03|2016-07-05|2018-08-08|2019-03-28|2019-01-29|2017-08-01|2018-01-29|2016-10-18|2016-10-18|2016-11-23|2017-07-05|2017-05-23|2019-04-05|2019-10-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown|germline|unknown	SCV000025180|SCV000489935|SCV000699691|SCV000839368|SCV001160517|SCV000186705|SCV000266058|SCV000292128|SCV000821717|SCV000262207|SCV000150048|SCV000600905|SCV000807133|SCV000404595|SCV000404594|SCV000489936|SCV000593778|SCV000611254|SCV000914252|SCV001140756	Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|not_provided|not_provided|not_provided|Fanconi_anemia|Neoplasm_of_the_breast|Neoplasm_of_ovary|Breast_cancer,_early-onset|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J/Tracheoesophageal_fistula|BRIP1-Related_Disorders|Familial_cancer_of_breast	||The_variant_BRIP1_c.2392C>T_(p.Arg798X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory._The_variant_allele_was_found_at_a_frequency_of_0.00019_in_262,689_control_chromosomes_(gnomAD,_Seal_2006,_Kote-Jarai_2009,_Rafnar_2011,_Weber-Lassalle_2018)._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_BRIP1_causing_Fanconi_Anemia_Complementation_Group_J,_allowing_no_conclusion_about_variant_significance._c.2392C>T_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Fanconi_Anemia_Complementation_Group_J,_ovarian_cancer,_breast_cancer,_prostate_cancer,_patients_undergoing_testing_on_cancer_gene_panels_(example,_Levitus_2005,_Levran_2005,_Weber-Lassalle_2018,_Seal_2006,_Rafnar_2011,_Susswein_2016_Kote-Jarai_2009,_Yurgelun_2015)._One_recent_study_evaluating_this_variant_among_cases_and_controls_in_the_Breast_Cancer_Association_Consortium_(BACA)_reported_a_weak_evidence_for_an_association_of_this_variant_with_ER-negative_and_triple_negative_breast_cancer,_however_the_95%_CI_reported_overlapped_1_(0.93-5.46)_thereby_mitigating_this_reported_association_even_further_(Easton_2016)._These_data_indicate_that_although_the_variant_is_likely_to_be_associated_with_disease_in_settings_of_Fanconi_Anemia_complementation_group_J,_its_association_in_settings_of_other_cancers_is_not_yet_unequivocally_demonstrated._At-least_one_co-occurrence_with_another_pathogenic_germline_variant_has_been_reported_(MSH6,_p.R1035X,_Pennington_2014)_in_a_patient_with_a_primary_endometrioid_(non_serous)_tumor_in_whom_a_somatic_PTEN_variant_(c.955delACTT)_was_also_identified._However,_due_to_an_inconsistency_in_data_illustration_between_the_body_and_the_supplemental_section_of_this_study,_this_co-occurrence_cannot_be_unequivocally_weighted._At_least_one_publication_reports_experimental_evidence_evaluating_an_impact_on_protein_function_suggesting_that_the_loss_of_C-terminal_binding_sites_of_BRIP1_and_elimination_of_helicase_activity_in_vitro_are_not_essential_to_maintain_microsatellite_repeats_during_replication_stress_(example,_Barthelemy_2016)._Therefore,_this_report_does_not_allow_convincing_conclusions_about_the_variant_effect._As_of_this_evaluation,_14_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation_(pathogenic,_n
NM_032043.2:c.2273dup	BRIP1	frameshift_variant	102558	1	NA	NA	-	-	-	-	128170	133627	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59820480dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	587780236	-	Ambry_Genetics|Color|GeneDx|Counsyl|Invitae	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-04-09|2018-03-25|2016-05-13|2016-11-18|2017-12-15	2020-02-26|2018-11-06|2019-01-29|2017-06-22|2018-04-02	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline	SCV000216196|SCV000911175|SCV000150047|SCV000677798|SCV000757526	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_one_nucleotide_in_BRIP1_is_denoted_c.2273dupT_at_the_cDNA_level_and_p.Ala759SerfsX6_(A759SfsX6)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_braces,_is_CTGG[T]AGCA._The_duplication_causes_a_frameshift_which_changes_an_Alanine_to_a_Serine_at_codon_759,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ala759Serfs*6)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780236,_ExAC_0.001%)._This_variant_has_been_reported_in_an_individual_affected_with_prostate_cancer_(PMID:_27433846),_and_an_individual_affected_with_endometrial_cancer_(PMID:_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128170)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_032043.2:c.2255_2256del	BRIP1	frameshift_variant,splice_region_variant	102574	2	NA	NA	-	-	-	-	182372	180934	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59821795_59821796del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	730881649	-	Ambry_Genetics|Color|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-09-26|2015-03-05|2018-12-17|2018-03-29|2019-03-27|2016-04-18|2017-12-18	2020-02-26|2016-07-05|2019-03-28|2019-01-29|2020-03-06|2018-01-25|2018-06-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown	SCV000214477|SCV000292165|SCV000218635|SCV000210871|SCV001134013|SCV000699686|SCV000785827	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys752Argfs*12)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs730881649,_ExAC_0.003%)._This_variant_has_been_reported_in_an_individual_with_Fanconi_anemia_(PMID:_16116423),_and_in_individuals_with_ovarian_cancer_or_breast_cancer_(PMID:_26315354,_26681312,_26681682,_26976419)._This_variant_is_also_known_as_c.2255_2256delTT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182372)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_pathogenic_variant_is_denoted_BRIP1_c.2255_2256delAA_at_the_cDNA_level_and_p.Lys752ArgfsX12_(K752RfsX12)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GAGA[delAA]Ggta,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._The_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_an_Arginine_at_codon_752,_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRIP1_c.2255_2256delAA,_also_reported_as_BRIP1_c.2255delAA,_has_been_observed_in_individuals_with_breast_and/or_ovarian_cancer_as_well_as_in_the_compound_heterozygous_state_in_an_individual_with_Fanconi_Anemia_(Levitus_2005,_Seal_2006,_Ramus_2015,_Tung_2016)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|Variant_summary:_The_variant_of_interest_causes_a_frameshift_mutation_resulting_in_a_premature_termination_codon,_a_known_mechanism_for_disease,_as_these_types_of_variants_are_predicted_to_cause_transcript_degradation_through_nonsense_mediated_decay_or_produce_a_truncated_protein._The_variant_of_interest_was_observed_in_the_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_2/121342_(1/60679),_which_does_not_exceed_the_predicted_maximum_expected_allele_frequency_for_a_pathogenic_BRIP1_variant_of_1/16000._In_addition,_this_observation_needs_to_be_cautiously_considered_due_to_the_cohort_including_individuals_that_could_harbor_a_BRIP1_phenotype._The_variant_of_interest_has_been_reported_in_affected_individuals_with_varying_phenotypes_BrC,_OvC_and_FANCJ,_including_the_variant_of_interest_segregating_with_disease_(BrC)_within_one_family_(Seal_2006)._In_addition,_multiple_reputable_clinical_laboratories_cite_the_variant_with_a_classification_of_pathogenic._Therefore,_taking_all_available_lines_of_evidence_into_consideration,_the_variant_of_interest_is_classified_as_Pathogenic.|
NM_032043.2:c.2250del	BRIP1	frameshift_variant	102590	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.2223_2225dup	BRIP1	stop_gained	102578	1	NA	NA	-	-	-	-	530323	531376	_complementation_group_J	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59821825_59821827dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001587|nonsense	1	1310861578	-	Invitae	Pathogenic	2018-08-01	2019-03-28	_single_submitter	germline	SCV000757556	_complementation_group_J	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr742*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 530323)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_032043.2:c.2108_2109insCC	BRIP1	frameshift_variant	102414	2	15428	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.2012del	BRIP1	frameshift_variant	102598	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.2010dup	BRIP1	frameshift_variant	102618	2	NA	NA	-	-	-	-	187476	185251	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59853851dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001587|nonsense	1	775537066	-	Ambry_Genetics|Color|Invitae|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-07-09|2017-07-31|2018-12-11|2018-05-11|2018-09-05	2020-02-26|2017-12-21|2019-03-28|2019-01-29|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000218046|SCV000689305|SCV000261237|SCV000568500|SCV000917083	_complementation_group_J|not_provided|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu671*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs775537066,_ExAC_0.003%)._This_variant_has_been_reported_in_individuals_affected_with_breast,_ovarian,_and_peritoneal_cancer_(PMID:_17033622,_22006311,_26315354,_26921362)._This_variant_is_also_known_as_2008insT_and_2010insT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_187476)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_duplication_of_one_nucleotide_is_denoted_BRIP1_c.2010dupT_at_the_cDNA_level_and_p.Glu671Ter_(E671X)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_CATT[dupT]GAGT._The_duplication_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRIP1_c.2010dupT,_previously_reported_as_BRIP1_2008insT_or_2010insT,_has_been_observed_in_individuals_with_breast,_ovarian,_or_peritoneal_cancer_(Seal_2006,_Walsh_2011,_Ramus_2015,_Easton_2016)._We_consider_this_variant_to_be_pathogenic.|Variant_summary:_BRIP1_c.2010dupT_(p.Glu671X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.2255_2256delAA_(p.Lys752fsX12)_and_c.2400C>G_(p.Tyr800X))._The_variant_allele_was_found_at_a_frequency_of_1.2e-05_in_256542_control_chromosomes_(gnomAD)._c.2010dupT_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Easton_2016,_Hu_2018,_Ramus_2015,_Seal_2006,_Walsh_2011,_and_Weber-Lassalle_2018)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_ClinVar_submissions_from_other_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_032043.2:c.1970del	BRIP1	frameshift_variant	102638	2	NA	NA	-	-	-	-	461039	467156	_complementation_group_J	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59853891del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	760782298	-	Invitae|Color|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2018-11-08|2015-02-18|2019-04-12	2019-03-28|2017-12-21|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000633505|SCV000689301|SCV001174536	_complementation_group_J|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gly657Valfs*31)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_032043.2:c.1888dup	BRIP1	frameshift_variant	102732	1	NA	NA	-	-	-	-	491418	485060	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000017.10:g.59857669dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	763818712	-	Color	Pathogenic	2017-08-17	2017-12-21	_single_submitter	germline	SCV000689290	Hereditary_cancer-predisposing_syndrome	
NM_032043.2:c.1871C>A	BRIP1	stop_gained	102734	3	15396	1	5&5&5&5	1&1&1&1	rs587781321	Hereditary cancer-predisposing syndrome&Familial cancer of breast&Fanconi anemia, complementation group J&not provided	140852	150566	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59857686G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	587781321	-	Ambry_Genetics|Color|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-02-20|2017-04-11|2018-12-28|2017-10-04|2017-02-13|2017-04-05|2019-08-09	2020-02-26|2017-12-21|2019-03-28|2017-11-28|2017-08-01|2017-06-22|2019-09-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline	SCV000183760|SCV000689288|SCV000290992|SCV000210847|SCV000600895|SCV000677799|SCV000699678	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|not_provided|not_provided|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary|Hereditary_breast_and_ovarian_cancer_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser624*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781321,_ExAC_0.001%)._This_variant_has_been_reported_in_individuals_affected_with_ovarian_cancer_(PMID:_26315354,_26720728),_and_an_individual_affected_with_breast_cancer_(PMID:_26921362)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140852)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_variant_is_denoted_BRIP1_c.1871C>A_at_the_cDNA_level_and_p.Ser624Ter_(S624X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Ser624Ter,_also_reported_as_S624*,_was_observed_in_multiple_individuals_with_ovarian_or_breast_cancer_and/or_a_family_history_of_ovarian_or_breast_cancer_(Kanchi_2014,_Lu_2015,_Ramus_2015,_Thompson_2016)._This_variant_is_considered_pathogenic.|||Variant_summary:_BRIP1_c.1871C>A_(p.Ser624X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_2e-05_in_255438_control_chromosomes_(gnomAD)._The_variant,_c.1871C>A,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_breast-_and/or_ovarian_cancer_(Kanchi_2014,_LaDuca_2014,_Ramus_2015,_Thompson_2016,_Huang_2018)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_ClinVar_submissions_from_other_clinical_diagnostic_laboratories_(evaluation_after_2014)_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_032043.2:c.1853_1854insG	BRIP1	frameshift_variant	102738	1	NA	NA	-	-	-	-	141753	151467	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59857703_59857704insC	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Insertion	SO:0000667	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	587781985	-	Ambry_Genetics|Color|Counsyl|Counsyl|GeneDx|Invitae|Counsyl	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2017-04-03|2018-02-11|2016-10-11|2016-10-11|2017-04-04|2018-05-24|2016-10-11	2020-02-26|2018-11-06|2016-11-23|2016-11-23|2019-01-29|2018-08-29|2017-06-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|unknown|germline|germline|unknown	SCV000185241|SCV000905213|SCV000490036|SCV000490035|SCV000618393|SCV000633504|SCV000677802	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Neoplasm_of_ovary|Fanconi_anemia,_complementation_group_J|not_provided|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||This_insertion_of_one_nucleotide_in_BRIP1_is_denoted_c.1853_1854insG_at_the_cDNA_level_and_p.Pro619ThrfsX20_(P619TfsX20)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_inserted_in_brackets,_is_TATC[insG]ACCA._The_insertion_causes_a_frameshift_which_changes_a_Proline_to_a_Threonine_at_codon_619,_and_creates_a_premature_stop_codon_at_position_20_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRIP1_c.1853_1854insG_has_been_observed_in_an_individual_undergoing_hereditary_cancer_multigene_testing_(LaDuca_2017)._Based_on_the_currently_available_information,_we_consider_this_insertion_to_be_a_likely_pathogenic_variant.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Pro619Thrfs*20)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141753)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_032043.2:c.1795-2A>T	BRIP1	splice_acceptor_variant	102690	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.1741C>T	BRIP1	stop_gained	102720	1	NA	NA	-	-	-	-	434539	429997	Ovarian_Neoplasms|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_J|Breast_cancer,_early-onset|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:C4016951|MedGen:CN517202	-	NC_000017.10:g.59858254G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	780020495	-	Genetic_Services_Laboratory,_University_of_Chicago|Ambry_Genetics|Color|GeneDx|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|Invitae	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2016-12-05|2019-02-23|2015-02-23|2018-03-01|2018-12-01|2018-11-08	2017-07-05|2020-02-26|2018-11-06|2019-01-29|2019-02-22|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000593777|SCV000661553|SCV000904990|SCV000779508|SCV000923996|SCV000944714	Breast_cancer,_early-onset|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ovarian_Neoplasms|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J	|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_BRIP1_c.1741C>T_at_the_cDNA_level_and_p.Arg581Ter_(R581X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_with_breast_and_colorectal_cancer_(Tung_2015,_Sorscher_2016,_Weber-Lassalle_2018)_and_is_considered_likely_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg581*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs780020495,_ExAC_0.01%)._This_variant_has_been_observed_in_several_individuals_affected_with_breast_and_colon_cancer_(PMID:_25186627,_27462233,_29368626)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_434539)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_032043.2:c.1473+1G>T	BRIP1	splice_donor_variant	95752	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.1372G>T	BRIP1	stop_gained	101304	1	15424	0	5&5	1&1	rs587780228	Hereditary cancer-predisposing syndrome&not provided	128156	133613	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59871059C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:201835	-	BRIP1:83990	SO:0001587|nonsense	1	587780228	-	Ambry_Genetics|Color|GeneDx|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-29|2015-08-03|2019-01-17|2018-03-11|2018-09-03|2018-12-12|2018-05-25|2018-11-08	2020-02-26|2017-01-26|2019-01-29|2018-10-10|2020-03-06|2019-03-28|2018-06-20|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline	SCV000217717|SCV000537633|SCV000150032|SCV000885120|SCV001134002|SCV000547328|SCV000786535|SCV000919068	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_variant_is_denoted_BRIP1_c.1372G>T_at_the_cDNA_level_and_p.Glu458Ter_(E458X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_identified_in_individuals_with_personal_and/or_family_history_of_breast_and_ovarian_cancer_(Norquist_2015,_Susswein_2015,_Schoolmeester_2017)._We_consider_BRIP1_Glu458Ter_to_be_pathogenic.|The_BRIP1_c.1372G>T:_p.Glu458Ter_variant_(rs587780228),_is_reported_in_the_literature_in_individuals_with_a_clinical_history_of_ovarian_cancer,_breast_cancer,_glioblastoma,_or_colon_polyps_(Norquist_2016,_Susswein_2016)._This_variant_is_classified_as_pathogenic_by_several_laboratories_in_ClinVar_(Variation_ID:_128156)._It_is_observed_in_the_general_population_at_a_low_overall_allele_frequency_of_0.006%_(2/30950_alleles)_in_the_Genome_Aggregation_Database._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_pathogenic._REFERENCES_Norquist_BM_et_al._Inherited_Mutations_in_Women_With_Ovarian_Carcinoma._JAMA_Oncol._2016_Apr:2(4):482-90._Susswein_LR_et_al._Pathogenic_and_likely_pathogenic_variant_prevalence_among_the_first_10,000_patients_referred_for_next-generation_cancer_panel_testing._Genet_Med._2016_Aug:18(8):823-32.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_significantly_disrupt_the_protein_structure._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu458*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780228,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer,_ovarian_cancer,_or_glioblastoma_(PMID:_26681312,_26720728)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128156)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRIP1_c.1372G>T_(p.Glu458X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_6.5e-05_in_30950_control_chromosomes_(gnomAD)._The_variant,_c.1372G>T,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Norquist_2016,_Schoolmeester_2017,_Susswein_2015)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Five_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cites_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_032043.2:c.1315C>T	BRIP1	stop_gained	102520	1	NA	NA	4&5	1&2	rs587780226	not provided&Hereditary cancer-predisposing syndrome	128154	133611	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59876486G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	587780226	-	_University_of_Washington|Ambry_Genetics|Counsyl|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-03-21|2015-11-20|2018-04-27|2017-10-02|2018-12-28	2019-01-29|2016-03-03|2020-02-26|2018-06-20|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline	SCV000150030|SCV000266056|SCV000274380|SCV000785606|SCV000827963	not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J	This_pathogenic_variant_is_denoted_BRIP1_c.1315C>T_at_the_cDNA_level_and_p.Arg439Ter_(R439X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_individuals_with_breast_cancer,_as_well_as_in_an_individual_with_a_seminoma_(Frey_2015,_Schrader_2015,_Easton_2016,_Frey_2017)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg439*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:Â¬â€ 26681312)_and_colon_cancer_(PMID:Â¬â€ 26845104)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128154)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_032043.2:c.1240C>T	BRIP1	stop_gained	102498	1	NA	NA	5	1	rs368796923	Hereditary cancer-predisposing syndrome	141382	151096	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59876561G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	368796923	-	Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2018-09-11|2017-07-17|2016-09-13|2016-09-13|2018-12-03|2018-11-12|2018-10-31|2018-08-03	2020-02-26|2017-12-21|2016-11-23|2016-11-23|2019-01-29|2019-03-28|2018-11-14|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|unknown|germline|germline|unknown|germline	SCV000184695|SCV000689256|SCV000489993|SCV000489994|SCV000515873|SCV000830666|SCV000893464|SCV000919060	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_J|Neoplasm_of_ovary|not_provided|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_variant_is_denoted_BRIP1_c.1240C>T_at_the_cDNA_level_and_p.Gln414Ter_(Q414X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_identified_in_at_least_one_individual_undergoing_multi-gene_panel_testing_in_a_clinical_laboratory_(LaDuca_2017)_and_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln414*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs368796923,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141382)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRIP1_c.1240C>T_(p.Gln414X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.1871C>A_(p.Ser624X),_c.2255_2256delAA_(p.Lys752fsX12),_c.2392C>T_(p.Arg798X))._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_245868_control_chromosomes_(gnomAD)._The_variant,_c.1240C>T,_has_been_reported_in_the_literature_with_limited_information_(Hu_2018,_La_Duca_2017)._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_likely_pathogenic/pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic.
NM_032043.2:c.1236del	BRIP1	frameshift_variant	102516	1	15416	1	-	-	-	-	216128	213372	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59876566del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	863224525	-	Invitae|Ambry_Genetics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-02|2019-02-13|2018-12-24|2018-10-17	2019-03-28|2020-02-26|2019-01-29|2020-03-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000253956|SCV000275943|SCV000564812|SCV001134000	_complementation_group_J|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_deletes_1_nucleotide_from_exon_9_of_the_BRIP1_mRNA_(c.1236delA),_causing_a_frameshift_at_codon_413._This_creates_a_premature_translational_stop_signal_(p.Val413Phefs*10)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_ovarian_cancer_(PMID:_26315354)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification|This_deletion_of_one_nucleotide_in_BRIP1_is_denoted_c.1236delA_at_the_cDNA_level_and_p.Val413PhefsX10_(V413FfsX10)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_CAGA[delA]GTTC._The_deletion_causes_a_frameshift,_which_changes_a_Valine_to_a_Phenylalanine_at_codon_413_and_creates_a_premature_stop_codon_at_position_10_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRIP1_c.1236delA_has_been_reported_in_at_least_two_individuals_with_ovarian_cancer_(Norquist_2015,_Ramus_2015)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_significantly_disrupt_the_protein_structure._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_032043.2:c.909del	BRIP1	frameshift_variant	102086	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.633del	BRIP1	frameshift_variant	101784	4	NA	NA	-	-	-	-	232527	236391	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59886113del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	779466229	-	Ambry_Genetics|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic	2017-08-29|2018-04-09|2018-05-01	2020-02-26|2019-01-29|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000276684|SCV000779004|SCV000835302	_complementation_group_J	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_deletion_of_one_nucleotide_in_BRIP1_is_denoted_c.633delT_at_the_cDNA_level_and_p.Gly212AlafsX62_(G212AfsX62)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GCCCCC[delT]GGCC._The_deletion_causes_a_frameshift_which_changes_a_Glycine_to_an_Alanine_at_codon_212,_and_creates_a_premature_stop_codon_at_position_62_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRIP1_c.633delT_has_been_reported_in_association_with_ovarian_and_breast_cancer_(Mannan_2016,_Easton_2016)._We_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gly212Alafs*62)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs779466229,_ExAC_0.005%)._This_variant_has_been_reported_in_an_individual_affected_with_ovarian_cancer_(PMID:Â¬â€ 26911350)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_232527)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_032043.2:c.394dup	BRIP1	frameshift_variant	102510	2	NA	NA	-	-	-	-	140984	150698	_complementation_group_J	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59926608dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	587781416	-	Ambry_Genetics|Color|Invitae	Pathogenic|Pathogenic|Pathogenic	2018-09-25|2014-12-05|2018-12-17	2020-02-26|2018-11-06|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000184043|SCV000911639|SCV000757544	_complementation_group_J	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Thr132Asnfs*10)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ovarian_cancer_(PMID:_26315354,_26720728)._This_variant_is_also_known_as_c.394insA_(p.T132fs)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140984)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_032043.2:c.379+1G>C	BRIP1	splice_donor_variant	102658	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.285del	BRIP1	frameshift_variant	102728	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.206-2A>G	BRIP1	splice_acceptor_variant	102342	1	NA	NA	-	-	-	-	187396	185321	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59934594T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001574|splice_acceptor_variant	1	786203700	-	Ambry_Genetics|Color|GeneDx|Invitae|Counsyl	Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-06-04|2018-10-31|2018-09-13|2018-04-15|2016-12-22	2020-02-26|2018-11-06|2019-01-29|2018-08-29|2017-06-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000217950|SCV000903619|SCV000279366|SCV000633507|SCV000677820	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:RNA_Studies||This_variant_is_denoted_BRIP1_c.206-2A>G_or_IVS3-2A>G_and_consists_of_an_A>G_nucleotide_substitution_at_the_-2_position_of_intron_3_of_the_BRIP1_gene._The_variant_destroys_a_canonical_splice_acceptor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_reported_in_at_least_one_individual_with_ovarian_cancer_(Norquist_2016),_but_has_also_been_observed_in_one_control_(Weber-Lassalle_2018)._Based_on_currently_available_evidence,_we_consider_BRIP1_c.206-2A>G_to_be_a_likely_pathogenic_variant.|This_sequence_change_affects_an_acceptor_splice_site_in_intron_3_of_the_BRIP1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_ovarian_cancer_(PMID:_26720728)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_187396)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_032043.2:c.193C>T	BRIP1	stop_gained	102662	3	NA	NA	-	-	-	-	479463	479227	_complementation_group_J|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59937169G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	575595017	-	Ambry_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Invitae|GeneDx	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2018-01-03|2016-08-01|2017-08-15|2018-01-11	2020-02-26|2018-01-25|2018-04-02|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000661579|SCV000699680|SCV000757611|SCV000779477	_complementation_group_J|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|Variant_summary:_The_BRIP1_c.193C>T_(p.Gln65X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRIP1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.1871C>A,_p.Ser624X:_c.2255_2256delAA,_p.Lys752fsX12:_c.2392C>T,_p.Arg798X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_4/121242_control_chromosomes_at_a_frequency_of_0.000033,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRIP1_variant_(0.0000625)._The_variant_of_interest_has_not,_to_our_knowledge,_been_reported_in_affected_individuals_via_publications_and/or_reputable_databases/clinical_diagnostic_laboratories:_nor_evaluated_for_functional_impact_by_in_vivo/vitro_studies._Taken_together,_this_variant_is_classified_as_likely_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln65*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs575595017,_ExAC_0.01%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_variant_is_denoted_BRIP1_c.193C>T_at_the_cDNA_level_and_p.Gln65Ter_(Q65X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_pathogenic.
NM_032043.2:c.128_131del	BRIP1	frameshift_variant	102696	1	NA	NA	-	-	-	-	419951	410163	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000017.10:g.59937232_59937235ACAA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Microsatellite	SO:0000289	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	1064794202	-	GeneDx|Ambry_Genetics	Likely_pathogenic|Pathogenic	2015-11-12|2018-07-20	2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000568180|SCV001170959	not_provided|Hereditary_cancer-predisposing_syndrome	This_deletion_of_4_nucleotides_in_BRIP1_is_denoted_c.128_131delTGTT_at_the_cDNA_level_and_p.Leu43TrpfsX11(L43WfsX11)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_TGTT[TGTT]GGAG._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_a_Tryptophan_at_codon_43,_and_creates_a_premature_stop_codon_at_position_11_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRIP1_c.128_131delTGTT_has_been_reported_in_an_individual_with_several_family_members_affected_with_ovarian_cancer_(Ramus_2015)._Based_on_the_current_evidence,_we_consider_this_variant_to_be_likely_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_032043.2:c.24T>A	BRIP1	stop_gained	102638	1	NA	NA	5	1	rs752411477	Hereditary cancer-predisposing syndrome	231431	236434	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000017.10:g.59938877A>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	752411477	-	Ambry_Genetics	Pathogenic	2015-04-22	2020-02-26	_single_submitter	germline	SCV000275276	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000455.4:c.493G>T	STK11	stop_gained	95730	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000455.4:c.1283C>A	STK11	stop_gained	51768	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.-14-1G>T	SEC23B	splice_acceptor_variant	102262	3	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.71G>A	SEC23B	stop_gained	102734	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.222_225del	SEC23B	splice_acceptor_variant,coding_sequence_variant,intron_variant	101386	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.222-1G>C	SEC23B	splice_acceptor_variant	101736	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.235C>T	SEC23B	stop_gained	101954	3	15428	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.246_247del	SEC23B	frameshift_variant	102074	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.367-1G>A	SEC23B	splice_acceptor_variant	102596	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.367C>T	SEC23B	stop_gained,splice_region_variant	102598	6	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.387del	SEC23B	frameshift_variant	102676	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.568C>T	SEC23B	stop_gained	102724	2	15420	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.576del	SEC23B	frameshift_variant	102726	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.584dup	SEC23B	frameshift_variant	102726	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.597_598del	SEC23B	frameshift_variant	102712	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.640C>T	SEC23B	stop_gained	102650	3	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.649C>T	SEC23B	stop_gained	102652	10	15326	5	5&5	0&1	rs121918226	Congenital dyserythropoietic anemia, type II&not provided	1227	16266	_type_II|not_provided	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007|MedGen:CN517202	-	NC_000020.10:g.18505624C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	HGMD:CM094614|OMIM_Allelic_Variant:610512.0006	-	SEC23B:10483	SO:0001587|nonsense	1	121918226	-	Eurofins_Clinical_Diagnostics	Pathogenic|Pathogenic	2009-09-01|2014-01-30	2018-07-11|2018-09-19	_single_submitter	germline|germline	SCV000021436|SCV000203543	_type_II|not_provided	|
NM_006363.4:c.689+1G>A	SEC23B	splice_donor_variant	102672	4	15370	1	-	-	-	-	95389	101288	_type_II|Cowden_syndrome_7|not_provided	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007|MedGen:C4225179,OMIM:616858|MedGen:CN517202	-	NC_000020.10:g.18505665G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	HGMD:CS094627	-	SEC23B:10483	SO:0001575|splice_donor_variant	1	398124226	-	Eurofins_Clinical_Diagnostics|Invitae	Pathogenic|Pathogenic	2012-09-05|2017-10-13	2018-09-19|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000113340|SCV000817517	_type_II/Cowden_syndrome_7	|This_sequence_change_affects_a_donor_splice_site_in_intron_6_of_the_SEC23B_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs398124226,_ExAC_0.006%)._This_variant_has_been_reported_in_the_compound_heterozygous_state_in_individuals_affected_with_congenital_dyserythropoietic_anemia_type_II_(PMID:_19561605,_19621418)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_95389)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_SEC23B_are_known_to_be_pathogenic_(PMID:_19561605,_25044164)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_006363.4:c.748C>T	SEC23B	stop_gained	102724	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.790C>T	SEC23B	stop_gained	102708	3	15432	0	5	0	rs121918224	Congenital dyserythropoietic anemia, type II	1225	16264	_type_II	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007	-	NC_000020.10:g.18506532C>T	no_assertion_criteria_provided	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:610512.0004	-	SEC23B:10483	SO:0001587|nonsense	1	121918224	-	OMIM	Pathogenic	2009-08-01	2015-07-01	no_assertion_criteria_provided	germline	SCV000021434	_type_II	
NM_006363.4:c.835-2A>G	SEC23B	splice_acceptor_variant	102734	6	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.923T>G	SEC23B	stop_gained	102744	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.970C>T	SEC23B	stop_gained	102608	6	15426	5	5	0	rs121918225	Congenital dyserythropoietic anemia, type II	1226	16265	_type_II	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007	-	NC_000020.10:g.18507152C>T	no_assertion_criteria_provided	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:610512.0005	-	SEC23B:10483	SO:0001587|nonsense	1	121918225	-	_University_of_Cambridge	Pathogenic|Likely_pathogenic	2009-08-01|0000-00-00	2018-07-11|2019-09-13	no_assertion_criteria_provided|no_assertion_criteria_provided	germline|unknown	SCV000021435|SCV001162260	Congenital_dyserythropoietic_anemia,_type_II|Congenital_dyserythropoietic_anemia,_type_II	|
NM_006363.4:c.1015C>T	SEC23B	stop_gained	102722	5	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1201C>T	SEC23B	stop_gained	102538	1	15364	1	-	-	-	-	632368	620652	_type_II	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007	-	NC_000020.10:g.18511415C>T	_single_submitter	Uncertain_significance	-	-	single_nucleotide_variant	SO:0001483	Illumina:603545	-	SEC23B:10483	SO:0001587|nonsense	1	1403456625	-	Illumina	Uncertain_significance	2018-10-31	2019-02-01	_single_submitter	germline	SCV000915933	_type_II	The_SEC23B_c.1201C>T_(p.Arg401Ter)_variant_is_a_stop-gained_variant_that_is_predicted_to_result_in_a_premature_termination_of_the_protein._The_p.Arg401Ter_variant_has_been_reported_in_at_least_two_studies,_in_which_it_is_found_in_a_compound_heterozygous_state_with_a_second_missense_variant_in_two_related_individuals_with_congenital_dyserythropoietic_anemia_(Schwarz_et_al._2009:_Iolascon_et_al._2010)._Control_data_are_unavailable_for_this_variant,_which_is_reported_at_a_frequency_of_0.000011_in_the_Total_population_of_the_Genome_Aggregation_Database._Expression_studies_showed_<5%_of_wildtype_expression_for_the_variant_protein_in_transient_transfections._Based_on_the_predicted_truncating_nature_of_the_variant_and_the_supporting_evidence,_the_p.Arg401Ter_variant_is_classified_as_a_variant_of_unknown_significance_but_suspicious_for_congenital_dyserythropoietic_anemia._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_006363.4:c.1512-2A>T	SEC23B	splice_acceptor_variant	102732	3	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1512-1G>T	SEC23B	splice_acceptor_variant	102730	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1603C>T	SEC23B	stop_gained	102726	4	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1648_1654del	SEC23B	frameshift_variant	102698	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1648C>T	SEC23B	stop_gained	102694	7	15422	0	5	1	rs199939108	not provided	167668	177037	not_provided	-	MedGen:CN517202	-	NC_000020.10:g.18523799C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	HGMD:CM102635	-	SEC23B:10483	SO:0001587|nonsense	1	199939108	-	Eurofins_Clinical_Diagnostics	Pathogenic	2014-01-23	2018-09-19	_single_submitter	germline	SCV000203546	not_provided	
NM_006363.4:c.1660C>T	SEC23B	stop_gained	102676	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1710dup	SEC23B	frameshift_variant	102714	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1818dup	SEC23B	frameshift_variant	102732	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1887del	SEC23B	frameshift_variant	102726	1	NA	NA	-	-	-	-	809228	797954	not_provided	-	MedGen:CN517202	-	NC_000020.10:g.18529396del	_single_submitter	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	SEC23B:10483	SO:0001589|frameshift_variant	1	-	-	CeGaT_Praxis_fuer_Humangenetik_Tuebingen	Likely_pathogenic	2019-04-01	2019-07-12	_single_submitter	germline	SCV001153437	not_provided	
NM_006363.4:c.1909del	SEC23B	frameshift_variant	102050	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.1989dup	SEC23B	frameshift_variant	102128	2	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.2062C>T	SEC23B	stop_gained	102728	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.2074_2077dup	SEC23B	frameshift_variant	102724	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.2083C>T	SEC23B	stop_gained	102724	4	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.2148+1G>A	SEC23B	splice_donor_variant	102728	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.2152C>T	SEC23B	stop_gained	102690	1	15418	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.2207G>A	SEC23B	stop_gained	102736	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_006363.4:c.2214+2T>C	SEC23B	splice_donor_variant	102726	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.1462-2A>G	CHEK2	splice_acceptor_variant	100024	1	NA	NA	-	-	-	-	142596	152310	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29085205T>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001574|splice_acceptor_variant	1	587782575	-	Ambry_Genetics|Color|Invitae	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2017-05-04|2018-09-02|2018-02-06	2020-02-26|2018-11-06|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000186856|SCV000684597|SCV000633137	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity||This_sequence_change_affects_an_acceptor_splice_site_in_intron_13_of_the_CHEK2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_three_individuals_who_underwent_genetic_testing_for_hereditary_cancer_(PMID:_24763289,_27751358)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142596)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_007194.3:c.1375+1_1375+2del	CHEK2	splice_donor_variant	102358	1	NA	NA	-	-	-	-	234023	236607	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29091113_29091114del	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001575|splice_donor_variant	1	876660801	-	Ambry_Genetics|Invitae	Likely_pathogenic|Likely_pathogenic	2019-01-28|2018-10-21	2020-02-26|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000278506|SCV000964756	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|This_sequence_change_affects_a_donor_splice_site_in_intron_12_of_the_CHEK2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234023)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_007194.3:c.1368dup	CHEK2	frameshift_variant	102384	4	NA	NA	-	-	-	-	182450	181095	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|CHEK2-Related_Cancer_Susceptibility|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29091122dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	730881700	-	Ambry_Genetics|Color|GeneDx|Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Snyder_Lab,_Genetics_Department,Stanford_University	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2018-10-05|2015-11-02|2018-05-09|2019-01-05|2017-01-09|2018-02-02|2017-01-01	2020-02-26|2017-10-26|2019-01-29|2019-03-28|2017-06-22|2019-04-24|2018-10-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|unknown|germline|germline	SCV000215087|SCV000684584|SCV000211014|SCV000550523|SCV000677807|SCV000917230|SCV000853094	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|CHEK2-Related_Cancer_Susceptibility	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_one_nucleotide_in_CHEK2_is_denoted_c.1368dupA_at_the_cDNA_level_and_p.Glu457ArgfsX33_(E457RfsX33)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_TCTC[dupA]GAGA._The_duplication_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_an_Arginine_at_codon_457,_and_creates_a_premature_stop_codon_at_position_33_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._CHEK2_c.1368dupA_has_been_reported_in_at_least_one_individual_with_breast_cancer_(Tung_2016)._We_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu457Argfs*33)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs730881700,_ExAC_0.02%)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer_(PMID:_26681312,_26976419,Â¬â€ 28724667)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182450)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_CHEK2_c.1368dupA_(p.Glu457ArgfsX33)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._At_least_one_publication_reports_experimental_evidence_evaluating_an_impact_on_protein_function,_which_demonstrated_that_the_truncated_protein_product_is_localizes_exclusively_to_the_cytoplasm,_suggesting_the_1368dupA_mutant_to_be_nonfunctional,_as_the_main_substrates_for_CHK2_phosphorylation_are_located_in_the_nucleus_(Staalesen_2004)._The_variant_allele_was_found_at_a_frequency_of_2.4e-05_in_245848_control_chromosomes._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_CHEK2_causing_Hereditary_Breast_and_Ovarian_Cancer_(2.4e-05_vs_0.00031),_allowing_no_conclusion_about_variant_significance:_moreover_pseudogene_interference_might_also_affect_the_validity_of_these_frequency_results._c.1368dupA_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Tung_2016,_Susswein_2016,_Leedom_2016)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014._All_laboratories_classified_the_variant_as_pathogenic/likely_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|
NM_007194.3:c.1334dup	CHEK2	stop_gained,frameshift_variant	102392	1	NA	NA	-	-	-	-	818971	815035	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000022.10:g.29091156dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	CHEK2:11200	SO:0001587|nonsense	1	-	-	Ambry_Genetics	Pathogenic	2019-02-07	2020-02-26	_single_submitter	germline	SCV001171392	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_007194.3:c.1263del	CHEK2	frameshift_variant	102090	9	15424	1	-	-	-	-	128053	133510	Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|CHEK2-Related_Cancer_Susceptibility|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29091228del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	Illumina:686221|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2842216	-	CHEK2:11200	SO:0001589|frameshift_variant	1	587780174	-	Ambry_Genetics|Color|True_Health_Diagnostics|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Invitae|Counsyl|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|Illumina_Clinical_Services_Laboratory,Illumina	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2018-07-31|2014-12-22|2018-01-12|2018-01-26|2019-01-16|2016-07-05|2018-11-08|2017-12-27|2017-01-26|2018-11-01	2020-02-26|2017-10-26|2018-03-08|2018-04-23|2019-03-28|2016-11-23|2019-01-29|2018-08-31|2018-01-25|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline	SCV000172936|SCV000684579|SCV000788000|SCV000992227|SCV000253898|SCV000488848|SCV000149901|SCV000888101|SCV000698766|SCV000915967	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|CHEK2-Related_Cancer_Susceptibility	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser422Valfs*15)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780174,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_affected_with_breast,_prostate,_bladder,_colon_and_urethral_cancer_(PMID:_21244692,_24113346,_24556621,_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128053)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_CHEK2_c.1263delT_at_the_cDNA_level_and_p.Ser422ValfsX15_(S422VfsX15)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_gCCT[delT]AGTG,_where_the_capital_letters_are_exonic_and_the_lowercase_is_intronic._The_deletion_causes_a_frameshift,_which_changes_a_Serine_to_a_Valine_at_codon_422,_and_creates_a_premature_stop_codon_at_position_15_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._CHEK2_c.1263delT_has_been_reported_in_individuals_with_breast_cancer_and_prostate_cancer_(Le_Calvez-Kelm_2011,_Mauer_2014,_Leongamornlert_2014,_Byers_2016,_Li_2016,_Wu_2018)._We_consider_this_variant_to_be_pathogenic.||Variant_summary:_The_CHEK2_c.1263delT_(p.Ser422Valfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_CHEK2_protein_due_to_nonsense_mediated_decay_(NMD),_which_are_commonly_known_mechanisms_for_disease._If_NMD_is_escaped,_this_variant_is_expected_to_truncate_protein_kinase_domain._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic/likely_pathogenic_by_our_laboratory_and_others_(e.g._p.Arg519X,_c.1434delA,_etc.)._This_variant_was_found_in_6/117456_control_chromosomes_at_a_frequency_of_0.0000511,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_CHEK2_variant_(0.0003125)._This_variant_has_been_reported_in_multiple_cancer_patients_including_breast_and_prostate_cancer_and_is_classified_as_pathogenic_in_literature_and_by_multiple_clinical_diagnostic_laboratories/reputable_databases._Taken_together,_this_variant_is_classified_as_Pathogenic.|The_CHEK2_c.1263delT_(p.Ser422ValfsTer15)_variant_results_in_a_frameshift_and_is_predicted_to_result_in_premature_termination_of_the_protein._The_p.Ser422ValfsTer15_variant_has_been_reported_in_at_least_six_studies_in_at_least_25_individuals_undergoing_hereditary_cancer_testing_or_diagnosed_with_various_cancer_types_(La_Calvez-Kelm_et_al._2011:_Leongamornlert_et_al._2014:_Mauer_et_al._2014:_Susswein_et_al._2015:_Byers_et_al._2016:_Leedom_et_al._2016)._Control_data_are_unavailable_for_this_variant,_which_is_reported_at_a_frequency_of_0.00010_in_the_European_(non-Finnish)_population_of_the_Genome_Aggregation_Database._Due_to_the_potential_impact_of_frameshift_variants,_the_p.Ser422ValfsTer15_variant_is_classified_as_likely_pathogenic_for_CHEK2-related_cancer_susceptibility._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_007194.3:c.1260C>A	CHEK2	stop_gained,splice_region_variant	102018	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.1232G>A	CHEK2	stop_gained	101984	2	NA	NA	4	1	rs371418985	not provided	234505	232124	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29091725C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001587|nonsense	1	371418985	-	GeneDx|Color|Ambry_Genetics|GeneKor_MSA|Invitae|Counsyl|Mendelics	Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2016-11-14|2016-08-29|2018-02-02|2018-08-01|2018-12-31|2017-04-18|2019-05-28	2017-07-13|2017-01-26|2020-02-26|2018-08-08|2019-03-28|2017-06-22|2019-10-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown	SCV000279396|SCV000537650|SCV000581179|SCV000821723|SCV000550559|SCV000677827|SCV001141352	not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast	This_variant_is_denoted_CHEK2_c.1232G>A_at_the_cDNA_level_and_p.Trp411Ter_(W411X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tryptophan_to_a_premature_stop_codon_(TGG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_likely_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Trp411*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234505)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||
NM_007194.3:c.1197dup	CHEK2	frameshift_variant	102348	1	NA	NA	-	-	-	-	479562	480081	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000022.10:g.29091761dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	876658302	-	Ambry_Genetics	Pathogenic	2016-06-07	2020-02-26	_single_submitter	germline	SCV000661745	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_007194.3:c.1139_1140del	CHEK2	frameshift_variant	102322	1	NA	NA	-	-	-	-	409999	403829	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29091818_29091819AG[2]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	1060502684	-	Invitae|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-02|2016-08-12|2017-09-18|2017-09-06	2018-08-29|2017-08-01|2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000550425|SCV000601145|SCV000778921|SCV000669300	Familial_cancer_of_breast|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu380Hisfs*14)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_21244692,_24549055,_19768534)._This_variant_is_also_known_as_c.1138delCT_andÂ¬â€ c.1140_1141delTCÂ¬â€ (p.L380fsX393)Â¬â€ in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_409999)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_deletion_of_two_nucleotides_in_CHEK2_is_denoted_c.1139_1140delTC_at_the_cDNA_level_and_p.Leu380HisfsX14_(L380HfsX14)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TCTC[delTC]ATGA._The_deletion_causes_a_frameshift_which_changes_a_Leucine_to_a_Histidine_at_codon_380,_and_creates_a_premature_stop_codon_at_position_14_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._CHEK2_c.1139_1140delTC,_also_reported_as_CHEK2_c.1268_1269delTC_(p.L423HfsX14)_or_c.1138delCT_(p.L380fs)_by_alternate_nomenclature,_has_been_observed_in_patients_undergoing_genetic_testing_for_hereditary_breast_and_ovarian_cancer_(Le_Calvez-Kelm_2011,_Castera_2014)._We_consider_this_variant_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_007194.3:c.1100del	CHEK2	frameshift_variant	101470	261	15432	41	-	-	-	-	128042	133499	Prostate_cancer,_susceptibility_to|Thrombocytopenia|Inflammation_of_the_large_intestine|Hematochezia|Colitis|Osteosarcoma|Astrocytoma|Malignant_tumor_of_prostate|Neoplasm_of_the_breast|Leiomyosarcoma|Ovarian_Neoplasms|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Hereditary_cancer|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|B_Lymphoblastic_Leukemia/Lymphoma,_Not_Otherwise_Specified|Diffuse_intrinsic_pontine_glioma|Breast_cancer,_susceptibility_to|not_specified|CHEK2-Related_Cancer_Susceptibility|not_provided	-	.|Human_Phenotype_Ontology:HP:0001873,MedGen:C0040034|Human_Phenotype_Ontology:HP:0002037,MedGen:C0578878|Human_Phenotype_Ontology:HP:0002573,MedGen:C0018932|Human_Phenotype_Ontology:HP:0002583,MedGen:C0009319|Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0009592,MeSH:D001254,MedGen:C0004114,Orphanet:ORPHA94,SNOMED_CT:38713004|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100243,MedGen:C0023269,Orphanet:ORPHA64720|MeSH:D010051,MedGen:CN236629|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C1333600|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C2698310|MedGen:C2986658|MedGen:C3469522|MedGen:CN169374|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29091857del	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:146783|Illumina_Clinical_Services_Laboratory,Illumina:719494|OMIM_Allelic_Variant:604373.0001|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2829863	-	CHEK2:11200	SO:0001589|frameshift_variant	3	555607708	-	OMIM|OMIM|Ambry_Genetics|Color|True_Health_Diagnostics|GeneKor_MSA|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Invitae|Pathway_Genomics|Counsyl|Mendelics|OMIM|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|GenomeConnect,_ClinGen|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Genome_Sciences_Centre,British_Columbia_Cancer_Agency|OMIM|Genetic_Services_Laboratory,_University_of_Chicago|GenomeConnect,_ClinGen|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_of_Molecular_Neuropathology,The_University_of_Texas_Health_Science_Center_at_Houston|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Illumina_Clinical_Services_Laboratory,Illumina|CHLA_Center_for_Personalized_Medicine,Children's_Hospital,_Los_Angeles|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|risk_factor|Pathogenic|not_provided|Pathogenic|Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2006-11-01|2006-11-01|2019-03-28|2015-02-17|2017-11-14|2018-08-01|2018-01-26|2019-01-11|2014-07-24|2016-01-20|2018-07-02|2006-11-01|2015-11-20|2018-08-28|2016-07-05|0000-00-00|2016-05-31|0000-00-00|0000-00-00|0000-00-00|2006-11-01|2016-08-29|0000-00-00|2017-05-18|2019-07-25|0000-00-00|2015-03-10|2017-04-27|0000-00-00|2016-10-05|2016-11-28|2018-12-01|2018-07-26	2017-11-21|2017-11-21|2020-02-26|2016-07-05|2018-03-08|2018-08-08|2018-04-23|2019-03-28|2014-08-08|2016-11-23|2018-08-20|2017-11-21|2016-03-03|2019-01-29|2018-08-31|2017-10-31|2018-01-29|2018-03-13|2016-12-06|2017-05-08|2017-11-21|2017-07-05|2017-08-22|2017-05-23|2019-09-24|2018-03-26|2019-03-21|2019-02-01|2018-11-19|2018-12-04|2018-12-04|2019-02-22|2019-08-05	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|unknown|germline|unknown|germline|germline|germline|germline|unknown|unknown|germline|somatic|germline|germline|germline|germline|germline|germline|germline	SCV000026114|SCV000026116|SCV000187220|SCV000292118|SCV000787999|SCV000821726|SCV000992228|SCV000166572|SCV000189922|SCV000488123|SCV000839467|SCV000026117|SCV000266067|SCV000149889|SCV000601142|SCV000691834|SCV000806862|SCV000840164|SCV000492465|SCV000574565|SCV000026115|SCV000594116|SCV000607207|SCV000611258|SCV000698761|SCV000692550|SCV000711416|SCV000915968|SCV000854533|SCV000891024|SCV000891063|SCV000924001|SCV000603087	Li-Fraumeni_syndrome_2|Prostate_cancer,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|not_provided|not_provided|Neoplasm_of_the_breast|Neoplasm_of_the_breast/Leiomyosarcoma|Breast_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|Hereditary_cancer|Familial_cancer_of_breast/Li-Fraumeni_syndrome_2/Osteosarcoma/Malignant_tumor_of_prostate|Li-Fraumeni_syndrome|Astrocytoma|CHEK2-Related_Cancer_Susceptibility|CHEK2-Related_Cancer_Susceptibility|Colitis/Inflammation_of_the_large_intestine/Hematochezia/Thrombocytopenia|Diffuse_intrinsic_pontine_glioma|B_Lymphoblastic_Leukemia/Lymphoma,_Not_Otherwise_Specified|Ovarian_Neoplasms|not_specified	||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification:Significant_disease_association_in_appropriately_sized_case-control_study(ies)||||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|This_sequence_change_deletes_1_nucleotide_from_exon_11_of_the_CHEK2_mRNA_(c.1100delC),_causing_a_frameshift_at_codon_367._This_creates_a_premature_translational_stop_signal_(p.Thr367Metfs*15)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic._This_particular_variant_has_been_well_described_in_the_literature._In_a_large_meta-analysis_comprising_16_studies_including_26,488_affected_individuals_and_27,402_controls,_women_heterozygous_for_this_variant_have_a_relative_risk_for_familial_breast_cancer_of_4.8_(95%_CI,_3.3-7.2)._The_cumulative_risk_at_age_70_years_is_37%_(95%_CI,_26%-56%),_compared_to_7.8%_for_the_average_Caucasian_woman_in_the_general_population_(PMID:_18172190)._Although_one_study_has_reported_that_the_c.1100delC_variant_confers_an_approximate_10-fold_increased_risk_of_male_breast_cancer_(PMID:Â¬â€ 11967536),_the_results_have_yet_to_be_confirmed_in_further_studies_(PMID:_14648717,_14648718,_14648719,_15488637)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||||This_pathogenic_variant_is_denoted_CHEK2_c.1100delC_at_the_cDNA_level_and_p.Thr367MetfsX15_(T367MfsX15)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ATTA[delC]TGAT._The_deletion_causes_a_frameshift,_which_changes_a_Threonine_to_a_Methionine_at_codon_367_and_creates_a_premature_stop_codon_at_position_15_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._In_vitro_functional_analyses_have_found_that_CHEK2_c.1100delC_results_in_loss_of_kinase_activity_and_the_inability_to_phosphorylate_Cdc25C,_supportive_of_a_pathogenic_effect_(Lee_2001,_Wu_2001)._Although_present_in_approximately_0.5_-_1%_of_healthy_European_individuals_(Meijers-Heijboer_2002,_Neuhausen_2004,_Wasielewski_2009,_Schmidt_2016),_based_on_functional_studies_and_the_case-control_data_summarized_below,_CHEK2_c.1100delC_is_considered_pathogenic._CHEK2_c.1100delC_is_associated_with_an_increased_risk_for_certain_cancers,_including_breast,_colon,_prostate,_and_others_as_described_below._The_National_Comprehensive_Cancer_Network_has_management_guidelines_for_individuals_with_pathogenic_variants_in_CHEK2_(NCCN)._Breast_Cancer:_CHEK2_c.1100delC_is_considered_a_breast_cancer_susceptibility_allele_in_Western_Populations_by_The_CHEK2_Breast_Cancer_Case-Control_Consortium_and_is_observed_at_higher_frequencies_among_breast_cancer_cases,_with_an_odds_ratio_(OR)_of_approximately_2.3-3.3_in_sporadic_or_unselected_cases,_and_3.1-4.2_in_familial_cases,_depending_on_strength_of_family_history_(The_CHEK2_Breast_Cancer_Consortium_2004,_Desrichard_2011,_Schmidt_2016,_Couch_2017,_Decker_2017)._Compared_with_breast_cancer_patients_without_CHEK2_c.1100delC,_women_who_carried_the_pathogenic_variant_had_higher_rates_of_a_second_breast_cancer,_particularly_if_the_first_was_estrogen-receptor_positive_(Weischer_2012,_Muranen_2016)._Although_previous_studies_have_not_observed_a_statistically_significant_association_with_male_breast_cancer_(Syrjakoski_2003,_Ohayon_2004,_Neuhausen_2004,_Falchetti_2008),_recent_reports,_including_a_large_meta-analysis,_indicate_a_statistically_higher_incidence_of_breast_cancer_in_men_with_c.1100delC_(Hallamies_2017,_Pritzlaff_2017,_Liang_2018)._Colon_and_Prostate_Cancer:_Earlier_studies_did_not_show_a_statistically_significant_association_for_CHEK2_c.1100delC_with_colorectal_cancer_(CRC)_(Kilpivaara_2003,_Djureinovic_2006,_Kleibl_2008)._However,_data_from_recent_large_meta-analyses_may_suggest_an_association_supported_by_a_modestly_elevated_OR_(approximately_1.8)_in_unselected_CRC_cases_(Ma_2014,_Katona_2017)._CHEK2_c.1100delC_has_previously_been_associated_with_familial_prostate_cancer_with_varying_odds_ratios_and_wide_confidence_intervals_(Seppala_2003,_Cybulski_2006)._A_meta-analysis_of_five_studies_with_independent_data_reported_an_increased_risk_for_prostate_cancer_in_men_with_CHEK2_c.1100delC_in_both_unselected_(OR
NM_007194.3:c.1011C>A	CHEK2	stop_gained,splice_region_variant	102536	1	NA	NA	5	1	rs760502479	Hereditary cancer-predisposing syndrome	185370	185605	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29092973G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001627|intron_variant	1	760502479	-	Ambry_Genetics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-07-11|2017-10-23|2017-07-20|2018-12-28	2020-02-26|2019-01-29|2017-08-01|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000215455|SCV000516126|SCV000601139|SCV000633081	Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_pathogenic_variant_is_denoted_CHEK2_c.1011C>A_at_the_cDNA_level_and_p.Tyr337Ter_(Y337X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_at_least_one_individual_undergoing_multi-gene_panel_testing_(LaDuca_2017)._This_variant_is_considered_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr337*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs760502479,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185370)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.1009-2A>G	CHEK2	splice_acceptor_variant	102530	1	NA	NA	-	-	-	-	428913	420730	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29092977T>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001627|intron_variant	1	766158073	-	Ambry_Genetics|Invitae	Likely_pathogenic|Likely_pathogenic	2016-08-29|2017-07-24	2020-02-26|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000581181|SCV000828483	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|This_sequence_change_affects_an_acceptor_splice_site_in_intron_9_of_the_CHEK2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs766158073,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_007194.3:c.915_924del	CHEK2	frameshift_variant	102728	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.902del	CHEK2	frameshift_variant	79282	1	NA	NA	-	-	-	-	185097	185613	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29099502del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	748005072	-	Ambry_Genetics|GeneKor_MSA|Color|GeneDx|Counsyl|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-04-17|2018-08-01|2018-05-29|2015-08-04|2017-04-11|2018-08-07	2020-02-26|2018-08-08|2018-11-06|2017-11-28|2017-06-22|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline	SCV000215101|SCV000821731|SCV000904453|SCV000567594|SCV000677815|SCV000933492	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_deletion_of_one_nucleotide_in_CHEK2_is_denoted_c.902delT_at_the_cDNA_level_and_p.Leu301TrpfsX3_(L301WfsX3)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_GTTT[T]GGAA._The_deletion_causes_a_frameshift,_which_changes_a_Leucine_to_a_Tryptophan_at_codon_301,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._CHEK2_c.902delT_has_been_observed_in_at_least_one_individual_with_a_personal_and_family_history_of_breast_cancer_(Cybulski_2014)._we_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Leu301Trpfs*3)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_observed_in_an_individual_affected_with_breast_cancer_(PMID:Â¬â€ 25330149)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185097)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.876del	CHEK2	frameshift_variant	88374	1	NA	NA	-	-	-	-	234765	232130	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29099530del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	772683219	-	GeneDx|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2017-05-10|2018-06-04|2017-11-14	2019-01-29|2018-08-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000279787|SCV000550473|SCV000669266	not_provided|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	This_deletion_of_one_nucleotide_in_CHEK2_is_denoted_c.876delT_at_the_cDNA_level_and_p.Phe292LeufsX12_(F292LfsX12)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_CTTTTT[delT]GATG._The_deletion_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Leucine_at_codon_292,_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Based_on_the_currently_available_information,_we_consider_this_deletion_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Phe292Leufs*12)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234765)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_007194.3:c.823del	CHEK2	frameshift_variant	102000	1	NA	NA	-	-	-	-	410070	404326	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29106017del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	769430546	-	Invitae|Ambry_Genetics	Pathogenic|Pathogenic	2018-03-30|2019-08-28	2018-08-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000550563|SCV001189850	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu275Lysfs*3)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_410070)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_007194.3:c.817_818del	CHEK2	frameshift_variant	102036	1	NA	NA	-	-	-	-	491643	485368	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29106023_29106024del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	1474786480	-	Color|Invitae	Pathogenic|Pathogenic	2016-06-13|2018-12-24	2017-12-21|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000689729|SCV000942812	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu273Asnfs*16)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individual(s)_affected_with_breast_cancer_(PMID:Â¬â€ 28779002)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 491643)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.817G>T	CHEK2	stop_gained	102028	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.792+2T>C	CHEK2	splice_donor_variant	102664	1	15416	1	-	-	-	-	220480	222866	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29107895A>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001575|splice_donor_variant	1	545982789	-	Invitae|Mendelics|Ambry_Genetics	Likely_pathogenic|Uncertain_significance|Likely_pathogenic	2018-04-29|2019-05-28|2018-10-08	2018-08-29|2019-10-22|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline	SCV000261050|SCV001141360|SCV000669261	Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	This_sequence_change_affects_a_donor_splice_site_in_intron_6_of_the_CHEK2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs545982789,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_220480)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity
NM_007194.3:c.715G>T	CHEK2	stop_gained	102706	1	NA	NA	5&5	0&1	rs121908702	Prostate cancer, somatic&Hereditary cancer-predisposing syndrome	5599	20638	_somatic|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C4015779|MedGen:CN517202	-	NC_000022.10:g.29107974C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:604373.0010	-	CHEK2:11200	SO:0001587|nonsense	3	121908702	-	OMIM|Ambry_Genetics|Invitae|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2003-02-01|2018-11-19|2018-04-17|2017-12-21	2013-08-16|2020-02-26|2018-08-29|2019-01-29	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	somatic|germline|germline|germline	SCV000026129|SCV000217106|SCV000757048|SCV000779347	_somatic|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|not_provided	|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu239*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_sporadic_prostate_cancer_(PMID:_12533788)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_5599)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_variant_is_denoted_CHEK2_c.715G>T_at_the_cDNA_level_and_p.Glu239Ter_(E239X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._This_variant_has_been_reported_in_at_least_one_individual_with_prostate_cancer_(Dong_2003)_and_is_considered_pathogenic.
NM_007194.3:c.683+2T>C	CHEK2	splice_donor_variant	83698	1	NA	NA	-	-	-	-	565542	571799	Familial_cancer_of_breast	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006	-	NC_000022.10:g.29115381A>G	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001627|intron_variant	1	781021132	-	Invitae	Likely_pathogenic	2018-03-16	2018-08-29	_single_submitter	germline	SCV000812600	Familial_cancer_of_breast	This_sequence_change_affects_a_donor_splice_site_in_intron_5_of_the_CHEK2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs781021132,_ExAC_0.005%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_007194.3:c.673del	CHEK2	frameshift_variant	89504	1	NA	NA	-	-	-	-	826589	815098	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000022.10:g.29115397del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001627|intron_variant	1	-	-	Ambry_Genetics	Pathogenic	2018-07-25	2020-02-26	_single_submitter	germline	SCV001187817	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_007194.3:c.606del	CHEK2	frameshift_variant	84846	3	NA	NA	-	-	-	-	265538	260260	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29115465del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	886039609	-	GeneDx|Color	Likely_pathogenic|Pathogenic	2015-12-18|2017-10-27	2019-01-29|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000322515|SCV000909481	not_provided|Hereditary_cancer-predisposing_syndrome	This_deletion_of_one_nucleotide_in_CHEK2_is_denoted_c.606delT_at_the_cDNA_level_and_p.Phe202LeufsX3_(F202LfsX3)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_CTTTTT[T]GATC._The_deletion_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Leucine_at_codon_202,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Based_on_the_currently_available_information,_we_consider_this_deletion_to_be_a_likely_pathogenic_variant.|
NM_007194.3:c.591del	CHEK2	frameshift_variant,splice_region_variant	102674	4	15420	1	-	-	-	-	142114	151828	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29120968del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	587782245	-	Eurofins_Clinical_Diagnostics	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2019-04-02|2015-03-05|2018-12-18|2016-07-05|2018-09-04|2017-06-02|2018-04-05	2020-02-26|2017-10-26|2019-03-28|2016-11-23|2019-01-29|2017-08-01|2018-09-19	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline	SCV000185863|SCV000684664|SCV000262460|SCV000488810|SCV000211013|SCV000601174|SCV000860260	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Val198Phefs*7)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_17721994,_26681312,_28008555),_and_an_individual_with_prostate_cancer_(PMID:_27433846)._This_variant_is_also_known_as_589delA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142114)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_deletion_of_one_nucleotide_in_CHEK2_is_denoted_c.591delA_at_the_cDNA_level_and_p.Val198PhefsX7_(V198FfsX7)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_ATAA[delA]Ggta,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._The_deletion_causes_a_frameshift_which_changes_a_Valine_to_a_Phenylalanine_at_codon_198,_and_creates_a_premature_stop_codon_at_position_7_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._CHEK2_c.591delA,_published_as_589delA_using_alternate_nomenclature,_has_been_observed_in_individuals_with_prostate_cancer_as_well_as_early-onset_or_male_breast_cancer_(Bell_2007,_Pritchard_2016,_Pritzlaff_2017)._We_consider_this_variant_to_be_pathogenic.||
NM_007194.3:c.575C>A	CHEK2	stop_gained	102714	1	NA	NA	-	-	-	-	641284	649288	Familial_cancer_of_breast	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006	-	NC_000022.10:g.29120982G>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001587|nonsense,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	-	-	Invitae	Pathogenic	2018-08-21	2019-03-28	_single_submitter	germline	SCV000933904	Familial_cancer_of_breast	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser192*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.529A>T	CHEK2	stop_gained	102712	1	NA	NA	-	-	-	-	485522	480130	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29121028T>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001587|nonsense,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	796389290	-	Ambry_Genetics|Invitae	Pathogenic|Pathogenic	2017-03-10|2018-04-23	2020-02-26|2018-08-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000673256|SCV000828814	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys177*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer_(PMID:_22527104)._This_variant_is_also_known_as_c.658T>A_(p.K220*)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 485522)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.507del	CHEK2	frameshift_variant	102704	1	NA	NA	-	-	-	-	128079	133536	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29121052del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	587780183	-	Ambry_Genetics|Color|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-16|2017-05-26|2017-08-21|2018-11-15	2020-02-26|2018-11-06|2019-01-29|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000184398|SCV000905463|SCV000149931|SCV000633194	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_CHEK2_c.507delT_at_the_cDNA_level_and_p.Phe169LeufsX2_(F169LfsX2)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_CCTT[T]GTAA._The_deletion_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Leucine_at_codon_169,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._CHEK2_507delT_was_reported_in_a_breast_cancer/sarcoma_family_(Manoukian_2011),_and_we_consider_this_variant_to_be_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Phe169Leufs*2)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780183,_ExAC_0.001%)._This_variant_has_been_reported_in_individuals_affected_with_sarcoma,_breast,_bladder,_and_endometrial_cancer_(PMID:_21562711,_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128079)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.444+1G>A	CHEK2	splice_donor_variant	102570	11	15430	5	-	-	-	-	128075	133532	Osteosarcoma|Malignant_tumor_of_prostate|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|CHEK2-Related_Cancer_Susceptibility|not_provided	-	Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C3469522|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29121230C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:712734|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2833744	-	CHEK2:11200	SO:0001575|splice_donor_variant	1	121908698	-	Ambry_Genetics|Color|Invitae|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|Genetic_Services_Laboratory,_University_of_Chicago|Fulgent_Genetics,Fulgent_Genetics|Illumina_Clinical_Services_Laboratory,Illumina	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2018-07-10|2015-03-11|2018-12-28|2016-01-24|2017-05-25|2017-11-22|2019-05-28|2015-11-20|2018-08-30|2017-02-11|2018-08-01|2016-09-29|2018-10-31|2018-09-21	2020-02-26|2017-01-26|2019-03-28|2016-11-23|2018-06-14|2019-04-24|2019-10-22|2016-03-03|2019-01-29|2018-08-31|2018-08-08|2017-07-05|2018-11-14|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|unknown|germline|germline|germline|germline|germline|unknown|germline	SCV000186195|SCV000537642|SCV000253902|SCV000488172|SCV000839944|SCV000917232|SCV001141371|SCV000266069|SCV000149926|SCV000601168|SCV000821730|SCV000594120|SCV000894257|SCV000915969	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|Breast_cancer,_susceptibility_to|Familial_cancer_of_breast/Li-Fraumeni_syndrome_2/Osteosarcoma/Malignant_tumor_of_prostate|CHEK2-Related_Cancer_Susceptibility	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Functionally-validated_splicing_mutation||This_sequence_change_affects_a_donor_splice_site_in_intron_3_of_the_CHEK2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs121908698,_ExAC_0.03%),_and_has_an_allele_count_higher_than_expected_for_a_pathogenic_variant_(PMID:_28166811)._This_variant_is_well-described_in_the_literature._In_multiple_studies,_women_heterozygous_for_this_variant_have_an_increased_risk_(OR
NM_007194.3:c.409C>T	CHEK2	stop_gained	102600	2	NA	NA	5&5&4	1&1&1	rs730881701	Hereditary cancer-predisposing syndrome&Familial cancer of breast&not provided	182452	181116	Osteosarcoma|Malignant_tumor_of_prostate|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome_2|Congenital_heart_defects,_multiple_types,_3|not_provided	-	Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836482,OMIM:609265|MedGen:C3554194,OMIM:614954|MedGen:CN517202	-	NC_000022.10:g.29121266G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2854623	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	17	730881701	-	Ambry_Genetics|Color|Invitae|Center_of_Medical_Genetics_and_Primary_Health_Care|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Fulgent_Genetics,Fulgent_Genetics|Genomic_Medicine_Lab,_University_of_California_San_Francisco	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-15|2016-09-27|2018-10-31|0000-00-00|2018-10-23|2019-05-17|2018-10-31|2017-12-21	2020-02-26|2018-11-06|2019-03-28|2019-08-31|2019-01-29|2020-03-06|2018-11-14|2019-09-17	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|maternal	SCV000274055|SCV000903769|SCV000289685|SCV000987253|SCV000211017|SCV001134166|SCV000894259|SCV001167572	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_provided|Familial_cancer_of_breast/Li-Fraumeni_syndrome_2/Osteosarcoma/Malignant_tumor_of_prostate|Congenital_heart_defects,_multiple_types,_3	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg137*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs730881701,_ExAC_0.004%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer_(PMID:_28724667),_and_who_underwent_genetic_tests_for_the_risk_of_hereditary_cancer,_including_breast_cancer_(PMID:_27751358)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182452)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_CHEK2_c.409C>T_at_the_cDNA_level_and_p.Arg137Ter_(R137X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_at_least_two_individuals_with_breast_cancer_as_well_as_in_three_individuals_who_underwent_multi-gene_panel_testing_for_hereditary_cancer_(Leedom_2016,_Sun_2017)._We_consider_CHEK2_Arg137Ter_to_be_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.||
NM_007194.3:c.372del	CHEK2	frameshift_variant	102596	1	NA	NA	-	-	-	-	234494	232133	Familial_cancer_of_breast|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:CN517202	-	NC_000022.10:g.29121303del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2848024	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	876661050	-	GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Likely_pathogenic|Likely_pathogenic|Pathogenic	2015-12-24|2018-09-04|2018-10-01	2019-01-29|2020-03-06|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000279362|SCV001134164|SCV000950893	not_provided|not_provided|Familial_cancer_of_breast	This_deletion_of_one_nucleotide_in_CHEK2_is_denoted_c.372delC_at_the_cDNA_level_and_p.Phe125LeufsX6_(F125LfsX6)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_ATTG[C]TTTG._The_deletion_causes_a_frameshift,_which_changes_a_Phenylalanine_to_a_Leucine_at_codon_125,_and_creates_a_premature_stop_codon_at_position_6_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_likely_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_significantly_disrupt_the_protein_structure._The_best_available_variant_frequency_is_uninformative.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Phe125Leufs*6)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234494)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.320-2A>G	CHEK2	splice_acceptor_variant	102224	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.319+2T>C	CHEK2	splice_donor_variant	102296	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.319+2T>A	CHEK2	splice_donor_variant	102296	5	15424	9	-	-	-	-	142352	152066	Osteosarcoma|Malignant_tumor_of_prostate|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome_2|not_provided	-	Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836482,OMIM:609265|MedGen:CN517202	-	NC_000022.10:g.29130389A>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001575|splice_donor_variant	1	587782401	-	Fulgent_Genetics|Invitae|Counsyl|Mendelics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-10-01|2018-05-08|2017-07-03|2018-08-02|2017-05-18|2018-11-28|2018-01-10|2018-07-02	2020-02-26|2018-11-06|2018-01-25|2019-01-29|2017-05-23|2019-03-28|2018-06-20|2018-08-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|unknown|unknown	SCV000186416|SCV000684628|SCV000698793|SCV000211009|SCV000611186|SCV000633168|SCV000785922|SCV000839501	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast/Li-Fraumeni_syndrome_2/Osteosarcoma/Malignant_tumor_of_prostate|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:RNA_Studies||Variant_summary:_The_CHEK2_c.319+2T>A_variant_involves_the_alteration_of_a_conserved_intronic_nucleotide._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._5/5_splice_prediction_tools_predict_that_this_variant_eliminates_5'_splicing_donor_site._However,_these_predictions_have_yet_to_be_confirmed_by_functional_studies._This_variant_was_found_in_7/121814_control_chromosomes_at_a_frequency_of_0.0000575,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_CHEK2_variant_(0.0003125)._This_variant_has_been_reported_in_patients_with_breast_cancer_or_colonrectal_cancer_(Susswein_2015,_Rohlin_2016,_Dominguez-Valentin_2017)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_likely_pathogenic._Taken_together,_this_variant_is_classified_as_likely_pathogenic.|This_variant_is_denoted_CHEK2_c.319+2T>A_or_IVS2+2T>A_and_consists_of_a_T>A_nucleotide_substitution_at_the_+2_position_of_intron_2_of_the_CHEK2_gene._This_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_observed_in_an_individual_with_early-onset_or_familial_breast_cancer,_another_with_thyroid_and_bilateral_breast_cancer,_and_at_least_one_other_with_a_microsatellite-stable_colorectal_cancer_(Mantere_2017,_Rohlin_2017,_Dominguez-Valentin_2018)._Based_on_the_currently_available_information,_we_consider_CHEK2_c.319+2T>A_to_be_a_likely_pathogenic_variant.||This_sequence_change_affects_a_donor_splice_site_in_intron_2_of_the_CHEK2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587782401,_ExAC_0.03%)._This_variant_has_been_reported_in_individuals_affected_with_thyroid_cancer,_breast_cancer,_and_colorectal_cancer_(PMID:_28608266,_26681312,_27696107)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142352)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_PMID:_21876083,_24713400)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||
NM_007194.3:c.319+1G>A	CHEK2	splice_donor_variant	102290	1	NA	NA	-	-	-	-	481726	480186	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29130390C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001575|splice_donor_variant	1	765080766	-	Ambry_Genetics|Invitae	Likely_pathogenic|Likely_pathogenic	2019-09-09|2019-01-05	2020-02-26|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000666379|SCV000757195	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|This_sequence_change_affects_a_donor_splice_site_in_intron_2_of_the_CHEK2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs765080766,_ExAC_0.006%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_481726)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_007194.3:c.283C>T	CHEK2	stop_gained	102564	1	NA	NA	5&5&5	1&1&1	rs587781269	Hereditary cancer-predisposing syndrome&not provided&Familial cancer of breast	140772	150486	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN517202	-	NC_000022.10:g.29130427G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2221688	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	587781269	-	Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Invitae|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-08-21|2017-01-17|2019-01-18|0000-00-00|2018-12-31|2017-05-23|2017-06-05|2018-01-15|2019-01-30	2020-02-26|2018-11-06|2019-01-29|2017-10-31|2019-03-28|2017-06-22|2018-06-14|2019-04-24|2019-08-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|unknown|germline|germline|germline	SCV000172762|SCV000911178|SCV000278920|SCV000691837|SCV000289680|SCV000677767|SCV000839945|SCV000919212|SCV001160238	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|not_specified	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_pathogenic_variant_is_denoted_CHEK2_c.283C>T_at_the_cDNA_level_and_p.Arg95Ter_(R95X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_multiple_individuals_with_breast,_prostate,_or_rectal_cancer,_and_an_in_vitro_functional_assay_found_it_to_be_devoid_of_kinase_activity_(Chrisanthar_2008,_Le_Calvez-Kelm_2011,_Knappskog_2016,_Raskin_2017)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg95*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781269,_ExAC_0.009%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_18725978,_21244692)._It_has_also_been_suggested_as_a_variant_restricted_to_the_Norwegian_population,_where_it_has_been_observed_in_individuals_affected_with_prostate_and_breast_cancer,_and_in_unaffected_individuals_(PMID:_27708748)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140772)._Experimental_studies_have_shown_that_this_nonsense_change_abolishes_the_kinase_activity_of_the_CHEK2_protein_(PMID:_18725978)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_c.283C>T_(p.Arg95*)_variant_in_the_CHEK2_gene_has_been_reported_in_two_patients_from_Norway_with_advanced_breast_cancer_[PMID_18725978]._The_c.283C>T_(p.Arg95*)_variant_was_subsequently_detected_in_12_individuals_from_a_case_control_study:_4_from_the_control_group_(no_cancer),_4_had_prostate_cancer_and_4_had_breast_cancer_[PMID_27708748]._The_variant_was_also_detected_in_a_cohort_of_patients_with_breast_cancer_[PMID_21244692]._This_c.283C>T_creates_a_stop_codon_at_amino_acid_position_95_of_the_CHEK2_protein_(p.Arg95*),_which_is_predicted_to_results_in_a_loss_of_function_of_the_protein._This_variant_has_been_observed_in_2_heterozygous_individuals_in_the_ExAC_population_database_(http://exac.broadinstitute.org/variant/22-29130427-G-A)._It_is_thus_interpreted_as_a_pathogenic_variant|Variant_summary:_The_CHEK2_c.283C>T_(p.Arg95X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_CHEK2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.1100delC,_p.Thr367fsX15:_c.1263delT,_p.Ser422fsX15:_c.1555C>T,_p.Arg519X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._One_study_showed_lack_of_dimerization_of_this_variant_with_the_WT_Chk2_protein_as_well_as_no_kinase_activity_(Chrisanthar_2008)._This_variant_was_found_in_6/255878_control_chromosomes_at_a_frequency_of_0.0000234,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_CHEK2_variant_(0.0000284)._This_variant_was_reported_in_multiple_patients_with_breast,_prostate,_and_colorectal_cancer_(Knappskog_2016,_Calvez-Kelm_2011,_Cragun_2014),_most_frequently_in_patients_of_Norwegian_descent_._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|The_CHEK2_c.283C>T:_p.Arg95Ter_variant_(rs587781269)_is_described_in_the_literature_in_individuals_with_breast,_prostate,_or_colorectal_cancer_(Chrisanthar_2008,_DeRycke_2017,_Knappskog_2016,_Le_Calvez-Kelm_2011,_Li_2019,_Raskin_2017,_Singh_2018)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_140772)._It_is_found_in_the_general_population_with_a_low_overall_allele_frequency_of_0.0008%_(2/251218_alleles)_in_the_Genome_Aggregation_Database._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Chrisanthar_R_et_al._CHEK2_mutations_affecting_kinase_activity_together_with_mutations_in_TP53_indicate_a_functional_pathway_associated_with_resistance_to_epirubicin_in_primary_breast_cancer._PLoS_One._2008_Aug_26:3(8):e3062._DeRycke_MS_et_al._Targeted_sequencing_of_36_known_or_putative_colorectal_cancer_susceptibility_genes._Mol_Genet_Genomic_Med._2017_Jul_23:5(5):553-569._Knappskog_S_et_al._Prevalence_of_the_CHEK2_R95*_germline_mutation._Hered_Cancer_Clin_Pract._2016_Sep_27:14:19._Le_Calvez-Kelm_F_et_al._Rare,_evolutionarily_unlikely_missense_substitutions_in_CHEK2_contribute_to_breast_cancer_susceptibility:_results_from_a_breast_cancer_family_registry_case-control_mutation-screening_study._Breast_Cancer_Res._2011_Jan_18:13(1):R6._Li_JY_et_al._Germline_mutations_in_40_cancer_susceptibility_genes_among_Chinese_patients_with_high_hereditary_risk_breast_cancer._Int_J_Cancer._2019_Jan_15:144(2):281-289._Raskin_L_et_al._Targeted_sequencing_of_established_and_candidate_colorectal_cancer_genes_in_the_Colon_Cancer_Family_Registry_Cohort._Oncotarget._2017_Jun_21:8(55):93450-93463._Singh_J_et_al._Screening_of_over_1000_Indian_patients_with_breast_and/or_ovarian_cancer_with_a_multi-gene_panel:_prevalence_of_BRCA1/2_and_non-BRCA_mutations._Breast_Cancer_Res_Treat._2018_Jul:170(1):189-196.
NM_007194.3:c.279G>A	CHEK2	stop_gained	102610	1	NA	NA	5&5	1&1	rs587782070	Hereditary cancer-predisposing syndrome&Familial cancer of breast	141866	151580	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29130431C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	587782070	-	Ambry_Genetics|Color|Invitae|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-03-20|2017-11-06|2018-05-03|2019-01-07	2020-02-26|2018-11-06|2018-08-29|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000185430|SCV000911685|SCV000253901|SCV000329277	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Trp93*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587782070,_ExAC_0.009%)._This_variant_has_been_reported_in_individuals_undergoing_multi-gene_panel_testing_for_breast_cancer_risk_(PMID:_27751358)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141866)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_variant_is_denoted_CHEK2_c.279G>A_at_the_cDNA_level_and_p.Trp93Ter_(W93X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tryptophan_to_a_premature_stop_codon_(TGG>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_at_least_one_individual_with_breast_cancer_(Decker_2017)_and_is_considered_pathogenic.
NM_007194.3:c.247del	CHEK2	frameshift_variant	102734	4	15412	1	-	-	-	-	142851	152565	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29130464del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	587782766	-	Ambry_Genetics|Invitae|Counsyl|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-06-21|2019-01-08|2016-06-04|2018-10-03	2020-02-26|2019-03-28|2016-11-23|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline	SCV000187378|SCV000260987|SCV000488749|SCV000279296	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_deletes_one_nucleotide_in_exon_2_of_the_CHEK2_mRNA_(c.247delC),_causing_a_frameshift_at_codon_83._This_creates_a_premature_translational_stop_signal_(p.Gln83Lysfs*27)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer_(PMID:_27751358)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_deletion_of_one_nucleotide_in_CHEK2_is_denoted_c.247delC_at_the_cDNA_level_and_p.Gln83LysfsX27_(Q83KfsX27)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GGAC[delC]AAGA._The_deletion_causes_a_frameshift,_which_changes_a_Glutamine_to_a_Lysine_at_codon_83,_and_creates_a_premature_stop_codon_at_position_27_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._CHEK2_c.247delC_has_been_identified_in_individuals_who_underwent_multigene_panel_testing_and/or_whole_exome_sequencing_(Leedom_2016,_Robinson_2017)._We_consider_this_variant_to_be_pathogenic.
NM_007194.3:c.219_223del	CHEK2	frameshift_variant	102740	2	NA	NA	-	-	-	-	460817	470079	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29130489_29130493ATAGA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	766416564	-	Invitae|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic	2018-11-09|2016-09-09|2018-05-11	2019-03-28|2020-02-26|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000633157|SCV000661762|SCV000913604	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ile74*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs766416564,_ExAC_0.001%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_007194.3:c.152del	CHEK2	frameshift_variant	102688	1	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.151C>T	CHEK2	stop_gained	102676	1	NA	NA	5&5	1&1	rs587781592	Hereditary cancer-predisposing syndrome&Familial cancer of breast	141231	150945	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29130559G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	587781592	-	Ambry_Genetics|Invitae	Pathogenic|Pathogenic	2019-08-02|2015-05-22	2020-02-26|2015-09-11	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000184443|SCV000253899	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_51_(p.Gln51*)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_truncating_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.85C>T	CHEK2	stop_gained	101184	2	NA	NA	5&5	2&1	rs761494650	Hereditary cancer-predisposing syndrome&Familial cancer of breast	187694	185659	Ovarian_Neoplasms|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29130625G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	761494650	-	University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic	2018-01-04|2015-03-05|2018-12-28|2016-12-23|2018-07-17|2018-12-01	2020-02-26|2016-07-05|2019-03-28|2017-06-22|2019-01-29|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|unknown|germline|germline	SCV000218300|SCV000292166|SCV000289713|SCV000677821|SCV000568938|SCV000924000	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|Ovarian_Neoplasms	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln29*)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs761494650,_ExAC_0.002%)._This_nonsense_change_has_been_observed_in_an_individual_with_breast_cancer_(PMID:Â¬â€ 28008555)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_187694)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_CHEK2_c.85C>T_at_the_cDNA_level_and_p.Gln29Ter_(Q29X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_at_least_one_individual_with_prostate_cancer_(Mandelker_2017)._It_is_considered_likely_pathogenic.|
NM_007194.3:c.14_20del	CHEK2	frameshift_variant	98556	1	NA	NA	-	-	-	-	233394	236715	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000022.10:g.29130692_29130698del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	757016287	-	Ambry_Genetics	Pathogenic	2019-09-04	2020-02-26	_single_submitter	germline	SCV000277759	Hereditary_cancer-predisposing_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_003000.2:c.725G>A	SDHB	missense_variant	102706	1	NA	NA	5&5&5&5&5	0&0&0&1&1	rs74315368	Paragangliomas 4&Pheochromocytoma&Gastrointestinal stromal tumor&Hereditary cancer-predisposing syndrome&not provided	12781	27820	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_4|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1861848,OMIM:115310|MedGen:CN517202	-	NC_000001.10:g.17349143C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P21912#VAR_017869|OMIM_Allelic_Variant:185470.0004	-	SDHB:6390	SO:0001583|missense_variant	1	74315368	-	National_Institutes_of_Health|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-01-04|2011-01-04|2011-01-04|2019-01-14|2019-01-09|0000-00-00|2018-12-28	2016-08-31|2016-08-31|2016-08-31|2020-02-26|2019-01-29|2017-07-10|2019-03-28	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	unknown|unknown|unknown|germline|germline|germline|germline	SCV000033866|SCV000033867|SCV000044067|SCV000183806|SCV000235636|SCV000599525|SCV000644767	Paragangliomas_4|Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma	|||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Well-characterized_mutation_at_same_position:Structural_Evidence|This_pathogenic_variant_is_denoted_SDHB_c.725G>A_at_the_cDNA_level,_p.Arg242His_(R242H)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Histidine_(CGC>CAC)._This_variant_has_been_reported_in_a_father_and_son_with_malignant_paragangliomas,_several_individuals_with_both_malignant_and_benign_paraganglioma/_pheochromocytoma_tumors,_a_young_adult_with_a_gastrointestinal_stromal_tumor,_and_a_patient_with_an_SDHB-deficient_renal_carcinoma_(Young_2002,_Neumann_2004,_Persu_2008,_Cascon_2009,_Ghayee_2009,_Sevilla_2009,_Janeway_2011,_Luiz_2013,_Gill_2014,_Rijken_2017)._SDHB_Arg242His_was_also_observed_in_a_patient_with_clinical_and_metabolic_features_suggestive_of_a_mitochondrial_disorder,_for_whom_assays_to_interrogate_mitochondrial_dysfunction_in_cultured_fibroblasts_and_muscle_tissue_revealed_reduced_complex_II_and_III_activities_and_SDHA_and_SDHB_expression_(Nesti_2015)._While_this_patient_also_harbored_a_heteroplasmic_MT-CYB_variant_which_might_have_contributed_to_these_laboratory_findings,_yeast-based_assays_interrogating_each_variant_separately_only_found_decreased_complex_II_and_III_activities_for_the_strain_expressing_the_yeast_corollary_of_SDHB_Arg242His_(Nesti_2015)._Additionally,_Kim_et_al._(2015)_found_SDHB_Arg242His_to_significantly_reduce_SDH_activity,_while_Dwight_et_al._(2017)_demonstrated_this_variant_to_completely_abrogate_SDHAF3_interaction._SDHB_Arg242His_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_an_L(I)YR_motif_required_for_interaction_with_Fe-S_cluster_transfer_machinery_and_acquisition_(Maio_2014,_Saxena_2015)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||This_sequence_change_replaces_arginine_with_histidine_at_codon_242_of_the_SDHB_protein_(p.Arg242His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs74315368,_ExAC_0.01%)._This_variant_has_been_reported_in_several_individuals_and_families_affected_with_sporadic_and_familial_hereditary_paragangliomas_and/or_pheochromocytomas_(PMID:_12000816,_20208144,Â¬â€ 24276837,_12213855,_17102084,_22270996),_gastrointestinal_stromal_tumors_(PMID:_21173220),_and_mitochondrial_encephalomyopathy_(PMID:_25736212)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12781)._Experimental_studies_using_model_organism_have_shown_that_this_variant_causes_deleterious_effects_on_several_aspects_of_protein_function_(PMID:_25972245,_25736212,_22835832)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_003000.2:c.689G>T	SDHB	missense_variant	102702	1	NA	NA	4	1	rs587782604	Hereditary cancer-predisposing syndrome	184933	181607	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Paragangliomas_4|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1861848,OMIM:115310|MedGen:CN517202	-	NC_000001.10:g.17349179C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	SDHB:6390	SO:0001583|missense_variant	1	587782604	-	Ambry_Genetics|Invitae|GeneDx	Likely_pathogenic|Pathogenic|Pathogenic	2014-05-05|2018-12-31|2017-08-23	2020-02-26|2019-03-28|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000214900|SCV000554032|SCV000616874	Hereditary_cancer-predisposing_syndrome|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma|not_provided	Well-characterized_mutation_at_same_position:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|This_sequence_change_replaces_arginine_with_leucine_at_codon_230_of_the_SDHB_protein_(p.Arg230Leu)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_leucine._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_several_individuals_affected_with_paraganglioma_(PMID:_18382370,_19351833,_27539324,_23934599)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_184933)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_(SIFT,_PolyPhen-2,_Align-GVGD)_all_suggest_that_this_variant_is_likely_to_be_disruptive,_but_these_predictions_have_not_been_confirmed_by_published_functional_studies_and_their_clinical_significance_is_uncertain._The_p.Arg230_amino_acid_residue_in_SDHB_has_been_determined_to_be_clinically_significant_(PMID:_25405498,_20592014,_26259135,_16912137)._This_suggests_that_variants_that_disrupt_this_residue_are_likely_to_be_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_R230L_variant_in_the_SDHB_gene_has_previously_been_reported_in_multiple_individuals_with_paraganglioma_and/or_other_features_suspicious_for_hereditary_paraganglioma-pheochromocytoma_syndrome_(for_examples,_see_Klein_et_al.,_2009:_Neumann_et_al.,_2009:_Pandit_et_al.,_2016)._This_variant_is_not_observed_in_large_population_cohorts_(Lek_et_al.,_2016:_1000_Genomes_Consortium_et_al.,_2015:_Exome_Variant_Server)._The_R230L_variant_is_a_non-conservative_amino_acid_substitution,_which_is_likely_to_impact_secondary_protein_structure_as_these_residues_differ_in_polarity,_charge,_size_and/or_other_properties._This_substitution_occurs_at_a_position_that_is_conserved_across_species,_and_in_silico_analysis_predicts_this_variant_is_probably_damaging_to_the_protein_structure/function._Alternate_missense_variants_at_the_same_residue_(R230C,_R230H)_have_been_reported_in_association_with_pheochromocytomas_or_functional_paragangliomas,_supporting_the_functional_importance_of_this_region_of_the_protein_(Gimenez-Roqueplo_et_al.,_2003:_Amar_et_al.,_2005)._Based_on_currently_available_evidence,_we_consider_R230L_to_be_pathogenic.
NM_003000.2:c.688C>T	SDHB	missense_variant	102696	1	NA	NA	5	1	rs138996609	Hereditary cancer-predisposing syndrome	185077	181608	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_4|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1861848,OMIM:115310|MedGen:CN517202	-	NC_000001.10:g.17349180G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	_Inc:SCN5A-A10|UniProtKB_(protein):P21912#VAR_054383	-	SDHB:6390	SO:0001583|missense_variant	1	138996609	-	Ambry_Genetics|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|GeneDx|Invitae|Center_for_Human_Genetics,_Inc|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-04-10|0000-00-00|2017-10-05|2018-11-20|2016-11-01|2018-01-14	2020-02-26|2017-07-10|2019-01-29|2019-03-28|2017-12-20|2018-06-14	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000215074|SCV000599523|SCV000617569|SCV000644765|SCV000782279|SCV000840068	Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|not_provided|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma|Paragangliomas_4|Paragangliomas_4	Well-characterized_mutation_at_same_position:Deficient_protein_function_in_appropriate_functional_assay(s):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_pathogenic_variant_is_denoted_SDHB_c.688C>T_at_the_cDNA_level,_p.Arg230Cys_(R230C)_at_theprotein_level,_and_results_in_the_change_of_an_Arginine_to_a_Cysteine_(CGC>TGC)._This_variant_was_observed_in_severalindividuals_with_pheochromocytoma_or_paraganglioma_(Gimenez-Roqueplo_2003,_Lefebvre_2012,_Hermsen_2010,Janssen,_Jochmanova_2017)._In_addition,_functional_assays_have_demonstrated_this_variant_to_result_in_an_unstableprotein,_and_in_the_tumor_of_an_individual_harboring_this_variant,_complete_and_selective_loss_of_mitochondrial_complex_IIenzyme_activity_was_observed_(Yang_2012,_Gimenez-Roqueplo_2003)._SDHB_Arg230Cys_was_not_observed_at_asignificant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Since_Arginine_and_Cysteine_differ_in_polarity,charge,_size_or_other_properties,_this_is_considered_a_non-conservative_amino_acid_substitution._SDHB_Arg230Cysoccurs_at_a_position_that_is_conserved_across_species_and_is_not_located_in_a_known_functional_domain._In_silicoanalyses_predict_that_this_pathogenic_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_currentlyavailable_evidence,_we_consider_this_variant_to_be_pathogenic|This_sequence_change_replaces_arginine_with_cysteine_at_codon_230_of_the_SDHB_protein_(p.Arg230Cys)._The_arginine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_arginine_and_cysteine._This_variant_is_present_in_population_databases_(rs138996609,_ExAC_0.002%)._This_variant_has_been_reported_in_several_individuals_affected_with_malignant_or_non-malignant_pheochromocytoma_or_paraganglioma_(PMID:_14500403,_17652212,_25873086,_19454582,_20208144,_22517554)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185077)._Experimental_studies_have_shown_that_this_missense_change_results_in_reduced_SDHB_protein_stability_(PMID:_22835832)._Two_other_missense_substitutions_at_this_codon_(p.Arg230His_and_p.Arg230Leu)_have_been_determined_to_be_pathogenic_(PMID:_18382370,_19351833,_23934599,_Invitae)._This_suggests_that_the_arginine_residue_is_critical_for_SDHB_protein_function_and_that_other_missense_substitutions_at_this_position_may_also_be_pathogenic._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_c.688C>T_(p.Arg230Cys)_variant_in_the_SDHB_gene_has_been_reported_in_several_unrelated_individuals_with_pheochromocytoma_or_paraganglioma_(PMID:_14500403,_24939699,_20208144,_and_28374168)._Functional_assays_have_demonstrated_that_this_missense_change_results_in_an_unstable_protein,_and_in_the_tumor_of_an_individual_with_this_variant_complete_and_selective_loss_of_mitochondrial_complex_II_enzyme_activity_was_observed_(PMID:_22835832,_14500403)._Additionally,_two_other_pathogenic/likely_pathogenic_missense_substitutions_at_this_codon_have_been_reported_(PMID:_22835832,_23934599,_18382370,_and_19351833,)_suggesting_that_the_Arg230_residue_is_critical_for_normal_functioning_of_the_SDHB_protein._In_light_of_the_currently_available_data_this_variant_in_the_SDHB_gene_is_classified_pathogenic.
NM_003000.2:c.590C>G	SDHB	missense_variant	102654	1	NA	NA	5&4	0&1	rs74315367	Paragangliomas 4&Hereditary cancer-predisposing syndrome	12779	27818	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_4|not_specified	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1861848,OMIM:115310|MedGen:CN169374	-	NC_000001.10:g.17350520G>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:185470.0002|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:1999|UniProtKB_(protein):P21912#VAR_017868	-	SDHB:6390	SO:0001583|missense_variant	1	74315367	-	OMIM|Integrated_Genetics/Laboratory_Corporation_of_America|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|Ambry_Genetics|Invitae|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|not_provided|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2001-07-01|2015-10-02|0000-00-00|2016-11-23|2016-11-29|2018-07-13	2016-08-31|2015-11-17|2017-07-10|2020-02-26|2017-03-14|2019-08-05	no_assertion_criteria_provided|no_assertion_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000033864|SCV000053301|SCV000599521|SCV000273721|SCV000553988|SCV001158579	Paragangliomas_4|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_cancer-predisposing_syndrome|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma|not_specified	|||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|This_sequence_change_replaces_proline_with_arginine_at_codon_197_of_the_SDHB_protein_(p.Pro197Arg)._The_proline_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_proline_and_arginine._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_and_families_affected_with_pheochromocytoma_and/or_paraganglioma_(PMID:_18419787,_27542510,_25047027,_21348866),_and_has_been_reported_to_segregate_with_disease_in_3_families_with_incomplete_penetrance_(PMID:_11404820,_18419787,_14974914)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12779)._Structural_modeling_based_on_human_SDH_predicts_this_variant_may_affect_electron_pathway_(PMID:_25972245)._However,_experimental_studies_have_shown_that_this_missense_change_does_not_affect_mitochondrial_localization_and_behaves_the_same_as_wild-type_in_vitro_(PMID:_25972245,_18519664)._In_summary,_this_variant_is_a_rare_missense_change_that_has_been_shown_to_preserve_some_aspects_of_protein_function_in_vitro._However,_this_variant_has_also_been_observed_in_numerous_affected_individuals_and_segregates_with_disease_in_affected_families._For_these_reasons,_this_variant_has_been_classified_as_Likely_Pathogenic.|The_SDHB_c.590C>G_p.Pro197Arg_variant_(rs74315367)_is_reported_in_the_literature_in_multiple_individuals_and_families_affected_with_hereditary_paraganglioma/pheochromocytoma_syndrome,_though_it_has_also_been_reported_in_a_several_asymptomatic_carriers_(Astuti_2001,_Lawrence_2004,_Srirangalingam_2008)._This_variant_is_reported_in_ClinVar_(Variation_ID:_12779)_and_is_found_in_the_general_population_with_an_overall_allele_frequency_of_0.0004%_(1/245986_alleles)_in_the_Genome_Aggregation_Database._Additionally,_another_variant_at_this_codon,_p.Pro197Ser,_has_been_reported_in_individuals_with_paragangliomas_(Hermsen_2010,_Lima_2007)._While_biochemical_characterization_of_p.Pro197Arg_variant_protein_showed_no_effect_on_SDH_activity_or_association_with_SDHA_protein,_in_silico_analysis_of_this_variant_suggested_defective_electron_transport_and_generation_of_reactive_oxygen_species,_attributes_not_explicitly_tested_in_the_assays_run_(Kim_2015)._The_proline_at_codon_197_is_highly_conserved_and_computational_analyses_(SIFT,_PolyPhen-2)_predict_that_this_variant_is_deleterious._Based_on_available_information,_this_variant_is_considered_to_be_likely_pathogenic._References:_Astuti_D_et_al._Gene_mutations_in_the_succinate_dehydrogenase_subunit_SDHB_cause_susceptibility_to_familial_pheochromocytoma_and_to_familial_paraganglioma._Am_J_Hum_Genet._2001_Jul:69(1):49-54._Hermsen_MA_et_al._Relevance_of_germline_mutation_screening_in_both_familial_and_sporadic_head_and_neck_paraganglioma_for_early_diagnosis_and_clinical_management._Cell_Oncol._2010_Jan_1:32(4):275-83._Kim_E_et_al._Structural_and_functional_consequences_of_succinate_dehydrogenase_subunit_B_mutations._Endocr_Relat_Cancer._2015_Jun:22(3):387-97._Lawrence_JK_et_al._Familial_paraganglioma:_a_novel_presentation_of_a_case_and_response_to_therapy_with_radiolabelled_MIBG._Hormones_(Athens)._2004_Apr-Jun:3(2):127-31._Lima_J_et_al._High_frequency_of_germline_succinate_dehydrogenase_mutations_in_sporadic_cervical_paragangliomas_in_northern_Spain:_mitochondrial_succinate_dehydrogenase_structure-function_relationships_and_clinical-pathological_correlations._J_Clin_Endocrinol_Metab._2007_Dec:92(12):4853-64._Srirangalingam_U_et_al._Clinical_manifestations_of_familial_paraganglioma_and_phaeochromocytomas_in_succinate_dehydrogenase_B_(SDH-B)_gene_mutation_carriers._Clin_Endocrinol_(Oxf)._2008_Oct:69(4):587-96.
NM_003000.2:c.286G>A	SDHB	missense_variant,splice_region_variant	102650	2	NA	NA	4	1	rs587782243	Hereditary cancer-predisposing syndrome	142111	151825	Pheochromocytoma|Gastrointestinal_stroma_tumor|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_4|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1861848,OMIM:115310|MedGen:CN517202	-	NC_000001.10:g.17359555C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	SDHB:6390	SO:0001583|missense_variant	1	587782243	-	National_Institutes_of_Health	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2017-06-19|2018-09-12|2018-02-22|0000-00-00	2020-02-26|2019-03-28|2019-01-29|2017-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline	SCV000185859|SCV000553993|SCV000577707|SCV000599493	Hereditary_cancer-predisposing_syndrome|Gastrointestinal_stroma_tumor/Paragangliomas_4/Pheochromocytoma|not_provided|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes	Last_nucleotide_of_exon:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|This_sequence_change_replaces_glycine_with_serine_at_codon_96_of_the_SDHB_protein_(p.Gly96Ser)._The_glycine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_glycine_and_serine._It_also_falls_at_the_last_nucleotide_of_exon_3_of_the_SDHB_coding_sequence._This_variant_is_present_in_population_databases_(rs587782243,_ExAC_<0.01%)._This_variant_has_been_reported_in_individuals_affected_with_paraganglioma_(PMID:_24436918,_Invitae),_at_least_one_individual_with_increased_risk_of_pheochromocytoma_or_head_and_neck_paraganglioma_(PMID:_1980289),_and_in_two_individuals_affected_with_renal_cell_carcinoma_from_a_single_family_(PMID:_2308387)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142111)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_(SIFT,_PolyPhen-2,_Align-GVGD)_all_suggest_that_this_variant_is_likely_to_be_disruptive,_but_these_predictions_have_not_been_confirmed_by_published_functional_studies._Nucleotide_substitutions_within_the_consensus_splice_site_are_relatively_common_causes_of_aberrant_splicing_(PMID:_17576681,_9536098)._Algorithms_developed_to_predict_the_effect_of_nucleotide_changes_on_mRNA_splicing_suggest_that_this_variant_may_alter_mRNA_splicing,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_variant_is_denoted_SDHB_c.286G>A_at_the_cDNA_level,_p.Gly96Ser_(G96S)_at_the_protein_level,_and_results_in_the_change_of_a_Glycine_to_a_Serine_(GGC>AGC)._This_variant_has_been_reported_in_multiple_individuals_with_paraganglioma/pheochromocytoma,_and_in_two_affected_members_of_a_familial_renal_cell_carcinoma_kindred_(Ricketts_2010,_Ricketts_2012,_Sridhara_2013,_Jochmanova_2017,_Andrews_2018)._SDHB_Gly96Ser_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_2Fe-2S_ferredoxin-type_domain_(Uniprot)._Protein-based_in_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect.?_In_addition,_multiple_splicing_models_predict_that_this_variant_may_damage_the_nearby_natural_splice_donor_site.?_However,_in_the_absence_of_RNA_or_functional_studies,_the_actual_effect_of_this_variant_is_unknown.?_Based_on_currently_available_evidence,_we_consider_SDHB_Gly96Ser_to_be_a_likely_pathogenic_variant.|
NM_001128425.1:c.1437_1439del	MUTYH	inframe_deletion	102740	14	NA	NA	-	-	-	-	127838	133295	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN169374|MedGen:CN517202	-	NC_000001.10:g.45796892_45796894CCT[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	Illumina:576414	-	MUTYH:4595	SO:0001822|inframe_deletion	1	587778541	-	Ambry_Genetics|Color|GeneKor_MSA|ITMI|Invitae|GeneReviews|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Illumina_Clinical_Services_Laboratory,Illumina|Counsyl|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Mendelics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-05-14|2016-08-04|2018-08-01|2013-09-19|2019-01-05|2019-10-08|2015-09-14|2016-06-14|2016-01-08|0000-00-00|2018-05-08|2018-07-02|2018-10-01|2017-01-20|2017-09-14	2020-02-26|2017-10-26|2018-08-08|2014-05-29|2019-03-28|2019-12-13|2019-03-21|2016-10-18|2016-11-23|2017-04-19|2019-08-01|2018-08-20|2019-01-29|2018-08-31|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown|unknown|germline|germline|germline	SCV000184946|SCV000685578|SCV000821745|SCV000085796|SCV000166448|SCV000246168|SCV000271402|SCV000357889|SCV000487331|SCV000592718|SCV000778607|SCV000837745|SCV000149667|SCV000601634|SCV000917798	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided|MUTYH-associated_polyposis	Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_strong_data_supporting_pathogenic_classification_:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||This_sequence_change_deletes_3_nucleotides_from_exon_14_of_the_MUTYH_mRNA_(c.1437_1439delGGA)._This_leads_to_the_deletion_of_1_amino_acid_residue_in_the_MUTYH_protein_(p.Glu480del)_but_otherwise_preserves_the_integrity_of_the_reading_frame._This_variant_is_present_in_population_databases_(rs587778541,_ExAC_0.02%)._This_variant_is_a_known_common_cause_of_MUTYH-associated_polyposis_(PMID:_23035301)._It_has_been_reported_to_co-segregate_with_disease_in_individuals_affected_with_colorectal_cancer,_familial_adenomatous_polyposis_(FAP),_or_attenuated_FAP_(PMID:_14999774,_15635083,_12707038,_19527492,_16134147,_19732755)._This_variant_is_also_known_as_c.1395_1397delGGA,_c.1395delGGA,_Glu466del,_E466del_and_452delEÂ¬â€ in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127838)._Experimental_studies_have_shown_that_this_in-frame_deletion_disrupts_MUTYH_protein_function_(PMID:_23108399,_20848659,_20418187)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Glu480del_variant_in_MUTYH_(previously_reported_as_p.Glu466del_or_c.1395__1397delGGA)_has_been_reported_in_more_than_15_individuals_with_MUTYH-associated_polyposis_either_as_homozygous_or_compound_heterozygous_with_another_MUTYH_varia_nt,_and_segregated_with_disease_in_at_least_6_affected_family_members_from_3_fam_ilies_(Halford_2003,_Gismondi_2004,_Di_Gregorio_2006,_Vogt_2009,_Buisine_2013)._This_variant_is_a_deletion_of_the_glutamate_residue_(Glu)_at_position_480_and_is_not_predicted_to_alter_the_protein_reading-frame._In_vitro_functional_studies_p_rovide_some_evidence_that_the_p.Glu480del_variant_may_impact_protein_function_(D_agostino_2010,_Goto_2010,_Molatore_2010)._This_variant_has_also_been_identified_in_10/66728_European_and_4/16512_of_South_Asian_chromosomes_by_the_Exome_Aggrega_tion_Consortium,_including_one_homozygote_(ExAC,_http://exac.broadinstitute.org)_._Please_note_that_variants_associated_with_diseases_that_have_reduced_penetranc_e_and_late_age-of-onset_may_be_present_at_a_low_frequency_in_large_population_st_udies:_therefore_the_frequency_of_this_variant_is_consistent_with_the_known_prev_alance_and_penetrance_of_this_disease._In_summary,_this_variant_meets_our_criter_ia_to_be_classified_as_pathogenic_for_MUTYH-associated_familial_polyposis_in_an_autosomal_recessive_manner_(http://www.partners.org/personalizedmedicine/LMM)_ba_sed_upon_its_frequency_in_patients,_segregation_studies,_and_functional_evidence_.|The_c.1395_1397delGGA_(p.Glu466del)_variant_is_an_in-frame_deletion_variant_that_has_been_reported_extensively_in_the_literature._Across_a_selection_of_the_available_literature,_the_p.Glu466del_variant_has_been_observed_in_polyposis_or_colon_cancer_patients,_including_in_one_patient_in_a_homozygous_state,_eight_patients_in_a_compound_heterozygous_state,_and_one_patient_in_a_heterozygous_state_(Halford_et_al._2003:_Gismondi_et_al._2004:_Peterlongo_et_al._2006:_DeLellis_et_al._2013)._The_p.Glu466del_variant_was_absent_from_1,019_healthy_control_individuals_but_is_reported_at_a_frequency_of_0.00024_in_the_South_Asian_population_of_the_Exome_Aggregation_Consortium._In_vitro_testing_demonstrated_that_the_p.Glu466del_variant_was_dysfunctional_in_base_excision_repair_and_had_severely_impaired_enzymatic_activity_(Molatore_et_al._2010:_D'Agostino_et_al._2010:_Komine_et_al._2015)._Based_on_the_collective_evidence,_the_p.Glu466del_variant_is_classified_as_pathogenic_for_MYH-associated_polyposis.|||||This_pathogenic_variant_is_denoted_MUTYH_c.1437_1439delGGA_at_the_cDNA_level_and_p.Glu480del_(E480del)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AGGA[delGGA]ATTT._This_in_frame_deletion_of_three_nucleotides_results_in_the_loss_of_a_single_Glutamic_Acid_that_is_located_in_the_Nudix_hydrolase_domain_(Ruggieri_2013,_UniProt)._MUTYH_Glu480del,_also_denoted_as_1395_1397delGGA_and_466delE_using_alternate_nomenclature,_has_been_published_in_the_literature_as_an_Italian_founder_pathogenic_variant,_and_when_found_in_the_homozygous_state_or_in_combination_with_another_pathogenic_MUTYH_variant,_is_known_to_cause_MUTYH-associated_polyposis_(MAP)_(Gismondi_2004,_Eliason_2005,_Di_Gregorio_2006,_Vogt_2009,_Ricci_2017,_de_Leon_2017)._Multiple_in_vivo_and_in_vitro_functional_studies_demonstrate_the_association_of_MUTYH_Glu480del_with_the_defective_removal_of_adenine_bases,_which_is_critical_to_base_excision_repair_(Molatore_2010,_D'Agostino_2010,_Goto_2010,_Ruggieri_2013)._We_consider_this_variant_to_be_pathogenic.||Variant_summary:_The_c.1437_1439delGGA_(p.Glu480del)_in_the_MUTYH_gene_leads_to_an_in-frame_deletion_of_Glu_amino_acid_from_a_non-repeat_region_that_is_located_within_helix-hairpin-helix_DNA-binding_motif._The_variant_is_present_in_the_control_population_dataset_of_gnomAD_at_frequency_of_8.657e-5_(24/_277218_chrs_tested,_including_1_homozygote)._The_variant_of_interest_has_been_reported_in_compound_heterozygosity_or_homozygousity_in_multiple_affected_individuals_who_presented_with_MUTYH-_associated_polyposis._Genotypephenotype_analysis_suggests_that_the_p.Glu480del_variant_is_associated_with_a_severe_phenotype_(Ricci,_2017)._In_vitro_studies_demonstrated_that_the_p.Glu466del_variant_was_dysfunctional_in_complementation_repair_assay_and_had_severely_impaired_glycosylase_activity_(Goto,_2014_and_Komine,_2015)._In_addition,_multiple_reputable_databases/clinical_laboratories_have_classified_the_variant_as_Pathogenic._Taking_together,_the_variant_was_classified_as_Pathogenic.
NM_001128425.1:c.1214C>T	MUTYH	missense_variant	102382	15	15426	2	5&5&5	1&0&1	rs529008617	Hereditary cancer-predisposing syndrome&Carcinoma of colon&MYH-associated polyposis	142604	152318	_no_ICD-O_subtype|not_provided	-	MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3472624|MedGen:CN517202	-	NC_000001.10:g.45797201G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:685669	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	529008617	-	Ambry_Genetics|Color|Pathway_Genomics|GeneReviews|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Counsyl|Illumina_Clinical_Services_Laboratory,Illumina|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-04-16|2016-09-19|2014-07-24|2019-10-08|2018-12-28|2013-01-02|2017-01-17|2018-12-13|2018-12-21|2017-05-12|2017-04-04	2020-02-26|2017-10-26|2014-08-08|2019-12-13|2019-03-28|2017-04-19|2017-06-22|2019-02-01|2019-01-29|2017-08-01|2018-08-09	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline	SCV000186969|SCV000685555|SCV000189960|SCV000246166|SCV000285918|SCV000592712|SCV000678195|SCV000915415|SCV000490629|SCV000601629|SCV000853210	_no_ICD-O_subtype	Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||||This_sequence_change_replaces_proline_with_leucine_at_codon_405_of_the_MUTYH_protein_(p.Pro405Leu)._The_proline_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_proline_and_leucine._This_variant_is_present_in_population_databases_(rs529008617,_ExAC_0.02%)._This_variant_is_clearly_defined_as_a_MUTYH-associated_polyposis_causative_allele_(PMID:_16140997,_16557584,_16616356,_19732775)._It_is_a_founder_mutation_in_the_Dutch_population._This_variant_is_also_known_as_1172C>T,_P391L,_and_P377L_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142604)._Experimental_studies_have_shown_that_this_missense_change_severely_impacts_protein_function_(PMID:_19836313,_20848659,_25820570,_23322991)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||The_MUTYH_c.1172C>T_(p.Pro391Leu)_is_a_missense_variant._Across_a_selection_of_the_available_literature,_the_p.Pro391Leu_variant_has_been_found_in_19_individuals_affected_with_polyposis,_including_six_in_a_homozygous_state_and_13_in_a_compound_heterozygous_state_(Kanter-Smoler_G_et_al._2006:_Nielsen_et_al._2005:_Aretz_et_al._2006:_Middeldorp_et_al._2008)._The_variant_was_absent_from_424_control_alleles_and_is_reported_at_a_frequency_of_0.000183_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium_(Kanter-Smoler_G_et_al._2006:_Aretz_et_al._2006)._Functional_studies_demonstrated_the_variant_resulted_in_severely_impaired_glycosylase_activity_(Kundu_et_al._2009:_Goto_et_al._2010)_and_mutation_suppression_compared_to_wild_type_(Kundu_et_al._2009:_Shinmura_et_al._2012:_Komine_et_al._2015)._The_Pro391_residue_is_conserved_across_species_and_is_located_in_a_functionally_important_domain_(Kundu_et_al._2009)._Based_on_the_collective_data,_the_p.Pro391Leu_variant_is_classified_as_pathogenic_for_MYH-associated_polyposis._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|This_variant_is_denoted_MUTYH_c.1214C>T_at_the_cDNA_level,_p.Pro405Leu_(P405L)_at_the_protein_level,_and_results_in_the_change_of_a_Proline_to_a_Leucine_(CCG>CTG)._MUTYH_Pro405Leu,_also_denoted_as_Pro391Leu_and_Pro377Leu_using_alternate_nomenclature,_has_been_published_in_the_literature_as_a_Dutch_founder_variant,_and_when_found_in_the_homozygous_state_or_in_combination_with_another_pathogenic_MUTYH_variant,_is_known_to_cause_MUTYH-associated_polyposis_(MAP)_(Nielsen_2005,_Aretz_2006,_Kanter-Smoler_2006,_Bouguen_2007,_Vogt_2009,_Morak_2010,_Wasielewski_2010)._Multiple_in_vivo_and_in_vitro_functional_studies_demonstrate_that_MUTYH_Pro405Leu_is_associated_with_severely_impaired_glycosylase_activity_and_severely_suppressed_oxidative_mutagenesis_(Kundu_2009,_Goto_2010,_Shinmura_2012)._MUTYH_Pro405Leu_was_observed_at_an_allele_frequency_of_0.013%_(16/126,332)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_NUDIX_Domain_(Ruggieri_2013)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||This_is_a_missense_alteration_in_which_a_C_is_replaced_by_a_T_at_coding_nucleotide_1214_and_is_predicted_to_change_a_Proline_to_a_Leucine_at_amino_acid_codon_405._Classification_criteria:_PS3,_PM2,_PM3,_PP3,_PP5.
NM_001128425.1:c.1187G>A	MUTYH	missense_variant,splice_region_variant	102092	501	15430	73	5&5&5&5&5	2&0&2&2&0	rs36053993	MYH-associated polyposis&Endometrial carcinoma&not provided&Hereditary cancer-predisposing syndrome&Carcinoma of colon	5294	20333	Small_intestine_carcinoid|Neoplasm_of_stomach|Pilomatrixoma|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|Colorectal_adenomatous_polyposis,_autosomal_recessive,_with_pilomatricomas|not_specified|endometrial_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0006722,MedGen:C1868072|Human_Phenotype_Ontology:HP:0006753,MeSH:D013274,MedGen:C0038356,OMIM:613659,SNOMED_CT:126824007|Human_Phenotype_Ontology:HP:0030434,MeSH:D018296,MedGen:C0206711,OMIM:132600,Orphanet:ORPHA91414|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:C4016911|MedGen:CN169374|MedGen:CN235594|MedGen:CN517202	-	NC_000001.10:g.45797228C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Center_for_Human_Genetics,_Inc:MUTYH-A4|Donald_Williams_Parsons_Laboratory,Baylor_College_of_Medicine:851773|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2010|HGMD:CM020287|OMIM_Allelic_Variant:604933.0002	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	36053993	-	OMIM|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|GeneReviews|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Donald_Williams_Parsons_Laboratory,Baylor_College_of_Medicine|Counsyl|Center_for_Human_Genetics,_Inc|Mendelics|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|OMIM|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Vantari_Genetics|Color|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|True_Health_Diagnostics|GeneKor_MSA|ITMI|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Pathway_Genomics|Division_of_Human_Genetics,Children's_Hospital_of_Philadelphia|Endocrine_oncology_group,Uppsala_University|Genetic_Services_Laboratory,_University_of_Chicago|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|GenomeConnect,_ClinGen	Pathogenic|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided	2011-09-01|2012-07-13|2019-10-08|2019-01-11|2015-03-04|2016-11-09|2015-10-12|2015-07-01|2016-11-01|2018-07-02|2019-12-18|2011-09-01|2018-02-27|2018-10-29|2016-08-15|0000-00-00|2016-03-22|2019-07-31|2015-11-20|2015-12-21|2016-02-16|2018-05-23|2017-12-29|2018-08-01|2013-09-19|2018-08-01|2014-07-24|2015-06-04|2017-03-09|2016-08-26|2017-05-18|2017-08-09|0000-00-00	2019-08-20|0000-00-00|2019-12-13|2019-03-28|2019-03-21|2017-04-19|2016-08-18|2017-06-22|2017-12-20|2018-08-20|2019-12-18|2019-08-20|2018-09-19|2019-01-29|2018-08-31|2017-10-31|2018-01-29|2020-02-26|2016-03-03|2016-03-29|2017-01-26|2018-05-23|2018-03-08|2018-08-08|2014-05-29|2019-08-05|2014-08-08|2017-01-23|2017-06-12|2017-07-05|2017-05-23|2018-01-25|2018-03-13	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided	germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown	SCV000025796|SCV000043370|SCV000057867|SCV000166443|SCV000245638|SCV000592711|SCV000599972|SCV000678192|SCV000781800|SCV000837751|SCV000993433|SCV000025797|SCV000111383|SCV000149657|SCV000601628|SCV000691947|SCV000806339|SCV000184573|SCV000266099|SCV000267061|SCV000537630|SCV000679736|SCV000788060|SCV000821744|SCV000085795|SCV000604306|SCV000189964|SCV000536693|SCV000536689|SCV000595873|SCV000611285|SCV000697670|SCV000840099	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|endometrial_cancer|not_provided|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|Carcinoma_of_colon|MYH-associated_polyposis/Neoplasm_of_stomach|Small_intestine_carcinoid|Colorectal_adenomatous_polyposis,_autosomal_recessive,_with_pilomatricomas|MYH-associated_polyposis/Pilomatrixoma/Neoplasm_of_stomach|MUTYH-associated_polyposis|MUTYH-associated_polyposis	|Converted_during_submission_to_Pathogenic.||This_sequence_change_replaces_glycine_with_aspartic_acid_at_codon_396_of_the_MUTYH_protein_(p.Gly396Asp)._The_glycine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_glycine_and_aspartic_acid._This_variant_is_a_known_common_cause_of_MUTYH-associated_polyposis_(PMID:_23035301)._This_variant_has_been_reported_to_co-segregate_with_disease_in_individuals_affected_with_colorectal_cancer,_familial_adenomatous_polyposis_(FAP),_and_attenuated_FAP_(PMID:_11818965,_16557584,_17489848,_19793053).Â¬â€ This_variant_is_also_known_as_c.1145G>A_(p.Gly382Asp)_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_5294)._MUTYH-related_conditions_are_inherited_in_an_autosomal_recessive_fashion._However,_there_is_evidence_that_monoallelic_pathogenic_MUTYH_variants_including_this_particular_variant_are_associated_with_increased_risk_of_colon_cancer_(PMID:_16492921,_19394335,_21171015,_24444654,_15931596)._Experimental_studies_have_shown_that_this_missense_change_disrupts_MUTYH_protein_function_(PMID:_15987719,_18534194,_20848659,_23108399)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Gly396Asp_variant_in_MUTYH_is_a_well-established_pathogenic_variant_for_MU_TYH-related_attenuated_familial_adenomatous_polyposis_and_is_estimated_to_accoun_t_for_50-82%_of_MUTYH-associated_polyposis_in_European_patients_(Al-Tassan_2002,_Nielsen_2009,_Vogt_2009,_Nascimbeni_2010,_Aretz_2014,_ClinVar:_Variation_ID_529_4)._In_vitro_functional_studies_provide_some_evidence_that_the_p.Gly396Asp_varia_nt_may_impact_protein_function_(Al-Tassan_2002,_Ali_2008,_Goto_2010)._This_vari_ant_has_also_been_identified_in_0.5%_(608/126146)_of_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org/:_dbSNP_r_s36053993):_however,_this_frequency_is_low_enough_to_be_consistent_with_a_recess_ive_carrier_frequency._Computational_prediction_tools_and_conservation_analysis_suggest_that_the_p.Gly396Asp_variant_may_impact_the_protein._In_summary,_this_va_riant_meets_criteria_to_be_classified_as_pathogenic_for_MUTYH-associated_polypos_is_in_an_autosomal_recessive_manner._ACMG/AMP_Criteria_applied:_PM3_VeryStrong,_PP3,_PS3_Supporting.||This_variant_has_been_previously_reported_as_disease-causing._It_would_be_pathogenic_in_a_recessive_state:_heterozygotes_would_be_carriers_for_the_condition._It_was_found_once_in_our_study_heterozygous_in_a_6-year-old_male_with_anaplastic_ganglioglioma.|||||||This_pathogenic_variant_is_denoted_MUTYH_c.1187G>A_at_the_cDNA_level,_p.Gly396Asp_(G396D)_at_the_protein_level,_and_results_in_the_change_of_a_Glycine_to_an_Aspartic_Acid_(GGT>GAT)._MUTYH_Gly396Asp,_also_annotated_as_Gly382Asp_using_a_different_gene_transcript,_is_one_of_two_common_MUTYH_pathogenic_variants_which_together_account_for_up_to_80%_of_pathogenic_MUTYH_variants._It_has_been_observed_in_the_homozygous_and_compound_heterozygous_state_in_multiple_individuals_with_MUTYH-Associated_Polyposis,_including_affected_siblings_(Al-Tassan_2002,_de_Leon_2017,_Yurgelun_2017)._Multiple_in_vitro_functional_studies_demonstrate_this_variant's_pathogenic_effect_(Al-Tassan_2002,_Ali_2008,_Goto_2010)._MUTYH_Gly396Asp_was_observed_at_an_allele_frequency_of_0.48%_(611/126146)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_8-oxo-G_binding_site_within_the_Nudix_domain_(Ruggieri_2013)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._We_consider_this_variant_to_be_pathogenic.||||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_strong_data_supporting_pathogenic_classification||||||||The_MUTYH_c.1187G>A:_p.Gly396Asp_variant_(rs36053993:_also_known_as_NM_001048171.1:_c.1145G>A:_p.Gly382Asp)_has_been_well_described_in_the_literature_as_one_of_the_two_common_MUTYH_pathogenic_variants._It_has_been_observed_in_homozygous_or_compound_heterozygous_form_with_other_pathogenic_MUTYH_variants_in_patients_with_adenomatous_polyposis_syndrome_(Al-Tassan_2002,_Nielsen_2009,_Ruggieri_2013),_and_is_enriched_in_patients_with_an_odds_ratio_of_6.47_(Theodoratou_2010)._Functional_characterization_of_the_variant_protein_indicates_a_partial_reduction_in_DNA_binding_and_glycosylase_activity_(Ali_2008,_D'Agostino_2010,_Goto_2010,_Komine_2015,_Kundu_2009,_Molatore_2010,_Ruggieri_2013)._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Ali_M_et_al._Characterization_of_mutant_MUTYH_proteins_associated_with_familial_colorectal_cancer._Gastroenterology._2008_135(2):499-507._Al-Tassan_N_et_al._Inherited_variants_of_MYH_associated_with_somatic_G:C-->T:A_mutations_in_colorectal_tumors._Nat_Genet._2002_30(2):227-32._D'Agostino_V_et_al._Functional_analysis_of_MUTYH_mutated_proteins_associated_with_familial_adenomatous_polyposis._DNA_Repair_(Amst)._2010_9(6):700-7._Goto_M_et_al._Adenine_DNA_glycosylase_activity_of_14_human_MutY_homolog_(MUTYH)_variant_proteins_found_in_patients_with_colorectal_polyposis_and_cancer._Hum_Mutat._2010_31(11):E1861-74._Komine_K_et_al._Functional_Complementation_Assay_for_47_MUTYH_Variants_in_a_MutY-Disrupted_Escherichia_coli_Strain._Hum_Mutat._2015_36(7):704-11._Kundu_S_et_al._Adenine_removal_activity_and_bacterial_complementation_with_the_human_MutY_homologue_(MUTYH)_and_Y165C,_G382D,_P391L_and_Q324R_variants_associated_with_colorectal_cancer._DNA_Repair_(Amst)._2009_8(12):1400-10._Molatore_S_et_al._MUTYH_mutations_associated_with_familial_adenomatous_polyposis:_functional_characterization_by_a_mammalian_cell-based_assay._Hum_Mutat._2010_31(2):159-66._Nielsen_M_et_al._Analysis_of_MUTYH_genotypes_and_colorectal_phenotypes_in_patients_With_MUTYH-associated_polyposis._Gastroenterology._2009_136(2):471-6._Ruggieri_V_et_al._Loss_of_MUTYH_function_in_human_cells_leads_to_accumulation_of_oxidative_damage_and_genetic_instability._Oncogene._2013_32(38):4500-8._Theodoratou_E_et_al._A_large-scale_meta-analysis_to_refine_colorectal_cancer_risk_estimates_associated_with_MUTYH_variants._Br_J_Cancer._2010_Dec_7:103(12):1875-84.||||||Variant_summary:_The_MUTYH_c.1187G>A_(p.Gly396Asp)_variant_involves_the_alteration_of_a_conserved_nucleotide._3/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant._Functional_studies_support_a_damaging_outcome,_and_at_least_2_independent_labs_have_down_reduced_DNA_glycosylase_activity_and_a_reduced_ability_to_suppress_the_mutation_frequency_in_a_complementation_assay._This_variant_was_found_in_339/120440_control_chromosomes_(2_homozygotes)_at_a_frequency_of_0.0028147,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MUTYH_variant_(0.0045644)._The_variant_has_been_reported_in_numerous_patients_in_the_literature,_and_is_known_as_a_common_pathogenic_variant._In_addition,_many_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.
NM_001128425.1:c.933+3A>C	MUTYH	splice_region_variant,intron_variant	102730	14	15420	2	-	-	-	-	135992	139704	Colon_cancer|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	Human_Phenotype_Ontology:HP:0003003,MedGen:C0007102|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45797835T>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	University_Medical_Centre_Ljubljana:CMGVARID00681	-	MUTYH:4595	SO:0001627|intron_variant	1	587780751	-	Invitae|Counsyl|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Mendelics|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Ambry_Genetics|Color|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance	2018-12-31|2016-03-18|2014-10-10|2016-03-28|2018-07-02|2018-10-10|2018-10-01|2016-06-20|2018-11-21|2015-07-09|2019-01-18|2016-02-08|2017-01-01	2019-03-28|2016-11-23|2017-04-19|2019-03-21|2018-08-20|2019-08-02|2020-02-26|2017-01-26|2019-01-29|2018-09-19|2020-03-06|2018-01-25|2017-12-08	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|unknown	SCV000166462|SCV000487342|SCV000592702|SCV000711785|SCV000837759|SCV000993568|SCV000184317|SCV000537683|SCV000211413|SCV000331108|SCV001134490|SCV000697716|SCV000747463	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|MUTYH-associated_polyposis|Colon_cancer	This_sequence_change_falls_in_intron_10_of_the_MUTYH_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_MUTYH_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs587780751,_0.01%)._This_variant_has_been_reported_in_the_literature_as_homozygous_or_in_trans_with_pathogenic_variants_in_multiple_individuals_affected_with_adenomatous_polyposis_and_it_is_considered_a_founder_mutation_for_MUTYH-associated_polyposis_in_North-Eastern_Italy_(PMID:_12853198,_16616356,_19732775,_22773231,_22865608)._This_variant_is_also_known_as_c.891+3A>C_in_the_literature._Clinvar_contains_an_entry_for_this_variant_(Variation_ID:_135992)._This_variant_falls_in_intron_10_of_the_MUTYH_mRNA_and_is_reported_to_cause_skipping_of_exon_10Â¬â€ (PMID:Â¬â€ 16616356,Â¬â€ 22865608)._The_absence_of_exon_10_in_the_MUTYH_mRNA_results_in_a_translational_frameshift_and_premature_stop_codon_(p.Gly264TrpfsX7),_which_ultimately_leads_to_nonsense_mediated_decay_and_severely_impaired_expression_of_the_MUTYH_mRNA_and_protein_(PMID:_16616356,_22865608,Â¬â€ 23108399)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||The_c.933+3A>C_variant_in_MUTYH_has_been_previously_reported_in_24_individuals_(_23_were_compound_heterozygotes,_1_was_a_homozygote,_and_1_was_a_heterozygote)_wi_th_MUTYH-related_attenuated_familial_adenomatous_polyposis_(FAP)and_segregated_w_ith_disease_in_7_affected_family_members_(Sampson_2003,_Vogt_2009,_Pin_2013)._It_has_been_identified_in_7/66554_of_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs587780751)._This_freq_uency_is_low_enough_to_be_consistent_with_the_carrier_frequency_of_MUTYH-related_attenuated_FAP_in_the_general_population._This_variant_is_located_in_the_5'_spl_ice_region._Computational_tools_do_suggest_an_impact_to_splicing_and_functional_studies_provide_evidence_that_this_variant_alters_splicing_(Pin_2013)._In_summar_y,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_FAP_in_an_aut_osomal_recessive_manner_based_on_the_reported_number_of_probands,_segregations,_and_functional_studies.|||Functionally-validated_splicing_mutation_:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_variant_is_denoted_MUTYH_c.933+3A>C_or_IVS10+3A>C_and_consists_of_an_A>C_nucleotide_substitution_at_the_+3_position_of_intron_10_of_the_MUTYH_gene._This_variant,_also_published_as_891+3A>C_or_Gly250TrpfsX7,_has_been_reported_in_multiple_polyposis_and_colorectal_cancer_patients,_is_considered_a_founder_variant_in_Italian_populations,_and_has_been_demonstrated_to_cause_skipping_of_exon_10_(Sampson_2003,_Kanter-Smoler_2006,_Olschwang_2007,_Vogt_2009,_Pin_2012,_Ruggieri_2013,_Yurgelun_2015)._MUTYH_c.933+3A>C_was_observed_at_an_allele_frequency_of_0.01%_(17/126656)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.||The_best_available_variant_frequency_is_uninformative._Found_in_at_least_one_symptomatic_patient._Predicted_to_negatively_affect_a_known_splice_site._Nucleotide_conservation_is_uninformative._Occurs_in_multiple_cases_with_a_recessive_pathogenic_variant_in_the_same_gene._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.|Variant_summary:_MUTYH_c.933+3A>C_variant_affects_a_non-conserved_intronic_nucleotide._Mutation_Taster_predicts_a_damaging_outcome_for_this_variant,_and_5/5_Alamut_algorithms_predict_the_variant_to_alter_normal_splicing,_which_is_supported_by_patient_cDNA_showing_that_this_variant_results_in_a_fusion_of_exon_9_to_exon_11._This_variant_is_found_in_8/124162_control_chromosomes_at_a_frequency_of_0.0000644,_which_does_not_significantly_exceed_maximal_expected_frequency_of_a_pathogenic_allele_(0.0055902)._However,_the_variant_has_been_cited_in_numerous_CRC_patients_in_the_literature._In_addition,_several_diagnostic_clinical_laboratories_and_databases_classified_this_variant_as_pathogenic._Taken_together,_this_is_a_disease_variant_and_was_classified_as_pathogenic.|
NM_001128425.1:c.884C>T	MUTYH	missense_variant	102614	3	NA	NA	5&5	1&1	rs374950566	Hereditary cancer-predisposing syndrome&not provided	185242	181683	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45797887G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	374950566	-	Sinai_Health_System|Counsyl	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2019-03-31|2017-03-06|2018-08-01|2016-02-22|2018-12-17|2014-08-29|2017-12-22	2020-02-26|2017-10-26|2018-08-08|2019-01-29|2019-03-28|2017-04-19|2018-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown	SCV000215289|SCV000685679|SCV000821747|SCV000293494|SCV000545714|SCV000592700|SCV000796726	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis	Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Deficient_protein_function_by_in_vitro/ex_vivo_assay:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|||This_pathogenic_variant_is_denoted_MUTYH_c.884C>T_at_the_cDNA_level,_p.Pro295Leu_(P295L)_at_the_protein_level,_and_results_in_the_change_of_a_Proline_to_a_Leucine_(CCA>CTA)._This_variant_was_observed_in_both_the_homozygous_and_compound_heterozygous_state_in_individuals_affected_with_MUTYH_Associated_Polyposis_(Jones_2009,_Nielsen_20009,_Vogt_2009,_Morak_2010)._In_addition,_this_variant_showed_defective_DNA_binding_capability,_compromised_base_excision_activity_and_near_absent_glycosylase_activity_(Ali_2008,_Brinkmeyer_2015,_Komine_2015),_MUTYH_Pro295Leu_was_not_observed_at_a_significant_allele_frequency_in_the_NHLBI_Exome_Sequencing_Project._Since_Proline_and_Leucine_differ_in_some_properties,_this_is_considered_a_semi-conservative_amino_acid_substitution._MUTYH_Pro295Leu_occurs_at_a_position_that_is_conserved_across_species_and_is_located_in_the_within_FeS_cluster_(Ruggieri_2013)._In_silico_analyses_predict_that_this_pathogenic_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|This_sequence_change_replaces_proline_with_leucine_at_codon_295_of_the_MUTYH_protein_(p.Pro295Leu)._The_proline_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_proline_and_leucine._This_variant_is_present_in_population_databases_(rs374950566,_ExAC_0.002%)._This_variant_has_been_reported_in_several_individuals_affected_with_polyposis_and/or_colorectal_cancer_(PMID:_19732775,_17219385,_20618354,_19394335,_19032956,_16557584),_and_in_the_Leiden_Open-source_Variation_Database_(PMID:_20725929)._This_variant_co-occurs_with_different_pathogenic_alterations_in_individuals_with_multiple_adenomatous_polyps_(PMID:_17219385,_19732775,_16941501),_and_has_been_reported_as_homozygous_in_an_affected_individual_(PMID:_20725929)._This_variant_is_also_known_as_c.842C>T_(P281L)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185242)._Experimental_studies_have_shown_that_this_missense_change_causes_defective_DNA_binding_and_reduced_glycosylase_activity_in_vitro_(PMID:_25820570,_26377631,_18534194)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||
NM_001128425.1:c.847A>G	MUTYH	missense_variant	102432	1	NA	NA	4	1	rs876659676	Hereditary cancer-predisposing syndrome	232291	232244	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45797924T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	876659676	-	Ambry_Genetics|Color|GeneDx|Invitae	Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2018-01-22|2018-07-12|2015-09-08|2018-12-11	2020-02-26|2018-11-06|2019-01-29|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000276384|SCV000911616|SCV000567803|SCV000639358	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|MYH-associated_polyposis	Rarity_in_general_population_databases_(dbSNP,_ESP,_1000_Genomes):in_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_in_appropriate_functional_assay(s):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_by_in_vitro/ex_vivo_assay:Other_data_supporting_pathogenic_classification||This_pathogenic_variant_is_denoted_MUTYH_c.847A>G_at_the_cDNA_level,_p.Met283Val_(M283V)_at_the_protein_level,_and_results_in_the_change_of_a_Methionine_to_a_Valine_(ATG>GTG)._This_variant,_also_published_as_MUTYH_c.805A>G_and_p.Met269Val_as_well_as_c.763A>G_and_p.Met255Val,_has_been_observed_in_a_compound_heterozygous_state_in_three_individuals,_two_of_whom_were_siblings:_one_was_reported_to_have_a_history_of_cecal_cancer_and_the_other_two_had_multiple_adenomatous_polyps_(Lejeune_2006,_van_Puijenbroek_2008)._Additionally,_MUTYH_Met283Val_has_been_shown_to_severely_reduce_gycosylase_activity_in_vitro_and_the_ability_of_MUTYH_to_repair_8-hydroxyguanine_induced_DNA_damage_in_human_cells_compared_to_wild_type_controls_(Goto_2010,_Shinmura_2012)._MUTYH_Met283Val_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_indicating_it_is_not_a_common_benign_variant_in_these_populations._Since_Methionine_and_Valine_share_similar_properties,_this_is_considered_a_conservative_amino_acid_substitution._MUTYH_Met283Val_occurs_at_a_position_that_is_conserved_across_species_and_is_located_in_the_FeS_cluster_(Ruggieri_2013)._In_silico_analyses_predict_that_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.Although_this_variant_is_considered_pathogenic,_a_second_mutation,_as_would_be_required_for_expression_of_the_recessive_condition_MAP,_was_not_detected_in_this_individual._The_possibility_that_this_patient_harbors_a_second_disease-causing_MUTYH_mutation_that_is_undetectable_by_this_test_cannot_be_excluded._While_a_single_variant_in_the_MUTYH_gene_has_been_reported_in_association_with_a_slightly_increased_risk_for_colon_cancer,_endometrial_cancer,_and_breast_cancer,_particularly_among_those_with_a_family_history_of_colorectal_cancer_(Jenkins_2006,_Win_2011,_Rennert_2012),_there_are_conflicting_data_regarding_these_associations_(Santonocito_2011,_Out_2012)._MUTYH-associated_polyposis_(MAP)_is_an_autosomal_recessive_condition_caused_by_two_mutations_(one_affecting_each_allele)_in_the_MUTYH_gene_which_results_in_an_increased_risk_for_the_development_of_colon_cancer_and_colon_polyps._If_a_MUTYH_mutation_carrier'spartner_is_also_heterozygous_for_a_MUTYH_mutation,_the_risk_to_have_a_child_with_MAP_is_25%_with_each_pregnancy._One_study_from_the_UK_estimated_the_overall_carrier_frequency_for_any_MUTYH_mutation_to_be_about_2%_(Aretz_2010).|This_sequence_change_replaces_methionine_with_valine_at_codon_283_of_the_MUTYH_protein_(p.Met283Val)._The_methionine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_methionine_and_valine._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_to_co-occur_with_another_MUTYH_variant_in_individuals_affected_with_MUTYH-associated_polyposis_including_evidence_of_segregation_in_one_family_(PMID:_18172263,_16941501)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_232291)._Experimental_studies_have_shown_that_this_missense_change_impairs_the_glycosylase_activity_and_the_suppression_of_oxidative_mutagenesis_activity_of_the_encoded_protein_(PMID:_20848659,_23322991)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_001128425.1:c.734G>A	MUTYH	missense_variant	102412	14	15412	0	5&5&5	1&1&1	rs140342925	Hereditary cancer-predisposing syndrome&MYH-associated polyposis&not provided	140877	150591	Neoplasm_of_stomach|Pilomatrixoma|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	Human_Phenotype_Ontology:HP:0006753,MeSH:D013274,MedGen:C0038356,OMIM:613659,SNOMED_CT:126824007|Human_Phenotype_Ontology:HP:0030434,MeSH:D018296,MedGen:C0206711,OMIM:132600,Orphanet:ORPHA91414|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45798117C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	140342925	-	Ambry_Genetics|Color|GeneKor_MSA|Invitae|Counsyl|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-10-01|2016-06-14|2018-08-01|2018-11-05|2016-03-31|2014-12-18|2019-01-16|2016-10-13|2017-05-18|2017-09-07	2020-02-26|2017-01-26|2018-08-08|2019-03-28|2016-11-23|2017-04-19|2019-01-29|2017-08-01|2017-05-23|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|unknown|germline	SCV000183816|SCV000537663|SCV000821746|SCV000253868|SCV000487344|SCV000592696|SCV000211405|SCV000601660|SCV000611287|SCV000919794	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided|MYH-associated_polyposis/Pilomatrixoma/Neoplasm_of_stomach|MUTYH-associated_polyposis	Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_strong_data_supporting_pathogenic_classification_:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|||This_sequence_change_replaces_arginine_with_histidine_at_codon_245_of_the_MUTYH_protein_(p.Arg245His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs140342925,_ExAC_0.02%)._This_variant_has_been_reported_as_homozygous_or_as_compound_heterozygous_in_several_individuals_affected_with_familial_adenomatous_polyposis_and_colorectal_cancer_(PMID:_16134147,_19732775,_23108399,_24444654,_26446593,_16557584)._This_variant_is_also_known_as_c.692G>A_(p.Arg231His)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140877)._Experimental_studies_have_shown_that_this_variant_severely_affects_several_aspects_of_MUTYH_protein_function_(PMID:_18534194,_17081686,_23108399,_24569162,_25820570)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||This_pathogenic_variant_is_denoted_MUTYH_c.734G>A_at_the_cDNA_level,_p.Arg245His_(R245H)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Histidine_(CGT>CAT)._This_variant,_also_known_as_MUTYH_Arg231His_using_an_alternative_reference_sequence_(NM_001048171.1),_has_been_observed_in_the_compound_heterozygous_or_homozygous_state_in_numerous_individuals_with_a_history_of_polyps_and/or_colon_cancer_(Aceto_2005,_Piccioli_2006,_Olschwang_2007,_Russell_2006,_Vogt_2009,_Win_2014,_Papp_2016,_Viel_2017,_Ricci_2017)._Functional_studies_have_shown_that_this_variant_results_in_decreased_MUTYH_protein_expression,_impaired_glycosylase_activity,_and_an_increase_in_spontaneous_mutation_events_(Ali_2008,_Ruggieri_2013,_Grasso_2014._Komine_2015)._MUTYH_Arg245His_was_observed_at_an_allele_frequency_of_0.03%_(5/18,840_alleles)_in_individuals_of_East_Asian_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_FeS_cluster_(Ruggieri_2013)._In-silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_information,_we_consider_MUTYH_Arg245His_to_be_pathogenic.|||Variant_summary:_The_MUTYH_c.734G>A_(p.Arg245His)_variant_causes_a_missense_change_involving_the_alteration_of_a_conserved_nucleotide_located_in_the_DNA_glycosylase_domain_and_the_Helix-turn-helix,_base-excision_DNA_repair,_C-terminal_domain_of_the_protein_(InterPro)._4/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant_(SNPsandGO_not_captured_due_to_low_reliability_index)._Functional_assays_showed_the_variant_to_be_associated_with_defective_glycosylase_and_DNA_binding_activity_and_concluded_that_this_variant_is_functionally_defective_(Ali_2008,_Komine_2015).The_variant_was_found_in_the_control_population_dataset_of_ExAC_in_16/119648_control_chromosomes_at_a_frequency_of_0.0001337,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MUTYH_variant_(0.0045644)._This_variant_has_been_reported_in_numerous_MUTYH-associated_polyposis_patients,_in_both_homozygotes_and_compound_heterozygotes_(Aceto_2005,_Vogt_2009)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.
NM_001128425.1:c.733C>T	MUTYH	missense_variant	102416	1	NA	NA	5	1	rs200495564	Hereditary cancer-predisposing syndrome	41761	50200	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|Familial_colorectal_cancer|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN029768|MedGen:CN517202	-	NC_000001.10:g.45798118G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	200495564	-	Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Ambry_Genetics|Color|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America|Snyder_Lab,_Genetics_Department,Stanford_University	probably_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-07-13|2018-12-11|2015-08-05|2019-04-05|2017-02-24|2017-05-30|2019-04-22|2017-01-01	0000-00-00|2019-03-28|2017-04-19|2020-02-26|2017-10-26|2019-01-29|2019-09-24|2018-10-29	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000043376|SCV000285964|SCV000592695|SCV000184645|SCV000685666|SCV000565259|SCV000697708|SCV000853090	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|MUTYH-associated_polyposis|Familial_colorectal_cancer	Converted_during_submission_to_Likely_pathogenic.|This_sequence_change_replaces_arginine_with_cysteine_at_codon_245_of_the_MUTYH_protein_(p.Arg245Cys)._The_arginine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_arginine_and_cysteine._This_variant_is_present_in_population_databases_(rs200495564,_ExAC_0.03%)._This_variant_has_been_reported_as_homozygous_or_compound_heterozygous_with_another_pathogenic_variant_in_several_individuals_with_MUTYH-associated_polyposis_and_familial_adenomatous_polyposis_(PMID:_15890374,_23108399,_17949294)._This_variant_is_also_known_as_c.691C>T_(p.Arg231Cys)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_41761)._Experimental_studies_have_shown_that_this_missense_change_disrupts_MUTYH_protein_function_(PMID:_23108399,_25820570)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Deficient_protein_function_by_in_vitro/ex_vivo_assay:2_of_classification_of_c_(below)_met_(2c_
NM_001128425.1:c.722G>A	MUTYH	missense_variant	102450	1	NA	NA	-	-	-	-	406867	391321	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798	-	NC_000001.10:g.45798129C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	1060501346	-	Invitae|Color|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-05-24|2018-09-07|2019-05-17	2018-08-29|2018-11-06|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000545803|SCV000690604|SCV001188511	MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_replaces_arginine_with_glutamine_at_codon_241_of_the_MUTYH_protein_(p.Arg241Gln)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_glutamine._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_with_a_second_pathogenic_MUTYH_variant_(p.Gly396Asp)_in_an_individual_with_polyposis_(100-500_polyps)_and_colorectal_cancer_(PMID:_19732775)._In_addition,_this_variant_has_been_observed_as_homozygous_in_individuals_with_polyposis_or_colon_cancer_(PMID:_21520333,_Invitae)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_406867)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_(SIFT,_PolyPhen-2,_Align-GVGD)_all_suggest_that_this_variant_is_likely_to_be_disruptive,_but_these_predictions_have_not_been_confirmed_by_published_functional_studies._A_different_missense_substitution_at_this_codon_(p.Arg241Trp,_also_known_as_p.Arg227Trp_in_the_literature)_has_been_determined_to_be_pathogenic_(PMID:_15673720,_25820570,_24470512,_14991577,_27194394,_Invitae)._This_suggests_that_the_arginine_residue_is_critical_for_MUTYH_protein_function_and_that_other_missense_substitutions_at_this_position_may_also_be_pathogenic._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_001128425.1:c.721C>T	MUTYH	missense_variant	102416	7	15406	0	4&5	1&1	rs34126013	Hereditary cancer-predisposing syndrome&not provided	185274	181693	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45798130G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:817461	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	34126013	-	Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Illumina_Clinical_Services_Laboratory,Illumina|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Counsyl|Mendelics	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-11-17|2018-07-25|2019-01-04|2018-09-04|2016-06-14|2018-12-26|2015-06-11|2017-01-04|2018-07-02	2020-02-26|2018-11-06|2019-01-29|2020-03-06|2016-10-18|2019-03-28|2017-04-19|2017-06-22|2018-08-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|unknown	SCV000215329|SCV000685663|SCV000292738|SCV001134483|SCV000357900|SCV000545770|SCV000592694|SCV000678194|SCV000837764	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Rarity_in_general_population_databases_(dbSNP,_ESP,_1000_Genomes):in_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous||This_pathogenic_variant_is_denoted_MUTYH_c.721C>T_at_the_cDNA_level,_p.Arg241Trp_(R241W)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Tryptophan_(CGG>TGG)._This_variant,_also_known_as_MUTYH_Arg227Trp_using_an_alternate_reference_sequence_(NM_001048171.1),_has_been_observed_in_individuals_in_the_compound_heterozygous_state_or_homozygous_state_in_individuals_with_multiple_polyps_and/or_colorectal_cancer_(Fleischmann_2004,_Isidro_2004,_Torrezan_2013,_Guarinos_2014)._Functional_studies_have_shown_that_this_variant_is_deficient_in_glycosylase_activity_and_partially_deficient_in_base_excision_repair_activity_(Bai_2005,_Komine_2015)._MUTYH_Arg241Trp_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_MSH6_binding_domain_(Gu_2002,_Ruggieri_2013)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|The_best_available_variant_frequency_is_uninformative_because_it_is_below_the_disease_allele_frequency._Found_in_at_least_one_symptomatic_patient._Predicted_to_have_a_damaging_effect_on_the_protein._Occurs_in_multiple_cases_with_a_recessive_pathogenic_variant_in_the_same_gene._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.|The_c.721C>T_(p.Arg241Trp)_variant,_also_referred_to_as_c.679C>T_(p.Arg227Trp),_has_been_reported_in_five_studies_in_which_it_is_found_in_a_total_of_six_MYH-associated_polyposis_patients,_including_two_siblings_in_a_homozygous_state_and_four_patients_in_a_compound_heterozygous_state_with_one_of_the_common_pathogenic_MUTYH_missense_variants_(Isidro_et_al._2004:_Fleischmann_et_al._2004:_Bai_et_al._2005:_Torrezan_et_al._2013:_Guarinos_et_al._2014)._The_variant_was_absent_from_354_controls_(Fleischmann_et_al._2004)_but_is_reported_at_a_frequency_of_0.00042_in_the_South_Asian_population_of_the_Exome_Aggregation_Consortium._Functional_studies_demonstrated_that_the_p.Arg241Trp_variant_has_a_severe_defect_in_adenine_(A)_/7,8-dihydro-8-oxo-guanine_binding_and_therefore_in_the_ability_to_catalyze_adenine_excision_from_A/GO_mismatches,_one_of_the_main_functions_of_the_protein._The_p.Arg241Trp_variant_was_also_shown_to_have_no_detectable_glycosylase_activity_and_failed_to_complement_mut_Y-deficiency_in_E._coli._The_variant_does_not_affect_binding_to_the_hMSH2/hMSH6_complex_(Bai_et_al._2005:_Komine_et_al._2015)._Based_on_the_collective_evidence,_the_p.Arg241Trp_variant_is_classified_as_likely_pathogenic_for_MYH-associated_polyposis.|This_sequence_change_replaces_arginine_with_tryptophan_at_codon_241_of_the_MUTYH_protein_(p.Arg241Trp)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_tryptophan._This_variant_is_present_in_population_databases_(rs34126013,_ExAC_0.04%)._This_variant_has_been_reported_as_heterozygous_with_another_pathogenic_variant_in_MUTYH_in_multiple_individuals_affected_with_polyposis_and/or_colorectal_cancer_(PMID:_24470512,_14991577,_27194394),_and_as_homozygous_in_two_siblings_from_a_family_affected_with_polyposis_(PMID:_23561487)._This_variant_is_also_known_as_c.679C>T_(p.Arg227Trp)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185274)._Experimental_studies_suggest_that_this_missense_change_disrupts_MUTYH_protein_function_in_vitro_and_in_a_bacteria-based_functional_assay_(PMID:_15673720,_25820570)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|||
NM_001128425.1:c.690G>A	MUTYH	splice_region_variant,synonymous_variant	102728	1	NA	NA	-	-	-	-	481804	472448	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45798246C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001819|synonymous_variant	1	199989617	-	Ambry_Genetics|Color|Invitae|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2016-04-28|2018-06-09|2018-09-04|2018-03-27	2020-02-26|2018-11-06|2019-03-28|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000666478|SCV000913515|SCV000831079|SCV000888323	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	Last_nucleotide_of_exon_with_predicted_splicing_impact_in_agreement:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_data_supporting_pathogenic_classification||This_sequence_change_affects_codon_230_of_the_MUTYH_mRNA._It_is_a_'silent'_change,_meaning_that_it_does_not_change_the_encoded_amino_acid_sequence_of_the_MUTYH_protein._This_variant_also_falls_at_the_last_nucleotide_of_exon_8_of_the_MUTYH_coding_sequence,_which_is_part_of_the_consensus_splice_site_for_this_exon._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_MUTYH-associated_polyposis_and_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_a_pathogenic_variant_in_at_least_two_of_these_individuals_(PMID:_19732775,Â¬â€ 25559809)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 481804)._Nucleotide_substitutions_within_the_consensus_splice_site_are_a_relatively_common_cause_of_aberrant_splicing_(PMID:_17576681,_9536098)._An_experimental_study_has_shown_that_this_silent_change_can_results_in_skipping_of_exon_8Â¬â€ or_exons_8-9_of_the_MUTYH_mRNA._(PMID:Â¬â€ 18515411)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_001128425.1:c.545G>A	MUTYH	missense_variant	102742	2	NA	NA	5&5&5	1&1&1	rs143353451	not provided&MYH-associated polyposis&Hereditary cancer-predisposing syndrome	182689	179937	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN169374|MedGen:CN517202	-	NC_000001.10:g.45798466C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2012	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	143353451	-	GeneDx|Invitae|Mendelics|Ambry_Genetics|Color|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-20|2018-10-07|2018-07-02|2019-03-17|2017-01-05|2016-11-02|2019-01-29	2019-01-29|2019-03-28|2018-08-20|2020-02-26|2017-10-26|2017-06-30|2019-09-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline	SCV000211402|SCV000253867|SCV000837774|SCV000273003|SCV000685639|SCV000604307|SCV000697702	not_provided|MYH-associated_polyposis|MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|MUTYH-associated_polyposis	This_pathogenic_variant_is_denoted_MUTYH_c.545G>A_at_the_cDNA_level,_p.Arg182His_(R182H)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Histidine_(CGT>CAT)._Using_alternate_nomenclature,_this_variant_has_been_previously_published_as_MUTYH_R168H_and_R154H._MUTYH_Arg182His_has_been_seen_in_multiple_individuals_as_compound_heterozygotes_with_known_pathogenic_variants_and_a_phenotype_consistent_with_MUTYH-associated_polyposis_(MAP)_(Isidro_2004,_Aretz_2006,_Di_Gregorio_2006,_Nielsen_2009,_Morak_2010)._In_addition,_several_functional_assays_have_determined_that_this_variant_severely_affects_glycosylation_and_suppresses_oxidative_mutagenesis_(Goto_2010,_Shinmura_2012,_Komine_2015)._MUTYH_Arg182His_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_not_located_in_a_known_functional_domain._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|This_sequence_change_replaces_arginine_with_histidine_at_codon_182_of_the_MUTYH_protein_(p.Arg182His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs143353451,_ExAC_<0.01%)._This_variant_has_been_reported_in_individuals_affected_with_MUTYH-associated_polyposis._In_these_cases_this_variant_was_found_in_compound_heterozygosity_with_a_pathogenic_MUTYH_variant_(PMID:_15366000,_16557584,_20618354,_19394335,_19032956)._This_variant_is_also_known_as_R154H_and_R168H_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182689)._Experimental_studies_have_shown_that_this_missense_change_disrupts_the_DNA_glycosylase_activity_(PMID:_20848659)_and_mutation_suppressive_activity_(PMID:_23322991)_of_the_MUTYH_protein._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Deficient_protein_function_by_in_vitro/ex_vivo_assay:Well-characterized_mutation_at_same_position:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|||Variant_summary:_The_variant,_MUTYH_c.545G>A_(p.Arg182His)_results_in_a_non-conservative_amino_acid_change_located_in_the_HhH-GPD_domain_of_the_encoded_protein_sequence._Five_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_8.1e-06_in_246268_control_chromosomes_(gnomAD)._The_variant,_c.545G>A_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Attenuated_familial_adenomatous_polyposis_and_colorectal_cancer_(Morak_2010,_Komine_2015,_AlDubayan_2018,_Yugelun_2017)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._At_least_one_publication_reports_experimental_evidence_evaluating_an_impact_on_protein_function._The_most_pronounced_variant_effect_results_in_<10%_of_normal_activity_(Shinmura_2012)._Five_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation_and_have_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_001128425.1:c.544C>T	MUTYH	missense_variant	102742	1	NA	NA	5&5&4	1&1&1	rs747993448	Hereditary cancer-predisposing syndrome&MYH-associated polyposis&not provided	187280	181710	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45798467G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	747993448	-	Ambry_Genetics|Invitae|Counsyl|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2018-10-19|2018-09-20|2016-12-16|2018-03-20	2020-02-26|2019-03-28|2017-06-22|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline	SCV000217819|SCV000285955|SCV000678196|SCV000293495	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MYH-associated_polyposis|not_provided	Well-characterized_mutation_at_same_position:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Deficient_protein_function_by_in_vitro/ex_vivo_assay:2_of_classification_of_c_(below)_met_(2c_
NM_001128425.1:c.536A>G	MUTYH	missense_variant	102734	270	15406	34	5&5&5&5&5	2&0&1&2&0	rs34612342	MYH-associated polyposis&Endometrial carcinoma&not provided&Hereditary cancer-predisposing syndrome&Carcinoma of colon	5293	20332	Neoplasm_of_stomach|Endometrial_carcinoma|Pilomatrixoma|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0006753,MeSH:D013274,MedGen:C0038356,OMIM:613659,SNOMED_CT:126824007|Human_Phenotype_Ontology:HP:0012114,MedGen:C0476089,OMIM:608089,SNOMED_CT:254878006|Human_Phenotype_Ontology:HP:0030434,MeSH:D018296,MedGen:C0206711,OMIM:132600,Orphanet:ORPHA91414|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN169374|MedGen:CN517202	-	NC_000001.10:g.45798475T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2013|Center_for_Human_Genetics,_Inc:MUTYH-A2|HGMD:CM020286|Illumina_Clinical_Services_Laboratory,Illumina:143054|OMIM_Allelic_Variant:604933.0001	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	34612342	-	OMIM|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|GeneReviews|Invitae|Knight_Diagnostic_Laboratories,Oregon_Health_and_Sciences_University|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Division_of_Genomic_Diagnostics,The_Children's_Hospital_of_Philadelphia|Illumina_Clinical_Services_Laboratory,Illumina|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Counsyl|Center_for_Human_Genetics,_Inc|Mendelics|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|OMIM|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|True_Health_Diagnostics|GeneKor_MSA|ITMI|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Pathway_Genomics|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2007-12-01|2012-07-13|2019-10-08|2019-01-05|2014-10-13|2015-07-30|2015-06-25|2016-06-14|2015-11-20|2015-05-26|2016-11-01|2018-07-02|2019-03-26|2007-12-01|2017-09-26|2018-08-17|2016-09-02|0000-00-00|2016-01-06|2019-04-17|2015-11-20|2015-03-21|2017-12-08|2018-08-01|2013-09-19|2019-01-30|2014-07-24|2017-05-18|2015-11-20	2011-10-11|0000-00-00|2019-12-13|2019-03-28|2015-05-29|2019-03-21|2015-08-10|2016-10-18|2017-04-19|2017-06-22|2017-12-20|2018-08-20|2019-08-01|2011-10-11|2018-09-19|2019-01-29|2018-08-31|2017-10-31|2018-01-29|2020-02-26|2016-03-03|2017-01-26|2018-03-08|2018-08-08|2014-05-29|2019-08-05|2014-08-08|2017-05-23|2018-01-25	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|germline|unknown|unknown|unknown|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline	SCV000025794|SCV000043377|SCV000057869|SCV000166454|SCV000223938|SCV000245637|SCV000257796|SCV000357903|SCV000592686|SCV000678191|SCV000781798|SCV000837775|SCV000993434|SCV000025795|SCV000111384|SCV000149675|SCV000601651|SCV000691950|SCV000806361|SCV000185514|SCV000266097|SCV000537631|SCV000788070|SCV000821743|SCV000085805|SCV000604310|SCV000189958|SCV000611286|SCV000697700	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|Endometrial_carcinoma|not_provided|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|Carcinoma_of_colon|MYH-associated_polyposis/Pilomatrixoma/Neoplasm_of_stomach|MUTYH-associated_polyposis	|Converted_during_submission_to_Pathogenic.||This_sequence_change_replaces_tyrosine_with_cysteine_at_codon_179_of_the_MUTYH_protein_(p.Tyr179Cys)._The_tyrosine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_tyrosine_and_cysteine._This_variant_is_a_known_common_cause_of_MUTYH-associated_polyposis_(PMID:_23035301)._This_variant_has_been_reported_to_co-segregate_with_disease_in_individuals_affected_with_colorectal_cancer,_familial_adenomatous_polyposis_(FAP),_and_attenuated_FAP_(PMID:_12606733,_16557584,_17489848,_19793053,_21063410,_24444654)._This_variant_is_also_known_as_c.494A>G_(p.Tyr165Cys)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_5293)._MUTYH-related_conditions_are_inherited_in_an_autosomal_recessive_fashion._However,_there_is_evidence_that_monoallelic_pathogenic_MUTYH_variants_including_this_particular_variant_are_associated_with_increased_risk_of_colon_cancer_(PMID:_16492921,_19394335,_21171015,_24444654)._Experimental_studies_have_shown_that_this_missense_change_disrupts_MUTYH_protein_function_(PMID:_11818965,_18534194,_19953527,_20848659)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Tyr179Cys_variant_in_MUTYH_is_a_well-established_pathogenic_variant_for_MU_TYH-associated_polyposis,_segregating_with_disease_in_multiple_affected_individu_als_(Nielsen_2009,_Vogt_2009)._This_variant_has_also_been_reported_by_other_clin_ical_laboratories_in_ClinVar_(Variation_ID_5293)_and_been_identified_in_0.2%_(31_0/126692)_of_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_ht_tp://gnomad.broadinstitute.org:_dbSNP_rs34612342)._Although_this_variant_has_bee_n_seen_in_the_general_population,_its_frequency_is_low_enough_to_be_consistent_w_ith_a_recessive_carrier_frequency._Functional_studies_indicate_this_variant_affe_cts_MUTYH_enzyme_activity_(Kundu_2009,_Molatore_2009)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_MUTYH-associated_polyposis_in_an_autosomal_recessive_manner_based_upon_presence_in_multiple_affected_individua_ls,_segregation_and_functional_studies._ACMG/AMP_Criteria_applied:_PM3_VeryStron_g,_PP1_strong,_PS3_supporting.||Several_studies_describe_the_c.494A>G_(p.Tyr165Cys)_as_a_common_pathogenic_variant,_also_referred_to_as_c.536A>G_(p.Tyr179Cys)_in_the_literature._In_2002,_Al-Tassan_et_al._described_a_family_with_three_siblings_with_multiple_colorectal_adenomas_and_carcinoma,_found_to_be_compound_heterozygous_for_the_p.Tyr165Cys_variant._Four_unaffected_siblings_were_all_heterozygous_for_a_single_variant_or_homozygous_wild-type._Nielson_et_al._(2005)_identified_the_p.Tyr165Cys_variant_in_a_presumed_compound_heterozygous_state_in_13_individuals_and_in_a_homozygous_state_in_14_individuals,_out_of_170_patients_with_polyposis_who_previously_tested_negative_for_APC_mutations._The_p.Tyr165Cys_variant_was_the_most_common_variant_identified_in_the_study_cohort._Control_data_are_unavailable_for_the_p.Tyr165Cys_variant_which_is_reported_at_a_frequency_of_0.00302_in_the_European_American_population_of_the_Exome_Sequencing_Project._In_2009,_Nielsen_et_al._assessed_genotype_phenotype_relationships_of_the_common_p.Tyr165Cys_and_p.Gly396Asp_variants._Patients_homozygous_for_the_p.Tyr165Cys_variant_had_a_significantly_increased_chance_of_developing_colorectal_cancer_compared_to_patients_homozygous_for_the_p.Gly396Asp_variant_or_compound_heterozygous_for_the_p.Tyr165Cys_and_Gly382Asp_variants_(Nielsen_et_al._2009)._Ali_et_al._(2008)_demonstrated_significantly_impaired_DNA_glycosylase_and_binding_activities_of_the_p.Tyr165Cys_variant_via_in_vitro_functional_assays,_which_were_unable_to_generate_any_detectable_cleavage_products_or_to_bind_to_the_substrates._Similarly,_Goto_et_al._(2010)_demonstrated_the_adenine_DNA_glycosylase_activity_of_the_p._p.Tyr165Cys_protein_was_4.5%_of_wild-type._The_collective_evidence_supports_p.Tyr165Cys_as_a_pathogenic_variant.||||||||This_pathogenic_variant_is_denoted_MUTYH_c.536A>G_at_the_cDNA_level,_p.Tyr179Cys_(Y179C)_at_the_protein_level,_and_results_in_the_change_of_a_Tyrosine_to_a_Cysteine_(TAC>TGC)._This_variant,_also_known_as_Tyr165Cys_using_an_alternate_reference_sequence_(NM_001048171.1),_has_been_published_in_the_literature_as_one_of_the_two_common_MUTYH_missense_pathogenic_variants_in_Western_populations,_and,_when_found_in_combination_with_another_pathogenic_variant,_is_known_to_cause_MUTYH-associated_polyposis_(MAP)_(Nielsen_2009,_Leoz_2015)._Multiple_in_vitro_functional_studies_demonstrate_this_variant's_pathogenic_effect_(Ali_2008,_Grasso_2014,_Komine_2015)._MUTYH_Tyr179Cys_was_observed_at_an_allele_frequency_of_0.24%_(310/126,692)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_Pseudo_HhH_motif_and_the_8-oxo-G_binding_domain_(Ruggieri_2013)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||||Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Deficient_protein_function_by_in_vitro/ex_vivo_assay:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Other_strong_data_supporting_pathogenic_classification||||||The_p.Tyr179Cys_variant_(also_known_as_NM_001048171.1:_c.494A>G_p.Tyr165Cys)_has_been_well_described_in_the_literature_as_one_of_the_two_common_MUTYH_pathogenic_variants._It_has_been_observed_in_homozygous_or_compound_heterozygous_form_with_other_pathogenic_MUTYH_variants_in_patients_with_colorectal_cancer,_familial_adenomatous_polyposis_(FAP)_or_attenuated_FAP_(Aretz_et_al.,_2014)._In_addition,_carriers_of_monoallelic_p.Tyr179Cys_variant_have_been_reported_to_be_at_increased_risk_of_colon_cancer_(Jenkins_et_al.,_2006:_Jones_et_al.,_2009:_Wink_et_al.,_2014)._Functional_studies_have_shown_that_the_p.Tyr179Cys_variant_results_severely_decreased_DNA_binding_and_adenine_DNA_glycosylase_activity_(Al-Tassan_et_al.,_2002:_Ali_et_al.,_2008:_Molatore_et_al.,_2010:_Goto_et_al.,_2010)._Altogether,_the_p.Tyr179Cys_meets_our_criteria_to_be_classified_as_a_pathogenic_variant._Pathogenic_variants_of_MUTYH_are_associated_with_autosomal_recessive_familial_adenomatous_polyposis-2_(MIM:_608456)._Therefore,_this_patient_would_be_at_least_a_carrier_and_may_have_an_increased_risk_for_colorectal_cancer_but_is_not_predicted_to_be_affected_with_FAP._However,_our_analysis_cannot_detect_variants_in_deep_intronic_or_enhancer_regions:_therefore,_the_presence_of_additional_pathogenic_variants_in_these_regions_cannot_be_excluded.|||
NM_001128425.1:c.504+19_504+31del	MUTYH	intron_variant	102404	2	NA	NA	-	-	-	-	406825	391385	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45798561_45798573del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	MUTYH:4595	SO:0001627|intron_variant	1	781222233	-	PreventionGenetics	Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-10-01|2018-04-23|2018-09-09|2019-09-23|2018-01-08	2019-03-28|2018-07-10|2018-11-06|2020-02-26|2018-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline	SCV000545720|SCV000799495|SCV000685635|SCV001185342|SCV000806359	MYH-associated_polyposis|MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	This_sequence_change_deletes_13_nucleotides_in_intron_6_of_the_MUTYH_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_MUTYH_protein._While_this_variant_is_not_present_in_population_databases_(rs781222233),_the_frequency_information_is_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_reported_to_segregate_with_MUTYH-associated_polyposis_in_two_families_(PMID:_20628285)_and_has_been_reported_in_other_affected_individuals_in_the_homozygous_and_compound_heterozygous_state_with_a_second_pathogenic_MUTYH_variant_(PMID:_19732775,_16890597,_21520333)._It_is_also_known_as_IVS6+19-31del13_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_406825)._An_experimental_study_using_RNAs_extracted_from_peripheral_leukocytes_of_individuals_carrying_this_variant_in_homozygous_and_heterozygous_states,_as_well_as_a_control_individual_with_wild-type_alleles,_has_shown_that_this_intronic_deletion_results_in_the_skipping_of_exon_6_of_the_MUTYH_mRNA_(PMID:_20628285)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|
NM_001128425.1:c.453_458dup	MUTYH	inframe_insertion	102744	1	NA	NA	-	-	-	-	233094	232268	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN517202	-	NC_000001.10:g.45798773_45798778dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant,SO:0001821|inframe_insertion,SO:0001627|intron_variant	1	876660190	-	Ambry_Genetics|Color|Invitae|GeneDx	Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2019-10-24|2018-06-16|2018-03-12|2018-11-12	2020-02-26|2018-11-06|2018-08-29|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000277400|SCV000685629|SCV000545709|SCV000568583	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_provided	Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)_:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||This_sequence_change_inserts_6_nucleotides_in_exon_5_of_the_MUTYH_mRNA_(c.453_458dupATGGAT)._This_leads_to_the_insertion_of_2_amino_acid_residues_in_the_MUTYH_protein_(p.Trp152_Met153insIleTrp)_but_otherwise_preserves_the_integrity_of_the_reading_frame._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_as_homozygous_or_as_co-occuring_with_pathogenic_variants_in_MUTYH_in_four_individuals_affected_with_MUTYH-associated_polyposis_(PMID:_26446593,_12606733,_16557584)._These_findings_are_consistent_with_autosomal_recessive_inheritance,_and_suggest_that_this_variant_contributes_to_disease._This_variant_is_also_known_as_137insIW,_p.137insIleTrp,_c.411_416dupATGGAT_and_411dupATGGAT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_233094)._Experimental_studies_have_shown_that_this_in-frame_insertion_results_in_reduced_substrate_binding,_impaired_glycosylase_activity_and_increased_sensitivity_to_DNA_damaging_agents_in_mouse_cells_harboring_this_variant_(PMID:_20418187,_19953527)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_in-frame_duplication_of_six_nucleotides_in_MUTYH_is_denoted_c.453_458dupATGGAT_at_the_cDNA_level_and_p.Trp152_Met153insIleTrp_(W152_M153insIW)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_duplicated_in_brackets,_is_CCGG[dupATGGAT]GCAG._This_duplication,_also_defined_as_MUTYH_c.411_416dupATGGAT_or_137insIW,_results_in_an_in-frame_insertion_of_two_amino_acids_(Isoleucine_and_Tryptophan)._MUTYH_Trp152_Met153insIleTrp_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_duplication_is_not_located_in_a_known_functional_domain._MUTYH_Trp152_Met153insIleTrp_was_observed_in_the_homozygous_state_in_an_individual_described_as_having_attenuated_polyposis_at_age_40_(Aretz_2006)._Additionally,_this_variant_has_been_reported_in_the_compound_heterozygous_state_with_a_second_MUTYH_variant_in_at_least_two_individuals_with_a_phenotype_consistent_with_either_classic_or_attenuated_familial_adenomatous_polyposis_(Sieber_2003,_Papp_2015)._Functional_studies_have_demonstrated_that,_compared_to_wild-type,_MUTYH_Trp152_Met153insIleTrp_had_weaker_localization_to_the_nucleus,_reduced_DNA_glycosylase_activity,_and_higher_levels_of_DNA_8-oxodG_accumulation_(D?Agostino_2010,_Molatore_2010)._We_consider_this_duplication_to_be_likely_pathogenic.
NM_001128425.1:c.325C>T	MUTYH	missense_variant	102742	6	15422	1	4&5	1&1	rs765123255	Hereditary cancer-predisposing syndrome&MYH-associated polyposis	183896	181726	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45799108G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	765123255	-	Ambry_Genetics|Color|Invitae|Knight_Diagnostic_Laboratories,Oregon_Health_and_Sciences_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Counsyl|Mendelics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2019-08-21|2018-10-29|2018-12-20|2016-03-30|2015-03-02|2015-09-18|2018-07-02|2018-04-26|2018-10-24|2015-10-16	2020-02-26|2018-11-06|2019-03-28|2016-08-10|2017-04-19|2017-06-22|2018-08-20|2019-01-29|2020-03-06|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline	SCV000213238|SCV000690558|SCV000285944|SCV000538049|SCV000592680|SCV000678193|SCV000837782|SCV000517270|SCV001134475|SCV000697691	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|not_provided|not_provided|MUTYH-associated_polyposis	In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_replaces_arginine_with_tryptophan_at_codon_109_of_the_MUTYH_protein_(p.Arg109Trp)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_tryptophan._This_variant_is_present_in_population_databases_(rs765123255,_ExAC_0.01%)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_a_pathogenic_variant_in_an_individual_affected_with_MUTYH-associated_polyposis_and_colorectal_cancer_(CRC)_(PMID:_19732775,_21520333)._It_also_co-occurred_with_a_pathogenic_variant_in_an_individual_affected_with_suspected_Lynch_syndrome_(PMID:_25980754),_and_was_reported_as_heterozygous_in_an_individual_affected_with_early-onset_CRC_(PMID:_24799981)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_183896)._Experimental_studies_have_shown_that_this_missense_change_disrupts_the_DNA_glycosylase_activity_of_the_MUTYH_protein_in_vitro,_and_its_ability_to_suppress_mutations_in_vivo_(PMID:_24799981)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_c.325C>T_(p.Arg109Trp)_missense_variant_in_the_MUTYH_gene_has_been_previously_reported_in_multiple_individuals_affected_with_Familial_Adenomatous_Polyposis_(Vogt_et_al.,_2009:_Shinmura_et_al.,_2014:_Nielsen_M_et_al.,_2009)._In_two_unrelated_individuals,_this_variant_was_observed_in_trans_with_a_known_pathogenic_variant,_Gly396Asp_(Vogt_et_al.,_2009:_Yurgelun_MB_et_al.,_2015)._Furthermore,_an_in_vitro_functional_assay_demonstrated_that_this_variant_resulted_in_reduced_DNA_glycosylase_activity_and_impaired_mutation-suppression_activity_(Shinmura_et_al.,_2014)._This_variant_is_reported_at_low_frequency_in_the_population_databases_(Exome_Sequencing_Project_
NM_002354.2:c.556-14A>G	EPCAM	intron_variant	101738	12	15422	0	-	-	-	-	157603	167463	Hereditary_nonpolyposis_colon_cancer|Hereditary_nonpolyposis_colorectal_cancer_type_8|Diarrhea_5,_with_tufting_enteropathy,_congenital	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C2750471,OMIM:613244|MedGen:C2750737,OMIM:613217	-	NC_000002.11:g.47606078A>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:185535.0009	-	EPCAM:4072	SO:0001627|intron_variant	1	376155665	-	Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-07-01|2016-10-10|2018-09-05|2018-10-31	2015-08-04|2017-03-31|2019-03-28|2018-11-14	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown	SCV000191953|SCV000579404|SCV000287358|SCV000894273	Diarrhea_5,_with_tufting_enteropathy,_congenital|Diarrhea_5,_with_tufting_enteropathy,_congenital|Hereditary_nonpolyposis_colon_cancer|Diarrhea_5,_with_tufting_enteropathy,_congenital/Hereditary_nonpolyposis_colorectal_cancer_type_8	||This_sequence_change_falls_in_intron_5_of_the_EPCAM_mRNA._It_has_been_shown_to_affect_mRNA_splicing_through_the_creation_of_new_splice_acceptor_site,_which_causes_a_frameshift_at_codon_186_and_creates_a_premature_translational_stop_signal_(p.Tyr186Phefs*6)_(PMID:_23462293,_24142340)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs376155665,_ExAC_0.01%)._This_variant_has_been_reported_in_multiple_individuals_affected_with_congenital_tufting_enteropathy_(CTE)Â¬â€ (PMID:_23462293,_24142340,_28701297)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_157603)._In_cDNA_sequence_analysis_using_patient-derived_RNA,_this_variant_resulted_in_a_frameshift_caused_by_abnormal_splicing_(PMID:_24142340)._An_experimental_study_using_cells_expressing_the_truncated_protein_(p.Tyr186Phefs*6)_has_shown_that_this_truncated_protein_lacks_the_transmembrane_domain_of_EPCAM,_resulting_in_loss_of_cell-surface_EPCAM_protein,_and_reduced_protein_secretion_in_vitro_(PMID:_23462293)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000251.2:c.942+3A>T	MSH2	splice_region_variant,intron_variant	12596	1	NA	NA	-	-	-	-	36580	45242	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.47641560A>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	HGMD:CS941511|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.942+3A>T|OMIM_Allelic_Variant:609309.0011|OMIM_Allelic_Variant:609309.0021	-	MSH2:4436	SO:0001627|intron_variant	1	193922376	-	OMIM|Counsyl|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Integrated_Genetics/Laboratory_Corporation_of_America|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Ambry_Genetics|Color|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|PreventionGenetics,PreventionGenetics|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2000-09-01|2015-11-17|2017-07-28|2015-09-21|2011-08-18|2013-09-05|2017-01-03|2016-03-18|2019-01-30|2019-03-05|2016-03-31|2013-07-25|2018-12-18|0000-00-00|2019-05-17|2017-06-27|2018-12-31	2013-03-26|2016-11-23|2018-04-17|2018-04-09|0000-00-00|2013-12-18|2017-04-19|2019-03-21|2019-02-11|2020-02-26|2017-12-21|2018-09-19|2019-01-29|2017-10-31|2020-03-06|2018-01-29|2019-03-28	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline	SCV000021989|SCV000487770|SCV000743207|SCV000744270|SCV000052923|SCV000107794|SCV000592480|SCV000711430|SCV000914299|SCV000185219|SCV000690146|SCV000110277|SCV000149458|SCV000257198|SCV000601495|SCV000806051|SCV000211911	Lynch_syndrome_I|Lynch_syndrome_I|Lynch_syndrome_I|Lynch_syndrome_I|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	||||Converted_during_submission_to_Pathogenic.|Multifactorial_likelihood_analysis_posterior_probability_>0.99._Variant_causes_in-frame_splicing_aberration_which_interrupts_know_functional_domains||The_c.942+3A>T_variant_in_MSH2_has_been_reported_in_>150_individuals_with_Lynch_syndrome_and_is_considered_a_founder_variant_in_the_Newfoundland_population_(Lab_Corp_database,_Woods_2010)._Data_from_large_population_studies_is_insufficient_t_o_assess_the_frequency_of_this_variant._In_vitro_functional_studies_provide_some_evidence_that_the_c.942+3A>T_variant_impacts_splicing_(Auclair_2006)._In_additi_on,_it_has_been_classified_as_Pathogenic_on_December_18,_2013_by_the_ClinGen-app_roved_InSiGHT_expert_panel_(ClinVar_SCV000107794.2)._In_summary,_this_variant_me_ets_our_criteria_to_be_classified_as_pathogenic_for_Lynch_syndrome_in_an_autosom_al_dominant_manner_based_upon_the_on_the_predicted_impact_to_the_protein.||Other_strong_data_supporting_pathogenic_classification:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Functionally-validated_splicing_mutation|||This_pathogenic_variant_is_denoted_MSH2_c.942+3A>T_or_IVS5+3A>T_and_consists_of_an_A>T_nucleotide_substitution_at_the_+3_position_of_intron_5_of_the_MSH2_gene._This_variant_has_been_reported_in_numerous_individuals_with_personal_and_family_histories_consistent_with_Lynch_syndrome_(Liu_1994,_Froggatt_1999,_Kurzawski_2005,_Buchanan_2014,_Rosty_2014,_Harper_2016,_Roth_2016,_Ziada-Bouchaar_2016)._MSH2_c.942+3A>T_was_originally_reported_to_be_a_pathogenic_founder_variant_in_Newfoundland,_but_has_since_been_hypothesized_to_be_a_mutational_hotspot_with_this_variant_being_identified_in_individuals_of_varying_ethnicities_without_a_common_haplotype_identified,_and_was_confirmed_de_novo_in_an_individual_diagnosed_with_colon_cancer_showing_absence_of_MSH2_and_MSH6_proteins_via_immunohistochemistry_and_endometrial_cancer_(Desai_2000,_Win_2011)._Additionally,_Auclair_et_al._(2006)_performed_mRNA_analysis_and_found_that_this_variant_led_to_skipping_of_exon_5._MSH2_c.942+3A>T_has_also_been_reported_to_be_overrepresented_in_individuals_with_the_Muir-Torre_variant,_suggesting_a_possible_association_with_an_increased_risk_for_sebaceous_neoplasms_(South_2008,_Roberts_2014)._MSH2_c.942+3A>T_was_not_observed_in_large_population_cohorts_(Lek_2016)._Based_on_the_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||The_best_available_variant_frequency_is_uninformative._Statistically_enriched_in_patients_compared_to_ethnically_matched_controls._Found_in_at_least_one_symptomatic_patient._Nucleotide_conservation_is_uninformative._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.||This_sequence_change_falls_in_intron_5_of_the_MSH2_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_MSH2_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_not_present_in_population_databases_(rs193922376,_ExAC_no_frequency)._This_variant_has_been_reported_to_segregate_with_disease_in_many_Lynch_syndrome_families_worldwide_(PMID:_8062247,_15222003,_19419416,_21681552,_22883484,_20682701,_10978353,_24310308)._It_is_recognized_as_a_causative_allele_for_Lynch_syndrome_by_the_American_College_of_Medical_Genetics_(PMID:_24310308)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_36580)._Functional_studies_demonstrate_that_this_variant_disrupts_mRNA_splicing_and_results_in_skipping_of_exon_5_(PMID:_16395668,_8062247)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000251.2:c.1786_1788del	MSH2	inframe_deletion	102728	1	NA	NA	-	-	-	-	1757	16796	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.47702190_47702192del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Children's_Hospital_of_Eastern_Ontario:1787209|OMIM_Allelic_Variant:609309.0005	-	MSH2:4436	SO:0001822|inframe_deletion	1	63749831	-	OMIM|Counsyl|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1994-11-01|2016-11-11|2013-09-05|2016-10-21|2018-07-12|2019-03-15|2016-10-12|2018-05-16|0000-00-00|2018-12-20	2013-03-26|2016-11-23|2013-12-18|2017-04-19|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2017-10-31|2019-03-28	no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline|germline|germline|unknown|germline	SCV000021983|SCV000489696|SCV000107306|SCV000592519|SCV000919714|SCV000172775|SCV000684976|SCV000211230|SCV000257152|SCV000255273	Lynch_syndrome_I|Lynch_syndrome_I|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	||Multifactorial_likelihood_analysis_posterior_probability_>0.99||Variant_summary:_MSH2_c.1786_1788delAAT_(p.Asn596del)_results_in_an_in-frame_deletion_that_is_predicted_to_remove_one_amino_acid_from_the_encoded_protein._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_246242_control_chromosomes_(gnomAD)._The_variant,_c.1786_1788delAAT,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Lynch_Syndrome_(Moslein_1996,_Katballe_2002,_Bonadona_2011,_Stormorken_2005,_Sunga_2017)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._At_least_one_publication_reports_experimental_evidence_evaluating_an_impact_on_protein_function_(Heinen_2003,_Drost_2011,_Heinen_2002)._The_most_pronounced_variant_effect_results_in_<10%_of_normal_activity_(Stormorken_2005)._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Good_segregation_with_disease_(lod_1.5-3_
NM_000251.2:c.1906G>C	MSH2	missense_variant	102724	1	15406	0	5&5&5&5	0&3&1&1	rs63750875	Colorectal cancer, hereditary, nonpolyposis, type 1&Lynch syndrome&Hereditary cancer-predisposing syndrome&not provided	1764	16803	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Muir-Torré_syndrome|Lynch_syndrome|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1321489,OMIM:158320,Orphanet:ORPHA587,SNOMED_CT:403824007|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.47702310G>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1906G>C|OMIM_Allelic_Variant:609309.0012|UniProtKB_(protein):P43246#VAR_012944	-	MSH2:4436	SO:0001583|missense_variant	1	63750875	-	Integrated_Genetics/Laboratory_Corporation_of_America|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Gharavi_Laboratory,Columbia_University|OMIM|Counsyl|Invitae|Fulgent_Genetics,Fulgent_Genetics	pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2011-08-18|2013-09-05|2012-11-12|2018-09-29|2016-08-30|2018-11-01|0000-00-00|2016-01-29|2017-02-23|2018-09-16|2005-10-01|2015-11-10|2018-12-17|2018-10-31	0000-00-00|2013-12-18|2017-04-19|2020-02-26|2017-10-26|2019-01-29|2017-10-31|2018-09-19|2018-08-31|2018-09-24|2013-03-26|2017-06-22|2019-03-28|2018-11-14	criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|unknown	SCV000052912|SCV000107338|SCV000592524|SCV000185292|SCV000684993|SCV000211191|SCV000257157|SCV000331841|SCV000601446|SCV000809450|SCV000021990|SCV000677734|SCV000166268|SCV000894279	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|Lynch_syndrome_I|Lynch_syndrome_I|Hereditary_nonpolyposis_colon_cancer|Lynch_syndrome_I/Turcot_syndrome/Muir-Torré_syndrome	Converted_during_submission_to_Pathogenic.|Abrogated_function_&_CMMRD,_>2_MSI-H_tumours,_co-segregation_with_disease_&_MAF_0.00._Multifactorial_likelihood_analysis_posterior_probability_>0.99||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Good_segregation_with_disease_(lod_1.5-3_
NM_000179.2:c.1346T>C	MSH6	missense_variant	102530	3	NA	NA	5	3	rs63750741	Lynch syndrome	89189	94663	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350	-	NC_000002.11:g.48026468T>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1346T>C|UniProtKB_(protein):P52701#VAR_043949	-	MSH6:2956	SO:0001583|missense_variant	1	63750741	-	_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|Color|Counsyl|Invitae	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2013-09-05|2017-03-03|2019-03-25|2018-06-25|2017-05-02|2018-12-28	2013-12-18|2019-03-21|2020-02-26|2018-11-06|2017-06-22|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline	SCV000107853|SCV000731318|SCV000580282|SCV000905449|SCV000677746|SCV000261013	Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colon_cancer	Multifactorial_likelihood_analysis_posterior_probability_>0.99|The_p.Leu449Pro_variant_in_MSH6_has_been_reported_in_>10_individuals_with_Lynch_syndrome-associated_cancers_from_a_large_multigenerational_Swedish_family_(Ceder_quist_2004,_Cederquist_2005)._In_addition,_the_majority_of_tumors_sampled_from_t_hese_individuals_showed_microsatellite_instability_and_lacked_MSH6_expression._T_his_variant_has_also_been_identified_in_2/66718_of_European_chromosomes_by_the_E_xome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs63750_741)._Computational_prediction_tools_and_conservation_analysis_suggest_that_thi_s_variant_may_impact_the_protein,_though_this_information_is_not_predictive_enou_gh_to_determine_pathogenicity._Furthermore,_this_variant_was_classified_as_Patho_genic_on_Sept._5,_2013_by_the_ClinGen-approved_InSiGHT_Expert_Panel_(ClinVar_SCV_000107853)._In_summary,_the_p.Leu449Pro_variant_meets_criteria_to_be_classified_as_pathogenic_for_Lynch_Syndrome_in_an_autosomal_dominant_manner_based_upon_segr_egation_studies_and_low_frequency_in_controls.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:in_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Good_segregation_with_disease_(lod_1.5-3_
NM_000179.2:c.1621A>C	MSH6	missense_variant	102592	1	NA	NA	-	-	-	-	126891	132403	Hereditary_cancer-predisposing_syndrome|Lynch_syndrome	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144	-	NC_000002.11:g.48026743A>C	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MSH6:2956	SO:0001583|missense_variant	1	587779778	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Ambry_Genetics	Likely_pathogenic|Likely_pathogenic	2019-06-21|2019-04-09	2019-06-21|2020-02-26	_single_submitter	germline|germline	SCV000148648|SCV000184007	Lynch_syndrome|Hereditary_cancer-predisposing_syndrome	Multifactorial_likelihood_analysis_posterior_probability_0.95-0.99|In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Structural_Evidence:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation
NM_000179.2:c.2314C>T	MSH6	missense_variant	102430	1	NA	NA	4&4	1&1	rs63750138	Hereditary cancer-predisposing syndrome&not provided	89267	94741	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48027436C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P52701#VAR_043958|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.2314C>T	-	MSH6:2956	SO:0001583|missense_variant	1	63750138	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Invitae	Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2018-10-18|2013-06-05|2019-02-15|2019-07-24|2018-05-10|2018-05-02|0000-00-00|2018-12-26	2019-02-21|2017-04-19|2019-09-24|2020-02-26|2018-11-06|2019-01-29|2017-10-31|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline	SCV000107941|SCV000592604|SCV000695806|SCV000212763|SCV000908396|SCV000279102|SCV000691930|SCV000551232	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	Multifactorial_likelihood_analysis_posterior_probability_>0.99||Variant_summary:_MSH6_c.2314C>T_(p.Arg772Trp)_results_in_a_non-conservative_amino_acid_change_located_in_the_DNA_mismatch_repair_protein_MutS,_core_domain_of_the_encoded_protein_sequence._Five_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function_(ACMG_PP3)._The_variant_allele_was_found_at_a_frequency_of_8.1e-06_in_246050_control_chromosomes_(gnomAD_and_publication,_ACMG_PM2)._c.2314C>T_has_been_reported_in_the_literature_in_individuals_affected_with_Lynch_Syndrome,_colon_cancer,_endometrial_cancer_and_breast_cancer_(Plaschke_2004,_Buchanan_2014,_Sunga_2017,_Lu_2018)._The_reported_patients_ranged_from_those_fulfilling_the_Amsterdam-II_criteria_(Jasperson_2008),_revised_Bethesda_guidelines_(Buchanan_2014)_as_well_as_not_fulfilling_the_Bethesda_guidelines_(Plaschke_2004)._In_addition,_in_one_comprehensively_genotyped_patient_affected_by_colon_and_urinary_bladder_cancer_who_had_reduced_expression_of_the_MSH6_protein_within_the_tumor_(and_normal_expression_of_MLH1_and_MSH2)_the_variant_was_also_found_in_her_affected_mother_(Jasperson_2008)._Loss_of_MSH6_expression_in_tumors_was_also_noted_in_other_studies_for_individuals_carrying_the_variant_(Plaschke_2004,_Buchanan_2014)._Furthermore,_this_variant_has_been_reported_in_homozygous_state_associated_with_the_phenotype_for_constitutional_mismatch_repair_deficiency_(CMMR-D)_syndrome:_immunohistochemical_analysis_of_skin_biopsies_revealed_MSH6_protein_deficiency_(Elhasid_2015,_Levi_2015)._The_variant_was_also_found_in_one_female_endometrial_cancer_patient_(47_y.o.)_as_a_somatic_variant,_who_carried_a_frameshift_19bps_insertion_in_MSH6_as_a_germ-line_variant_(Goodfellow_2003)._Lastly,_somatic_point_mutations_affecting_a_different_nucleotide_but_the_same_amino_acid_residue_(c.2315G>A_[p.R772Q]),_have_been_identified_in_a_colon_and_a_gastric_cancer,_both_with_the_MSI-H_phenotype_(Ohmiya_et_al.,_2001)._This_points_to_p.Arg772Trp_fulfilling_the_LOH_(Loss_of_Heterozygosity)_criteria_for_tumor_suppressor_genes_and_highlighting_functional_importance_of_this_residue_within_the_MSH6_protein._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease_(ACMG_PS4)._A_co-occurrence_with_another_pathogenic_variant_has_been_reported_in_our_internal_database_(CHEK2_c.1434delA,_p.Glu479fsX3)._Three_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_likely_pathogenic._The_International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)_has_recently_classified_this_variant_as_a_class-5_pathogenic_variant_using_the_same_evidence_outlined_above._Based_on_the_evidence_outlined_above,_the_variant_meets_sufficient_clinical_criteria_to_be_classified_as_pathogenic.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Moderate_segregation_with_disease_(at_least_3_informative_meioses)_for_rare_diseases.:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Other_data_supporting_pathogenic_classification||This_variant_is_denoted_MSH6_c.2314C>T_at_the_cDNA_level,_p.Arg772Trp_(R772W)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Tryptophan_(CGG>TGG)._This_variant_was_observed_in_multiple_individuals_with_a_personal_and/or_family_history_of_Lynch-syndrome_associated_cancers_(Plaschke_2004,_Jasperson_2008,_Buchanan_2014)._In_these_studies,_immunohistochemistry_performed_on_three_colon_tumors_and_one_endometrial_tumor_showed_either_reduction_or_loss_of_MSH6_expression._MSH6_Arg772Trp_was_also_observed_in_the_homozygous_state_in_three_children_reported_to_have_constitutional_mismatch_repair_deficiency_(CMMR-D)_syndrome_and_immunohistochemistry_performed_on_skin_biopsies_procured_from_two_of_these_children_were_found_to_be_deficient_in_MSH6_expression_(Elhasid_2015,_Levi_2015)._MSH6_Arg772Trp_was_not_observed_in_large_population_cohorts_(NHLBI_Exome_Sequencing_Project,_The_1000_Genomes_Consortium_2015,_Lek_2016)._Since_Arginine_and_Tryptophan_differ_in_polarity,_charge,_size_or_other_properties,_this_is_considered_a_non-conservative_amino_acid_substitution._MSH6_Arg772Trp_occurs_at_a_position_that_is_conserved_across_species_and_is_located_within_the_lever_domain_(Warren_2007,_Kansikas_2011)._In_silico_analyses_predict_that_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_the_currently_available_evidence,_we_consider_MSH6_Arg772Trp_to_be_a_likely_pathogenic_variant.||This_sequence_change_replaces_arginine_with_tryptophan_at_codon_772_of_the_MSH6_protein_(p.Arg772Trp)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_tryptophan._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_Lynch_syndrome,_constitutional_mismatch_repair_deficiency,_colorectal_cancer,_and_endometrial_cancer_(PMID:Â¬â€ 18176851,Â¬â€ 25307252,Â¬â€ 14974087,Â¬â€ 24323032,Â¬â€ 28449805).Â¬â€ This_variant_has_also_been_reported_in_individuals_with_suspected_Lynch_syndrome_(PMID:_28514183).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89267)._Algorithms_developed_specifically_for_the_MSH6_gene_suggest_that_this_missense_change_is_likely_to_be_deleterious_(PMID:_23621914,Â¬â€ 26333163)._However,_this_prediction_has_not_been_confirmed_by_published_functional_studies_and_its_clinical_significance_is_uncertain._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_000179.2:c.2906A>G	MSH6	missense_variant	99878	2	NA	NA	-	-	-	-	234622	231565	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.48028028A>G	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MSH6:2956	SO:0001583|missense_variant	1	63749919	-	GeneDx|Invitae|Ambry_Genetics|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2017-04-20|2018-11-21|2019-04-16|2018-03-09	2019-01-29|2019-03-28|2020-02-26|2018-03-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel	germline|germline|germline|germline	SCV000279613|SCV000551056|SCV000580279|SCV000740676	not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_I	This_variant_is_denoted_MSH6_c.2906A>G_at_the_cDNA_level,_p.Tyr969Cys_(Y969C)_at_the_protein_level,_and_results_in_the_change_of_a_Tyrosine_to_a_Cysteine_(TAT>TGT)_in_exon_4._This_variant_has_been_reported_in_at_least_three_colorectal_cancer_families_where_loss_of_MSH6_has_been_observed_via_mismatch_repair_immunohistochemistry_(MMR_IHC)_in_several_individuals'_colon_tumors_(Suchy_2006,_Grindedal_2009,_Sjursen_2010)._In_addition,_this_variant_is_noted_to_segregate_with_cancer_in_at_least_two_families_(Grindedal_2009,_Sjursen_2010)._MSH6_Tyr969Cys_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_suggesting_it_is_not_a_common_benign_variant_in_these_populations._Since_Tyrosine_and_Cysteine_differ_in_polarity,_charge,_size_or_other_properties,_this_is_considered_a_non-conservative_amino_acid_substitution._MSH6_Tyr969Cys_occurs_at_a_position_that_is_conserved_in_mammals_and_is_located_in_the_MutS_IV_domain_(Terui_2013)._In_silico_analyses_predict_that_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_currently_available_evidence_and_internal_data,_we_consider_MSH6_Tyr969Cys_to_be_a_likely_pathogenic_variant.|This_sequence_change_replaces_tyrosine_with_cysteine_at_codon_969_of_the_MSH6_protein_(p.Tyr969Cys)._The_tyrosine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_tyrosine_and_cysteine._This_variant_is_present_in_population_databases_(rs63749919,_ExAC_0.007%)._This_variant_has_been_observed_to_segregate_with_Lynch_syndrome_in_at_least_one_family_(PMID:_20587412,Â¬â€ 16813607,Â¬â€ 19723918)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234622)._General_algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_(SIFT,_PolyPhen-2,_Align-GVGD),_and_an_algorithm_developed_specifically_for_the_MSH6_gene_(PMID:_23621914),_suggest_that_this_missense_change_is_likely_to_be_deletrious._However,_these_predictions_have_not_been_confirmed_by_published_functional_studies._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|Class_4_-_Likely_Pathogenic_Classification_using_multifactorial_probability:_0.9528
NM_000179.2:c.3226C>T	MSH6	missense_variant	102660	9	NA	NA	4&4	1&1	rs63750617	Hereditary cancer-predisposing syndrome&not provided	89357	94831	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.48030612C>T	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3226C>T|UniProtKB_(protein):P52701#VAR_043965	-	MSH6:2956	SO:0001583|missense_variant	1	63750617	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Invitae|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-03-09|2019-08-30|2018-07-09|2019-01-15|2018-01-18|2018-09-01|2018-12-09|2017-10-15|2018-09-11|2019-05-28|2018-09-06	2018-03-23|2020-02-26|2018-11-06|2019-01-29|2018-08-31|2019-07-12|2019-03-28|2018-06-14|2019-08-02|2019-10-22|2019-04-24	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|unknown|unknown|germline	SCV000108034|SCV000212797|SCV000690333|SCV000321908|SCV000601562|SCV001152299|SCV000283794|SCV000840015|SCV000993566|SCV001135834|SCV000917733	Lynch_syndrome_I|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Lynch_syndrome	Co-occurrence_in_trans_with_a_known_pathogenic_sequence_variant_in_the_same_gene_in_a_patient_with_clinical_features_consistent_with_CMMRD_and_documented_MMR_deficiency_in_normal_cells|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Other_data_supporting_pathogenic_classification||This_variant_is_denoted_MSH6_c.3226C>T_at_the_cDNA_level,_p.Arg1076Cys_(R1076C)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Cysteine_(CGC>TGC)._This_variant_has_been_observed_in_individuals_with_a_personal_and/or_family_history_of_colorectal_cancer_(Nilbert_2009,_Liccardo_2017,_Rohlin_2017)_as_well_as_at_least_three_individuals_with_colorectal_cancer_and_one_with_synchronous_endometrial_and_ovarian_cancers,_with_most_tumors_demonstrating_loss_of_MSH6_protein_expression_(Schofield_2009,_Limburg_2011,_Schultheis_2016,_Rubio_2016)._In_addition,_this_variant_has_been_observed_in_the_compound_heterozygous_state_with_a_truncating_MSH6_variant_in_five_individuals_from_four_families_with_histories_suggestive_of_constitutional_mismatch_repair_deficiency_syndrome,_with_absent_MSH6_expression_in_both_tumor_and_normal_tissue_from_most_individuals_(Plaschke_2006,_Okkels_2006,_Rahner_2008,_Jasperson_2011,_Bush_2018)._This_variant_may_be_a_hypomorphic_allele_as_it_was_observed_in_the_homozygous_state_in_a_patient_with_relatively_late_onset_colorectal_cancer,_and_among_heterozygotes,_a_limited_number_of_Lynch-associated_cancers_have_been_observed_in_multiple_internal_and_published_families_(Gardes_2012,_Okkels_2006,_Rahner_2008)._MSH6_Arg1076Cys_was_observed_at_an_allele_frequency_of_0.03%_(5/17,240)_in_individuals_of_East_Asian_ancestry_in_large_population_cohorts_(Lek_2016)._MSH6_Arg1076Cys_is_located_in_the_Lever_domain_(Warren_2007,_Kansikas_2011)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_currently_available_evidence,_we_consider_MSH6_Arg1076Cys_to_be_a_likely_pathogenic_variant.|||This_sequence_change_replaces_arginine_with_cysteine_at_codon_1076_of_the_MSH6_protein_(p.Arg1076Cys)._The_arginine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_arginine_and_cysteine._This_variant_is_present_in_population_databases_(rs63750617,_ExAC_0.03%)._This_variant_has_been_reported_in_individuals_with_colon_cancer_(PMID:_21056691,_27696107)_and_in_two_families_from_the_Danish_HNPCC_register_(PMID:_18566915)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89357)._In_several_unrelated_individuals_with_constitutional_mismatch_repair_deficiency_(CMMR-D)_syndrome,_this_p.Arg1076Cys_missense_variant_was_found_in_trans_with_different_pathogenic_MSH6_truncating_variants_(PMID:_15483016,_16418736,_16525781,_21039432,_18409202)._These_individuals_were_affected_with_early-onset_colorectal_cancer,_glioblastoma,_endometrial_cancer,_adenomatous_polyposis,_and/or_cafe-au-lait_spots._An_individual_homozygous_for_this_variant_did_not_present_with_CMMR-D,_but_did_develop_colorectal_tumors_at_45_and_49_years_old_(PMID:_22250089)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_(SIFT,_PolyPhen-2,_Align-GVGD)_all_suggest_that_this_variant_is_likely_to_be_disruptive,_but_these_predictions_have_not_been_confirmed_by_published_functional_studies._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_c.3226C>T_(p.Arg1076Cys)_variant_in_the_MSH6_gene_has_been_reported_in_the_homozygous_state_in_1_individual_with_colorectal_cancer_(PMID:_22250089)._It_has_also_been_reported_in_trans_configuration_with_a_pathogenic_variant_in_3_unrelated_individuals_with_autosomal_recessive_hereditary_nonpolyposis_colorectal_cancer_type_5_(HNPCC5:_PMID:_16418736,_16525781,_18409202)_and_in_2_related_individuals_with_mismatch_repair_cancer_syndrome_(MMRCS:_MIM_600678:_PMID:_21039432)._Segregation_studies_in_this_family_confirmed_that_the_c.3226C>T_(p.Arg1076Cys)_variant_segregated_together_with_a_second_pathogenic_variant_in_the_2_affected_individuals,_but_not_in_6_unaffected_family_members_(PMID:_21039432)._The_c.3226C>T_variant_is_very_rare_in_the_general_population._While_not_validated_for_clinical_use,_the_computer-based_algorithms_PolyPhen-2_and_SIFT_predict_the_p.Arg1076Cys_change_to_be_deleterious._Based_on_this_information,_the_c.3226C>T_(p.Arg1076Cys)_variant_in_the_MSH6_gene_is_classified_as_likely_pathogenic.|||Variant_summary:_MSH6_c.3226C>T_(p.Arg1076Cys)_results_in_a_non-conservative_amino_acid_change_located_in_the_DNA_mismatch_repair_protein_MutS,_core_domain_(IPR007696)_of_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_9.8e-05_in_246118_control_chromosomes_(gnomAD)._This_frequency_is_lower_than_expected_for_a_pathogenic_variant_in_MSH6_causing_Lynch_Syndrome_(9.8e-05_vs_0.00014),_allowing_no_conclusion_about_variant_significance._The_variant,_c.3226C>T,_has_been_reported_in_compound_heterozygous_state_with_other_pathogenic_MSH6_truncating_variants_in_several_patients_with_constitutional_mismatch_repair_deficiency_(CMMRD)_syndrome,_i.e._early-onset_colorectal_cancer,_adenomatous_polyposis_and_cafe-au-lait_spots_(Okkels_2006,_Plaschke_2006,_Rahner_2008,_Allred_2013)._In_many_of_these_cases_the_loss_of_MSH6_staining_in_both_the_tumor_and_normal_cells_was_described,_pointing_to_a_bi-allelic_MSH6_mutation._The_variant_was_also_reported_in_heterozygosity_in_individuals_affected_by_Lynch_syndrome_(Schofield_2009,_Lagerstedt-Robinson_2016,_Rohlin_2016,_Liccardo_2017,_Espenschied_2017),_where_in_several_cases_the_associated_tumor_demonstrated_isolated_loss_of_MSH6_staining._However,_within_the_reported_CMMRD_families_the_variant_was_also_observed_in_heterozygous_state_in_unaffected_family_members_(Plaschke_2006,_Okkels_2006,_Allred_2013),_suggesting_its_role_in_causing_Lynch_syndrome_is_uncertain._This_variant_was_also_found_in_a_homozygote_who_developed_colorectal_tumors_at_the_age_of_45_and_49_year,_together_with_multiple_colon_adenomas_and_polyps_(Gardes_2012),_a_disease_history_that_is_closer_to_Lynch_syndrome_than_CMMRD._However,_in_LCLs_derived_from_this_patient,_though_MSH6_mRNA_was_detectable,_Western_blot_analysis_demonstrated_the_lack_of_MSH6_protein,_a_finding_that_is_consistent_with_CMMRD_(Gardes_2012)._These_data_indicate_that_the_variant_may_be_a_hypomorphic_allele,_though_no_functional_studies_are_available_to_support_this_assumption._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic_(1x)_/_likely_pathogenic_(5x)._ACMG_recommends_reporting_incidental_findings_(mutations_that_cause_or_are_likely_to_cause_other_phenotypes_than_those_indicated_for_testing,_i.e._Lynch_Syndrome_here)_in_this_gene._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic_for_constitutional_mismatch_repair_deficiency_(CMMRD)_syndrome.
NM_000179.2:c.3417C>T	MSH6	synonymous_variant	102660	1	NA	NA	-	-	-	-	233242	232814	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000002.11:g.48030803C>T	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MSH6:2956	SO:0001819|synonymous_variant	1	876660283	-	Ambry_Genetics	Likely_pathogenic	2018-04-06	2020-02-26	_single_submitter	germline	SCV000277579	Hereditary_cancer-predisposing_syndrome	Insufficient_or_conflicting_evidence:RNA_Studies:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species
NM_000179.2:c.3724_3726del	MSH6	inframe_deletion	102556	2	NA	NA	-	-	-	-	89450	94924	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48033420_48033422del	reviewed_by_expert_panel	Likely_pathogenic	-	-	Deletion	SO:0000159	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3724_3726del	-	MSH6:2956	SO:0001822|inframe_deletion	1	63749942	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Ambry_Genetics|Color|GeneDx|Invitae	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic	2019-06-21|2019-02-01|2018-06-14|2017-01-17|2018-11-20	2019-06-21|2020-02-26|2018-11-06|2019-01-29|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000108130|SCV000183865|SCV000690391|SCV000322122|SCV000551262	Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_nonpolyposis_colon_cancer	Multifactorial_likelihood_analysis_posterior_probability_0.95-0.99|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Structural_Evidence:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_in-frame_deletion_of_3_nucleotides_in_MSH6_is_denoted_c.3724_3726delCGT_at_the_cDNA_level_and_p.Arg1242del_(R1242del)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ATGT[delCGT]ACAT._This_deletion_of_a_single_Arginine_residue_occurs_at_a_position_that_is_conserved_across_species_and_is_located_within_domain_V_of_the_MutS_domain_(Terui_2013)._This_variant_has_been_observed_in_individuals_with_endometrial_and_colorectal_cancer,_segregating_with_disease_in_at_least_one_family,_and_immunohistochemistry_(IHC)_of_two_tumors_revealed_absence_of_MSH6_protein_(Roncari_2007,_Batte_2014)._In_addition,_the_International_Society_for_Gastrointestinal_Hereditary_Tumours_Incorporated_(InSiGHT)_classifies_this_variant_as_likely_pathogenic_(Thompson_2014)._MSH6_Arg1242del_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_suggesting_it_is_not_a_common_benign_variant_in_these_populations._Based_on_currently_available_evidence,_we_consider_MSH6_Arg1242del_to_be_a_likely_pathogenic_variant.|This_sequence_change_deletes_3_nucleotides_from_exon_8_of_the_MSH6_mRNA_(c.3724_3726delCGT)._This_leads_to_the_deletion_of_1_amino_acid_residue_in_the_MSH6_protein_(p.Arg1242del)_but_otherwise_preserves_the_integrity_of_the_reading_frame._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_Lynch_syndrome_(PMID:_20028993)_and_endometrial_cancer_(PMID:_24933100,_27443514),_and_shown_to_segregate_with_colorectal_cancer_in_3_members_of_a_single_family_(PMID:_17718861)._This_variant_has_also_been_reported_in_multiple_individuals_with_Lynch_syndrome_spectrum_cancers_in_the_Universal_Mutation_Database_(PMID:_22144684)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89450)._Based_on_a_multifactorial_likelihood_algorithm_using_genetic_and_in_silico_data,_this_variant_has_been_determined_to_have_a_high_probability_of_being_pathogenic_(PMID:_24362816)._A_missense_substitution_at_this_codon_(p.Arg1242His)_has_been_determined_to_be_pathogenic_(PMID:_24763289,_23729658)._This_suggests_that_the_arginine_residue_is_critical_for_MSH6_protein_function_and_that_other_variants_at_this_position_that_disrupt_or_delete_the_arginine_residue_may_also_be_pathogenic._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000249.3:c.2T>C	MLH1	start_lost	102754	1	NA	NA	-	-	-	-	90135	95609	Lynch_syndrome_I	-	OMIM:120435	-	NC_000003.11:g.37035040T>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.2T>C	-	MLH1:4292	SO:0001582|initiatior_codon_variant,SO:0001583|missense_variant,SO:0001623|5_prime_UTR_variant	1	111052004	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)	Pathogenic	2016-12-14	2018-04-18	reviewed_by_expert_panel	germline	SCV000106623	Lynch_syndrome_I	variant_in_initiation_codon
NM_000249.3:c.244A>G	MLH1	missense_variant	102680	1	NA	NA	4&4	3&1	rs587778998	Lynch syndrome&Hereditary cancer-predisposing syndrome	90116	95590	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Lynch_syndrome_I|not_specified	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C2936783,OMIM:120435|MedGen:CN169374	-	NC_000003.11:g.37042482A>G	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Children's_Hospital_of_Eastern_Ontario:1786447|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.244A>G	-	MLH1:4292	SO:0001583|missense_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	587778998	-	Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Invitae	Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic	2013-01-17|2016-03-14|2017-12-19|2018-07-17|2018-06-13|2016-12-27|2018-08-08	2017-04-19|2018-01-25|2020-02-26|2018-11-06|2018-09-05|2017-06-30|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline	SCV000592341|SCV000696155|SCV000216818|SCV000908603|SCV000106599|SCV000604231|SCV000625139	Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_I|not_specified|Hereditary_nonpolyposis_colon_cancer	|Variant_summary:_This_c.244A>G_variant_affects_a_conserved_nucleotide,_resulting_in_amino_acid_change_from_Thr_to_Ala._4/4_in-silico_tools_predict_this_variant_to_be_damaging._This_variant_was_found_in_1/122056_control_chromosomes_from_the_broad_and_large_populations_of_ExAC_at_a_frequency_of_0.0000082,_which_does_not_exceed_maximal_expected_frequency_of_a_pathogenic_allele_(0.0007105)_in_this_gene._This_variant_has_been_reported_in_multiple_patients_(at_least_five_independent_occurrences)_affected_with_HNPCC_or_HNPCC-related_cancers._There_are_no_reported_cosegregation_studies_for_this_variant._The_variant_has_been_functionally_characterized_to_impair_the_MMR_activity,_strongly_suggesting_for_pathogenic_outcome._Multiple_clinical_laboratories_as_well_as_reputable_databases_have_classified_this_variant_as_likely_pathogenic._Multifactorial_likelihood_analysis_for_the_variant_is_also_in_line_with_likely_pathogenic_outcome._Taken_together_this_variant_has_currently_been_classfied_as_a_Probable_Disease_Variant/Likely_Pathogenic.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Well-characterized_mutation_at_same_position:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||Variant_reclassification_due_to_new_tumour_Likelihood_Ratios:_Multifactorial_likelihood_analysis_posterior_probability_>_0.95_(0.965)||This_sequence_change_replaces_threonine_with_alanine_at_codon_82_of_the_MLH1_protein_(p.Thr82Ala)._The_threonine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_threonine_and_alanine._This_variant_is_present_in_population_databases_(rs587778998,_ExAC_0.001%)._This_variant_has_been_observed_in_several_individuals_affected_with_Lynch_syndrome_(PMID:_21239990,_21404117,_22736432,_26300997,Â¬â€ 28514183)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_90116)._Experimental_studies_have_shown_that_this_missense_change_significantly_reduced_DNA_mismatch_repair_activity_of_MLH1_(PMID:_22736432)._The_p.Thr82_amino_acid_residue_in_MLH1_has_been_determined_to_be_clinically_significant_(PMID:_10422993,_20587412,_19690142,Â¬â€ 17510385,_23403630)._This_suggests_that_variants_that_disrupt_this_residue_are_likely_to_be_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000249.3:c.380G>C	MLH1	missense_variant,splice_region_variant	102642	1	NA	NA	-	-	-	-	824248	807544	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000003.11:g.37045965G>C	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MLH1:4292	SO:0001623|5_prime_UTR_variant	1	-	-	Ambry_Genetics	Likely_pathogenic	2018-10-02	2020-02-26	_single_submitter	germline	SCV001182788	Hereditary_cancer-predisposing_syndrome	Last_nucleotide_of_exon:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Well-characterized_mutation_at_same_position
NM_000249.3:c.793C>A	MLH1	missense_variant,splice_region_variant	102724	1	NA	NA	4&5	3&0	rs63751194	Lynch syndrome&not provided	90380	95854	Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000003.11:g.37058999C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.793C>A|UniProtKB_(protein):P40692#VAR_076344	-	MLH1:4292	SO:0001627|intron_variant	3	63751194	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Ambry_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2018-10-18|2013-04-10|2018-05-01|0000-00-00|2017-01-30	2019-02-21|2017-04-19|2018-12-28|2015-11-19|2020-02-26	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|somatic|unknown|germline	SCV000106885|SCV000592379|SCV000887314|SCV000257116|SCV000664835	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome	Paper_by_Van_der_Klift_et_al._2015_shows_aberrant_splicing_(exon_10_exclusion)_in_patient_sample_and_minigene_assay,_confirmed_by_minigene_assay_in_Soukarieh_et_al.,_2016_(Plos_Genet).||MLH1_NM_000249.3:c.793C>A_has_a_97.7%_probability_of_pathogenicity_based_on_combining_prior_probability_from_public_data_with_a_likelihood_ratio_of_1.56_to_1,_generated_from_evidence_of_seeing_this_as_a_somatic_mutation_in_a_tumor_without_loss_of_heterozygosity_at_the_MLH1_locus._See_Shirts_et_al_2018,_PMID_29887214.||Other_strong_data_supporting_pathogenic_classification:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)
NM_000249.3:c.2059C>T	MLH1	missense_variant	102522	1	NA	NA	5&5	3&1	rs63751275	Lynch syndrome&Hereditary cancer-predisposing syndrome	90014	95488	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Muir-Torré_syndrome|Lynch_syndrome|Lynch_syndrome_II|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1321489,OMIM:158320,Orphanet:ORPHA587,SNOMED_CT:403824007|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1333991,OMIM:609310|MedGen:CN517202	-	NC_000003.11:g.37090464C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P40692#VAR_012931|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.2059C>T	-	MLH1:4292	SO:0001627|intron_variant	1	63751275	-	Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2013-09-05|2019-04-23|2018-07-24|2015-12-18|2018-11-20|2018-10-26|2018-09-12|2018-10-31	2013-12-18|2019-09-24|2020-02-26|2016-11-23|2019-01-29|2020-03-06|2019-03-28|2018-11-14	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|unknown	SCV000106495|SCV000696141|SCV000276415|SCV000488014|SCV000565167|SCV000601383|SCV000253681|SCV000893648	Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_II|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Turcot_syndrome/Muir-Torré_syndrome/Lynch_syndrome_II	Multifactorial_likelihood_analysis_posterior_probability_>0.99|Variant_summary:_MLH1_c.2059C>T_(p.Arg687Trp)_results_in_a_non-conservative_amino_acid_change_located_in_the_DNA_mismatch_repair_protein_Mlh1,_C-terminal_(IPR032189)_of_the_encoded_protein_sequence._Five_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_2e-05_in_251916_control_chromosomes_(gnomAD)._It_has_also_has_been_reported_in_the_literature_in_multiple_individuals_and_families_affected_with_Lynch_syndrome,_constitutional_mismatch_repair_deficiency_syndrome,_colorectal_and_gastrointestinal_cancers_from_different_populations_(e.g._Arnold_2009,_Caldes_2002:_Lagerstedt_Robinson_2007:_Furukawa_2002,_Bakry_2014,_Gallinger_2004)._The_variant_co-segregated_with_the_disease_in_multiple_families_(e.g._Arnold_2009,_Caldes_2002,_Christensen_2009)_but_not_in_all_(Lagerstedt_Robinson_2007)._In_addition,_International_Society_for_Gastrointestianl_Heriditary_Tumors_(InSiGHT)_and_others_have_performed_systematic_investigation_and_classified_this_variant_as_pathogenic_(Tricarico_2017)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._One_experimental_study_demonstrated_that_this_variant_affects_function_in_yeast_functional_assays_and_reduce_in_vitro_MMR_activity_and_MLH1_expression_(Takahashi_2007)._In_contrast_Christensen_et_al_(Christensen_2009)_has_shown_that_this_variant_behaved_like_WT-MLH1_in_its_expression,_MMR_efficiency_and_subcellular_localization._Six_submitters_have_provided_clinical_significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._They_classified_the_variant_as_pathogenic_(4x)_/likely_pathogenic_(2x)._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Good_segregation_with_disease_(lod_1.5-3_
NM_000038.5:c.423-3T>A	APC	splice_region_variant,intron_variant	93956	34	14684	1	-	-	-	-	142189	151903	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|not_specified	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2713442,OMIM:175100|MedGen:CN169374	-	NC_000005.9:g.112111323T>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(4)	-	single_nucleotide_variant	SO:0001483	Mayo_Clinic:95	-	APC:324	SO:0001627|intron_variant	1	587782293	-	Ambry_Genetics|Color|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Invitae|Mendelics	Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2019-05-21|2018-10-26|0000-00-00|2016-02-10|2018-12-23|2019-05-28	2020-02-26|2018-11-06|2015-11-19|2017-04-19|2019-03-28|2019-10-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|unknown	SCV000186122|SCV000905871|SCV000256993|SCV000591027|SCV000814096|SCV001136873	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||This_sequence_change_falls_in_intron_4_of_the_APC_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_APC_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_an_individual_with_typical_or_attenuated_FAP_and_individuals_undergoing_APC_testing_(PMID:_20223039,_23159591)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142189)._Nucleotide_substitutions_within_the_consensus_splice_site_are_a_relatively_common_cause_of_aberrant_splicing_(PMID:_17576681,_9536098)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|
NM_000038.5:c.3183_3187del	APC	frameshift_variant	102034	1	NA	NA	-	-	-	-	88913	94472	Craniopharyngioma|Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis|not_provided	-	Human_Phenotype_Ontology:HP:0030062,MeSH:D003397,MedGen:C0010276,Orphanet:ORPHA54595|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2713442,OMIM:175100|MedGen:CN240755|MedGen:CN517202	-	NC_000005.9:g.112174474_112174478del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	HGMD:CD920810|Center_for_Human_Genetics,_Inc:APC-A11|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic:70	-	APC:324	SO:0001589|frameshift_variant	1	587779352	-	EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|Pathway_Genomics|Invitae|Counsyl|National_Molecular_Genetics_Centre_of_Cancer_Research,N.N._Alexandrov_National_Cancer_Centre_of_Belarus|Mendelics|Ambry_Genetics|Color|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Center_for_Human_Genetics,_Inc|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-08-22|0000-00-00|2018-11-06|2017-04-03|2018-08-01|2014-07-24|2018-12-16|2016-03-03|2018-05-28|2018-07-02|2019-02-13|2018-03-09|0000-00-00|2016-07-15|2016-11-01|2016-02-29	2017-06-30|2017-10-31|2019-01-29|2017-08-01|2018-08-08|2014-08-08|2019-03-28|2016-11-23|2018-07-02|2018-08-20|2020-02-26|2018-11-06|2017-10-30|2018-01-25|2017-12-20|2018-08-09	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000226392|SCV000256968|SCV000293390|SCV000600078|SCV000821693|SCV000189853|SCV000253730|SCV000488338|SCV000778310|SCV000838100|SCV000213245|SCV000905975|SCV000591132|SCV000694026|SCV000781075|SCV000853185	not_provided|not_provided|not_provided|not_provided|not_provided|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis|Familial_adenomatous_polyposis|Familial_adenomatous_polyposis|Craniopharyngioma	||This_deletion_of_five_nucleotides_is_denoted_APC_c.3183_3187delACAAA_at_the_cDNA_level_and_p.Gln1062Ter_(Q1062X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TAAA[delACAAA]GTGA._The_deletion_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._Even_though_this_frameshift_occurs_near_the_end_of_the_gene_and_nonsense-mediated_decay_is_not_expected_to_occur,_it_is_significant_since_the_last_1782_amino_acids_are_no_longer_translated._APC_c.3183_3187delACAAA_has_been_observed_in_multiple_individuals_with_Familial_Adenomatous_Polyposis_(Aceto_2005,_Plawski_2008,_Gomez-Fernandez_2009,_Rivera_2011,_Papp_2015,_Liu_2016,_Zhang_2016,_Khan_2017)._This_variant_is_considered_pathogenic.||||This_sequence_change_deletes_5_nucleotides_from_exon_16_of_the_APC_mRNA_(c.3183_3187delACAAA),_causing_a_frameshift_at_codon_1061._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_APC_mRNA_(p.Gln1062*)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_delete_the_last_1782_amino_acids_(~63%)_of_the_APC_protein._Loss-of-function_variants_in_APC_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_many_individuals_affected_with_familial_adenomatous_polyposis_(PMID:_1316610,_8162022,_15771908)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_sequence_change_(c.3183_3187delACAAA)_creates_a_stop_codon_(p.Gln1062*)_in_exon_16_of_the_APC_mRNA.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|||Variant_summary:_The_APC_c.3183_3187delACAAA_(p.Gln1062fs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_APC_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_absent_in_120668_control_chromosomes,_but_has_been_cited_in_numerous_FAP_patients_reported_in_the_literature_and_is_considered_a_common_pathogenic_variant._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic/causal._Taken_together,_this_variant_is_classified_as_Pathogenic.||This_is_a_frameshift_mutation_in_which_5_nucleotides_are_deleted_between_coding_positions_3183_and_3187_and_is_predicted_to_shift_the_reading_frame_at_codon_1061.
NM_000038.5:c.3927_3931del	APC	frameshift_variant	102426	1	NA	NA	-	-	-	-	816	15855	Gastric_polyposis|Duodenal_polyposis|Adenomatous_colonic_polyposis|Intestinal_polyp|Hyperplastic_colonic_polyposis|Adenocarcinoma_of_the_colon|Carcinoma_of_colon|Gardner_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_multiple_polyposis_syndrome|Malignant_Colorectal_Neoplasm|Adenomatous_polyposis_coli_with_congenital_cholesteatoma|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis|not_provided	-	Human_Phenotype_Ontology:HP:0004394,MedGen:C0236048,OMIM:175020,SNOMED_CT:87252009|Human_Phenotype_Ontology:HP:0004783,MedGen:C0578477|Human_Phenotype_Ontology:HP:0005227,MedGen:C1868071|Human_Phenotype_Ontology:HP:0005266,MedGen:C0021846|Human_Phenotype_Ontology:HP:0012183,MedGen:C4023010|Human_Phenotype_Ontology:HP:0040276,MedGen:C0338106|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0017097,Orphanet:ORPHA79665,SNOMED_CT:60876000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0032580,Orphanet:ORPHA733,SNOMED_CT:72900001|MedGen:C0346629|MedGen:C2673229|MedGen:C2713442,OMIM:175100|MedGen:CN240755|MedGen:CN517202	-	NC_000005.9:g.112175213_112175217AAAGA[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Microsatellite	SO:0000289	GenePathDx,Causeway_Health_Care_Private_Ltd:GPDx_APC|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2487239|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana:CMGVARID00797|OMIM_Allelic_Variant:611731.0023|OMIM_Allelic_Variant:611731.0041	-	APC:324	SO:0001589|frameshift_variant	3	121913224	-	OMIM|GeneReviews|Pathway_Genomics|Invitae|Counsyl|GenePathDx,Causeway_Health_Care_Private_Ltd|Cancer_Diagnostics_Division,Gene_Solutions|Department_of_Molecular_Diagnostics,Institute_of_Oncology|OMIM|OMIM|Ambry_Genetics|Color|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Genome_Sciences_Centre,British_Columbia_Cancer_Agency|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|3DMed_Clinical_Laboratory_Inc|3DMed_Clinical_Laboratory_Inc|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine	Pathogenic|pathologic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1999-01-01|2011-10-27|2014-07-24|2018-12-16|2016-04-28|2017-08-27|2018-01-03|2019-06-27|1999-01-01|1999-01-01|2019-04-26|2017-01-03|2015-09-14|0000-00-00|2018-10-16|2015-06-12|2015-03-27|2016-11-10|2016-07-11|2017-01-01|2017-10-25|2017-10-25|2012-01-09	2013-04-04|2013-01-08|2014-08-08|2019-03-28|2016-11-23|2017-10-11|2018-06-18|2019-07-02|2013-04-04|2013-04-04|2020-02-26|2017-10-26|2018-09-19|2017-10-31|2019-01-29|2018-08-31|2017-10-30|2018-01-25|2018-02-09|2017-12-08|2018-06-19|2018-06-19|2019-03-21	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter	unknown|not_provided|germline|germline|unknown|germline|germline|germline|unknown|unknown|germline|germline|germline|unknown|germline|germline|germline|germline|somatic|unknown|germline|germline|germline	SCV000021006|SCV000040393|SCV000189857|SCV000260059|SCV000488559|SCV000616343|SCV000803435|SCV000930652|SCV000021007|SCV000021008|SCV000172816|SCV000681641|SCV000226389|SCV000256981|SCV000490405|SCV000600092|SCV000591161|SCV000694043|SCV000693731|SCV000747271|SCV000803935|SCV000803936|SCV000058712	Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Gardner_syndrome|Adenomatous_polyposis_coli_with_congenital_cholesteatoma|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|Familial_adenomatous_polyposis|Familial_adenomatous_polyposis|Malignant_Colorectal_Neoplasm|Gastric_polyposis/Duodenal_polyposis/Adenomatous_colonic_polyposis/Intestinal_polyp/Hyperplastic_colonic_polyposis|Carcinoma_of_colon|Adenocarcinoma_of_the_colon|Familial_multiple_polyposis_syndrome	|Converted_during_submission_to_Pathogenic.||This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_APC_gene_(p.Glu1309Aspfs*4)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_1535_amino_acids_of_the_APC_protein._This_variant_is_present_in_population_databases_(rs763847228,_ExAC_0.01%)._This_variant_has_been_reported_in_numerous_individuals_and_families_affected_with_familial_adenomatous_polyposis_(FAP)_(PMID:_20223039,_1316610,_23159591,_24664542),_and_is_the_most_frequently_observed_APC_pathogenic_variant_in_individuals_with_FAP_(PMID:_20223039)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_816)._Numerous_pathogenic_truncating_variants_have_been_reported_downstream_of_this_variant_(PMID:_8940264,_11247896,_20434453),_suggesting_that_deletion_of_this_region_of_the_APC_protein_is_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Carriers_of_this_heterozygous_deletion_develop_classic_FAP_at_young_age_(18-24).||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||This_deletion_of_five_nucleotides_in_APC_is_denoted_c.3927_3931delAAAGA_at_the_cDNA_level_and_p.Glu1309AspfsX4_(E1309DfsX4)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AAGA[delAAAGA]TTGG._The_deletion_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_an_Aspartic_Acid_at_codon_1309_and_creates_a_premature_stop_codon_at_position_4_of_the_new_reading_frame._It_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_as_the_last_1535_amino_acids_are_lost_and_replaced_with_3_incorrect_amino_acids._The_disrupted_region_at_the_end_of_the_gene_includes_the_EB1_and_hDLG_binding_domains_and_a_portion_of_the_basic_domain_(Azzopardi_2008)._APC_c.3927_3931delAAAGA_is_a_common_pathogenic_variant_that_has_been_observed_in_numerous_families_with_Familial_Adenomatous_Polyposis_(Miyoshi_1992,_Aretz_2004,_Friedl_2005,_Papp_2015)._We_consider_this_variant_to_be_pathogenic.|||Variant_summary:_The_APC_c.3927_3931delAAAGA_(p.Glu1309Aspfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_APC_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_is_absent_in_121054_control_chromosomes._The_variant_has_been_reported_in_numerous_affected_families_and_individuals_in_the_literature_from_various_countries/ethnicities._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||||The_p.Glu1309fs_variant_in_APC_has_been_seen_in_over_100_individuals_with_famili_al_adenomatous_polyposis_(FAP)_and_is_the_most_common_pathogenic_APC_variant_in_patients_with_FAP_(Aretz_2004,_Friedl_2005,_Plawski_2008,_GeneReviews)._It_has_b_een_shown_to_occur_de_novo_and_to_segregate_with_disease_in_multiple_families_(A_retz_2004)._This_variant_has_also_been_reported_by_other_clinical_laboratories_i_n_ClinVar_(Variation_ID#_816)._In_vitro_functional_studies_provide_some_evidence_that_the_p.Glu1309fs_variant_may_impact_protein_function_(Dihlmann_2009)._This_variant_has_been_identified_in_2/111348_European_chromosomes_by_the_Genome_Aggre_gation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs80338757)._Th_is_variant_is_predicted_to_cause_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1309_and_leads_to_a_premature_termination_co_don_4_amino_acids_downstream._This_termination_codon_occurs_within_the_last_exon_and_is_more_likely_to_escape_nonsense_mediated_decay_(NMD)_and_result_in_a_trun_cated_protein._Downstream_nonsense_and_frameshift_variants_at_the_3'_end_of_the_gene_have_been_reported_in_individuals_with_APC_and_lead_to_a_non-functional_pro_tein._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_FAP_in_an_autosomal_dominant_manner_based_upon_presence_in_multiple_affected_in_dividuals,_segregation_studies,_low_frequency_in_the_general_population_and_de_n_ovo_occurrence._ACMG/AMP_Criteria_applied_(Richards_2015):_PS2_VeryStrong:_PS4:_PM2:_PM4:_PP1:_PS3_Supporting.
NM_000038.5:c.4012C>T	APC	stop_gained	102408	1	NA	NA	5&5	0&1	rs121913327	Carcinoma of colon&Familial adenomatous polyposis 1	801	15840	Neoplasm_of_the_large_intestine|Carcinoma_of_colon|Familial_adenomatous_polyposis_1	-	Human_Phenotype_Ontology:HP:0100834,MeSH:D015179,MedGen:C0009404,SNOMED_CT:126837005|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C2713442,OMIM:175100	-	NC_000005.9:g.112175303C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:611731.0009	-	APC:324	SO:0001587|nonsense	3	121913327	-	OMIM|Invitae|Counsyl|Database_of_Curated_Mutations_(DoCM)	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	1991-08-09|2014-11-01|2016-03-22|2015-07-14	2016-10-20|2015-09-11|2016-11-23|2016-07-18	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	somatic|germline|unknown|somatic	SCV000020988|SCV000218793|SCV000488416|SCV000505000	Carcinoma_of_colon|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Neoplasm_of_the_large_intestine	_this_sequence_change_has_been_classified_as_Pathogenic.||
NM_000038.5:c.4669_4670del	APC	frameshift_variant	101808	1	NA	NA	-	-	-	-	183857	182406	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000005.9:g.112175960_112175961del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	APC:324	SO:0001587|nonsense	1	786201118	-	Ambry_Genetics|GeneDx	Pathogenic|Pathogenic	2014-11-11|2016-07-20	2020-02-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000213160|SCV000568281	Hereditary_cancer-predisposing_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|This_deletion_of_two_nucleotides_is_denoted_APC_c.4669_4670delAT_at_the_cDNA_level_and_p.Ile1557Ter_(I1557X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_AACT[AT]TGAT._The_deletion_creates_a_nonsense_variant,_which_changes_an_Isoleucine_to_a_premature_stop_codon._Even_though_nonsense-mediated_decay_is_not_expected_to_occur_due_to_the_position_of_the_variant,_it_is_significant_since_the_last_1287_amino_acids_are_no_longer_translated_correctly_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._The_lost_residues_disrupt_part_of_the_beta-catenin_down-regulating_domain,_axin_binding_domain,_basic_domain,_EB1_binding_domain_and_hDLg_binding_domain_(Azzopardi_2008)._APC_c.4669_4670delAT_has_been_observed_in_individuals_with_familial_adenomatous_polyposis_(FAP)_with_reported_features_including_colonic_polyposis,_osteomas_and_desmoids_(De_Rosa_2004,_Latchford_2007)._This_variant_is_considered_pathogenic.
NM_000038.5:c.6905C>G	APC	stop_gained	102468	1	NA	NA	-	-	-	-	428166	419673	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000005.9:g.112178196C>G	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	APC:324	SO:0001587|nonsense	1	767372014	-	Ambry_Genetics	Pathogenic	2017-09-14	2020-02-26	_single_submitter	germline	SCV000579911	Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000535.6:c.903G>A	PMS2	splice_region_variant,synonymous_variant	102652	3	NA	NA	-	-	-	-	237932	240133	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144	-	NC_000007.13:g.6035165C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PMS2:5395	SO:0001619|non-coding_transcript_variant,SO:0001819|synonymous_variant,SO:0001623|5_prime_UTR_variant	1	267608153	-	_Partners_HealthCare_Personalized_Medicine	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2017-07-06|2019-01-24|2017-07-24	2017-10-05|2020-02-26|2019-03-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000285162|SCV000676178|SCV000731660	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome	This_sequence_change_affects_codon_301_of_the_PMS2_mRNA._It_is_a_'silent'_change,_meaning_that_it_does_not_change_the_encoded_amino_acid_sequence_of_the_PMS2_protein._This_variant_also_falls_at_the_last_nucleotide_of_exon_8_of_the_PMS2_coding_sequence,_which_is_part_of_the_consensus_splice_site_for_this_exon._Nucleotide_substitutions_within_the_consensus_splice_site_are_relatively_common_causes_of_aberrant_splicing_(PMID:_17576681,_9536098)._This_variant_is_present_in_population_databases_(rs267608153,_ExAC_0.003%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_PMS2-related_disease._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._A_different_variant_at_the_same_nucleotide_(c.903G>T)_has_been_reported_in_six_individuals_with_Lynch_syndrome_from_four_families_(PMID:_18602922,_26110232)._Experimental_studies_have_shown_that_the_c.903G>T_change_results_in_skipping_of_exon_8_and_a_premature_stop_codon_(p.Tyr268*),_indicating_that_variants_at_this_position_likely_disrupt_mRNA_splicing_and_lead_to_an_absent_or_truncated_protein._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|Last_nucleotide_of_exon:Well-characterized_mutation_at_same_position:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|The_c.903G>A_(p.Lys301Lys)_variant_in_PMS2_has_not_been_previously_reported_in_i_ndividuals_with_Lynch_syndrome_but_has_been_reported_in_ClinVar_by_another_clini_cal_laboratory_(Variation_ID_237932)._This_variant_has_also_been_identified_in_2_/111538_European_chromosomes_by_the_genome_Aggregation_Database_(gnomAD,_http://_gnomad.broadinstitute.org/:_dbSNP_rs267608153)._Although_this_silent_variant_doe_s_not_alter_an_amino_acid_residue,_it_is_located_in_the_last_base_of_the_exon,_w_hich_is_part_of_the_5?_splice_region._Computational_tools_suggest_an_impact_to_s_plicing:_however,_this_information_is_not_predictive_enough_to_determine_pathoge_nicity._A_different_variant_at_the_same_nucleotide_position_(c.903G>T,_p.Lys301A_sn)_has_been_reported_in_individuals_with_Lynch_syndrome_(Senter_2008,_Lavoine_2_015,_Suerink_2015)._Additionally,_in_vitro_functional_splicing_studies_have_show_n_that_the_c.903G>T_change_causes_aberrant_splicing_that_leads_to_skipping_of_ex_on_8_and_results_in_a_premature_stop_codon_(van_der_Klift_2015),_suggesting_that_variants_at_this_position_are_likely_to_disrupt_RNA_splicing._In_summary,_altho_ugh_additional_studies_are_required_to_fully_establish_its_clinical_significance_,_the_c.903G>A_(p.Lys301Lys)_variant_is_likely_pathogenic.
NM_000535.6:c.137G>T	PMS2	missense_variant	100432	27	15430	6	4&5&5	3&2&1	rs121434629	Lynch syndrome&Hereditary cancer-predisposing syndrome&not provided	9245	24284	Pituitary_carcinoma|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0011763,MedGen:C0346300,Orphanet:ORPHA300385|MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1838333,OMIM:614337|MedGen:CN169374|MedGen:CN517202	-	NC_000007.13:g.6045549C>A	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:600259.0012|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:3554|Illumina_Clinical_Services_Laboratory,Illumina:616257|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.137G>T_2|UniProtKB_(protein):P54278#VAR_066838	-	PMS2:5395	SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	121434629	-	OMIM|CSER__CC_NCGL,_University_of_Washington|OMIM|Illumina_Clinical_Services_Laboratory,Illumina|Counsyl|Equipe_Genetique_des_Anomalies_du_Developpement,_Université_de_Bourgogne|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Mendelics|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Vantari_Genetics|Color|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Invitae|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2013-08-01|2014-06-01|2013-08-01|2016-09-27|2015-05-14|2017-04-19|2018-04-10|2019-05-28|2019-06-21|2015-11-20|2018-03-23|2014-12-11|2018-07-02|2017-11-21|2019-02-12|2016-01-26|2015-07-25|2018-09-28|2015-02-27|2015-12-04|2018-07-16|2018-12-30|2016-03-18|2018-10-31	2016-12-27|2014-08-28|2016-12-27|2019-02-01|2017-06-22|2018-02-06|2018-06-14|2019-10-22|2019-06-21|2016-03-03|2019-03-21|2017-04-19|2018-08-20|2019-04-24|2020-02-26|2016-03-29|2017-10-26|2019-01-29|2018-09-19|2017-08-01|2019-08-05|2019-03-28|2018-08-09|2018-11-14	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|unknown|germline|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown	SCV000030047|SCV000190470|SCV000087493|SCV000469744|SCV000677739|SCV000803859|SCV000840051|SCV001137331|SCV000108292|SCV000266116|SCV000271259|SCV000592923|SCV000838198|SCV000918033|SCV000184825|SCV000267076|SCV000686122|SCV000149566|SCV000227140|SCV000601815|SCV000604885|SCV000253845|SCV000853190|SCV000894431	Turcot_syndrome|Turcot_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_specified|Hereditary_nonpolyposis_colon_cancer|Pituitary_carcinoma|Turcot_syndrome/Hereditary_nonpolyposis_colorectal_cancer_type_4	|||Across_a_selection_of_the_available_literature,_the_PMS2_c.137G>T_(p.Ser46Ile)_missense_variant_has_been_identified_in_at_least_18_heterozygous_or_compound_heterozygous_cases_with_various_cancers_and_three_as-yet_unaffected_heterozygous_family_members_(Agostini_et_al._2005:_Auclair_et_al._2007:_Senter_et_al._2008:_Pastrello_et_al._2011:_Herkert_et_al._2011:_Tomsic_et_al._2013:_Borras_et_al._2013)._The_p.Ser46Ile_variant_was_absent_from_188_control_individuals_and_436_control_chromosomes_but_is_reported_at_a_frequency_of_0.00022_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._The_variant_occurs_at_a_strongly_conserved_residue_in_an_important_functional_domain._Borras_et_al._(2013)_demonstrated_through_in_vitro_expressions_studies_that_the_p.Ser46Ile_variant_had_significantly_reduced_mismatch_repair_activity,_approximately_13%_that_of_wild_type,_while_Drost_et_al._(2013)_showed_that_the_p.Ser46Ile_variant_had_a_mismatch_repair_efficiency_similar_to_that_of_a_known_pathogenic_variant._Based_on_the_evidence,_the_p._Ser46Ile_variant_is_classified_as_likely_pathogenic_for_Lynch_syndrome._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|||This_c.137G>T_(p.S46I)_variant_in_PMS2_has_been_reported_in_individuals_with_mismatch_repair_deficiency_syndrome,_colon,_endometrial,_colorectal_and_bladder_cancer_(PMID:_21376568,_16144131,_21204794,_22577899,_16619239,_23709753)._In_addition,_functional_studies_have_shown_that_the_c.137G>T_(p.S46I)_variant_significantly_impairs_mismatch_repair_activity_(PMID:_23709753,_24027009)._Therefore,_the_c.137G>T_(p.S46I)_in_the_PMS2_gene_is_classified_as_pathogenic.||>2_MSI_tumours:_deficient_protein_function_inferred_from_2_independent_assays||The_p.Ser46Ile_variant_in_PMS2_has_been_described_as_a_founder_variant_for_lynch_syndrome_in_Caucasians_(Ponti_2015,_Tomsic_2013)._It_has_been_reported_in_the_h_eterozygous_state_in_>15_individuals_with_Lynch_syndrome-associated_cancers,_whe_re_the_tumors_showed_microsatellite_instability_and_loss_of_PMS2_expression_in_s_ome_individuals_(Borras_2013,_Clendenning_2006,_Cock-Rada_2017,_Haraldsdottir_20_13,_Le_2017,_Nakagawa_2004,_Pritchard_2016,_Senter_2008,_Tomsic_2013,_ClinVar:_V_ariation_ID_9245)._This_variant_has_also_been_reported_in_the_biallelic_state_(h_omozygous_or_compound_heterozygous_with_a_second_pathogenic_variant)_in_at_least_9_individuals_with_constitutional_mismatch_repair_deficiency_syndrome_(CMMRD)_a_nd_segregated_with_disease_in_at_least_3_affected_relatives_from_at_least_2_fami_lies_(Auclair_2007,_Borras_2013,_Giunti_2009,_Herkert_2011)._Normal_and_tumor_ti_ssue_from_some_individuals_with_CMMRD_showed_loss_of_expression_of_PMS2_(Agostin_i_2005,_Auclair_2007,_Bodo_2015,_Giunti_2009,_Herkert_2011,_Jackson_2008,_Lavoin_e_2015,_Pastrello_2011,_Stark_2014)._Additionally,_some_relatives_who_were_heter_ozygous_carriers_of_this_variant_were_clinically_unaffected,_suggesting_reduced_penetrance._In_vitro_functional_studies_provide_some_evidence_that_the_p.Ser46Il_e_variant_may_impact_protein_function_(Borras_2013,_Drost_2013,_Nakagawa_2004)._This_variant_has_been_identified_in_35/122744_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs1214346_29)._Although_this_variant_has_been_seen_in_the_general_population,_its_frequenc_y_is_low_enough_to_be_consistent_with_the_frequency_and_penetrance_of_PMS2-relat_ed_Lynch_syndrome._Computational_prediction_tools_and_conservation_analysis_sugg_est_that_the_p.Ser46Ile_variant_may_impact_the_protein._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_Lynch_syndrome_in_an_autosoma_l_dominant_manner_and_for_CMMRD_in_an_autosomal_recessive_manner_based_upon_pres_ence_in_multiple_affected_individuals,_segregation_studies,_and_functional_evide_nce._ACMG/AMP_Criteria_applied_(Richards_2015):_PM3_Very_strong:_PS3:_PS4:_PP1:_PP3.|||Variant_summary:_The_PMS2_c.137G>T_(p.Ser46Ile)_variant_involves_the_alteration_of_a_conserved_nucleotide_that_results_in_a_missense_change_within_the_nucleotide_binding_pocket_of_the_ATPase_domain_(Borras_2013)._4/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant_(SNPsandGO_not_captured_due_to_low_reliability_index)._Functional_studies_have_shown_the_variant_to_cause_deficient_MMR_activity_(Borras_2013,_Drost_2013,_van_der_Klift_2016)._This_variant_was_found_in_47/271742_control_chromosomes_(in_gnomAD_and_publication_controls),_however_the_technology_utilized_for_the_gnomAD_dataset_does_not_rule_out_pseudogene_interference_and_thus_this_data_cannot_be_relied_upon._This_variant_has_been_reported_in_several_patients/families_with_Lynch_syndrome-associated_cancers_(in_many_cases_isolated_loss_of_PMS2_was_detected_in_the_tumors)_as_well_as_in_patients_with_constitutional_MMR_deficiency_(CMMR-D)_syndrome_who_also_have_a_second_pathogenic_PMS2_mutation_(in_many_of_these_cases_PMS2_loss_in_normal_tissues_was_documented)_(Clendenning_2006,_Senter_2008,_Herkert_2011,_Tomsic_2013,_Borras_2013,_van_der_Klift_2016)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification|||This_pathogenic_variant_is_denoted_PMS2_c.137G>T_at_the_cDNA_level,_p.Ser46Ile_(S46I)_at_the_protein_level,_and_results_in_the_change_of_a_Serine_to_an_Isoleucine_(AGT>ATT)._PMS2_Ser46Ile_was_observed_at_an_allele_frequency_of_0.03%_(11/34312)_in_individuals_of_Latino_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_Motif_I_of_the_ATPase_domain_(Guarne_2001)._In-silico_analyses,_including_protein_predictors_and_evolutionary_conservation,_support_a_deleterious_effect._PMS2_Ser46Ile_has_been_published_in_the_literature_as_a_Caucasian_founder_pathogenic_variant_(Senter_2008,_Tomsic_2013,_Ponti_2015)._It_has_been_reported_in_many_individuals_with_Lynch_syndrome-associated_tumors_and_in_many_individuals_with_autosomal_recessive_constitutional_mismatch_repair_deficiency_syndrome_(CMMR-D)_in_the_homozygous_state_or_in_the_compound_heterozygous_state_with_a_second_PMS2_pathogenic_variant_on_the_opposite_chromosome._Tumor_testing_in_many_of_these_individuals_showed_microsatellite_instability_(MSI-H)_and/or_loss_of_PMS2_protein_expression_(Nakagawa_2004,_Agostini_2005,_Clendenning_2006,_Auclair_2007,_Jackson_2008,_Senter_2008,_Van_der_Klift_2010,_Hekert_2011,_Leenen_2011,_Lavoine_2015,_ten_Broeke_2015,_Heath_2016,_Nowak_2016,_van_der_Klift_2016,_Rengifo-Cam_2017)._While_some_functional_studies_have_been_inconclusive,_several_independent_in_vitro_cell-free_complementation_assays_showed_deficient_mismatch_repair_activity_as_well_as_reduced_PMS2_expression_(Nakagawa_2004,_Borras_2013,_Drost_2013)._Based_on_currently_available_evidence,_we_consider_PMS2_Ser46Ile_to_be_a_pathogenic_variant.|||The_PMS2_c.137G>T:p.Ser46Ile_variant_has_been_published_in_the_literature_in_individuals_and_families_with_Lynch_syndrome-associated_cancers_and_constitutional_mismatch_repair-deficiency_(Auclair_2007,_Borras_2013,_Jackson_2008,_Senter_2008,_Tosmic_2013)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_9245)_and_is_found_in_the_Latino_population_with_an_overall_allele_frequency_of_0.03%_(11/34312_alleles)_in_the_Genome_Aggregation_Database._Several_individuals_with_constitutional_mismatch_repair-deficiency_carried_this_variant_in_trans_to_a_second_pathogenic_PMS2_variant_(Auclair_2007,_Jackson_2008,_Senter_2008),_including_another_variant_at_the_same_codon,_p.Ser46Asn,_observed_in_two_affected_individuals_(Jackson_2008,_Senter_2008)._The_serine_at_codon_46_is_highly_conserved_and_both_the_p.Ser46Ile_and_p.Ser46Asn_variants_exhibit_less_than_10%_of_wild-type_activity_in_mismatch_repair_in_vitro_assays_(Borras_2013,_Drost_2013)._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Auclair_J_et_al._Novel_biallelic_mutations_in_MSH6_and_PMS2_genes:_gene_conversion_as_a_likely_cause_of_PMS2_gene_inactivation._Hum_Mutat._2007_Nov:28(11):1084-90._Borras_E_et_al._Refining_the_role_of_PMS2_in_Lynch_syndrome:_germline_mutational_analysis_improved_by_comprehensive_assessment_of_variants._J_Med_Genet._2013_Aug:50(8):552-63._Drost_M_et_al._Inactivation_of_DNA_mismatch_repair_by_variants_of_uncertain_significance_in_the_PMS2_gene._Hum_Mutat._2013_Nov:34(11):1477-80._Jackson_CC_et_al._Cafe-au-lait_macules_and_pediatric_malignancy_caused_by_biallelic_mutations_in_the_DNA_mismatch_repair_(MMR)_gene_PMS2._Pediatr_Blood_Cancer._2008_Jun:50(6):1268-70._Senter_L_et_al._The_clinical_phenotype_of_Lynch_syndrome_due_to_germ-line_PMS2_mutations._Gastroenterology._2008_Aug:135(2):419-28._Tomsic_J_et_al._Recurrent_and_founder_mutations_in_the_PMS2_gene._Clin_Genet._2013_Mar:83(3):238-43.|This_sequence_change_replaces_serine_with_isoleucine_at_codon_46_of_the_PMS2_protein_(p.Ser46Ile)._The_serine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_serine_and_isoleucine._This_variant_is_present_in_population_databases_(rs121434629,_ExAC_0.02%)._This_variant_has_been_reported_in_trans_with_pathogenic_PMS2_variants_in_multiple_families_with_constitutional_mismatch_repair_deficiency_syndrome_(CMMR-D)_(PMID:_21376568,_16144131,_21204794)._In_separate_analyses,_this_c.137G>T_missense_variant_was_identified_in_more_than_10_probands_with_colon_and/or_endometrial_cancer_(PMID:_22577899,_16619239),_and_has_been_reported_to_segregate_with_colorectal_and_bladder_cancer_in_a_single_family_with_suspected_Lynch_syndrome_(PMID:_23709753)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_9245)._Experimental_studies_have_shown_that_this_missense_change_significantly_impairs_the_mismatch_repair_activity_of_PMS2_(PMID:_23709753,_24027009)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_is_a_missense_variant_in_which_a_G_is_replaced_by_a_T_at_coding_position_137_and_is_predicted_to_change_a_Serine_to_an_Isoleucine_at_codon_46.|
NM_000535.6:c.137G>A	PMS2	missense_variant	100432	2	NA	NA	-	-	-	-	91301	96776	Hereditary_nonpolyposis_colon_cancer|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000007.13:g.6045549C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.137G>A|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2846740	-	PMS2:5395	SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	121434629	-	Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Invitae|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2014-12-11|2018-11-16|0000-00-00|2018-07-12	2017-04-19|2019-03-28|2017-10-31|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|unknown|germline	SCV000592922|SCV000552059|SCV000691980|SCV000888391	Lynch_syndrome|Hereditary_nonpolyposis_colon_cancer|not_provided|not_provided	|This_sequence_change_replaces_serine_with_asparagine_at_codon_46_of_the_PMS2_protein_(p.Ser46Asn)._The_serine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_serine_and_asparagine._This_variant_is_present_in_population_databases_(rs121434629,_ExAC_0.003%)._This_variant_has_been_reported_in_individuals_with_a_personal_or_family_history_of_colorectal_cancer_and_sebaceous_adenoma_(PMID:_26866578,_25006859)._This_variant_has_also_been_observed_on_the_opposite_chromosome_(in_trans)_from_a_pathogenic_variant_in_an_individual_affected_with_constitutional_mismatch_repair_deficiency_syndrome_(PMID:_18273873)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_91301)._Experimental_studies_have_shown_that_this_missense_change_disrupts_PMS2_mismatch_repair_activity_(PMID:_24027009)._A_different_missense_substitution_at_this_codon_(p.Ser46Ile)_has_been_determined_to_be_pathogenic_(PMID:_22577899,_23709753)._This_suggests_that_the_serine_residue_is_critical_for_PMS2_protein_function_and_that_other_missense_substitutions_at_this_position_may_also_be_pathogenic._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||
NM_000535.6:c.2T>A	PMS2	start_lost	102190	1	NA	NA	5&5&5	1&1&1	rs587780059	Hereditary cancer-predisposing syndrome&not provided&Lynch syndrome	182809	180273	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1838333,OMIM:614337|MedGen:CN517202	-	NC_000007.13:g.6048649A>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PMS2:5395	SO:0001582|initiatior_codon_variant,SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	587780059	-	Ambry_Genetics|Color|GeneDx|Invitae|Genetic_Services_Laboratory,_University_of_Chicago|Counsyl|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-01-09|2016-08-02|2017-04-03|2018-12-10|2016-08-29|2017-10-27|2018-10-31|2018-01-29	2020-02-26|2017-12-21|2019-01-29|2019-03-28|2017-07-05|2018-06-20|2018-11-14|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown|germline	SCV000214325|SCV000691064|SCV000211587|SCV000285128|SCV000596477|SCV000785677|SCV000894432|SCV000920019	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Turcot_syndrome/Hereditary_nonpolyposis_colorectal_cancer_type_4|Lynch_syndrome	Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Well-characterized_mutation_at_same_position:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||PMS2_c.2T>A_results_in_the_loss_of_the_initiator_Methionine_codon,_and_the_resultant_protein_would_be_described_as_p.Met1?_to_signify_that_it_is_not_known_if_the_loss_of_Met1_prevents_all_protein_translation_or_if_an_abnormal_protein_is_produced_using_an_alternate_Methionine_codon._This_variant_has_been_reported_in_an_individual_with_a_personal_and_family_history_of_colorectal_cancer_(Chubb_2015)_as_well_as_in_the_compound_heterozygous_state_in_an_individual_with_constitutional_mismatch_repair_deficiency_syndrome_and_absent_PMS2_expression_in_tumor_and_normal_tissues_(Adam_2016)._In_addition,_the_adjacent_variant_c.1A>G,_which_also_results_in_p.Met1?,_has_been_reported_in_a_patient_with_endometrial_cancer_for_which_loss_of_PMS2_protein_was_observed_via_immunohistochemistry,_as_well_as_in_trans_(on_opposite_chromosomes)_with_other_pathogenic_PMS2_variants_in_at_least_three_individuals_with_a_phenotype_suspicious_for_constitutional_mismatch_repair_deficiency_syndrome_and_absent_PMS2_expression_in_both_tumor_and_normal_tissues_(Senter_2008,_Borras_2013)._Based_on_current_evidence,_we_consider_PMS2_c.2T>A_to_be_pathogenic.|This_sequence_change_affects_the_initiator_methionine_of_the_PMS2_mRNA._The_next_in-frame_methionine_is_located_at_codon_136._This_variant_is_present_in_population_databases_(rs587780059,_ExAC_0.003%)._This_variant_has_been_reported_in_individuals_with_colorectal_cancer_(PMID:_25559809)_and_breast_and/or_ovarian_cancer_(PMID:_26898890),_as_well_as_in_an_individual_with_constitutional_mismatch-repair_deficiency_syndrome_who_also_carried_a_second_pathogenic_PMS2_variant_(PMID:_27476653).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_182809)._This_variant_is_expected_to_result_in_an_absent_or_disrupted_protein_product._If_translation_initiation_is_rescued_by_the_downstream_methionine_at_codon_136,_this_would_result_in_the_partial_disruption_of_the_ATPase_domain,_which_is_important_for_the_mismatch_repair_activity_of_the_PMS2_protein_(PMID:_11574484,_11897781)._However,_functional_studies_have_not_been_published_for_this_variant._A_different_change_(c.1A>G)_at_the_initiator_codon_has_been_reported_in_individuals_with_colorectal_and_endometrial_cancer_(PMID:_20487569,_23709753),_andÂ¬â€ individuals_with_a_personal_history_consistent_with_constitutional_mismatch_repair_deficiency_syndrome_who_also_carried_a_second_pathogenic_PMS2_variant_(PMID:_18602922)._The_c.1A>G_variant_has_been_determined_to_be_pathogenic,_suggesting_that_other_substitutions_at_this_position_may_also_be_pathogenic._For_these_reason,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_PMS2_c.2T>A_(p.Met1Lys)_alters_the_initiation_codon_and_is_predicted_to_result_either_in_absence_of_the_protein_or_truncation_of_the_encoded_protein_due_to_translation_initiation_at_a_downstream_codon._Three_of_four_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_8.2e-06_in_245322_control_chromosomes._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_PMS2_causing_Lynch_Syndrome_(8.2e-06_vs_0.00011),_allowing_no_conclusion_about_variant_significance._c.2T>A_has_been_reported_in_the_literature_in_individuals_affected_with_CRC_and_CMMRD_(Chubb_2015,_Adam_2016,_and_Susswein_2016)._Among_them,_one_patient_carried_biallelic_PMS2_mutation_(variant_of_interest_and_c.863delA/p.Gln288Argfs*19),_IHC_staining_showed_complete_loss_of_PMS2_in_both_tumor_and_normal_tissue_(Adam_2016)._Moreover,_Ambry_genetics_reported_three_occurrences_of_this_variant_(Espenschied__2017)._Haraldsdottir_2017_reported_variant_associated_with_a_significantly_increased_risk_of_endometrial,_colorectal_and_ovarian_cancer,_although_the_overall_cancer_risks_are_lower_than_for_the_MSH6_mutation_among_Icelanders._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Variants_involving_the_same_codon_(such_as_M1L,_M1T,_and_M1V)_have_been_reported_in_affected_individuals_suggesting_the_functional_importance_of_this_position._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_000535.6:c.1A>G	PMS2	start_lost	102176	2	15428	1	4&5	0&1	rs587779333	Lynch syndrome I&not provided	91323	96798	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1838333,OMIM:614337|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000007.13:g.6048650T>C	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:3561|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1A>G_3	-	PMS2:5395	SO:0001582|initiatior_codon_variant,SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	587779333	-	Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Pathway_Genomics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Counsyl|Invitae|Ambry_Genetics|Color	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-03-20|2019-01-31|2017-06-30|2014-07-24|2018-03-26|2017-04-26|2017-10-20|2016-03-08|2018-12-17|2018-08-10|2017-08-08	2018-01-25|2019-03-21|2018-03-23|2014-08-08|2019-01-29|2017-08-01|2018-10-10|2016-11-23|2019-03-28|2020-02-26|2017-12-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline	SCV000697323|SCV000711436|SCV000108326|SCV000189976|SCV000211586|SCV000601834|SCV000885991|SCV000488365|SCV000166382|SCV000663423|SCV000691053	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome_I|Lynch_syndrome_I|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	Variant_summary:_The_PMS2_c.1A>G_(p.Met1Val)_variant_involves_the_alteration_of_a_conserved_nucleotide_that_results_with_the_alteration_of_the_translational_start_site._The_nearest_in-frame_alternate_methionine_residue_that_could_be_used_to_initiate_PMS2_translation_occurs_at_codon_136,_therefore_this_variant_is_expected_to_result_in_an_absent_or_disrupted_protein_product,_although_these_findings_have_not_been_confirmed_by_functional_studies._3/5_in_silico_tools_predict_a_benign_outcome._The_variant_of_interest_was_observed_in_controls_obtained_from_the_Tomsic_2013_paper_that_performed_long-range_PCR_analysis_to_eliminate_the_possibility_of_the_pseudogene_and_was_found_to_have_an_allele_frequency_of_0.04375,_which_does_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_PMS2_variant_(0.0001136)._Multiple_publications_have_cited_the_variant_in_affected_individuals_including_a_family_with_an_unaffected_individual_carrying_the_variant_(Borras_2013)._Additionally,_publications_and_clinical_labs_cite_affected_individuals_who_carry_another_potentially_pathogenic_PMS2_variant_in_trans_such_as_deletion_of_exons_9_and_10,_c.251-2A>G_(Senter_2008)_and_a_patient_who_is_homozygous_for_the_variant_(Ambry_Genetics)._Individuals_from_the_Senter_2008_publication_also_showed_loss_of_PMS2_expression._Carrying_two_MMR_mutations_in_the_same_gene_in_trans_has_been_associated_with_constitutional_mismatch_repair-deficiency,_which_is_characterized_by_colonic_polyposis_and_hematologic,_brain_and_gastrointestinal_malignancies,_as_well_as_neurofribromas,_which_present_at_a_young_age_and_thus_both_mutations_may_be_explaining_the_phenotype_in_the_individuals_reported._Additionally,_another_alteration_at_this_position,_c.1A>T_(p.Met1Leu)_has_been_classified_as_likely_pathogenic_by_LCA,_although_the_variant_was_only_observed_once_in_controls._Furthermore,_multiple_clinical_diagnostic_laboratories_in_ClinVar_have_classified_this_variant_as_Pathogenic/Likely_Pathogenic_and_one_lab_has_classified_it_as_a_variant_of_uncertain_clinical_significance._Therefore,_until_additional_evidence_becomes_available,_particularly_functional_evidence,_the_variant_of_interest_has_been_classified_as_a_Likely_Pathogenic_variant.|The_c.1A>G_variant_in_PMS2_has_been_reported_in_the_heterozygous_state_at_least_2_individuals_with_Lynch_syndrome-associated_cancers_and_1_individual_who_was_re_ferred_for_clinical_genetic_testing_of_germline_cancer_genes_(Talseth-Palmer_201_0,_Borras_2013,_Susswein_2015)._It_has_also_been_also_reported_in_the_compound_h_eterozygous_state_in_at_least_3_individuals_with_constitutional_mismatch_repair_deficiency_(CMMRD:_Senter_2008,_LOVD_database)._Additionally,_the_c.1A>G_variant_has_been_identified_in_4/125936_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs587779333)._This_var_iant_affects_the_translation_initiation_start_codon_(ATG)_and_is_therefore_predi_cted_to_disrupt_translation._The_precise_effect_on_the_protein_cannot_be_predict_ed,_as_this_variant_may_lead_to_no_protein_synthesis_or_the_activation_of_an_ups_tream_translation_initiation_codon,_resulting_in_an_aberrant_protein._Heterozygo_us_loss_of_function_of_the_PMS2_gene_is_an_established_disease_mechanism_in_Lync_h_Syndrome._However,_this_exon_is_not_present_on_all_PMS2_transcripts._Moreover_,_this_variant_has_been_classified_as_likely_pathogenic_on_June_30,_2017_by_the_ClinGen-approved_InSiGHT_Expert_Panel_(ClinVar_SCV000108326.2)._In_summary,_whil_e_additional_studies_are_required_to_fully_establish_its_clinical_significance,_the_c.1A>G_variant_is_likely_pathogenic.|meets_criteria_for_Class_4||The_c.1A>G_variant_in_the_PMS2_gene_alters_the_initiator_Methionine_codon,_and_the_resultant_protein_would_be_described_as_p.Met1?_to_signify_that_it_is_not_known_if_the_loss_of_Met1_prevents_all_protein_translation_or_if_an_abnormal_protein_is_produced_using_an_alternate_Methionine_codon._This_variant_has_been_reported_in_an_individual_with_a_history_of_endometrial_cancer_for_which_loss_of_PMS2_protein_was_observed_via_mismatch_repair_immunohistochemistry_(Borras_2013)._PMS2_c.1A>G_has_also_been_observed_in_trans_(on_opposite_chromosomes)_with_known_pathogenic_variants_in_PMS2_in_at_least_three_individuals_with_a_phenotype_consistent_with_constitutional_mismatch_repair_deficiency_syndrome:_loss_of_PMS2_protein_was_observed_in_both_tumor_and_normal_surrounding_tissue_(Senter_2008)._We_therefore_consider_this_variant_to_be_pathogenic.||||This_sequence_change_affects_the_initiator_methionine_of_the_PMS2_mRNA._The_nearest_in-frame_methionine_that_could_be_used_to_initiate_PMS2_translation_occurs_at_codon_136,_and_therefore_this_variant_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587779333,_0.01%)._This_variant_has_been_reported_in_individuals_affected_with_colorectal_cancer_(PMID:_20487569)_and_endometrial_cancer_(PMID:_23709753),_and_several_individuals_with_a_personal_history_consistent_with_constitutional_mismatch_repair_deficiency_syndrome_(PMID:_18602922)._In_addition_to_the_c.1A>G_variant,_each_individual_carried_a_second_PMS2_variant_that_is_likely_pathogenic,_and_immunohistochemistry_results_from_the_tumors_of_these_individuals_showed_absence_of_PMS2_expression_(PMID:_18602922)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_91323)._Two_different_variants_(c.1A>T_and_c.2T>A)_that_also_disrupt_the_PMS2_initiator_codon_have_been_reported_in_an_individual_with_a_history_of_Lynch_syndrome-associated_cancer_and/or_colorectal_polyps_(PMID:_25980754),_and_an_individual_with_breast_cancer_and_multiple_myeloma_(Invitae),_suggesting_that_this_initiator_codon_is_critical_for_PMS2_translation._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion):Significant_disease_association_in_appropriately_sized_case-control_study(ies):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|
NM_000136.2:c.1661T>C	FANCC	missense_variant	102652	3	15410	1	5	0	rs104886458	Fanconi anemia, complementation group C	12043	27082	_complementation_group_C|not_provided	-	OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97864005A>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q00597#VAR_005233|OMIM_Allelic_Variant:613899.0001	-	FANCC:2176|AOPEP:84909	SO:0001583|missense_variant	1	104886458	-	OMIM|GeneReviews|Counsyl|Baylor_Genetics|SNPedia|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|not_provided|Pathogenic	1993-02-01|2016-09-22|2018-10-09|0000-00-00|0000-00-00|2018-06-27	2019-11-07|2016-09-27|2019-08-05|2019-09-27|2011-04-26|2019-01-29	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline	SCV000033063|SCV000057806|SCV001132190|SCV001163619|SCV000090446|SCV000512973	Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|not_provided|not_provided	|||||This_variant_is_denoted_FANCC_c.1661T>C_at_the_cDNA_level,_p.Leu554Pro_(L554P)_at_the_proteinlevel,_and_results_in_the_change_of_a_Leucine_to_a_Proline_(CTG>CCG)_in_exon_15._This_variant_has_observed_in_atleast_two_individuals_with_Fanconi_Anemia_(Verlander_1994)._This_variant_was_also_identified_in_an_individual_with_twoprimary_breast_cancers_and_a_family_history_of_breast_cancer_(Thompson_2012)._Functional_studies_of_this_pathogenic_variantresults_in_decreased_capacity_to_tolerate_mitomycin_C_and_the_inability_to_bind_to_FANCA,_FANCE,_and_cdc2_(Gavish1993,_Youssoufian_1996,_Kupfer_1997a,_Kupfer_1997b,_Gordon_2003)._FANCC_Leu554Pro_was_not_observed_at_asignificant_allele_frequency_in_the_NHLBI_Exome_Sequencing_Project._Since_Leucine_and_Proline_differ_in_someproperties,_this_is_considered_a_semi-conservative_amino_acid_substitution._FANCC_Leu554Pro_alters_a_position_that_ishighly_conserved_across_species_and_is_located_in_the_cdc2_binding_domain_(Gordon_2000)._In_silico_analyses_predictthat_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_the_current_evidence,_we_considerthis_to_be_a_pathogenic_variant.
NM_000136.2:c.1642C>T	FANCC	stop_gained	102666	6	15426	1	5&5&5	0&1&1	rs104886457	Fanconi anemia, complementation group C&not provided&Fanconi anemia	12047	27086	_complementation_group_C|not_provided	-	Human_Phenotype_Ontology:HP:0002575,MedGen:C1861028,OMIM:189960|MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97864024G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:613899.0005	-	FANCC:2176|AOPEP:84909	SO:0002152|genic_downstream_transcript_variant	1	104886457	-	OMIM|GeneReviews|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Fulgent_Genetics,Fulgent_Genetics|Baylor_Genetics|SNPedia|GeneDx|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Fulgent_Genetics,Fulgent_Genetics|Ambry_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1993-09-11|2016-09-22|2015-06-14|2016-08-31|2018-07-02|2018-10-31|0000-00-00|0000-00-00|2018-08-07|2018-12-17|2018-05-14|2017-05-18|2019-02-14	2015-06-15|2016-09-27|2017-06-22|2018-01-25|2018-08-20|2018-11-14|2019-09-27|2011-04-26|2019-01-29|2019-03-28|2019-03-21|2017-05-23|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|unknown|unknown|germline|germline|germline|germline|germline|unknown|germline	SCV000033067|SCV000057805|SCV000677975|SCV000695427|SCV000838339|SCV000894483|SCV001163620|SCV000090445|SCV000211058|SCV000261073|SCV000967666|SCV000611188|SCV000673286	Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|not_provided|not_provided|Fanconi_anemia|Fanconi_anemia|Fanconi_anemia,_complementation_group_C/Tracheoesophageal_fistula|Hereditary_cancer-predisposing_syndrome	|||Variant_summary:_The_c.1642C>T_(p.Arg548*)_variant_in_FANCC_gene_is_a_nonsense_change_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_or_nonsense-mediated_mRNA_decay._The_p.Arg548*_is_expected_to_lack_last_11_amino_acids_and_was_unable_to_restore_MMC_hypersensitivity_in_the_functional_assay._The_variant_is_present_in_the_large_control_population_dataset_of_ExAC_at_a_low_frequency_0.00002_(3/120522_chrs_tested),_which_does_not_exceed_the_maximal_expected_frequency_of_a_pathogenic_allele_(0.002)_in_this_gene._The_variant_of_interest_has_been_reported_in_multiple_affected_individuals_in_homozygous_or_compound_heterozygous_state_with_a_confirmed_diagnosis_of_FA._Per_multiple_reports,_this_variant_is_strongly_correlated_with_increased_numbers_of_severe_congenital_malformation,_earlier_onsets_of_marrow_failure,_and_overall_poorer_survival_rate._In_addition,_multiple_reputable_databases/clinical_laboratories_classified_this_variant_as_Pathogenic._Taken_together,_the_variant_was_classified_as_Pathogenic.|||||This_pathogenic_variant_is_denoted_FANCC_c.1642C>T_at_the_cDNA_level_and_p.Arg548Ter_(R548X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._This_variant_has_been_reported_in_several_individuals_with_Fanconi_anemia,_in_both_the_homozygous_and_compound_heterozygous_state,_and_is_known_to_cause_premature_termination_of_translation_(Murer-Orlando_1993,_Gibson_1996,_Gillio_1997,_De_Rocco_2014,_Wenger_2016)._A_functional_study_showed_that_FANCC_Arg548Ter_was_unable_to_correct_the_cellular_Fanconi_Anemia_phenotype_in_transfected_cells_and_that_the_presence_of_the_C-terminal_region_is_functionally_necessary_(Lo_ten_Foe_1996)._We_therefore_consider_this_variant_to_be_pathogenic.|This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_last_exon_of_the_FANCC_mRNA_at_codon_548_(p.Arg548*)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_create_a_truncated_FANCC_protein_lacking_the_last_11_amino_acid_residues._This_variant_is_present_in_population_databases_(rs104886457,_ExAC_0.005%)._This_variant_has_been_reported_as_homozygous_and_in_trans_with_a_second_loss-of-function_variant_in_individuals_affected_with_Fanconi_anemia_(PMID:_8103176,_24584348).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12047)._An_experimental_study_has_shown_that_this_nonsense_change_renders_FANCC_unable_to_correct_the_hypersensitivity_to_mitomycin_C_in_a_Fanconi_anemia_cell_line_(PMID:_8882868),_suggesting_that_the_very_C-terminal_amino_acids_are_critical_for_proper_FANCC_function._Loss-of-function_variants_in_FANCC_are_known_to_be_pathogenic_(PMID:_17924555)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Arg548X_variant_in_FANCC_has_been_identified_in_the_homozygous_or_compound_heterozygous_state_in_more_than_9_individuals_with_Fanconi_anemia,_and_segregat_ed_with_disease_in_at_least_1_affected_family_member_(Murer-Orlando_1993,_Gillio_1997,_Aftab_2017)._This_variant_has_also_been_identified_in_8/111606_European_c_hromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstit_ute.org:_dbSNP_rs104886457)._Although_this_variant_has_been_seen_in_the_general_population,_its_frequency_is_low_enough_to_be_consistent_with_a_recessive_carrie_r_frequency._This_nonsense_variant_leads_to_a_premature_termination_codon_at_pos_ition_548._This_alteration_occurs_within_the_last_exon_and_is_more_likely_to_esc_ape_nonsense_mediated_decay_(NMD)_and_result_in_a_truncated_protein._Nevertheles_s,_in_vitro_functional_studies_provide_evidence_that_this_variant_disrupts_FANCC_function_(Lo_Ten_Foe_1996)._In_summary,_this_variant_meets_criteria_to_be_class_ified_as_pathogenic_for_autosomal_recessive_Fanconi_anemia._ACMG/AMP_Criteria_ap_plied:_PM3_Very_Strong:_PM4:_PS3_Moderate.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)
NM_000136.2:c.1628C>A	FANCC	stop_gained	102690	2	NA	NA	-	-	-	-	370412	357819	_complementation_group_C|not_provided	-	OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97864038G>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001587|nonsense	1	867319477	-	Counsyl|GeneDx	Likely_pathogenic|Likely_pathogenic	2016-02-03|2016-10-10	2016-11-23|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline	SCV000485726|SCV000779448	_complementation_group_C|not_provided	|This_variant_is_denoted_FANCC_c.1628C>A_at_the_cDNA_level_and_p.Ser543Ter_(S543X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._Even_though_this_truncation_occurs_near_the_end_of_the_gene_and_nonsense-mediated_decay_is_not_expected_to_occur,_it_is_significant_since_the_last_49_amino_acids_are_no_longer_translated._Furthermore,_the_truncation_would_disrupt_the_region_of_interaction_with_cdc2_(Gordon_2000)._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_we_consider_it_to_be_likely_pathogenic.
NM_000136.2:c.843+5G>A	FANCC	splice_region_variant,intron_variant	102730	3	15426	2	-	-	-	-	216291	212683	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97897623C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(4)	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001627|intron_variant	1	369082921	-	Invitae|GeneDx|Counsyl|Mendelics|Ambry_Genetics	Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2018-11-06|2018-10-08|2017-03-16|2018-07-02|2019-12-13	2019-03-28|2019-01-29|2018-07-10|2018-08-20|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|unknown|germline	SCV000254265|SCV000566528|SCV000790355|SCV000838349|SCV001178903	Fanconi_anemia|not_provided|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Hereditary_cancer-predisposing_syndrome	This_sequence_change_falls_in_intron_8_of_the_FANCC_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_FANCC_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs369082921,_ExAC_0.01%)_but_has_not_been_reported_in_the_literature_in_individuals_with_a_FANCC-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variant_ID:_216291)._Nucleotide_substitutions_at_the_+5_position_of_the_intron_are_relatively_common_causes_of_aberrant_splicing_(PMID:_17576681)._Algorithms_developed_to_predict_the_effect_of_nucleotide_changes_on_mRNA_splicing_suggest_that_this_variant_may_alter_mRNA_splicing,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_this_is_a_rare_intronic_change_with_uncertain_impact_on_splicing._It_has_been_classified_as_a_Variant_of_Uncertain_Significance.|This_variant_is_denoted_FANCC_c.843+5G>A_or_IVS8+5G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_+5_position_of_intron_8_of_the_FANCC_gene._In_silico_analyses,_which_include_splice_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect:_however,_in_the_absence_of_RNA_or_functional_studies,_the_actual_effect_of_this_variant_is_unknown._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature_as_a_pathogenic_or_benign_germline_variant._FANCC_c.843+5G>A_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Based_on_currently_available_evidence,_it_is_unclear_whether_FANCC_c.843+5G>A_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Insufficient_evidence:RNA_Studies
NM_000136.2:c.456+4A>T	FANCC	splice_region_variant,intron_variant	102382	7	15432	1	-	-	-	-	12045	27084	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97934315T>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:107636|OMIM_Allelic_Variant:613899.0003	-	FANCC:2176	SO:0001627|intron_variant	1	104886456	-	OMIM|GeneReviews|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Fulgent_Genetics,Fulgent_Genetics|Illumina_Clinical_Services_Laboratory,Illumina|Baylor_Genetics|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Center_for_Pediatric_Genomic_Medicine,Children's_Mercy_Hospital_and_Clinics|Invitae|Reproductive_Health_Research_and_Development,BGI_Genomics|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2001-06-27|2016-09-22|2015-06-14|2016-01-18|2018-07-02|2018-10-31|2018-10-05|0000-00-00|2018-07-17|2015-04-07|2015-02-11|2018-12-28|2020-01-06|2018-11-13	2015-06-15|2016-09-27|2019-08-05|2018-01-25|2018-08-20|2018-11-14|2019-02-01|2019-09-27|2019-01-29|2018-09-19|2017-10-05|2019-03-28|2020-01-06|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|unknown|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline	SCV000033065|SCV000057808|SCV000677963|SCV000695432|SCV000838356|SCV000894484|SCV000916270|SCV001163628|SCV000149263|SCV000230847|SCV000281326|SCV000253765|SCV001142398|SCV000673287	Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|not_provided|not_provided|not_provided|Fanconi_anemia|Fanconi_anemia|Hereditary_cancer-predisposing_syndrome	|||Variant_summary:_FANCC_c.456+4A>T_affects_a_conserved_intronic_nucleotide._Mutation_Taster_predicts_a_damaging_outcome_for_this_variant,_and_4/5_Alamut_algorithms_predict_a_weaker_splice_donor_site_for_the_variant,_which_is_predicted_to_increase_exon_skipping._These_in_silico_predictions_are_supported_by_functional_studies_showing_that_this_variant_leads_to_a_truncated_protein_product._This_variant_is_found_in_28/117194_control_chromosomes_at_a_frequency_of_0.0002389,_which_does_not_significantly_exceed_maximal_expected_frequency_of_a_pathogenic_FANCC_allele_(0.0017678).The_variant_has_been_cited_in_multiple_severe_FA_patients_in_homozygous_state_and_in_mild_FA_patients_in_compound_heterozygous_state._In_addition,_multiple_clinical_diagnostic_labs_classified_this_variant_as_pathogenic._This_intronic_variant_is_considered_a_known_common_disease_variant_in_the_literature,_therefore,_this_is_a_disease_variant_and_was_classified_as_pathogenic.|||The_FANCC_c.456+4A>T_variant_is_a_common_pathogenic_FANCC_variant,_particularly_in_the_Ashkenazi_Jewish_population_(Verlander_et_al._1995:_Auerbach,_2009)._Across_a_selection_of_available_literature,_the_c.456+4A>T_variant_has_been_identified_in_a_homozygous_state_in_12_probands,_in_a_heterozygous_state_in_one_proband_in_whom_a_second_variant_was_not_identified,_and_in_a_heterozygous_state_in_seven_unaffected_family_members_(Whitney_et_al._1993:_Futaki_et_al._2000:_Auerbach,_2009)._The_c.456+4A>T_variant_was_absent_from_25_controls_and_is_reported_at_a_frequency_of_0.006016_in_the_European_(non-Finnish)_population_of_the_Genome_Aggregation_Database._Verlander_et_al._(1995)_determined_that_the_carrier_frequency_of_the_c.456+4A>T_variant_in_the_Ashkenazi_Jewish_population_is_approximately_one_in_89,_or_1.1%._RT-PCR_analysis_indicated_the_c.456+4A>T_variant_disrupts_splicing_and_results_in_the_production_of_two_abnormal_products,_an_111bp_in-frame_deletion_and_a_40bp_partial_removal_of_exon_4_(Whitney_et_al._1993)._Patient-derived_fibroblasts_demonstrated_that_the_c.456+4A>T_variant_significantly_reduced_DNA_end-joining_activity_compared_with_wild_type_cells_(Donahue_et_al._2004)._Based_on_the_evidence,_the_c.456+4A>T_variant_is_classified_as_pathogenic_for_Fanconi_anemia._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.||This_pathogenic_variant_is_denoted_FANCC_c.456+4A>T_or_IVS5+4A>T_and_consists_of_an_A>T_nucleotide_substitution_at_the_+4_position_of_exon_5_of_the_FANCC_gene._This_variant_has_been_shown_to_result_in_the_skipping_of_exon_5_due_to_abnormal_gene_splicing_(Whitney_1993)._FANCC_c.456+4A>T,_historically_referred_to_as_IVS4+4A>T,_has_been_published_in_both_the_compound_heterozygous_and_homozygous_state_in_individuals_with_Fanconi_Anemia_(Whitney_1993),_and_is_recognized_as_a_pathogenic_founder_variant_in_the_Ashkenazi_Jewish_population_with_a_carrier_frequency_of_approximately_1.1%_(Verlander_1995,_Futaki_2000,_Chandrasekharappa_2013)._Additionally,_this_variant_has_been_observed_in_at_least_one_woman_with_a_history_of_early-onset_breast_cancer_(Laitman_2015)._Based_on_current_evidence,_we_consider_FANCC_c.456+4A>T_to_be_pathogenic.|||This_sequence_change_falls_in_intron_5_of_the_FANCC_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_FANCC_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs104886456,_ExAC_0.04%)._This_variant_has_been_well_described_in_the_literature_as_causative_for_Fanconi_anemia_in_multiple_populations_(PMID:_8348157,_8081385,_10666230)._In_the_literature,_this_variant_is_also_known_as_IVS+4A>T._ClinVar_has_an_entry_for_this_variant_(Variation_ID:_12045)._Nucleotide_substitutions_within_the_consensus_splice_site_are_a_relatively_common_cause_of_aberrant_splicing_(PMID:_17576681,_9536098)._Experimental_studies_have_shown_that_this_variant_disrupts_splicing_(PMID:_8348157)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|NG_011707.1(NM_000136.2):c.456+4A>T_is_also_known_as_IVS4+4A>T_in_literatures._It_has_an_allele_frequency_of_0.006_in_Ashkenazi_Jewish_subpopulation_in_the_gnomAD_database._Whitney_et_al_reported_that_this_variant_resulted_exon_skipping_due_to_abnormal_gene_splicing_(PMID:_8348157)._FANCC_c.456+4A>T_has_been_published_in_both_the_compound_heterozygous_and_homozygous_state_in_individuals_with_Fanconi_Anemia_(PMID:_8348157)._It_is_also_determined_as_a_pathogenic_founder_variant_in_the_Ashkenazi_Jewish_population(PMID:_7492758)._Taken_together,_we_interprete_this_variant_as_Pathogenic/Likely_pathogenic._ACMG/AMP_Criteria_applied:_PS3:_PM3_Strong:_PP4.|Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)
NM_000051.3:c.2T>C	ATM	start_lost	102694	1	NA	NA	5	1	rs786203606	Hereditary cancer-predisposing syndrome	187275	183068	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108098353T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001583|missense_variant	1	786203606	-	Ambry_Genetics|Color|Invitae|Counsyl|GeneReviews|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-03-24|2015-04-27|2018-12-27|2015-01-29|2016-10-27|2016-01-25|2018-12-10	2020-02-26|2018-11-06|2019-03-28|2015-03-11|2016-10-27|2018-01-25|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline	SCV000217813|SCV000905152|SCV000219068|SCV000221102|SCV000328296|SCV000694244|SCV000616967	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion)||This_sequence_change_affects_the_initiator_methionine_of_the_ATM_mRNA._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_pathogenic_ATM_variants_in_several_individuals_with_ataxia-telangiectasia_(PMID:_8845835,_12552559,_22649200,_9463314,_21792198)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._This_variant_is_also_referred_to_as_p.(Met1Thr)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_187275)._Experimental_studies_have_shown_that_this_sequence_change_leads_to_markedly_reduced_expression_of_a_smaller,_truncated_ATM_protein_with_no_kinase_activity,_likely_explained_by_the_use_of_an_alternate_downstream_ATG_(PMID:_22146522,_21593342,_21792198)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||This_variant,_denoted_ATM_c.2T>C_at_the_cDNA_level,_alters_the_initiator_Methionine_codon,_and_the_resultant_protein_would_be_described_as_?p.Met1??_to_signify_that_it_is_not_known_if_the_loss_of_Met1_prevents_all_protein_translation_or_if_an_abnormal_protein_is_produced_using_an_alternate_Methionine_codon._This_variant,_also_reported_as_ATM_Met1Thr_in_the_literature,_has_been_observed_with_a_second_ATM_variant_in_multiple_individuals_with_ataxia-telangiectasia_(Stankovic_1998,_Buzin_2003,_Exley_2011,_Reiman_2011)._It_has_also_been_observed_in_individuals_with_breast,_ovarian,_prostate,_and_brain_cancer_(Crawford_2017,_Decker_2017,_Gardner_2018,_Waszak_2018,_Zafeiriou_2019)._Functional_studies_of_this_variant_have_demonstrated_the_possible_use_of_a_downstream_initiation_codon,_resulting_in_trace_levels_of_a_truncated_protein_with_no_kinase_activity,_while_other_studies_have_shown_completely_absent_protein_production_(Stankovic_1998,_Exley_2011,_Reiman_2011,_Byrd_2012,_Carney_2012)._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.331+5G>A	ATM	splice_region_variant,intron_variant	101590	1	NA	NA	-	-	-	-	230851	233909	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108100055G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001627|intron_variant	1	752135143	-	Ambry_Genetics|Counsyl|CeGaT_Praxis_fuer_Humangenetik_Tuebingen	Pathogenic|Likely_pathogenic|Likely_pathogenic	2018-11-14|2016-06-29|2018-07-01	2020-02-26|2016-11-23|2019-07-12	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline	SCV000274529|SCV000486591|SCV000891999	Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Functionally-validated_splicing_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Deficient_protein_function_by_in_vitro/ex_vivo_assay:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)_:Good_segregation_with_disease_(lod_1.5-3_
NM_000051.3:c.875C>T	ATM	missense_variant	102152	1	15416	1	4	1	rs747727055	Hereditary cancer-predisposing syndrome	229794	233943	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108115727C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_010802	-	ATM:472	SO:0001583|missense_variant	1	747727055	-	Ambry_Genetics|Color|GeneDx|Invitae|Counsyl	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-08-08|2018-09-18|2018-03-26|2019-01-02|2018-05-04	2020-02-26|2018-11-06|2019-01-29|2019-03-28|2018-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000273133|SCV000910967|SCV000322064|SCV000622847|SCV000800812	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)||This_variant_is_denoted_ATM_c.875C>T_at_the_cDNA_level,_p.Pro292Leu_(P292L)_at_the_protein_level,_and_results_in_the_change_of_a_Proline_to_a_Leucine_(CCG>CTG)._ATM_Pro292Leu_has_been_observed_in_the_compound_heterozygous_state_in_at_least_one_child_with_classic_ataxia_telangiectasia,_one_with_a_mild_presentation_of_ataxia_telangiectasia,_and_one_who_presented_with_severe_combined_immunodeficiency_in_infancy_(Stankovic_1998,_Sun_2002,_Mitui_2009,_Mallott_2013)._Functional_studies_have_shown_this_variant_to_have_reduced_ATM_protein_levels_and_reduced_or_absent_kinase_activity_(Stankovic_1998,_Barone_2009,_Mitui_2009,_Reiman_2011)._Additionally,_ATM_Pro292Leu_was_consistently_shown_to_exhibit_higher_levels_of_radiosensitivity_after_exposure_to_ionizing_radiation_than_normal_cells_(Becker-Catania_2000,_Mitui_2009)._ATM_Pro292Leu_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_not_located_in_a_known_functional_domain._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_ATM_Pro292Leu_to_be_a_likely_pathogenic_variant.|This_sequence_change_replaces_proline_with_leucine_at_codon_292_of_the_ATM_protein_(p.Pro292Leu)._The_proline_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_proline_and_leucine._This_variant_is_present_in_population_databases_(rs747727055,_ExAC_0.01%)._This_variant_has_been_reported_in_trans_with_a_second_pathogenic_ATM_variant_in_individuals_with_a_milder_phenotype_of_ataxia_telangiectasia_(A-T)_(PMID:_19431188,_18634022,_10873394)Â¬â€ and_an_individual_with_severe_combined_immunodeficiency_and_A-T_(PMID:_23264026)._This_variant_is_also_known_as_1260C>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_229794)._Experimental_studies_have_shown_that_this_missense_change_causes_unstable_ATM_expression,_reduced_kinase_activity,_elevated_radiosensitivity,_intermediate_checkpoint_activity,_and_interfered_phosphorylation_on_other_proteins,_when_transfected_into_lymphoblastoid_cells_lacking_ATM_activity_(PMID:_19431188,_18634022)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_000051.3:c.2250G>A	ATM	splice_region_variant,synonymous_variant	102444	8	NA	NA	-	-	-	-	3044	18083	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108127067G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:607585.0027	-	ATM:472	SO:0001819|synonymous_variant	1	1137887	-	OMIM|Invitae|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneKor_MSA|GeneDx|Athena_Diagnostics_Inc|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-04-01|2019-01-05|2017-07-11|2016-05-27|2018-03-23|2019-05-23|2018-09-17|2018-08-01|2018-07-12|2018-04-25|2018-10-31	2016-09-16|2019-03-28|2018-03-09|2016-11-23|2019-04-24|2020-02-26|2018-11-06|2018-08-08|2019-01-29|2018-08-31|2018-11-14	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|unknown	SCV000023343|SCV000166090|SCV000266148|SCV000486402|SCV000918520|SCV000183940|SCV000682042|SCV000821696|SCV000149058|SCV000840925|SCV000893175	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	|This_sequence_change_affects_codon_750_of_the_ATM_mRNA._It_is_a_'silent'_change,_meaning_that_it_does_not_change_the_encoded_amino_acid_sequence_of_the_ATM_protein._It_also_falls_at_the_last_nucleotide_of_exon_14_of_the_ATM_coding_sequence,_which_is_part_of_the_consensus_splice_site_for_this_exon._This_variant_is_present_in_population_databases_(rs1137887,_ExAC_0.002%)._This_variant_has_been_observed_in_individuals_and_families_affected_with_ataxia-telangiectasia_(PMID:_9463314,_10980530,_9887333,_10330348,_19691550)._Exon_14_is_also_referred_to_as_exon_16_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_3044)._Experimental_studies_evaluating_the_splicing_effect_of_this_variant_reported_that_it_resulted_in_skipping_of_exon_14_(c.2125_2250del,_p.Ile709_Lys750del)_from_the_ATM_mRNA_(PMID:_9887333,_10330348)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_ATM_c.2250G>A_(p.Lys750Lys)_alters_a_conserved_nucleotide_located_close_to_a_canonical_splice_site_and_therefore_could_affect_mRNA_splicing,_leading_to_a_significantly_altered_protein_sequence._Several_computational_tools_predict_a_significant_impact_on_normal_splicing:_One_predict_the_variant_abolishes_a_5'_splicing_donor_site_and_three_predict_the_variant_weakens_a_5'_donor_site._At_least_one_publication_reports_experimental_evidence_that_this_variant_affects_mRNA_splicing._The_variant_allele_was_found_at_a_frequency_of_4.5e-05_in_245598_control_chromosomes._This_frequency_is_not_higher_than_expected_for_a_pathogenic_variant_in_ATM_causing_Ataxia-Telangiectasia_(4.5e-05_vs_0.004),_allowing_no_conclusion_about_variant_significance._c.2250G>A_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Ataxia-Telangiectasia._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_labs_classified_it_as_pathogenic/likely_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Functionally-validated_splicing_mutation:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Last_nucleotide_of_exon|||This_variant_is_denoted_ATM_c.2250G>A_at_the_DNA_level._Although_the_variant_is_silent_at_the_coding_level,_preserving_a_Lysine_at_codon_750,_it_disrupts_the_nearby_natural_splice_donor_site_and_causes_abnormal_splicing._ATM_c.2250G>A_has_been_shown_to_cause_skipping_of_exon_14,_also_known_as_exon_16_using_alternate_nomenclature,_and_reduced_ATM_protein_expression_levels_(Sandoval_1999,_Teraoka_1999,_Prodosmo_2013,_Shirts_2016)._This_variant_has_been_observed_in_the_homozygous_or_compound_heterozygous_state_in_multiple_patients_with_Ataxia-telangiectasia_(Byrd_1996,_Laake_2000,_Buzin_2003,_Cavalieri_2006,_Chessa_2009,_Podralska_2014,_Milligan_2016,_Leuzzi_2018)._ATM_c.2250G>A_has_also_been_reported_in_the_heterozygous_state_individuals_with_a_personal_and/or_family_history_of_breast,_pancreatic,_colon,_or_prostate_cancer_(Grana_2011,_Castera_2014,_Shirts_2016,_Barnes_2017,_Decker_2017,_Goidescu_2018)._This_variant_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Based_on_currently_available_evidence,_we_consider_ATM_c.2250G>A_to_be_a_pathogenic_variant.||
NM_000051.3:c.2251-10T>G	ATM	intron_variant	102592	2	15434	1	-	-	-	-	181926	180411	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108128198T>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2218868	-	ATM:472	SO:0001627|intron_variant	1	730881346	-	GeneDx|PreventionGenetics,PreventionGenetics|Invitae|Counsyl|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics|Color|Ambry_Genetics	Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic	2019-01-18|2016-01-20|2018-12-24|2017-02-09|2018-12-27|2017-05-18|2018-07-26|2019-04-23	2019-01-29|2018-01-29|2019-03-28|2017-06-22|2019-08-05|2017-05-23|2018-11-06|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|unknown|germline|germline	SCV000209697|SCV000805513|SCV000211913|SCV000678106|SCV001158080|SCV000611162|SCV000682043|SCV001175711	not_provided|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_ATM_c.2251-10T>G_or_IVS14-10T>G_and_consists_of_a_T>G_nucleotide_substitution_at_the_-10_position_of_intron_14_of_the_ATM_gene._This_variant,_previously_referred_to_as_IVS16-10T>G,_has_been_reported_in_the_compound_heterozygous_state_in_individuals_with_ataxia-telangiectasia_and,_consistent_with_in_silico_splicing_models,_has_been_shown_to_create_a_new_splice_acceptor_site,_which_results_in_the_addition_of_nine_nucleotides_and_subsequently_a_truncated_protein_(Telatar_1998,_Teraoka_1999,_Becker-Catania_2000,_Buzin_2003,_Reiman_2011)._Additionally,_this_variant_has_been_observed_in_the_heterozygous_state_in_at_least_three_individuals_with_breast_cancer_(Decker_2017)._ATM_c.2251-10T>G_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Based_on_currently_available_evidence,_we_consider_ATM_c.2251-10T>G_to_be_a_likely_pathogenic_variant.||This_sequence_change_falls_in_intron_14_of_the_ATM_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_ATM_protein._This_variant_is_present_in_population_databases_(rs730881346,_ExAC_0.002%)._This_variant_has_been_reported_to_co-occur_with_at_least_3_different_pathogenic_ATM_variants_(c.2806_2809dupCTAG,_p.Arg2832Cys,_c.8786+1G>A)_in_individuals_with_ataxia-telangiectasia_(PMID:_9443866,_10330348,_10873394,_9463314,_12552559)._While_it_was_not_explicitly_stated_that_the_two_ATM_variants_in_these_individuals_were_on_opposite_chromosomes,_this_observation_suggests_that_the_c.2251-10T>G_substitution_contributes_to_the_cause_of_disease._It_has_also_been_observed_as_homozygous_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_9463314),_and_as_a_heterozygous_change_in_an_individual_with_breast_cancer_(PMID:_26681312)._This_variant_is_also_known_as_IVS16-10T>G_and_2249ins9nt_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181926)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_alters_RNA_splicing_by_creating_a_cryptic_acceptor_splice_site_9_nucleotides_upstream_of_the_consensus_acceptor_splice_site,_leading_to_the_use_of_a_premature_stop_codon._This_prediction_is_supported_by_experimental_studies,_although_the_data_was_not_made_available_for_review_(PMID:_10330348)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_ATM_c.2251-10T>G_variant_(rs730881346),_also_known_as_IVS16-10T>G,_is_reported_in_the_literature_in_multiple_individuals_with_ataxia-telangiectasia,_both_in_the_homozygous_state_and_in_trans_to_other_pathogenic_variants_(Becker-Catania_2000,_Buzin_2003,_Stankovic_1998,_Telatar_1998)._This_variant_has_also_been_reported_in_an_individual_affected_with_breast_cancer_(Susswein_2016)._The_c.2251-10T>G_variant_is_reported_as_pathogenic/likely_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_181926),_and_it_is_found_on_only_three_chromosomes_in_the_Genome_Aggregation_Database,_indicating_it_is_not_a_common_polymorphism._This_is_an_intronic_variant_in_a_moderately_conserved_nucleotide,_and_computational_analyses_(Alamut_v.2.11)_predict_that_this_variant_impacts_splicing_by_creating_a_novel_cryptic_acceptor_splice_site,_leading_to_inclusion_of_nine_nucleotides_containing_a_premature_stop_codon._RNA_studies_from_patient_cells_containing_this_variant_support_this_effect_on_splicing_(Teraoka_1999),_and_immunoblotting_performed_on_cells_homozygous_for_this_variant_indicate_no_detectable_ATM_variant_present_(Stankovic_1998,_Wang_2017)._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Becker-Catania_SG_et_al._Ataxia-telangiectasia:_phenotype/genotype_studies_of_ATM_protein_expression,_mutations,_and_radiosensitivity._Mol_Genet_Metab._2000_Jun:70(2):122-33._Buzin_CH_et_al._Comprehensive_scanning_of_the_ATM_gene_with_DOVAM-S._Hum_Mutat._2003_Feb:21(2):123-31._Stankovic_T_et_al._ATM_mutations_and_phenotypes_in_ataxia-telangiectasia_families_in_the_British_Isles:_expression_of_mutant_ATM_and_the_risk_of_leukemia,_lymphoma,_and_breast_cancer._Am_J_Hum_Genet._1998_Feb:62(2):334-45._Susswein_LR_et_al._Pathogenic_and_likely_pathogenic_variant_prevalence_among_the_first_10,000_patients_referred_for_next-generation_cancer_panel_testing._Genet_Med._2016_Aug:18(8):823-32._Telatar_M_et_al._Ataxia-telangiectasia:_identification_and_detection_of_founder-effect_mutations_in_the_ATM_gene_in_ethnic_populations._Am_J_Hum_Genet._1998_Jan:62(1):86-97._Teraoka_SN_et_al._Splicing_defects_in_the_ataxia-telangiectasia_gene,_ATM:_underlying_mutations_and_consequences._Am_J_Hum_Genet._1999_Jun:64(6):1617-31._Wang_C_et_al._ATM-Deficient_Colorectal_Cancer_Cells_Are_Sensitive_to_the_PARP_Inhibitor_Olaparib._Transl_Oncol._2017_Apr:10(2):190-196.|||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:RNA_Studies
NM_000051.3:c.3284G>A	ATM	missense_variant,splice_region_variant	102402	1	NA	NA	4	1	rs587781815	Hereditary cancer-predisposing syndrome	141522	151236	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.108143579G>A	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001583|missense_variant	1	587781815	-	Ambry_Genetics	Likely_pathogenic	2019-05-21	2020-02-26	_single_submitter	germline	SCV000184916	Hereditary_cancer-predisposing_syndrome	Last_nucleotide_of_exon:Well-characterized_mutation_at_same_position
NM_000051.3:c.3576G>A	ATM	splice_region_variant,synonymous_variant	102564	3	NA	NA	-	-	-	-	3035	18074	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108151895G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:607585.0018	-	ATM:472	SO:0001819|synonymous_variant	1	587776551	-	OMIM|Counsyl|Invitae|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1999-01-01|2016-03-08|2018-11-30|2018-07-02|2018-09-24|2019-10-28|2016-07-13|2017-10-09	2016-09-16|2016-11-23|2019-03-28|2018-08-20|2019-04-24|2020-02-26|2017-10-26|2019-01-29	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|unknown|germline|germline|germline|germline	SCV000023332|SCV000485198|SCV000546861|SCV000838524|SCV000916595|SCV000216383|SCV000682142|SCV000293312	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	||This_sequence_change_affects_codon_1192_of_the_ATM_mRNA._It_is_a_'silent'_change,_meaning_that_it_does_not_change_the_encoded_amino_acid_sequence_of_the_ATM_protein._It_also_falls_at_the_last_nucleotide_of_exon_24_of_the_ATM_coding_sequence._This_variant_is_present_in_population_databases_(rs587776551,_ExAC_0.003%)._This_variant_has_been_reported_in_several_individuals_and_families_affected_with_ataxia-telangiectasia_(PMID:_22071889,_19691550,_17124347,_9887333,_8845835)_as_well_as_in_an_individual_affected_with_early-onset_breast_and_thyroid_cancer_(PMID:_27599564)._This_variant_is_also_known_as_3403del174_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_3035)._Experimental_studies_have_shown_that_this_sequence_change_results_in_aberrant_splicing_of_the_ATM_mRNA,_reduced_ATM_abundance,_and_defective_ATM_protein_function_(PMID:_22071889,_9887333)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_ATM_c.3576G>A_(p.Lys1192Lys)_alters_a_conserved_nucleotide_located_close_to_a_canonical_splice_site_and_therefore_could_affect_mRNA_splicing,_leading_to_a_significantly_altered_protein_sequence._Several_computational_tools_predict_a_significant_impact_on_normal_splicing:_Three_predict_the_variant_abolishes_a_5_splicing_donor_site._Two_predict_the_variant_weakens_a_5'_donor_site._An_experimental_study,_Demuth_2011,_supports_these_predictions_by_finding_that_this_variant_is_associated_with_an_in-frame_exclusion_of_exon_26_from_the_mRNA._The_variant_allele_was_found_at_a_frequency_of_1.6e-05_in_246056_control_chromosomes_(gnomAD)._The_variant,_c.3576G>A,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Ataxia-Telangiectasia_(Chessa_2009,_Demuth_2011)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._Five_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Functionally-validated_splicing_mutation_:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Last_nucleotide_of_exon||This_variant_is_denoted_ATM_c.3576G>A_at_the_DNA_level_and_is_located_in_the_last_nucleotide_of_exon_24,_previously_reported_in_the_literature_as_exon_26._ATM_c.3576G>A_is_silent_at_the_coding_level,_preserving_a_Lysine_at_codon_1192._While_the_literature_agrees_that_this_variant_disrupts_a_natural_splice_donor_site,_leading_to_abnormal_splicing,_there_are_some_inconsistencies_between_reports._For_example,_this_variant_has_been_variably_reported_to_result_in_transcripts_with_a_deletion_of_exon_24,_a_deletion_of_exons_24-25,_and/or_a_residual_amount_of_normal_transcripts:_similarly,_ATM_protein_has_been_reported_as_absent_and_as_only_moderately_reduced_(Sandoval_1999,_Teraoka_1999,_Demuth_2011,_Jacquemin_2012,_Verhagen_2012)._However_this_variant_has_been_consistently_reported_to_demonstrate_very_low_to_absent_ATM_kinase_activity_(Demuth_2011,_Jacquemin_2012,_Verhagen_2012).
NM_000051.3:c.5763-1050A>G	ATM	intron_variant	47092	3	15426	2	-	-	-	-	3021	18060	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_variant|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1876175,Orphanet:ORPHA370109|MedGen:CN517202	-	NC_000011.9:g.108179837A>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:607585.0004	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	774925473	-	Eurofins_Clinical_Diagnostics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Pathogenic	2004-06-01|2018-12-23|2016-10-27|2016-01-05|2019-06-20|2018-08-16|2016-12-12	2015-07-16|2019-03-28|2016-10-27|2016-11-23|2020-02-26|2018-11-06|2018-09-19	no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline	SCV000023315|SCV000282999|SCV000328266|SCV000485197|SCV000581456|SCV000902857|SCV000700719	Ataxia-telangiectasia_variant|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|This_sequence_change_falls_in_intron_38_of_the_ATM_mRNA._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_ATM_protein._This_variant_is_not_present_in_population_databases_(rs774925473,_ExAC_no_frequency)._This_variant_has_been_reported_in_several_individuals_affected_with_atypical_ataxia-telangiectasia_(characterized_by_later_disease_onset_and/or_slower_disease_progression_and_attenuated_disease_features_than_classical_ataxia-telangiectasia)_(PMID:_8755918,_21792198,_10330348,_8808599)._Notably,_one_individual_carried_this_variant_in_trans_with_a_second_pathogenic_variant,_c.9139C>T_(p.Arg3047*),_and_two_affected_brothers_have_been_reported_to_be_homozygous_for_this_variant_(PMID:_10234507,_15174027)._This_variant_is_also_known_as_5762ins137,_the_4-1-8_variant,_IVS40-1050A>G,_IVS40+1126A>G,_IVS40ins137,_and_5763ins130_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_3021)._Experimental_studies_have_shown_that_this_intronic_change_results_in_the_insertion_of_part_of_intron_38_in_between_exons_38_and_39,_resulting_in_a_frameshift_(PMID:_8755918,_19823873)._However,_this_variant_is_described_as_a_leaky_splice_site_mutation,_as_only_a_portion_of_the_transcripts_from_this_allele_contain_this_insertion,_as_shown_by_cDNA_sequencing_(PMID:_8755918)._The_remaining_transcripts_expressed_from_this_allele_result_in_low-level_expression_of_ATM_protein_with_near_wild-type_levels_of_kinase_activity_(PMID:_11382771,_25040471)._These_results_may_explain_the_atypical_disease_associated_with_this_variant._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Functionally-validated_splicing_mutation:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Other_strong_data_supporting_pathogenic_classification||
NM_000051.3:c.6095G>A	ATM	missense_variant,splice_region_variant	102712	5	NA	NA	5&5	1&1	rs139770721	Hereditary cancer-predisposing syndrome&not provided	181974	180483	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108186638G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	139770721	-	Ambry_Genetics|Color|Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Blueprint_Genetics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-09-04|2015-09-08|2019-01-06|2014-12-23|2015-12-07|2018-10-02|2019-02-05|2018-01-30|2018-10-31	2020-02-26|2017-10-26|2019-03-28|2015-03-11|2018-01-25|2019-01-29|2019-05-08|2018-06-14|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|unknown	SCV000214152|SCV000682303|SCV000218594|SCV000220988|SCV000694316|SCV000209757|SCV000928203|SCV000839886|SCV000893182	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	Functionally-validated_splicing_mutation:Last_nucleotide_of_exon:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:RNA_Studies:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||This_sequence_change_replaces_arginine_with_lysine_at_codon_2032_of_the_ATM_protein_(p.Arg2032Lys)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_lysine._It_also_falls_at_the_last_nucleotide_of_exon_41_of_the_ATM_coding_sequence._This_variant_is_present_in_population_databases_(rs139770721,_ExAC_0.008%)._This_variant_has_been_reported_as_compound_heterozygous_or_homozygous_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_9887333,_16266405,_10330348,_25614872,_10980530,_27159176)._It_has_also_been_reported_in_individuals_affected_with_pancreatic_cancer_(PMID:_22585167)_and_gastric_cancer_(PMID:_26506520)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181974)._Experimental_studies_have_shown_that_this_missense_change_causes_skipping_of_exon_41_(called_exon_43)_in_lymphocytes_derived_from_an_affected_individual_(PMID:Â¬â€ 9887333)._Skipping_of_exon_41_is_predicted_to_lead_to_a_frameshift_and_premature_translational_stop_signal_at_codon_2007,_resulting_in_an_absent_or_disrupted_protein_product_(PMID:_10330348)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||This_variant_is_denoted_ATM_c.6095G>A_at_the_cDNA_level._Located_in_the_last_nucleotide_of_its_exon,_splicing_models_predict_ATM_c.6095G>A_to_result_in_loss_of_the_adjacent_splice_donor_site,_and_Western_blot_studies_have_revealed_exonic_skipping_(Telatar_1998,_Teraoka_1999)._Although_the_nucleotide_substitution_results_in_the_change_of_an_Arginine_to_a_Lysine_at_codon_2032,_and_this_variant_also_is_called_Arg2032Lys_in_the_literature,_we_are_using_only_the_nucleotide_nomenclature_to_refer_to_the_variant_since_the_defect_is_determined_to_be_one_of_splicing_rather_than_the_resulting_missense_change._This_variant_has_been_reported_individuals_with_pancreatic_and_familial_breast/ovarian_cancer,_and_has_been_observed_in_the_compound_heterozygous_state_with_a_second_pathogenic_ATM_variant_in_several_individuals_with_Ataxia-telangiectasia_(Sandoval_1999,_Thorstenson_2003,_Roberts_2012,_Podralska_2014)._ATM_c.6095G>A_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._The_nucleotide_which_is_altered,_a_Guanine_(G)_at_base_6095,_is_conserved_across_species._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.||This_c.6095G>A_(p.R2032K)_variant_in_the_ATM_gene_has_been_reported_in_multiple_Ataxia-telangiectasia_(AT)_patients_with_significantly_higher_prevalence_[PMID:_10980530,_15390180,16266405]_than_that_observed_as_extremely_low_in_general_population_according_to_gnomad_database._This_variant,_in_trans_with_other_deleterious_variants,_has_been_reported_in_AT_patients_[PMID:_27159176,_25614872]._Functional_studies_showed_that_this_mutant_causes_abnormal_splicing_and_loss_of_expression_of_ATM_proteins_[PMID:_9887333,_10330348]._Multiple_in_silico_predictions_suggest_this_arginine_to_lysine_is_deleterious,_while_the_c.6095G>A_change_might_affect_the_splicing_of_messenger_RNA_as_the_last_nucleotide_on_exon_41._Based_upon_above_evidences,_this_c.6095G>A_(p.R2032K)_variant_in_the_ATM_gene_is_classified_as_pathogenic.|
NM_000051.3:c.6154G>A	ATM	missense_variant	102702	1	15424	1	4&4	1&1	rs202206540	Hereditary cancer-predisposing syndrome&Ataxia-telangiectasia syndrome	181975	180484	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108186796G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(3),Pathogenic(1),Uncertain_significance(2)	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	17	202206540	-	Klinikum_rechts_der_Isar|Baylor_Genetics|GeneDx	Likely_pathogenic|Uncertain_significance|Uncertain_significance|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2019-08-15|2018-08-06|2018-12-28|2016-10-27|2019-06-13|0000-00-00|2018-10-08	2020-02-26|2018-11-06|2019-03-28|2016-10-27|2020-01-21|2019-09-27|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|maternal|germline|germline	SCV000216022|SCV000911078|SCV000218611|SCV000328267|SCV001150023|SCV001163272|SCV000209758	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Moderate_segregation_with_disease_(at_least_3_informative_meioses)_for_rare_diseases.:Deficient_protein_function_in_appropriate_functional_assay(s):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_sequence_change_replaces_glutamic_acid_with_lysine_at_codon_2052_of_the_ATM_protein_(p.Glu2052Lys)._The_glutamic_acid_residue_is_moderately_conserved_and_there_is_a_small_physicochemical_difference_between_glutamic_acid_and_lysine._This_variant_is_present_in_population_databases_(rs202206540,_ExAC_0.03%)._This_variant_has_been_reported_to_segregate_in_one_family_with_dopa-responsive_dystonia_in_individuals_who_also_carry_a_loss-of-function_variant_(c.7886_7890del)Â¬â€ on_the_opposite_chromosome_(in_trans)Â¬â€ in_the_ATM_gene._One_family_member_who_presented_with_typical_manifestations_of_ataxia-telangiectasia_(A-T)_was_homozygous_for_the_c.7886_7890del_variant_and_did_not_carry_the_p.Glu2052Lys_variant_(PMID:_23946315)._This_variant_was_also_found_to_be_homozygous_in_an_individual_with_A-T,_and_heterozygous_in_several_individuals_with_breast_cancer_(PMID:_10330348,_27616075,Â¬â€ 29470806)._However,_it_has_also_been_observed_in_trans_with_a_pathogenic_variant_in_ATM_in_an_individual_not_affected_with_A-T,_indicating_that_this_variant_might_not_be_causative_of_disease_(Invitae).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181975)._An_experimental_study_using_a_lymphoblastoid_cell_line_derived_from_an_A-T_affected_individual_has_shown_that_this_missense_change_can_produce_a_defect_in_RNA_splicing_and_loss_of_ATM_protein_(PMID:_10330348)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.||||This_variant_is_denoted_ATM_c.6154G>A_at_the_cDNA_level,_p.Glu2052Lys_(E2052K)_at_the_protein_level,_and_results_in_the_change_of_a_Glutamic_Acid_to_a_Lysine_(GAA>AAA)._This_variant_was_observed_in_the_homozygous_state_in_an_individual_with_ataxia_telangiectasia,_and_cDNA_derived_from_this_patient_was_identified_to_have_ATM_transcripts_with_exon_42_deleted,_also_known_as_exon_44_using_alternate_nomenclature,_and_absence_of_ATM_protein_by_Western_blot_(Teraoka_1999)._Although_ATM_Glu2052Lys_is_not_predicted_to_affect_splicing_by_published_and_internal_splicing_models,_authors_suggest_that_this_variant_may_alter_the_secondary_structure_of_the_transcript,_which_may_disrupt_the_formation_of_the_spliceosome_(Teraoka_1999)._This_variant_was_also_identified_in_trans_with_an_ATM_frameshift_variant_in_multiple_members_of_a_family_affected_with_cervical_dopa-responsive_dystonia,_elevated_AFP,_and_telangiectasias_(Charlesworth_2013),_as_well_as_in_an_individual_with_bilateral_breast_cancer_and_a_family_history_of_pancreatic_cancer_(Kraus_2017)._ATM_Glu2052Lys_was_observed_at_an_allele_frequency_of_0.03%_(5/16476)_in_individuals_of_South_Asian_ancestry_in_large_population_cohorts_(Lek_2016)._ATM_Glu2052Lys_is_located_in_the_FAT_domain_(Stracker_2013)._Based_on_the_currently_available_evidence,_we_consider_ATM_Glu2052Lys_to_be_a_likely_pathogenic_variant.
NM_000051.3:c.6200C>A	ATM	missense_variant,splice_region_variant	102666	1	NA	NA	5	0	rs397514577	Ataxia-telangiectasia variant	39749	48348	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_variant	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1876175,Orphanet:ORPHA370109	-	NC_000011.9:g.108188101C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:607585.0033|UniProtKB_(protein):Q13315#VAR_010840	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	397514577	-	Fulgent_Genetics	Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-02-28|2019-10-30|2018-06-07|2016-10-27|2018-11-08|2017-06-23|2018-10-31	2016-09-16|2020-02-26|2018-11-06|2016-10-27|2019-03-28|2018-07-10|2018-11-14	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown	SCV000056740|SCV000217431|SCV000903208|SCV000328268|SCV000547142|SCV000800774|SCV000893183	Ataxia-telangiectasia_variant|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome	|In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_in_appropriate_functional_assay(s):Good_segregation_with_disease_(lod_1.5-3_
NM_000051.3:c.7271T>G	ATM	missense_variant	102460	8	15400	2	5&5&5&5&5	0&0&2&2&1	rs28904921	Ataxia-telangiectasia variant&T-cell prolymphocytic leukemia&Hereditary cancer-predisposing syndrome&Ataxia-telangiectasia syndrome&not provided	3023	18062	_susceptibility_to|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1876175,Orphanet:ORPHA370109|MedGen:C2363142,Orphanet:ORPHA86871|MedGen:C3469522|MedGen:CN517202	-	NC_000011.9:g.108199929T>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_010854|OMIM_Allelic_Variant:607585.0005|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:122236	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	11	28904921	-	OMIM|OMIM|OMIM|Ambry_Genetics|Color|Invitae|Baylor_Genetics|Genetic_Services_Laboratory,_University_of_Chicago|Counsyl|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|GenomeConnect,_ClinGen|CSER__CC_NCGL,_University_of_Washington|Fulgent_Genetics,Fulgent_Genetics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine	Pathogenic|Pathogenic|risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic	2006-11-01|2006-11-01|2006-11-01|2018-06-13|2015-03-09|2018-12-26|2014-09-22|2014-06-27|2016-05-16|2019-05-04|2017-06-05|2018-12-31|0000-00-00|2016-08-01|2017-05-18|2017-04-03	2016-09-16|2016-09-16|2016-09-16|2020-02-26|2016-07-05|2019-03-28|2015-08-17|2015-09-15|2016-11-23|2019-08-05|2018-01-25|2019-01-29|2019-01-30|2016-12-02|2017-05-23|2018-06-14	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|somatic|germline|germline|germline|germline|paternal|germline|unknown|germline|germline|germline|unknown|germline|unknown|germline	SCV000023317|SCV000023318|SCV000023319|SCV000172910|SCV000292134|SCV000218891|SCV000245452|SCV000246619|SCV000486203|SCV000602560|SCV000694344|SCV000149153|SCV000986703|SCV000503552|SCV000611166|SCV000839881	_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|Neoplasm_of_the_breast|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast	|||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_in_appropriate_functional_assay(s):Strong_segregation_with_disease_(lod_>3_
NM_000051.3:c.7328G>A	ATM	missense_variant	102486	1	15432	1	-	-	-	-	142211	151925	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108200961G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_041577	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587782310	-	Ambry_Genetics|Color|Invitae|GeneDx	Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2019-04-25|2018-06-16|2018-11-07|2018-08-09	2020-02-26|2018-11-06|2019-03-28|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000186153|SCV000682405|SCV000283048|SCV000292481	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Insufficient_evidence||This_sequence_change_replaces_arginine_with_glutamine_at_codon_2443_of_the_ATM_protein_(p.Arg2443Gln)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_glutamine._This_variant_is_present_in_population_databases_(rs587782310,_ExAC_0.006%)._This_variant_has_been_observed_in_an_individual_affected_with_multiple_cancers,_including_colon,_prostate,_multiple_myeloma,_melanoma_and_brain_(Invitae)._However,_in_that_individual,_a_pathogenic_allele_was_also_identified_in_ATM,_which_suggests_that_this_c.7328G>A_variant_was_not_the_primary_cause_of_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142211)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_do_not_agree_on_the_potential_impact_of_this_missense_change_(SIFT:_Deleterious:_PolyPhen-2:_Probably_Damaging:_Align-GVGD:_Class_C0)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|This_variant_is_denoted_ATM_c.7328G>A_at_the_cDNA_level,_p.Arg2443Gln_(R2443Q)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Glutamine_(CGA>CAA)._This_variant_has_been_identified_in_at_least_one_breast_cancer_patient_(Hauke_2018),_and_has_been_observed_internally_in_the_compound_heterozygous_state_in_two_individuals_with_features_consistent_with_atypical_ataxia-telangiectasia._Additionally,_it_has_been_reported_as_a_somatic_variant_in_lymphoma,_breast,_colorectal,_and_other_tumor_specimens_(Greiner_2006,_Yip_2012,_Balko_2014,_Giannakis_2014)._ATM_Arg2443Gln_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Since_Arginine_and_Glutamine_differ_in_some_properties,_this_is_considered_a_semi-conservative_amino_acid_substitution._ATM_Arg2443Gln_is_located_in_the_FAT_domain_(Stracker_2013)._In_silico_analyses_including_protein_predictors_and_evolutionary_conservation,_support_that_this_variant_does_not_alter_protein_structure/function._Based_on_currently_available_evidence_and_internal_data,_we_consider_ATM_Arg2443Gln_to_be_a_likely_pathogenic_variant.
NM_000051.3:c.7638_7646del	ATM	inframe_deletion	102512	5	NA	NA	-	-	-	-	3019	18058	Neoplasm_of_the_breast|Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|T-cell_prolymphocytic_leukemia|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2363142,Orphanet:ORPHA86871|MedGen:CN517202	-	NC_000011.9:g.108202614_108202622del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:607585.0007|OMIM_Allelic_Variant:607585.0002	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	3	587776547	-	OMIM|Ambry_Genetics|Color|OMIM|Invitae|GeneReviews|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|PreventionGenetics,PreventionGenetics|CSER__CC_NCGL,_University_of_Washington|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Likely_pathogenic	2002-09-01|2018-07-26|2015-04-23|1995-06-23|2019-01-09|2016-10-27|2016-09-26|2017-10-27|2018-08-29|2016-08-31|2016-06-24|2016-08-01|2017-04-03	2015-07-16|2020-02-26|2017-10-26|2015-07-01|2019-03-28|2016-10-27|2016-11-23|2019-04-24|2019-01-29|2018-09-19|2018-01-29|2016-12-02|2018-06-14	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	somatic|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000023321|SCV000186502|SCV000682427|SCV000023313|SCV000262210|SCV000328309|SCV000487009|SCV000916557|SCV000209607|SCV000331662|SCV000805616|SCV000503545|SCV000839880	T-cell_prolymphocytic_leukemia|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|not_provided|Neoplasm_of_the_breast|Familial_cancer_of_breast	|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Other_strong_data_supporting_pathogenic_classification:Deficient_protein_function_in_appropriate_functional_assay(s):Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Deficient_protein_function_by_in_vitro/ex_vivo_assay|||This_sequence_change_deletes_9_nucleotides_from_exon_52_of_the_ATM_mRNA_(c.7638_7646delTAGAATTTC)._This_leads_to_the_deletion_of_3_amino_acid_residues_in_the_ATM_protein_(p.Arg2547_Ser2549del)_but_otherwise_preserves_the_integrity_of_the_reading_frame._The_frequency_data_for_this_variant_(rs587776547)_in_the_population_databases_is_unreliable,_as_metrics_indicate_poor_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_reported_as_homozygous_and_compound_heterozygous_in_individuals_affected_with_ataxia-telangiectasia,_as_well_as_heterozygous_in_individuals_with_breast_cancer_(PMID:_7792600,_12552559,_22649200,_11382771,_8797579,_21787400)._This_variant_is_also_known_as_7636del9_and_7638del9_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_3019)._Experimental_studies_have_shown_that_this_deletion_disrupts_ATM_kinase_function_and_leads_to_impaired_cellular_response_to_ionizing_radiation_(PMID:_19431188,_22649200,_11382771,_12195425)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_ATM_c.7638_7646delTAGAATTTC_(p.Arg2547_Ser2549del)_variant_involves_the_inframe_deletion_of_9_nucleotides_located_in_the_PIK-related_kinase_domain_(IPR014009)_(InterPro)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._Functional_studies_confirmed_that_there_is_no_detectable_ATM_kinase_activity_associated_with_this_variant_and_that_LCLs_with_this_variant_exhibited_p53,_p21,_and_MDM2_response_that_was_indistinguishable_from_classical_A-T_(Stewart_2001)._This_variant_was_found_in_5/246251_control_chromosomes_at_a_frequency_of_0.0000203,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_ATM_variant_(0.0039528)._This_variant_was_reported_in_multiple_AT_patients_(Stankovic_1998,_Skowronska_2012,_Stewart_2001)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_deletion_of_nine_nucleotides_in_ATM_is_denoted_c.7638_7646delTAGAATTTC_at_the_cDNA_level_and_p.Arg2547_Ser2549del_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_TCTC{TAGAATTTC}AATG._This_in_frame_deletion_is_located_within_the_FAT_domain_(Stracker_2013,_UniProt)._This_variant,_also_known_as_7636del9_by_alternate_nomenclature,_was_observed_in_both_the_homozygous_and_compound_heterozygous_state_in_multiple_individuals_with_classic_Ataxia-telangiectasia_(Byrd_1996,_Wright_1996,_Watters_1997,_Stankovic_1998)._Multiple_functional_analyses_have_confirmed_the_pathogenicity_of_this_variant,_showing_complete_absence_of_kinase_activity_and_reduced_ATM_protein_expression_(Stewart_2001,_Barone_2009,_Reiman_2011)._Based_on_current_information,_we_consider_this_variant_to_be_pathogenic.|||Found_in_a_male_patient_having_exome_sequencing_for_an_unrelated_indication._No_known_personal_or_family_history_of_breast_cancer.|This_c.7638_7646del_(p.Arg2547_Ser2549del)_has_previously_been_reported_in_compound_heterozygous_and_homozygous_patients_with_ataxia_telangiectasia_[PMID_8808599]._Functional_assays_showed_that_the_variant_does_not_affect_the_level_of_ATM_protein_but_does_reduce_the_level_of_kinase_activity_[PMID_19431188]._A_mouse_model_carrying_this_deletion_has_an_increase_susceptibility_to_develop_tumors_[reported_as_7636del9_in_PMID_12195425]._This_variant_was_further_detected_in_12_out_of_294_families_with_breast_cancer._However,_the_difference_in_tumor_incidence_between_carrier_and_non_carrier_was_not_statistically_significant._However,_this_variant_was_detected_in_another_patient_with_breast_cancer_[PMID_8797579]._This_c.7638_7646del_(p.Arg2547_Ser2549del)_variant_has_not_been_observed_the_ExAC_population_database_and_has_been_observed_in_one_individual_in_our_internal_database._It_is_thus_interpreted_as_a_likely_pathogenic_variant.
NM_000051.3:c.7788G>A	ATM	splice_region_variant,synonymous_variant	102276	1	NA	NA	-	-	-	-	135778	139490	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108202764G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587780639	-	Invitae|Counsyl|GeneDx|Ambry_Genetics|Color	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2018-09-24|2017-02-10|2014-09-02|2017-05-03|2018-08-02	2019-03-28|2018-07-10|2019-01-29|2020-02-26|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline	SCV000166142|SCV000789712|SCV000209647|SCV000275620|SCV000682435	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_affects_codon_2596_of_the_ATM_mRNA._It_is_a_'silent'_change,_meaning_that_it_does_not_change_the_encoded_amino_acid_sequence_of_the_ATM_protein._It_also_falls_at_the_last_nucleotide_of_exon_52_of_the_ATM_coding_sequence._This_variant_is_present_in_population_databases_(rs587780639,_ExAC_0.002%)._This_variant_has_been_reported_in_three_individuals_affected_with_ataxia_telangiectasia:_in_two_of_these_individuals_this_variant_was_observed_in_the_homozygous_state_(PMID:_9792409,_26693373)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_135778)._Nucleotide_substitutions_within_the_consensus_splice_site_are_a_relatively_common_cause_of_aberrant_splicing_(PMID:_17576681,_9536098).Â¬â€ Experimental_studies_using_protein_truncation_tests_have_shown_that_this_variant_can_result_in_skipping_of_exon_52,_also_known_as_exon_54_in_the_literature_(PMID:_9792409)._If_skipping_of_exon_52_occurs,_it_is_expected_to_result_in_an_in-frame_deletion_of_53_amino_acid_residues_from_the_FAT_domain_of_the_ATM_protein._The_FAT_domain_is_required_for_proper_kinase_activity_of_the_ATM_protein_(PMID:_23532176,_25460276)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_pathogenic_variant_is_denoted_ATM_c.7788G>A_at_the_DNA_level._Although_the_variant_is_silent_at_the_coding_level,_preserving_a_Glutamic_Acid_at_codon_2596,_has_been_demonstrated_to_cause_abnormal_splicing,_specifically_skipping_of_exon_52_(Broeks_1998)._This_exon_comprises_a_large_part_of_the_FAT_functional_domain,_involved_in_stability_of_the_protein_(Stracker_2013)._The_nucleotide_which_is_altered,_a_guanine_(G)_at_base_7788,_is_the_last_nucleotide_of_exon_52_and_is_highly_conserved_across_species_(Stracker_2013)._This_mutation_was_identified_in_two_Ataxia-Telangiectasia_patients,_once_with_a_pathogenic_variant,_and_once_in_a_homozygous_state_(Broeks_1998)._ATM_7788G>A_was_not_observed_in_1000_Genomes_database,_and_not_evaluated_in_Exome_Sequencing_Project._Based_on_the_currently_available_information,_we_consider_ATM_7788G>A_to_be_pathogenic.The_presence_of|Last_nucleotide_of_exon:Last_nucleotide_of_exon_with_predicted_splicing_impact_in_agreement:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_strong_data_supporting_pathogenic_classification:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Moderate_segregation_with_disease_(at_least_3_informative_meioses)_for_rare_diseases.:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|
NM_000051.3:c.8147T>C	ATM	missense_variant	102676	4	15434	0	4&4	1&1	rs587782652	Hereditary cancer-predisposing syndrome&not provided	142700	152414	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108205832T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	17	587782652	-	Ambry_Genetics|Color|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Counsyl|Invitae|GeneReviews|Integrated_Genetics/Laboratory_Corporation_of_America|Institute_of_Human_Genetics,Klinikum_rechts_der_Isar|GeneDx|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2019-07-31|2018-08-29|2018-01-26|2014-05-13|2018-12-28|2016-10-27|2018-09-10|2018-01-10|2018-04-20|2017-06-05	2020-02-26|2018-11-06|2018-04-23|2015-03-11|2019-03-28|2016-10-27|2019-04-24|2020-01-21|2019-01-29|2018-06-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|maternal|germline|germline	SCV000187129|SCV000682458|SCV000992207|SCV000220304|SCV000260088|SCV000328271|SCV000918562|SCV001149689|SCV000209770|SCV000839884	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Familial_cancer_of_breast	in_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rarity_in_general_population_databases_(dbSNP,_ESP,_1000_Genomes):Other_data_supporting_pathogenic_classification:Deficient_protein_function_in_appropriate_functional_assay(s)||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.||This_sequence_change_replaces_valine_with_alanine_at_codon_2716_of_the_ATM_protein_(p.Val2716Ala)._The_valine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_valine_and_alanine._This_variant_is_present_in_population_databases_(rs587782652,_ExAC_0.02%)._This_variant_has_been_reported_in_several_individuals_affected_with_ataxia-telangiectasia_(A-T)_(PMID:_16864838,_19535770,_21354641,_21965147),_as_well_as_in_an_individual_with_generalized_dystonia_(PMID:_2557216),_and_an_individual_with_breast_cancer_(PMID:_26976419)._This_variant_has_been_reported_to_segregate_with_another_pathogenic_variant_in_ATM_in_a_single_family_with_dystonia_(PMID:_25957637)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142700)._Experimental_studies_have_shown_that_this_missense_change_reduces_ATM_kinase_activity_and_increases_radiosensitivity_(PMID:_11805335)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_ATM_c.8147T>C_(p.Val2716Ala)_results_in_a_non-conservative_amino_acid_change_located_in_the_Phosphatidylinositol_3-/4-kinase,_catalytic_domain_of_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_3.2e-05_in_277104_control_chromosomes_(gnomAD)._The_variant,_c.8147T>C,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Ataxia-Telangiectasia_(Demuth_2011,_Hiel_2006,_Lohmann_2015)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._At_least_one_publication_reports_experimental_evidence_evaluating_an_impact_on_protein_function._The_most_pronounced_variant_effect_results_in_<10%_of_normal_activity_(Scott_2001)._Five_ClinVar_submission_from_other_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_likely_pathogenic/pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.||This_variant_is_denoted_ATM_c.8147T>C_at_the_cDNA_level,_p.Val2716Ala_(V2716A)_at_the_protein_level,_and_results_in_the_change_of_a_Valine_to_an_Alanine_(GTT>GCT)._This_variant_has_been_observed_in_the_compound_heterozygous_state_in_multiple_individuals_with_atypical_or_later-onset_ataxia_telangiectasia_(Hiel_2006,_Verhagen_2009,_Demuth_2011,_Keimling_2011,_M?neret_2014,_Kuhm_2015,_Lohmann_2015,_van_Os_2017)._In_addition,_ATM_Val2716Ala_has_been_published_in_the_heterozygous_state_in_at_least_three_individuals_with_early-onset_breast_cancer,_one_of_whom_also_had_a_history_of_unexplained_childhood_onset_choreoathetosis,_oculocutaneous_telangiectasias,_and_elevated_serum_alpha-fetoprotein_(Mandigers_2011,_Reiman_2011)._Although_this_variant_may_express_some_level_of_kinase_activity,_it_has_been_associated_with_reduced_ATM_protein_expression,_and_transfected_cells_have_exhibited_reduced_radiation-induced_kinase_activity_(Scott_2002,_Verhagen_2009,_Demuth_2011,_Reiman_2011)._ATM_Val2716Ala_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_kinase_domain_and_the_ATP-binding_domain_(Lavin_2004,_Stracker_2013)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_ATM_Val2716Ala_to_be_pathogenic.|This_c.8147T>C_(p.Val2716Ala)_has_previously_been_reported_in_compound_heterozygous_patients_with_ataxia_telangiectasia_most_of_them_diagnosed_in_adulthood_[PMID_19535770,_16864838,_21965147]._This_variant_is_located_in_the_kinase_domain_and_in_vitro_data_showed_reduced_kinase_activity_and_lower_ATM_protein_[PMID_11805335]._This_variant_was_observed_in_5_individuals_at_the_heterozygous_state_in_the_ExAC_database_(http://exac.broadinstitute.org/variant/11-108205832-T-C)._Valine_at_amino_acid_position_2716_of_the_ATM_protein_is_conserved_in_mammals._While_not_validated_for_clinical_use,_computer-based_algorithms_SIFT_and_Polyphen-2_did_not_yield_concordant_predictions_regarding_the_pathogenicity_of_the_change._It_is_thus_interpreted_as_a_likely_pathogenic_variant._However,_the_estimated_cancer_risk_for_this_variant_has_not_been_determined.
NM_000051.3:c.8293G>A	ATM	missense_variant	102678	2	NA	NA	5&4	1&1	rs748634900	Hereditary cancer-predisposing syndrome&Ataxia-telangiectasia syndrome	186351	183426	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108213973G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_010876	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	748634900	-	Ambry_Genetics|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Likely_pathogenic|Likely_pathogenic	2018-07-03|2017-08-30|2017-04-06	2020-02-26|2018-04-02|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000216688|SCV000253672|SCV000694377	Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|This_sequence_change_replaces_glycine_with_serine_at_codon_2765_of_the_ATM_protein_(p.Gly2765Ser)._The_glycine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_glycine_and_serine._This_variant_is_present_in_population_databases_(rs748634900,_ExAC_0.001%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_21792198)_and_breast_cancer_(PMID:_10534763,_19781682)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186351)._Experimental_studies_have_shown_that_this_missense_change_causes_the_loss_of_ATM_kinase_activity_and_a_cell-cycle_checkpoint_defect_in_cells_from_affected_individuals_(PMID:_19431188,_21792198)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|Variant_summary:_The_ATM_c.8293G>A_(p.Gly2765Ser)_variant_involves_the_alteration_of_a_conserved_nucleotide_located_in_the_Protein_kinase-like_domain_(InterPro)._4/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant_(SNPs&GO_not_captured_due_to_low_reliability_index)._This_variant_was_found_in_1/121582_control_chromosomes_at_a_frequency_of_0.0000082,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_ATM_variant_(0.0039528)._The_variant_has_been_reported_in_Ataxia_Telangectasia_(A-T)_patients_as_well_as_breast_cancer_patients,_however_segregation_studies_in_a_breast_cancer_family_showed_the_variant_to_be_absent_in_an_affected_grandmother,_while_the_variant_was_present_in_two_unaffected_siblings_(age_at_testing_was_not_specified)._This_data_indicate_a_lack_of_co-segregation_of_this_variant_with_breast_cancer_in_this_family_(Izatt_1999),_although_the_effect_of_a_limited_penetrance,_cannot_be_ruled_out._Furthermore,_a_sample_tested_at_our_laboratory_also_carries_another_pathogenic_BRCA2_c.5946delT._Among_the_cohort_of_patients_clinically_diagnosed_with_A-T,_this_variant_was_seen_in_compound_heterozygosity_with_other_possibly_pathogenic_variants._Well_controlled_functional_studies_have_shown_the_variant_to_lead_to_loss_of_ATM_Kinase_activity,_while_retaining_almost_complete_ATM_protein_expression_(Barone_2009,_Reiman_2011)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_likely_pathogenic/pathogenic._In_summary,_while_this_variants_association_with_breast_cancer_cannot_be_firmly_established,_the_fact_that_it_results_in_complete_loss_of_ATM_Kinase_activity,_along_with_its_presence_in_A-T_patients_suggests_that_the_variant_to_be_Likely_Pathogenic_for_a_phenotype_of_Ataxia_Telangectasia.
NM_000051.3:c.8494C>T	ATM	missense_variant	102608	4	NA	NA	5&5	1&1	rs587779872	Hereditary cancer-predisposing syndrome&not provided	127459	132916	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108216545C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_010881	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	9	587779872	-	Mayo_Clinic|Mendelics|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-03|2017-03-27|2014-09-23|2018-12-20|2016-10-27|2018-07-10|2018-07-02|2018-10-12	2020-02-26|2017-10-26|2015-03-11|2019-03-28|2016-10-27|2018-07-18|2018-08-20|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|paternal|unknown|germline	SCV000186811|SCV000682491|SCV000220724|SCV000260807|SCV000328272|SCV000809109|SCV000838615|SCV000149174	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Well-characterized_mutation_at_same_position:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|||This_sequence_change_replaces_arginine_with_cysteine_at_codon_2832_of_the_ATM_protein_(p.Arg2832Cys)._The_arginine_residue_is_moderately_conserved_and_there_is_a_large_physicochemical_difference_between_arginine_and_cysteine._This_variant_is_present_in_population_databases_(rs587779872,_ExAC_0.001%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(A-T),_in_individuals_with_breast_cancer_in_A-T_families_(PMID:_9443866,_10817650,_10873394,_18634022,_12552559),_and_in_individuals_affected_with_breast_cancer_(PMID:_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127459)._This_variant_affects_a_moderately_conserved_amino_acid_in_theÂ¬â€ semi-conserved_region_of_the_PI3-kinase_domain_in_the_ATM_protein_(PMID:_10873394)._Functional_studies_of_this_sequence_change_in_transfected_human_cells_show_trace_levels_of_ATM_protein_expression_and_intermediate_colony_survival_rates_(PMID:_10873394,_19431188)._Furthermore,_functional_studies_in_cell_lines_from_affected_individuals_that_carry_this_sequence_change_along_with_a_nonsense_or_other_missense_variant_also_show_decreased_colony_survival_rate_(PMID:_18634022)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||This_pathogenic_variant_is_denoted_ATM_c.8494C>T_at_the_cDNA_level,_p.Arg2832Cys_(R2832C)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Cysteine_(CGT>TGT)._ATM_Arg2832Cys_has_been_reported_in_association_with_a_mild_presentation_of_recessively-inherited_ataxia_telangiectasia_(Telatar_1998,_Buzin_2003,_Mitui_2009),_and_in_individuals_with_breast_cancer,_colorectal_cancer,_and_family_history_of_breast_and/or_ovarian_cancer_(Schroeder_2015,_Hansen_2017,_Pritzlaff_2017,_Renault_2018)._Some_functional_studies_have_demonstrated_reduced_amount_of_ATM_protein,_no_detectable_kinase_activity,_and_intermediate_radiosensitivity_associated_with_Arg2832Cys_(Becker-Catania_2000,_Mitui_2009),_while_others_showed_reduced,_but_not_absent,_ATM_kinase_activity_and_a_low_level_of_ATM_protein_(Sun_2002,_Butch_2004,_Chun_2004,_Barone_2009,_Reiman_2011)._ATM_Arg2832Cys_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._ATM_Arg2832Cys_is_located_in_the_kinase_domain_(Stracker_2013)._In-silico_analyses,_including_protein_predictors_and_evolutionary_conservation,_support_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.9022C>T	ATM	missense_variant	102698	2	NA	NA	5&5	1&1	rs587782292	Hereditary cancer-predisposing syndrome&not provided	142187	151901	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108236086C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_010893	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587782292	-	Ambry_Genetics|Color|Counsyl|Invitae|Mendelics|GeneDx	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-03-06|2015-02-17|2014-08-06|2019-01-01|2018-07-02|2018-01-11	2020-02-26|2017-12-21|2015-03-11|2019-03-28|2018-08-20|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|unknown|germline	SCV000186119|SCV000687871|SCV000220577|SCV000259422|SCV000838622|SCV000209774	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Well-characterized_mutation_at_same_position:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_in_appropriate_functional_assay(s)|||This_sequence_change_replaces_arginine_with_cysteine_at_codon_3008_of_the_ATM_protein_(p.Arg3008Cys)._The_arginine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_arginine_and_cysteine._This_variant_is_present_in_population_databases_(rs587782292,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(A-T),_as_homozygous_as_well_as_compound_heterozygous_with_a_second_pathogenic_ATM_variant_in_trans_(PMID:_9872980,_10817650,Â¬â€ 12552566)._This_variant_has_also_been_reported_in_an_individual_with_breast_cancer_(PMID:_26094658)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142187)._Experimental_studies_have_shown_that_this_missense_change_results_in_inactivation_of_ATM_kinase_activity,_increased_radio-sensitivity,_and_cell_cycle_defects_in_vitro_(PMID:_12552566,_15101044,_18573109)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_ATM_c.9022C>T_at_the_cDNA_level,_p.Arg3008Cys_(R3008C)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Cysteine_(CGT>TGT)._This_variant_has_been_observed_in_both_the_homozygous_and_compound_heterozygous_state_in_multiple_individuals_with_Ataxia-telangiectasia_(Hacia_1998,_Li_2000,_Angele_2003,_Reiman_2011,_Carney_2012)_and_has_been_shown_in_functional_studies_to_abolish_ATM_kinase_activity_(Angele_2003,_Austen_2008,_Barone_2009)._This_variant_has_also_been_observed_in_the_heterozygous_state_in_at_least_one_individual_with_familial_breast_cancer_(Aloraifi_2015)._ATM_Arg3008Cys_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_FATC_domain_(Stracker_2013)._In-silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.9023G>A	ATM	missense_variant	102680	1	15422	0	4&4&4	1&1&1	rs587781894	Hereditary cancer-predisposing syndrome&Ataxia-telangiectasia syndrome&not provided	141634	151348	Ovarian_Neoplasms|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108236087G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_010894	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	3	587781894	-	University_Hospital_Cologne	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-09-24|2018-08-01|2018-12-11|2018-07-02|2018-08-08|2018-12-01	2020-02-26|2018-11-06|2019-03-28|2018-08-20|2019-01-29|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|unknown|germline|somatic	SCV000185070|SCV000687872|SCV000253673|SCV000838623|SCV000322217|SCV000923963	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Ovarian_Neoplasms	In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Well-characterized_mutation_at_same_position:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_sequence_change_replaces_arginine_with_histidine_at_codon_3008_of_the_ATM_protein_(p.Arg3008His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs587781894,_ExAC_0.001%)._This_variant_has_been_reported_in_an_individual_with_ataxia-telangiectasia_(A-T)_in_combination_with_a_pathogenic_(p.Arg1466*)_variant_(PMID:_21665257)._This_variant_has_also_been_reported_in_an_individual_with_breast_cancer_(PMID:_19404735)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141634)._This_variant_has_also_been_reported_in_tumor_samples_from_individuals_with_chronic_lymphocytic_leukemia,_mantle_cell_lymphoma_and_malignant_B-cell_lymphoma_with_either_a_11q_deletion_or_with_a_pathogenic_ATM_variant_(PMID:_17968022,_21933854,_23585524,_12697903,_10397742,_11756177)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_are_either_unavailable_or_do_not_agree_on_the_potential_impact_of_this_missense_change_(SIFT:_Deleterious:_PolyPhen-2:_Probably_Damaging:_Align-GVGD:_Class_C0)._A_different_missense_substitution_at_this_codon_(p.Arg3008Cys)_has_been_determined_to_be_pathogenic_(PMID:_9872980,_10817650,_12552566,_15101044,_18573109,_19431188)._This_suggests_that_the_arginine_residue_is_critical_for_ATM_protein_function_and_that_other_missense_substitutions_at_this_position_may_also_be_pathogenic._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||This_variant_is_denoted_ATM_c.9023G>A_at_the_cDNA_level,_p.Arg3008His_(R3008H)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Histidine_(CGT>CAT)._This_variant_has_been_reported_in_at_least_one_individual_with_breast_cancer_and_another_with_Ataxia-telangiectasia_who_also_harbored_an_ATM_nonsense_variant,_although_phase_was_not_reported_(Paglia_2010,_Micol_2011)._Camacho_et_al._(2002)_reported_this_variant_resulted_in_reduced_ATM_protein_expression_levels_while_Navrkalova_et_al._(2013)_reported_normal_protein_expression,_but_deficient_p21_activation._ATM_Arg3008His_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(NHLBI_Exome_Sequencing_Project,_The_1000_Genomes_Consortium_2015,_Lek_2016)._Since_Arginine_and_Histidine_share_similar_properties,_this_is_considered_a_conservative_amino_acid_substitution._ATM_Arg3008His_occurs_at_a_position_that_is_conserved_across_species_and_is_located_in_the_FATC_domain_(Stracker_2013)._In_silico_analyses_predict_that_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_the_currently_available_evidence,_we_consider_ATM_Arg3008His_to_be_a_likely_pathogenic_variant.|
NM_003002.3:c.1A>T	SDHD	start_lost	102704	1	NA	NA	-	-	-	-	422629	408270	Pheochromocytoma|Hereditary_cancer-predisposing_syndrome|Paraganglioma_and_gastric_stromal_sarcoma|Paragangliomas_1|Cowden_syndrome_3|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1847319,OMIM:606864,Orphanet:ORPHA97286|MedGen:C1868633,OMIM:168000|MedGen:C3554516|MedGen:CN517202	-	NC_000011.9:g.111957632A>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	SDHD:6392	SO:0001582|initiatior_codon_variant,SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant	1	104894307	-	GeneDx|Ambry_Genetics|Invitae	Pathogenic|Pathogenic|Pathogenic	2018-06-01|2012-06-19|2018-09-28	2019-01-29|2020-02-26|2019-03-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000572141|SCV000581226|SCV000953729	not_provided|Hereditary_cancer-predisposing_syndrome|Paraganglioma_and_gastric_stromal_sarcoma/Pheochromocytoma/Paragangliomas_1/Cowden_syndrome_3	This_variant_alters_the_initiator_Methionine_codon,_and_the_resultant_protein_would_be_described_as_Â“p.Met1?Â”_to_signify_that_it_is_not_known_if_the_loss_of_Met1_prevents_all_protein_translation_or_if_an_abnormal_protein_is_produced_using_an_alternate_Methionine_codon._While_SDHD_c.1A>T_has_not,_to_our_knowledge,_been_reported_in_the_literature_as_pathogenic_or_benign,_several_other_nucleotide_changes_also_resulting_in_p.Met1?_have_been_reported_in_individuals_affected_with_multiple_and/or_early-onset_paragangliomas,_with_both_sporadic_and_familial_presentations_(Riemann_2003,_Neumayer_2007,_Burnichon_2009,_Zha_2011,_Wang_2012,_Piccini_2012),_Based_on_the_current_evidence,_we_consider_SDHD_c.1A>T_to_be_pathogenic.||This_sequence_change_affects_the_initiator_methionine_of_the_SDHD_mRNA._An_alternate_in-frame_methionine_downstream_of_the_initiator_codon_is_located_at_codon_91,_which_could_potentially_rescue_translational_initiation._This_variant_is_present_in_population_databases_(rs104894307,_ExAC_0.001%)._Disruption_of_the_initiator_codon_has_been_observedÂ¬â€ in_individuals_and_families_withÂ¬â€ head_and_neck_paragangliomas_(HNPGLs)Â¬â€ or_non-HNPGLs,_and_were_shown_to_segregate_with_disease_in_the_affected_families_(PMID:_17406045,_12782822,_11391796,_17576205,_21945342)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 422629)._While_this_variant_is_expected_to_result_in_an_absent_protein_product,_possible_rescue_of_translational_initiation_by_the_downstream_methionine_would_lead_to_the_loss_of_~60%_of_the_SDHD_protein,_including_the_signal_peptide_domain_required_for_entering_the_mitochondrial_membrane_(PMID:_12612654,_15066320)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_003002.3:c.242C>T	SDHD	missense_variant	102688	2	15432	1	5&5&5&5&5&5&5&5&5	1&0&0&0&1&1&1&1&1	rs80338844	Paragangliomas 1&Pheochromocytoma&Hereditary Paraganglioma-Pheochromocytoma Syndromes&Paragangliomas 1 with sensorineural hearing loss&Hereditary cancer-predisposing syndrome&not provided&Paraganglioma and gastric stromal sarcoma&Paragangliomas 1&Pheochromocytoma	6896	21935	Pheochromocytoma|Hereditary_cancer-predisposing_syndrome|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paraganglioma_and_gastric_stromal_sarcoma|Mitochondrial_complex_II_deficiency|Paragangliomas_1|Paragangliomas_1_with_sensorineural_hearing_loss|Cowden_syndrome_3|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0002666,MedGen:C0031511,OMIM:171300|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1708353,Orphanet:ORPHA29072|MedGen:C1847319,OMIM:606864,Orphanet:ORPHA97286|MedGen:C1855008,OMIM:252011,Orphanet:ORPHA3208|MedGen:C1868633,OMIM:168000|MedGen:C3276074|MedGen:C3554516|MedGen:CN169374|MedGen:CN517202	-	NC_000011.9:g.111959663C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):O14521#VAR_010038|OMIM_Allelic_Variant:602690.0003|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2196|Center_for_Human_Genetics,_Inc:SDHC-A5	-	SDHD:6392	SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	3	80338844	-	OMIM|UCLA_Clinical_Genomics_Center,_UCLA|Center_for_Human_Genetics,_Inc|OMIM|GeneReviews|Section_on_Medical_Neuroendocrinolgy,National_Institutes_of_Health|GenomeConnect,_ClinGen|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|OMIM|Ambry_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Invitae|Fulgent_Genetics,Fulgent_Genetics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|pathologic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2003-08-01|2014-01-21|2016-11-01|2003-08-01|2012-08-30|0000-00-00|0000-00-00|2016-09-21|2003-08-01|2018-10-09|2017-08-21|2018-12-05|2018-12-11|2018-10-31|2018-11-16	2019-07-24|2015-05-14|2017-12-20|2019-07-24|2013-01-08|2017-07-10|2017-08-22|2019-03-21|2019-07-24|2020-02-26|2018-01-25|2019-01-29|2019-03-28|2018-11-14|2019-08-05	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|unknown|germline|somatic|not_provided|germline|unknown|germline|unknown|germline|germline|germline|germline|unknown|germline	SCV000027499|SCV000255463|SCV000782285|SCV000027500|SCV000040976|SCV000599533|SCV000607172|SCV000711451|SCV000044497|SCV000212801|SCV000698141|SCV000279171|SCV000287817|SCV000893859|SCV000605086	Paragangliomas_1|Paragangliomas_1|Paragangliomas_1|Pheochromocytoma|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Hereditary_Paraganglioma-Pheochromocytoma_Syndromes|Paragangliomas_1_with_sensorineural_hearing_loss|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Paraganglioma_and_gastric_stromal_sarcoma/Pheochromocytoma/Paragangliomas_1/Cowden_syndrome_3|Paraganglioma_and_gastric_stromal_sarcoma/Pheochromocytoma/Mitochondrial_complex_II_deficiency/Paragangliomas_1|not_specified	||||Converted_during_submission_to_Pathogenic.||GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.|The_p.Pro81Leu_variant_in_SDHD_has_been_reported_in_>25_individuals_with_paragan_gliomas_and/or_pheochromocytomas_(PGL/PCC),_segregated_with_disease_in_at_least_16_relatives_from_7_families_(Xekouki_2015,_Sridhara_2013,_Yeap_2011,_Baysal_200_2,_Mannelli_2006,_Astrom_2003)._This_variant,_along_with_loss_of_heterozygosity,_has_also_been_found_as_a_somatic_change_in_the_tumor_of_an_individual_with_an_i_solated_pheochromocytoma_(Gimm_2000)._It_has_also_been_reported_by_other_clinica_l_laboratories_in_ClinVar_(Variation_ID_6896)._This_variant_has_also_been_identi_fied_in_3/126674_of_European_chromosomes_by_the_Genome_Aggregation_Database_(gno_mAD,_http:/gnomad.broadinstitute.org:_dbSNP_rs80338844)._This_frequency_is_low_e_nough_to_be_consistent_with_the_frequency_of_hereditary_PGL/PCC_syndrome_in_the_general_population._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_hereditary_paraganglioma-pheochromocytoma_syndrome_in_an_autosoma_l_dominant_manner_based_upon_segregation_studies_and_presence_in_multiple_affect_ed_individuals._ACMG/AMP_Criteria_applied:_PS4,_PP1_Strong_(Richards_2015).||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Moderate_segregation_with_disease_(at_least_3_informative_meioses)_for_rare_diseases.:Other_data_supporting_pathogenic_classification:Good_segregation_with_disease_(lod_1.5-3_
NM_003002.3:c.278_280dup	SDHD	inframe_insertion	102740	1	NA	NA	-	-	-	-	821802	810763	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.111959699_111959701dup	_single_submitter	Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	SDHD:6392	SO:0001619|non-coding_transcript_variant,SO:0001821|inframe_insertion,SO:0001627|intron_variant	1	-	-	Ambry_Genetics	Likely_pathogenic	2019-03-28	2020-02-26	_single_submitter	germline	SCV001177555	Hereditary_cancer-predisposing_syndrome	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Insufficient_evidence:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Structural_Evidence
NM_000059.3:c.7007G>C	BRCA2	missense_variant,splice_region_variant	101514	1	NA	NA	5&5&5	0&1&1	rs28897743	Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&not provided	52241	66909	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32921033G>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001583|missense_variant	1	28897743	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|GeneKor_MSA|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Baylor_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-05|2014-01-31|2013-01-08|2017-08-23|2018-08-01|2011-05-04|2006-05-05|2015-10-02|2018-01-25|2016-03-10|2017-10-18|2017-02-23	2019-03-28|2017-08-04|2017-04-19|2018-01-25|2018-08-08|2013-06-26|2014-03-28|2016-10-28|2020-02-26|2017-10-26|2019-01-29|2017-02-23	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000073126|SCV000587879|SCV000592087|SCV000695023|SCV000821714|SCV000109191|SCV000146992|SCV000327566|SCV000276750|SCV000683838|SCV000321480|SCV000541008	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast	This_sequence_change_replaces_arginine_with_proline_at_codon_2336_of_the_BRCA2_protein_(p.Arg2336Pro)._The_arginine_residue_is_weakly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_proline._This_variant_also_falls_at_the_last_nucleotide_of_exon_13_of_the_BRCA2_coding_sequence,_which_is_part_of_the_consensus_splice_site_for_this_exon._This_variant_is_not_present_in_population_databases_(rs28897743,_ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_with_breast_and/or_ovarian_cancer_and_Fanconi_anemia_(PMID:_9150172,_22399190,_20960228,_21548014)._This_variant_is_also_known_as_7235G>C_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52241)._Experimental_studies_have_shown_that_this_missense_change_causes_skipping_of_exons_12_and_13_(PMID:_22505045)._A_different_variant_affecting_this_nucleotide,_c.7007G>A_(p.Arg2336His),_has_also_been_reported_in_patients_with_breast_and/or_ovarian_cancer_and_causes_skipping_of_exons_12_and_13_(PMID:_16792514,_20215541,_22505045),_indicating_that_this_nucleotide_may_be_critical_for_normal_RNA_splicing._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA2_c.7007G>C_(p.Arg2336Pro)_variant_involves_the_alteration_of_a_conserved_nucleotide_affecting_the_last_nucleotide_of_the_exon_13._3/5_in_silico_tools_predict_damaging_outcome_for_this_variant._4/5_splice_prediction_tools_predict_a_significant_impact_on_normal_splicing._ESE_finder_predicts_that_this_variant_may_generate_a_novel_ESE_site._Functional_studies_showed_that_the_variant_causes_skipping_of_exons_12_and_13_(and_increase_of_alternative_splicing)_(Serova-Sinilnikova,_1997,_Houdayer,_2012)._This_variant_is_absent_in_115936_control_chromosomes_from_ExAC._The_variant_was_found_in_multiple_individuals_with_a_personal/or_family_history_of_breast_and/or_ovarian_cancer_(Serova-Sinilnikova_1997,_Sagi_2010,_Adams_2011,_Laitman_2011,_Laitman_2012,_Pritzlaff_2017,_Wang_2014)._In_addition,_several_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||||Last_nucleotide_of_exon:Functionally-validated_splicing_mutation:Well-characterized_mutation_at_same_position||This_variant_is_denoted_BRCA2_c.7007G>C_at_the_cDNA_level._Located_in_the_last_nucleotide_of_exon_13,_it_disrupts_a_natural_splice_donor_site_and_causes_abnormal_splicing._Multiple_RNA_analyses_have_demonstrated_that_BRCA2_c.7007G>C_causes_out-of-frame_skipping_of_exons_12_and_13_(Serova-Sinilnikova_1997,_Houdayer_2012)._This_variant,_also_defined_as_BRCA2_7235G>C_using_alternate_nomenclature,_has_been_reported_in_multiple_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_(Laitman_2011,_Sagi_2011,_Laitman_2012,_Wang_2014)._BRCA2_c.7007G>C_was_also_reported_in_the_compound_heterozygous_state_with_a_frameshift_variant_in_an_individual_with_a_phenotype_consistent_with_Fanconi_Anemia_(Myers_2012)._Although_the_nucleotide_substitution_results_in_the_change_of_an_Arginine_to_a_Proline_at_codon_2336,_and_is_called_Arg2336Pro_in_the_literature,_we_are_only_using_the_nucleotide_nomenclature_to_refer_to_the_variant_since_the_defect_is_determined_to_be_one_of_splicing_rather_than_a_resulting_missense_variant._BRCA2_c.7007G>C_was_not_observed_at_a_significant_frequency_in_large_population_cohorts_(Lek_2016)._The_nucleotide_which_is_altered,_a_Guanine_(G)_at_base_7007,_is_conserved_across_species._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.7878G>C	BRCA2	missense_variant	102574	1	NA	NA	5&5&4	3&1&1	rs80359013	Breast-ovarian cancer, familial 2&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome	38125	46681	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32936732G>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001583|missense_variant	1	80359013	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Division_Human_Genetics,Medical_University_Innsbruck|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Department_of_Medical_Genetics,Oslo_University_Hospital|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx	Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2012-12-19|2002-05-29|2015-02-11|2015-08-10|2015-10-02|2016-01-15|2016-12-16|2018-12-27|2019-10-28|2017-07-20|2019-09-30|2018-08-22|2016-11-02|2018-05-31	2014-07-28|2014-03-28|2015-02-11|2015-08-17|2016-10-28|2016-11-23|2017-10-18|2019-03-28|2019-10-28|2019-03-21|2020-02-26|2018-11-06|2017-08-01|2019-01-29	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054314|SCV000147208|SCV000212029|SCV000244475|SCV000327755|SCV000488157|SCV000605699|SCV000073349|SCV000494423|SCV000605791|SCV000213513|SCV000689074|SCV000296697|SCV000564795	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_000059.3:c.7987G>A	BRCA2	missense_variant	102104	1	NA	NA	-	-	-	-	52461	67129	_familial_2	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32937326G>A	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001583|missense_variant	1	80359030	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Pathway_Genomics|Ambry_Genetics	Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2009-01-13|2004-02-20|2014-07-24|2019-04-19	2012-10-30|2014-03-28|2014-08-08|2020-02-26	_single_submitter	germline|germline|germline|germline	SCV000109219|SCV000147241|SCV000189902|SCV000213624	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome	|||Deficient_protein_function_in_appropriate_functional_assay(s):Good_segregation_with_disease_(lod_1.5-3_
NM_000059.3:c.8243G>A	BRCA2	missense_variant	100412	2	NA	NA	5&4	3&1	rs80359071	Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome	52535	67203	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32937582G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001583|missense_variant	1	80359071	-	Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Sharing_Clinical_Reports_Project_(SCRP)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx	Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-21|2012-09-26|2016-12-21|2016-04-04|2018-07-02|2002-05-29|2015-08-10|2010-04-26|2015-10-02|2016-11-28|2018-03-05|2019-08-27|2017-08-01|2015-03-30|2018-09-14	2019-03-28|2017-04-19|2019-03-21|2018-01-25|2018-08-20|2014-03-28|2015-08-17|2015-08-20|2016-10-28|2017-06-22|2018-06-14|2020-02-26|2017-12-21|2017-08-01|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|reviewed_by_expert_panel|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline	SCV000073473|SCV000592180|SCV000605806|SCV000695136|SCV000838871|SCV000147307|SCV000244484|SCV000297564|SCV000327843|SCV000677699|SCV000839922|SCV000274383|SCV000689109|SCV000296703|SCV000568124	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_replaces_glycine_with_aspartic_acid_at_codon_2748_of_the_BRCA2_protein_(p.Gly2748Asp)._The_glycine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_glycine_and_aspartic_acid._This_variant_is_not_present_in_population_databases_(rs80359071,_ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_15026808,_17924331,_22711857)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52535)._Based_on_a_multifactorial_likelihood_algorithm_using_genetic_data,_this_variant_has_been_determined_to_have_a_high_probability_of_being_pathogenic_(PMID:_17924331)._Experimental_studies_have_shown_that_this_missense_change_disrupts_homology_directed_recombination_and_the_regulation_of_centrosome_amplification_(PMID:_18451181,_21671020,_23108138,_23328489,_25146914)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Gly2748Asp_variant_in_BRCA2_has_been_reported_in_at_least_10_individuals_w_ith_BRCA2-associated_cancers_(Claes_2014,_Breast_Cancer_Information_Core_(BIC)_d_atabase),_and_it_was_absent_from_large_population_studies._In_vitro_functional_s_tudies_provide_some_evidence_that_the_p.Gly2748Asp_variant_may_impact_protein_fu_nction_(Guidugli_2014,_Spugnesi_2013)._In_addition,_this_variant_was_classified_as_Pathogenic_on_August_10,_2015_by_the_ClinGen-approved_ENIGMA_expert_panel_(Cl_inVar_SCV000244484.1)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner.|Variant_Summary:_The_variant_c.8243G>A_causes_a_missense_change_from_Gly_to_Asp_involving_a_conserved_nucleotide_with_5/5_in_silico_tools_predicting_a_deleterious_outcome._The_variant_of_interest_was_not_observed_in_controls_(ExAC,_1000_Gs_or_ESP)_and_has_been_reported_in_several_HBOC_patients/families_via_publications_and_in_individuals_undergoing_BRCA1/2_testing_by_clinical_labs._However,_no_cosegregation_studies_for_the_variant_have_been_reported_so_far_in_literature._Multiple_independent_functional_studies_demonstrated_a_deleterious_impact_by_the_variant_resulting_in_impaired_homologous_recombination_activity_of_BRCA2_further_supporting_a_disease-causing_impact_(Hendriks_2014,_Guidugli_2012,_and_Farrugia_2009)._Furthermore,_multiple_reputable_databases/clinical_laboratories_report_the_variant_as_Causal/Pathogenic._Multifactorial_probability_models_are_also_consistent_with_the_disease-causing_outcome_of_the_variant_(Easton_2007,_Farrugia_2008,_Karchin_2008,_and_Lindor_2012)._Taking_all_available_lines_of_evidence_into_consideration,_the_variant_of_interest_is_classified_as_likely_pathogenic_until_additional_information_(such_as_the_variants_cosegregation_with_disease)_becomes_available.|||IARC_class_based_on_posterior_probability_from_multifactorial_likelihood_analysis,_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_000059.3:c.9117G>A	BRCA2	splice_region_variant,synonymous_variant	100898	1	NA	NA	-	-	-	-	38215	46771	Tracheoesophageal_fistula|Medulloblastoma|Malignant_tumor_of_prostate|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Glioma_susceptibility_3|Pancreatic_cancer_2|Wilms_tumor_1|not_provided	-	Human_Phenotype_Ontology:HP:0002575,MedGen:C1861028,OMIM:189960|Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:C2751641,OMIM:613029|MedGen:C3150546,OMIM:613347|MedGen:CN033288,OMIM:194070|MedGen:CN517202	-	NC_000013.10:g.32954050G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001819|synonymous_variant	1	28897756	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Fulgent_Genetics,Fulgent_Genetics|Department_of_Medical_Genetics,Oslo_University_Hospital|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Mendelics|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Mendelics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Fulgent_Genetics,Fulgent_Genetics|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-08-31|2004-02-20|2015-10-02|2016-02-03|2015-09-18|2015-11-02|0000-00-00|2014-10-10|2015-09-21|2017-05-25|2019-05-28|2018-12-22|2015-08-10|2014-01-31|2018-07-02|2018-08-03|2019-08-06|2019-04-04|2015-10-21|2017-05-18|2018-10-31	2014-07-28|2014-03-28|2016-10-28|2016-11-23|2017-04-18|2017-10-18|2018-04-04|2018-04-17|2018-04-09|2018-06-14|2019-10-22|2019-03-28|2016-11-14|2017-08-04|2018-08-20|2019-01-29|2020-03-06|2020-02-26|2017-01-26|2017-05-23|2018-11-14	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|unknown|germline|germline|germline|unknown|germline|germline|germline|germline|unknown|unknown	SCV000054406|SCV000147546|SCV000328057|SCV000488254|SCV000575743|SCV000605690|SCV000733331|SCV000743359|SCV000744555|SCV000839919|SCV001139248|SCV000073738|SCV000494420|SCV000587988|SCV000838896|SCV000108645|SCV000296758|SCV000185969|SCV000537643|SCV000611181|SCV000894007	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_2/Fanconi_anemia,_complementation_group_D1/Medulloblastoma/Wilms_tumor_1/Malignant_tumor_of_prostate/Pancreatic_cancer_2/Glioma_susceptibility_3/Tracheoesophageal_fistula|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_2/Fanconi_anemia,_complementation_group_D1/Medulloblastoma/Wilms_tumor_1/Malignant_tumor_of_prostate/Pancreatic_cancer_2/Glioma_susceptibility_3	|||||||||The_c.9117G>A_(p.Pro3039Pro)_variant_in_the_BRCA2_gene_has_been_detected_in_multiple_patients_and_families_with_breast_and/or_ovarian_cancer_[PMID_10638982_reported_as_3398delAAAAG,_27000661]_and_a_cohort_of_patients_with_prostate_cancer_[PMID_23035815,_reported_as_c.9117_G>A_(p.Val2985fs)]._The_nucleotide_position_9117_is_the_last_nucleotide_of_exon_23._Several_in_vitro_assays_showed_that_the_change_leads_aberrant_splicing_and_the_skipping_of_exon_23_[PMID_22505045,_23451180]._This_variant_is_thus_predicted_to_result_in_a_loss_of_function_of_the_protein._This_variant_has_not_been_reported_in_the_ExAC_database._This_variant_thus_classified_as_pathogenic.||This_sequence_change_affects_codon_3039_of_the_BRCA2_mRNA._It_is_a_'silent'_change,_meaning_that_it_does_not_change_the_encoded_amino_acid_sequence_of_the_BRCA2_protein._It_also_falls_at_the_last_nucleotide_of_exon_23_of_the_BRCA2_coding_sequence._This_variant_is_not_present_in_population_databases_(rs28897756,_ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_10638982,_17011978,_22923021,_17148771,_26026974),_and_prostate_cancer_(PMID:_23035815)._This_variant_is_also_known_as_9345G>A_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_38215)._Nucleotide_substitutions_within_the_consensus_splice_site_are_a_relatively_common_cause_of_aberrant_splicing_(PMID:_17576681,_9536098)._Experimental_studies_have_shown_that_this_sequence_change_causes_aberrant_splicing,_leading_to_skipping_of_exon_23_of_the_BRCA2_mRNA._This_leads_to_a_frameshift_at_codon_2985_and_a_premature_stop_signal_(Val2985Glyfs*3),_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product_(PMID:_22632462,_23451180,_22505045,_25382762,_23035815)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_Summary:_The_variant_of_interest_is_a_conserved_nucleotide_that_causes_a_synonymous_change,_however,_the_variant_is_located_at_the_exon/intron_junction_at_the_3'end_of_exon_23_and_predicted_to_be_disease-causing_by_Mutation_Taster._3/5_in_silico_programs_via_Alamut_predict_the_elminiation_of_a_splice_site_and_the_removal_of_an_ESE_binding_motif._The_effect_of_this_variant_on_splicing_has_been_evaluated_by_multiple_functional_studies_(Acedo_2012,_Bonatti_2006,_Colombo_2013,_and_Houdayer_2012),_which_all_consistently_showed_the_skipping_of_exon_23._The_variant_of_interest_has_reported_in_multiple_affected_individuals_via_publications._In_addition,_multiple_reputable_databases/clinical_laboratories,_BIC,_UMD,_kConFab,_ARUP,_HGMD,_Ambry_Genetics,_GeneDx,_and_SCRP,_cites_the_variant_with_a_classification_of_pathogenic._Therefore,_taking_all_lines_of_evidence_into_consideration,_the_variant_of_interest_is_classified_as_pathogenic.|||This_pathogenic_variant_is_denoted_BRCA2_c.9117G>A_at_the_DNA_level._Although_this_variant_is_silent_at_the_coding_level,_preserving_a_Proline_at_codon_3039,_it_disrupts_a_splice_donor_site_and_has_been_shown_in_functional_assays_to_cause_aberrant_RNA_processing,_specifically_skipping_of_exon_23_(Peelan_2000,_Bonatti_2006,_Colombo_2013)._Previously_reported_as_BRCA2_9345G>A_(del_exon_23),_this_variant_has_been_observed_in_multiple_breast/ovarian_cancer_families_(Peelan_2000,_Risch_2006,_Novakovic_2012,_Tea_2014,_de_Juan_2015,_Gabald?_Barrios_2017)._BRCA2_c.9117G>A_was_not_observed_in_large_population_cohorts_(Lek_2016)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|The_best_available_variant_frequency_is_uninformative._Statistically_enriched_in_patients_compared_to_ethnically_matched_controls._Found_in_at_least_one_symptomatic_patient._Predicted_to_negatively_affect_a_known_splice_site._Nucleotide_conservation_is_uninformative._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.|Functionally-validated_splicing_mutation:Last_nucleotide_of_exon:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Moderate_segregation_with_disease_(at_least_3_informative_meioses)_for_rare_diseases.|||
NM_000059.3:c.9154C>T	BRCA2	missense_variant	102580	1	NA	NA	5&5&5&5&5	1&3&1&1&1	rs45580035	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome&Breast-ovarian cancer, familial 1&not provided	52763	67431	Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_1|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:C2676676,OMIM:604370|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32954180C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001583|missense_variant	1	45580035	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Department_of_Medical_Genetics,Oslo_University_Hospital|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Ambry_Genetics|Color|True_Health_Diagnostics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-03|2014-01-31|2017-04-20|2018-07-02|2017-09-11|2012-11-28|2002-05-29|2015-08-10|2015-10-02|2017-01-01|2015-07-01|2017-04-10|0000-00-00|2014-10-08|2015-09-21|2018-08-06|2015-07-28|2017-11-10|2015-11-20|2018-10-09|2016-04-12|2018-08-01|2016-11-01	2019-03-28|2017-08-04|2017-08-04|2018-08-20|2019-04-24|2015-08-20|2014-03-28|2015-08-17|2016-10-28|2017-03-15|2017-10-18|2017-06-22|2018-04-04|2018-04-17|2018-04-09|2020-02-26|2017-01-26|2018-03-08|2016-03-03|2019-01-29|2018-08-31|2018-08-08|2018-04-30	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000073745|SCV000587990|SCV000588126|SCV000838897|SCV000918902|SCV000109259|SCV000147553|SCV000244491|SCV000328069|SCV000577975|SCV000605661|SCV000677705|SCV000733333|SCV000743360|SCV000744557|SCV000213515|SCV000537644|SCV000787960|SCV000266050|SCV000279425|SCV000296544|SCV000693592|SCV000902218	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer	This_sequence_change_replaces_arginine_with_tryptophan_at_codon_3052_of_the_BRCA2_protein_(p.Arg3052Trp)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_tryptophan._This_variant_is_present_in_population_databases_(rs45580035,_ExAC_0.006%)._This_variant_has_been_reported_in_individuals_affected_with_breast,_ovarian,_and_prostate_cancer_(PMID:_24728189,_24504028,_25556971,_20104584,_26845104)_and_it_co-segregated_with_BRCA2-related_disease_in_several_families_(PMID:_18451181,_19200354)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52763)._This_variant_disrputs_DNA_repair_activity_of_the_encoded_protein_product_in_vitro_(PMID:_18451181,_23108138)_and_fails_to_rescue_lethality_in_mouse_embryonic_stem_cells_lacking_BRCA2_(PMID:_25146914,_18607349)._Analyses_from_several_statistical_modeling_algorithms_using_genetic_and_functional_data_have_concluded_that_this_variant_has_a_high_probability_of_causing_disease_(PMID:_21990134,_23108138)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_The_BRCA2_c.9154C>T_(p.Arg3052Trp)_variant_located_in_the_Nucleic_acid-binding,_OB-fold_domain_(via_InterPro)_involves_the_alteration_of_a_conserved_nucleotide_and_5/5_in_silico_tools_predict_a_damaging_outcome_for_this_variant._These_predictions_are_supported_by_multiple_functional_studies_(Farrugia_2008,_Kuznetsov_2008,_and_Walker_2010)_that_implicate_the_variant_to_affect_proper_BRCA2_protein_function._This_variant_was_found_in_3/246052_control_chromosomes_from_gnomAD_database_at_a_frequency_of_0.0000122,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._This_variant_has_been_reported_in_several_patients/families_with_breast_and/or_ovarian_cancer,_including_an_evidence_of_cosegregation_with_disease_in_a_large_multi-generation_family_(Farrugia_2008)._In_addition,_several_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||IARC_class_based_on_posterior_probability_from_multifactorial_likelihood_analysis,_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_000059.3:c.9285C>G	BRCA2	missense_variant	102312	1	NA	NA	4&5&5	1&1&1	rs80359198	Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&not provided	52805	67473	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32968854C>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001583|missense_variant	1	80359198	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2018-12-17|2014-01-31|2018-07-25|2010-03-30|2002-05-29|2018-05-03|2018-02-28|2018-11-13|2016-10-24	2019-03-28|2017-08-04|2018-11-27|2015-08-20|2014-03-28|2020-02-26|2018-11-06|2019-01-29|2017-08-01	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000073792|SCV000587995|SCV000695233|SCV000109265|SCV000147600|SCV000276898|SCV000684048|SCV000292530|SCV000600853	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	This_sequence_change_replaces_aspartic_acid_with_glutamic_acid_at_codon_3095_of_the_BRCA2_protein_(p.Asp3095Glu)._The_aspartic_acid_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_aspartic_acid_and_glutamic_acid._This_variant_is_not_present_in_population_databases_(no_ExAC_frequency)._This_variant_has_been_reported_in_many_families_with_supportive_evidence_of_segregation_with_a_BRCA2-related_disease_(PMID:_18451181,_18951446,_22678057)._It_is_also_known_as_9513C>G_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52805)._Experimental_studies_have_shown_that_this_variant_disrupts_BRCA2_homology_directed_repair_activity,_and_suppresses_the_ability_of_BRCA2_to_restore_viability_to_BRCA2-null_mouse_embryonic_stem_cells_(PMID:_22678057,_23108138,_18451181)._Based_on_a_multifactorial_likelihood_algorithm_using_genetic,_in_silico,_and_statistical_data,_this_variant_has_been_determined_to_have_a_very_high_probability_of_being_pathogenic_(PMID:_17924331,_21990134,_22678057)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_BRCA2_c.9285C>G_(p.Asp3095Glu)_results_in_a_conservative_amino_acid_change_located_in_the_oligonucleotide/oligosaccharide-binding,_domain_3_of_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_245472_control_chromosomes._c.9285C>G_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._The_variant_has_been_reportedly_identified_in_at_least_27_HBOC_families_(Maillet__2006,_Biswas_2012,_Gabaldo_2018)_with_segregation_data_suggestive,_but_not_conclusive_of_causality._Several_publications_report_experimental_evidence_evaluating_an_impact_on_protein_function._In_the_functional_studies_the_variant_was_shown_to_cause_significantly_reduced_HDR_activity_and_increased_aberrant_centriole_amplification,_both_suggestive_of_a_deleterious_impact_(Guidugli-2012,_Biswas_2012,_Farrugia_2008)._Multiple_multifactorial_algorithms_favor_pathogenicity_(Easton_2007,_Lindor_2012,_Guidugli_2018)._Five_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic/likely_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_likely_pathogenic.|||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_in_appropriate_functional_assay(s):Structural_Evidence||This_pathogenic_variant_is_denoted_BRCA2_c.9285C>G_at_the_cDNA_level,_p.Asp3095Glu_(D3095E)_at_the_protein_level,_and_results_in_the_change_of_an_Aspartic_Acid_to_a_Glutamic_Acid_(GAC>GAG)._Also_published_as_BRCA2_9513C>G_using_alternate_nomenclature,_this_variant_has_been_observed_in_an_individual_with_personal_and_family_history_of_breast/ovarian_cancer_as_well_as_in_two_individuals_with_male_breast_cancer_(Plon_2008,_Gabald?_Barrios_2017)._This_variant_has_exhibited_reduced_homology-directed_repair_(HDR)_activity,_aberrant_centriole_amplification_and_failure_to_rescue_the_lethality_of_Brca2_null_ES_cells,_all_suggestive_of_pathogenicity_(Farrugui_2008,_Biswas_2012,_Guidugli_2012)._Various_multifactorial_models_have_strongly_predicted_this_variant_to_be_pathogenic,_based_on_clinical_histories,_family_studies,_co-occurrence_with_deleterious_variants,_tumor_histopathology,_and_other_factors_(Easton_2007,_Lindor_2012,_Vallee_2012)._BRCA2_Asp3095Glu_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_within_the_DNA_binding_domain_(Yang_2002)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.9371A>T	BRCA2	missense_variant	102656	1	NA	NA	4&5	1&1	rs28897759	Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome	38233	46789	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32968940A>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001583|missense_variant	1	28897759	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genetic_Services_Laboratory,_University_of_Chicago|Counsyl|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|Mendelics|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Ambry_Genetics|Color|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA	Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	2013-07-16|2004-02-20|2015-10-02|2016-02-01|2016-06-17|2017-07-28|2019-05-28|2019-06-18|2018-12-21|2015-12-17|2015-09-03|2017-08-09|2018-07-02|2018-06-15|2016-10-19|2017-08-31|2019-01-04|2017-05-08|2018-08-01	2015-08-20|2014-03-28|2016-10-28|2017-07-05|2017-06-22|2018-04-17|2019-10-22|2019-07-23|2019-03-28|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2020-02-26|2017-10-26|2018-09-19|2019-01-29|2018-08-31|2018-08-08	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000054424|SCV000147620|SCV000328117|SCV000593759|SCV000677707|SCV000743365|SCV001139258|SCV001161567|SCV000073815|SCV000588000|SCV000592279|SCV000695235|SCV000838902|SCV000185187|SCV000684058|SCV000228185|SCV000278888|SCV000600859|SCV000693549	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Familial_cancer_of_breast	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_000059.3:c.9666del	BRCA2	frameshift_variant	102032	1	NA	NA	-	-	-	-	52888	67556	_familial_2	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32972316del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):9894&base_change%3Ddel_T	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359772	-	Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	0000-00-00|2015-03-11|2016-09-08|2015-10-02|2019-04-29|2014-01-31|2013-11-28|2018-12-01	2014-03-28|2016-07-18|2016-09-13|2016-10-28|2020-02-26|2017-08-04|2017-04-19|2019-02-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline	SCV000147695|SCV000296712|SCV000301406|SCV000328159|SCV000184845|SCV000588013|SCV000592301|SCV000923800	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Ovarian_Neoplasms	_nonsense)|||
NM_000059.3:c.9672dup	BRCA2	frameshift_variant	102220	1	NA	NA	-	-	-	-	126217	131755	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32972322dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	OMIM_Allelic_Variant:600185.0019|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2843476|Breast_Cancer_Information_Core__(BRCA2):9900&base_change%3Dins_A	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359773	-	OMIM|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Ambry_Genetics|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|Color|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-07-26|2002-05-29|2014-11-03|2016-09-08|2015-10-02|0000-00-00|2014-10-10|2015-09-21|2018-10-18|2018-05-23|2015-10-02|2018-11-21|2016-06-24|2016-10-28|2016-04-26|2018-09-20|2018-03-02	2017-11-28|2014-03-28|2016-04-21|2016-09-13|2016-10-28|2018-04-04|2018-04-17|2018-04-09|2020-02-26|2018-05-23|2018-11-06|2019-03-28|2017-04-19|2019-03-21|2018-01-25|2019-01-29|2018-08-31	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000030143|SCV000147696|SCV000196029|SCV000301407|SCV000328160|SCV000733341|SCV000743528|SCV000744792|SCV000185507|SCV000803165|SCV000911347|SCV000255257|SCV000592302|SCV000605805|SCV000695261|SCV000329588|SCV000889186	Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_sequence_change_inserts_1_nucleotide_in_exon_27_of_the_BRCA2_mRNA_(c.9672dupA),_causing_a_frameshift_at_codon_3225._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_BRCA2_mRNA_(p.Tyr3225Ilefs*30)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_195_amino_acids_of_the_BRCA2_protein._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_and_families_affected_by_breast_and/or_ovarian_cancer_(PMID:_24156927,_16683254)._It_has_been_reported_in_trans_with_a_pathogenic_variant_in_BRCA2_in_an_individual_with_Fanconi_anemia_(PMID:_12065746)._This_variant_is_also_known_as_9900insA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126217)._Experimental_evidence_indicates_that_this_variant_encodes_a_truncated_protein_product_(PMID:_12065746),_and_that_cells_carrying_this_variant_display_increased_sensitivity_to_mitomycin_C_(PMID:_12065746)._This_variant_removes_a_stretch_of_36_conserved_residues_(amino_acids_3270-3305)_in_BRCA2_that_is_important_for_interaction_with_RAD51_to_mediate_homologous_recombination_during_the_repair_of_double-strand_DNA_breaks_(PMID:_17515903)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Tyr3225fs_variant_in_BRCA2_has_been_reported_in_the_heterozygous_state_in_>30_individuals_with_BRCA2-associated_cancers_and_in_the_compound_heterozygous_s_tate_in_1_individual_with_Fanconi_anemia_(Howlett_2002,_Tea_2014,_Hout_2006,_Dru_sedau_2013,_Karami_2013,_Breast_Cancer_Information_Core_(BIC)_database)._This_va_riant_was_absent_from_large_population_studies._This_variant_is_predicted_to_cau_se_a_frameshift,_which_alters_the_protein?s_amino_acid_sequence_beginning_at_pos_ition_3225_and_leads_to_a_premature_termination_codon_30_amino_acids_downstream._Heterozygous_loss_of_function_of_the_BRCA2_gene_is_an_established_disease_mecha_nism_in_hereditary_breast_and_ovarian_cancer_(HBOC)._In_summary,_this_variant_me_ets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_ma_nner.|Variant_summary:_The_c.9672dupA_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein,_which_is_a_known_disease_mechanism_for_BRCA2-related_phenotypes._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic/likely_pathogenic_by_our_laboratory_(e.g._c.9788delA,_c.9800dupA,_p.Tyr3308X,_etc.)._This_variant_is_not_found_in_120572_control_chromosomes_including_the_large_and_broad_populations_of_ExAC._It_was_reported_in_multiple_patients_affected_with_breast_and/or_ovarian_cancer_reported_in_clinical_database/publications._In_addition,_the_variant_is_reported_to_cause_Fanconi_Anemia_in_compound_heterozygous_with_other_pathogenic/likely_pathogenic_variants._This_variant_was_also_found_in_homozygous_state_in_one_patient_with_intellectual_disability_and_microcephaly_who_had_focal_temporal_cortical_dysplasia._Multiple_clinical_laboratories_as_well_as_reputable_databases_have_classified_it_as_pathogenic._Taken_together,_this_variant_has_been_classified_as_Pathogenic.|This_duplication_of_one_nucleotide_in_BRCA2_is_denoted_c.9672dupA_at_the_cDNA_level_and_p.Tyr3225IlefsX30_(Y3225IfsX30)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_AGAT[dupA]TATT._The_duplication_causes_a_frameshift,_which_changes_a_Tyrosine_to_an_Isoleucine_at_codon_3225,_and_creates_a_premature_stop_codon_at_position_30_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._BRCA2_c.9672dupA,_previously_published_as_BRCA2_9900insA,_has_been_observed_in_the_heterozygous_state_in_multiple_suspected_hereditary_breast/ovarian_cancer_families,_and_in_the_compound_heterozygous_or_homozygous_state_in_at_least_three_individuals_with_Fanconi_anemia_(Howlett_2002,_van_der_Hout_2006,_Tea_2014,_Dodgshun_2016,_Rump_2016)._Based_on_currently_available_information,_we_consider_this_variant_to_be_pathogenic.|
NM_000059.3:c.9682del	BRCA2	frameshift_variant	102236	1	NA	NA	-	-	-	-	91530	97007	_familial_2	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32972332del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	398122618	-	_c/o_University_of_Cambridge|Color|GeneKor_MSA	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-10-18|2016-09-08|2015-10-02|2017-03-10|2018-08-01	2013-06-26|2016-09-13|2016-10-28|2017-10-26|2018-08-08	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000108844|SCV000301410|SCV000328163|SCV000684084|SCV000693594	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||
NM_000059.3:c.9699_9702del	BRCA2	frameshift_variant	102370	2	15436	1	-	-	-	-	38260	46816	_familial_2|not_specified|Genetic_non-acquired_premature_ovarian_failure|not_provided	-	MeSH:D030342,MedGen:C0950123|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN258378,Orphanet:ORPHA485382|MedGen:CN517202	-	NC_000013.10:g.32972349_32972352del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	Breast_Cancer_Information_Core__(BRCA2):9927&base_change%3Ddel_TATG	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359775	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Fulgent_Genetics,Fulgent_Genetics|Department_of_Medical_Genetics,Oslo_University_Hospital|Ambry_Genetics|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|PreventionGenetics,PreventionGenetics|Center_for_Reproductive_Medicine,Shandong_Provincial_Hospital_Affiliated_to_Shandong_University|Color|Ambry_Genetics	Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Pathogenic|Uncertain_significance|Pathogenic	2012-07-30|2002-05-29|2014-07-29|2016-09-08|2015-10-02|2016-01-13|2017-01-02|2014-06-05|2019-01-09|2014-01-31|0000-00-00|2019-04-18|2019-01-09|2016-02-01|2018-10-01|2018-07-29|2019-10-26	2013-06-26|2014-03-28|2015-03-11|2016-09-13|2016-10-28|2017-04-18|2017-10-18|2018-02-08|2019-03-28|2017-08-04|2017-04-19|2019-09-24|2019-01-29|2018-01-29|2019-02-16|2018-11-06|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000054451|SCV000147700|SCV000220562|SCV000301412|SCV000328164|SCV000575748|SCV000605701|SCV000185974|SCV000073900|SCV000588014|SCV000592303|SCV000695262|SCV000210802|SCV000805800|SCV000902413|SCV000902932|SCV001181012	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Inborn_genetic_diseases|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_specified|not_specified|not_provided|not_provided|Genetic_non-acquired_premature_ovarian_failure|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||Lines_of_evidence_used_in_support_of_classification:_POSITIVE:_Relevant_Alteration(s)_Detected|This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_BRCA2_gene_(p.Cys3233Trpfs*15)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_186_amino_acids_of_the_BRCA2_protein._This_variant_is_present_in_population_databases_(rs781465150,_ExAC_0.08%)._This_variant_has_been_observed_on_the_opposite_chromosome_(in_trans)_from_other_pathogenic_variants_in_individuals_with_features_of_a_mild_form_of_Fanconi_anemia_(PMID:_25639900,_Invitae)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease.Â¬â€ However,_family_testing_has_not_shown_consistent_segregation_of_this_variant_with_breast_and/or_ovarian_cancer,_resulting_in_it_being_classified_as_a_special_interpretation_variant_for_autosomal_dominant_hereditary_breast_and_ovarian_cancer_(PMID:_25639900).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_38260)._This_variant_disrupts_the_C-terminus_of_the_BRCA2_protein._Other_variants_that_disrupt_this_region_(p.Gln3299Ilefs*29_and_p.Tyr3308*)_have_been_determined_to_be_pathogenic_(PMID:_17026620,_22711857,Â¬â€ 18593900,_18607349,_Invitae)._This_suggests_that_variants_that_disrupt_this_region_of_the_protein_are_likely_to_be_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_BRCA2_c.9699_9702delTATG_(p.Cys3233TrpfsX15)_results_in_a_premature_termination_codon_located_in_the_BRCA2_C-terminal_domain_encoded_by_exon_27_that_contains_a_nuclear_localization_signal,_interacts_with_RAD51_in_a_CDK-dependent_manner,_and_is_required_for_maintaining_genomic_stability_after_DNA_damage._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(c.9770_9773delAAGA,_p.Lys3257fsX17:_c.9924C>G,_p.Tyr3308X)_and_cited_in_HBOC_patients._3/5_splicing_prediction_tools_predict_that_this_variant_may_strengthen_a_cryptic_3'_splicing_acceptor_site,_which_may_lead_to_alternative_start_of_exon_27_and_frameshit._However,_these_predictions_have_yet_to_be_confirmed_by_functional_studies._This_variant_was_predicted_not_to_result_in_Nonsense-Mediated_Decay_and_associated_with_stable_mutant_proteins_(Rebbeck_2018)._The_variant_allele_was_found_at_a_frequency_of_6e-05_in_281678_control_chromosomes_(gnomAD)._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_BRCA2_causing_Hereditary_Breast_and_Ovarian_Cancer_(6e-05_vs_0.00075),_allowing_no_conclusion_about_variant_significance._The_variant,_c.9699_9702delTATG,_has_been_reported_in_the_literature_in_individuals_affected_with_Breast_and_Ovarian_Cancer_(Castera_2014,_Rosenthal_2015,_Kan_2015,_Alemar_2017,_Bunnell_2017,_Rebbeck_2018)._In_our_evaluation_of_this_supporting_literature,_we_conservatively_ascertained_at-least_10_transmissions_of_the_variant_allele_and_3_transmissions_of_the_reference_allele_to_affected_individuals_In_families_with_this_variant._Since_the_ascertained_penetrance_of_Hereditary_Breast_and_Ovarian_Cancer_(0.42)_due_to_this_variant_appears_to_be_lower_than_expected_(estimated_at_0.5),_no_conclusions_can_be_drawn_from_these_data._Rosenthal_2015_evaluated_the_variant_of_interest_and_observed_the_variant_in_at_least_1_Family_with_a_suggested_mild_form_of_Fanconi_Anemia._This_family_was_ascertained_because_a_female_was_diagnosed_with_BrC_at_22_y/o_and_carried_the_variant_of_interest_and_another_BRCA2_variant,_c.145G>T_(p.Glu49X)_believed_to_be_in_trans,_although_not_confirmed._Her_brother_(15_y/o)_who_carried_the_same_two_variants_(identical_genotype)_was_indicated_to_have_no_symptoms_at_the_time_of_publication._However,_both_siblings_were_reported_to_have_had_abnormal_chromosome_mitomycin_C_stress_testing._The_authors_went_on_to_state_that_they_detected_this_variant_in_67_apparently_unrelated_individuals_undergoing_comprehensive_analysis_of_BRCA1_and_BRCA2,_it_has_been_seen_in_two_individuals_who_also_carry_a_pathogenic_variant_in_BRCA1._The_authors_further_evaluated_the_variant_of_interest_in_the_Myriad_database_and_found_multiple_relatives_of_probands_that_carried_the_variant_of_interest_that_were_either_affected_or_unaffected,_along_with_affected_individuals_that_did_not_carry_the_variant_of_interest._Therefore,_the_authors_concluded_that_the_variant_of_interest_needs_to_be_reported_as_a_special_interpretation_variant_and_conclude_there_is_as_yet_no_compelling_hypothetical_mechanism_as_to_why_BRCA2_c.9699_9702del_is_not_causative_of_HBOC._It_is_important_to_note_that_the_variant_of_interest_described_here_is_yet_proven_to_have_absolutely_no_impact_on_cancer_risk,_although_the_available_data_in_each_case_suggest_that_the_risk_falls_far_short_of_what_is_considered_to_be_diagnostic_of_the_associated_clinical_syndrome._Co-occurrences_with_other_pathogenic_variants_have_been_reported_from_database_and_publications_(Rosenthal_2015,_Alemar_2017),_providing_supporting_evidence_for_a_benign_role_(UMD-BRCA1_c.3979C>T,_p.Gln1327X:_BIC-BRCA1_c.3759_3760delTA,_p.Lys1254fsX12:_Alemar_2017-BRCA2_c.8878C>T,_p.Gln2960X:_Rosenthal_2015-BRCA2_c.145G>T_,_p.Glu49*)._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Seven_submitters_including_one_expert_panel_(ENIGMA)_have_provided_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._The_classifications_are_conflicting_with_pathogenic_(n
NM_000059.3:c.9770_9773del	BRCA2	frameshift_variant	102672	1	NA	NA	-	-	-	-	141469	151183	_familial_2	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32972420_32972423del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	587781772	-	Ambry_Genetics|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic	2017-02-13|2016-09-08|2016-06-21	2020-02-26|2016-09-13|2018-01-25	criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter	germline|germline|germline	SCV000184831|SCV000301414|SCV000695270	_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|Variant_summary:_The_BRCA2_c.9770_9773delAAGA_(p.Lys3257Argfs)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.9924C>G/p.Tyr3308X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_1/121392_control_chromosomes_at_a_frequency_of_0.0000082,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._In_addition,_one_clinical_diagnostic_laboratory_classified_this_variant_as_pathogenic._The_variant_of_interest_has_not,_to_our_knowledge,_been_reported_in_affected_individuals_via_publications_and/or_reputable_databases/clinical_diagnostic_laboratories:_nor_evaluated_for_functional_impact_by_in_vivo/vitro_studies._Taken_together,_this_variant_is_classified_as_pathogenic.
NM_002528.6:c.819del	NTHL1	frameshift_variant	100838	1	NA	NA	-	-	-	-	545891	536452	not_provided	-	MedGen:CN517202	-	NC_000016.9:g.2090045del	_single_submitter	Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	NTHL1:4913	SO:0001589|frameshift_variant	1	1173366565	-	GeneDx	Likely_pathogenic	2018-03-23	2019-01-29	_single_submitter	germline	SCV000779226	not_provided	This_deletion_of_one_nucleotide_in_NTHL1_is_denoted_c.819delG_at_the_cDNA_level_and_p.Glu273AspfsX68_(E273DfsX68)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GGGA[delG]CTGT._The_deletion_causes_a_frameshift_which_changes_a_Glutamic_Acid_to_an_Aspartic_Acid_at_codon_273,_and_creates_a_premature_stop_codon_at_position_68_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_as_the_last_40_amino_acids_are_lost_and_replaced_with_67_incorrect_amino_acids._The_disrupted_region_at_the_end_of_the_gene_contains_four_metal-binding_residues_(Uniprot)._Based_on_currently_available_evidence,_we_consider_this_deletion_to_be_a_likely_pathogenic_variant.
NM_024675.3:c.3549C>G	PALB2	stop_gained	102712	3	NA	NA	5&5&5&5	0&0&2&1	rs118203998	Fanconi anemia, complementation group N&Pancreatic cancer 3&Hereditary cancer-predisposing syndrome&not provided	1245	16284	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_N|Breast_cancer,_susceptibility_to|not_specified|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1835817,OMIM:610832|MedGen:C3469522|MedGen:CN169374|MedGen:CN517202	-	NC_000016.9:g.23614792G>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:154899|OMIM_Allelic_Variant:610355.0003	-	PALB2:79728	SO:0001587|nonsense	1	118203998	-	PALB2_database|OMIM|OMIM|Invitae|Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|Counsyl|ITMI|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|GeneDx|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|GeneKor_MSA	Pathogenic|Pathogenic|risk_factor|Pathogenic|Likely_pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-10-18|2007-02-01|2007-02-01|2018-12-28|2015-06-01|2015-11-13|2013-09-19|2018-09-11|2015-11-20|2016-05-02|2018-12-11|2017-05-09|2018-08-01	2013-09-12|2012-04-17|2012-04-17|2019-03-28|2015-08-13|2017-06-22|2014-05-29|2020-02-26|2016-03-03|2017-10-26|2019-01-29|2018-10-10|2018-08-08	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000148582|SCV000021454|SCV000021455|SCV000253945|SCV000267976|SCV000677737|SCV000085940|SCV000183885|SCV000266110|SCV000686050|SCV000211538|SCV000604598|SCV000821759	Pancreatic_cancer_3|Fanconi_anemia,_complementation_group_N|Breast_cancer,_susceptibility_to|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|not_specified|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided	|||This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_PALB2_gene_(p.Tyr1183*)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_delete_the_last_4_amino_acids_of_the_PALB2_protein._This_variant_is_present_in_population_databases_(rs118203998,_ExAC_0.003%)._This_variant_has_been_observed_in_individuals_affected_with_breast,_ovarian_and_pancreatic_cancer,_and_Fanconi_anemia_(PMID:_17200668,_26315354,_17200671,_21365267,_22241545)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_1245)._Experimental_studies_have_shown_that_this_variant_prevents_closure_of_the_WD40_ring_structure_and_destabilizes_the_PALB2_protein_in_cell_culture_(PMID:_19609323)._In_addition,_while_truncating_mutations_close_to_the_end_of_a_proteinÂ¬â€ are_generally_expected_to_escape_nonsense-mediated_RNA_decay,_there_was_no_detectable_PALB2_protein_in_lymphoblastoid_cells_from_two_individuals_carrying_this_variant,_indicating_that_the_mutation_results_in_a_null_allele_(PMID:_17200671)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification:Well-characterized_mutation_at_same_position|||This_pathogenic_variant_is_denoted_PALB2_c.3549C>G_at_the_cDNA_level_and_p.Tyr1183Ter_(Y1183X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._This_variant_and_a_different_nucleotide_substitution_at_the_same_position,_c.3549C>A,_resulting_in_the_same_nonsense_variant_at_the_protein_level,_have_been_reported_in_multiple_individuals_with_a_personal_and/or_family_history_of_melanoma,_breast,_and_other_cancers,_and_was_observed_in_the_compound_heterozygous_state_with_other_truncating_PALB2_variants_in_two_individuals_with_Fanconi_Anemia_(Rahman_2007,_Reid_2007,_Ding_2011,_Antoniou_2014,_Thompson_2015)._We_consider_this_variant_to_be_pathogenic.|The_PALB2_c.3549C>G:p.Tyr1183Ter_variant_has_been_described_in_individuals_and_families_affected_with_breast_cancer_and_Fanconi_anemia_(Rahman_2007,_Reid_2007,_Tischkowitz_2012)._This_variant_removes_four_amino_acids_thought_to_be_critical_in_the_protein_structure,_which_may_destabilize_the_protein_(Oliver_2009)._In_support_of_this_theory,_cells_derived_from_individuals_with_this_variant_do_not_produce_PALB2_protein_(Reid_2007)._The_variant_is_listed_in_the_ClinVar_database_(Variation_ID:_1245)_and_the_dbSNP_variant_database_(rs118203998)_with_an_allele_frequency_of_0.001625_percent_in_the_Genome_Aggregation_Database._Considering_available_information,_this_variant_is_classified_as_pathogenic._Pathogenic_PALB2_variants_increase_susceptibility_to_breast_and_pancreatic_cancer_(OMIM#601355)._References:_Oliver_AW_et_al._Structural_basis_for_recruitment_of_BRCA2_by_PALB2._EMBO_Rep._2009_Sep:10(9):990-6._Rahman_N_et_al._PALB2,_which_encodes_a_BRCA2-interacting_protein,_is_a_breast_cancer_susceptibility_gene._Nat_Genet._2007_Feb:39(2):165-7._Reid_S_et_al._Biallelic_mutations_in_PALB2_cause_Fanconi_anemia_subtype_FA-N_and_predispose_to_childhood_cancer._Nat_Genet._2007_Feb:39(2):162-4._Tischkowitz_M_et_al._Rare_germline_mutations_in_PALB2_and_breast_cancer_risk:_a_population-based_study._Hum_Mutat._2012_Apr:33(4):674-80.|
NM_024675.3:c.3549C>A	PALB2	stop_gained	102712	1	NA	NA	5&5&5	1&1&1	rs118203998	Hereditary cancer-predisposing syndrome&Familial cancer of breast&not provided	128144	133601	_complementation_group_N|Pancreatic_cancer_3|not_provided	-	Human_Phenotype_Ontology:HP:0002575,MedGen:C1861028,OMIM:189960|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1835817,OMIM:610832|MedGen:C3150547,OMIM:613348|MedGen:CN517202	-	NC_000016.9:g.23614792G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:173186	-	PALB2:79728	SO:0001587|nonsense	1	118203998	-	Ambry_Genetics|Color|Invitae|Counsyl|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-03-06|2015-10-16|2018-12-27|2016-09-14|2019-01-14|2016-01-22|2018-02-01|2017-05-18|2016-07-15|2018-10-31	2020-02-26|2017-01-26|2019-03-28|2016-11-23|2019-01-29|2018-08-31|2018-10-10|2017-05-23|2018-01-25|2018-11-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|unknown|germline|unknown	SCV000172793|SCV000537656|SCV000253944|SCV000489276|SCV000150017|SCV000601789|SCV000884280|SCV000611292|SCV000699600|SCV000894073	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_provided|not_provided|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_N/Pancreatic_cancer_3/Tracheoesophageal_fistula|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_N/Pancreatic_cancer_3	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification||This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_last_exon_of_the_PALB2_mRNA_at_codon_1183_(p.Tyr1183*)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_create_a_truncated_PALB2_protein._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_and_Fanconi_anemia_(PMID:_17200671,_20927582,_21165770,_21365267,_26283626,_26296701)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128144)._An_experimental_study_has_shown_that_patient-derived_lymphoblastoid_cells_carrying_this_variant_do_not_express_PALB2_protein,_which_suggests_that_this_variant_results_in_a_null_allele_(PMID:_17200671)._In_addition,_X-ray_crystallography_analysis_of_the_PALB2_protein_suggests_that_this_variant_will_destabilize_the_PALB2_protein,_leading_to_its_degradation_(PMID:_19609323)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_PALB2_c.3549C>A_at_the_cDNA_level_and_p.Tyr1183Ter_(Y1183X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAA)_and_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._Both_this_variant_and_PALB2_c.3549C>G,_which_also_results_in_Tyr1183Ter,_have_been_reported_in_multiple_individuals_with_female_breast_cancer,_ovarian_cancer,_melanoma,_or_male_breast_cancer_(Rahman_2007,_Ding_2011,_Hofstatter_2011,_Antoniou_2014,_Ellingson_2015,_Ramus_2015)._PALB2_Tyr1183Ter_has_also_been_seen_in_the_compound_heterozygous_state_in_two_individuals_with_Fanconi_Anemia_(Reid_2007)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||The_PALB2_c.3549C>A:_p.Tyr1183Ter_variant_(rs118203998)_is_described_in_individuals_and_families_affected_with_breast_cancer,_ovarian_cancer_and_pancreatic_cancer:_and_in_Fanconi_anemia_when_paired_with_another_pathogenic_variant_on_the_opposite_chromosome_(Hoffstatter_2011,_Reid_2007,_Susswein_2016)._This_variant_removes_four_amino_acids_thought_to_be_critical_in_the_protein_structure,_which_may_destabilize_the_protein_(Oliver_2009)._In_support_of_this_theory,_cells_derived_from_individuals_harboring_this_variant_and_another_truncation_variant_on_the_opposite_chromosome_do_not_produce_PALB2_protein_(Reid_2007)._The_variant_is_listed_in_the_ClinVar_database_(Variation_ID:_128144)._The_variant_is_also_listed_in_the_Genome_Aggregation_Database_in_1_out_of_246208_alleles._Considering_available_information,_this_variant_is_classified_as_pathogenic._Pathogenic_PALB2_variants_increase_susceptibility_to_breast_and_pancreatic_cancer_(OMIM#601355)._References:_Hofstatter_EW_et_al._PALB2_mutations_in_familial_breast_and_pancreatic_cancer._Fam_Cancer._2011_Jun:10(2):225-31._Oliver_AW_et_al._Structural_basis_for_recruitment_of_BRCA2_by_PALB2._EMBO_Rep._2009_Sep:10(9):990-6._Reid_S_et_al._Biallelic_mutations_in_PALB2_cause_Fanconi_anemia_subtype_FA-N_and_predispose_to_childhood_cancer._Nat_Genet._2007_Feb:39(2):162-4._Susswein_LR_et_al._Pathogenic_and_likely_pathogenic_variant_prevalence_among_the_first_10,000_patients_referred_for_next-generation_cancer_panel_testing._Genet_Med._2016_Aug:18(8):823-32.||Variant_summary:_The_PALB2_c.3549C>A_(p.Tyr1183X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_PALB2_protein,_which_are_commonly_known_mechanisms_for_disease._Remove_of_the_last_four_amino_acids_in_WD40_domain_(partner_and_localiser_of_BRCA2)_were_shown_to_destablize_the_protein_and_lead_to_loss_of_expression_(Reid_2007,_Oliver_2009)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_has_been_reported_in_numerous_patients_with_HBOC_or_Fanconi_Anemia_and_is_absent_in_128476_control_chromosomes._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|
NM_024675.3:c.3426_3429del	PALB2	frameshift_variant	102738	1	NA	NA	-	-	-	-	185799	184156	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23614912_23614915AAGT[1]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Microsatellite	SO:0000289	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	587776424	-	SNPedia|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Invitae	pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic	0000-00-00|2016-11-10|2017-06-19|2016-12-15|2018-10-31	2014-08-20|2019-01-29|2017-08-01|2020-02-26|2019-03-28	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000188560|SCV000568196|SCV000601784|SCV000216007|SCV000633431	not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Converted_during_submission_to_Pathogenic.|This_deletion_of_four_nucleotides_in_PALB2_is_denoted_c.3426_3429delACTT_at_the_cDNA_level_and_p.Leu1142PhefsX20_(L1142FfsX20)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ACTT[ACTT]CTCG._The_deletion_causes_a_frameshift_which_changes_a_Leucine_to_a_Phenylalanine_at_codon_1142,_and_creates_a_premature_stop_codon_at_position_20_of_the_new_reading_frame._Even_though_this_frameshift_occurs_in_the_last_exon_of_the_gene,_and_nonsense-mediated_decay_is_not_expected_to_occur,_it_is_significant_since_the_last_45_amino_acids_are_replaced_with_19_incorrect_amino_acids._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._PALB2_Leu1142PhefsX20,_also_published_as_PALB2_c.3423_3426del,_has_been_observed_in_at_least_one_individual_with_a_personal_and/or_family_history_of_breast_cancer_(Antoniou_2014)._Based_on_the_currently_available_information,_we_consider_this_deletion_to_be_a_likely_pathogenic_variant.||Other_acmg-defined_mutation_(i.e._initiation_codon_or_gross_deletion):Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_deletes_4_nucleotides_from_exon_13_of_the_PALB2_mRNA_(c.3426_3429delACTT),_causing_a_frameshift_at_codon_1142._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_PALB2_mRNA_(p.Leu1142Phefs*20)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_45_amino_acid_residues_of_the_PALB2_protein._This_variant_has_been_reported_in_the_literature_in_an_individual_with_a_personal_and/or_family_history_of_breast_cancer_(PMID:_25099575)._This_variant_is_also_known_as_c.3423_3426del_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_185799)._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_25099575,_17200668)._This_frameshift_is_located_within_the_WD40-repeat_domain_of_the_PALB2_protein,_which_is_involved_in_BRCA2_binding_(PMID:_19609323)._This_variant_disrupts_amino_acid_residues_expected_to_be_essential_for_PALB2_protein_function,_since_a_downstream_truncation_(p.Tyr1183*),_that_only_deletes_the_final_4_amino_acid_residues_results_in_a_nonfunctional_PALB2_protein_(PMID:_17200671)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_024675.3:c.3362del	PALB2	frameshift_variant	102684	1	NA	NA	-	-	-	-	126739	132249	Ovarian_Neoplasms|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MeSH:D010051,MedGen:CN236629|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23614980del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2841616	-	PALB2:79728	SO:0001589|frameshift_variant	1	515726117	-	Invitae|Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-19|2015-06-01|2019-01-18|2015-01-20|2018-10-30|2017-11-24|2018-12-01	2019-03-28|2015-08-13|2020-02-26|2017-12-21|2019-01-29|2018-08-31|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline	SCV000219007|SCV000267974|SCV000185631|SCV000690914|SCV000292661|SCV000888374|SCV000924014	Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Ovarian_Neoplasms	This_sequence_change_deletes_1_nucleotide_from_exon_13_of_the_PALB2_gene_(c.3362delG),_causing_a_frameshift_at_codon_1121_and_creating_a_premature_translational_stop_signal_in_the_last_exon_of_the_PALB2_mRNA_(p.Gly1121Valfs*3)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_a_protein_domain_important_for_PALB2_protein_function_(PMID:_19423707)._This_variant_is_present_in_population_databases_(rs515726117,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_and_families_affected_with_breast_cancer_(PMID:_23935836,_24136930,_24549055,_25099575,_26283626,_Invitae)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126739)._This_variant_disrupts_the_WD40-repeat_domain_of_the_PALB2_protein,_which_is_involved_in_BRCA2_binding_(PMID:_16793542,_19423707)._Several_downstream_truncating_variants,_including_p.Leu1143Thrfs*14_and_p.Tyr1183*,_have_been_observed_in_individuals_and_families_affected_with_breast,_ovarian,_and_pancreatic_cancer,_and_Fanconi_anemia_(PMID:_17200668,_17200671,_21365267,_25099575,_25452441,_26315354,_Invitae)._In_addition,_the_truncating_variant_p.Tyr1183*_that_only_deletes_the_final_4_amino_acid_residues_results_in_a_nonfunctional_PALB2_protein_(PMID:_17200671),_further_supporting_the_functional_importance_of_the_last_exon._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic_(PMID:_17200668,_24136930,_25099575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_deletion_of_one_nucleotide_in_PALB2_is_denoted_c.3362delG_at_the_cDNA_level_and_p.Gly1121ValfsX3_(G1121VfsX3)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_GAAG[delG]TGAC._The_deletion_causes_a_frameshift,_which_changes_a_Glycine_to_a_Valine_at_codon_1121,_and_creates_a_premature_stop_codon_at_position_3_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation._PALB2_c.3362delG_has_been_reported_in_individuals_with_breast_and_pancreatic_cancer,_some_of_whom_also_reported_a_family_history_of_breast_and/or_pancreatic_cancer_(Blanco_2013,_Janatova_2013,_Antoniou_2014,_Thompson_2015,_Johns_2017)._The_disrupted_region_at_the_end_of_the_gene_encodes_the_seventh_WD_repeat_as_well_as_a_portion_of_the_sixth_WD_repeat,_a_region_that_interacts_with_RAD51,_POLH,_and_BRCA2,_and_a_region_required_for_POLH_DNA_synthesis_stimulation_(Buisson_2014,_UniProt)._Furthermore,_truncating_pathogenic_variants_downstream_of_PALB2_c.3362delG_have_been_identified_in_other_breast/pancreatic_cancer_families_and_in_patients_with_Fanconi_Anemia_(Rahman_2007,_Reid_2007,_Peterlongo_2011)._We_consider_this_variant_to_be_pathogenic.||
NM_024675.3:c.3350+4A>G	PALB2	splice_region_variant,intron_variant	102678	1	NA	NA	-	-	-	-	126737	132247	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23619181T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001627|intron_variant	1	180177136	-	PALB2_database|Invitae|Counsyl|Ambry_Genetics|Color|GeneDx	Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2012-04-08|2018-12-16|2017-04-25|2018-06-12|2018-06-21|2015-05-05	2013-09-12|2019-03-28|2017-06-22|2020-02-26|2018-11-06|2017-07-13	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline	SCV000148568|SCV000550742|SCV000677779|SCV000274431|SCV000686032|SCV000516977	_complementation_group_N|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|This_sequence_change_falls_in_intron_12_of_the_PALB2_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_PALB2_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_an_individual_affected_with_breast_cancer_(PMID:Â¬â€ 26976419Â¬â€ )_and_was_also_observed_on_the_opposite_chromosome_(in_trans)_from_a_pathogenic_variant_in_an_individual_affected_with_Fanconi_anemia,_type_N_(PMID:Â¬â€ 17200671)._This_finding_is_consistent_with_autosomal_recessive_inheritance,_and_suggests_that_this_variant_contributes_to_disease._This_variant_is_also_known_asÂ¬â€ IVS12+4A>G_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126737)._Experimental_studies_performed_on_patient_cellsÂ¬â€ _demonstrate_a_decrease_in_DNA_damage_repair_response_to_ionizing_radiation_compared_to_control_cells,_as_well_as_structural_nuclear_abnormalities_and_disrupted_spindle_assembly_checkpoint_(SAC)_activity,_suggesting_that_this_variant_alters_a_critical_step_of_the_cell_cycle_(PMID:Â¬â€ 23934222,Â¬â€ 17200671)._Nucleotide_substitutions_within_the_consensus_splice_site_are_a_relatively_common_cause_of_aberrant_splicing_(PMID:_17576681,_9536098)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_create_or_strengthen_a_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Functionally-validated_splicing_mutation:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_variant_is_denoted_PALB2_c.3350+4A>G_or_IVS12+4A>G_and_consists_of_a_A>G_nucleotide_substitution_at_the_+4_position_of_intron_12_of_the_PALB2_gene._Multiple_in_silico_models_predict_this_variant_to_create_a_new_cryptic_splice_donor_site_and_to_possibly_cause_abnormal_gene_splicing._This_variant_was_observed_in_the_compound_heterozygous_state_in_a_child_with_Fanconi_Anemia,_whose_fibroblasts_showed_absence_of_PALB2_protein_on_immunoblotting_and_blood_lymphocytes_demonstrated_impaired_double_strand_break_repair_in_an_irradiation_assay_(Reid_2007,_Rube_2010)._The_adenine_(A)_nucleotide_that_is_altered_is_conserved_across_species._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.
NM_000546.5:c.818G>A	TP53	missense_variant	102572	3	NA	NA	5&5&5&5	0&0&1&1	rs28934576	Li-Fraumeni syndrome 1&Thyroid cancer, anaplastic&Hereditary cancer-predisposing syndrome&not provided	12366	27405	Li-Fraumeni_syndrome_1|Hepatocellular_carcinoma|Neoplasm|Osteosarcoma|Medulloblastoma|Acute_myeloid_leukemia|Chronic_lymphocytic_leukemia|Pancreatic_adenocarcinoma|Transitional_cell_carcinoma_of_the_bladder|Adrenocortical_carcinoma|Multiple_myeloma|Brainstem_glioma|Carcinoma_of_esophagus|Anaplastic_thyroid_carcinoma|Lung_adenocarcinoma|Small_cell_lung_cancer|Squamous_cell_lung_carcinoma|Neoplasm_of_brain|Neoplasm_of_the_breast|Neoplasm_of_the_large_intestine|Choroid_plexus_papilloma|Squamous_cell_carcinoma_of_the_head_and_neck|Malignant_melanoma_of_skin|Carcinoma_of_pancreas|Glioblastoma|Ovarian_Neoplasms|Familial_cancer_of_breast|Adenocarcinoma_of_prostate|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Ovarian_Serous_Cystadenocarcinoma|Uterine_Carcinosarcoma|Adrenocortical_carcinoma,_hereditary|Glioma_susceptibility_1|Nasopharyngeal_carcinoma|Basal_cell_carcinoma,_susceptibility_to,_7|not_specified|not_provided	-	Gene:553989,MedGen:C1835398,OMIM:151623|Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0002664,MeSH:D009369,MedGen:C0027651,SNOMED_CT:108369006|Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007|Human_Phenotype_Ontology:HP:0005550,MeSH:D015451,MedGen:C0023434,OMIM:151400,Orphanet:ORPHA67038,SNOMED_CT:277473004,SNOMED_CT:51092000|Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0006744,MeSH:D018268,MedGen:C0206686,Orphanet:ORPHA1501|Human_Phenotype_Ontology:HP:0006775,MeSH:D009101,MedGen:C0026764,OMIM:254500,Orphanet:ORPHA29073,SNOMED_CT:109989006,SNOMED_CT:55921005|Human_Phenotype_Ontology:HP:0010796,MedGen:C0677865|Human_Phenotype_Ontology:HP:0011459,MedGen:C0152018,Orphanet:ORPHA70482|Human_Phenotype_Ontology:HP:0011779,MedGen:C0238461,Orphanet:ORPHA142|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0030357,MeSH:D055752,MedGen:C0149925,OMIM:182280,Orphanet:ORPHA70573|Human_Phenotype_Ontology:HP:0030359,MedGen:C0149782|Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100834,MeSH:D015179,MedGen:C0009404,SNOMED_CT:126837005|Human_Phenotype_Ontology:HP:0200022,MedGen:C0205770,OMIM:260500,Orphanet:ORPHA2807,SNOMED_CT:18021007|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:C562463,MedGen:C0235974,OMIM:260350,Orphanet:ORPHA217074,SNOMED_CT:372142002|MeSH:D005909,MedGen:C0017636,Orphanet:ORPHA360,SNOMED_CT:63634009|MeSH:D010051,MedGen:CN236629|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0007112|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0279663|MedGen:C0280630,Orphanet:ORPHA213610|MedGen:C1859972,OMIM:202300|MedGen:C2750850,OMIM:137800,Orphanet:ORPHA301|MedGen:C2931822,OMIM:607107,Orphanet:ORPHA150|MedGen:C3553606,OMIM:614740|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.7577120C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:191170.0020|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:14505|UniProtKB_(protein):P04637#VAR_005995|ClinGen_TP53_Variant_Curation_Expert_Panel,ClinGen:8d32df42-16ac-41f2-9bf1-e2b9ce206190	-	TP53:7157	SO:0001583|missense_variant	3	28934576	-	OMIM|Pathway_Genomics|Counsyl|OMIM|Ambry_Genetics|GeneKor_MSA|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|ClinGen_TP53_Variant_Curation_Expert_Panel,ClinGen|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	1993-01-01|2014-07-24|2017-02-22|1993-01-01|2018-08-17|2018-08-01|2018-07-19|2017-04-26|0000-00-00|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2015-07-14|2016-05-31|2016-05-31|2016-05-31|2019-01-05|2017-02-09|2018-07-02|2019-08-28|2017-02-28|2017-05-18|2018-12-01	2013-04-09|2014-08-08|2017-06-22|2013-04-09|2020-02-26|2018-08-08|2019-01-29|2017-08-01|2017-10-31|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2019-03-28|2018-01-25|2018-08-20|2019-09-23|2017-06-30|2017-05-23|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown|somatic|germline|germline|germline|germline|unknown|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|germline|germline|unknown|germline|germline|unknown|somatic	SCV000033410|SCV000190004|SCV000677727|SCV000033411|SCV000186052|SCV000821786|SCV000149647|SCV000602280|SCV000692068|SCV000504676|SCV000504679|SCV000504662|SCV000504665|SCV000504685|SCV000504682|SCV000504668|SCV000504674|SCV000504671|SCV000504677|SCV000504680|SCV000504663|SCV000504683|SCV000504666|SCV000504669|SCV000504672|SCV000504675|SCV000504678|SCV000504661|SCV000504681|SCV000504664|SCV000504684|SCV000504673|SCV000504667|SCV000504670|SCV000545317|SCV000697450|SCV000839110|SCV001142550|SCV000605425|SCV000611327|SCV000923913	Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Anaplastic_thyroid_carcinoma|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Squamous_cell_lung_carcinoma|Adenocarcinoma_of_stomach|Squamous_cell_carcinoma_of_the_head_and_neck|Adenocarcinoma_of_prostate|Uterine_Carcinosarcoma|Chronic_lymphocytic_leukemia|Neoplasm_of_brain|Adrenocortical_carcinoma|Multiple_myeloma|Ovarian_Serous_Cystadenocarcinoma|Transitional_cell_carcinoma_of_the_bladder|Malignant_neoplasm_of_body_of_uterus|Lung_adenocarcinoma|Malignant_melanoma_of_skin|Brainstem_glioma|Carcinoma_of_esophagus|Glioblastoma|Small_cell_lung_cancer|Pancreatic_adenocarcinoma|Medulloblastoma|Acute_myeloid_leukemia|Neoplasm|Neoplasm_of_the_breast|Hepatocellular_carcinoma|Neoplasm_of_the_large_intestine|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|not_specified|Adrenocortical_carcinoma,_hereditary/Familial_cancer_of_breast/Glioma_susceptibility_1/Osteosarcoma/Li-Fraumeni_syndrome_1/Nasopharyngeal_carcinoma/Carcinoma_of_pancreas/Choroid_plexus_papilloma/Carcinoma_of_colon/Basal_cell_carcinoma,_susceptibility_to,_7/Hepatocellular_carcinoma|Ovarian_Neoplasms	||||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Well-characterized_mutation_at_same_position||This_pathogenic_variant_is_denoted_TP53_c.818G>A_at_the_cDNA_level_and_p.Arg273His_(R273H)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Histidine_(CGT>CAT)._TP53_Arg273His_has_been_reported_in_several_individuals_meeting_classic_Li-Fraumeni_or_Chompret_criteria,_occurring_de_novo_in_at_least_one_individual_and_segregating_with_disease_in_affected_families_(Malkin_1992,_Flaman_1995,_Varley_1997,_Chompret_2000,_Cavalier_2005,_Wong_2006,_Bemis_2007,_Ruijs_2010,_Sugawara_2011,_Wasserman_2015,_Schlegelberger_2015,_Park_2016)._This_variant_is_reported_as_having_non-functional_transactivation_in_the_International_Agency_for_Research_on_Cancer_TP53_database_based_on_functional_assays_by_Kato_et_al._(2003)._Additionally,_other_functional_studies_have_also_demonstrated_that_TP53_Arg273His_severely_impacts_growth_suppression,_transactivation,_and_DNA_binding,_and_exerts_a_dominant-negative_effect_over_wild-type_p53_(Dong_2007,_Malcikova_2010,_Monti_2011,_Li_2014,_Wasserman_2015)._TP53_Arg273His_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_DNA_binding_domain_(Bode_2004)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||||||||||||||||||||||||||||This_sequence_change_replaces_arginine_with_histidine_at_codon_273_of_the_TP53_protein_(p.Arg273His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs28934576,_ExAC_0.05%)._This_variant_has_been_observed_in_numerous_individuals_and_families_with_Li-Fraumeni_syndrome_(LFS)_or_Li-Fraumeni-associated_cancers,_and_has_been_shown_to_segregate_with_disease_in_affected_families_(PMID:_9242456,_21484931,_17540308,_1565144,_20693561,_21552135)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12366)._This_variant_is_located_in_the_DNA-binding_domain_of_the_TP53_protein_and_is_defined_as_a_contact_mutation_that_eliminates_an_essential_DNA_contact_(PMID:_20516128)._A_mutant_mouse_model_for_this_variant_develops_a_variety_of_tumors_and_carcinomas_by_recapitulating_LFS_(PMID:_15607980)._In_addition,_experimental_studies_have_shown_that_this_variant_disrupts_transcriptional_activity_in_yeast-based_assays_(PMID:_12826609)_and_enhances_cell_proliferation,_invasion,_migration,_and_drug_resistance_in_vitro_(PMID:_17636407,_24677579)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_TP53_c.818G>A_(p.Arg273His)_variant_involves_the_alteration_of_a_conserved_nucleotide._5/5_in_silico_tools_predict_a_damaging_outcome_for_this_variant._This_variant_was_found_in_3/114148_control_chromosomes_at_a_frequency_of_0.0000263,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_TP53_variant_(0.0000398)._The_variant_has_been_reported_in_numerous_affected_individuals_in_the_literature_and_the_codon_location_is_a_known_hotspot_mutation_occurring_as_a_frequent_mutation_in_affected_individuals._Functional_studies_report_a_dominant_negative_affect_of_the_variant._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||This_variant_is_within_a_codon_that_is_an_established_hotspot_in_the_TP53_gene_(PM1:_PMID:_2046748)._This_variant_has_a_BayesDel_score_>_0.16_and_Align_GVGD_(Zebrafish)_is_Class_15_or_higher_(PP3)._Transactivation_assays_show_a_low_functioning_allele_according_to_Kato,_et_al._and_there_is_evidence_of_a_dominant_negative_effect_and_loss_of_function_according_to_Giacomelli,_et_al._(PS3:_PMID:_12826609,_30224644)._This_variant_has_been_reported_in_at_least_2_probands_meeting_classic_Li-Fraumeni_syndrome_criteria_and_4_probands_meeting_Chompret_criteria_(PS4:_PMID:_16401470,_15390294,_9242456,_10864200,_1565144,_7732013)._Additionally,_there_is_a_de_novo_observation_of_a_proband_with_breast_cancer_at_age_29_with_parental_confirmation_(PS2:_PMID:_12672316)._In_summary,_TP53_c.818G>A:_p.Arg273His_meets_criteria_to_be_classified_as_pathogenic_for_Li-Fraumeni_syndrome._ACMG/AMP_criteria_applied,_as_specified_by_the_TP53_Variant_Curation_Expert_Panel:_PM1,_PP3,_PS3,_PS4,_PS2.|||
NM_000546.5:c.817C>T	TP53	missense_variant	102466	1	15416	0	5&5&5	1&0&1	rs121913343	Hereditary cancer-predisposing syndrome&Li-Fraumeni syndrome 1&not provided	43594	52763	Li-Fraumeni_syndrome_1|Hepatocellular_carcinoma|Neoplasm|Acute_myeloid_leukemia|Malignant_tumor_of_prostate|Neoplasm_of_the_breast|Ovarian_Neoplasms|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|not_provided	-	Gene:553989,MedGen:C1835398,OMIM:151623|Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0002664,MeSH:D009369,MedGen:C0027651,SNOMED_CT:108369006|Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D010051,MedGen:CN236629|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:CN517202	-	NC_000017.10:g.7577121G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P04637#VAR_005993	-	TP53:7157	SO:0001583|missense_variant	3	121913343	-	Ambry_Genetics|Pathway_Genomics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Science_for_Life_laboratory,__Karolinska_Institutet|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Unknown|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-10-15|2014-07-24|2017-07-06|0000-00-00|2010-08-05|2019-01-05|2018-07-24|2017-07-14|0000-00-00|2016-03-10|2015-07-14|2015-07-14|2014-10-02|2018-12-01	2020-02-26|2014-08-08|2018-06-14|2011-11-10|2019-03-21|2019-03-28|2019-01-29|2017-08-01|2017-10-31|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2019-02-22	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|somatic|germline|germline|germline|germline|unknown|somatic|somatic|somatic|somatic|somatic	SCV000187024|SCV000189996|SCV000840079|SCV000088693|SCV000060191|SCV000261042|SCV000211760|SCV000602279|SCV000692069|SCV000504688|SCV000504689|SCV000504686|SCV000504687|SCV000924042	Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Malignant_tumor_of_prostate|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|not_provided|not_provided|not_provided|Neoplasm_of_the_breast|Neoplasm|Hepatocellular_carcinoma|Acute_myeloid_leukemia|Ovarian_Neoplasms	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Well-characterized_mutation_at_same_position:Deficient_protein_function_in_appropriate_functional_assay(s):Structural_Evidence||This_c.817C>T_(p.Arg273Cys)_variant_has_previously_been_detected_in_multiple_patients_with_Li-Fraumeni_syndrome_or_Li-Fraumeni_related_cancers_[PMID_8479749,_21535297,_21552135]._Functional_data_showed_that_this_variant_leads_to_a_severe_deficiency_of_TP53_activity_[PMID_21343334,_24677579,_17606709]._The_amino_acid_position_273_of_the_TP53_protein_is_a_hot_spot_for_pathogenic_variants_causing_Li-Fraumeni_syndrome:_additional_variants_affecting_the_same_amino_acid_at_position_273_have_been_reported_(p.Arg273Gly_and_p.Arg273His)._This_variant_was_observed_in_three_heterozygous_individuals_in_the_gnomAD_database_(http://gnomad.broadinstitute.org/variant/17-7577121-G-A)._This_variant_is_highly_conserved_in_mammals_and_computer-based_algorithms_predict_this_p.Arg273Cys_change_to_be_deleterious._It_is_thus_classified_as_pathogenic._The_next_generation_sequencing_(NGS)_reads_indicated_a_skewed_mutant_to_reference_allele_ratio_(about_25%_mutant),_which_was_confirmed_by_Sanger_sequencing,_indicating_mosaicism_in_this_sample._Mosaic_somatic_pathogenic_variants_in_cancer_related_genes,_including_TP53,_have_been_reported_in_DNA_extracted_from_blood_samples_in_aging_populations_[PMID_25426837,_25426838,_25326804]._While_an_increase_risk_for_hematologic_cancer_was_reported_in_these_studies,_the_clinical_significance_of_these_somatic_variants_in_blood_is_currently_unclear._While_this_variant_is_a_known_disease-causing_variant_observed_in_patients_with_Li-Fraumeni_syndrome,_considering_the_age_of_this_individual,_this_finding_may_result_from_a_somatic_event_observed_in_aging_process._Studies_in_another_tissue_sample_such_as_a_skin_biopsy_is_thus_suggested_to_help_clarify_the_clinical_significance_of_this_change.|Converted_during_submission_to_Uncertain_significance.|The_Arg273Cys_variant_has_been_reported_in_the_literature_in_one_individual_with_clinical_features_consistent_with_Li-Fraumeni_Syndrome_(LFS,_Gonzales_2009)._Th_is_individual_had_cancer_as_a_teenager_followed_by_two_additional_cancers_in_the_ir_twenties._Two_other_variants_at_the_same_amino_acid_position_(Arg273His_and_A_rg273Leu)_have_also_been_identified_in_individuals_with_features_of_LFS,_and_one_of_these_variants_was_shown_to_have_occurred_de_novo_in_a_proband_(Gonzalez_200_9)._The_Arg273Cys_variant_is_the_most_common_somatic_mutation_listed_in_the_Cata_logue_of_Somatic_Mutations_in_Cancer_(www.sanger.ac.uk/cosmic/)_and_this_change_is_found_in_tumors_throughout_the_body,_including_the_central_nervous_system_(10_tumors),_haematopoietic_and_lymphoid_tissue_(5),_bone_(3),_large_intestine_(2),_and_ovaries_(1)._Arg273_is_highly_conserved_across_divergent_species_and_three_bioinformatic_algorithms_predict_this_variant_to_affect_protein_function._Theref_ore,_this_variant_is_likely_to_be_pathogenic.|This_sequence_change_replaces_arginine_with_cysteine_at_codon_273_of_the_TP53_protein_(p.Arg273Cys)._The_arginine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_arginine_and_cysteine._This_variant_is_present_in_population_databases_(rs121913343,_ExAC_0.002%)._This_variant_has_been_observed_in_individuals_and_families_affected_with_Li-Fraumeni_syndrome_(LFS),_and_has_been_shown_to_segregate_with_disease_in_affected_familiesÂ¬â€ (PMID:_17606709,_8479749,_21535297,_21552135).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_43594)._Experimental_studies_have_shown_that_this_missense_change_disrupts_the_DNA-binding,_transcriptional_transactivation,_and_tumor_suppressor_activities_of_the_TP53_protein_(PMID:_20128691,_12826609,_24677579)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_variant_is_denoted_TP53_c.817C>T_at_the_cDNA_level,_p.Arg273Cys_(R273C)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Cysteine_(CGT>TGT)._This_variant_has_been_reported_in_multiple_individuals_meeting_Chompret_criteria_or_with_early-onset_Li-Fraumeni_related_cancers_(Eeles_1993,_Frebourg_1995,_Chompret_2000,_Nutting_2000,_Bougeard_2001,_Pepper_2003,_Gonzalez_2009,_Kim_2010,_Janavicius_2011,_Masciari_2011,_Park_2016,_Meiss_2018)._Multiple_functional_studies_have_found_this_variant_to_impact_cell_proliferation_and_apoptosis_as_well_as_binding_and_transactivation_of_known_TP53_response_elements_(Dearth_2007,_Malcikova_2010,_Monti_2011,_Li_2014)._Consistent_with_these_results,_this_variant_is_reported_as_having_non-functional_transactivation_in_the_International_Agency_for_Research_on_Cancer_TP53_database_based_on_functional_assays_by_Kato_et_al._(2003)._TP53_Arg273Cys_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_DNA_binding_domain_(Bode_2004)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.|||||||
NM_000546.5:c.743G>A	TP53	missense_variant	102740	2	NA	NA	5&5&5&5&5	0&0&1&1&1	rs11540652	Li-Fraumeni syndrome 1&Sarcoma&Li-Fraumeni syndrome 2&Li-Fraumeni syndrome&not provided	12356	27395	Li-Fraumeni_syndrome_1|Hepatocellular_carcinoma|Neoplasm|Lymphoma|Osteosarcoma|Medulloblastoma|Acute_myeloid_leukemia|Chronic_lymphocytic_leukemia|Pancreatic_adenocarcinoma|Squamous_cell_carcinoma_of_the_skin|Transitional_cell_carcinoma_of_the_bladder|Multiple_myeloma|Brainstem_glioma|Carcinoma_of_esophagus|Lung_adenocarcinoma|Small_cell_lung_cancer|Squamous_cell_lung_carcinoma|Neoplasm_of_brain|Neoplasm_of_the_breast|Sarcoma|Neoplasm_of_the_large_intestine|Choroid_plexus_papilloma|Squamous_cell_carcinoma_of_the_head_and_neck|Malignant_melanoma_of_skin|Carcinoma_of_pancreas|Glioblastoma|Myelodysplastic_syndrome|Ovarian_Neoplasms|Familial_cancer_of_breast|Adenocarcinoma_of_prostate|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Ovarian_Serous_Cystadenocarcinoma|Uterine_Carcinosarcoma|Malignant_Colorectal_Neoplasm|Adrenocortical_carcinoma,_hereditary|Glioma_susceptibility_1|Nasopharyngeal_carcinoma|Basal_cell_carcinoma,_susceptibility_to,_7|not_provided	-	Gene:553989,MedGen:C1835398,OMIM:151623|Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0002664,MeSH:D009369,MedGen:C0027651,SNOMED_CT:108369006|Human_Phenotype_Ontology:HP:0002665,MeSH:D008223,MedGen:C0024299,Orphanet:ORPHA223735|Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007|Human_Phenotype_Ontology:HP:0005550,MeSH:D015451,MedGen:C0023434,OMIM:151400,Orphanet:ORPHA67038,SNOMED_CT:277473004,SNOMED_CT:51092000|Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|Human_Phenotype_Ontology:HP:0006739,MedGen:C0553723|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0006775,MeSH:D009101,MedGen:C0026764,OMIM:254500,Orphanet:ORPHA29073,SNOMED_CT:109989006,SNOMED_CT:55921005|Human_Phenotype_Ontology:HP:0010796,MedGen:C0677865|Human_Phenotype_Ontology:HP:0011459,MedGen:C0152018,Orphanet:ORPHA70482|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0030357,MeSH:D055752,MedGen:C0149925,OMIM:182280,Orphanet:ORPHA70573|Human_Phenotype_Ontology:HP:0030359,MedGen:C0149782|Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100242,MedGen:C1261473|Human_Phenotype_Ontology:HP:0100834,MeSH:D015179,MedGen:C0009404,SNOMED_CT:126837005|Human_Phenotype_Ontology:HP:0200022,MedGen:C0205770,OMIM:260500,Orphanet:ORPHA2807,SNOMED_CT:18021007|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:C562463,MedGen:C0235974,OMIM:260350,Orphanet:ORPHA217074,SNOMED_CT:372142002|MeSH:D005909,MedGen:C0017636,Orphanet:ORPHA360,SNOMED_CT:63634009|MeSH:D009190,MedGen:C3463824,OMIM:614286,Orphanet:ORPHA52688|MeSH:D010051,MedGen:CN236629|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0007112|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0279663|MedGen:C0280630,Orphanet:ORPHA213610|MedGen:C0346629|MedGen:C1859972,OMIM:202300|MedGen:C2750850,OMIM:137800,Orphanet:ORPHA301|MedGen:C2931822,OMIM:607107,Orphanet:ORPHA150|MedGen:C3553606,OMIM:614740|MedGen:CN517202	-	NC_000017.10:g.7577538C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ClinGen:cf887752-8539-4177-a74d-dc5c8f8a36ed|OMIM_Allelic_Variant:191170.0010|UniProtKB_(protein):P04637#VAR_005983	-	TP53:7157	SO:0001583|missense_variant	19	11540652	-	OMIM|Pathway_Genomics|Donald_Williams_Parsons_Laboratory,Baylor_College_of_Medicine|Counsyl|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Color|GeneKor_MSA|CSER__CC_NCGL,_University_of_Washington|Invitae|Mendelics|ClinGen_TP53_Variant_Curation_Expert_Panel,ClinGen|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Xiao_lab,_Department_of_Pathology,_Memorial_Sloan_Kettering_Cancer_Center|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Genome_Sciences_Centre,British_Columbia_Cancer_Agency|Fulgent_Genetics,Fulgent_Genetics|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne|Xiao_lab,_Department_of_Pathology,_Memorial_Sloan_Kettering_Cancer_Center	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2000-05-15|2014-07-24|2012-12-27|2017-07-27|2018-09-07|2015-11-20|2015-04-14|2018-08-01|2014-06-01|2018-12-22|2018-07-02|2019-08-28|2018-10-05|2014-06-09|0000-00-00|2018-11-21|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2019-08-31|2016-05-31|2016-05-31|2015-07-14|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-04-12|2018-10-31|2018-12-01|2019-07-25	2013-04-09|2014-08-08|2016-08-18|2018-06-20|2020-02-26|2016-03-03|2017-10-26|2018-08-08|2014-08-28|2019-03-28|2018-08-20|2019-09-23|2019-01-29|2018-09-19|2017-10-31|2020-03-06|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2019-09-12|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2018-02-09|2018-11-14|2019-02-22|2019-07-25	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|maternal|unknown|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|unknown|germline|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|unknown|somatic|somatic	SCV000033397|SCV000190000|SCV000599966|SCV000785422|SCV000185472|SCV000266133|SCV000686766|SCV000821785|SCV000190659|SCV000253851|SCV000839112|SCV001142549|SCV000149645|SCV000232078|SCV000692073|SCV001134877|SCV000504702|SCV000504696|SCV000504716|SCV000504699|SCV000504705|SCV000504708|SCV000504717|SCV001132099|SCV000504711|SCV000504697|SCV000504694|SCV000504714|SCV000504703|SCV000504700|SCV000504709|SCV000504706|SCV000504712|SCV000504718|SCV000504695|SCV000504715|SCV000504698|SCV000504704|SCV000504707|SCV000504701|SCV000504713|SCV000504710|SCV000504693|SCV000693734|SCV000894154|SCV000923912|SCV000930032	Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Sarcoma|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|not_provided|not_provided|not_provided|not_provided|Acute_myeloid_leukemia|Neoplasm_of_the_breast|Small_cell_lung_cancer|Malignant_melanoma_of_skin|Ovarian_Serous_Cystadenocarcinoma|Neoplasm_of_the_large_intestine|Multiple_myeloma|Multiple_myeloma|Adenocarcinoma_of_prostate|Neoplasm_of_brain|Neoplasm|Medulloblastoma|Adenocarcinoma_of_stomach|Squamous_cell_carcinoma_of_the_skin|Uterine_Carcinosarcoma|Transitional_cell_carcinoma_of_the_bladder|Brainstem_glioma|Chronic_lymphocytic_leukemia|Carcinoma_of_esophagus|Malignant_neoplasm_of_body_of_uterus|Myelodysplastic_syndrome|Hepatocellular_carcinoma|Pancreatic_adenocarcinoma|Squamous_cell_lung_carcinoma|Squamous_cell_carcinoma_of_the_head_and_neck|Lung_adenocarcinoma|Glioblastoma|Malignant_Colorectal_Neoplasm|Adrenocortical_carcinoma,_hereditary/Familial_cancer_of_breast/Glioma_susceptibility_1/Osteosarcoma/Li-Fraumeni_syndrome_1/Nasopharyngeal_carcinoma/Carcinoma_of_pancreas/Choroid_plexus_papilloma/Carcinoma_of_colon/Basal_cell_carcinoma,_susceptibility_to,_7/Hepatocellular_carcinoma|Ovarian_Neoplasms|Lymphoma	||This_variant_has_been_previously_reported_as_disease-causing_and_was_found_once_in_our_study_maternally_inherited_in_a_2-year-old_female_with_neuroblastoma,_in_a_family_meeting_criteria_for_Li-Fraumeni_(history_of_early_breast,_brain_tumors,_rhabdomyosarcoma).||Confirmed_de_novo_alteration_in_the_setting_of_a_new_disease_(appropriate_phenotype)_in_the_family:Well-characterized_mutation_at_same_position:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification|||||This_sequence_change_replaces_arginine_with_glutamine_at_codon_248_of_the_TP53_protein_(p.Arg248Gln)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_glutamine._This_variant_is_present_in_population_databases_(rs11540652,_ExAC_0.02%)._This_variant_was_reported_in_multiple_individuals_and_families_affected_with_Li-Fraumeni_and_Li-Fraumeni-like_syndromes_(PMID:_1565143,_17606709,_21601526,_7887414,_21305319)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12356)._Experimental_studies_have_shown_that_this_missense_change_severely_affects_the_functional_activity_of_the_p53_protein,_abolishing_its_DNA-binding_and_transcriptional_transactivation_activities._This_variant_is_classified_as_a_severe_deficiency_allele_with_possible_dominant-negative_inhibitory_effects_(PMID:_21343334,_17606709,_20128691)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_within_a_codon_that_is_an_established_hotspot_in_the_TP53_gene_(PM1:_PMID:_2046748)._This_variant_has_a_BayesDel_score_>_0.16_and_Align_GVGD_(Zebrafish)_is_Class_15_or_higher_(PP3)._Transactivation_assays_show_a_low_functioning_allele_according_to_Kato,_et_al._and_there_is_evidence_of_a_dominant_negative_effect_and_loss_of_function_according_to_Giacomelli,_et_al._(PS3:_PMID:_12826609,_30224644)._This_variant_has_been_reported_in_at_least_3_probands_meeting_classic_Li-Fraumeni_syndrome_and_2_probands_meeting_Chompret_criteria_(PS4:_PMID:_1565143,_9242456,_15381368,_7887414)._There_is_a_de_novo_observation_of_a_proband_with_adrenocortical_carcinoma_with_parental_confirmation_(PS2:_PMID:_15381368)._In_summary,_TP53_c.743G>A:_p.Arg248Gln_meets_criteria_to_be_classified_as_pathogenic_for_Li-Fraumeni_syndrome._ACMG/AMP_criteria_applied,_as_specified_by_the_TP53_Variant_Curation_Expert_Panel:_PM1,_PP3,_PS3,_PS4,_PS2.|This_pathogenic_variant_is_denoted_TP53_c.743G>A_at_the_cDNA_level,_p.Arg248Gln_(R248Q)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Glutamine_(CGG>CAG)._This_variant_has_been_observed_in_several_Li-Fraumeni_or_Li-Fraumeni-like_families_and_has_also_been_reported_as_an_apparently_de_novo_heterozygous_or_mosaic_finding_in_individuals_meeting_Chompret_criteria_(Toguchida_1992,_Monti_2007,_Prochazkova_2009,_Masciari_2011,_Villani_2011,_Behjati_2014,_Patrier-Sallebert_2015,_Parsons_2016,_Sherborne_2016)._Functional_studies_have_found_that_TP53_Arg248Gln_impacts_DNA_binding,_apoptosis,_growth_suppression,_and_transactivation_activities_and_leads_to_a_dominant-negative_effect_(Lomax_1998,_Dearth_2007,_Malcikova_2010,_Monti_2011)._This_variant_is_also_reported_as_having_non-functional_transactivation_in_the_International_Agency_for_Research_on_Cancer_TP53_database_based_on_functional_studies_by_Kato_et_al._(2003)._TP53_Arg248Gln_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_within_the_DNA_binding_domain_(Bode_2004)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_that_this_variant_does_not_alter_protein_structure/function._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.|||The_best_available_variant_frequency_is_uninformative_because_it_is_below_the_disease_allele_frequency._Statistically_enriched_in_patients_compared_to_ethnically_matched_controls._Found_in_at_least_one_symptomatic_patient._Predicted_to_have_a_damaging_effect_on_the_protein._Two_other_pathogenic_or_likely_pathogenic_variants_affect_the_same_amino_acid._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function._One_de_novo_case_with_parental_identity_confirmed.|||||||||||||||||||||||||||||||
NM_000546.5:c.742C>T	TP53	missense_variant	102740	1	NA	NA	5&5&5	0&1&1	rs121912651	Li-Fraumeni syndrome 1&Hereditary cancer-predisposing syndrome&not provided	12347	27386	Li-Fraumeni_syndrome_1|Abnormality_of_the_tongue|Webbed_neck|Pectus_excavatum|Hepatocellular_carcinoma|Pancytopenia|Neoplasm|Medulloblastoma|Short_stature|Acute_myeloid_leukemia|Chronic_lymphocytic_leukemia|Pancreatic_adenocarcinoma|Squamous_cell_carcinoma_of_the_skin|Transitional_cell_carcinoma_of_the_bladder|Multiple_myeloma|Brainstem_glioma|Carcinoma_of_esophagus|Lung_adenocarcinoma|Small_cell_lung_cancer|Squamous_cell_lung_carcinoma|Neoplasm_of_brain|Neoplasm_of_the_breast|Cognitive_impairment|Neoplasm_of_the_large_intestine|Squamous_cell_carcinoma_of_the_head_and_neck|Malignant_melanoma_of_skin|Glioblastoma|Myelodysplastic_syndrome|Ovarian_Neoplasms|Adenocarcinoma_of_prostate|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Ovarian_Serous_Cystadenocarcinoma|Uterine_Carcinosarcoma|not_provided	-	Gene:553989,MedGen:C1835398,OMIM:151623|Human_Phenotype_Ontology:HP:0000157,MedGen:C0878638|Human_Phenotype_Ontology:HP:0000465,MedGen:C0221217|Human_Phenotype_Ontology:HP:0000767,MedGen:C0016842,OMIM:169300|Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0001876,MedGen:C0030312|Human_Phenotype_Ontology:HP:0002664,MeSH:D009369,MedGen:C0027651,SNOMED_CT:108369006|Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0004322,MedGen:C0349588|Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007|Human_Phenotype_Ontology:HP:0005550,MeSH:D015451,MedGen:C0023434,OMIM:151400,Orphanet:ORPHA67038,SNOMED_CT:277473004,SNOMED_CT:51092000|Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|Human_Phenotype_Ontology:HP:0006739,MedGen:C0553723|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0006775,MeSH:D009101,MedGen:C0026764,OMIM:254500,Orphanet:ORPHA29073,SNOMED_CT:109989006,SNOMED_CT:55921005|Human_Phenotype_Ontology:HP:0010796,MedGen:C0677865|Human_Phenotype_Ontology:HP:0011459,MedGen:C0152018,Orphanet:ORPHA70482|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0030357,MeSH:D055752,MedGen:C0149925,OMIM:182280,Orphanet:ORPHA70573|Human_Phenotype_Ontology:HP:0030359,MedGen:C0149782|Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100543,MedGen:C0338656|Human_Phenotype_Ontology:HP:0100834,MeSH:D015179,MedGen:C0009404,SNOMED_CT:126837005|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D005909,MedGen:C0017636,Orphanet:ORPHA360,SNOMED_CT:63634009|MeSH:D009190,MedGen:C3463824,OMIM:614286,Orphanet:ORPHA52688|MeSH:D010051,MedGen:CN236629|MedGen:C0007112|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0279663|MedGen:C0280630,Orphanet:ORPHA213610|MedGen:CN517202	-	NC_000017.10:g.7577539G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ClinGen:55c3283e-f0f6-4e18-b837-99a275ea7d90|UniProtKB_(protein):P04637#VAR_005984|OMIM_Allelic_Variant:191170.0001	-	TP53:7157	SO:0001583|missense_variant	3	121912651	-	OMIM|Counsyl|Ambry_Genetics|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Invitae|Mendelics|ClinGen_TP53_Variant_Curation_Expert_Panel,ClinGen|GeneDx|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|CHLA_Center_for_Personalized_Medicine,Children's_Hospital,_Los_Angeles|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	1992-07-15|2016-07-25|2019-05-03|2017-07-10|2018-12-14|2018-07-02|2019-08-28|2018-07-02|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2015-07-14|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|0000-00-00|2018-12-01	2013-04-09|2016-11-23|2020-02-26|2019-03-21|2019-03-28|2018-08-20|2019-09-23|2019-01-29|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2018-11-19|2019-02-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided	unknown|unknown|germline|germline|germline|unknown|germline|germline|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|germline|somatic	SCV000033387|SCV000488942|SCV000212766|SCV000204074|SCV000218912|SCV000839113|SCV001142555|SCV000149644|SCV000504862|SCV000504848|SCV000504865|SCV000504868|SCV000504851|SCV000504854|SCV000504871|SCV000504857|SCV000504860|SCV000504863|SCV000504849|SCV000504866|SCV000504869|SCV000504872|SCV000504858|SCV000504852|SCV000504855|SCV000504861|SCV000504864|SCV000504873|SCV000504850|SCV000504867|SCV000504853|SCV000504870|SCV000504856|SCV000504859|SCV000854446|SCV000924057	Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|not_provided|Acute_myeloid_leukemia|Lung_adenocarcinoma|Glioblastoma|Small_cell_lung_cancer|Squamous_cell_carcinoma_of_the_head_and_neck|Chronic_lymphocytic_leukemia|Brainstem_glioma|Ovarian_Serous_Cystadenocarcinoma|Myelodysplastic_syndrome|Adenocarcinoma_of_prostate|Neoplasm_of_the_breast|Carcinoma_of_esophagus|Adenocarcinoma_of_stomach|Multiple_myeloma|Uterine_Carcinosarcoma|Neoplasm_of_brain|Squamous_cell_lung_carcinoma|Hepatocellular_carcinoma|Transitional_cell_carcinoma_of_the_bladder|Neoplasm|Neoplasm_of_the_large_intestine|Medulloblastoma|Malignant_neoplasm_of_body_of_uterus|Squamous_cell_carcinoma_of_the_skin|Malignant_melanoma_of_skin|Pancreatic_adenocarcinoma|Pectus_excavatum/Acute_myeloid_leukemia/Short_stature/Cognitive_impairment/Webbed_neck/Pancytopenia/Abnormality_of_the_tongue|Ovarian_Neoplasms	||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Well-characterized_mutation_at_same_position:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|The_p.Arg248Trp_variant_in_TP53_is_a_well-established_pathogenic_variant_for_Li-_Fraumeni_syndrome_(IARC_TP53_Database,_http://p53.iarc.fr:_ClinVar_Variation_ID_12347)._It_has_also_been_identified_in_1/111704_European_chromosomes_by_the_Geno_me_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs12191_2651):_however_this_frequency_is_low_enough_to_be_consistent_with_the_frequency_of_Li-Fraumeni_syndrome_in_the_general_population._Amino_acid_position_248_is_a_known_TP53_mutation_hotspot,_with_several_different_variants_(including_p.Arg248_Gln)_that_have_been_well_reported_in_individuals_with_TP53-associated_cancers_(F_reed-Pastor_2012,_Xu_2014)._Furthermore,_both_in_vitro_and_in_vivo_functional_st_udies_support_that_this_variant_impacts_protein_function_(Frebourg_1992,_Dittmer_1993)._In_summary,_the_p.Arg248Trp_variant_meets_criteria_to_be_classified_as_p_athogenic_for_Li-Fraumeni_syndrome_in_an_autosomal_dominant_manner.|This_sequence_change_replaces_arginine_with_tryptophan_at_codon_248_of_the_TP53_protein_(p.Arg248Trp)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_tryptophan._This_variant_is_present_in_population_databases_(rs121912651,_ExAC_0.001%)._This_variant_has_been_reported_in_the_literature_as_one_of_the_most_commonly_identified_variants_in_individuals_with_Li-Fraumeni_syndrome._It_is_also_associated_with_a_high_incidence_of_breast_cancer_(PMID:Â¬â€ 24573247,Â¬â€ 23172776,Â¬â€ 23950206,Â¬â€ 1978757)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12347)_Experimental_studies_have_shown_that_this_missense_change_severely_disrupts_essential_activities_of_the_TP53_protein_(PMID:Â¬â€ 17606709,Â¬â€ 20128691,Â¬â€ 21343334,Â¬â€ 23172776)._Another_missense_substitution_at_this_codon_(p.Arg248Gln)_has_also_been_determined_to_be_deleterious_(PMID:Â¬â€ 17606709,Â¬â€ 20128691),_confirming_that_the_Arg248_residue_is_important_for_TP53_protein_function._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_within_a_codon_that_is_an_established_hotspot_in_the_TP53_gene_(PM1:_PMID:_20182602)._This_variant_has_a_BayesDel_score_>_0.16_and_Align_GVGD_(Zebrafish)_is_Class_65_(PP3_Moderate)._Transactivation_assays_show_a_low_functioning_allele_according_to_Kato,_et_al._and_there_is_evidence_of_a_dominant_negative_effect_and_loss_of_function_according_to_Giacomelli,_et_al._(PS3:_PMID:_12826609,_30224644)._This_variant_has_been_reported_in_at_least_3_probands_with_classic_Li-Fraumeni_syndrome_criteria_and_2_probands_meeting_Chrompret_criteria_(PS4:_PMID:_8425176,_20522432,_23667202,_9242456)._This_variant_was_found_to_co-segregate_with_disease_in_multiple_affected_family_members,_with_>7_meioses_observed_across_at_least_two_families_(PP1_Strong:_PMID:_1978757,_9825943)._There_is_a_de_novo_observation_of_a_proband_with_a_rhabdomyosarcoma_with_parental_confirmation_(PS2:_PMID:_10089074)._In_summary,_TP53_c.742C>T:_p.Arg248Trp_meets_criteria_to_be_classified_as_pathogenic_for_Li-Fraumeni_syndrome._ACMG/AMP_criteria_applied,_as_specified_by_the_TP53_Variant_Curation_Expert_Panel:_PM1,_PP3_Moderate,_PS3,_PS4,_PP1_Strong,_PS2.|This_variant_is_denoted_TP53_c.742C>T_at_the_cDNA_level,_p.Arg248Trp_(R248W)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Tryptophan_(CGG>TGG)._This_variant_has_been_observed_in_several_individuals_and_families_meeting_Li-Fraumeni_or_Li-Fraumeni_like_criteria_(Malkin_1990,_Hwang_2003,_Birch_1994,_Monti_2007,_Rossbach_2008,_Serra_2013,_Villani_2016)._Functional_assays_have_consistently_found_that_TP53_Arg248Trp_significantly_impacts_transcriptional_activation_of_typical_p53_targets_and_causes_a_dominant-negative_effect_(Willis_2004,_Grochova_2008,_Monti_2011)._Additionally,_this_variant_is_reported_as_having_non-functional_transactivation_in_the_International_Agency_for_Research_on_Cancer_TP53_database_based_on_functional_assays_by_Kato_et_al._(2003)._TP53_Arg248Trp_is_considered_a_hot_spot_mutant_and_is_one_of_the_most_common_somatic_variants_in_human_cancer_(Brachmann_2004,_Willis_2004,_Xu_2014)._This_variant_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._TP53_Arg248Trp_is_located_in_the_DNA_binding_domain_(Bode_2004)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||||||||||||||||||||||||||||
NM_000546.5:c.722C>T	TP53	missense_variant	102742	1	NA	NA	5&5&4	0&0&1	rs28934573	Hepatoblastoma&Osteosarcoma&Hereditary cancer-predisposing syndrome	12359	27398	Osteosarcoma|Hepatoblastoma|Renal_cell_carcinoma,_papillary,_1|Pancreatic_adenocarcinoma|Squamous_cell_carcinoma_of_the_skin|Transitional_cell_carcinoma_of_the_bladder|Brainstem_glioma|Carcinoma_of_esophagus|Non-Hodgkin_lymphoma|Lung_adenocarcinoma|Neoplasm_of_brain|Neoplasm_of_the_breast|Neoplasm_of_the_large_intestine|Squamous_cell_carcinoma_of_the_head_and_neck|Papillary_renal_cell_carcinoma,_sporadic|Malignant_melanoma_of_skin|Glioblastoma|Ovarian_Neoplasms|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Malignant_neoplasm_of_body_of_uterus|Carcinoma_of_gallbladder|Ovarian_Serous_Cystadenocarcinoma|Uterine_Carcinosarcoma	-	Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0002884,MedGen:C0206624,Orphanet:ORPHA449|Human_Phenotype_Ontology:HP:0005584,MeSH:D002292,MedGen:C0007134,OMIM:605074,Orphanet:ORPHA217071,SNOMED_CT:41607009|Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|Human_Phenotype_Ontology:HP:0006739,MedGen:C0553723|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0010796,MedGen:C0677865|Human_Phenotype_Ontology:HP:0011459,MedGen:C0152018,Orphanet:ORPHA70482|Human_Phenotype_Ontology:HP:0012539,MedGen:C4721532,OMIM:605027,SNOMED_CT:1929004|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100834,MeSH:D015179,MedGen:C0009404,SNOMED_CT:126837005|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C538614,MedGen:C1336078|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D005909,MedGen:C0017636,Orphanet:ORPHA360,SNOMED_CT:63634009|MeSH:D010051,MedGen:CN236629|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0235782|MedGen:C0279663|MedGen:C0280630,Orphanet:ORPHA213610	-	NC_000017.10:g.7577559G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:191170.0013|UniProtKB_(protein):P04637#VAR_005969	-	TP53:7157	SO:0001583|missense_variant	3	28934573	-	University_Hospital_Cologne	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	1993-01-01|1993-01-01|2019-08-02|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2018-11-25|2018-12-01	2016-12-19|2016-12-19|2020-02-26|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2019-03-28|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|germline|somatic	SCV000033400|SCV000033401|SCV000185004|SCV000509694|SCV000509691|SCV000509697|SCV000509700|SCV000509703|SCV000509686|SCV000509689|SCV000509695|SCV000509692|SCV000509698|SCV000509701|SCV000509704|SCV000509690|SCV000509693|SCV000509687|SCV000509696|SCV000509699|SCV000509702|SCV000509688|SCV000629860|SCV000923858	Hepatoblastoma|Osteosarcoma|Hereditary_cancer-predisposing_syndrome|Squamous_cell_carcinoma_of_the_skin|Non-Hodgkin_lymphoma|Brainstem_glioma|Carcinoma_of_esophagus|Neoplasm_of_the_breast|Squamous_cell_carcinoma_of_the_head_and_neck|Uterine_Carcinosarcoma|Lung_adenocarcinoma|Malignant_melanoma_of_skin|Papillary_renal_cell_carcinoma,_sporadic|Neoplasm_of_brain|Glioblastoma|Malignant_neoplasm_of_body_of_uterus|Transitional_cell_carcinoma_of_the_bladder|Neoplasm_of_the_large_intestine|Pancreatic_adenocarcinoma|Ovarian_Serous_Cystadenocarcinoma|Carcinoma_of_gallbladder|Renal_cell_carcinoma,_papillary,_1|Li-Fraumeni_syndrome|Ovarian_Neoplasms	||Deficient_protein_function_in_appropriate_functional_assay(s):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Structural_Evidence:Other_data_supporting_pathogenic_classification:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||||||||||||||||||This_sequence_change_replaces_serine_with_phenylalanine_at_codon_241_of_the_TP53_protein_(p.Ser241Phe)._The_serine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_serine_and_phenylalanine._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_shown_to_arise_likely_de_novo_in_an_individual_affected_with_osteosarcoma_and_hepatoblasoma_(PMID:_1565143)._It_has_also_been_observed_in_another_individual_affected_with_osteosarcoma,_without_parental_testing_performed_(PMID:_23031740),_as_well_as_in_individuals_affected_with_breast_and/or_ovarian_cancer,_and_colorectal_cancer_(PMID:_26911350,Â¬â€ 28975465)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12359)._Experimental_studies_have_shown_that_this_missense_change_disrupts_transactivation_and_DNA_binding_activities_(PMID:_20128691,_21343334,_26585234,Â¬â€ 12826609)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_000546.5:c.659A>G	TP53	missense_variant	102706	2	NA	NA	5&5&4	1&1&1	rs121912666	Hereditary cancer-predisposing syndrome&not provided&Li-Fraumeni syndrome	127819	133276	Hepatocellular_carcinoma|Acute_myeloid_leukemia|Renal_cell_carcinoma,_papillary,_1|Pancreatic_adenocarcinoma|Transitional_cell_carcinoma_of_the_bladder|Lung_adenocarcinoma|Small_cell_lung_cancer|Squamous_cell_lung_carcinoma|Neoplasm_of_brain|Neoplasm_of_the_breast|Neoplasm_of_the_large_intestine|Squamous_cell_carcinoma_of_the_head_and_neck|Papillary_renal_cell_carcinoma,_sporadic|Malignant_melanoma_of_skin|Glioblastoma|Ovarian_Neoplasms|Adenocarcinoma_of_prostate|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Malignant_neoplasm_of_body_of_uterus|Adenocarcinoma_of_stomach|Ovarian_Serous_Cystadenocarcinoma|Uterine_Carcinosarcoma|not_provided	-	Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0004808,MeSH:D015470,MedGen:C0023467,OMIM:601626,Orphanet:ORPHA519,SNOMED_CT:17788007|Human_Phenotype_Ontology:HP:0005584,MeSH:D002292,MedGen:C0007134,OMIM:605074,Orphanet:ORPHA217071,SNOMED_CT:41607009|Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0030357,MeSH:D055752,MedGen:C0149925,OMIM:182280,Orphanet:ORPHA70573|Human_Phenotype_Ontology:HP:0030359,MedGen:C0149782|Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100834,MeSH:D015179,MedGen:C0009404,SNOMED_CT:126837005|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C538614,MedGen:C1336078|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D005909,MedGen:C0017636,Orphanet:ORPHA360,SNOMED_CT:63634009|MeSH:D010051,MedGen:CN236629|MedGen:C0007112|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C0153574,Orphanet:ORPHA213569|MedGen:C0278701|MedGen:C0279663|MedGen:C0280630,Orphanet:ORPHA213610|MedGen:CN517202	-	NC_000017.10:g.7578190T>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ClinGen:4795612b-c5d2-4229-a5ec-172fedfbcf55	-	TP53:7157	SO:0001583|missense_variant	3	121912666	-	Ambry_Genetics|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|ClinGen_TP53_Variant_Curation_Expert_Panel,ClinGen|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-09-20|2018-07-20|2017-03-02|2018-08-01|2019-01-05|2017-04-27|2018-07-02|2019-08-28|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2014-10-02|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2018-12-01	2020-02-26|2019-01-29|2018-09-19|2018-08-31|2019-03-28|2018-01-25|2018-08-20|2019-09-23|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|unknown|germline|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic	SCV000183774|SCV000149640|SCV000700520|SCV000888669|SCV000285206|SCV000697444|SCV000839116|SCV001142546|SCV000504719|SCV000504722|SCV000504728|SCV000504725|SCV000504731|SCV000504734|SCV000504737|SCV000504720|SCV000504723|SCV000504726|SCV000504732|SCV000504729|SCV000504735|SCV000504738|SCV000504724|SCV000504721|SCV000504727|SCV000504730|SCV000504733|SCV000504736|SCV000924116	Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|Glioblastoma|Ovarian_Serous_Cystadenocarcinoma|Renal_cell_carcinoma,_papillary,_1|Malignant_neoplasm_of_body_of_uterus|Neoplasm_of_the_breast|Squamous_cell_lung_carcinoma|Malignant_melanoma_of_skin|Transitional_cell_carcinoma_of_the_bladder|Papillary_renal_cell_carcinoma,_sporadic|Squamous_cell_carcinoma_of_the_head_and_neck|Adenocarcinoma_of_stomach|Adenocarcinoma_of_prostate|Neoplasm_of_brain|Uterine_Carcinosarcoma|Hepatocellular_carcinoma|Acute_myeloid_leukemia|Pancreatic_adenocarcinoma|Lung_adenocarcinoma|Neoplasm_of_the_large_intestine|Small_cell_lung_cancer|Ovarian_Neoplasms	Well-characterized_mutation_at_same_position:Deficient_protein_function_in_appropriate_functional_assay(s):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Other_strong_data_supporting_pathogenic_classification|This_variant_is_denoted_TP53_c.659A>G_at_the_cDNA_level,_p.Tyr220Cys_(Y220C)_at_the_protein_level,_and_results_in_the_change_of_a_Tyrosine_to_a_Cysteine_(TAT>TGT)._TP53_Tyr220Cys_has_been_identified_in_several_Li-Fraumeni_kindreds,_with_at_least_two_de_novo_occurrences_reported_(Birch_1994,_Huusko_1999,_Capponcelli_2005,_Izawa_2008,_Lin_2009,_Debelenko_2010,_Wilson_2010,_Melhem-Bertrandt_2012,_Fostira_2015,_Andrade_2016,_Zerdoumi_2017)._On_functional_interrogation,_TP53_Tyr220Cys_has_been_found_to_impact_binding_to_typical_p53-responsive_elements_and_cause_decreased_transcriptional_activation_(Malcikova_2010,_Monti_2011)._Consistent_with_these_findings,_this_variant_is_reported_as_having_non-functional_transactivation_in_the_International_Agency_for_Research_on_Cancer_TP53_database_based_on_functional_assays_by_Kato_et_al._(2003)._TP53_Tyr220Cys_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_DNA_binding_domain_(Bode_2004)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|||This_sequence_change_replaces_tyrosine_with_cysteine_at_codon_220_of_the_TP53_protein_(p.Tyr220Cys)._The_tyrosine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_tyrosine_and_cysteine._This_variant_is_present_in_population_databases_(rs121912666,_ExAC_0.005%)._This_variant_has_been_reported_as_de_novo_in_an_individual_with_Li-Fraumeni_syndrome_(LFS)_(PMID:_18307025),_as_well_as_in_individuals_with_breast_cancer_and_adrenal_carcinoma_(PMID:_21761402,_20805372)._This_variant_has_also_been_reported_toÂ¬â€ segregate_with_LFS_in_several_families_(PMID:_8118819,_10432928,_19101993)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127819)._Experimental_studies_have_shown_that_this_missense_change_destabilizes_the_TP53_protein,_and_disrupts_its_DNA_binding_and_transactivation_activity_(PMID:_20128691,_21343334,_22923379,_17015838)._Many_of_these_properties_are_reversed_in_cell_culture_by_treatment_with_a_small_molecule_(PMID:_23630318)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_TP53_c.659A>G_(p.Tyr220Cys)_variant_involves_the_alteration_of_a_conserved_nucleotide,_resulting_in_a_missense_substitution_that_lies_within_the_p53_DNA-binding_domain_(InterPro)._5/5_in_silico_tools_predict_damaging_outcome_for_this_variant._This_variant_was_found_in_the_large_control_database_ExAC_at_a_frequency_of_0.000025_(3/119860_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_TP53_variant_(0.0000398)._This_variant_has_been_reported_as_a_germline_variant_in_several_patients/families_with_Li-Fraumeni_syndrome._This_germline_variant_has_also_been_reported_in_early-onset_breast_cancer_patients_(Wilson_2010:_Melhem-Bertrandt_2012)._In_three_LFS_families,_the_variant_co-segregated_with_disease_in_affected_members_genotyped_over_two-generations_(Birch_1994/Varley_1997:_Huusko_1999:_Lin_2009)._Functional_studies_show_that_the_variant_severely_compromises_the_p53_binding_and_transactivation_(Jordan_2010:_Zachos_1998:_TP53_database)._Multiple_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Another_missense_change_at_this_residue_Y220S_is_also_classified_as_pathogenic_in_ClinVar_by_multiple_submitters._This_variant_is_located_in_a_mutational_hot_spot_and_a_small_molecule_capable_of_targeting_the_p.Y220C_mutant_has_been_identified_(Reviewed_by_Soussi_2015)._Taken_together,_this_variant_is_classified_as_pathogenic.||This_variant_has_a_BayesDel_score_>_0.16_and_Align_GVGD_(Zebrafish)_is_Class_65_(PP3_Moderate)._This_variant_has_>10_observations_as_a_somatic_hotspot_variant_in_tumors_(PM1:_cancerhotspots.org_v(2))._Transactivation_assays_show_a_low_functioning_allele_according_to_Kato,_et_al.,_and_there_are_two_assays_demonstrating_loss_of_function._One_study_demonstrates_a_structural_defect_that_destabilizes_the_protein_and_another_study_showed_essentially_no_apoptosis_activity_in_mutant_cells_(PS3:_PMID:_12826609,_20516128,_15037740)._This_variant_has_been_reported_in_at_least_4_probands_meeting_classic_Li-Fraumeni_syndrome_criteria_(PS4:_PMID:_8118819,_10432928,_10589545,_15977174)._This_variant_was_found_to_co-segregate_with_disease_in_multiple_affected_family_members,_with_>7_meioses_observed_across_at_least_two_families_(PP1_Strong:_PMID:_15977174,_9242456,_19101993,_10432928)._Additionally,_there_was_a_de_novo_observation_in_an_individual_with_10_Classic_Li-Fraumeni_syndrome_spectrum_tumors_without_mention_of_parental_confirmation_(PM6:_PMID:_18307025)._In_summary,_TP53_c.659A>G:_p.Tyr220Cys_meets_criteria_to_be_classified_as_pathogenic_for_Li-Fraumeni_syndrome._ACMG/AMP_criteria_applied,_as_specified_by_the_TP53_Variant_Curation_Expert_Panel:_PP3_Moderate,_PM1,_PS3,_PS4,_PP1_Strong,_PM6.|||||||||||||||||||||
NM_000546.5:c.542G>A	TP53	missense_variant	102624	3	15430	1	4&5&4	1&1&1	rs397514495	Hereditary cancer-predisposing syndrome&Li-Fraumeni syndrome&not provided	142320	152034	Li-Fraumeni_syndrome_1|Squamous_cell_carcinoma_of_the_head_and_neck|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|not_provided	-	Gene:553989,MedGen:C1835398,OMIM:151623|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:CN517202	-	NC_000017.10:g.7578388C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P04637#VAR_044948	-	TP53:7157	SO:0001583|missense_variant	1	397514495	-	_Partners_HealthCare_Personalized_Medicine|GeneDx|Counsyl|Mendelics	Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-05-22|2018-09-09|2018-12-18|2017-11-06|2018-08-24|2017-03-16|2019-05-28	2020-02-26|2018-11-06|2019-03-28|2019-03-21|2019-01-29|2017-06-22|2019-10-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown	SCV000186358|SCV000686749|SCV000218918|SCV000731671|SCV000322072|SCV000677774|SCV001140260	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|not_provided|Li-Fraumeni_syndrome_1|Squamous_cell_carcinoma_of_the_head_and_neck	Deficient_protein_function_in_appropriate_functional_assay(s):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):Well-characterized_mutation_at_same_position||This_sequence_change_replaces_arginine_with_histidine_at_codon_181_of_the_TP53_protein_(p.Arg181His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs397514495,_ExAC_0.003%)._This_variant_has_been_reported_in_an_individual_with_breast_cancer_and_a_strong_family_history_of_breast_cancer,_leiomyosarcoma,_and_other_neoplasms_(PMID:_1591732,Â¬â€ 1631137),_a_29_year_old_with_early-onset_breast_cancer_and_family_history_of_multiple_cancers_(PMID:_21059199),_and_an_individual_affected_with_adrenocortical_carcinoma_and_a_contralateral_pheochromocytoma_also_clinically_diagnosed_with_neurofibromatosis_type_1_(PMID:_23175693)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142320)._Experimental_studies_indicate_that_this_missense_change_disrupts_protein_function_(PMID:_20128691,_21343334,_11429705)._Three_different_missense_changes_involving_this_codon_(p.Arg181Cys,_p.Arg181Leu,_p.Arg181Pro)_have_been_reported_in_individuals_with_TP53-related_conditions_(PMID:_1581912,_8308926,_15925506),_suggesting_that_the_arginine_residue_is_clinically_important._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Arg181His_variant_in_TP53_has_been_observed_as_a_germline_variant_in_4_ind_ividuals_with_Li-Fraumeni_syndrome_(LFS)_related_cancers_(Borresen_1992,_Heyman_2010,_Raymond_2013)._In_two_of_these_individuals,_the_reported_age_at_diagnosis_was_significantly_older_than_what_is_typically_observed_for_LFS_(median_age_at_d_iagnosis_
NM_000546.5:c.524G>A	TP53	missense_variant	102596	1	NA	NA	5&5&5&5&5	0&1&1&1&0	rs28934578	Li-Fraumeni syndrome 1&Hereditary cancer-predisposing syndrome&Li-Fraumeni syndrome&not provided&Malignant tumor of esophagus	12374	27413	Li-Fraumeni_syndrome_1|Hepatocellular_carcinoma|Neoplasm|Osteosarcoma|Neoplasm_of_the_breast|Choroid_plexus_papilloma|Carcinoma_of_pancreas|Ovarian_Neoplasms|Familial_cancer_of_breast|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Malignant_tumor_of_esophagus|Adrenocortical_carcinoma,_hereditary|Glioma_susceptibility_1|Nasopharyngeal_carcinoma|Basal_cell_carcinoma,_susceptibility_to,_7|not_provided	-	Gene:553989,MedGen:C1835398,OMIM:151623|Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0002664,MeSH:D009369,MedGen:C0027651,SNOMED_CT:108369006|Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0200022,MedGen:C0205770,OMIM:260500,Orphanet:ORPHA2807,SNOMED_CT:18021007|MeSH:C562463,MedGen:C0235974,OMIM:260350,Orphanet:ORPHA217074,SNOMED_CT:372142002|MeSH:D010051,MedGen:CN236629|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C0546837,OMIM:133239,SNOMED_CT:363402007|MedGen:C1859972,OMIM:202300|MedGen:C2750850,OMIM:137800,Orphanet:ORPHA301|MedGen:C2931822,OMIM:607107,Orphanet:ORPHA150|MedGen:C3553606,OMIM:614740|MedGen:CN517202	-	NC_000017.10:g.7578406C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P04637#VAR_005932|OMIM_Allelic_Variant:191170.0030	-	TP53:7157	SO:0001583|missense_variant	3	28934578	-	OMIM|Pathway_Genomics|Counsyl|Ambry_Genetics|Color|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Institute_of_Biochemistry,_Molecular_Biology_and_Biotechnology,University_of_Colombo|Database_of_Curated_Mutations_(DoCM)|Database_of_Curated_Mutations_(DoCM)|Fulgent_Genetics,Fulgent_Genetics|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|not_provided|Pathogenic|Likely_pathogenic	2005-08-01|2014-07-24|2016-03-18|2018-09-13|2015-04-15|2018-11-17|2017-07-24|2018-11-14|0000-00-00|2017-04-17|2016-07-29|2015-07-14|2016-03-10|2018-10-31|2018-12-01	2019-07-08|2014-08-08|2016-11-23|2020-02-26|2018-11-06|2019-03-28|2019-03-21|2019-01-29|2017-10-31|2018-01-29|2016-08-09|2016-07-18|2016-07-18|2018-11-14|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown|germline|germline|germline|germline|germline|unknown|germline|somatic|somatic|somatic|unknown|somatic	SCV000033420|SCV000189994|SCV000488375|SCV000186273|SCV000905051|SCV000261917|SCV000731790|SCV000211798|SCV000692083|SCV000806241|SCV000297733|SCV000504891|SCV000504892|SCV000894156|SCV000923920	Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Li-Fraumeni_syndrome_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome|not_provided|not_provided|not_provided|Malignant_tumor_of_esophagus|Neoplasm|Neoplasm_of_the_breast|Adrenocortical_carcinoma,_hereditary/Familial_cancer_of_breast/Glioma_susceptibility_1/Osteosarcoma/Li-Fraumeni_syndrome_1/Nasopharyngeal_carcinoma/Carcinoma_of_pancreas/Choroid_plexus_papilloma/Carcinoma_of_colon/Basal_cell_carcinoma,_susceptibility_to,_7/Hepatocellular_carcinoma|Ovarian_Neoplasms	|||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Structural_Evidence:Deficient_protein_function_in_appropriate_functional_assay(s)||This_sequence_change_replaces_arginine_with_histidine_at_codon_175_of_the_TP53_protein_(p.Arg175His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs28934578,_ExAC_0.001%)._This_variant_has_been_reported_in_individuals_and_families_affected_with_Li-Fraumeni_syndrome,_osteosarcoma,_breast_cancer_and_ovarian_carcinoma_(PMID:_8825920,_8164043,_21761402,_22006311,_16401470)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_12374)._This_is_a_well-studied_variant,_located_in_a_known_mutation_hotspot_within_the_central_DNA-binding_domain_of_TP53_(PMID:_23263379,_20516128,_24573247,_12007217)._It_causes_not_only_loss_of_the_tumor_suppressor_function_of_the_TP53_protein,_but_also_oncogenic_gain-of-function_(PMID:_23792586,_23263379)._In_addition,_a_mouse_model_of_Li-Fraumeni_syndrome_was_engineered_using_this_missense_variant_(PMID:_15607980,_15607981),_and_these_mice_developed_a_variety_of_carcinomas_and_reproduced_the_metastatic_phenotype._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Arg175His_variant_in_TP53_has_been_reported_in_>16_individuals_with_Li-Fra_umeni_syndrome,_and_segregated_with_disease_in_3_affected_relatives_from_1_famil_y_(McIntyre_1994,_Varley_1997,_Wong_2006,_Bougeard_2008,_Walsh_2011,_Melhem-Bert_randt_2012,_Park_2016)._This_variant_has_also_been_reported_by_another_clinical_laboratory_in_ClinVar_(Variation_ID#_12374)._In_vitro_functional_studies_provide_some_evidence_that_the_p.Arg175His_variant_may_impact_protein_function_(Kogan-S_akin_2011,_Grugan_2013)_and_an_in-vivo_mouse_model_has_shown_that_this_variant_c_auses_TP53-related_tumors_(Liu_2010)._Additionally,_the_p.Arg175His_variant_has_been_identified_in_1/111550_European_chromosomes_by_gnomAD_(http://gnomad.broadi_nstitute.org)._Computational_prediction_tools_and_conservation_analysis_suggest_that_the_p.Arg175His_variant_may_impact_the_protein_and_3_other_amino_acid_chang_es_at_this_position_(Leu,_Gly,_Cys)_have_been_associated_with_Li-Fraumeni_syndro_me_(HGMD_database:_Stenson_2017)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_Li-Fraumeni_syndrome_in_an_autosomal_dominant_manne_r_based_on_segregation_studies,_increased_prevalence_in_affected_individuals,_ve_ry_low_frequency_in_controls_and_functional_evidence._ACMG/AMP_Criteria_applied:_PS4,_PP1,_PS3,_PM2.|This_variant_is_denoted_TP53_c.524G>A_at_the_cDNA_level_and_p.Arg175His_(R175H)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Histidine_(CGC>CAC)._TP53_Arg175His_has_been_reported_in_several_individuals_meeting_clinical_diagnostic_criteria_for_Li-Fraumeni_syndrome_or_Chompret_criteria_for_TP53_testing_(Birch_1994,_Kyritsis_1994,_McIntyre_1994,_Chompret_2000,_Bougeard_2001,_Malkin_2001,_Potzsch_2002,_Walsh_2006,_Wong_2006,_Choong_2012,_Melhem-Bertrandt_2012,_Zerdoumi_2013,_Maxwell_2016,_Park_2016,_Zerdoumi_2017)_and_is_considered_a_common_hotspot_variant_present_in_diverse_cell_lines_and_tumors_(Soussi_2014,_COSMIC,_IARC_TP53_Database)._Functional_studies_have_consistently_found_this_variant_to_impact_control_of_cell_growth_as_well_as_DNA_binding_and_transcriptional_activation_(Dittmer_1993,_Malcikova_2010,_Monti_2011,_Wasserman_2015),_and_TP53_Arg175His_is_reported_as_having_non-functional_transactivation_in_the_International_Agency_for_Research_on_Cancer_TP53_database_based_on_functional_assays_by_Kato_et_al._(2003)._TP53_Arg175His_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_DNA_binding_domain_(Bode_2004)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_TP53_Arg175His_to_be_pathogenic.|||SIFT:Deleterious_(score:_0)_MutationTaster:Disease_causing_(p-value:_1)||||
NM_000546.5:c.401T>G	TP53	missense_variant	102280	1	NA	NA	4	1	rs780442292	Hereditary cancer-predisposing syndrome	230477	236493	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000017.10:g.7578529A>C	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P04637#VAR_044749	-	TP53:7157	SO:0001623|5_prime_UTR_variant	1	780442292	-	Mayo_Clinic	Likely_pathogenic|Likely_pathogenic	2015-02-10|2013-04-09	2020-02-26|2018-03-09	_single_submitter|no_assertion_criteria_provided	germline|unknown	SCV000274039|SCV000778630	Hereditary_cancer-predisposing_syndrome|not_provided	Deficient_protein_function_in_appropriate_functional_assay(s):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Other_data_supporting_pathogenic_classification|
NM_007294.3:c.5497G>A	BRCA1	missense_variant	102496	1	NA	NA	4&4&4	1&1&1	rs80357268	Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&not provided	55598	70265	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41197790C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001624|3_prime_UTR_variant	1	80357268	-	Sinai_Health_System|GeneKor_MSA|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|GeneDx	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-06-12|2015-06-10|2017-11-01|2016-03-28|2012-10-15|2004-02-20|2016-05-20|2019-09-27|2016-05-06	2018-08-29|2017-04-19|2017-11-21|2018-01-25|2013-06-26|2014-03-28|2016-07-18|2020-02-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000077030|SCV000591635|SCV000693500|SCV000699266|SCV000109429|SCV000145548|SCV000296422|SCV000187393|SCV000322039	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|not_provided	This_sequence_change_replaces_valine_with_methionine_at_codon_1833_of_the_BRCA1_protein_(p.Val1833Met)._The_valine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_valine_and_methionine._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_and_families_with_breast_and/or_ovarian_cancer,_with_evidence_of_segregation_with_disease_in_a_single_family_(PMID:_23536787,_12142080,_16284991)._This_variant_has_also_been_reported_in_individuals_in_the_Breast_Cancer_Information_Core_database_(PMID:_10923033)._It_is_also_known_as_5616G>A_in_the_literature._ClinVar_has_an_entry_for_this_variant_(Variation_ID:_55598)._This_variant_is_located_within_the_BRCT_domain_that_is_important_for_BRCA1_function._Experimental_studies_have_shown_that_this_missense_change_affects_protein_folding_and_stability,_as_well_as_functional_activity_of_the_BRCA1_protein_(PMID:_20526115,_18992264,_20378548,_15004537,_28781887),_while_binding_specificity_to_phosphopeptides_required_for_structural_integrity_is_preserved_(PMID:_17493881,_20516115)._For_these_reasons,_this_variant_has_been_classified_as_Likely_Pathogenic.|||Variant_Summary:_Variant_affects_a_conserved_nucleotide_and_results_in_replacement_of_a_medium_size_and_hydrophobic_Valine_(V)_with_a_medium_size_and_hydrophobic_Methionine_(M)._4/5_in_silico_tool_predict_deleterious_outcome_for_this_change._The_variant_is_absent_in_the_large_and_broad_cohorts_of_the_NHLBI-ES_and_ExAC_projects_but_has_been_observed_in_both_sporadic_and_familial_HBOC_spectrum_patients._In_one_Greek_family_the_variant_co-segregated_with_the_disease_(Stavropoulou_BRCA1&2_PlosOne_2013)_supporting_a_pathogenic_nature_for_variant._In_agreement_with_a_pathogenic_impact_for_the_variant_functional_studies_showed_that_the_variant_abolishes_the_transcriptional_activity_of_BRCA1_and_destabilizes_the_protein_(Lee_CR_2010,_Rowling_JBC_2010)._Reputable_databases_and_clinical_diagnostic_centers_classify_variant_as_Likely_Pathogenic/Pathogenic._Considering_all_evidences_the_variant_was_classified_as_likely_pathogenic.||||Other_strong_data_supporting_pathogenic_classification:Deficient_protein_function_in_appropriate_functional_assay(s):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|This_variant_is_denoted_BRCA1_c.5497G>A_at_the_cDNA_level,_p.Val1833Met_(V1833M)_at_the_protein_level,_and_results_in_the_change_of_a_Valine_to_a_Methionine_(GTG>ATG)._This_variant,_also_published_as_BRCA1_5616G>A_using_alternate_nomenclature,_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Ladopoulou_2002,_Pal_2005,_Stavropoulou_2013)._While_BRCA1_Val1833Met_has_been_associated_with_binding_activity_similar_to_wild_type,_functional_assays_also_report_it_significantly_reduces,_but_does_not_destroy,_transactivation_activity_in_both_yeast_and_human_embryonic_cell_models,_mildly_to_severely_impacts_protein_thermostability,_and_abrogates_the_small_colony_phenotype_in_yeast_(Coyne_2004,_Nikolopoulos_2007,_Carvalho_2009,_Lee_2010,_Rowling_2010)._BRCA1_Val1833Met_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_suggesting_it_is_not_a_common_benign_variant_in_these_populations._Since_Valine_and_Methionine_share_similar_properties,_this_is_considered_a_conservative_amino_acid_substitution._BRCA1_Val1833Met_occurs_at_a_position_that_is_conserved_in_mammals_and_is_located_within_the_BRCT2_domain_and_a_region_known_to_interact_with_multiple_proteins_(Paul_2014,_UniProt)._In_silico_analyses_predict_that_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_the_currently_available_evidence,_we_consider_BRCA1_Val1833Met_to_be_a_likely_pathogenic_variant.
NM_007294.3:c.5485dup	BRCA1	frameshift_variant	102326	1	NA	NA	-	-	-	-	254471	249073	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41197802dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRCA1:672	SO:0001578|stop_lost,SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant	1	768401297	-	_c/o_University_of_Cambridge|Invitae	Pathogenic|Pathogenic|Pathogenic	2016-09-08|2015-10-02|2018-06-06	2016-09-13|2016-10-28|2018-08-29	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000300267|SCV000326334|SCV000815254	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome	Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_sequence_change_duplicates_1_nucleotide_from_exon_23_of_the_BRCA1_mRNA_(c.5485dupG),_causing_a_frameshift_at_codon_1829._This_is_expected_to_delete_the_last_35_amino_acids_of_the_BRCA1_protein_and_replace_them_with_15_additional_amino_acid_residues,_creating_a_new_downstream_translational_stop_signal_in_the_last_exon_that_extends_the_length_of_the_protein_(p.Glu1829Glyfs*51)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_may_result_in_a_disrupted_BRCA1_protein._This_variant_is_present_in_population_databases_(rs768401297,_ExAC_0.001%)._This_variant_has_been_observed_in_an_individual_affected_with_ovarian_cancer_(PMID:Â¬â€ 27767231)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_254471)._A_different_truncation_(p.Gln1857Argfs*65)_that_lies_downstream_of_this_variant_has_been_determined_to_be_pathogenic_(PMID:Â¬â€ 21520333,Â¬â€ 11573086,_14576433,_15133503,_25652403)._This_suggests_that_deletion_of_this_region_of_the_BRCA1_protein_is_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007294.3:c.5434C>G	BRCA1	missense_variant	102748	1	NA	NA	-	-	-	-	37670	46226	_familial_1|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41199693G>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	5	1800751	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Department_of_Medical_Genetics,University_Hospital_of_North_Norway|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|GeneDx|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Ambry_Genetics|Color	Uncertain_significance|Uncertain_significance|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic	2012-05-01|2009-06-05|2016-05-01|2015-10-02|2015-07-01|2017-01-01|2017-08-02|2014-01-31|2019-09-17|2018-07-25	2013-12-30|2014-03-28|2016-09-20|2016-10-28|2017-04-17|2017-03-15|2019-01-29|2017-08-04|2020-02-26|2018-11-06	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|inherited|germline|germline|germline|germline|germline|germline|germline	SCV000053855|SCV000145514|SCV000301440|SCV000326312|SCV000564312|SCV000577941|SCV000564753|SCV000587508|SCV000665890|SCV000903563	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|not_specified|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	||||||This_variant_is_denoted_BRCA1_c.5434C>G_at_the_cDNA_level,_p.Pro1812Ala_(P1812A)_at_the_protein_level,_and_results_in_the_change_of_a_Proline_to_an_Alanine_(CCA>GCA)._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA1_5553C>G._This_variant_has_been_observed_in_several_individuals_with_a_personal_and_family_history_consistent_with_Hereditary_Breast_and_Ovarian_Cancer_syndrome,_segregating_with_disease_in_two_kindreds_(Martinez-Ferrandis_2003,_Diez_2003,_Kaufman_2006,_Gaildrat_2010,_Laitman_2011,_Stavropoulou_2013,_Jarhelle_2016)._RNA_and_minigene_assays_have_demonstrated_that_this_variant_causes_skipping_of_exon_22,_published_as_exon_23,_in_most_transcripts,_leading_to_a_truncated_protein_product_and_disrupting_the_second_BRCT_domain_(Gaildrat_2010,_Jarhelle_2016)._When_present_in_a_full-length_transcript,_BRCA1_Pro1812Ala_has_been_found_to_cause_a_slight_reduction_in_transcriptional_activity,_protein_binding_capacity,_and_thermostability_(Kaufman_2006,_Drikos_2009)._Although_the_nucleotide_substitution_results_in_the_change_of_a_Proline_to_an_Alanine_at_codon_1812,_and_may_also_be_called_Pro1812Ala_in_the_literature,_we_are_using_the_nucleotide_nomenclature_to_refer_to_the_variant_since_the_defect_is_determined_to_be_one_of_splicing_rather_than_a_resulting_missense_variant._BRCA1_c.5434C>G_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_suggesting_it_is_not_a_common_benign_variant_in_these_populations._The_nucleotide_which_is_altered,_a_cytosine_(C)_at_base_5434,_is_conserved_through_mammals._Based_on_current_evidence,_we_consider_BRCA1_c.5434C>G_to_be_a_likely_pathogenic_variant.||Functionally-validated_splicing_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|
NM_007294.3:c.5123C>A	BRCA1	missense_variant	102672	3	NA	NA	5&5&5	1&3&1	rs28897696	not provided&Breast-ovarian cancer, familial 1&Hereditary cancer-predisposing syndrome	55407	70074	_familial_1|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41215920G>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Children's_Hospital_of_Eastern_Ontario:1829675	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	28897696	-	GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|PreventionGenetics,PreventionGenetics|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Division_Human_Genetics,Medical_University_Innsbruck|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Genologica_Medica|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Baylor_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-18|2015-03-20|2017-08-09|2013-01-29|2002-05-29|2015-02-11|2015-08-10|2015-10-02|2017-01-01|2017-01-26|0000-00-00|2015-09-21|2018-07-16|2016-06-06|2019-01-03|2014-01-31|2012-09-11|2016-03-21|2017-01-26|2018-07-02|0000-00-00|2017-02-23	2019-01-29|2018-08-31|2018-01-29|2015-12-29|2014-03-28|2015-02-11|2015-08-17|2016-10-28|2017-03-15|2017-06-22|2018-04-04|2018-04-09|2020-02-26|2017-01-26|2019-03-28|2017-08-04|2017-04-19|2019-03-21|2018-01-25|2018-08-20|2016-12-06|2017-02-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000210200|SCV000296313|SCV000806966|SCV000109402|SCV000145320|SCV000212006|SCV000244385|SCV000326160|SCV000577935|SCV000677657|SCV000733598|SCV000744598|SCV000186886|SCV000537686|SCV000076815|SCV000587466|SCV000591583|SCV000605743|SCV000699205|SCV000839216|SCV000492454|SCV000540948	not_provided|not_provided|not_provided|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Neoplasm_of_the_breast|Familial_cancer_of_breast	This_pathogenic_variant_is_denoted_BRCA1_c.5123C>A_at_the_cDNA_level,_p.Ala1708Glu_(A1708E)_at_the_protein_level,_and_results_in_the_change_of_an_Alanine_to_a_Glutamic_Acid_(GCG>GAG)._Using_alternate_nomenclature,_this_variant_has_been_previously_published_as_BRCA1_5242C>A._This_variant_was_observed_in_numerous_breast/ovarian_cancer_families_and_reported_as_a_recurrent_pathogenic_variant_in_Spain,_Columbia,_and_in_other_Hispanic_populations_(Diez_2003,_Vogel_2007,_Janavicus_2010,_de_Juan_Jimenez_2013,_Weitzel_2013,_Hernandez_2014,_Torres_2017)._RNA_and_minigene_assays_have_demonstrated_that_BRCA1_c.5123C>A_causes_either_complete_or_partial_exonic_skipping_(Millevoi_2010,_Sanz_2010,_Quiles_2016)._When_present_in_a_full-length_transcript,_functional_assays_interrogating_the_impact_of_BRCA1_Ala1708Glu_on_transcription_activity,_protease_sensitivity,_peptide_binding,_thermodynamic_stability,_cellular_localization,_centrosome_amplification,_cell_growth_and_survival,_homologous_recombination,_and_cisplatin_sensitivity_have_confirmed_the_pathogenic_nature_of_this_variant_(Chapman_1996,_Monteiro_1996,_Humphrey_1997,_Vallon-Christersson_2001,_Lovelock_2006,_Lee_2010,_Rowling_2010,_Bouwman_2013,_Gaboriau_2015,_Thouvenot_2016,_Anantha_2017)._In_addition,_this_variant_was_strongly_predicted_by_Lindor_et_al._(2012)_to_be_pathogenic_based_on_tumor_pathology,_clinical_histories,_family_studies,_and_co-occurrence_with_deleterious_variants._BRCA1_Ala1708Glu_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._BRCA1_Ala1708Glu_is_located_in_the_BRCT1_domain_and_a_region_that_interacts_with_multiple_proteins_(Narod_2004,_Paul_2014)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||||||IARC_class_based_on_posterior_probability_from_multifactorial_likelihood_analysis,_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.5096G>A	BRCA1	missense_variant	102642	6	NA	NA	4&5&5	1&1&1	rs41293459	not provided&Hereditary cancer-predisposing syndrome&Hereditary breast and ovarian cancer syndrome	37636	46192	_familial_1|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41215947C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:113705.0037|UniProtKB_(protein):P38398#VAR_070501	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	41293459	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Counsyl|Division_Human_Genetics,Medical_University_Innsbruck|Department_of_Medical_Genetics,University_Hospital_of_North_Norway|GeneReviews|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Mendelics|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|GeneDx|GeneKor_MSA|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Likely_pathogenic	2011-09-25|2013-07-16|2002-05-29|2014-01-02|2015-02-11|2016-05-01|2016-12-15|2017-06-02|2019-05-28|2017-05-10|2018-10-26|2017-11-01|2018-05-04|2018-08-23|2018-05-23|2018-12-28|2015-12-17|2017-01-27|2019-01-04|2018-07-02|2013-08-26|2018-12-01	2018-03-12|2013-12-30|2014-03-28|2014-05-01|2015-02-11|2016-09-20|2016-12-15|2018-06-14|2019-10-22|2019-08-19|2019-01-29|2017-11-21|2018-08-31|2020-02-26|2018-11-06|2019-03-28|2017-08-04|2019-03-21|2019-09-24|2018-08-20|2018-07-18|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided	germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000043748|SCV000053817|SCV000145310|SCV000153998|SCV000212005|SCV000301436|SCV000484957|SCV000839901|SCV001140488|SCV001156534|SCV000210198|SCV000693499|SCV000887711|SCV000186568|SCV000683252|SCV000076803|SCV000587462|SCV000605739|SCV000699200|SCV000839217|SCV000863582|SCV000923994	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast_and/or_ovarian_cancer|Ovarian_Neoplasms	|||||||The_c.5096G>A_(p.Arg1699Gln)_variant_has_been_reported_in_multiple_patients_with_breast_and/or_ovarian_cancer_[PMID_12827452,_24504028,_25782689]._Several_functional_in_vitro_assays_showed_ambiguous_results:_the_p.Arg1699Gln_showed_intermediate_deleterious_effects_but_not_to_the_extend_of_a_well_-characterized_pathogenic_variant_[PMID_22889855,_23867111,_21473589]._Additionally,_this_variant_showed_a_reduced_penetrance_in_a_study_[PMID_22889855]_and_the_risk_for_breast_or_ovarian_cancer_was_reduced_to_24_%_by_age_70._Additional_changes_affecting_the_same_amino_acid_position_(p.Arg1699Arg,_p.Arg1699Leu,_p.Arg1699Trp)_have_also_been_reported_in_patients_with_breast_and/or_ovarian_cancer._This_variant_was_reported_in_3_heterozygous_individuals_in_ExAC_(http://exac.broadinstitute.org/variant/17-41215947-C-T)._This_variant_is_conserved_in_mammals._Although_not_validated_for_clinical_use,_computer-based_algorithms_SIFT_and_Polyphen2_predict_this_p.Arg1699Gln_change_to_be_deleterious._This_variant_thus_classified_as_likely_pathogenic.||This_variant_has_been_shown_to_impact_function_(PMID:18036263,_23867111,_30257991,_30765603,_11157798)._A_genetic_study_(PMID:22889855)_reported_it_to_be_associated_with_reduced_risk_compared_to_another_pathogenic_missense_substitution_variant_at_the_same_residue_(BRCA1_c.5095C>T_p.(Arg1699Trp))._A_subsequent_larger_genetic_study_including_129_families_(PMID:28490613)_reported_HRs_of_2.83_for_breast_cancer_and_5.83_for_ovarian_cancer_risk,_and_estimated_the_cumulative_risk_to_age_70_to_be_20%_for_breast_cancer_and_6%_for_ovarian_cancer._This_variant_is_considered_pathogenic_with_reduced_penetrance_relative_to_the_average_BRCA1_truncating_pathogenic_variant._Management_recommendations_for_this_specific_variant_were_published_in_2017_(PMID:28490613)._In_line_with_a_recent_publication_that_provides_guidance_on_reporting_for_reduced_penetrance_variants_in_cancer_susceptibility_genes_(PMID:30962250),_clinical_management_recommendations_should_consider_knowledge_of_personal_and_family_history_of_disease,_and_other_known_genetic_and_environmental_risk_factors,_that_together_can_strongly_influence_absolute_risk_for_an_individual.|This_variant_is_denoted_BRCA1_c.5096G>A_at_the_cDNA_level,_p.Arg1699Gln_(R1699Q)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Glutamine_(CGG>CAG)._Using_alternate_nomenclature,_this_variant_is_defined_as_BRCA1_5215G>A._BRCA1_Arg1699Gln_has_been_observed_in_multiple_breast_and_ovarian_cancer_patients_and_families_(Rostagno_2003,_Spurdle_2012,_Cunningham_2014)._While_several_in_vitro_functional_assays_demonstrated_impairment,_specifically_with_respect_to_phosphopeptide_binding_activity,_in_other_assays_the_variant_performed_similar_to_wild-type_(Williams_2003,_Lovelock_2007,_Lee_2010,_Chang_2011)._BRCA1_Arg1699Gln_was_weakly_predicted_to_be_disease-causing_by_multiple_models_based_on_tumor_pathology,_clinical_histories,_family_studies_and_co-occurrence_with_deleterious_variants_(Chenevix-Trench_2006,_Lindor_2012)._This_variant_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._BRCA1_Arg1699Gln_is_located_within_the_BRCT1_domain_as_well_as_a_region_known_to_interact_with_multiple_other_proteins_(Paul_2014)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_currently_available_information,_we_consider_BRCA1_Arg1699Gln_to_be_a_pathogenic_variant_that_displays_reduced_penetrance._This_variant_has_been_reported_to_confer_lower_breast_and_ovarian_cancer_risk_than_a_typical_BRCA1_pathogenic_variant_in_multiple_studies_(Spurdle_2012,_Moghadasi_2017,_Shimelis_2017)._Moghadasi_et_al._(2017),_on_behalf_of_the_ENIGMA_consortium_(Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles),_reported_variant-specific_cancer_risks_for_BRCA1_Arg1699Gln_based_on_a_study_of_4,024_individuals_from_129_families._This_study_estimated_that_this_variant_confers_a_20%_risk_of_breast_cancer_and_a_6%_risk_of_ovarian_cancer_by_age_70._Lifetime_risks_associated_with_typical_BRCA1_variants_are_estimated_to_be_57_to_87%_for_female_breast_cancer_and_24_to_54%_for_ovarian_cancer_(Claus_1996,_Antoniou_2003,_King_2003,_Risch_2006,_Chen_2007)._This_variant_may_confer_risks_for_other_cancers_typically_associated_with_BRCA1_pathogenic_variants,_including_fallopian_tube,_primary_peritoneal,_and_serous_uterine_cancer_(Levine_2003,_Pennington_2013)._Other_cancer_risks_associated_with_a_typical_BRCA1_pathogenic_variant_include_a_slightly_increased_risk_for_prostate_cancer_before_age_65,_male_breast_cancer,_and_pancreatic_cancer_in_both_men_and_women_(Brose_2002,_Thompson_2002,_Liede_2004,_Tai_2007,_Leongamornlert_2012)._The_National_Comprehensive_Cancer_Network_has_management_guidelines_for_individuals_with_typical_BRCA1_pathogenic_variants_(NCCN)._Given_the_lower_cancer_risks_associated_with_this_variant,_the_ENIGMA_consortium_has_proposed_modified_variant-specific_breast_and_ovarian_cancer_management_recommendations_(Moghadasi_2017).|||Other_strong_data_supporting_pathogenic_classification:Deficient_protein_function_in_appropriate_functional_assay(s)||This_sequence_change_replaces_arginine_with_glutamine_at_codon_1699_of_the_BRCA1_protein_(p.Arg1699Gln)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_glutamine._This_variant_is_present_in_population_databases_(rs41293459,_ExAC_0.005%)._This_variant_has_been_reported_in_individuals_and_families_affected_with_breast_and/or_ovarian_cancer_(PMID:_11504767,_12827452,_16683254,_20455026,_24504028,_24728189,_25452441,_28490613)._In_a_large_family_cohort_study,_including_67_families_in_which_the_probands_carried_the_Arg1699Gln_change,_this_variant_was_shown_to_segregate_with_breast_and_ovarian_cancer_(PMID:_22889855)._This_variant_is_also_known_as_5215G>A_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37636)._This_missense_change_affects_the_highly_conserved_arginine_1699_residue_within_the_BRCT-N_domain_(PMID:_22843421,_11157798)._While_the_results_are_somewhat_conflicting_among_the_different_reports,_experimental_studies_have_shown_that_this_missense_change_can_disrupt_several_functional_activities_of_the_BRCA1_protein,_including_transactivation_(PMID:_18036263,_17308087,_11157798),_phosphopeptide_binding_(PMID:_21473589,_15133503,_15133502),_and_nuclear_foci_formation_(PMID:_18036263)._However,_this_variant_generally_exhibits_reduced_or_intermediate_BRCA1_protein_function._Modified_segregation_analysis_of_129_families_carrying_Arg1699Gln_has_shown_that_this_variant_confers_intermediate_risk_for_breast_and_ovarian_cancer_(PMID:_28490613)._The_risk_of_breast_cancer_by_age_70_years_is_20%_when_compared_to_8%_risk_for_women_in_the_general_population,_versus_65%_risk_for_carriers_of_an_average_pathogenic_BRCA1_variant._The_risk_of_ovarian_cancer_by_age_70_years_is_6%_when_compared_to_1%_risk_for_women_in_the_general_population,_versus_39%_risk_for_carriers_of_an_average_pathogenic_BRCA1_variant._In_summary,_this_variant_is_reported_to_cause_an_increased_risk_for_breast_and_ovarian_cancer._However,_since_this_variant_is_associated_with_a_lower_risk_than_other_pathogenic_alleles_in_the_BRCA1_gene,_it_has_been_classified_as_Pathogenic_(low_penetrance).||The_p.Arg1699Gln_variant_in_BRCA1_has_been_reported_in_>60_individuals_with_BRCA_1-associated_cancers_and_segregated_with_disease_in_multiple_relatives_from_30_f_amilies_(Spurdle_2012)._This_variant_has_been_described_as_having_reduced_penetr_ance_compared_to_other_disease-causing_variants:_24%_risk_of_BRCA1-associated_ca_ncer_to_age_70_(95%_CI,_10%_to_40%)_for_Arg1699Gln_carriers_vs._58%_(95%_CI,_7%_to_72%)_for_Arg1699Trp_carriers_vs._4.6%_risk_for_women_in_the_general_populatio_n_(Spurdle_2012)._It_has_been_identified_in_3/66110_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs4129_3459)._While_some_studies_have_demonstrated_impaired_in_vitro_protein_activity,_others_report_that_the_variant_performed_similar_to_wild-type_(Williams_2003,_Lo_velock_2007,_Chang_2011)._Computational_prediction_tools_and_conservation_analys_is_suggest_that_this_variant_may_impact_the_protein._In_summary,_although_additi_onal_studies_are_required_to_fully_establish_its_clinical_significance,_the_p.Ar_g1699Gln_variant_is_likely_pathogenic.|Variant_summary:_BRCA1_c.5096G>A_(p.Arg1699Gln)_involves_the_alteration_of_a_conserved_nucleotide_that_results_in_a_conservative_amino_acid_change_located_to_the_first_BRCT_domain_(IPR001357)_that_is_involved_in_interactions_with_phosphorylated_partner_proteins_(Petitalot_2018)_and_also_functions_as_a_transcriptional_activation_domain_(Langerud_2018)._The_variant_allele_was_found_at_a_frequency_of_2.4e-05_in_246952_control_chromosomes_(gnomAD)._c.5096G>A_has_been_reported_in_the_literature_in_multiple_individuals/families_affected_with_Hereditary_Breast_and_Ovarian_Cancer,_and_was_also_noted_to_cosegregate_with_the_disease_(Ricevuto_2001),_though,_in_one_family_the_variant_was_absent_in_an_affected_individual_(Gomez_Garcia_2009)._Although_the_variant_of_interest_was_found_to_co-occur_with_another_potentially_pathogenic_BRCA2_variant,_c.631+4A>G,_within_a_HBOC_family,_the_authors_indicated_that_both_variants_contributed_to_the_family_phenotype_(Steffensen_2010)._Co-occurrences_with_other_pathogenic_variant(s)_have_also_been_reported_elsewhere_(BRCA2_c.9026_9030delATCAT,_p.Tyr3009fsX7_in_the_UMD_database)._Case-control_studies_concluded_that_the_variant_confers_lower_breast_and_ovarian_cancer_risk_than_a_typical_BRCA1_pathogenic_variant_(Spurdle_2012,_Shimelis_2017,_Moghadasi_2018),_the_cumulative_risk_of_breast_and_ovarian_cancer_by_age_70_years_was_20%_and_6%,_respectively,_which_the_authors_refer_to_the_variant_as_an_intermediate_risk_variant_conferring_risks_lower_than_that_for_the_average_pathogenic_variant_(Moghadasi_2018)._Multiple_independent_functional_studies_reporting_this_variant_have_demonstrated:_1._proper_or_reduced_BRCT_domain_folding,_2._loss_of_phosphopeptide_binding,_3._decreased_or_intermediate_transcriptional_activity_of_the_mutant_BRCA1_constructs_expressed_in_mammalian_cell_lines,_and_4._defective_homology-directed_DNA_repair_(HDR)_capacity_and_nuclear_foci_formation_in_mammalian_cells,_but_preserved_wild-type_centrosome_amplification_function_(Vallon-Christersson_2001,_Williams_2003,_Williams_2004,_Carvalho_2007,_Lovelock_2007,_Rowling_2010,_Lee_2010,_Petitalot_2018,_Langerud_2018)._Although_it_is_not_clear_how_all_the_results_and_conclusions_drawn_from_these_in-vitro_studies_are_applicable_to_the_mechanism_and_presentation_of_disease,_the_convergence_of_results_obtained_from_multiple_independent_functional_assays_are_supportive_of_a_hypomorphic_and_damaging_effect_of_this_variant_on_the_BRCA1_gene_product._Twelve_ClinVar_submissions_from_other_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_likely_pathogenic/pathogenic._Based_on_the_evidence_outlined_above,_the_variant_is_classified_as_pathogenic.|||
NM_007294.3:c.5095C>T	BRCA1	missense_variant	102634	1	NA	NA	5&5&5&5&5&5&4	1&3&1&0&1&0&1	rs55770810	Hereditary breast and ovarian cancer syndrome&Breast-ovarian cancer, familial 1&Hereditary cancer-predisposing syndrome&Breast and colorectal cancer&not provided&Fanconi anemia, complementation group A&Ovarian cancer	55396	70063	Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Ovarian_cancer|Breast-ovarian_cancer,_familial_1|Fanconi_anemia,_complementation_group_A|FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S|Breast_and_colorectal_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1140680,Orphanet:ORPHA213500|MedGen:C2676676,OMIM:604370|MedGen:C3469521,OMIM:227650|MedGen:C4554406,OMIM:617883|MedGen:CN221560|MedGen:CN517202	-	NC_000017.10:g.41215948G>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Database_of_BRCA1_and_BRCA2_sequence_variants_that_have_been_clinically_reclassified_by_a_quantitative_integrated_evaluation:BRCA1_00046|UniProtKB_(protein):P38398#VAR_075666|OMIM_Allelic_Variant:113705.0040	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	9	55770810	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genologica_Medica|Bioinformatics_dept.,Datar_Cancer_Genetics_Limited,_India|OMIM|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Ambry_Genetics|CSER__CC_NCGL,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|University_of_Washington_Center_for_Mendelian_Genomics,University_of_Washington|GeneKor_MSA|Baylor_Genetics|OMIM	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-27|2014-01-31|2017-11-16|2012-05-01|2004-02-20|2015-08-10|2015-10-02|2015-10-20|2017-01-01|2017-06-20|2015-02-01|0000-00-00|2017-07-28|2015-09-21|2019-01-22|2019-02-01|2014-06-01|2018-07-11|2016-08-04|2015-05-19|2017-11-01|2017-02-23|2015-02-01	2019-03-28|2017-08-04|2019-04-24|2015-08-20|2014-03-28|2015-08-17|2016-10-28|2017-04-17|2017-03-15|2017-07-24|2018-03-12|2018-04-04|2018-04-17|2018-04-09|2019-08-02|2020-02-26|2014-08-28|2019-01-29|2018-08-31|2015-09-11|2017-11-21|2017-02-23|2018-03-12	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|paternal|germline|germline|germline	SCV000076802|SCV000587461|SCV000918722|SCV000109398|SCV000145309|SCV000244382|SCV000326154|SCV000564374|SCV000577934|SCV000584018|SCV000693740|SCV000733599|SCV000743380|SCV000744600|SCV000993551|SCV000186876|SCV000190089|SCV000210197|SCV000605901|SCV000246115|SCV000296777|SCV000540931|SCV000693739	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Breast_and_colorectal_cancer|not_provided|not_provided|Fanconi_anemia,_complementation_group_A|Ovarian_cancer|Familial_cancer_of_breast|FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S	This_sequence_change_replaces_arginine_with_tryptophan_at_codon_1699_of_the_BRCA1_protein_(p.Arg1699Trp)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_tryptophan._This_variant_is_present_in_population_databases_(rs55770810,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_with_breast_and/or_ovarian_cancer_(PMID:_22889855,_21324516,_21356067),_and_was_shown_to_segregate_with_breast/ovarian_cancer_in_two_families_(PMID:_11157798,_17574969)._It_was_also_found_in_trans_with_a_pathogenic_BRCA1_variant_in_an_individual_affected_with_Fanconi_anemia_(PMID:_25472942)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_55396)._Experimental_studies_have_shown_that_this_missense_change_disrupts_BRCA1_binding_ability_and_transcriptional_activity_(PMID:_21473589,_20516115,_17308087,_23867111)._Also,_a_multifactorial_likelihood_algorithm_using_genetic,_in_silico,_and_statistical_data_has_determined_that_this_variant_has_a_very_high_probability_of_being_deleterious_(PMID:_17924331,_21990134)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_BRCA1_c.5095C>T_(p.Arg1699Trp)_variant_involves_the_alteration_of_a_conserved_nucleotide_located_in_the_BCRT_domain_(InterPro)._5/5_in_silico_tools_predict_a_damaging_outcome_for_this_variant._This_variant_was_found_in_6/246572_control_chromosomes_at_a_frequency_of_0.0000243,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._This_variant_is_widely_known_as_a_recurrent_pathogenic_variant_found_in_several_HBOC_families,_including_one_patient_with_potential_de_novo/germline_mosaicism_transmission_(Antonucci_2016)._Patient_data,_functional_data,_and_data_from_multifactorial_probability_based_model_consistently_suggests_for_a_pathogenic_outcome._The_residue_p.Arg1699_is_a_critical_residue_that_plays_an_important_role_in_phosphopeptide_recognition_and_functional_assays_have_shown_that_the_variant_significantly_impairs_transcriptional_activity_in_mammalian_cell_line,_is_unable_to_fully_functionally_complement_BRCA1-deficient_mouse_embryonic_stem_cells,_and_leads_to_defective_phosphopeptide_binding_(Vallon-Christersson_2001,_Coquelle_2011,_and_Bouwman_2013)._The_residue_p.Arg1699_is_also_a_mutational_hot-spot_and_two_other_likely_pathogenic_variants_p.Arg1699Gln_and_p.Arg1699Leu_have_been_reported_in_it._In_addition,_numerous_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||IARC_class_based_on_posterior_probability_from_multifactorial_likelihood_analysis,_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.5074G>C	BRCA1	missense_variant,splice_region_variant	102672	1	NA	NA	5&5&4	0&1&1	rs80187739	Breast-ovarian cancer, familial 1&Hereditary cancer-predisposing syndrome&not provided	37633	46189	_familial_1|not_provided	-	MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41219625C>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80187739	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Invitae|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|GeneDx|GeneKor_MSA|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2010-11-17|2004-11-25|2015-10-02|2017-08-17|2019-06-18|2018-09-24|2013-08-13|2017-03-24|2018-04-27|2017-12-26|2016-10-03|2017-11-01|2019-03-01|2018-12-01	2013-06-26|2014-03-28|2016-10-28|2018-06-20|2019-07-23|2019-03-28|2017-04-19|2018-01-25|2019-03-21|2020-02-26|2019-01-29|2017-11-21|2020-03-06|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053814|SCV000145294|SCV000326136|SCV000785478|SCV001161554|SCV000076781|SCV000591568|SCV000699198|SCV000966915|SCV000277819|SCV000322068|SCV000693542|SCV001133606|SCV000923992	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Ovarian_Neoplasms	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.4868C>G	BRCA1	missense_variant	102652	1	NA	NA	4&5	1&1	rs80356862	not provided&Hereditary cancer-predisposing syndrome	37614	46170	_familial_1|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41223063G>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P38398#VAR_063901	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80356862	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Counsyl|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Invitae|Cancer_Genetics_and_Genomics_Laboratory,British_Columbia_Cancer_Agency|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto	Pathogenic|Uncertain_significance|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Uncertain_significance	2012-02-24|2002-05-29|2015-02-05|2015-10-02|2018-12-12|2017-04-18|2016-08-31|2019-02-20|2017-07-20|2018-05-09|2015-07-23|2018-04-25|2018-06-06|2014-01-31	2013-08-08|2014-03-28|2015-03-11|2016-10-28|2019-03-28|2017-08-04|2017-04-19|2019-09-24|2019-03-21|2019-01-29|2018-08-31|2020-02-26|2018-11-06|2017-08-04	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053795|SCV000145198|SCV000221119|SCV000326053|SCV000076693|SCV000586903|SCV000591543|SCV000699180|SCV000966914|SCV000108683|SCV000605895|SCV000186722|SCV000683223|SCV000587430	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified	||||This_sequence_change_replaces_alanine_with_glycine_at_codon_1623_of_the_BRCA1_protein_(p.Ala1623Gly)._The_alanine_residue_is_moderately_conserved_and_there_is_a_small_physicochemical_difference_between_alanine_and_glycine._This_variant_is_present_in_population_databases_(rs80356862,_ExAC_0.009%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_26681312,_23210696,_12491499,_22711857,_18312450,_27208206)._This_variant_is_also_known_as_4987C>G_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37614)._A_multifactorial_likelihood_analysis_based_on_genetic_evidence_such_as_family_history,_co-segregation_with_disease,_and_co-occurrence_with_pathogenic_variants_predicts_that_this_variant_is_likely_deleterious_(PMID:_17924331)._Experimental_studies_have_shown_that_this_variant_alters_RNA_splicing,_resulting_in_a_119_nucleotide_deletion_that_leads_to_a_truncated_BRCA1_protein_(PMID:_20513136,_27273131)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|||Variant_summary:_BRCA1_c.4868C>G_(p.Ala1623Gly)_results_in_a_non-conservative_amino_acid_change_in_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_benign_effect_of_the_variant_on_protein_function._However,_several_computational_tools_predict_a_significant_impact_on_normal_splicing:_four_predict_the_variant_creates_a_cryptic_exonic_5'_donor_site._This_prediction_has_been_confirmed_by_studies_using_patient_derived_lymphocyte_mRNA_that_has_demonstrated_the_variant_to_result_in_a_119_bp_deletion_from_exon_16,_leading_to_a_truncated_protein_(Walker_2010,_Byers_2016)._The_variant_had_an_incomplete_effect_on_splicing,_as_the_full_length_product_coding_for_the_missense_protein_was_also_detected,_although_in_a_minor_fraction_of_the_transcripts_(Walker_2010)._Another_in_vitro_study,_examining_the_protein_level_effects_of_this_missense_change,_demonstrated_that_the_missense_variant_had_comparable_activity_to_the_wild_type_in_a_transcriptional_activation_assay_(Woods_2016):_however_since_authors_used_the_BRCA1_cDNA_sequence_cloned_into_their_vectors_for_mutagenesis,_these_data_only_represent_the_protein_level_effects_of_the_missense_change._Therefore,_in_light_of_the_strong_spliceogenic_effect,_this_finding_does_not_reflect_the_overall_consequence_of_the_variant._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_246142_control_chromosomes_(gnomAD)_indicating_that_this_is_a_rare_variant_(ACMG_PM2)._The_variant_was_reported_in_the_literature_in_several_affected_individuals_from_unrelated_families_with_a_history_of_breast_and/or_ovarian_cancer_in_their_40's,_but_without_strong_evidence_for_cosegregation_with_disease_(Adem_2002,_Evans_2008,_Alsop_2012,_Chiang_2012,_Senter_2014,_Susswein_2015,_Byers_2016,_de_Jonge_2018,_Rebbeck_2018,_Delgado-Balderas_2018)._Based_on_the_population_data_and_the_number_of_reported_patients,_the_prevalence_of_the_variant_in_affected_individuals_is_significantly_increased_(ACMG_PS4)._In_addition,_multifactorial_probability_models,_performing_systematic_assessments_of_BRCA_variants,_which_included_analysis_of_personal_and_family_history_of_cancer,_tumor_pathology,_co-occurrence_in_trans_with_known_deleterious_mutations_and_co-segregation_with_disease_in_pedigrees,_predicted_this_variant_to_be_likely_deleterious_(Easton_2007):_and_when_the_spliceogenic_effect_of_the_variant_was_also_taken_into_account,_this_variant_was_predicted_to_be_clearly_pathogenic_(posterior_probability_of_pathogenicity:_0.999:_Vallee_2016)._Nine_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic_(4x)_/_likely_pathogenic_(5x)._Therefore,_the_community_consensus_seems_to_be_converging_on_a_pathological_outcome_for_this_variant.This_variant_was_previously_classified_conservatively_as_a_VUS-possibly_pathogenic_awaiting_additional_co-segregation_in_large_families_and_functional_evidence_of_the_altered_splice_variant_at_the_protein_level._Based_on_the_evidence_outlined_above,_and_further_supported_by_ACMG_guidelines_(ACMG_PM2_and_PS4),_the_variant_was_classified_as_likely_pathogenic.|The_p.Ala1623Gly_variant_in_BRCA1_has_been_reported_in_>10_individuals_with_BRCA_1-associated_cancers_(Adem_2003,_Easton_2007,_Evans_2008,_Walker_2010,_Alsop_201_2,_Chiang_2012,_Breast_Cancer_Information_Core_(BIC)_database)._This_variant_has_been_identified_in_1/11578_Latino_chromosomes_by_the_Exome_Aggregation_Consorti_um_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs80356862)_and_has_been_reporte_d_in_ClinVar_(Variation_ID:_37614)._Computational_prediction_tools_and_conservat_ion_analysis_suggest_that_this_variant_may_not_impact_the_protein:_however,_RNA_analysis_from_affected_individuals_show_that_the_p.Ala1623Gly_variant_causes_a_d_eletion_of_119_nucleotides_in_a_fraction_of_transcripts_Walker_2010)._In_summary_,_although_additional_studies_are_required_to_fully_establish_its_clinical_signi_ficance,_the_p.Ala1623Gly_variant_is_likely_pathogenic._ACMG/AMP_Criteria_applie_d:_PS4,_PM2,_PS3_Supporting.|This_variant_is_denoted_BRCA1_c.4868C>G_at_the_cDNA_level,_p.Ala1623Gly_(A1623G)_at_the_protein_level,_and_results_in_the_change_of_an_Alanine_to_a_Glycine_(GCT>GGT)._This_variant,_also_reported_as_4987C>G_by_alternative_nomenclature,_has_been_observed_in_individuals_with_breast_and_ovarian_cancer_(Adem_2003,_Evans_2008,_Alsop_2012,_Chiang_2012)._BRCA1_Ala1623Gly_has_also_been_reported_in_a_family_where_it_segregated_in_individuals_with_breast,_ovarian,_and_pancreatic_cancer_(Senter_2014)._In_vitro_studies_have_demonstrated_that_this_variant_results_in_abnormal_gene_splicing_causing_a_deletion_of_119_nucleotides_of_the_BRCA1_gene,_resulting_in_disruption_to_the_open_reading_frame:_however,_one_author_has_noted_this_abnormal_splicing_to_be_incomplete_(Walker_2010,_Byers_2016)._Easton_et_al._(2007)_report_31:1_odds_in_favor_of_causality_based_on_personal_and_family_history_of_cancer,_co-occurrence,_and_co-segregation_data._BRCA1_Ala1623Gly_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_a_region_known_to_interact_with_multiple_proteins_(Paul_2014)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_BRCA1_Ala1623Gly_to_be_a_likely_pathogenic_variant.||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Functionally-validated_splicing_mutation:Other_strong_data_supporting_pathogenic_classification||
NM_007294.3:c.4484G>T	BRCA1	missense_variant,splice_region_variant	102588	1	NA	NA	5&5&5&5&5	2&1&1&1&1	rs80357389	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&not provided&not specified	37598	46154	_familial_1|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41228505C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P38398#VAR_063900|Breast_Cancer_Information_Core__(BRCA1):4603&base_change%3DG_to_T	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80357389	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Pathway_Genomics|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Mendelics|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneKor_MSA|Baylor_Genetics|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-05-01|2002-05-29|2014-10-30|2015-10-02|2019-05-28|2018-12-20|2014-01-31|2015-04-17|2017-02-25|2016-07-31|2018-07-02|2018-09-11|2015-10-05|2018-11-20|2015-09-04|2016-07-01|2017-02-23|2016-05-17	2015-08-20|2014-03-28|2015-05-28|2016-10-28|2019-10-22|2019-03-28|2017-08-04|2017-04-19|2019-03-21|2018-01-25|2018-08-20|2020-02-26|2017-01-26|2019-01-29|2017-08-01|2016-07-19|2017-02-23|2018-04-30	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000053779|SCV000145100|SCV000223754|SCV000325979|SCV001140523|SCV000076589|SCV000587401|SCV000591519|SCV000605750|SCV000699152|SCV000839231|SCV000186941|SCV000537652|SCV000210177|SCV000296380|SCV000296803|SCV000540946|SCV000902222	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_specified|Familial_cancer_of_breast|Breast_and/or_ovarian_cancer	|||||This_sequence_change_replaces_arginine_with_methionine_at_codon_1495_of_the_BRCA1_protein_(p.Arg1495Met)._The_arginine_residue_is_moderately_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_methionine._This_variant_also_falls_at_the_last_nucleotide_of_exon_13_of_the_BRCA1_coding_sequence,_which_is_part_of_the_consensus_splice_site_for_this_exon._This_variant_is_present_in_population_databases_(rs80357389,_ExAC_0.001%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_23096355,_10571952,_10923033,_22144684)._It_has_also_been_shown_to_co-segregate_with_disease_in_a_family_affected_with_breast_cancer_(PMID:_24607278)._This_variant_is_also_known_as_4603G>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37598)_Experimental_studies_evaluating_the_effect_of_this_sequence_change_on_RNA_splicing_have_shown_that_this_variant_results_in_aberrant_BRCA1_splicing,_leading_to_the_skipping_of_exon_13_as_well_as_exons_13-14_(PMID:_24607278,_10571952,_12915465,_21120943)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||proposed_classification_-_variant_undergoing_re-assessment,_contact_laboratory|Variant_summary:_The_BRCA1_c.4484G>T_(p.Arg1495Met)_variant_causes_a_missense_change_involving_a_conserved_nucleotide,_located_at_the_most_3'_position,_i.e.,_the_last_nucleotide_of_exon_13._It_is_predicted_to_disrupt_the_natural_splice_donor_site_and_cause_abnormal_splicing._5/5_splicing_prediction_tools,_predict_alterations_to_splicing,_consistent_with_the_observed_functional_studies_that_implicate_an_affect_on_splicing._The_variant_of_interest_was_observed_in_a_large,_broad_control_population,_ExAC,_with_an_allele_frequency_of_1/121358,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_BRCA1_variant_of_1/1000._The_variant_of_interest_has_been_reported_in_multiple_affected_individuals_via_publications,_along_with_multiple_reputable_databases/clinical_laboratories_citing_the_variant_as_pathogenic._Therefore,_taking_all_available_lines_of_evidence_into_consideration,_the_variant_of_interest_has_been_classified_as_Pathogenic.||Functionally-validated_splicing_mutation:Last_nucleotide_of_exon:Other_strong_data_supporting_pathogenic_classification||This_pathogenic_variant_is_denoted_BRCA1_c.4484G>T_at_the_cDNA_level._Located_at_the_last_nucleotide_of_exon_13,_it_disrupts_the_natural_splice_donor_site_and_causes_abnormal_splicing._Multiple_protein_and_RNA_analyses_have_consistently_demonstrated_that_BRCA1_c.4484G>T_causes_skipping_of_exon_13,_and_to_a_lesser_extent,_skipping_of_exons_13-14_(also_referred_to_as_exons_14_and_15_in_the_literature)_and_subsequently_fails_to_produce_a_full_length_transcript_(Ozcelik_1999,_Yang_2003,_Houdayer_2012,_Colombo_2013,_Santos_2014)._BRCA1_c.4484G>T,_also_known_as_4603G>T_using_alternate_nomenclature,_has_been_reported_in_multiple_individuals_with_personal_and/or_family_histories_of_breast_and_ovarian_cancer,_segregating_with_cancer_in_at_least_one_of_these_families_(Aziz_2001,_Caux-Moncoutier_2011,_Zhang_2011,_Lara_2012,_Ripamonti_2013,_Santos_2014,_Pal_2015,_Finch_2015,_Pellegrino_2016,_Brianese_2017)._Additionally,_this_variant_was_strongly_predicted_by_Lindor_et_al._(2012)_to_be_deleterious_based_on_tumor_pathology,_clinical_histories,_family_studies_and_co-occurrence_with_deleterious_variants._Although_the_nucleotide_substitution_results_in_the_change_of_an_Arginine_to_a_Methionine_at_codon_1495,_and_is_called_Arg1495Met_in_the_literature,_we_are_using_the_nucleotide_nomenclature_to_refer_to_the_variant_since_the_defect_is_determined_to_be_one_of_splicing_rather_than_a_resulting_missense_variant._BRCA1_c.4484G>T_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._The_nucleotide_which_is_altered,_a_guanine_(G)_at_base_4484,_is_conserved_across_species._Based_on_the_current_evidence,_we_consider_BRCA1_c.4484G>T_to_be_a_pathogenic_variant.||||
NM_007294.3:c.213-11T>G	BRCA1	intron_variant	102602	2	NA	NA	-	-	-	-	37449	46005	_familial_1|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000017.10:g.41256984A>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA1):332-11&base_change%3DT_to_G	-	BRCA1:672	SO:0001627|intron_variant	1	80358061	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Counsyl|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Baylor_Genetics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-07-17|2002-05-29|2014-10-24|2015-10-02|2018-12-31|2014-01-31|2016-04-15|2017-07-20|2017-09-12|2019-05-10|2018-11-08|2015-02-10|2017-02-23|2016-09-19|2007-01-26	2015-12-29|2014-03-28|2015-03-11|2016-10-28|2019-03-28|2017-08-04|2018-01-25|2019-03-21|2017-11-28|2020-03-06|2020-02-26|2016-07-05|2017-02-23|2017-06-30|2018-07-18	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053624|SCV000144670|SCV000220836|SCV000325254|SCV000075738|SCV000587038|SCV000698919|SCV000966958|SCV000108655|SCV000296273|SCV000186953|SCV000292144|SCV000540930|SCV000602679|SCV000863669	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|not_specified|Breast_and/or_ovarian_cancer	||||This_sequence_change_falls_in_intron_4_of_the_BRCA1_mRNA._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_BRCA1_protein._This_variant_is_present_in_population_databases_(rs80358061,_ExAC_0.002%)._This_variant_was_reported_to_segregate_with_disease_in_a_large_family_affected_with_breast_and_ovarian_cancer_(PMID:_7894493),_and_has_been_observed_in_many_unrelated_individuals_with_breast_and/or_ovarian_cancer_(PMID:_18284688,_21993507,_25452441,_10923033,_22144684)._In_the_literature,_this_variant_is_also_known_as_c.332-11T>G_and_IVS5-11T>G._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37449)._Experimental_studies_have_demonstrated_that_this_variant_weakens_the_consensus_acceptor_splice_site_in_intron_4,_which_leads_to_the_use_of_a_cryptic_acceptor_splice_site_59_nucleotides_upstream_of_the_5'_end_of_exon_5_(PMID:_18424508,_23451180)._This_is_expected_to_result_in_a_frameshift_in_the_BRCA1_mRNA_and_an_absent_or_truncated_protein._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_BRCA1_c.213-11T>G_variant_affects_a_conserved_intronic_nucleotide._3/5_splice-site_tools_predict_the_variant_to_create_a_new_cryptic_splice_site_and/or_weaken_the_cononical_splice_site._This_in_silico_predicted_result_is_proven_by_multiple_functional_studies_showing_that_this_variant_leads_to_a_splicing_defect,_resulting_in_an_extra_59_base_pairs_at_the_end_of_intron_4_and_introducing_a_premature_stop_codon._This_variant_was_found_in_1/121156_control_chromosomes_at_a_frequency_of_0.0000083,_which_does_not_exceed_maximal_expected_frequency_of_a_pathogenic_BRCA1_allele_(0.0010005)._However,_the_variant_has_been_found_in_multiple_HBOC_patients_or_individuals_undergoing_BRCA1/2_testing_as_reported_in_literature_and_clinical_databases._Additionally,_several_clinical_labs_and_clinical_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_has_been_classified_as_a_Disease_Variant/Pathogenic.|The_c.213-11T>G_variant_in_BRCA1_has_been_reported_in_>100_individuals_with_BRCA_1-associated_cancers_and_has_segregated_with_disease_in_multiple_affected_relati_ves_(Friedman_1994,_John_2007,_Smith_2012,_Wong-Brown_2015,_BIC_database)._This_variant_has_also_been_reported_by_multiple_clinical_laboratories_in_ClinVar_(Var_iation_ID#_37449)._Additionally,_this_variant_has_been_identified_in_3/111540_Eu_ropean_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.bro_adinstitute.org)._Sequencing_of_patient_RNA_has_shown_that_this_variant_leads_to_a_retention_of_59_base_pairs_at_the_3'_end_of_intron_5,_which_is_predicted_to_r_esult_in_a_premature_stop_codon_(Friedman_1994,_Colombo_2013)._Heterozygous_loss_of_function_of_the_BRCA1_gene_is_an_established_disease_mechanism_in_individual_s_with_hereditary_breast_and/or_ovarian_cancer_(HBOC)._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_frequency_in_patients_and_segregation_studies._ACMG/AMP_cr_iteria_applied:_PS4,_PP1_Strong.|This_pathogenic_variant_is_denoted_BRCA1_c.213-11T>G_or_IVS4-11T>G_and_consists_of_a_T>G_nucleotide_substitution_at_the_-11_position_of_intron_4_of_the_BRCA1_gene._This_variant_is_also_known_as_BRCA1_332-11T>G_or_BRCA1_IVS5-11T>G_using_alternate_nomenclature._RNA_and_minigene_assays_have_demonstrated_that_BRCA1_c.213-11T>G_causes_aberrant_splicing_through_activation_of_a_cryptic_splice_acceptor_site,_introducing_a_premature_stop_codon_and_leading_to_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product_(Bonnet_2008,_Colombo_2013)._This_variant_has_been_observed_in_multiple_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer,_and_has_been_shown_to_segregate_with_disease_(Friedman_1994,_Musolino_2005,_John_2007,_Colombo_2013,_Song_2014,_Wong-Brown_2015)._We_consider_this_variant_to_be_pathogenic.|The_best_available_variant_frequency_is_uninformative._Found_in_at_least_one_symptomatic_patient_in_literature._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function._Strong_co-segregation_with_disease_in_affected_individuals.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification||||
NM_007294.3:c.211A>G	BRCA1	missense_variant,splice_region_variant	102222	1	NA	NA	5&5&5	1&1&1	rs80357382	Breast-ovarian cancer, familial 1&not provided&Hereditary cancer-predisposing syndrome	17693	32732	Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_1|Pancreatic_cancer_4|FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S|not_specified|breast_cancer|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:C3280442,OMIM:614320|MedGen:C4554406,OMIM:617883|MedGen:CN169374|MedGen:CN235590|MedGen:CN517202	-	NC_000017.10:g.41258474T>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:148446|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario:1776756|Department_of_Pathology_and_Molecular_Medicine,Queen's_University:721884|OMIM_Allelic_Variant:113705.0034	-	BRCA1:672	SO:0001583|missense_variant	3	80357382	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Genologica_Medica|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Baylor_Genetics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics|Center_of_Medical_Genetics_and_Primary_Health_Care	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2003-10-01|2012-10-15|2002-05-29|2015-10-02|2016-03-16|2017-01-01|2019-06-18|2018-10-22|2019-06-04|2019-01-18|2015-04-02|2018-12-03|2014-01-31|2017-04-20|2016-04-18|2018-07-02|2017-02-23|2018-07-02|2018-10-31|0000-00-00	2018-03-12|2015-12-29|2014-03-28|2016-10-28|2016-11-23|2017-03-15|2019-07-23|2019-01-29|2020-03-06|2020-02-26|2017-01-26|2019-03-28|2017-08-04|2017-08-04|2018-01-25|2018-08-20|2017-02-23|2019-08-05|2018-11-14|2019-09-25	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|unknown	SCV000039551|SCV000053620|SCV000144658|SCV000325237|SCV000488382|SCV000577917|SCV001161539|SCV000210069|SCV000296343|SCV000186954|SCV000537653|SCV000075726|SCV000587031|SCV000588028|SCV000698917|SCV000839310|SCV000540947|SCV000602724|SCV000893454|SCV000978253	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|not_specified|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_1/Pancreatic_cancer_4/FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S|breast_cancer	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.181T>G	BRCA1	missense_variant	102510	5	NA	NA	5&5&5&5&4	3&2&2&1&1	rs28897672	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&not provided&Familial cancer of breast	17661	32700	Breast_carcinoma|Neoplasm_of_the_breast|Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_1|Pancreatic_cancer_4|FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0003002,MedGen:C0678222,Orphanet:ORPHA180257|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:C3280442,OMIM:614320|MedGen:C4554406,OMIM:617883|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41258504A>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Department_of_Pathology_and_Molecular_Medicine,Queen's_University:721612|OMIM_Allelic_Variant:113705.0002|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:16611|UniProtKB_(protein):P38398#VAR_007757|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario:1776902|Database_of_BRCA1_and_BRCA2_sequence_variants_that_have_been_clinically_reclassified_by_a_quantitative_integrated_evaluation:BRCA1_00099	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	3	28897672	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Genetic_Services_Laboratory,_University_of_Chicago|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Mendelics|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Ambry_Genetics|Color|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|GeneKor_MSA|Baylor_Genetics|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2000-06-01|2013-09-18|0000-00-00|2014-11-03|2015-08-10|2015-10-02|2015-07-01|2016-12-02|2015-11-12|0000-00-00|2017-05-25|2019-05-28|2018-12-30|2015-12-22|2014-01-31|2017-04-20|2012-06-15|2017-08-24|2018-07-02|2019-03-04|2014-12-30|2017-07-12|2018-12-04|2015-05-13|2019-04-14|2016-12-07|2018-08-01|2017-02-23|0000-00-00|2016-04-06|2018-07-17|2018-10-31|2018-12-01	2018-03-12|2015-12-29|2014-03-28|2016-04-21|2015-08-17|2016-10-28|2017-04-17|2017-07-05|2017-06-22|2018-04-04|2018-06-14|2019-10-22|2019-03-28|2019-03-21|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2018-08-20|2020-02-26|2016-07-05|2017-08-08|2019-01-29|2018-09-19|2020-03-06|2018-03-09|2018-08-08|2017-02-23|2016-12-06|2016-11-12|2019-08-05|2018-11-14|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|unknown|germline|unknown|germline	SCV000039517|SCV000109295|SCV000144574|SCV000195877|SCV000244308|SCV000325150|SCV000564349|SCV000593687|SCV000677634|SCV000733679|SCV000839890|SCV001140644|SCV000075610|SCV000271313|SCV000587024|SCV000588026|SCV000591246|SCV000698888|SCV000839313|SCV000186957|SCV000292141|SCV000679704|SCV000210067|SCV000230340|SCV000296283|SCV000778779|SCV000296762|SCV000540933|SCV000492470|SCV000492590|SCV000602706|SCV000893455|SCV000923767	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_provided|Familial_cancer_of_breast|Familial_cancer_of_breast|Neoplasm_of_the_breast|Breast_carcinoma|not_specified|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_1/Pancreatic_cancer_4/FANCONI_ANEMIA,_COMPLEMENTATION_GROUP_S|Ovarian_Neoplasms	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.134+3_134+6del	BRCA1	splice_region_variant,intron_variant	102142	1	NA	NA	-	-	-	-	54213	68880	_familial_1	-	OMIM:604370	-	NC_000017.10:g.41267737_41267740ACTT[1]	_single_submitter	Pathogenic	-	-	Microsatellite	SO:0000289	-	-	BRCA1:672	SO:0001627|intron_variant	1	397508858	-	_c/o_University_of_Cambridge	Pathogenic	2015-10-02	2016-10-28	_single_submitter	germline	SCV000325028	_familial_1	
NM_058216.2:c.404G>A	RAD51C	missense_variant,splice_region_variant	100690	1	NA	NA	4	1	rs767796996	Hereditary cancer-predisposing syndrome	234175	236214	_complementation_group_O	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390	-	NC_000017.10:g.56772550G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	RAD51C:5889	SO:0001583|missense_variant,SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant	1	767796996	-	Ambry_Genetics|Color|Invitae|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-10-30|2018-07-31|2018-12-11|2018-07-02|2019-11-20	2020-02-26|2018-11-06|2019-03-28|2018-08-20|2019-12-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline	SCV000278700|SCV000909441|SCV000550186|SCV000839327|SCV000920120	_complementation_group_O|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	Last_nucleotide_of_exon:Deficient_protein_function_in_appropriate_functional_assay(s):Well-characterized_mutation_at_same_position||This_sequence_change_replaces_cysteine_with_tyrosine_at_codon_135_of_the_RAD51C_protein_(p.Cys135Tyr)._The_cysteine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_cysteine_and_tyrosine._It_also_falls_at_the_last_nucleotide_of_exon_2_of_the_RAD51C_coding_sequence._This_variant_is_present_in_population_databases_(rs767796996,_ExAC_0.002%)._This_variant_has_been_reported_in_an_individual_affected_with_breast_and_ovarian_cancer_(PMID:_22451500)._It_has_also_been_observed_in_an_individual_with_ovarian_cancer_(Invitae_database)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234175)._Experimental_studies_have_shown_that_this_missense_change_results_in_a_functionally_impaired_protein_(PMID:_22451500)._Nucleotide_substitutions_within_the_consensus_splice_site_are_relatively_common_causes_of_aberrant_splicing_(PMID:_17576681,_9536098)._Algorithms_developed_to_predict_the_effect_of_nucleotide_changes_on_RNA_splicing_suggest_that_this_variant_may_alter_RNA_splicing,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._Two_additional_variants_affecting_this_nucleotide_(c.404G>C,_c.404G>T)_have_been_shown_to_disrupt_the_naturally_occurring_RNA_splicing_of_RAD51C,_activating_a_cryptic_donor_splice_site_27_nucleotides_downstream_in_intron_2._The_resultant_reading_frame_contains_a_stop_codon,_that_may_trigger_an_NMD_response._This_suggests_that_this_nucleotide_is_important_for_normal_RNA_splicing,_and_that_other_variants_at_this_position_may_also_be_pathogenic._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||Variant_Summary:_RAD51C_c.404G>A_(p.Cys135Tyr)_results_in_a_non-conservative_amino_acid_change_located_in_the_DNA_recombination_and_repair_protein_RecA-like,_ATP-binding_domain_(IPR020588)_of_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._In_addition,_the_variant_also_affects_a_conserved_nucleotide_located_in_the_last_position_of_exon_2._Several_computational_tools_predict_a_significant_impact_on_normal_splicing:_three_predict_the_variant_abolishes_a_5'_splicing_donor_site,_while_one_predicts_the_variant_weakens_a_5'_donor_site._However,_these_predictions_have_yet_to_be_confirmed_by_functional_studies._In_an_in_vitro_study,_two_different_nucleotide_changes_affecting_the_same_position,_namely_c.404G>C_and_c.404G>T,_have_been_shown_to_disrupt_RAD51C_pre-mRNA_processing,_resulting_in_the_utilization_of_a_cryptic_intronic_donor_site_27_bp_downstream_of_the_canonical_splice_site_(Neidhart_2017)._Both_these_variants_were_shown_to_completely_abolish_proper_splicing,_causing_the_inclusion_of_intronic_sequences_resulting_in_a_missense_substitution_immediately_followed_by_a_stop_codon_in_both_instances._Based_on_these_data,_our_variant_of_interest_can_be_predicted_to_result_in_a_similar_outcome._The_variant_allele_was_found_at_a_frequency_of_4e-06_in_247064_control_chromosomes._c.404G>A_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Osorio_2012,_Sanchez-Bermudez_2018)._These_data_indicate_that_the_variant_may_be_associated_with_disease._An_in_vitro_study,_examining_the_effect_of_this_variant_at_the_protein_level,_using_an_(intronless)_cDNA_construct,_demonstrated_an_approximately_50%_reduction_in_RAD51C_foci_formation_(a_surrogate_measure_of_homology-directed_repair)_(Osorio_2012)._However,_in_light_of_the_potential_strong_spliceogenic_effect,_this_finding_might_not_reflect_the_overall_physiological_consequence_of_the_variant_in-vivo._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_likely_pathogenic_citing_overlapping_evidence_utilized_in_the_context_of_this_evaluation._Based_on_the_evidence_outlined_above,_the_variant_was_re-classified_as_likely_pathogenic.
NM_058216.2:c.414G>C	RAD51C	missense_variant	102736	1	NA	NA	4	1	rs267606999	Hereditary cancer-predisposing syndrome	6825	21864	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399	-	NC_000017.10:g.56774063G>C	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:602774.0004|UniProtKB_(protein):O43502#VAR_063840	-	RAD51C:5889	SO:0001583|missense_variant	1	267606999	-	OMIM|Ambry_Genetics|Color|Invitae|Counsyl	risk_factor|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2010-05-01|2019-11-07|2018-06-12|2018-11-09|2018-01-23	2019-08-21|2020-02-26|2018-11-06|2019-03-28|2018-06-20	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000027423|SCV000184611|SCV000909442|SCV000770083|SCV000785964	Breast-ovarian_cancer,_familial_3|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O	|Deficient_protein_function_in_appropriate_functional_assay(s):Other_data_supporting_pathogenic_classification:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_replaces_leucine_with_phenylalanine_at_codon_138_of_the_RAD51C_protein_(p.Leu138Phe)._The_leucine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_leucine_and_phenylalanine._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_and_families_with_breast_cancer_and/or_ovarian_cancer_and_has_been_reported_to_segregate_with_disease_in_two_of_these_families_(PMID:_20400964,_22451500,_27328445)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_6825)._Experimental_studies_have_shown_that_this_missense_change_disrupts_protein_function,_resulting_in_a_defective_DNA_damage_response_(PMID:_20400964,_22167183,_24141787,_25292178,_26354865)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_058216.2:c.773G>A	RAD51C	missense_variant	102712	4	NA	NA	5&4	0&1	rs267606997	Fanconi anemia, complementation group O&Hereditary cancer-predisposing syndrome	6822	21861	_complementation_group_O|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:CN517202	-	NC_000017.10:g.56787287G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:602774.0001|UniProtKB_(protein):O43502#VAR_064032	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	267606997	-	OMIM|Invitae|Mendelics|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2010-05-01|2018-12-27|2019-05-28|2019-09-29|2018-09-05|2017-07-21	2019-08-21|2019-03-28|2019-10-22|2020-02-26|2018-11-06|2017-08-01	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline	SCV000027420|SCV000550214|SCV001140720|SCV000186741|SCV000686387|SCV000602145	Fanconi_anemia,_complementation_group_O|Fanconi_anemia,_complementation_group_O|Fanconi_anemia,_complementation_group_O|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|This_sequence_change_replaces_arginine_with_histidine_at_codon_258_of_the_RAD51C_protein_(p.Arg258His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs267606997,_ExAC_0.003%)._This_variant_has_been_reported_to_segregate_in_individuals_with_features_of_Fanconi_anemia_in_a_single_family_(PMID:Â¬â€ 20400963)._It_has_also_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:Â¬â€ 25154786,Â¬â€ 26740214)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_6822)._Experimental_studies_have_shown_that_this_missense_change_results_in_increased_chromosomal_disruption_and_G2_arrest_(PMID:_20400963,_22167183)._Wild-type_RAD51C_cDNA_was_able_to_rescue_G2_arrest,_while_cDNA_carrying_this_variant_failed_to_rescue._Another_study_showed_that_this_missense_change_results_in_decreased_replication_restart_at_stalled_replication_forks,_which_may_result_in_increased_replication-associated_double-stranded_breaks_(PMID:_26354865)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||
NM_058216.2:c.904+5G>T	RAD51C	splice_region_variant,intron_variant	102574	4	NA	NA	-	-	-	-	142762	152476	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56798178G>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	RAD51C_@_LOVD:RAD51C_000046|OMIM_Allelic_Variant:602774.0002	-	RAD51C:5889	SO:0001627|intron_variant	1	587782702	-	OMIM|Ambry_Genetics|Color|Invitae|GeneDx|GeneKor_MSA	risk_factor|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2010-05-01|2019-10-22|2018-06-12|2018-12-16|2018-01-23|2018-08-01	2019-08-21|2020-02-26|2018-11-06|2019-03-28|2019-01-29|2018-08-08	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000027421|SCV000187215|SCV000691285|SCV000291252|SCV000566207|SCV000821778	Breast-ovarian_cancer,_familial_3|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|not_provided|not_provided	|Moderate_segregation_with_disease_(at_least_3_informative_meioses)_for_rare_diseases.:Other_data_supporting_pathogenic_classification:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Functionally-validated_splicing_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_falls_in_intron_6_of_the_RAD51C_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_RAD51C_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs587782702,_ExAC_0.002%)._This_variant_has_been_reported_individuals_affected_with_breast_or_ovarian_cancer_(PMID:_22538716,_24993905),_and_was_shown_to_segregate_with_disease_in_a_family_with_breast_and_ovarian_cancer_(PMID:_20400964)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142762)._Nucleotide_substitutions_within_the_consensus_splice_site_are_relatively_common_causes_of_aberrant_splicing_(PMID:_17576681,_9536098)._Experimental_studies_have_shown_that_this_variant_disrupts_splicing_and_leads_to_the_deletion_of_the_exon_6_coding_sequence_from_the_RAD51C_mRNA._This_is_predicted_to_result_in_a_frameshift_and_premature_stop_codon_(PMID:_20400964)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_variant_is_denoted_RAD51C_c.904+5G>T_or_IVS6+5G>T_and_consists_of_a_G>T_nucleotide_substitution_at_the_+5_position_of_intron_6_of_the_RAD51C_gene._Multiple_in_silico_models_predict_this_variant_to_destroy_the_nearby_natural_donor_site,_and_functional_analyses,_including_an_RT-PCR_assay_and_a_minigene_assay,_demonstrated_that_this_variant_causes_skipping_of_exon_6_(Meindl_2010)._This_variant_has_been_observed_in_several_individuals_with_breast_and/or_ovarian_cancer,_and_analysis_of_breast_and_ovarian_tumor_tissue_in_two_carriers_of_this_variant_showed_loss_of_the_wild_type_allele,_supporting_a_pathogenic_role_(Meindl_2010,_Loveday_2012)._The_guanine_(G)_nucleotide_that_is_altered_is_important_for_splicing_and_is_conserved_across_species._Based_on_the_currently_available_evidence,_we_consider_RAD51C_c.904+5G>T_to_be_a_likely_pathogenic_variant.|
NM_058216.2:c.1026+5_1026+7del	RAD51C	splice_region_variant,intron_variant	102668	1	NA	NA	-	-	-	-	128201	133658	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56809910_56809912del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	RAD51C:5889	SO:0001627|intron_variant	1	587781410	-	Ambry_Genetics|Color|Invitae|GeneDx|PreventionGenetics,PreventionGenetics|Laboratoire_de_Biologie_et_Génétique_du_Cancer,Centre_François_Baclesse|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Counsyl	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2019-10-09|2018-10-17|2018-12-28|2018-11-15|2016-10-17|0000-00-00|2018-05-17|2016-08-06	2020-02-26|2018-11-06|2019-03-28|2019-01-29|2018-01-29|2017-03-06|2018-11-05|2017-06-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown	SCV000184030|SCV000691214|SCV000255311|SCV000150079|SCV000807165|SCV000536678|SCV000886446|SCV000677795	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|not_provided|not_provided|Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O	Deficient_protein_function_in_appropriate_functional_assay(s):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_falls_in_intron_8_of_the_RAD51C_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_RAD51C_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs587781410,_ExAC_0.004%)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer,_ovarian_cancer,_and_uterine_cancer,_as_well_as_in_an_unaffected_control_individual_(PMID:_22538716,_24139550,_26057125,_27616075,Â¬â€ 29255180)._Segregation_studies_have_not_been_reported_for_this_variant._ClinVar_also_contains_an_entry_for_this_variant_(Variation_ID:_128201)._This_small_deletion_disrupts_the_consensus_donor_splice_site_at_intron_8_of_the_RAD51C_gene._RT-PCR_analysis_using_RNA_extracted_from_the_peripheral_blood_of_carrier_individuals_shows_that_this_variant_may_lead_to_the_skipping_of_exon_8,_resulting_in_a_frameshift_and_the_generation_of_a_premature_stop_codon_in_the_final_exon_of_RAD51C_(PMID:_24139550,_26057125,_28905878)._Although_it_is_not_predicted_to_result_in_nonsense_mediated_decay,_it_does_affect_the_C-terminus_of_the_RAD51C_protein,_which_includes_a_nuclear_localization_signal_that_when_deleted_has_been_shown_to_cause_cellular_mislocalization_(PMID:_12966089)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_variant_is_denoted_RAD51C_c.1026+5_1026+7delGTA_or_IVS8+5_IVS8+7delGTA_and_consists_of_a_deletion_of_three_nucleotides_at_the_+5_to_+7_positions_in_intron_8_of_the_RAD51C_gene._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_gtca[delgta]ttat._This_variant_has_been_observed_in_at_least_four_breast/ovarian_cancer_families,_as_well_as_in_one_healthy_control_(Loveday_2012,_Golmard_2013,_Janatova_2015,_Kraus_2017)._In_silico_analyses,_which_include_splice_predictors_and_evolutionary_conservation,_are_inconsistent_in_their_assessment_as_to_whether_or_not_the_variant_is_damaging:_however,_mRNA_studies_showed_this_variant_causes_out-of-frame_skipping_of_exon_8,_resulting_in_a_frameshift_and_truncated_protein_(Golmard_2013,_Davy_2017)._The_disrupted_region_at_the_end_of_the_gene_includes_the_nuclear_localization_signal_(French_2003)._RAD51C_c.1026+5_1026+7delGTA_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Based_on_currently_available_evidence,_we_consider_RAD51C_c.1026+5_1026+7delGTA_to_be_a_likely_pathogenic_variant.|||The_RAD51C_variant_designated_as_NM_058216.2:c.1026+5_1026+7delGTA_was_previously_classified_as_a_variant_of_uncertain_significance_and_is_now_classified_as_likely_pathogenic._This_variant_is_a_nucleotide_deletion_that_affects_a_consensus_splice_site_in_intron_8_of_the_RAD51C_gene._RNA_studies_of_peripheral_blood_from_individuals_with_the_variant_have_demonstrated_that_the_variant_leads_to_skipping_of_exon_8,_resulting_in_a_frameshift_and_the_generation_of_a_premature_stop_codon_in_the_final_exon_(Golmard_2013,_PMID:241395:_Janatova_2015,_PMID:26057125)._Nonsense-mediated_decay_is_not_expected_to_result_from_this_variant,_but_it_leads_to_a_removal_of_the_nuclear_localization_signal_which_can_cause_cellular_mislocalization_(French_2003,_PMID:12966089)._This_variant_is_not_listed_in_population_databases._It_has_been_reported_in_an_unaffected_control_individual_and_in_individuals_with_breast_cancer,_ovarian_cancer,_and_uterine_cancer_in_multiple_studies_(Loveday_2012,_PMID:22538716:_Golmard_2013,_PMID:2413955:_Janatova_2015,_PMID:26057125:_Kraus_2017,_PMID:27616075)._Bayesian_analysis_integrating_all_of_this_data_(Tavtigian_et_al,_2018,_PMID:29300386)_gives_about_98%_probability_of_pathogenicity_based_largely_on_splice_prediction_and_functional_studies,_which_are_consistent_with_a_classification_of_likely_pathogenic._This_variant_is_predicted_to_alter_RAD51C_function_and_modify_risk_for_cancer._This_analysis_was_performed_in_conjunction_with_the_family_studies_project_as_part_of_the_University_of_Washington_Find_My_Variant_Study.|
NM_032043.2:c.3260dup	BRIP1	frameshift_variant	102450	1	NA	NA	-	-	-	-	232062	236273	_complementation_group_J	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59761152dup	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	771654971	-	Ambry_Genetics|Mendelics	Likely_pathogenic|Likely_pathogenic	2017-04-21|2018-07-02	2020-02-26|2018-11-11	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown	SCV000276104|SCV000839353	_complementation_group_J	_nonsense):Other_data_supporting_pathogenic_classification:Structural_Evidence|
NM_032043.2:c.2992_2995del	BRIP1	frameshift_variant	102606	2	15426	1	-	-	-	-	187416	185211	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59761413_59761416del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	786203717	-	Ambry_Genetics|Color|Invitae|GeneDx|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-30|2016-09-27|2018-11-16|2018-08-22|2018-04-13	2020-02-26|2017-10-26|2019-03-28|2019-01-29|2018-06-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000217971|SCV000684241|SCV000547323|SCV000564817|SCV000786341	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|not_provided|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Deficient_protein_function_in_appropriate_functional_assay(s)||This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_BRIP1_gene_(p.Lys998Glufs*60)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_252_amino_acids_of_the_BRIP1_protein._This_variant_is_not_present_in_population_databases_(rs786203717,_ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_18628483,_26921362,_28423363)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_187416)._This_variant_disrupts_the_C-terminal_252_amino_acid_residues_of_the_BRIP1_protein,_partially_disrupting_the_BRCA1-interacting_domain_that_is_essential_for_proper_BRIP1_function_(PMID:_21345144)._It_is_also_expected_to_disrupt_the_TopBP1-BRIP1_interaction_that_plays_a_critical_role_in_RPA_chromatin_loading_in_response_to_DNA_damage_(PMID:_20159562,_21127055)._Experimental_studies_have_shown_that_this_variant_leads_to_the_expression_of_a_truncated,_unstable_protein_that_has_impaired_ability_to_bind_to_BRCA1_(PMID:_18628483)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_four_nucleotides_in_BRIP1_is_denoted_c.2992_2995delAAGA_at_the_cDNA_level_and_p.Lys998GlufsX60_(K998EfsX60)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_AACA[delAAGA]GAGT._The_deletion_causes_a_frameshift,_which_changes_a_Lysine_to_a_Glutamic_Acid_at_codon_998,_and_creates_a_premature_stop_codon_at_position_60_of_the_new_reading_frame._It_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_as_the_last_252_correct_amino_acids_are_replaced_by_59_incorrect_ones,_disrupting_the_BRCA1_binding_domain_(Cantor_2011)._BRIP1_c.2992_2995delAAGA_was_reported_in_a_woman_with_early-onset_breast_cancer_whose_tumor_demonstrated_loss_of_heterozygosity_of_the_wild_type_allele_as_well_as_in_1/1,313_breast_cancer_cases_in_a_case-control_study_(De_Nicolo_2008,_Thompson_2016)._In_addition,_functional_studies_found_that_this_variant_impaired_both_protein_stability_and_interaction_with_BRCA1_(De_Nicolo_2008)._We_consider_this_variant_to_be_pathogenic.|
NM_032043.2:c.2990_2993del	BRIP1	frameshift_variant	102586	7	NA	NA	-	-	-	-	234281	231995	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59761416_59761419TGTT[2]	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Microsatellite	SO:0000289	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	771028677	-	GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Color|Ambry_Genetics|Counsyl|Mendelics|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2018-08-22|2018-12-10|2019-01-05|2015-03-05|2018-04-02|2016-09-20|2018-07-02|2016-09-20	2019-01-29|2020-03-06|2019-03-28|2016-07-05|2020-02-26|2016-11-23|2018-08-20|2016-11-23	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown|unknown	SCV000278904|SCV001134021|SCV000291027|SCV000292145|SCV000661461|SCV000490005|SCV000839357|SCV000490006	not_provided|not_provided|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J|Neoplasm_of_ovary	This_deletion_of_four_nucleotides_in_BRIP1_is_denoted_c.2990_2993delCAAA_at_the_cDNA_level_and_p.Thr997ArgfsX61_(T997RfsX61)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CAAA[delCAAA]GAGA._The_deletion_causes_a_frameshift,_which_changes_a_Threonine_to_an_Arginine_at_codon_997,_and_creates_a_premature_stop_codon_at_position_61_of_the_new_reading_frame._It_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_as_the_last_253_amino_acid_residues_are_replaced_by_60_incorrect_ones,_disrupting_the_BRCA1_binding_domain_(Cantor_2011)._This_variant_has_been_observed_in_individuals_with_personal_and/or_family_history_of_breast_or_ovarian_cancer_and_in_an_individual_with_colon_cancer_(Ramus_2015,_Easton_2016,_Thompson_2016,_Yurgelun_2017)._Additionally,_a_nearby_variant_resulting_in_a_similar_protein_change,_BRIP1_c.2992_2995delAAGA,_was_found_to_impair_protein_stability_and_BRCA1_interaction_(De_Nicolo_2008)._Based_on_currently_available_evidence,_we_consider_BRIP1_c.2990_2993delCAAA_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|This_sequence_change_deletes_4_nucleotides_from_exon_20_of_the_BRIP1_mRNA_(c.2990_2993delCAAA),_causing_a_frameshift_at_codon_997._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_BRIP1_mRNA_(p.Thr997Argfs*61)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_result_in_a_truncated_BRIP1_protein._This_variant_is_present_in_population_databases_(rs771028677,_ExAC_0.003%)._This_variant_has_been_reported_in_an_individual_with_a_family_history_of_breast_and_ovarian_cancer_(PMID:_26315354)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234281)._This_variant_affects_the_C-terminal_BRCA1-binding_domain_(residues_888-1063)_of_the_BRIP1_protein,_and_therefore_is_expected_to_disrupt_BRIP1-BRCA1_interaction_(PMID:_21345144).Â¬â€ Other_variant_that_similarly_disrupts_this_region_(p.Lys998Glufs*60)_have_been_determined_to_be_pathogenic_(PMID:_18628483,_Invitae)._This_suggests_that_variants_that_disrupt_this_region_of_the_protein_are_likely_to_be_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||
NM_032043.2:c.2947dup	BRIP1	frameshift_variant	102488	1	NA	NA	-	-	-	-	407863	402677	_complementation_group_J	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59761465dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	774684620	-	Invitae|Color	Pathogenic|Pathogenic	2018-05-18|2017-04-06	2018-08-29|2017-10-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000547362|SCV000684238	_complementation_group_J|Hereditary_cancer-predisposing_syndrome	This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_BRIP1_gene_(p.Ile983Asnfs*19)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_267_amino_acids_of_the_BRIP1_protein._This_variant_is_present_in_population_databases_(rs774684620,_ExAC_0.01%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_407863)._This_variant_affects_the_BRCA1-binding_domain_(residues_888-1063)_of_BRIP1_protein_and_therefore_is_expected_to_disrupt_the_protein-protein_interaction_(PMID:_21345144)._In_experimental_studies,_the_protein_product_of_the_downstream_c.2992_2995delAAGA_variant_resulted_in_reduced_protein_stability_and_impaired_BRCA1_interaction_(PMID:_18628483)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_032043.2:c.2947del	BRIP1	frameshift_variant	102488	1	NA	NA	-	-	-	-	461044	468579	_complementation_group_J	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59761465del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	774684620	-	Invitae|GeneKor_MSA|Ambry_Genetics	Pathogenic|Likely_pathogenic|Pathogenic	2019-01-09|2018-08-01|2019-04-23	2019-03-28|2018-08-08|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000633513|SCV000821719|SCV001178729	_complementation_group_J|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_deletes_1_nucleotide_from_exon_20_of_the_BRIP1_mRNA_(c.2947delA),_causing_a_frameshift_at_codon_983._This_creates_a_premature_translational_stop_signal_in_the_last_exon_of_the_BRIP1_mRNA_(p.Ile983Leufs*2)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_delete_the_last_265_amino_acids_of_the_BRIP1_protein._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._This_variant_affects_the_BRCA1-binding_domain_(residues_888-1063)_of_the_BRIP1_protein,_and_therefore_is_expected_to_disrupt_BRIP1-BRCA1_interaction_(PMID:_21345144)._Different_truncations_downstream_of_this_variant_(p.Thr997Argfs*61,_p.Lys998Glufs*3,_and_p.Lys998Glufs*60)_have_been_determined_to_be_pathogenic_(Invitae_database_and_PMID:_Â¬â€ 18628483),_suggesting_that_deletion_of_this_region_of_the_BRIP1_protein_is_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_032043.2:c.2492+2dup	BRIP1	splice_region_variant,intron_variant	101860	3	15416	1	-	-	-	-	128174	133631	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59793310dup	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001575|splice_donor_variant	1	587780240	-	Ambry_Genetics|Color|Invitae|GeneDx	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-03-15|2018-05-30|2018-10-23|2017-10-12	2020-02-26|2018-11-06|2019-03-28|2017-11-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000214993|SCV000912104|SCV000261358|SCV000150052	_complementation_group_J|not_provided	In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Other_data_supporting_pathogenic_classification:Deficient_protein_function_in_appropriate_functional_assay(s):RNA_Studies:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_sequence_change_affects_a_donor_splice_site_in_intron_17_of_the_BRIP1_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780240,_ExAC_0.002%)._This_variant_has_been_reported_in_an_individual_affected_with_Fanconi_anemia_(PMID:_16116423),_an_individual_affected_with_breast_cancer_(PMID:_17033622),_and_an_individual_referred_for_cancer_panel_testing_(PMID:_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128174)._Experimental_studies_have_shown_that_this_variant_affects_the_proper_splicing_of_intron_17,_producing_transcripts_lacking_either_exon_17_or_exon_18,_resulting_in_premature_truncation_(PMID:_16116423)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_variant_is_denoted_BRIP1_c.2492+2dupT_or_IVS17+2dupT,_also_known_as_IVS17+2insT,_and_consists_of_a_duplication_of_a_single_nucleotide_at_the_+2_position_of_intron_17_of_the_BRIP1_gene,_altering_the_nucleotides_starting_at_the_+3_position._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_TAGg[t]aagt,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._Multiple_in_silico_models_predict_that_this_variant_results_in_loss_of_the_natural_splice_donor_site,_possibly_causing_abnormal_gene_splicing._This_variant_has_been_observed_in_an_individual_with_Fanconi_Anemia_where_sequencing_of_cDNA_identified_three_different_species_of_BRIP1_(also_known_as_FANCJ)_mRNA,_two_of_which_lacked_either_exon_17_or_18_and_resulted_in_a_frameshift_(Levitus_2005)._Seal_et_al._(2006)_identified_BRIP1_c.2492+2dupT_in_one_case_of_familial_breast_cancer_but_segregation_with_disease_was_not_observed_in_this_family._Based_on_the_currently_available_information,_we_consider_BRIP1_c.2492+2dupT_to_be_a_likely_pathogenic_variant.
NM_032043.2:c.1045G>C	BRIP1	missense_variant	102618	1	15426	0	5&4	0&1	rs149364097	Fanconi anemia, complementation group J&not provided	30535	39492	_complementation_group_J|Diffuse_intrinsic_pontine_glioma|not_specified|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:C2986658|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.59878709C>G	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:605882.0004	-	BRIP1:83990	SO:0001583|missense_variant	1	149364097	-	OMIM|ITMI|Ambry_Genetics|GeneDx|PreventionGenetics,PreventionGenetics|Invitae|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital	Pathogenic|not_provided|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2010-11-11|2013-09-19|2019-07-09|2018-01-29|2017-09-23|2018-12-28|2016-01-15	2019-04-19|2014-05-29|2020-02-26|2019-01-29|2018-01-29|2019-03-28|2018-12-04	no_assertion_criteria_provided|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline	SCV000044783|SCV000084564|SCV000186543|SCV000279247|SCV000807119|SCV000547344|SCV000890925	Fanconi_anemia,_complementation_group_J|not_specified|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Diffuse_intrinsic_pontine_glioma	||Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Structural_Evidence:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Deficient_protein_function_by_in_vitro/ex_vivo_assay:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|This_variant_is_denoted_BRIP1_c.1045G>C_at_the_cDNA_level,_p.Ala349Pro_(A349P)_at_the_protein_level,_and_results_in_the_change_of_an_Alanine_to_a_Proline_(GCC>CCC)._Functional_assays_have_shown_this_variant_to_impact_iron_binding,_abolish_helicase_activity,_and_exert_a_dominant-negative_effect_via_cell_survival_and_gamma-H2AX_foci_formation_assays_(Rudolf_2006,_Wu_2010)._Kanchi_et_al._(2014)_observed_BRIP1_Ala349Pro_once_in_the_heterozygous_state_in_a_series_of_387_ovarian_cancer_cases_but_not_in_557_controls._In_addition,_Levran_et_al._(2005)_observed_this_variant_in_the_compound_heterozygous_state_with_a_BRIP1_nonsense_variant_in_an_individual_with_Fanconi_anemia._BRIP1_Ala349Pro_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_not_located_in_a_known_functional_domain._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_currently_available_information,_we_consider_BRIP1_Ala349Pro_to_be_a_likely_pathogenic_variant.||This_sequence_change_replaces_alanine_with_proline_at_codon_349_of_the_BRIP1_protein_(p.Ala349Pro)._The_alanine_residue_is_weakly_conserved_and_there_is_a_small_physicochemical_difference_between_alanine_and_proline._This_variant_is_present_in_population_databases_(rs149364097,_ExAC_0.02%)._This_variant_has_been_reported_in_a_compound_heterozygous_state_on_the_opposite_chromosome_with_a_pathogenic_variant_(p.Arg798*)_in_an_individual_affected_with_Fanconia_anemia,_and_has_been_reported_in_a_heterozygous_state_in_an_individual_affected_with_ovarian_cancer_(PMID:_16116424,_24448499)._This_variant_is_also_known_as_(c.1186G>C)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_30535)._Experimental_studies_have_shown_that_this_missense_change,_which_is_located_in_the_metal_binding_domain,_destabilizes_the_Fe-S_cluster,_abolishes_helicase_activity,_and_exerts_a_dominant-negative_effect,_indicating_that_the_mutant_protein_interferes_with_normal_DNA_metabolism_(PMID:_16973432,_20639400,_27107905)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|
NM_006363.4:c.40C>T	SEC23B	missense_variant	102716	24	15422	5	5&5	0&1	rs121918222	Congenital dyserythropoietic anemia, type II&not provided	1223	16262	_type_II|Cowden_syndrome_7|not_provided	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007|MedGen:C4225179,OMIM:616858|MedGen:CN517202	-	NC_000020.10:g.18491519C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q15437#VAR_062294|HGMD:CM094610|OMIM_Allelic_Variant:610512.0002	-	SEC23B:10483	SO:0001583|missense_variant	1	121918222	-	Eurofins_Clinical_Diagnostics|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2009-09-01|2016-10-10|2015-08-26|2017-07-17	2018-07-11|2019-01-29|2017-06-30|2018-08-29	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000021432|SCV000330039|SCV000331589|SCV000816367	Congenital_dyserythropoietic_anemia,_type_II|not_provided|not_provided|Congenital_dyserythropoietic_anemia,_type_II/Cowden_syndrome_7	|The_R14W_variant_in_the_SEC23B_gene_has_been_reported_previously_in_association_with_congenital_dyserythropoietic_anemia_type_II_in_multiple_unrelated_individuals_when_present_with_a_second_variant_in_the_SEC23B_gene_(Bianchi_et_al.,_2009:_Schwarz_et_al.,_2009:_Satchwell_et_al.,_2013)._The_R14W_variant_is_one_of_the_most_common_recurrent_variants_in_the_SEC23B_gene_and_is_considered_a_founder_mutation_in_Italy,_Morocco,_and_Israel_(Russo_et_al.,_2014)._The_R14W_variant_was_not_observed_at_any_significant_frequency_in_approximately_6500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_indicating_it_is_not_a_common_benign_variant_in_these_populations._The_R14W_variant_is_a_non-conservative_amino_acid_substitution,_which_is_likely_to_impact_secondary_protein_structure_as_these_residues_differ_in_polarity,_charge,_size_and/or_other_properties._This_substitution_occurs_at_a_position_that_is_not_conserved._However,_in_vitro_studies_demonstrate_that_R14W-SEC23B_is_unstable_with_less_than_5%_of_the_protein_detectable_compared_to_wild_type_(Schwarz_et_al.,_2009)._Therefore,_we_interpret_R14W_as_a_pathogenic_variant.||This_sequence_change_replaces_arginine_with_tryptophan_at_codon_14_of_the_SEC23B_protein_(p.Arg14Trp)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_tryptophan._This_variant_is_present_in_population_databases_(rs121918222,_ExAC_0.04%)._This_variant_is_one_of_the_most_common_variants_identified_in_individuals_with_congenital_dyserythropoietic_anemia_type_II_(PMID:_19561605,_19621418,_20015893,_21850656)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_1223)._An_experimental_study_has_shown_that_this_missense_change_results_in_<5%_of_the_expression_of_wild-type_protein_(PMID:_19561605)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_006363.4:c.325G>A	SEC23B	missense_variant	102724	43	15420	2	5&5	0&1	rs121918221	Congenital dyserythropoietic anemia, type II&not provided	1222	16261	_type_II|Cowden_syndrome_7|not_provided	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007|MedGen:C4225179,OMIM:616858|MedGen:CN517202	-	NC_000020.10:g.18496339G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:141190|UniProtKB_(protein):Q15437#VAR_062296	-	SEC23B:10483	SO:0001583|missense_variant	1	121918221	-	OMIM|Illumina_Clinical_Services_Laboratory,Illumina|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2009-09-01|2018-10-05|2013-11-18|2018-08-14	2014-02-11|2019-02-01|2018-09-19|2019-03-28	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000021431|SCV000915932|SCV000113338|SCV000815954	Congenital_dyserythropoietic_anemia,_type_II|Congenital_dyserythropoietic_anemia,_type_II|not_provided|Congenital_dyserythropoietic_anemia,_type_II/Cowden_syndrome_7	|The_SEC23B_c.325G>A_(p.Glu109Lys)_variant_has_been_reported_in_at_least_three_studies_and_is_found_in_a_total_of_25_individuals_including_23_in_a_homozygous_state_and_two_in_a_compound_heterozygous_state_with_congenital_dyserythropoietic_anemia_(Schwarz_et_al._2009:_Bianchi_et_al._2009:_Punzo_et_al._2011:_Amir_et_al._2011)._The_p.Glu109Lys_variant_is_described_as_a_founder_mutation_among_the_Israeli_Moroccan_Jewish_population_(Amir_et_al._2011)._Control_data_are_unavailable_for_this_variant,_which_is_reported_at_a_frequency_of_0.000577_in_the_African_population_of_the_Exome_Aggregation_Consortium._Expression_analysis_in_HeLa-Kyoto_cells_determined_the_p.Glu109Lys_variant_had_less_than_5%_of_wildtype_expression_(Schwarz_et_al._2009)._Based_on_the_evidence,_the_p.Glu109Lys_variant_is_classified_as_pathogenic_for_congenital_dyserythropoietic_anemia._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.||This_sequence_change_replaces_glutamic_acid_with_lysine_at_codon_109_of_the_SEC23B_protein_(p.Glu109Lys)._The_glutamic_acid_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_glutamic_acid_and_lysine._This_variant_is_present_in_population_databases_(rs121918221,_ExAC_0.06%)._This_is_the_most_common_variant_associated_with_congenital_dyserythropoietic_anemia_type_II,_which_many_homozygous_affected_individuals_reported_(PMID:_19561605,_19621418,_20015893,_21252497,_21850656,_25044164)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_1222)._Experimental_studies_have_shown_that_this_missense_change_destabilizes_the_protein_in_cell_culture_(PMID:_19561605)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_006363.4:c.1489C>T	SEC23B	missense_variant	102720	1	15430	3	5	1	rs727504145	not provided	167667	177431	_type_II|not_provided	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007|MedGen:CN517202	-	NC_000020.10:g.18523024C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:697830	-	SEC23B:10483	SO:0001583|missense_variant	1	727504145	-	EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Illumina_Clinical_Services_Laboratory,Illumina	Pathogenic|Pathogenic	2014-01-23|2018-10-31	2018-09-19|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000203545|SCV000915934	_type_II	|The_SEC23B_c.1489C>T_(p.Arg497Cys)_variant_has_been_reported_in_five_studies_and_in_a_total_of_nine_individuals_with_dyserythropoietic_anemia_including_one_individual_in_a_homozygous_state_and_eight_individuals_in_a_compound_heterozygous_state_(Schwarz_et_al._2009,_Bianchi_et_al._2009,_Iolascon_et_al._2010,_Russo_et_al._2010,_Russo_et_al._2013)._The_variant_was_absent_from_407_controls_and_is_reported_at_a_frequency_of_0.000032_in_the_European_(non-Finnish)_population_of_the_Genome_Aggregation_Database._The_Arg497_amino_acid_residue_is_conserved_among_several_species._Based_on_the_evidence,_the_p.Arg497Cys_variant_is_classified_as_pathogenic_for_congenital_dyserythropoietic_anemia._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_006363.4:c.1571C>T	SEC23B	missense_variant	102730	1	NA	NA	5	1	rs398124225	not provided	95384	101283	not_provided	-	MedGen:CN517202	-	NC_000020.10:g.18523722C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q15437#VAR_062306|HGMD:CM094617	-	SEC23B:10483	SO:0001583|missense_variant	1	398124225	-	Eurofins_Clinical_Diagnostics	Pathogenic	2013-11-18	2018-09-19	_single_submitter	germline	SCV000113334	not_provided	
NM_006363.4:c.1873C>A	SEC23B	missense_variant	102734	3	NA	NA	-	-	-	-	422376	410734	not_provided	-	MedGen:CN517202	-	NC_000020.10:g.18529382C>A	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	SEC23B:10483	SO:0001583|missense_variant	1	368458175	-	GeneDx	Likely_pathogenic	2016-10-10	2019-01-29	_single_submitter	germline	SCV000571840	not_provided	The_L625I_variant_in_the_SEC23B_gene_has_not_been_reported_previously_as_a_pathogenic_variant_nor_as_a_benign_variant,_to_our_knowledge._The_L625I_variant_was_not_observed_at_any_significant_frequency_in_approximately_6500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_indicating_it_is_not_a_common_benign_variant_in_these_populations._The_L625I_variant_is_a_conservative_amino_acid_substitution,_which_is_not_likely_to_impact_secondary_protein_structure_as_these_residues_share_similar_properties._This_substitution_occurs_at_a_position_that_is_conserved_across_species._In_silico_analysis_is_inconsistent_in_its_predictions_as_to_whether_or_not_the_variant_is_damaging_to_the_protein_structure/function._The_L625I_variant_is_a_strong_candidate_for_a_pathogenic_variant,_however_the_possibility_it_may_be_a_rare_benign_variant_cannot_be_excluded.
NM_007194.3:c.1427C>T	CHEK2	missense_variant	100144	52	15420	3	4&4	1&1	rs142763740	Hereditary cancer-predisposing syndrome&not provided	128060	133517	_susceptibility_to|not_specified|CHEK2-Related_Cancer_Susceptibility|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1527249|MedGen:C1858433|MedGen:CN169374|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29090054G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(8)	-	single_nucleotide_variant	SO:0001483	Illumina:655839	-	CHEK2:11200	SO:0001583|missense_variant	17	142763740	-	Ambry_Genetics|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|GeneID_Lab_-_Advanced_Molecular_Diagnostics|Color|GeneKor_MSA|Invitae|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Counsyl|Mendelics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Illumina_Clinical_Services_Laboratory,Illumina|Illumina_Clinical_Services_Laboratory,Illumina|Genetic_Services_Laboratory,_University_of_Chicago|Illumina_Clinical_Services_Laboratory,Illumina	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic	2019-08-16|2017-02-14|2017-09-07|2018-10-03|2018-08-01|2018-12-30|2018-04-16|2017-10-06|2018-07-02|2015-11-20|2019-01-07|2018-12-10|2016-10-14|2016-09-30|2016-06-14|2016-06-14|2016-11-21|2017-04-27	2020-02-26|2017-02-16|2017-09-11|2018-11-06|2018-08-08|2019-03-28|2018-05-24|2018-06-20|2018-08-20|2016-03-03|2019-01-29|2020-03-06|2018-01-25|2018-01-29|2016-10-18|2016-10-18|2017-07-05|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000186804|SCV000576430|SCV000680448|SCV000689655|SCV000821724|SCV000254925|SCV000778585|SCV000785095|SCV000839455|SCV000266166|SCV000149910|SCV000601155|SCV000698777|SCV000806869|SCV000437713|SCV000437714|SCV000594113|SCV000914986	_susceptibility_to|not_provided|not_provided|not_provided|not_provided|Colorectal_cancer|Neoplasm_of_the_breast|not_specified|CHEK2-Related_Cancer_Susceptibility	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|||||This_sequence_change_replaces_threonine_with_methionine_at_codon_476_of_the_CHEK2_protein_(p.Thr476Met)._The_threonine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_threonine_and_methionine._This_variant_is_present_in_population_databases_(rs142763740,_ExAC_0.07%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_21244692),_endometrial_cancer_(PMID:_27443514),_colorectal_cancer_(PMID:Â¬â€ 28944238),_prostate_cancer_(PMID:Â¬â€ 29368341,Â¬â€ 29520813),_and_in_a_male_with_breast_and_colon_cancer_(PMID:_28008555)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128060)._Experimental_studies_have_shown_that_this_missense_change_disrupts_CHEK2_kinase_activity_in_vitro_and_impairs_DNA_damage_response_in_a_yeast_assay_(PMID:_22114986,_22419737)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||||This_variant_is_denoted_CHEK2_c.1427C>T_at_the_cDNA_level,_p.Thr476Met_(T476M)_at_the_protein_level,_and_results_in_the_change_of_a_Threonine_to_a_Methionine_(ACG>ATG)._This_variant_has_been_reported_in_individuals_with_a_personal_and/or_family_history_of_breast,_pancreatic,_or_prostate_cancer_(Desrichard_2011,_Le_Calvez-Kelm_2011,_Hu_2015,_Leedom_2016,_Pritzlaff_2016,_Shirts_2016,_Frey_2017,_Isaacsson_Velho_2018,_Schubert_2018,_Wu_2018)._This_variant_was_shown_in_an_in_vitro_study_to_abolish_kinase_activity,_and_was_shown_in_an_in_vivo_study_to_impair_CHEK2-mediated_response_to_DNA_damage_(Desrichard_2011,_Roeb_2012)._A_different_nucleotide_change_(CHEK2_c.1427C>A)_resulting_in_the_same_amino_acid_substitution_was_identified_in_a_patient_with_a_clinical_diagnosis_of_Li-Fraumeni_syndrome_(Sadri_2014)._Although_this_variant_was_observed_in_large_population_cohorts,_population_data_in_this_region_of_CHEK2_are_not_considered_reliable_due_to_high_pseudogene_homology_(Lek_2016)._CHEK2_Thr476Met_is_located_in_the_protein_kinase_domain_(Cai_2009,_Roeb_2012)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_currently_available_evidence,_we_consider_CHEK2_Thr476Met_to_be_a_likely_pathogenic_variant.|The_best_available_variant_frequency_is_uninformative._Statistically_enriched_in_patients_compared_to_ethnically_matched_controls._Found_in_at_least_one_symptomatic_patient._Predicted_to_have_a_damaging_effect_on_the_protein._Occurs_in_a_single_case_with_an_otherwise_positive_result._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.||||Across_three_studies,_the_c.1427C>T_(p.Thr476Met),_was_reported_in_five_of_1,955_breast_cancer_patients_(Le_Calvez-Kelm_et_al._2011:_Desrichard_et_al._2011:_Angelova_et_al._2012)._The_variant_was_absent_from_a_total_of_1,622_controls,_but_is_reported_at_a_frequency_of_0.00068_in_the_European_(Non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Desrichard_et_al._(2011)_developed_an_in_vitro_kinase_activity_assay_to_assess_the_activity_of_missense_variants_in_CHEK2._In_this_assay_the_p.Thr476Met_variant_demonstrated_no_kinase_activity_and_was_similar_to_a_known_non-functional_kinase_variant_of_CHEK2._In_addition,_Roeb_et_al._(2012)_developed_a_yeast-based_in-vivo_functional_assay_to_assess_the_effect_of_CHEK2_variants_on_the_repair_of_DNA_damage._Cells_with_wild-type_CHEK2_repaired_the_DNA_damage_while_cells_with_a_known_non-functional_variant_of_CHEK2_did_not._The_p.Thr476Met_variant_was_shown_to_have_loss_of_function_by_this_DNA_damage_response_assay._Based_on_the_evidence,_the_p.Thr476Met_variant_is_classified_as_likely_pathogenic_for_breast_cancer.||The_CHEK2_c.1427C>T_(p.Thr476Met)_missense_variant,_also_referred_to_as_c.1556C>T_(p.Thr519Met),_was_reported_in_five_of_1,955_breast_cancer_patients_(Le_Calvez-Kelm_et_al._2011:_Desrichard_et_al._2011:_Angelova_et_al._2012)._The_variant_was_absent_from_a_total_of_1,622_controls,_but_is_reported_at_a_frequency_of_0.00068_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Desrichard_et_al._(2011)_developed_an_in_vitro_kinase_activity_assay_to_assess_the_activity_of_missense_variants_in_CHEK2._In_this_assay_the_p.Thr476Met_variant_demonstrated_no_kinase_activity_and_was_similar_to_a_known_non-functional_kinase_variant_of_CHEK2._In_addition,_Roeb_et_al._(2012)_developed_a_yeast-based_in-vivo_functional_assay_to_assess_the_effect_of_CHEK2_variants_on_the_repair_of_DNA_damage._Cells_with_wild_type_CHEK2_repaired_the_DNA_damage_while_cells_with_a_known_non-functional_variant_of_CHEK2_did_not._The_p.Thr476Met_variant_was_shown_to_have_loss_of_function_by_this_DNA_damage_response_assay._Based_on_the_evidence,_the_p.Thr476Met_variant_is_classified_as_pathogenic_for_CHEK2-related_cancer_susceptibility._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_007194.3:c.1283C>T	CHEK2	missense_variant	102268	8	15434	1	5&5&5&5	2&1&1&1	rs137853011	Hereditary cancer-predisposing syndrome&Familial cancer of breast&Breast and colorectal cancer, susceptibility to&not provided	5603	20642	Osteosarcoma|Malignant_tumor_of_prostate|Neoplasm_of_the_breast|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Colorectal_cancer|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|CHEK2-Related_Cancer_Susceptibility|not_provided	-	Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1527249|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C3469522|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29091207G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(5),Pathogenic(11),Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	Illumina:203534|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2833351|OMIM_Allelic_Variant:604373.0014|UniProtKB_(protein):O96017#VAR_022463	-	CHEK2:11200	SO:0001583|missense_variant	1	137853011	-	OMIM|Genetic_Services_Laboratory,_University_of_Chicago|Ambry_Genetics|Color|GeneKor_MSA|Invitae|Counsyl|Mendelics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Illumina_Clinical_Services_Laboratory,Illumina|Illumina_Clinical_Services_Laboratory,Illumina|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Illumina_Clinical_Services_Laboratory,Illumina	risk_factor|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2005-02-15|2017-02-21|2019-10-30|2015-02-16|2018-08-01|2019-01-08|2017-05-22|2018-07-02|2017-06-05|2015-11-20|2019-01-02|2019-03-22|2018-06-01|2016-06-14|2016-06-14|2017-05-18|2019-01-15|2017-09-05	2017-11-21|2017-07-05|2020-02-26|2016-07-05|2018-08-08|2019-03-28|2017-06-22|2018-08-20|2018-06-14|2016-03-03|2019-01-29|2020-03-06|2019-07-12|2016-10-18|2016-10-18|2017-05-23|2019-09-24|2019-02-01	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000026135|SCV000594114|SCV000187227|SCV000292126|SCV000821728|SCV000253983|SCV000677740|SCV000839461|SCV000839938|SCV000266068|SCV000149903|SCV000601148|SCV000892318|SCV000437716|SCV000437715|SCV000611259|SCV000698769|SCV000914987	Breast_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|Colorectal_cancer|Neoplasm_of_the_breast|Familial_cancer_of_breast/Li-Fraumeni_syndrome_2/Osteosarcoma/Malignant_tumor_of_prostate|Hereditary_breast_and_ovarian_cancer_syndrome|CHEK2-Related_Cancer_Susceptibility	||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Significant_disease_association_in_appropriately_sized_case-control_study(ies):Good_segregation_with_disease_(lod_1.5-3_
NM_007194.3:c.483_485del	CHEK2	inframe_deletion	102706	3	15426	1	-	-	-	-	141783	151497	_susceptibility_to|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1858433|MedGen:CN517202	-	NC_000022.10:g.29121072_29121074TCT[1]	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(6)	-	Microsatellite	SO:0000289	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2841958	-	CHEK2:11200	SO:0001822|inframe_deletion,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	587782008	-	Ambry_Genetics|Color|Invitae|Counsyl|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Dr._Peter_K._Rogan_Lab,Western_University	Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2019-08-30|2018-06-01|2018-12-28|2016-08-23|2015-11-20|2018-08-17|2016-07-10|2017-06-15|2019-07-03|2015-12-22	2020-02-26|2018-11-06|2019-03-28|2016-11-23|2016-03-03|2019-01-29|2018-01-25|2018-01-29|2020-03-06|2015-12-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|unknown|germline|germline|germline|germline|germline|unknown	SCV000185293|SCV000903081|SCV000255306|SCV000489121|SCV000266065|SCV000211012|SCV000698807|SCV000806882|SCV000889336|SCV000262585	_susceptibility_to|not_provided|not_provided|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	Deficient_protein_function_in_appropriate_functional_assay(s):Structural_Evidence:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||This_sequence_change_deletes_3_nucleotides_from_exon_4_of_the_CHEK2_mRNA_(c.483_485delAGA)._This_leads_to_the_deletion_of_1_amino_acid_residue_in_the_CHEK2_protein_(p.Glu161del)_but_otherwise_preserves_the_integrity_of_the_reading_frame._This_variant_is_present_in_population_databases_(rs587782008,_ExAC_0.01%)._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer,_although_it_was_absent_from_the_tumors_of_affected_family_members_(PMID:_12442270)._It_was_also_observed_in_two_other_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_26845104,_26898890)._This_variant_is_also_known_as_481_483del_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141783)._Experimental_studies_have_shown_that_this_missense_change_reduces_CHEK2_stability,_DNA_damage-induced_phosphorylation,_and_kinase_activity_in_vitro_(PMID:_16982735,_22114986)._In_summary,_this_variant_is_a_rare_in-frame_deletion_of_one_amino_acid_that_has_been_observed_in_affected_individuals_and_disrupts_CHEK2_activity_in_vitro._However,_it_is_unclear_whether_or_not_this_variant_segregates_with_disease_and_the_available_evidence_is_currently_insufficient_to_determine_its_role_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||This_in-frame_deletion_of_three_nucleotides_in_CHEK2_is_denoted_c.483_485delAGA_at_the_cDNA_level_and_p.Glu161del_(E161del)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TAGA[delAGA]TCAC._This_variant_has_been_observed_in_several_individuals_with_a_personal_and_family_history_of_breast_cancer_and_was_absent_in_unaffected_controls_(Sodha_2002,_Desrichard_2011,_Caminsky_2016,_Shirts_2016)._Functional_studies_led_to_the_conclusion_that_CHEK2_Glu161del_was_likely_pathogenic_based_on_absent_kinase_activity,_reduced_protein_expression_and_stability,_and_reduced_activation_in_response_to_DNA_damage_(Sodha_2006,_Desrichard_2011)._CHEK2_Glu161del_was_not_observed_at_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_deletion_of_a_single_Glutamic_Acid_amino_acid_is_located_in_the_FHA_domain_(Cai_2009,_Roeb_2012)._In-silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_CHEK2_Glu161del_to_be_likely_pathogenic.|Variant_summary:_The_c.483_485delAGA_(p.Glu161del)_in_CHEK2_gene_is_an_in-frame_deletion_leading_to_removal_of_a_single_Glutamic_Acid_residue_in_a_region_that_is_conserved_across_species_and_is_located_in_the_FHA_domain._Functional_studies_have_shown_that_this_in-frame_deletion_reduces_CHEK2_stability,_DNA_damage-induced_phosphorylation_and_significantly_diminish_kinase_activity_in_vitro._The_variant_is_present_in_control_dataset_of_ExAC_at_a_low_frequency_of_0.000016_(2/122994_chrs_tested)_which_does_not_exceed_the_estimated_maximum_allele_frequency_for_a_pathogenic_allele_in_this_gene_(0.000028)._The_variant_was_identified_in_at_least_3_affected_individuals_(BRCA1/2_and_TP53_mutation_free._For_2_of_these_individuals_with_personal_and_family_history_of_BrC_segregation_analysis_was_not_performed_and_in_1_LFS_family_2_affected_individuals_did_not_carry_the_variant,_raising_the_question_about_pathogenicity_of_the_variant_of_interest._The_variant_of_interest_has_been_reported_as_Likely_Pathogenic/VUS_by_reputable_databases/clinical_laboratories._Additional_clinical,_segregation_and_population_data_needed_to_classify_this_variant_with_confidence._Taking_together,_based_on_the_results_of_the_functional_studies,_the_variant_was_classified_as_VUS-Possibly_Pathogenic.|||Sequenced_patient_with_familial_breast_cancer
NM_007194.3:c.470T>C	CHEK2	missense_variant	102706	369	15432	239	5&5&4&4	0&2&1&1	rs17879961	Li-Fraumeni syndrome 2&Hereditary cancer-predisposing syndrome&Breast and colorectal cancer, susceptibility to&not provided	5591	20630	Cancer_of_multiple_types,_susceptibility_to|Prostate_cancer,_susceptibility_to|Gastrointestinal_carcinoma|Adrenocortical_carcinoma|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|Colorectal_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|COLON_CANCER,_SUSCEPTIBILITY_TO|not_specified|not_provided	-	.|.|Human_Phenotype_Ontology:HP:0002672,MedGen:C0151544|Human_Phenotype_Ontology:HP:0006744,MeSH:D018268,MedGen:C0206686,Orphanet:ORPHA1501|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C1858438|MedGen:C3469522|MedGen:C4016820|MedGen:CN169374|MedGen:CN517202	-	NC_000022.10:g.29121087A>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(7),Pathogenic(7),Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:181664|OMIM_Allelic_Variant:604373.0002|UniProtKB_(protein):O96017#VAR_008555	-	CHEK2:11200	SO:0001583|missense_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	17879961	-	OMIM|OMIM|OMIM|OMIM|Ambry_Genetics|Color|True_Health_Diagnostics|GeneKor_MSA|ITMI|Integrated_Genetics/Laboratory_Corporation_of_America|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Pathway_Genomics|Invitae|Counsyl|Mendelics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Center_of_Medical_Genetics_and_Primary_Health_Care|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Division_of_Genomic_Diagnostics,The_Children's_Hospital_of_Philadelphia|GeneDx|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Genetic_Services_Laboratory,_University_of_Chicago|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|GenomeConnect,_ClinGen	Pathogenic|risk_factor|risk_factor|risk_factor|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|not_provided|Uncertain_significance|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Uncertain_significance|not_provided	2006-11-01|2006-11-01|2006-11-01|2006-11-01|2018-06-20|2014-12-26|2017-11-16|2018-08-01|2013-09-19|2019-04-15|2019-01-02|2014-07-24|2019-01-09|2016-03-15|2018-07-02|2017-06-02|0000-00-00|2015-11-20|2018-05-03|2019-09-30|2019-04-01|2017-02-17|0000-00-00|2016-09-14|2017-06-13|2017-01-01|0000-00-00	2011-11-22|2011-11-22|2011-11-22|2011-11-22|2020-02-26|2016-07-05|2018-03-08|2018-08-08|2014-05-29|2019-09-24|2019-08-05|2014-08-08|2019-03-28|2017-06-22|2018-08-20|2018-06-14|2019-08-31|2016-03-03|2018-05-04|2020-01-06|2019-07-12|2017-08-01|2017-10-31|2018-01-29|2017-07-05|2017-12-08|2019-01-30	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|unknown	SCV000026118|SCV000026119|SCV000026120|SCV000026121|SCV000183804|SCV000292120|SCV000788004|SCV000821722|SCV000084709|SCV000698803|SCV001159433|SCV000189923|SCV000253984|SCV000677722|SCV000839491|SCV000839939|SCV000987254|SCV000266064|SCV000296968|SCV000149927|SCV000575329|SCV000601169|SCV000691835|SCV000806880|SCV000594119|SCV000747421|SCV000986797	Li-Fraumeni_syndrome_2|Colorectal_cancer,_susceptibility_to|Cancer_of_multiple_types,_susceptibility_to|Prostate_cancer,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|not_specified|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|not_provided|not_provided|Breast_cancer,_susceptibility_to|Gastrointestinal_carcinoma/Adrenocortical_carcinoma|Breast_cancer,_susceptibility_to/COLON_CANCER,_SUSCEPTIBILITY_TO	||||Significant_disease_association_in_appropriately_sized_case-control_study(ies):Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification|||||Variant_summary:_CHEK2_c.470T>C_(p.Ile157Thr)_results_in_a_non-conservative_amino_acid_change_located_in_the_Forkhead-associated_(FHA)_domain_(IPR000253)_of_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_0.0042_in_253524_control_chromosomes_in_the_gnomAD_database,_including_11_homozygotes._The_observed_variant_frequency_is_approximately_13.5_fold_of_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_CHEK2_causing_Hereditary_Breast_and_Ovarian_Cancer_phenotype_(0.00031)._In_addition,_this_variant_has_been_reported_in_47/7325_European_American_women_(including_1_homozygote)_who_are_older_than_age_70_and_cancer_free_(in_the_FLOSSIES_database)._These_data_suggest_that_the_variant_is_benign_polymorphism._However,_c.470T>C_has_been_reported_in_the_literature_in_several_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._In_families_with_this_variant,_transmissions_of_the_variant_allele_and_transmissions_of_the_reference_allele_to_affected_individuals_was_reported_in_addition_to_unaffected_individuals_who_harbored_the_variant_(Allinen_2001,_Dong_2003,_Roeb_2012,_Bak_2014,_Cragun_2014,_Stradella_2018)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease_but_also_suggests_incomplete_segregation_and_incomplete_penetrance_associated_with_this_variant._Co-occurrences_with_other_pathogenic_variants_have_been_reported_in_CHEK2_as_well_as_in_other_genes_associated_with_cancer_(e.g._BRCA2_c.6468_6469delTC_[p.Gln2157fsX18]:_NBN_c.657_661delACAAA_[p.Lys219fsX16]:_BRCA1_c.3700_3704delGTAAA_[p.Val1234fsX8]:_CHEK2_c.444+1G>A:_CHEK2_1100delC_[p.Thr367fsX15]:_CHEK2_c.433C>T_[p.Arg145Trp]),_providing_supporting_evidence_for_a_benign_role,_though_in_some_of_these_cases_the_observed_phenotype_(earlier_onset),_could_also_suggest_an_additive_effect_(Stradella_2018)._Multiple_association_studies_have_produced_conflicting_results,_but_with_an_overall_consensus_for_the_variant_being_associated_with_a_moderate_increased_risk_for_breast_cancer_based_on_a_large_meta-analysis_by_Liu_2012_that_included_a_total_of_fifteen_case-control_studies_(19,621_cases_and_27,001_controls),_showing_a_significant_association_for_unselected_breast_cancer_(OR_
NM_007194.3:c.433C>T	CHEK2	missense_variant	102586	4	15424	0	5&4&4&5	0&1&1&1	rs137853007	Li-Fraumeni syndrome 2&Hereditary cancer-predisposing syndrome&Familial cancer of breast&not provided	5592	20631	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Li-Fraumeni_syndrome_2|not_specified|CHEK2-Related_Cancer_Susceptibility|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C1836482,OMIM:609265|MedGen:CN169374|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29121242G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Illumina:30635	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	137853007	-	OMIM|Ambry_Genetics|Color|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|ITMI|Invitae|Counsyl|Mendelics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Illumina_Clinical_Services_Laboratory,Illumina|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|not_provided|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2001-11-15|2019-10-14|2018-07-19|2018-01-26|2013-09-19|2018-12-31|2016-10-28|2018-07-02|2018-01-30|2017-04-27|2018-05-25|2019-02-22|2017-07-24	2017-11-21|2020-02-26|2018-11-06|2018-04-23|2014-05-29|2019-03-28|2016-11-23|2018-08-20|2018-06-14|2019-02-01|2019-01-29|2020-03-06|2018-01-25	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline	SCV000026122|SCV000185008|SCV000537624|SCV000992231|SCV000084708|SCV000253711|SCV000489610|SCV000839492|SCV000839946|SCV000437721|SCV000149925|SCV001134168|SCV000698801	Li-Fraumeni_syndrome_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|CHEK2-Related_Cancer_Susceptibility|not_provided|not_provided|Li-Fraumeni_syndrome	|Other_data_supporting_pathogenic_classification:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_in_appropriate_functional_assay(s):Moderate_segregation_with_disease_(at_least_3_informative_meioses)_for_rare_diseases.||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.||This_sequence_change_replaces_arginine_with_tryptophan_at_codon_145_of_the_CHEK2_protein_(p.Arg145Trp)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_tryptophan._This_variant_is_present_in_population_databases_(rs137853007,_ExAC_0.009%)._This_variant_has_been_reported_in_multiple_individuals_affected_with_breast_cancer_(PMID:_11719428,_15535844,Â¬â€ 29356917,Â¬â€ 29356917,_29909963),_and_was_reported_to_segregate_with_disease_in_one_family_(PMID:_22419737).Â¬â€ This_variant_is_also_known_asÂ¬â€ c.562C>T_(p.Arg188Trp)Â¬â€ in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_5592)._Experimental_studies_have_shown_that_this_missense_change_disrupts_protein_stability_(PMID:_11719428,_16982735)_and_prevents_DNA_damage_induced_phosphorylation_of_CHEK2_and_activation_of_downstream_factors_(PMID:_11390408,_11298456,_12049740,_11571648,_15239132)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|||This_c.562C>T_(p.Arg188Trp)_variant_in_the_CHEK2_gene_has_been_reported_in_multiple_breast_cancer_patients_[PMID:_11719428,_22419737]_than_that_observed_as_extremely_low_in_general_population_according_to_gnomad_database._Functional_studies_showed_that_this_mutant_is_defective_of_phosphorylation_with_significantly_reduced_kinase_activity_[PMID:_11053450,_11298456,_11390408,_11571648,_12049740,_22114986]._This_variant_has_been_observed_for_co-segregation_with_individuals_affected_by_breast/lung_cancers_in_a_family_with_Li-Fraumeni_syndrome._Multiple_in_silico_predictions_suggest_this_arginine_to_tryptophan_is_deleterious._Based_upon_above_evidences,_c.562C>T_(p.Arg188Trp)_variant_in_the_CHEK2_gene_is_classified_as_likely_pathogenic.|The_CHEK2_c.433C>T_(p.Arg145Trp)_missense_variant_has_been_identified_in_a_heterozygous_state_in_seven_individuals_with_various_types_of_cancer,_including_breast,_colon,_lung,_and_Li-Fraumeni_syndrome_(Bell_et_al._1999:_Lee_et_al._2001:_Friedrichsen_et_al._2004:_Roeb_et_al._2012)._The_p.Arg145Trp_variant_was_absent_from_659_controls_and_is_reported_at_a_frequency_of_0.00003_in_the_total_population_of_the_Exome_Aggregation_Consortium._Functional_studies_in_cell_lines_and_yeast_cells_demonstrated_that_p.Arg145Trp-CHEK2_protein_has_a_reduced_half-life_compared_with_wild_type_CHEK2_and_does_not_become_activated_in_response_to_DNA_damage_(Lee_et_al._2001:_Falck_et_al._2001:_Li_et_al._2002:_Sodha_et_al._2006:_Roeb_et_al._2012)._Based_on_the_evidence,_the_p.Arg145Trp_variant_is_classified_as_likely_pathogenic_for_CHEK2-related_cancer_susceptibility._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|This_variant_is_denoted_CHEK2_c.433C>T_at_the_cDNA_level,_p.Arg145Trp_(R145W)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Tryptophan_(CGG>TGG)._CHEK2_Arg145Trp_was_published_as_a_germline_variant_in_a_case_of_neuroblastoma_and_in_an_individual_with_breast_cancer_from_a_family_with_a_history_of_Li_Fraumeni-like_disease_whose_tumor_demonstrated_loss_of_heterozygosity_(Lee_2001b,_Pugh_2013)._In_addition,_it_has_been_observed_in_several_hereditary_breast_cancer_families,_one_of_which_had_co-segregation_analysis_that_showed_the_variant_tracking_with_cancer_(Friedrichsen_2004,_Desrichard_2011,_Roeb_2012,_Caminsky_2016,_Thompson_2016)._Multiple_in_vitro_and_in_vivo_functional_studies_have_confirmed_that_this_variant_results_in_decreased_or_absent_kinase_activity_(Falck_2001a,_Falck_2001b,_Lee_2001a,_Wu_2001,_Desrichard_2011)._In_addition,_this_variant_has_been_shown_to_have_deficient_response_to_DNA_damage,_increased_sensitivity_to_ionizing_radiation,_cyclohexamide_and_lactacystin,_and_inability_to_bind_to_wild_type_BRCA1_and_TP53_(Falck_2001b,_Lee_2001a,_Lee_2001b,_Wu_2001,_Li_2002,_Kilpivaara_2004,_Roeb_2012)._CHEK2_Arg145Trp_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_FHA_domain_(Cai_2009,_Roeb_2012)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_CHEK2_Arg145Trp_to_be_a_likely_pathogenic_variant.|The_best_available_variant_frequency_is_uninformative._Found_in_at_least_one_symptomatic_patient._Predicted_to_have_a_damaging_effect_on_the_protein._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function._Moderate_co-segregation_with_disease_in_affected_and_unaffected_individuals,_but_from_a_single_family.|Variant_summary:_The_CHEK2_c.433C>T_(p.Arg145Trp)_variant_involves_the_alteration_of_a_conserved_nucleotide_located_in_the_Forkhead-associated_(FHA)_domain._4/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant_(SNPsandGO_not_captured_due_to_low_reliability_index)._Functional_studies_confirmed_that_the_protein_with_this_variant_had_a_half-life_of_30_minutes_(Lee_Cancer_Res_2001)_and_lack_of_CHEK2-mediated_response_to_DNA_damage_(Roeb_Hum._Mol._Genet._2012)._This_variant_was_found_in_4/121756_control_chromosomes_at_a_frequency_of_0.0000329,_which_is_slightly_higher_than_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_CHEK2_variant_(0.0000284),_suggesting_this_variant_may_be_a_benign_polymorphism._However,_this_variant_has_been_reported_in_multiple_breast_and_lung_cancer_patients,_with_familial_co-segregation_evidence_(Roeb_Hum._Mol._Genet._2012,_Lee_Cancer_Res_2001)._Also,_another_variant,_p.R145P_has_also_been_reported_to_associate_with_prostate_cancer_(HGMD),_suggesting_R145_is_critical._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_likely_pathogenic._Taken_together,_this_variant_is_classified_as_likely_pathogenic.
NM_007194.3:c.349A>G	CHEK2	missense_variant	102520	21	15430	1	4&4&4	1&1&1	rs28909982	Hereditary cancer-predisposing syndrome&Familial cancer of breast&not provided	128071	133528	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000022.10:g.29121326T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):O96017#VAR_022461|Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva:8_July_2017|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2691966	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	28909982	-	Ambry_Genetics|Color|Invitae|Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|GenomeConnect,_ClinGen|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|CeGaT_Praxis_fuer_Humangenetik_Tuebingen	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|not_provided|Likely_pathogenic|Pathogenic|Likely_pathogenic	2019-08-09|2018-08-07|2019-01-09|2017-03-22|2017-02-27|2019-03-13|2018-07-02|2018-12-24|0000-00-00|0000-00-00|2017-09-08|2017-12-21|2018-08-01	2020-02-26|2018-11-06|2019-03-28|2017-07-06|2017-06-22|2019-09-24|2018-08-20|2019-01-29|2017-10-31|2018-03-13|2018-01-29|2018-08-31|2019-07-12	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|unknown|germline|unknown|unknown|germline|germline|germline	SCV000183898|SCV000537618|SCV000262374|SCV000590881|SCV000677766|SCV000698796|SCV000839495|SCV000149921|SCV000691836|SCV000784695|SCV000806879|SCV000889334|SCV000892319	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_provided|not_provided|not_provided|not_provided|not_provided	In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_in_appropriate_functional_assay(s):Structural_Evidence||This_sequence_change_replaces_arginine_with_glycine_at_codon_117_of_the_CHEK2_protein_(p.Arg117Gly)._The_arginine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_arginine_and_glycine._This_variant_is_present_in_population_databases_(rs28909982,_0.02%)._This_variant_has_been_reported_in_families_affected_with_breast_and_other_cancers_(PMID:_12454775,_12610780,_21244692,_28503720)._It_has_been_shown_to_co-segregate_with_disease_in_several_affected_families,_but_the_segregation_was_considered_incomplete_because_two_affected_individuals_did_not_carry_this_variant_(PMID:_12610780)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128071)._Experimental_studies_have_shown_that_this_variant_results_in_a_CHEK2_protein_with_impaired_function_due_to_reduced_kinase_activity,_reduced_protein_stability,_and_incomplete_phosphorylation_(PMID:_18725978,_16982735,_22419737)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_CHEK2_variant_was_identified_in_a_female_patient_diagnosed_with_breast_cancer_at_38_years_old,_and_whose_mother_also_have_had_bilateral_breast_cancer_at_ages_40_and_42_years_old._Mutation_screening_in_BRCA1_and_BRCA2_genes_gave_negative_results.||Variant_summary:_CHEK2_c.349A>G_(p.Arg117Gly)_results_in_a_non-conservative_amino_acid_change_located_in_the_Forkhead-associated_(FHA)_domain_(IPR000253)_of_the_encoded_protein_sequence._Five_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._This_variant_allele_was_found_in_34/290848_control_chromosomes_at_a_frequency_of_0.00012_(gnomAD_and_publications)._This_frequency_is_not_higher_than_expected_for_a_pathogenic_variant_in_CHEK2_causing_Breast_Cancer_(0.00012_vs_0.00031),_allowing_no_conclusion_about_variant_significance._The_variant,_c.349A>G,_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_cancer_including_breast_cancer,_pancreatic_cancer,_colorectal_cancer_and_prostate_cancer_(but_also_in_controls)_(Hu_2018,_Lu_2018,_Martin-Morales_2018,_Paulo_2018,_Rummel_2017,_Pinto_2016,_Southey_2016),_with_limited_cosegregation_information._In_one_study,_in_3_families,_8_transmissions_of_the_variant_allele_and_2_transmissions_of_the_reference_allele_to_affected_individuals_was_reported_(Schutte_2003)._The_variant_has_also_been_reported_in_studies_that_included_cohorts_of_comprehensively_genotyped_patients_with_early_onset_breast_cancer_meeting_the_NCCN_guidelines_(Rummel_2017),_and_a_family_history_of_breast_cancer_(Pinto_2016:_Moran_2017,_Lu_2018)._A_case-control_study_showed_evidence_of_association_with_breast_cancer_(OR_
NM_001128425.1:c.789G>A	MUTYH	stop_gained,splice_region_variant	NA	NA	15400	1	-	-	-	-	565890	557300	MYH-associated_polyposis	-	MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798	-	NC_000001.10:g.45797982C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	1338038953	-	Invitae	Pathogenic	2018-01-25	2018-08-29	_single_submitter	germline	SCV000813048	MYH-associated_polyposis	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Trp263*)_in_the_MUTYH_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MUTYH-related_disease._Loss-of-function_variants_in_MUTYH_are_known_to_be_pathogenic_(PMID:_18534194,_20663686)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_002354.2:c.184+1G>T	EPCAM	splice_donor_variant	NA	NA	15424	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000251.2:c.1808_1809insAAAAAGTCGAGAGGCCAATCGCGCCGTACCTCCTTATACTAGTGAACAATGGGCTGAACGTATTGATAAAGAGATAATGACCCTTTCACAACTCCCGGAAAATGCCAAATTAAAAATTAAGCGTCCAG	MSH2	frameshift_variant	NA	NA	15424	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000251.2:c.2131C>T	MSH2	stop_gained	NA	NA	15418	1	5&5&5	3&1&1	rs63750636	Lynch syndrome&Hereditary cancer-predisposing syndrome&not provided	90903	96378	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Muir-Torré_syndrome|Lynch_syndrome|Lynch_syndrome_I|not_specified|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1321489,OMIM:158320,Orphanet:ORPHA587,SNOMED_CT:403824007|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C2936783,OMIM:120435|MedGen:CN169374|MedGen:CN517202	-	NC_000002.11:g.47703631C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:10585|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.2131C>T|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario:1787165	-	MSH2:4436	SO:0001587|nonsense	1	63750636	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|Ambry_Genetics|Color|GeneKor_MSA|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Fulgent_Genetics,Fulgent_Genetics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2013-03-01|2017-01-10|2018-07-02|2019-01-30|2018-06-05|2017-03-13|2018-08-01|0000-00-00|2018-11-20|2015-10-20|2018-11-07|2018-10-31|2019-04-30	2013-12-18|2017-04-19|2018-01-25|2018-08-20|2019-02-11|2020-02-26|2017-10-26|2018-08-08|2015-11-19|2019-01-29|2017-08-01|2019-03-28|2018-11-14|2019-08-05	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|unknown|germline	SCV000107434|SCV000592536|SCV000696236|SCV000837849|SCV000914304|SCV000184105|SCV000685015|SCV000821737|SCV000257170|SCV000292625|SCV000601456|SCV000253805|SCV000894280|SCV001156679	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Lynch_syndrome_I/Turcot_syndrome/Muir-Torré_syndrome|not_specified	Coding_sequence_variation_introducing_premature_termination_codon||Variant_summary:_The_MSH2_c.2131C>T_(p.Arg711X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH2_protein_due_to_nonsense_mediated_decay_(NMD),_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_and_others_(e.g._c.2152C>T(p.Gln718X),_c.2633_2634delA(p.Glu878fsX3),_etc.)._This_variant_is_absent_in_121400_control_chromosomes_from_ExAC._In_literature_and_clinical_databases,_this_variant_is_reported_as_a_pathogenic_variant_and_is_found_in_several_HNPCC_families/patients,_including_one_patient_with_Muir-Torre_Syndrome._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_have_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||||This_variant_is_denoted_MSH2_c.2131C>T_at_the_cDNA_level_and_p.Arg711Ter_(R711X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_with_early-onset_familial_colorectal,_endometrial,_and_other_Lynch_syndrome-associated_cancers,_with_some_patients_exhibiting_the_Muir-Torre_variant_phenotype_(Kurzawski_2002,_Mangold_2004,_Apessos_2005,_Papp_2007,_Pedroni_2007,_Rios_2014,_Tanyi_2014,_Nowak_2016,_Pearlman_2016)._Most_tumor_studies_reported_in_the_literature_demonstrate_microsatellite_instability_and_loss_of_MSH2_protein_expression_(Pedroni_2007,_Rios_2014,_Tanyi_2014,_Nowak_2016,_Pearlman_2016)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg711*)_in_the_MSH2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_patients_and_families_affected_with_non-polyposis_colorectal_cancer,_and_with_Muir-Torre_syndrome_(PMID:_12132870,_12362047,_15849733,_16451135,_17569143,_18289827,_15235030,_17473388)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_90903)._Loss-of-function_variants_in_MSH2_are_known_to_be_pathogenic_(PMID:_15849733,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_MSH2_c.2131C>T:_p.Arg711Ter_variant_(rs63750636)_is_reported_in_several_individuals_with_Lynch_syndrome_and_an_individual_with_Muir-Torre_syndrome_(Rios_2014,_Rossi_2017,_Schneider_2018,_see_LOVD_InSiGHT_link)._This_variant_is_classified_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_90903)._It_is_only_observed_on_one_allele_in_the_Genome_Aggregation_Database,_indicating_it_is_not_a_common_polymorphism._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Link_to_InSiGHT_database:_https://databases.lovd.nl/shared/variants/MSH2#object_id
NM_000179.2:c.651dup	MSH6	frameshift_variant	NA	NA	15436	1	-	-	-	-	8932	23971	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48025773dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.651dup|OMIM_Allelic_Variant:600678.0007|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2578444	-	MSH6:2956	SO:0001623|5_prime_UTR_variant	1	63750955	-	OMIM|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2001-10-01|0000-00-00|2015-09-21|2013-09-05|2012-11-09|2016-11-08|2019-05-07|2016-12-13|2018-06-21|2015-09-10|2018-11-02	2018-01-24|2018-04-04|2018-04-09|2013-12-18|2017-04-19|2018-01-25|2020-02-26|2017-10-26|2019-01-29|2018-08-31|2019-03-28	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000029705|SCV000734212|SCV000744289|SCV000108239|SCV000592572|SCV000695923|SCV000213905|SCV000685513|SCV000149347|SCV000888295|SCV000283853	Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	|||Coding_sequence_variation_resulting_in_a_stop_codon|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_duplication_of_one_nucleotide_is_denoted_MSH6_c.651dupT_at_the_cDNA_level_and_p.Lys218Ter_(K218X)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_CAGA[T]AAGA._The_duplication_creates_a_nonsense_variant,_which_changes_a_Lysine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_c.651dupT,_previously_reported_as_217insT,_650insT,_and_651_652insT,_has_been_observed_in_multiple_individuals_with_suspected_Lynch_syndrome,_with_tumors_showing_absent_MSH6_on_immunohistochemistry,_and_was_shown_to_segregate_with_disease_in_several_families_(Wu_1999,_Plaschke_2000,_Wu_2001,_Berends_2002,_Berends_2004,_Hendriks_2004,_Domingo_2005,_Kets_2006,_Overbeek_2007,_Ramsoekh_2008,_Steinke_2008,_Ou_2009,_van_der_Post_2010)._MSH6_c.651dupT_is_considered_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys218*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_with_colorectal_cancer_and_Lynch_syndrome_(PMID:_10521294,_2059188,_20028993,_17453009,_18625694)._This_variant_is_also_known_as_217insT_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_8932)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.1095G>A	MSH6	stop_gained	NA	NA	15426	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.2354_2355insAGCATTGGCTTTGTGCCCCACTCTGTAACCA	MSH6	frameshift_variant	NA	NA	15430	1	-	-	-	-	234743	231560	not_provided	-	MedGen:CN517202	-	NC_000002.11:g.48027476_48027477insAGCATTGGCTTTGTGCCCCACTCTGTAACCA	_single_submitter	Pathogenic	-	-	Insertion	SO:0000667	-	-	MSH6:2956	SO:0001587|nonsense	1	876661193	-	GeneDx	Pathogenic	2016-01-11	2017-11-28	_single_submitter	germline	SCV000279759	not_provided	This_insertion_of_31_nucleotides_in_MSH6_is_denoted_c.2354_2355ins31_at_the_cDNA_level_and_p.His785GlnfsX10_(H785QfsX10)_at_the_protein_level._The_surrounding_sequence_is_ACCA[ins31]TTAT._The_insertion_causes_a_frameshift,_which_changes_a_Histidine_to_a_Glutamine_at_codon_785,_and_creates_a_premature_stop_codon_at_position_10_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.
NM_000179.2:c.2601_2602del	MSH6	frameshift_variant	NA	NA	15424	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.2604_2611del	MSH6	frameshift_variant	NA	NA	15434	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000179.2:c.2731C>T	MSH6	stop_gained	NA	NA	15426	1	5&5&5&5	3&1&0&1	rs63751017	Lynch syndrome&Hereditary cancer-predisposing syndrome&Endometrial carcinoma&not provided	89312	94786	Endometrial_carcinoma|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	Human_Phenotype_Ontology:HP:0012114,MedGen:C0476089,OMIM:608089,SNOMED_CT:254878006|MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48027853C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:3194|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.2731C>T	-	MSH6:2956	SO:0001587|nonsense	1	63751017	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Ambry_Genetics|Color|CSER__CC_NCGL,_University_of_Washington|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Invitae|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2012-10-23|2016-07-22|2018-07-31|2019-03-18|2016-10-29|2014-06-01|2018-12-17|0000-00-00|2016-09-08|2017-09-08|2015-12-06|0000-00-00|2017-05-31|2017-11-26|2018-12-19|2018-10-31	2013-12-18|2017-04-19|2018-01-25|2019-03-21|2020-02-26|2017-10-26|2014-08-28|2019-01-29|2017-10-31|2018-08-31|2018-10-10|2016-11-23|2018-04-04|2018-04-09|2018-06-14|2019-03-28|2018-11-14	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|germline|germline|germline|germline|unknown	SCV000107987|SCV000592613|SCV000695825|SCV000967753|SCV000184618|SCV000685320|SCV000190360|SCV000211301|SCV000257227|SCV000601541|SCV000884139|SCV000487951|SCV000734216|SCV000744293|SCV000840013|SCV000261510|SCV000894281	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Endometrial_carcinoma|not_provided|not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colon_cancer|Endometrial_carcinoma/Turcot_syndrome/Hereditary_nonpolyposis_colorectal_cancer_type_5	Coding_sequence_variation_resulting_in_a_stop_codon||Variant_summary:_The_MSH6_c.2731C>T_(p.Arg911X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_MSH6_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Arg1005X,_p.Arg1068X,_p.Phe1088fsX5,_etc.)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_1/120692_control_chromosomes_at_a_frequency_of_0.0000083,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MSH6_variant_(0.0001421)._The_variant_was_identified_in_patients_from_the_literature,_patients_with_various_types_of_cancer_and_HNPCC_families._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|The_p.Arg911X_variant_in_MSH6_has_been_reported_in_at_least_13_individual_with_M_SH6-associated_cancers_and_segregated_in_at_least_4_affected_relatives_(Goodfell_ow_2003,_Buttin_2004,_Hendriks_2004,_Plaschke_2004,_Hampel_2006,_Talseth-Palmer_2010,_Pal_2012,_Palles_2013,_Rosty_2014,_Susswein_2015,_Akbari_2017,_Raskin_2017_)._This_variant_has_also_been_reported_by_other_clinical_laboratories_in_ClinVar_(Variation_ID_89312)_and_has_been_identified_in_1/15006_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSN_P_rs63751017)._This_nonsense_variant_leads_to_a_premature_termination_codon_at_p_osition_911,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Hetero_zygous_loss_of_function_of_the_MSH6_gene_is_an_established_disease_mechanism_in_individuals_with_Lynch_syndrome._In_summary,_this_variant_meets_criteria_to_be_c_lassified_as_pathogenic_for_Lynch_syndrome_in_an_autosomal_dominant_manner._ACMG_/AMP_Criteria_applied_(Richards_2015):_PVS1:_PS4:_PP1:_PM2.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||This_pathogenic_variant_is_denoted_MSH6_c.2731C>T_at_the_cDNA_level_and_p.Arg911Ter_(R911X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_several_Lynch_syndrome_families_(Goodfellow_2003,_Buttin_2004,_Plaschke_2004,_Talseth-Palmer_2010,_Egoavil_2013)._MSH6_Arg911Ter_has_also_been_observed_de_novo,_reported_with_a_second_MSH6_nonsense_variant_in_a_child_with_Constitutional_Mismatch_Repair_Deficiency_(CMMRD)_syndrome_with_absent_MSH6_protein_expression_on_IHC_in_both_tumor_and_normal_tissue_(Galuppini_2018)._We_consider_this_variant_to_be_pathogenic.|||The_MSH6_c.2731C>T:_p.Arg911Ter_variant_(rs63751017)_has_previously_been_described_in_individuals_and_families_with_Lynch_syndrome_(Goodfellow_2003,_Pal_2012,_Plaschke_2004,_Rosty_2014,_Talseth-Palmer_2010)._It_is_reported_in_the_ClinVar_database_as_pathogenic_(Variation_ID:_89312),_and_observed_in_the_general_population_at_a_very_low_allele_frequency_of_0.008_percent_(1/13006_alleles)_in_the_Exome_Variant_Server,_and_0.003_percent_(1/30970_alleles)_in_the_Genome_Aggregation_Database._This_variant_induces_an_early_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_absent_transcript._Based_on_the_above_information,_this_variant_is_considered_pathogenic._REFERENCES_Link_to_ClinVar_database_for_p.Arg911Ter:_https://www.ncbi.nlm.nih.gov/clinvar/variation/89312/_Goodfellow_PJ_et_al._Prevalence_of_defective_DNA_mismatch_repair_and_MSH6_mutation_in_an_unselected_series_of_endometrial_cancers._Proc_Natl_Acad_Sci_U_S_A._2003_May_13:100(10):5908-13._Pal_T_et_al._Frequency_of_mutations_in_mismatch_repair_genes_in_a_population-based_study_of_women_with_ovarian_cancer._Br_J_Cancer._2012_Nov_6:107(10):1783-90._Plaschke_J_et_al._Lower_incidence_of_colorectal_cancer_and_later_age_of_disease_onset_in_27_families_with_pathogenic_MSH6_germline_mutations_compared_with_families_with_MLH1_or_MSH2_mutations:_the_German_Hereditary_Nonpolyposis_Colorectal_Cancer_Consortium._J_Clin_Oncol._2004_Nov_15:22(22):4486-94._Rosty_C_et_al._High_prevalence_of_mismatch_repair_deficiency_in_prostate_cancers_diagnosed_in_mismatch_repair_gene_mutation_carriers_from_the_colon_cancer_family_registry._Fam_Cancer._2014_Dec:13(4):573-82._Talseth-Palmer_BA_et_al._MSH6_and_PMS2_mutation_positive_Australian_Lynch_syndrome_families:_novel_mutations,_cancer_risk_and_age_of_diagnosis_of_colorectal_cancer._Hered_Cancer_Clin_Pract._2010_May_21:8(1):5.||||The_c.2731C>T_(p.Arg911*)_variant_in_the_MSH6_gene_is_predicted_to_introduce_a_premature_translation_stop_codon._This_variant_has_been_reported_in_the_literature_in_multiple_individuals_with_ovarian,_colorectal,_or_prostate_cancer_(PMID:_12732731,_23047549,_23263490,_15236168,_15483016,_25117503,_16885385)._The_c.2731C>T_(p.Arg911*)_variant_in_the_MSH6_gene_is_classified_as_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg911*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_multiple_individuals_with_Lynch_syndrome_(PMID:_12732731,_23047549,_23263490,_20487569,_15483016)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89312)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000179.2:c.3487G>T	MSH6	stop_gained	NA	NA	15428	1	5&5	3&1	rs587779267	Lynch syndrome&not provided	89399	94873	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48032097G>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3487G>T	-	MSH6:2956	SO:0001587|nonsense	1	587779267	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|A.C.Camargo_Cancer_Center_/_LGBM,_A.C.Camargo_Cancer_Center|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Ambry_Genetics|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2019-01-30|2014-03-05|0000-00-00|2019-03-13|2018-09-22	2013-12-18|2019-02-11|2019-01-29|2017-10-31|2020-02-26|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline	SCV000108079|SCV000914311|SCV000149326|SCV000691939|SCV000580168|SCV000551275	Lynch_syndrome|Lynch_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||This_pathogenic_variant_is_denoted_MSH6_c.3487G>T_at_the_cDNA_level_and_p.Glu1163Ter_(E1163X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_changing_a_Glutamic_Acid_to_a_premature_stop_codon_(GAA>TAA)._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1163_(p.Glu1163*)_of_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_individuals_affected_with_colon_cancer,_ovarian_cancer_or_endometrial_cancer_(PMID:_26437257,_26681312,_25093288)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89399)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_000179.2:c.3920_3927dup	MSH6	frameshift_variant	NA	NA	15420	1	-	-	-	-	89481	94955	Hereditary_nonpolyposis_colon_cancer|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.48033709_48033716dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.3920_3927dup|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2847159	-	MSH6:2956	SO:0001589|frameshift_variant	1	587779295	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-09-05|2018-08-09|2018-07-24|2018-07-10	2013-12-18|2019-01-29|2018-08-31|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000108164|SCV000779089|SCV000889504|SCV000820282	Lynch_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon|This_duplication_of_eight_nucleotides_in_MSH6_is_denoted_c.3920_3927dupATCTCCCA_at_the_cDNA_level_and_p.Glu1310IlefsX20_(E1310IfsX20)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_duplicated_in_brackets,_is_GCTA[dupATCTCCCA]GAGG._The_duplication_causes_a_frameshift_which_changes_a_Glutamic_Acid_to_an_Isoleucine_at_codon_1310,_and_creates_a_premature_stop_codon_at_position_20_of_the_new_reading_frame._It_is_predicted_to_cause_loss_of_normal_protein_function_through_protein_truncation_as_the_last_51_amino_acids_are_lost_and_replaced_with_19_incorrect_amino_acids._The_disrupted_region_at_the_end_of_the_gene_is_located_within_the_ATPase_domain_and_the_MSH2_binding_site_(Kariola_2002,_Warren_2007,_Kansikas_2011)._MSH6_c.3920_3927dupATCTCCCA_has_been_reported_in_at_least_one_family_with_Lynch_syndrome_(Sjursen_2016)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_MSH6_gene_(p.Glu1310Ilefs*20)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_disrupt_the_last_51_amino_acids_of_the_MSH6_protein._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_in_the_Leiden_Open-source_Variation_Database_(PMID:_21520333)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:Â¬â€ 89481)._A_different_truncation_(p.Leu1330Valfs*12)_that_lies_downstream_of_this_variant_has_been_determined_to_be_pathogenic_(PMID:Â¬â€ 14520694,_15236168,_16237223,_19851887,_21155762,Â¬â€ 24440087)._This_suggests_that_deletion_of_this_region_of_the_MSH6_protein_is_causative_of_disease._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_006218.3:c.10C>T	PIK3CA	stop_gained	NA	NA	15420	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000038.5:c.477C>G	APC	stop_gained	NA	NA	15320	1	5	1	rs863224281	not provided	246084	244416	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2713442,OMIM:175100|MedGen:CN517202	-	NC_000005.9:g.112111380C>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	APC:324	SO:0001623|5_prime_UTR_variant	1	863224281	-	GeneDx|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2018-06-20|2017-09-18|2018-11-08	2019-01-29|2018-04-02|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000293415|SCV000768138|SCV001184844	not_provided|Familial_adenomatous_polyposis_1|Hereditary_cancer-predisposing_syndrome	This_pathogenic_variant_is_denoted_APC_c.477C>G_at_the_cDNA_level_and_p.Tyr159Ter_(Y159X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_with_familial_adenomatous_polyposis_(Marshall_1996,_Friedl_2005,_Truta_2005,_Rashid_2016)_and_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr159*)_in_the_APC_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_familial_adenomatous_polyposis_(PMID:_8956059,_15951963,_20223039)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_246084)._Loss-of-function_variants_in_APC_are_known_to_be_pathogenic_(PMID:_17963004,_20685668)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000038.5:c.613_616dup	APC	frameshift_variant	NA	NA	15418	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000038.5:c.763_764del	APC	frameshift_variant	NA	NA	15428	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000038.5:c.768_772del	APC	frameshift_variant	NA	NA	15432	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000535.6:c.1144+1G>A	PMS2	splice_donor_variant	102662	0	15420	1	-	-	-	-	162508	172174	Lynch_syndrome|not_provided	-	Orphanet:ORPHA144|MedGen:CN517202	-	NC_000007.13:g.6029430C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PMS2:5395	SO:0001627|intron_variant	1	373885654	-	_University_of_Washington|GeneDx	Likely_pathogenic|Pathogenic	2014-06-01|2017-03-20	2015-11-22|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000196743|SCV000279941	Lynch_syndrome|not_provided	|This_variant_is_denoted_PMS2_c.1144+1G>A_or_IVS10+1G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_+1_position_of_intron_10_of_the_PMS2_gene._This_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_been_observed_in_two_individuals_included_in_a_population_screening_cohort,_however_personal_and_family_cancer_histories_were_not_provided_(Amendola_2015)._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.
NM_000535.6:c.765C>A	PMS2	stop_gained	NA	NA	15280	1	5&5	1&2	rs573125799	Hereditary cancer-predisposing syndrome&Lynch syndrome	183716	182785	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000007.13:g.6036995G>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	PMS2:5395	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant	1	573125799	-	_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-02-01|2017-09-07|2018-06-18|2016-03-03|2017-09-27|2018-10-09|2016-08-04|2018-12-14	2020-02-26|2018-03-08|2018-11-06|2019-03-21|2019-04-24|2019-01-29|2017-08-01|2019-03-28	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000212750|SCV000788119|SCV000911689|SCV000271441|SCV000920038|SCV000490729|SCV000601860|SCV000219144	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Lynch_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||The_p.Tyr255X_variant_in_PMS2_has_been_reported_in_2_individuals_with_PMS2-assoc_iated_cancers_(Dudley_2015,_Yurgelun_2015),_and_was_absent_from_large_population_studies._This_nonsense_variant_leads_to_a_premature_termination_codon_at_positi_on_255,_which_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygou_s_loss_of_function_of_the_PMS2_gene_is_an_established_disease_mechanism_in_indiv_iduals_with_Lynch_syndrome._In_summary,_this_variant_meets_our_criteria_to_be_cl_assified_as_pathogenic_for_Lynch_syndrome_in_an_autosomal_dominant_manner_based_upon_the_predicted_impact_to_the_protein.|Variant_summary:_The_PMS2_c.765C>A_(p.Tyr255X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_PMS2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.823C>T_(p.Gln275X),_c.861_864delACAG_(p.Arg287fsX19),_c.1021delA_(p.Arg341fsX15))._The_variant_has_been_reported_in_multiple_patients_with_colorectal_cancer_and_other_LS-associated_tumors_from_Lynch_syndrome_families_(e.g._Rosty_2016,_Yurgelun_2015,_Dudley_2015)._This_variant_was_found_in_1/30666_control_chromosomes_at_a_frequency_of_0.0000326,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_PMS2_variant_(0.0001136)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_PMS2_c.765C>A_at_the_cDNA_level_and_p.Tyr255Ter_(Y255X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_multiple_individuals_with_a_personal_and/or_family_history_of_colorectal_cancer_(Dudley_2015,_Goodenberger_2016,_Rosty_2016,_Yurgelun_2017)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr255*)_in_the_PMS2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variantÂ¬â€ has_been_reported_in_the_literature_in_individuals_affected_with_Lynch_syndrome_and_colorectal_cancer_(PMID:_25871621,_23012243,_25980754,25856668).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_183716)._Loss-of-function_variants_in_PMS2_are_known_to_be_pathogenic_(PMID:_21376568,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_021930.5:c.712C>T	RINT1	stop_gained	NA	NA	15434	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_021930.5:c.1457del	RINT1	frameshift_variant	NA	NA	15436	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002485.4:c.2117C>G	NBN	stop_gained	102618	0	15408	2	5&5	1&1	rs730881857	Hereditary cancer-predisposing syndrome&not provided	182728	180280	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90955548G>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001587|nonsense	1	730881857	-	Ambry_Genetics|Color|GeneDx|Counsyl|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2018-06-25|2015-10-07|2018-04-24|2015-12-21|2018-10-24|2018-06-25	2020-02-26|2017-01-26|2019-01-29|2016-11-23|2019-03-28|2019-04-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline	SCV000217454|SCV000537662|SCV000211460|SCV000485485|SCV000553078|SCV000917858	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_pathogenic_variant_is_denoted_NBN_c.2117C>G_at_the_cDNA_level_and_p.Ser706Ter_(S706X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._NBN_Ser706Ter_has_been_reported_in_a_European_male_with_early_onset_prostate_cancer_and_showed_partial_co-segregation_among_affected_family_members_(Zuhlke_2012)._We_consider_this_variant_to_be_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_706_(p.Ser706*)_of_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_a_family_with_prostate_cancer_and_bladder_cancer_(PMID:_22864661)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_NBN_c.2117C>G_(p.Ser706X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_in_a_highly_conserved_region_of_NBN_near_the_MRE11_binding_site_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_4e-06_in_247890_control_chromosomes_(gnomAD_and_controls)._The_variant,_c.2117C>G,_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_cancer,_along_with_one_family,_Zuhkle_2012,_in_whom_the_variant_was_reported_to_partially_co-segregate_with_prostate_cancer._Individuals_who_are_heterozygous_for_NBN_mutations_are_clinically_asymptomatic,_but_may_display_an_elevated_risk_for_certain_cancers_including,_but_not_limited_to,_ovarian_and_prostate_cancer_as_well_as_various_lymphoid_malignancies._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Five_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cites_the_variant_as_likely_pathogenic/pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_002485.4:c.1716dup	NBN	frameshift_variant	NA	NA	15416	1	-	-	-	-	411780	396697	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90965601dup	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Duplication	SO:1000035	-	-	NBN:4683	SO:0001589|frameshift_variant	1	1060503483	-	Invitae|GeneDx|Color|Ambry_Genetics	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2018-11-08|2016-12-23|2017-08-17|2019-03-30	2019-03-28|2019-01-29|2017-12-21|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000553106|SCV000572538|SCV000690674|SCV001173326	_normal_intelligence_and_immunodeficiency|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu573Argfs*5)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_411780)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_duplication_of_one_nucleotide_in_NBN_is_denoted_c.1716dupA_at_the_cDNA_level_and_p.Glu573ArgfsX5_(E573RfsX5)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_duplicated_in_brackets,_is_AACC[dupA]GAGT._The_duplication_causes_a_frameshift,_which_changes_a_Glutamic_Acid_to_an_Arginine_at_codon_573,_and_creates_a_premature_stop_codon_at_position_5_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Based_on_currently_available_information,_we_consider_this_to_be_a_likely_pathogenic_variant.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_002485.4:c.37+1G>A	NBN	splice_donor_variant	99714	0	15430	2	-	-	-	-	186314	182906	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90996752C>T	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NBN:4683	SO:0001575|splice_donor_variant	1	574673404	-	Ambry_Genetics|Color|Invitae|Counsyl|GeneKor_MSA	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2019-10-31|2018-07-26|2018-04-25|2018-03-01|2018-08-01	2020-02-26|2018-11-06|2018-08-29|2018-07-10|2018-08-08	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline	SCV000216641|SCV000537621|SCV000553112|SCV000798225|SCV000821750	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|not_provided	Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity||This_sequence_change_affects_a_donor_splice_site_in_intron_1_of_the_NBN_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs574673404,_ExAC_0.01%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NBN-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_186314)._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||
NM_000136.2:c.1417C>T	FANCC	stop_gained	NA	NA	15430	1	-	-	-	-	551836	544971	_complementation_group_C	-	OMIM:227645	-	NC_000009.11:g.97869464G>A	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001587|nonsense	0	1410356625	-	Counsyl	Likely_pathogenic	2017-05-09	2018-07-10	_single_submitter	unknown	SCV000791373	_complementation_group_C	
NM_000136.2:c.1309C>T	FANCC	stop_gained	NA	NA	15426	1	-	-	-	-	370350	357826	_complementation_group_C|not_provided	-	OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97873765G>A	criteria_provided,_multiple_submitters,_no_conflicts	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001587|nonsense	1	944083227	-	Counsyl|GeneDx	Likely_pathogenic|Likely_pathogenic	2016-01-18|2016-05-05	2016-11-23|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline	SCV000485642|SCV000779429	_complementation_group_C|not_provided	|This_variant_is_denoted_FANCC_c.1309C>T_at_the_cDNA_level_and_p.Gln437Ter_(Q437X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_likely_pathogenic.
NM_000314.4:c.253+2T>C	PTEN	splice_donor_variant	NA	NA	15352	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.217_218del	ATM	frameshift_variant	102142	0	15396	1	-	-	-	-	569567	565062	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000011.9:g.108099936_108099937del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472	SO:0001589|frameshift_variant	1	762089971	-	Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2018-06-26|2018-04-16|2019-07-22	2018-08-29|2019-04-24|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000817907|SCV000916574|SCV001175369	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu73Metfs*26)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._The_frequency_data_for_this_variant_in_the_population_databases_is_considered_unreliable,_as_metrics_indicate_poor_data_quality_at_this_position_in_the_ExAC_database._This_variant_has_been_observed_in_the_homozygous_state_in_an_individual_affected_with_ataxia_telangiectasia_(PMID:Â¬â€ 10817650)._This_variant_is_also_known_as_216delAG_in_the_literature._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_ATM_c.217_218delGA_(p.Glu73MetfsX26)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(eg._c.513C>G_(p.Tyr171X),_c.790delT_(p.Tyr264fsX12),_and_c.1027_1030delGAAA_(p.Glu343fsX2))._The_variant_of_interest_was_observed_with_an_allele_frequency_of_7.2e-06_in_275964_control_chromosomes_(gnomAD)._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_ATM_causing_Ataxia-Telangiectasia_(7.2e-06_vs_0.004),_allowing_no_conclusion_about_variant_significance._The_variant,_c.217_218delGA,_has_been_reported_in_the_literature_in_individuals_affected_with_Ataxia-Telangiectasia_(Li_2000,_Carney_2012),_which_one_compound_heterozygote_pt_was_found_to_have_no_ATM_protein_expression_(Carney_2012)._No_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.538C>T	ATM	stop_gained	NA	NA	15332	1	5	1	rs730881333	not provided	181910	180387	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108114721C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	730881333	-	GeneDx|Invitae|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2017-09-07|2018-11-19|2018-09-17	2018-06-26|2019-03-28|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000209675|SCV000622584|SCV001185970	not_provided|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_ATM_c.538C>T_at_the_cDNA_level_and_p.Gln180Ter_(Q180X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_the_compound_heterozygous_state_in_at_least_two_patients_with_ataxia-telangiectasia_(Heinrich_2006,_Soukupova_2011),_and_in_the_heterozygous_state_in_at_least_one_patient_with_breast_cancer_(Frey_2017)._This_variant_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_180_(p.Gln180*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_breast_cancer_(PMID:_26681312)._It_has_also_been_observed_to_occur_with_a_pathogenic_ATM_variant_in_an_individual_with_ataxia-telangiectasia_(PMID:_16411093)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)
NM_000051.3:c.742C>T	ATM	stop_gained	102368	0	15416	1	5&5	1&1	rs730881336	Hereditary cancer-predisposing syndrome&not provided	181913	180391	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108115594C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	9	730881336	-	Ambry_Genetics|Color|GeneDx|Counsyl|Invitae|Department_of_Rehabilitation_Medicine,_Incheon_St._Mary’s_Hospital,College_of_Medicine,_The_Catholic_University_of_Korea|Fulgent_Genetics,Fulgent_Genetics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-02|2015-04-21|2016-03-16|2015-11-20|2018-08-28|2019-11-20|2017-05-18|2017-05-24	2020-02-26|2017-12-21|2017-11-28|2016-11-23|2019-03-28|2019-11-27|2017-05-23|2018-06-14	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|paternal|unknown|germline	SCV000217771|SCV000687770|SCV000209680|SCV000485320|SCV000622747|SCV000999057|SCV000611167|SCV000839882	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_variant_is_denoted_ATM_c.742C>T_at_the_cDNA_level_and_p.Arg248Ter_(R248X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_ataxia-telangiectasia_patients_in_the_compound_heterozygous_state_(Mitui_2005,_Sasaki_1998),_and_in_at_least_one_breast_cancer_patient_who_also_carried_a_BRCA2_nonsense_variant_(Churpek_2015)._This_variant_is_considered_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg248*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs730881336,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_affected_with_ataxia_telangiectasia_(PMID:_9711876,_16266405),_prostate_cancer_(PMID:_27433846)_and_breast_cancer_(PMID:_26681312,_28281021)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181913)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_25614872,_23807571)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_patient_has_another_variant_on_the_other_allele_(arr[GRCh37]_11q22.3(108151766-108183226)x1,_31460_bp).||This_c.742C>T_(p.Arg248*)_variant_in_the_ATM_gene_has_previously_been_reported_in_two_Japanese_patients_with_ataxia_telangiectasia_[PMID_9711876]._Both_patients_were_compound_heterozygous_for_this_variant_and_a_loss_of_function_variant_[PMID_9711876]._This_c.742C>T_encodes_for_a_premature_stop_codon_in_exon_7_at_amino_acid_position_248_of_the_ATM_protein,_leading_to_a_loss_of_function_of_the_protein._This_variant_has_been_observed_in_one_heterozygous_East_Asian_individual_in_the_ExAC_database_(http://exac.broadinstitute.org/variant/11-108115594-C-T)._It_is_thus_classified_as_a_pathogenic_variant.
NM_000051.3:c.901+1G>T	ATM	splice_donor_variant	NA	NA	15422	1	-	-	-	-	234172	233946	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000011.9:g.108115754G>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001575|splice_donor_variant	1	748840480	-	Ambry_Genetics	Pathogenic	2015-09-28	2020-02-26	_single_submitter	germline	SCV000278694	Hereditary_cancer-predisposing_syndrome	_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Well-characterized_mutation_at_same_position
NM_000051.3:c.1235G>A	ATM	stop_gained,splice_region_variant	NA	NA	15414	1	5	1	rs587779813	not provided	127334	132791	Hereditary_cancer-predisposing_syndrome|not_provided	-	SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108119829G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	587779813	-	GeneDx|Ambry_Genetics	Pathogenic|Pathogenic	2013-09-27|2018-06-07	2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000149047|SCV000660570	not_provided|Hereditary_cancer-predisposing_syndrome	This_pathogenic_variant_is_denoted_c.1235G>A_at_the_cDNA_level_or_p.Trp412Stop_(W412X)_at_the_protein_level._The_G>A_substitution_at_nucleotide_position_1235_results_in_the_replacement_of_a_Tryptophan_codon_(TGG)_with_a_Stop_codon_(TAG)_at_amino_acid_position_412_in_exon_9_of_the_ATM_gene._This_mutation_is_predicted_to_cause_loss_of_normal_protein_function_either_through_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not_been_reported_previously_to_our_knowledge,_it_is_considered_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.1238_1239insTTTT	ATM	frameshift_variant,splice_region_variant	NA	NA	12674	1	-	-	-	-	802739	791048	Ataxia-telangiectasia_syndrome	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005	-	NC_000011.9:g.108121430_108121431insTTTT	_single_submitter	Uncertain_significance	-	-	Insertion	SO:0000667	-	-	ATM:472	SO:0001589|frameshift_variant	0	-	-	Mendelics	Uncertain_significance	2019-05-28	2019-10-22	_single_submitter	unknown	SCV001138457	Ataxia-telangiectasia_syndrome	
NM_000051.3:c.1463G>A	ATM	stop_gained	NA	NA	15406	1	5	1	rs879254093	not provided	246090	244585	Ataxia-telangiectasia_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:CN517202	-	NC_000011.9:g.108121655G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	879254093	-	GeneDx|Invitae|Counsyl	Pathogenic|Pathogenic|Pathogenic	2017-04-18|2018-09-12|2018-05-31	2019-01-29|2019-03-28|2018-07-10	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown	SCV000293431|SCV000546982|SCV000800321	not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome	This_variant_is_denoted_ATM_c.1463G>A_at_the_cDNA_level_and_p.Trp488Ter_(W488X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tryptophan_to_a_premature_stop_codon_(TGG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_patients_with_classical_ataxia-telangiectasia_(Cavalieri_2006,_Magliozzi_2006,_Broccoletti_2011)_and_is_considered_pathogenic.|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Trp488*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_16941484,_17124347)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_246090)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|
NM_000051.3:c.1894G>T	ATM	stop_gained	NA	NA	15424	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.3244_3245insTG	ATM	frameshift_variant	NA	NA	15428	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.3247del	ATM	frameshift_variant	NA	NA	15432	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.3663G>A	ATM	stop_gained	102506	0	15428	1	5&5	1&1	rs864622490	Ataxia-telangiectasia syndrome&not provided	220358	222073	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108153523G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	864622490	-	Invitae|Counsyl|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-11-18|2016-10-04|2018-02-08|2017-05-25|2019-09-13	2019-03-28|2016-11-23|2019-04-24|2019-01-29|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline	SCV000260841|SCV000487075|SCV000918512|SCV000293436|SCV000672666	Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome	This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1221_(p.Trp1221*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_ataxia-telangiectasia_(PMID:_10330348,_22071889)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_220358)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_ATM_c.3663G>A_(p.Trp1221X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_p.Leu1238fsX6_and_p.Arg1466X)._The_variant_was_absent_in_120132_control_chromosomes._The_c.3663G>A_variant_has_been_reported_in_the_literature_in_several_compound_heterozygous_individuals_affected_with_Ataxia-Telangiectasia._These_data_indicate_that_the_variant_may_be_associated_with_disease._Four_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_variant_is_denoted_ATM_c.3663G>A_at_the_cDNA_level_and_p.Trp1221Ter_(W1221X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Tryptophan_to_a_premature_stop_codon_(TGG>TGA)_,_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_the_compound_heterozygous_state_with_pathogenic_ATM_variants_in_individuals_with_ataxia-telangiectasia_(Teraoka_1999,_Bernstein_2003,_Jacquemin_2012,_Hoche_2014)_and_is_considered_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.4106C>A	ATM	stop_gained	NA	NA	15418	1	-	-	-	-	379550	371819	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108158439C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472	SO:0001587|nonsense	1	1057520640	-	GeneDx|Invitae|Counsyl|Ambry_Genetics	Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2015-04-14|2017-02-16|2017-05-04|2016-05-25	2019-01-29|2017-10-05|2017-06-22|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline	SCV000516711|SCV000546927|SCV000678102|SCV000660627	not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome	This_pathogenic_variant_is_denoted_ATM_c.4106C>A_at_the_cDNA_level_and_p.Ser1369Ter_(S1369X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_considered_pathogenic._The_presence_of|This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1369_(p.Ser1369*)_of_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_10817650,_19781682)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000051.3:c.4174del	ATM	frameshift_variant	NA	NA	15430	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.6100C>T	ATM	stop_gained	102688	0	15426	1	5&5	1&1	rs532480170	Ataxia-telangiectasia syndrome&not provided	127417	132874	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108186742C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	17	532480170	-	_University_of_Washington|Color|Invitae|Baylor_Genetics|GeneDx	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2019-04-17|2015-11-20|2015-12-02|2018-08-21|2017-09-01|2018-11-19	2020-02-26|2016-03-03|2016-07-05|2019-03-28|2017-10-16|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|maternal|germline	SCV000214025|SCV000266019|SCV000292138|SCV000166125|SCV000807216|SCV000149131	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg2034*)_in_the_ATM_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_ataxia-telangiectasia,_breast_cancer_and_multiple_cancer_types_(PMID:_8659541,_21833744,_11505391,_26845104,_26681312)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127417)._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_23807571,_25614872)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_mutation_has_been_previously_reported_as_disease-causing_and_was_found_once_in_our_laboratory_in_trans_with_a_missense_mutation_in_a_10-year-old_male_with_global_delays,_myopathy,_epilepsy,_generalize_muscle_weakness,_and_abnormal_brain_MRI.|This_variant_is_denoted_ATM_c.6100C>T_at_the_cDNA_level_and_p.Arg2034Ter_(R2034X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_multiple_individuals_with_breast_cancer_(Teraoka_2001,_Ang?le_2003,_Shirts_2016,_Tavera-Tapia_2017)._In_addition,_this_variant_has_been_identified_in_several_patients_with_ataxia_telangiectasia,_including_one_family_with_multiple_siblings_affected_in_the_confirmed_homozygous_state_(Telatar_1996,_Buzin_2003,_An_2016)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.6765del	ATM	frameshift_variant	NA	NA	15382	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000051.3:c.8036_8051del	ATM	frameshift_variant	NA	NA	15432	1	-	-	-	-	185795	183414	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108205721_108205736del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587780640	-	Invitae|Ambry_Genetics|GeneDx	Pathogenic|Pathogenic|Pathogenic	2015-11-14|2014-08-07|2017-04-26	2016-08-15|2020-02-26|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000166143|SCV000216001|SCV000779049	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	This_sequence_change_deletes_16_nucleotide_from_exon_55_of_the_ATM_mRNA_(c.8036_8051delATCTGGTGACTATACA),_causing_a_frameshift_at_codon_2679._This_creates_a_premature_translational_stop_signal_(p.Asn2679Serfs*9)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_truncating_variants_in_ATM_are_known_to_be_pathogenic_(PMID:_10817650,_19781682)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_deletion_of_16_nucleotides_in_ATM_is_denoted_c.8036_8051del16_at_the_cDNA_level_and_p.Asn2679SerfsX9_(N2679SfsX9)_at_the_protein_level._The_surrounding_sequence_is_GGAA[del16]GTCA._The_deletion_causes_a_frameshift_which_changes_an_Asparagine_to_a_Serine_at_codon_2679,_and_creates_a_premature_stop_codon_at_position_9_of_the_new_reading_frame._Although_this_variant_has_not,_to_our_knowledge,_been_reported_in_the_literature,_it_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._We_consider_this_variant_to_be_pathogenic.
NM_000051.3:c.8264_8268del	ATM	frameshift_variant,splice_region_variant	102262	0	15412	1	-	-	-	-	181865	180515	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108206684_108206688del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva:9_April2016|Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva:22_May_2017	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	25	730881294	-	GeneDx|Center_for_Individualized_Medicine,Mayo_Clinic|Center_of_Genomic_medicine,_Geneva,University_Hospital_of_Geneva|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Counsyl|Mendelics|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-06-01|2014-01-01|2016-09-12|2018-12-22|2015-11-25|2017-08-02|2018-07-02|2018-07-26|2017-06-02	2019-01-29|2015-09-10|2017-05-19|2019-03-28|2018-01-25|2018-07-10|2018-08-20|2020-02-26|2017-10-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|maternal|germline|germline|unknown|unknown|germline|germline	SCV000209609|SCV000245683|SCV000268516|SCV000283075|SCV000694374|SCV000793072|SCV000838611|SCV000274579|SCV000682470	not_provided|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_deletion_of_five_nucleotides_in_ATM_is_denoted_c.8264_8268delATAAG_at_the_cDNA_level_and_p.Tyr2755CysfsX12_(Y2755CfsX12)_at_the_protein_level._The_normal_sequence_using_uppercase_letters_to_denote_exonic_sequence_and_lowercase_letters_to_denote_intronic_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_ACTT[delATAAG]gtaa._The_deletion_causes_a_frameshift,_which_changes_a_Tyrosine_to_a_Cysteine_at_codon_2755,_and_creates_a_premature_stop_codon_at_position_12_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._An_additional_possible_mechanism_of_pathogenicity_is_that_given_this_deletion's_location_at_the_exon/intron_boundary,_this_variant_may_result_in_aberrant_splicing_and_skipping_of_exon_56_(also_reported_as_exon_58_using_alternate_exon_numbering)_(Laake_2000,_Tavtigian_2009)._Whether_the_effect_of_this_variant_is_that_of_a_frameshift_or_splicing_defect,_the_resultant_protein_would_be_impaired._ATM_c.8264_8268delATAAG_has_been_observed_in_the_compound_heterozygous_state_in_patients_with_Ataxia-telangiectasia_(Stankovic_1998,_Mitui_2003,_Demuth_2011,_Carranza_2017),_and_in_the_single_heterozygous_state_in_individuals_with_breast_cancer_(Tavtigian_2009,_Gra?a_2011,_Ellingson_2015,_Decker_2017)._Furthermore,_functional_studies_showed_that_this_variant_was_associated_with_no_detectable_kinase_activity_(Barone_2009)._We_consider_this_variant_to_be_pathogenic.||This_heterozygous_variant_in_the_ATM_gene_(autosomal_recessive_transmission),_inherited_from_the_mother,_was_present_in_a_female_patient_who_also_harbours_a_second_variant_in_the_same_gene_inherited_by_the_father_(compound_heterozygosity).|This_sequence_change_deletes_5_nucleotides_from_exon_56_of_the_ATM_mRNA_(c.8264_8268delATAAG),_causing_a_frameshift_at_codon_2755._This_creates_a_premature_translational_stop_signal_(p.Tyr2755Cysfs*12)_and_is_expected_to_result_in_a_disrupted_protein_product._Loss-of-function_variants_in_ATM_are_known_to_be_pathogenic._This_particular_variant_has_been_well_described_in_the_literature_as_a_recurrent,_causative_mutation_in_individuals_affected_with_ataxia-telangiectesia_(PMID:_9463314,_12815592,_21965147,_10980530)._Â¬â€ This_variant_has_also_been_reported_in_an_individuals_affected_with_breast_cancer_(PMID:_21445571,_26296701,_26681312)_and_has_been_reported_to_incur_a_2-fold_risk_for_developing_breast_cancer_(PMID:_20346647).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181865)._Experimental_studies_have_reported_that_this_variant_causes_aberrant_splicing_and_results_in_an_mRNA_transcript_lacking_exon_56_(also_reported_as_exon_58)_(PMID:_15039971,_21792198)._Â¬â€ Additional_publications_have_reported_that_although_this_variant_produces_a_protein_product_that_allows_for_ATM_expression,_this_protein_lacks_the_kinase_activity_required_for_normal_function_of_the_ATM_protein_(PMID:_19431188)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_The_variant_is_a_deletion_of_five_nucleotides_spanning_over_the_border_of_exon_and_intron_56._5/5_in_silico_tools_via_Alamut_predict_this_deletion_to_result_in_loss_of_splice_donor_site_along_with_mutation_taster_predicting_disease_causing_outcome._The_variant_was_observed_in_the_large_and_broad_cohorts_of_the_ExAC_project_at_an_allele_frequency_of_0.00084%_which_does_not_exceed_the_maximal_expected_allele_frequency_of_a_disease_causing_ATM_allele_(0.4%)._It_was_reported_in_AT_patients_in_compound_heterozygosity_with_potentially_pathogenic_ATM_variants_and_was_also_observed_in_breast_cancer_patients_in_a_heterozygous_form_indicating_the_variant_to_be_pathogenic_for_both_AT_and_breast_cancer._Additionally,_clinical_diagnostic_laboratories_classify_variant_as_Pathogenic_via_ClinVar_(without_evidence_to_independently_evaluate)._Considering_all_evidence,_the_variant_is_classified_as_pathogenic.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|
NM_000059.3:c.468dup	BRCA2	frameshift_variant	NA	NA	15434	1	-	-	-	-	548417	538642	_familial_2	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32900280dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRCA2:675	SO:0001587|nonsense	1	1555280955	-	Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Color|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2017-12-15|2018-05-17|2018-01-18	2018-05-21|2018-11-06|2020-02-26	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000784101|SCV000906243|SCV001184691	_familial_2|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000059.3:c.2312T>G	BRCA2	stop_gained	NA	NA	15424	1	5&5	1&3	rs587782095	Hereditary cancer-predisposing syndrome&Breast-ovarian cancer, familial 2	141901	151615	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32910804T>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	587782095	-	Ambry_Genetics|Color|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|GeneDx	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2016-08-09|2018-03-29|2016-09-08|2015-10-02|2014-01-31|2017-12-27	2020-02-26|2018-11-06|2016-09-13|2016-10-28|2017-08-04|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000185481|SCV000911670|SCV000300506|SCV000326690|SCV000587628|SCV000779373	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_variant_is_denoted_BRCA2_c.2312T>G_at_the_cDNA_level_and_p.Leu771Ter_(L771X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA2_c.2540T>G._The_substitution_creates_a_nonsense_variant,_which_changes_a_Leucine_to_a_premature_stop_codon_(TTA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_at_least_two_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_(Tea_2014)_and_is_considered_pathogenic.
NM_000059.3:c.4037del	BRCA2	frameshift_variant	NA	NA	15424	1	-	-	-	-	438976	432793	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32912529del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	1162394508	-	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)	Likely_pathogenic|Pathogenic|Pathogenic	2016-10-14|2017-01-13|2017-12-15	2017-08-01|2017-10-05|2018-05-21	criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel	germline|germline|germline	SCV000600573|SCV000635329|SCV000784086	_familial_2	|This_sequence_change_deletes_1_nucleotides_from_exon_11_of_the_BRCA2_mRNA_(c.4037delC),_causing_a_frameshift_at_codon_1346._This_creates_a_premature_translational_stop_signal_(p.Thr1346Metfs*28)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.
NM_000059.3:c.4039_4043del	BRCA2	frameshift_variant	NA	NA	15428	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_000059.3:c.4965C>G	BRCA2	stop_gained	99352	0	15404	1	5&5&5&5&5&5	3&1&1&1&1&2	rs80358721	Breast-ovarian cancer, familial 2&not provided&Hereditary cancer-predisposing syndrome&Breast-ovarian cancer, familial 2&Fanconi anemia, complementation group D1&Hereditary breast and ovarian cancer syndrome	37936	46492	Medulloblastoma|Malignant_tumor_of_prostate|Ovarian_Neoplasms|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Glioma_susceptibility_3|Pancreatic_cancer_2|Wilms_tumor_1|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MeSH:D010051,MedGen:CN236629|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:C2751641,OMIM:613029|MedGen:C3150546,OMIM:613347|MedGen:CN033288,OMIM:194070|MedGen:CN169374|MedGen:CN517202	-	NC_000013.10:g.32913457C>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:149228	-	BRCA2:675	SO:0001587|nonsense	1	80358721	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Pathway_Genomics|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|True_Health_Diagnostics|Knight_Diagnostic_Laboratories,Oregon_Health_and_Sciences_University|Invitae|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Fulgent_Genetics,Fulgent_Genetics|German_Consortium_for_Hereditary_Breast_and_Ovarian_Cancer_Center_Cologne,University_Hospital_Cologne	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-01-03|2002-05-29|2014-10-30|2016-04-21|2016-09-08|2015-10-02|2015-12-10|2018-07-31|2015-03-12|2019-04-09|2015-04-10|2018-05-30|2015-02-02|2018-12-20|2016-04-25|2015-03-23|2014-01-31|2012-12-12|2016-05-18|2017-04-20|2018-11-11|2018-10-31|2018-12-01	2015-12-29|2014-03-28|2015-05-28|2016-04-21|2016-09-13|2016-10-28|2016-11-23|2019-01-29|2018-08-31|2020-02-26|2017-01-26|2018-06-26|2015-05-29|2019-03-28|2016-04-26|2019-03-21|2017-08-04|2017-04-19|2018-01-25|2017-08-04|2019-08-05|2018-11-14|2019-02-22	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline	SCV000054122|SCV000146514|SCV000223757|SCV000267775|SCV000300809|SCV000327115|SCV000487907|SCV000210343|SCV000296707|SCV000172795|SCV000537670|SCV000805244|SCV000223921|SCV000072546|SCV000267859|SCV000271328|SCV000587734|SCV000591934|SCV000694816|SCV000588096|SCV000602864|SCV000893330|SCV000923789	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_2/Fanconi_anemia,_complementation_group_D1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_specified|not_specified|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_2/Fanconi_anemia,_complementation_group_D1/Medulloblastoma/Wilms_tumor_1/Malignant_tumor_of_prostate/Pancreatic_cancer_2/Glioma_susceptibility_3|Ovarian_Neoplasms	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_pathogenic_variant_is_denoted_BRCA2_c.4965C>G_at_the_cDNA_level_and_p.Tyr1655Ter_(Y1655X)_at_the_protein_level._The_substitution,_also_known_as_BRCA2_5193C>G_using_alternate_nomenclature,_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_Tyr1655Ter_has_been_reported_in_patients_with_histories_consistent_with_Hereditary_Breast_and_Ovarian_Cancer_(Ramus_2007,_Sakai_2009,_Castro_2013,_Song_2014)_and_is_considered_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||||This_sequence_change_creates_a_premature_translational_stop_signal_at_codon_1655_(p.Tyr1655*)._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80358721,_ExAC_0.002%)._This_variant_has_been_reported_in_individuals_affected_with_breast,_ovarian_and_prostate_cancer_(PMID:_20858050,_26681312,_24728189,_21709188,_17688236,_23569316).Â¬â€ This_variant_is_also_known_as_5685C>G_and_5193C>GÂ¬â€ in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37936)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||The_p.Tyr1655X_variant_in_BRCA2_has_been_reported_in_at_least_5_individuals_with_BRCA2-associated_cancers_(Ramus_2007,_Bayraktar_2012,_Castro_2013,_Chong_2014)._This_variant_has_also_been_identified_in_1/65580_European_chromosomes_by_the_Ex_ome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_rs80358721)._T_his_nonsense_variant_leads_to_a_premature_termination_codon_at_position_1655,_wh_ich_is_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_BRCA2_function_is_an_established_disease_mechanism_in_hereditary_breast_and_ovar_ian_cancer_(HBOC)._In_summary,_this_variant_meets_criteria_to_be_classified_as_p_athogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_predicted_impa_ct_to_the_protein_and_low_frequency_in_controls.|||Variant_summary:_The_BRCA2_c.4965C>G_(p.Tyr1655X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._p.Arg3128X,_p.Glu3111X)._Mutation_taster_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_1/121918_control_chromosomes_at_a_frequency_of_0.0000082,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._It_was_observed_in_several_breast_and/or_ovarian_cancer_patients_indicating_pathogenicity._It_has_also_been_reported_21_times_in_BIC_which_supports_the_fact_that_this_variant_is_a_recurrent_mutation._Additionally,_a_functional_study_demonstrated_the_variant_to_impair_homology_directed_repair_activity_of_BRCA2_which_is_a_known_to_be_important_for_BRCA2s_role_in_tumor_suppression._Furthermore,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_Pathogenic._Taken_together,_this_variant_is_classified_as_Pathogenic.||The_BRCA2_c.4965C>G:p.Tyr1655Ter_variant_(also_known_as_c.5685C>G_or_5193C>G)_has_been_published_in_the_medical_literature_in_individuals_with_breast_and_ovarian_cancer_(Pruss_2014,_Ramus_2007)._The_variant_is_listed_in_the_dbSNP_variant_database_(rs80358721)_with_an_allele_frequency_of_0.0008_percent_in_the_Exome_Aggregation_Consortium_(1/118848_alleles)._This_variant_introduces_a_premature_termination_codon_and_is_predicted_to_result_in_a_truncated_or_absent_protein._Based_on_the_information_listed_above,_this_variant_is_considered_pathogenic._References:_Pruss_D_et_al._Development_and_validation_of_a_new_algorithm_for_the_reclassification_of_genetic_variants_identified_in_the_BRCA1_and_BRCA2_genes._Breast_Cancer_Res_Treat._2014_Aug:147(1):119-32._Ramus_SJ_et_al._Contribution_of_BRCA1_and_BRCA2_mutations_to_inherited_ovarian_cancer._Hum_Mutat._2007_Dec:28(12):1207-15.||
NM_000059.3:c.5350_5351del	BRCA2	frameshift_variant	NA	NA	15316	1	-	-	-	-	37959	46515	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32913842_32913843del	reviewed_by_expert_panel	Pathogenic	-	-	Deletion	SO:0000159	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:56135|Breast_Cancer_Information_Core__(BRCA2):5578&base_change%3Ddel_AA	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359507	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-07-17|2002-05-29|2014-11-03|2016-04-22|2015-10-02|2015-07-08|0000-00-00|2015-09-21|2018-02-25|2018-09-07|2019-01-08|2014-01-31|2014-07-16|2015-12-15|2016-05-02|2018-09-11|2019-07-10|2017-12-12|2018-03-13|2019-02-26|2015-03-10	2015-12-29|2014-03-28|2016-04-21|2016-06-09|2016-10-28|2017-06-22|2018-04-04|2018-04-09|2018-06-14|2019-08-02|2019-03-28|2017-08-04|2017-04-19|2019-03-21|2018-01-25|2019-01-29|2020-03-06|2018-03-09|2018-10-10|2020-02-26|2017-10-26	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline	SCV000054145|SCV000146602|SCV000195990|SCV000282406|SCV000327201|SCV000677682|SCV000733267|SCV000744468|SCV000839933|SCV000993555|SCV000072652|SCV000587763|SCV000591962|SCV000605783|SCV000694862|SCV000108622|SCV000296699|SCV000778684|SCV000883477|SCV000186040|SCV000683699	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||||This_c.5350_5351delAA_(p.Asn1784Hisfs*2)_frameshift_variant_in_the_BRCA2_gene_is_predicted_to_introduce_a_premature_translation_termination_codon_and_has_been_reported_in_multiple_unrelated_individuals_with_breast,_ovarian,_prostate,_fallopian,_and/or_peritoneal_cancer_(PMID:_8988179,_21324516,_22006311,_23569316,_23633455,_24504028)._The_c.5350_5351delAA_(p.Asn1784Hisfs*2)_variant_in_the_BRCA2_gene_is_classified_as_pathogenic.||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Asn1784Hisfs*2)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_10923033,_22144684,_21324516,_22006311,_23633455)._This_variant_is_also_known_as_5573delAA_and_5578delAA_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37959)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||The_p.Asn1784fs_variant_in_BRCA2_has_been_identified_in_greater_than_30_individu_als_with_BRCA2_associated_cancers_(Gayther_1997,_Walsh_2011,_Zhang_2011,_George_2013,_Cunningham_2014,_Breast_Cancer_Information_Core_(BIC)_database,_Sharing_Cl_inical_Reports_Project)._This_variant_has_been_identified_in_1/66234_of_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitu_te.org:_dbSNP_rs80359507)._This_variant_is_predicted_to_cause_a_frameshift,_whic_h_alters_the_protein?s_amino_acid_sequence_beginning_at_position_1784_and_leads_to_a_premature_termination_codon_2_amino_acids_downstream._This_alteration_is_th_en_predicted_to_lead_to_a_truncated_or_absent_protein._Heterozygous_loss_of_func_tion_of_the_BRCA2_gene_is_an_established_disease_mechanism_in_individuals_with_h_ereditary_breast_and_ovarian_cancer_(HBOC)._In_summary,_this_variant_meets_our_c_riteria_to_be_classified_as_pathogenic_for_HBOC_in_an_autosomal_dominant_manner_based_upon_the_predicted_impact_to_the_protein.|Variant_summary:_The_c.5350_5351delAA_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein,_which_is_a_commonly_known_mechanism_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.5386_5387delGA/p.Asp1796fs)._One_in-silico_tool_predicts_damaging_outcome_for_this_variant._This_variant_is_absent_in_122212_control_chromosomes._In_addition,_multiple_clinical_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_was_classified_as_pathogenic.|This_deletion_of_two_nucleotides_is_denoted_BRCA2_c.5350_5351delAA_at_the_cDNA_level_and_p.Asn1784HisfsX2_(N1784HfsX2)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CAAAAA[delAA]CACT._The_deletion_causes_a_frameshift,_changing_an_Asparagine_to_a_Histidine_at_codon_1784,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._BRCA2_c.5350_5351delAA_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_denoted_as_BRCA2_5573delAA_or_5578delAA_using_alternate_nomenclature,_has_been_reported_in_association_with_breast,_ovarian,_and_prostate_cancer_(Gayther_1997,_Walsh_2011,_Zhang_2011,_Castro_2013,_Cunningham_2014)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.||The_c.5350_5351delAA:_p.Asn1784fs_variant_(rs80359507)_has_been_identified_in_multiple_patients_diagnosed_with_ovarian,_fallopian_tube_or_peritoneal_cancer_(Gayther_1997,_Walsh_2011,_Zhang_2011,_Cunningham_2014)._It_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_37959)_and_observed_in_only_1/30754_alleles_in_the_Genome_Aggregation_Database._This_variant_causes_a_frameshift_by_deleting_2_nucleotides,_so_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-mediated_decay._Based_on_the_above_information,_this_variant_is_considered_pathogenic._References:_Cunningham_J_et_al._Clinical_characteristics_of_ovarian_cancer_classified_by_BRCA1,_BRCA2,_and_RAD51C_status._Sci_Rep._2014._4:4026._Gayther_S_et_al._Variation_of_risks_of_breast_and_ovarian_cancer_associated_with_different_germline_mutations_of_the_BRCA2_gene._Nat_Genet._1997._15(1):103-5._Walsh_T_et_al._Mutations_in_12_genes_for_inherited_ovarian,_fallopian_tube,_and_peritoneal_carcinoma_identified_by_massively_parallel_sequencing.Proc_Natl_Acad_Sci_U_S_A._2011._108(44):18032-7._Zhang_S_et_al._Frequencies_of_BRCA1_and_BRCA2_mutations_among_1,342_unselected_patients_with_invasive_ovarian_cancer.Gynecol_Oncol._2011._121(2):353-7.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_000059.3:c.7180A>T	BRCA2	stop_gained	NA	NA	15434	1	5&5	3&1	rs80358946	Breast-ovarian cancer, familial 2&Hereditary cancer-predisposing syndrome	52279	66947	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32929170A>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80358946	-	Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Ambry_Genetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-28|2014-01-31|2017-01-30|2018-07-02|2010-10-28|2002-05-29|2016-09-08|2015-10-02|2016-09-06|2017-12-11|2018-09-28	2019-03-28|2017-08-04|2018-01-25|2018-08-20|2013-08-08|2014-03-28|2016-09-13|2016-10-28|2016-11-23|2020-02-26|2020-03-06	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline|germline|unknown|germline|germline	SCV000073169|SCV000587885|SCV000695047|SCV000838850|SCV000109195|SCV000147034|SCV000301138|SCV000327603|SCV000489150|SCV000185963|SCV001133888	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_cancer-predisposing_syndrome|not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg2394*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_individuals_affected_with_breast_and/or_ovarian_cancer,_and_pancreatic_cancer_(PMID:_15340362,_25366421,_25136594,_28454591),_and_an_individual_with_suspected_hereditary_breast_and_ovarian_cancer_syndrome_(PMID:_24065114)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_52279)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_BRCA2_c.7180A>T_(p.Arg2394X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_of_interest_was_not_observed_in_controls_(ExAC,_1000_Gs,_or_ESP)_and_has_been_reported_in_multiple_affected_individuals_via_publications._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_significantly_disrupt_the_protein_structure._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.
NM_000059.3:c.7254_7255del	BRCA2	frameshift_variant	NA	NA	15434	1	-	-	-	-	52300	66968	_familial_2|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32929242_32929243AG[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA2):7482&base_change%3Ddel_AG	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359644	-	_c/o_University_of_Cambridge|GeneDx|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1999-06-22|2016-09-08|2015-10-02|2016-07-19|2016-12-07|2017-05-29	2014-03-28|2016-09-13|2016-10-28|2019-01-29|2020-02-26|2017-10-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000147062|SCV000301147|SCV000327621|SCV000279439|SCV000665941|SCV000683859	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||This_deletion_of_2_nucleotides_in_BRCA2_is_denoted_c.7254_7255delAG_at_the_cDNA_level_and_p.Arg2418SerfsX2_(R2418SfsX2)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_has_been_reported_as_BRCA2_7482delAG._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_ACAG[AG]TTGA._The_deletion_causes_a_frameshift,_which_changes_an_Arginine_to_a_Serine_at_codon_2418,_and_creates_a_premature_stop_codon_at_position_2_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.7254_7255delAG_has_been_reported_in_association_with_early_onset_breast_cancer_in_a_Nigerian_patient_(Fackenthal_2012)._We_consider_this_variant_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_000059.3:c.7567_7568del	BRCA2	frameshift_variant	NA	NA	15420	1	-	-	-	-	38105	46661	_familial_2|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN517202	-	NC_000013.10:g.32930692_32930693CT[2]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	Breast_Cancer_Information_Core__(BRCA2):7795&base_change%3Ddel_CT	-	BRCA2:675	SO:0001589|frameshift_variant	1	80359664	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-01-12|0000-00-00|2016-04-21|2016-09-08|2015-10-02|0000-00-00|2015-09-21|2016-11-15|2014-01-31|2017-02-15|2017-09-12|2019-10-10	2013-06-26|2014-03-28|2016-04-21|2016-09-13|2016-10-28|2018-04-04|2018-04-09|2017-03-14|2017-08-04|2017-08-01|2019-01-29|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054294|SCV000147126|SCV000267808|SCV000301178|SCV000327687|SCV000733302|SCV000744522|SCV000073263|SCV000587900|SCV000600756|SCV000778884|SCV000665942	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||This_sequence_change_deletes_2_nucleotides_from_exon_15_of_the_BRCA2_mRNA_(c.7567_7568delCT),_causing_a_frameshift_at_codon_2523._This_creates_a_premature_translational_stop_signal_(p.Leu2523Glufs*15)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_11030417,_16683254)._This_variant_is_also_known_in_the_literature_as_7795delCT._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||This_deletion_of_two_nucleotides_in_BRCA2_is_denoted_c.7567_7568delCT_at_the_cDNA_level_and_p.Leu2523GlufsX15_(L2523EfsX15)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_CTCT[delCT]GAAA._The_deletion_causes_a_frameshift_which_changes_a_Leucine_to_a_Glutamic_Acid_at_codon_2523,_and_creates_a_premature_stop_codon_at_position_15_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA2_c.7567_7568delCT,_previously_reported_as_7795delCT,_has_been_observed_in_individuals_with_breast_and/or_ovarian_cancer_(Gao_2000,_van_der_Hout_2006)._We_consider_this_variant_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000059.3:c.8572C>T	BRCA2	stop_gained	NA	NA	15372	3	5	3	rs80359112	Breast-ovarian cancer, familial 2	52624	67292	_familial_2	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555	-	NC_000013.10:g.32945177C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001587|nonsense	1	80359112	-	Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1999-06-22|2016-09-08|2015-10-02|2014-01-31|2012-05-28|2018-04-17	2014-03-28|2016-09-13|2016-10-28|2017-08-04|2017-04-19|2020-02-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000147402|SCV000301290|SCV000327926|SCV000587960|SCV000592210|SCV001179206	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_000059.3:c.9097_9098insT	BRCA2	frameshift_variant	NA	NA	15424	1	-	-	-	-	409583	399914	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000013.10:g.32954030_32954031insT	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Insertion	SO:0000667	-	-	BRCA2:675	SO:0001589|frameshift_variant	1	1555288494	-	Invitae|Color|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic	2016-10-14|2017-05-17|2019-01-07	2017-03-14|2017-12-21|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000549832|SCV000689174|SCV001180112	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_inserts_1_nucleotide_in_exon_23_of_the_BRCA2_mRNA_(c.9097_9098insT),_causing_a_frameshift_at_codon_3033._This_creates_a_premature_translational_stop_signal_(p.Thr3033Ilefs*11)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_an_individual_with_suspected_hereditary_breast_and/or_ovarian_cancer_syndrome_(PMID:_25556971)._A_different_variant_(c.9097dupA)_giving_rise_to_a_similar_protein_effect_(p.Thr3033Asnfs*11)_has_been_reported_in_individuals_and_families_with_breast_and/or_ovarian_cancer_(PMID:_9150172,_21138478,_22970155)_or_pancreatic_adenocarcinoma_(PMID:_25940717)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)
NM_000059.3:c.9294C>G	BRCA2	stop_gained	102430	0	15422	1	5&5&5&5&5	3&1&1&1&1	rs80359200	Breast-ovarian cancer, familial 2&Hereditary breast and ovarian cancer syndrome&not provided&Hereditary cancer-predisposing syndrome&Breast-ovarian cancer, familial 1	38229	46785	Medulloblastoma|Malignant_tumor_of_prostate|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_D1|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_1|Glioma_susceptibility_3|Pancreatic_cancer_2|Wilms_tumor_1|not_provided	-	Human_Phenotype_Ontology:HP:0002885,MeSH:D008527,MedGen:C0025149,OMIM:155255,Orphanet:ORPHA616|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1838457,OMIM:605724,Orphanet:ORPHA319462|MedGen:C2675520,OMIM:612555|MedGen:C2676676,OMIM:604370|MedGen:C2751641,OMIM:613029|MedGen:C3150546,OMIM:613347|MedGen:CN033288,OMIM:194070|MedGen:CN517202	-	NC_000013.10:g.32968863C>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:108680	-	BRCA2:675	SO:0001587|nonsense	1	80359200	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Equipe_Genetique_des_Anomalies_du_Developpement,_Université_de_Bourgogne|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Baylor_Genetics|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2013-01-03|2002-05-29|2016-04-22|2015-06-16|2015-10-02|2016-05-26|2018-04-27|2018-11-21|2018-12-27|2014-01-31|0000-00-00|2017-03-24|2018-09-04|2018-01-25|2015-06-16|2018-04-12|2015-01-21|2015-11-20|2017-02-23|2018-10-31	2015-08-20|2014-03-28|2016-06-09|2016-07-18|2016-10-28|2016-11-23|2018-06-14|2018-11-26|2019-03-28|2017-08-04|2017-04-19|2018-01-25|2019-01-29|2018-10-10|2018-08-31|2020-02-26|2017-10-26|2016-03-03|2017-02-23|2018-11-14	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown	SCV000054420|SCV000147604|SCV000282471|SCV000296654|SCV000328102|SCV000488714|SCV000839911|SCV000883122|SCV000073797|SCV000587997|SCV000592274|SCV000695234|SCV000108647|SCV000885085|SCV000887959|SCV000185971|SCV000684052|SCV000266052|SCV000540995|SCV000894008	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Breast-ovarian_cancer,_familial_1|Familial_cancer_of_breast|Familial_cancer_of_breast/Breast-ovarian_cancer,_familial_2/Fanconi_anemia,_complementation_group_D1/Medulloblastoma/Wilms_tumor_1/Malignant_tumor_of_prostate/Pancreatic_cancer_2/Glioma_susceptibility_3	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||A_heterozygous_c.9294C>G_(p.Tyr3098*)_pathogenic_variant_in_the_BRCA2_gene_was_detected_in_this_individual._This_variant_has_been_previously_described_in_multiple_individuals_with_breast,_ovarian,_prostate_and_pancreatic_cancer_(PMID:_12698193,_24728189,_26787237,_23569316,_26845104).Therefore,_we_consider_this_variant_to_be_pathogenic._[alaimo,_2018-01-30]||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Tyr3098*)_in_the_BRCA2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80359200,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_with_breast_and/or_ovarian_cancer_(PMID:_12698193,_24728189,_26787237),_prostate_cancer_(PMID:_23569316),_and_pancreatic_cancer_(PMID:_26845104)._This_variant_is_also_known_as_9522C>G_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_38229)._Loss-of-function_variants_in_BRCA2_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Variant_summary:_The_BRCA2_c.9294C>G_(p.Tyr3098X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA2_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_c.9331G>T_[p.Glu3111X],_c.9382C>T_[p.Arg3128X],_and_c.9403delC_[p.Leu3135fsX28])._The_variant_lies_within_a_nucleic_acid-binding,_OB-fold_domain_(InterPro)_and_one_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_the_large_control_database_ExAC_at_a_frequency_of_0.0000083_(1/120548_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA2_variant_(0.0007503)._Several_publications_cite_the_variant_in_patients_and_classify_it_as_a_pathogenic_mutation_(e.g.,_Kwong_BRCA_JMG_2015)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_BRCA2_c.9294C>G_at_the_cDNA_level_and_p.Tyr3098Ter_(Y3098X)_at_the_protein_level._The_substitution,_also_denoted_BRCA2_9522C>G_using_alternate_nomenclature,_creates_a_nonsense_variant,_which_changes_a_Tyrosine_to_a_premature_stop_codon_(TAC>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_multiple_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_(Frank_1998,_The_Scottish/Northern_Irish_BRCA1/BRCA2_Consortium_2003,_Lubinski_2004,_Kurian_2008,_Kwong_2016)_and_is_considered_pathogenic.|The_BRCA2_c.9294C>G:_p.Tyr3098Ter_variant_(rs80359200),_also_known_as_9522C>G,_is_reported_in_the_literature_in_individuals_and_families_with_hereditary_breast_and_ovarian_cancer_syndrome_(Lubinski_2004,_Scottish/Northern_Irish_BRCA1/BRCA2_Consortium_2003),_and_is_classified_as_pathogenic_in_ClinVar_(Variation_ID:_38229)._This_variant_is_found_in_the_general_population_with_a_low_overall_allele_frequency_of_0.001%_(3/276620_alleles)_in_the_Genome_Aggregation_Database._This_variant_induces_a_premature_termination_codon_and_is_predicted_to_result_in_a_truncated_protein_or_mRNA_subject_to_nonsense-medicated_decay._Based_on_available_information,_this_variant_is_considered_pathogenic._References:_Lubinski_J_et_al._Cancer_variation_associated_with_the_position_of_the_mutation_in_the_BRCA2_gene._Fam_Cancer._2004:3(1):1-10._Scottish/Northern_Irish_BRCAI/BRCA2_Consortium._BRCA1_and_BRCA2_mutations_in_Scotland_and_Northern_Ireland._Br_J_Cancer._2003:88(8):1256-62.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||
NM_014967.4:c.-153+8_-153+20del	FAN1	splice_donor_variant,5_prime_UTR_variant,intron_variant	NA	NA	15346	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.141C>A	FAN1	stop_gained	102710	0	15434	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.504dup	FAN1	frameshift_variant	NA	NA	15416	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.1811+2T>C	FAN1	splice_donor_variant	NA	NA	15432	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2175dup	FAN1	frameshift_variant,splice_region_variant	NA	NA	15434	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_014967.4:c.2299C>T	FAN1	stop_gained	102702	0	15422	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_002528.6:c.628G>T	NTHL1	stop_gained	102554	0	15412	1	-	-	-	-	655543	644011	not_provided	-	MedGen:CN517202	-	NC_000016.9:g.2093649C>A	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	NTHL1:4913	SO:0001587|nonsense	1	-	-	Invitae	Pathogenic	2018-08-10	2019-03-28	_single_submitter	germline	SCV000952022	not_provided	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu210*)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_NTHL1-related_disease._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_024675.3:c.229del	PALB2	frameshift_variant	NA	NA	15426	1	-	-	-	-	126644	132154	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23647638del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001589|frameshift_variant	1	180177084	-	Invitae|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2017-04-04|2018-10-02|2018-09-11|2017-12-15	2017-10-05|2019-01-29|2020-03-06|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000260770|SCV000293388|SCV001134542|SCV000905195	Familial_cancer_of_breast|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome	This_sequence_change_deletes_1_nucleotide_in_exon_4_of_the_PALB2_mRNA_(c.229delT),_causing_a_frameshift_at_codon_77._This_creates_a_premature_translational_stop_signal_(p.Cys77Valfs*100)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer_(PMID:_17420451,_23341105)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_deletion_of_one_nucleotide_in_PALB2_is_denoted_c.229delT_at_the_cDNA_level_and_p.Cys77ValfsX100_(C77VfsX100)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_braces,_is_AATA[T]GTGT._The_deletion_causes_a_frameshift,_which_changes_a_Cysteine_to_a_Valine_at_codon_77,_and_creates_a_premature_stop_codon_at_position_100_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.229delT_has_been_observed_in_at_least_one_family_with_multiple_diagnoses_of_breast_cancer_(Tischkowitz_2007,_Antoniou_2014)_and_was_shown_to_have_significantly_decreased_BRCA2_binding_capacity_and_was_defective_in_regards_to_homologous_recombination_/double_strand_break_repair_(Tischkowitz_2007)._We_consider_this_variant_to_be_pathogenic.|The_variant_results_in_a_shift_of_the_reading_frame,_and_is_therefore_predicted_to_significantly_disrupt_the_protein_structure._Found_in_at_least_one_symptomatic_patient,_and_not_found_in_general_population_data._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.|
NM_007294.3:c.5467+2T>C	BRCA1	splice_donor_variant	NA	NA	15426	1	-	-	-	-	125851	131389	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41199658A>G	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA1):5586+2&base_change%3DT_to_C	-	BRCA1:672	SO:0001575|splice_donor_variant	1	80358009	-	_c/o_University_of_Cambridge|Ambry_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	0000-00-00|2015-10-02|2017-05-08|2016-03-24	2014-03-28|2016-10-28|2020-02-26|2018-01-25	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000145522|SCV000326320|SCV000213376|SCV000699241	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	||Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity|Variant_summary:_The_c.5467+2T>C_in_a_BRCA1_gene_is_a_splice-site_variant_that_alters_a_conserved_nucleotide._5/5_in_silico_tools_via_Alamut_predict_this_variant_to_disrupt_a_canonical_donor_sequence,_however_these_predictions_have_yet_to_be_confirmed_by_functional_assay._The_variant_is_absent_from_ExAC_and_been_reported_in_affected_individual(s)_via_publications_and/or_reputable_database/clinical_laboratory_as_Likely_Pathogenic._Taken_together,_the_variant_was_classified_as_Likely_Pathogenic_until_additional_information_becomes_available.
NM_007294.3:c.2138C>G	BRCA1	stop_gained	102532	0	15422	1	5&5&5&5	3&1&1&1	rs80357233	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&not provided&Hereditary cancer-predisposing syndrome	37451	46007	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41245410G>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357233	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-11-27|2002-05-29|2015-11-20|2016-09-08|2015-10-02|2016-04-21|2018-12-28|2014-01-31|2017-02-16|2018-08-03|2015-11-18|2019-04-15|2017-10-27	2013-12-30|2014-03-28|2016-03-03|2016-09-13|2016-10-28|2017-04-17|2019-03-28|2017-08-04|2018-01-25|2019-01-29|2018-08-31|2020-02-26|2018-11-06	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053626|SCV000144310|SCV000266027|SCV000299705|SCV000325263|SCV000564388|SCV000075743|SCV000587190|SCV000698921|SCV000108656|SCV000296379|SCV000213338|SCV000911170	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Ser713*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs80357233,_ExAC_0.001%)._This_variant_has_beenÂ¬â€ observed_in_individuals_with_a_personal_and/or_family_history_of_breast_and_ovarian_cancer_(PMID:_11139249,_22430266,_21913181)._This_variant_is_also_known_as_2257C>G_in_the_literature._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_The_BRCA1_c.2138C>G_(p.Ser713X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g._c.2157dupA._p.Glu720fsX6:_c.2197_2201delGAGAA,_p.Glu733fsX5:_c.2241delC,_p.Asp749fsX4)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_1/122388_control_chromosomes_at_a_frequency_of_0.0000082,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._The_variant_has_been_reported_in_numerous_affected_individuals_in_the_literature._Functional_studies_have_demonstrated_a_reduction_on_multiple_aspects_of_BRCA1_function_attributed_to_this_variant._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_BRCA1_c.2138C>G_at_the_cDNA_level_and_p.Ser713Ter_(S713X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Serine_to_a_premature_stop_codon_(TCA>TGA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_reported_as_BRCA1_2257C>G_using_alternate_nomenclature,_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Vaziri_2001,_Finkleman_2012,_Litton_2012,_Monk_2015,_Donenberg_2016),_and_is_considered_pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|
NM_007294.3:c.1960A>T	BRCA1	stop_gained	NA	NA	15428	1	5&5&5&5	3&1&1&1	rs80357355	Breast-ovarian cancer, familial 1&not provided&Hereditary cancer-predisposing syndrome&Hereditary breast and ovarian cancer syndrome	37436	45992	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41245588T>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357355	-	_c/o_University_of_Cambridge|Counsyl|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-01-06|2002-05-29|2016-09-08|2015-10-02|2015-11-23|2018-12-19|2019-03-13|2018-08-21|2018-06-11|2018-12-30|2018-09-13	2015-12-29|2014-03-28|2016-09-13|2016-10-28|2016-11-23|2019-01-29|2020-03-06|2020-02-26|2018-11-06|2019-03-28|2019-04-24	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000053610|SCV000144259|SCV000299674|SCV000325201|SCV000487835|SCV000210117|SCV000296279|SCV000186950|SCV000905034|SCV000075671|SCV000918779	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome	||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.|||This_pathogenic_variant_is_denoted_BRCA1_c.1960A>T_at_the_cDNA_level_and_p.Lys654Ter_(K654X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA1_2079A>T._The_substitution_creates_a_nonsense_variant,_which_changes_a_Lysine_to_a_premature_stop_codon_(AAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_association_with_Hereditary_Breast_and_Ovarian_Cancer_(John_2007,_Weitzel_2013,_Tung_2015,_Rebbeck_2018)_and_is_considered_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys654*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_studies_of_Hispanic_cohorts_in_individuals_with_a_personal_or_family_history_of_breast_and/or_ovarian_cancer_(PMID:_16030099,_23233716,_18159056)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_37436)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Variant_summary:_BRCA1_c.1960A>T_(p.Lys654X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.,_p.Lys654fsX47_and_p.Leu668fsX5)._The_variant_was_absent_in_121332_control_chromosomes_(gnomAD)._c.1960A>T_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Seven_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.
NM_007294.3:c.1840A>T	BRCA1	stop_gained	NA	NA	15434	1	5	3	rs80357282	Breast-ovarian cancer, familial 1	54369	69036	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41245708T>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357282	-	Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto	Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-05-29|2016-09-08|2015-10-02|2014-01-31	2014-03-28|2016-09-13|2016-10-28|2017-08-04	_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline	SCV000144200|SCV000299655|SCV000325158|SCV000587164	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome	|Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||
NM_007294.3:c.1292dup	BRCA1	frameshift_variant	NA	NA	15430	1	-	-	-	-	54188	68855	_familial_1	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370	-	NC_000017.10:g.41246257dup	reviewed_by_expert_panel	Pathogenic	-	-	Duplication	SO:1000035	Breast_Cancer_Information_Core__(BRCA1):1411&base_change%3Dins_T	-	BRCA1:672	SO:0001589|frameshift_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357528	-	Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Department_of_Medical_Genetics,Oslo_University_Hospital|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Ambry_Genetics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2002-05-29|2016-09-08|2015-10-02|2015-07-01|2014-01-31|2018-01-14	2014-03-28|2016-09-13|2016-10-28|2017-04-17|2017-08-04|2020-02-26	no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000144052|SCV000299572|SCV000325005|SCV000564333|SCV000587119|SCV001171046	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome	_nonsense)
NM_058216.2:c.692C>G	RAD51C	stop_gained	NA	NA	15422	1	-	-	-	-	629241	618728	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000017.10:g.56780677C>G	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	1060502588	-	Color	Pathogenic	2018-09-14	2018-11-06	_single_submitter	germline	SCV000907640	Hereditary_cancer-predisposing_syndrome	
NM_032043.2:c.2053C>T	BRIP1	stop_gained	NA	NA	15422	2	5	1	rs876659533	Hereditary cancer-predisposing syndrome	232067	236324	_complementation_group_J	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59853806G>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	876659533	-	Ambry_Genetics|Counsyl	Pathogenic|Likely_pathogenic	2015-06-02|2018-02-23	2020-02-26|2018-06-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown	SCV000276111|SCV000786078	_complementation_group_J/Neoplasm_of_ovary	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Rarity_in_general_population_databases_(dbSNP,_ESP,_1000_Genomes)|
NM_032043.2:c.1594dup	BRIP1	frameshift_variant	NA	NA	15430	1	-	-	-	-	530301	531846	_complementation_group_J	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C1836860,OMIM:609054	-	NC_000017.10:g.59861665dup	_single_submitter	Pathogenic	-	-	Duplication	SO:1000035	-	-	BRIP1:83990	SO:0001589|frameshift_variant	1	1339743866	-	Invitae	Pathogenic	2018-01-10	2018-04-02	_single_submitter	germline	SCV000757512	_complementation_group_J	This_sequence_change_creates_a_premature_translational_stop_signal_(p.Met532Asnfs*4)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_BRIP1-related_disease._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_032043.2:c.806C>G	BRIP1	stop_gained	NA	NA	15416	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_032043.2:c.133G>T	BRIP1	stop_gained	102692	0	15428	1	5&5	1&1	rs587781292	Hereditary cancer-predisposing syndrome&Familial cancer of breast	140808	150522	_complementation_group_J|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59937229C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001587|nonsense	1	587781292	-	Fulgent_Genetics|GeneDx|Counsyl	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-12-29|2018-07-05|2018-10-31|2017-09-28|2017-06-21	2020-02-26|2019-03-28|2018-11-14|2019-01-29|2018-06-20	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|unknown	SCV000172885|SCV000253957|SCV000893466|SCV000568502|SCV000785234	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|not_provided|Fanconi_anemia,_complementation_group_J/Neoplasm_of_ovary	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu45*)_in_the_BRIP1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587781292,_ExAC_0.001%)._This_variant_has_been_reported_in_the_literature_in_an_individual_affected_with_hereditary_cancer_(PMID:_24763289)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_140808)._Loss-of-function_variants_in_BRIP1_are_known_to_be_pathogenic_(PMID:_16116423,_17033622,_21964575)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_BRIP1_c.133G>T_at_the_cDNA_level_and_p.Glu45Ter_(E45X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_an_individual_undergoing_multi-gene_hereditary_cancer_panel_testing,_in_a_woman_with_high_grade_serous_ovarian_cancer_and_in_a_woman_with_early_onset_breast_cancer_(Laduca_2014,_Ramus_2015)._We_consider_this_variant_to_be_pathogenic.|
NM_006363.4:c.-15+1G>A	SEC23B	splice_donor_variant	NA	NA	15434	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.1188del	CHEK2	frameshift_variant	102370	0	15430	1	-	-	-	-	240730	243664	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29091770del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	753159426	-	Invitae|Mendelics|Ambry_Genetics|Color	Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2017-07-31|2018-07-02|2017-08-02|2018-03-23	2017-10-05|2018-08-20|2020-02-26|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline	SCV000289652|SCV000839464|SCV000581180|SCV000913580	Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_sequence_change_deletes_1_nucleotide_from_exon_11_of_the_CHEK2_mRNA_(c.1188delT),_causing_a_frameshift_at_codon_397._This_creates_a_premature_translational_stop_signal_(p.Val397Phefs*17)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._While_this_particular_variant_has_not_been_reported_in_the_literature,_loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_007194.3:c.920del	CHEK2	frameshift_variant	NA	NA	15398	1	-	-	-	-	233191	236644	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009	-	NC_000022.10:g.29095918del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	CHEK2:11200	SO:0001589|frameshift_variant	1	786203053	-	Ambry_Genetics|Invitae	Pathogenic|Pathogenic	2016-12-23|2017-09-19	2020-02-26|2018-04-02	criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline	SCV000277521|SCV000757298	Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gly307Glufs*13)_in_the_CHEK2_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_CHEK2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_233191)._Loss-of-function_variants_in_CHEK2_are_known_to_be_pathogenic_(PMID:_21876083,_24713400)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.
NM_007194.3:c.555del	CHEK2	frameshift_variant	NA	NA	15422	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.342G>A	CHEK2	stop_gained	NA	NA	15434	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_007194.3:c.166_170del	CHEK2	frameshift_variant	NA	NA	15410	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NM_001128425.1:c.1477G>T	MUTYH	missense_variant,splice_region_variant	97786	0	15428	3	4&4	1&1	rs587782228	MYH-associated polyposis&Hereditary cancer-predisposing syndrome	219953	221097	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45796229C>A	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	587782228	-	Invitae|Counsyl|Ambry_Genetics|Color|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-12-26|2016-05-04|2019-01-25|2018-10-07|2017-06-08|2015-10-16	2019-03-28|2016-11-23|2020-02-26|2018-11-06|2019-01-29|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline	SCV000260144|SCV000487353|SCV000274772|SCV000690532|SCV000565264|SCV000697680	MYH-associated_polyposis|MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|MUTYH-associated_polyposis	This_sequence_change_replaces_valine_with_phenylalanine_at_codon_493_of_the_MUTYH_protein_(p.Val493Phe)._The_valine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_valine_and_phenylalanine._This_variant_is_present_in_population_databases_(rs587782228,_ExAC_<0.01%)._This_variant_has_been_reported_as_homozygous_or_biallelic_with_other_pathogenic_MUTYH_variants_in_patients_with_atypical_familial_adenomatous_polyposis_and_multiple_colorectal_adenomas_(PMID:_16557584,_17949294,_19806110)._Furthermore,_this_variant_has_also_been_reported_in_multiple_individuals_in_the_Universal_Mutation_Database_(UMD)_as_co-occurring_with_other_pathogenic_MUTYH_variants_(PMID:_23729658)._In_addition,_it_has_been_reported_as_heterozygous_in_individuals_affected_with_polyposis_or_colorectal_cancer_(PMID:_17931073,_20618354)._This_variant_is_also_known_as_c.1435G>T_(p.Val479Phe)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_219953)._Experimental_studies_have_shown_that_this_missense_change_results_in_a_partially_defective_MUTYH_protein_in_an_E.coli_complementation_assay_(PMID:_25820570),_and_is_reported_to_show_exon_15_skipping_in_an_ex_vivo_splicing_assay_although_the_data_was_not_shown_(PMID:_25368107,_23729658)_In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_data_supporting_pathogenic_classification||This_variant_is_denoted_MUTYH_c.1477G>T_at_the_cDNA_level,_p.Val493Phe_(V493F)_at_the_protein_level,_and_results_in_the_change_of_a_Valine_to_a_Phenylalanine_(GTT>TTT)._This_variant,_also_known_as_MUTYH_c.1435G>T_and_Val479Phe_using_an_alternate_transcript,_has_been_reported_in_the_homozygous_or_compound_heterozygous_state,_in_at_least_3_individuals_with_multiple_colorectal_adenomas,_with_or_without_colorectal_cancer_(Aretz_2006,_Buecher_2008,_Reggoug_2009)._This_variant_was_found_to_be_partially_defective_in_an_E._coli-based_complementation_assay_(Komine_2015)._MUTYH_Val493Phe_was_not_observed_at_a_significant_frequency_in_large_population_cohorts_(Lek_2016,_The_1000_Genomes_Consortium_2015,_NHLBI_Exome_Sequencing_Project)._Since_Valine_and_Phenylalanine_differ_in_some_properties,_this_is_considered_a_semi-conservative_amino_acid_substitution._MUTYH_Val493Phe_occurs_at_a_position_that_is_conserved_through_mammals_and_is_located_in_the_NUDIX_hydrolase_domain_(Ruggieri_2013,_UniProt)._In_silico_analyses_predict_that_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_the_currently_available_information,_we_consider_MUTYH_Val493Phe_to_be_a_likely_pathogenic_variant.|Variant_summary:_c.1477G>T_affects_a_conserved_nucleotide_located_at_the_first_position_of_exon_15,_resulting_in_amino_acid_change_from_Val_to_Phe._3/4_in-silico_tools_predict_this_variant_to_be_damaging_(SNPs&GO_not_captured_due_to_low_reliability_index)._5/5_programs_in_Alamut_predict_that_this_variant_does_not_significantly_affect_normal_splicing._ESE_finder_predicts_that_this_variant_may_affect_ESE_site_of_SC35._Grandval_2015_predicted_that_this_variant_leads_to_major_loss_of_exon_5_and_an_inframe_deletion_(p.Val479_Met492del)_based_on_RT-PCR_product_sequencing_(data_not_shown)._This_variant_has_been_reported_in_homozygous_and_compound_heterozygous_state_in_patients_with_atypical_polyposis,_colorectal_adenomas,_MUTYH_associated_polyposis._Heterozygous_variant_was_found_in_3/87104_control_chromosomes_at_a_frequency_of_0.0000344_and_one_patient_with_sporadic_colorectal_cancer._One_functional_study_in_E.coli_showed_that_protein_with_this_variant_partially_lost_the_normal_function_in_suppressing_spontaneous_mutations_(Komine_2015)._However,_its_function_in_human_cells_is_still_not_clear._Taken_together,_this_variant_was_classified_as_likely_pathogenic.
NM_003001.3:c.214C>T	SDHC	missense_variant	100290	0	15422	1	-	-	-	-	653952	627041	Gastrointestinal_stroma_tumor|Paragangliomas_3	-	Human_Phenotype_Ontology:HP:0100723,MeSH:D046152,MedGen:C0238198,OMIM:606764,Orphanet:ORPHA44890|MedGen:C1854336,OMIM:605373	-	NC_000001.10:g.161310418C>T	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	SDHC:6391	SO:0001619|non-coding_transcript_variant	1	-	-	Invitae	Likely_pathogenic	2018-12-10	2019-03-28	_single_submitter	germline	SCV000949996	Gastrointestinal_stroma_tumor/Paragangliomas_3	This_sequence_change_replaces_arginine_with_cysteine_at_codon_72_of_the_SDHC_protein_(p.Arg72Cys)._The_arginine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_arginine_and_cysteine._This_variant_is_present_in_population_databases_(rs756676111,_ExAC_0.01%)._This_variant_has_been_observed_in_several_individuals_affected_with_paraganglioma-pheochromocytoma_syndromes_(PMID:_18212813,_27867439,_16249420,_23666964,_19454582,_21348866,_19906784)._This_variant_has_been_reported_to_affect_SDHC_protein_function_(PMID:_17636259,_25950479)._This_variant_disrupts_the_p.Arg72_amino_acid_residue_in_SDHC._Other_variant(s)_that_disrupt_this_residue_have_been_observed_in_individuals_with_SDHC-related_conditions_(PMID:_19454582,_24758179,_27262318),_which_suggests_that_this_may_be_a_clinically_significant_amino_acid_residue._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.
NM_000038.5:c.7960del	APC	frameshift_variant	NA	NA	15424	1	-	-	-	-	433678	427315	Familial_adenomatous_polyposis	-	MedGen:CN240755	-	NC_000005.9:g.112179251del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	APC:324	SO:0001589|frameshift_variant	1	1305971005	-	Sinai_Health_System	Pathogenic	2012-11-07	2017-10-30	_single_submitter	germline	SCV000591217	Familial_adenomatous_polyposis	
NM_000051.3:c.9139C>T	ATM	stop_gained	102734	0	15428	1	5&5	0&1	rs121434219	Ataxia-telangiectasia without immunodeficiency&Ataxia-telangiectasia syndrome	3029	18068	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_without_immunodeficiency|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C4017102|MedGen:CN517202	-	NC_000011.9:g.108236203C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:607585.0012	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	121434219	-	OMIM|Invitae|Counsyl|GeneDx|Ambry_Genetics|Color	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	1998-01-13|2018-12-03|2017-11-08|2017-06-07|2018-10-18|2018-10-10	2016-09-16|2019-03-28|2018-07-10|2019-01-29|2020-02-26|2018-11-06	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline	SCV000023326|SCV000253749|SCV000795374|SCV000565861|SCV000581447|SCV000682541	Ataxia-telangiectasia_without_immunodeficiency|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|This_sequence_change_results_in_a_premature_translational_stop_signal_in_the_ATM_gene_(p.Arg3047*)._While_this_is_not_anticipated_to_result_in_nonsense_mediated_decay,_it_is_expected_to_delete_the_last_10_amino_acids_of_the_ATM_protein._This_variant_has_been_reported_as_homozygous_or_in_trans_with_different_pathogenic_variants_in_multiple_individuals_with_ataxia-telangiectasia_(PMID:_8755918,_19691550,_18560558,_10980530,_26628246)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_3029)._Experimental_studies_have_shown_that_this_truncated_protein_is_expressed_in_cell_culture_but_fails_to_phosphorylate_ATM_target_proteins_(PMID:_19431188)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||This_variant_is_denoted_ATM_c.9139C>T_at_the_cDNA_level_and_p.Arg3047Ter_(R3047X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon_(CGA>TGA)._This_variant_has_been_observed_in_the_homozygous_state_in_at_least_one_patient_with_Ataxia-telangiectasia_(A-T)_and_in_trans_with_ATM_pathogenic_variants_in_other_patients_(Toyoshima_1998,_Chessa_2009,_Byrd_2012,_Liu_2016)._ATM_protein_was_shown_to_be_expressed_in_a_cell_line_from_one_patient_with_A-T_who_carried_this_variant_in_trans_with_another_pathogenic_variant,_consistent_with_the_prediction_that_Arg3047Ter_does_not_cause_nonsense-mediated_decay_(Byrd_2012)._Even_though_only_the_ten_terminal_amino_acids_are_lost,_the_variant_is_reported_to_result_in_absent_kinase_activity_and_deficient_activation_by_oxidation_(Barone_2009,_Guo_2010)._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|
NM_000546.5:c.824G>A	TP53	missense_variant	NA	NA	15416	1	4&5	1&1	rs863224451	Li-Fraumeni syndrome&not provided	215997	213392	Hepatocellular_carcinoma|Chronic_lymphocytic_leukemia|Renal_cell_carcinoma,_papillary,_1|Pancreatic_adenocarcinoma|Transitional_cell_carcinoma_of_the_bladder|Adrenocortical_carcinoma|Multiple_myeloma|Carcinoma_of_esophagus|Lung_adenocarcinoma|Neoplasm_of_brain|Neoplasm_of_the_breast|Neoplasm_of_the_large_intestine|Squamous_cell_carcinoma_of_the_head_and_neck|Malignant_melanoma_of_skin|Glioblastoma|Ovarian_Neoplasms|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome|Ovarian_Serous_Cystadenocarcinoma|not_provided	-	Human_Phenotype_Ontology:HP:0001402,MedGen:C2239176,OMIM:114550,Orphanet:ORPHA88673,SNOMED_CT:187769009,SNOMED_CT:25370001|Human_Phenotype_Ontology:HP:0005550,MeSH:D015451,MedGen:C0023434,OMIM:151400,Orphanet:ORPHA67038,SNOMED_CT:277473004,SNOMED_CT:51092000|Human_Phenotype_Ontology:HP:0005584,MeSH:D002292,MedGen:C0007134,OMIM:605074,Orphanet:ORPHA217071,SNOMED_CT:41607009|Human_Phenotype_Ontology:HP:0006725,MedGen:C0281361|Human_Phenotype_Ontology:HP:0006740,MedGen:C0279680|Human_Phenotype_Ontology:HP:0006744,MeSH:D018268,MedGen:C0206686,Orphanet:ORPHA1501|Human_Phenotype_Ontology:HP:0006775,MeSH:D009101,MedGen:C0026764,OMIM:254500,Orphanet:ORPHA29073,SNOMED_CT:109989006,SNOMED_CT:55921005|Human_Phenotype_Ontology:HP:0011459,MedGen:C0152018,Orphanet:ORPHA70482|Human_Phenotype_Ontology:HP:0030078,MeSH:C538231,MedGen:C0152013|Human_Phenotype_Ontology:HP:0030692,MeSH:D001932,MedGen:C0006118,SNOMED_CT:126952004|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|Human_Phenotype_Ontology:HP:0100834,MeSH:D015179,MedGen:C0009404,SNOMED_CT:126837005|MeSH:C535575,MedGen:C1168401,OMIM:275355,Orphanet:ORPHA67037|MeSH:C562393,MedGen:C0151779,SNOMED_CT:93655004|MeSH:D005909,MedGen:C0017636,Orphanet:ORPHA360,SNOMED_CT:63634009|MeSH:D010051,MedGen:CN236629|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0085390,Orphanet:ORPHA524,SNOMED_CT:428850001|MedGen:C0279663|MedGen:CN517202	-	NC_000017.10:g.7577114C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P04637#VAR_005998	-	TP53:7157	SO:0001583|missense_variant	3	863224451	-	University_Hospital_Cologne	Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic	2018-08-06|2015-10-26|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2016-05-31|2019-10-25|2018-12-01	2019-03-28|2019-01-29|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2016-07-18|2020-02-26|2019-02-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|somatic|germline|somatic	SCV000253702|SCV000293284|SCV000507839|SCV000507825|SCV000507828|SCV000507831|SCV000507837|SCV000507834|SCV000507826|SCV000507829|SCV000507832|SCV000507838|SCV000507835|SCV000507824|SCV000507827|SCV000507833|SCV000507836|SCV000507830|SCV000664383|SCV000924105	Li-Fraumeni_syndrome|not_provided|Malignant_melanoma_of_skin|Multiple_myeloma|Neoplasm_of_brain|Pancreatic_adenocarcinoma|Hepatocellular_carcinoma|Transitional_cell_carcinoma_of_the_bladder|Squamous_cell_carcinoma_of_the_head_and_neck|Neoplasm_of_the_breast|Renal_cell_carcinoma,_papillary,_1|Lung_adenocarcinoma|Neoplasm_of_the_large_intestine|Ovarian_Serous_Cystadenocarcinoma|Chronic_lymphocytic_leukemia|Carcinoma_of_esophagus|Adrenocortical_carcinoma|Glioblastoma|Hereditary_cancer-predisposing_syndrome|Ovarian_Neoplasms	This_sequence_change_replaces_cysteine_with_tyrosine_at_codon_275_of_the_TP53_protein_(p.Cys275Tyr)._The_cysteine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_cysteine_and_tyrosine._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_multiple_individuals_and_families_affected_with_Li-Fraumeni_syndrome_(PMID:_7887414,_14584079,_17606709),_and_an_individual_affected_with_chronic_lymphocytic_leukemia_(PMID:_19850740)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_215997)._Functional_analysis_of_this_variant_in_transactivation_assays_using_yeast_model_system_shows_this_variant_is_non-functional_(PMID:_12826609,_21343334)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_pathogenic_variant_is_denoted_TP53_c.824G>A_at_the_cDNA_level,_p.Cys275Tyr_(C275Y)_at_the_protein_level,_and_results_in_the_change_of_a_Cysteine_to_a_Tyrosine_(TGT>TAT)._This_variant_has_been_reported_in_at_least_two_families_with_multiple_sarcomas_meeting_Chompret_criteria_(Frebourg_1995,_Lynch_2003)._Multiple_yeast-_and_tumor-based_functional_assays_have_found_that_TP53_Cys275Tyr_eliminates_or_greatly_reduces_transcriptional_activity_of_several_p53-responsive_elements_(Tada_1997,_Flaman_1998,_Marutani_1999,_Waddell_2001,_Deissler_2004)._This_variant_is_reported_as_having_non-functional_transactivation_in_the_International_Agency_for_Research_on_Cancer_TP53_database_based_on_functional_assays_by_Kato_et_al._(2003)_and_is_classified_as_a_severe_deficiency_allele_by_Monti_et_al._(2011)._TP53_Cys275Tyr_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_suggesting_it_is_not_a_common_benign_variant_in_these_populations._Since_Cysteine_and_Tyrosine_differ_in_polarity,_charge,_size_or_other_properties,_this_is_considered_a_non-conservative_amino_acid_substitution._TP53_Cys275Tyr_occurs_at_a_position_that_is_conserved_across_species_and_is_located_in_the_DNA_binding_domain_and_region_of_interaction_with_multiple_proteins_(UniProt)._In_silico_analyses_predict_that_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.|||||||||||||||||Deficient_protein_function_in_appropriate_functional_assay(s):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Other_data_supporting_pathogenic_classification:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|
NM_007294.3:c.5117G>A	BRCA1	missense_variant	NA	NA	15432	1	5&4&4&5	3&1&1&1	rs80356860	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&Hereditary cancer-predisposing syndrome&not provided	37638	46194	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41215926C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P38398#VAR_063905|Database_of_BRCA1_and_BRCA2_sequence_variants_that_have_been_clinically_reclassified_by_a_quantitative_integrated_evaluation:BRCA1_00048	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80356860	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2011-02-16|2002-05-29|2015-08-10|2015-10-02|2015-11-17|2016-07-12|2017-07-24|2018-10-10|2016-05-12|2019-07-24	2015-08-20|2014-03-28|2015-08-17|2016-10-28|2019-03-21|2018-01-25|2020-02-26|2018-11-06|2019-01-29|2020-03-06	no_assertion_criteria_provided|no_assertion_criteria_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000053819|SCV000145318|SCV000244383|SCV000326159|SCV000271207|SCV000699203|SCV000277516|SCV000908991|SCV000321440|SCV000887714	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.4675G>A	BRCA1	missense_variant,splice_region_variant	NA	NA	15422	1	5&5	0&1	rs80356988	Breast-ovarian cancer, familial 1&Hereditary cancer-predisposing syndrome	37604	46160	_familial_1|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41226348C>T	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	80356988	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Ambry_Genetics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2012-05-01|2004-11-25|2015-10-02|2019-06-18|2018-10-01|2015-02-28|2019-02-11|2014-01-31	2013-12-30|2014-03-28|2016-10-28|2019-07-23|2020-02-26|2019-01-29|2020-03-06|2017-08-04	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline	SCV000053785|SCV000145148|SCV000326020|SCV001161548|SCV000186878|SCV000564744|SCV001133595|SCV000587416	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.4358-2786G>A	BRCA1	intron_variant	99312	0	15418	1	-	-	-	-	162503	172181	Hereditary_breast_and_ovarian_cancer_syndrome	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145	-	NC_000017.10:g.41231417C>T	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001627|intron_variant	1	374435098	-	_University_of_Washington	Likely_pathogenic	2014-06-01	2015-11-22	_single_submitter	germline	SCV000196736	Hereditary_breast_and_ovarian_cancer_syndrome	
NM_007294.3:c.212+3A>G	BRCA1	splice_region_variant,intron_variant	NA	NA	15430	1	-	-	-	-	54467	69134	_familial_1|not_specified|Breast_and/or_ovarian_cancer	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN221562	-	NC_000017.10:g.41258470T>C	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Breast_Cancer_Information_Core__(BRCA1):331+3&base_change%3DA_to_G|Database_of_BRCA1_and_BRCA2_sequence_variants_that_have_been_clinically_reclassified_by_a_quantitative_integrated_evaluation:BRCA1_00134	-	BRCA1:672	SO:0001627|intron_variant	1	80358083	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Ambry_Genetics|Foulkes_Cancer_Genetics_LDI,_Lady_Davis_Institute_for_Medical_Research	Pathogenic|not_provided|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Uncertain_significance	2010-02-17|0000-00-00|2015-08-10|2015-10-02|2015-12-17|2016-11-04|2018-12-07|2015-04-09	2013-12-30|2014-03-28|2015-08-17|2016-10-28|2017-08-04|2017-06-30|2020-02-26|2018-07-18	no_assertion_criteria_provided|no_assertion_provided|reviewed_by_expert_panel|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline	SCV000115252|SCV000144666|SCV000244314|SCV000325243|SCV000587034|SCV000602702|SCV000607764|SCV000863667	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|not_specified|Hereditary_cancer-predisposing_syndrome|Breast_and/or_ovarian_cancer	_thresholds_for_class_as_per_Plon_et_al._2008_(PMID:_18951446)._Class_5_based_on_posterior_probability_
NM_007294.3:c.116G>A	BRCA1	missense_variant	NA	NA	15426	1	5&5	1&1	rs80357498	Hereditary cancer-predisposing syndrome&not provided	37392	45948	_familial_1|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN517202	-	NC_000017.10:g.41267761C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	80357498	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Ambry_Genetics|Color|GeneDx|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|3DMed_Clinical_Laboratory_Inc	Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2006-12-11|2002-05-29|2015-10-02|2018-06-18|2017-01-09|2016-03-08|2015-12-17|2017-08-19	2012-07-24|2014-03-28|2016-10-28|2020-02-26|2017-12-21|2019-01-29|2017-08-04|2018-06-19	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline	SCV000053564|SCV000144352|SCV000324974|SCV000277193|SCV000688318|SCV000293476|SCV000587014|SCV000803963	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome|Neoplasm_of_the_breast	|||Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification:Well-characterized_mutation_at_same_position||This_pathogenic_variant_is_denoted_BRCA1_c.116G>A_at_the_cDNA_level,_p.Cys39Tyr_(C39Y)_at_the_protein_level,_and_results_in_the_change_of_a_Cysteine_to_a_Tyrosine_(TGT>TAT)._Using_alternate_nomenclature,_this_pathogenic_variant_has_been_previously_published_as_BRCA1_235G>A._This_variant_was_observed_in_multiple_Hereditary_Breast_and_Ovarian_Cancer_families_and_has_been_described_as_a_pathogenic_founder_variant_from_the_border_regions_of_Italy_and_Slovenia_(Santarosa_1998,_Stegel_2011,_Juwle_2012,_Novakovic_2012,_Krajc_2014,_Cini_2016)._In_addition,_multiple_functional_studies_have_confirmed_the_pathogenicity_of_this_variant._BRCA1_Cys39Tyr_was_abolished_ubiquitin_ligase_activity,_failed_to_restore_radiation_resistance,_failed_to_promote_homology_directed_repair_and_demonstrated_absence_of_BARD1_binding_(Ruffner_2001,_Ransburgh_2010)._In_addition,_this_variant_abrogated_the_ability_of_yeast_to_induce_growth_arrest_in_a_small_colony_phenotype_assay,_displayed_centrosome_amplification_and_exhibited_deficient_double-strand_break_repair_in_a_single_strand_annealing_assay_(Millot_2011,_Kais_2012,_Towler_2013)._BRCA1_Cys39Tyr_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_suggesting_it_is_not_a_common_benign_variant_in_these_populations._Since_Cysteine_and_Tyrosine_differ_in_polarity,_charge,_size_or_other_properties,_this_is_considered_a_non-conservative_amino_acid_substitution._BRCA1_Cys39Tyr_occurs_at_a_position_that_is_conserved_in_mammals_and_is_located_in_located_in_the_RING_domain_and_in_a_region_known_to_interact_with_multiple_other_proteins_(Borg_2010,_Paul_2014)._In_silico_analyses_predict_that_this_pathogenic_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_currently_available_evidence,_we_consider_this_variant_to_be_pathogenic.||
NM_006363.4:c.742G>A	SEC23B	missense_variant	NA	NA	15424	1	4	1	rs398124227	not provided	95390	101289	not_provided	-	MedGen:CN517202	-	NC_000020.10:g.18506484G>A	_single_submitter	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	HGMD:CM137874	-	SEC23B:10483	SO:0001583|missense_variant	1	398124227	-	Eurofins_Clinical_Diagnostics	Likely_pathogenic	2014-02-27	2018-09-19	_single_submitter	germline	SCV000113341	not_provided	
